var images_info;if (!images_info) images_info =[]; images_info["65"]={"65000":{"type":"graphic_table","displayName":"Clinical characteristics essential thrombocythemia","title":"Initial clinical characteristics in 150 patients with essential thrombocythemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial clinical characteristics in 150 patients with essential thrombocythemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Characteristic</td> <td class=\"subtitle1\">Percent or median result (range)</td> </tr> <tr> <td>Age</td> <td>49.8 (17-98)</td> </tr> <tr> <td>Sex, percent female</td> <td>66</td> </tr> <tr> <td>Hemoglobin (g/dL) </td> <td>13.7 (9.1-16.8) </td> </tr> <tr> <td>WBC count (x 10<sup>3</sup>/microL) </td> <td>9.0 (4.1-25.2)</td> </tr> <tr> <td>Platelet count (x 10<sup>3</sup>/microL)</td> <td>1000 (454-3460)</td> </tr> <tr> <td>Palpable splenomegaly, percent</td> <td>34.7</td> </tr> <tr> <td>Asymptomatic, percent</td> <td>45.3</td> </tr> <tr> <td>Vasomotor symptoms, percent </td> <td>13.3</td> </tr> <tr> <td>History of fetal loss (women only), percent </td> <td>11.2</td> </tr> <tr> <td>History of thrombosis, percent </td> <td>21.3</td> </tr> <tr> <td>History of hemorrhage, percent</td> <td>9.3</td> </tr> <tr> <td>Normal cytogenetics, percent</td> <td>87.4</td> </tr> <tr> <td>JAK2 mutation, percent</td> <td>48.7</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Wolanskyj AP, Lasho TL, Schwager SM,&nbsp;et al.JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.&nbsp;Br J Haematol 2005; 131:208.</div><div id=\"graphicVersion\">Graphic 65000 Version 2.0</div></div></div>"},"65002":{"type":"graphic_diagnosticimage","displayName":"AP view transverse patella fracture","title":"AP view of transverse patella fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AP view of transverse patella fracture</div><div class=\"cntnt\"><img style=\"width:357px; height:477px;\" src=\"images/EM/65002_Tranverse_patella_fx_AP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note how the fracture line (arrow) is relatively narrow and irregular compared with the bipartite patella. Also note that the location of the fracture line does not correspond with any of the common ossification centers.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Jim Blount, MD.</div><div id=\"graphicVersion\">Graphic 65002 Version 4.0</div></div></div>"},"65003":{"type":"graphic_table","displayName":"Aberrant receptor screen","title":"In vivo screening protocol to detect the presence of aberrant adrenal hormone receptors in adrenal Cushing's syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">In vivo screening protocol to detect the presence of aberrant adrenal hormone receptors in adrenal Cushing's syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Time (min)</td> <td class=\"subtitle1\">Day 1</td> <td class=\"subtitle1\">Day 2</td> <td class=\"subtitle1\">Day 3</td> </tr> <tr> <td>&ndash;60</td> <td>Fasting-supine</td> <td>Fasting-supine</td> <td>Fasting-supine</td> </tr> <tr> <td>&ndash;15</td> <td>*</td> <td>*</td> <td>*</td> </tr> <tr> <td>0</td> <td>Upright*</td> <td>GnRH 100 microgram IV*</td> <td>Glucagon 1 mg IV*</td> </tr> <tr> <td>+30</td> <td>Upright*</td> <td>*</td> <td>*</td> </tr> <tr> <td>+60</td> <td>Upright*</td> <td>*</td> <td>*</td> </tr> <tr> <td>+90</td> <td>Upright*</td> <td>*</td> <td>*</td> </tr> <tr> <td>+120</td> <td>Upright*</td> <td>*</td> <td>*</td> </tr> <tr> <td>+150</td> <td>Supine*</td> <td>(Meal)</td> <td>&nbsp;</td> </tr> <tr> <td>+180</td> <td>Mixed meal*</td> <td>&nbsp;</td> <td>Vasopressin 10 international units IM*<sup>&#182;</sup></td> </tr> <tr> <td>+210</td> <td>*</td> <td>&nbsp;</td> <td>*</td> </tr> <tr> <td>+240</td> <td>*</td> <td>&nbsp;</td> <td>*</td> </tr> <tr> <td>+270</td> <td>*</td> <td>*</td> <td>*</td> </tr> <tr> <td>+300</td> <td>*</td> <td>TRH 200 microgram IV*<sup>&#182;</sup></td> <td>*</td> </tr> <tr> <td>+330</td> <td>&nbsp;</td> <td>*</td> <td>&nbsp;</td> </tr> <tr> <td>+360</td> <td>ACTH 1-24 250 microgram IV*</td> <td>*</td> <td>Metoclopramide 10 mg orally*</td> </tr> <tr> <td>+390</td> <td>*</td> <td>*</td> <td>*</td> </tr> <tr> <td>+420</td> <td>*</td> <td>*</td> <td>*</td> </tr> <tr> <td>+450</td> <td>*</td> <td>&nbsp;</td> <td>*</td> </tr> <tr> <td>+480</td> <td>*</td> <td>&nbsp;</td> <td>*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone; IV: intravenous; IM: intramuscular;&nbsp;TRH: thyrotropin-releasing hormone; ACTH: corticotropin.<br />* Blood samples for determination of cortisol, ACTH, other hormones, and vital signs.<br />¶ Availability of certain compounds varies between different countries. TRH not available in United States; vasopressin can be replaced by terlipressin 1 mg IV in some countries.</div><div class=\"graphic_reference\">Reproduced with permission from: Lacroix A, Mircescu, Hamet P. Clinical evaluation of the presence of abnormal hormone receptors in adrenal Cushing's syndrome. The Endocrinologist 1999; 9:9. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65003 Version 8.0</div></div></div>"},"65005":{"type":"graphic_figure","displayName":"Accelerated t PA in acute MI","title":"Benefit of accelerated t-PA in acute myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Benefit of accelerated t-PA in acute myocardial infarction</div><div class=\"cntnt\"><img style=\"width:493px; height:243px;\" src=\"images/CARD/65005_Accelerated_t_PA_in_acute_M.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The overall one-year mortality for patients treated with different thrombolytic strategies in the GUSTO-1 trial. The mortality rate was lower in patients treated with accelerated t-PA compared to those receiving streptokinase and either intravenous (IV) or subcutaneous (SQ) heparin (p = 0.003) or t-PA and streptokinase in combination (p = 0.05).</div><div class=\"graphic_reference\">Data from Califf RM, White HD, Van de Werk F, et al for the GUSTO-1 Investigators, Circulation 1996; 94:1233.</div><div id=\"graphicVersion\">Graphic 65005 Version 2.0</div></div></div>"},"65009":{"type":"graphic_diagnosticimage","displayName":"Tracheomalacia CXR","title":"Tracheomalacia following longterm intubation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheomalacia following longterm intubation</div><div class=\"cntnt\"><img style=\"width:320px; height:318px;\" src=\"images/PULM/65009_Tracheomalacia_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest&nbsp;radiograph showing&nbsp;a tracheostomy tube with hyperexpanded cuff. The tracheal air column is abnormally distended by the tracheostomy cuff (red arrows).</div><div id=\"graphicVersion\">Graphic 65009 Version 3.0</div></div></div>"},"65011":{"type":"graphic_picture","displayName":"Antiphospholipid antibody syndrome - purpura","title":"Purpura in antiphospholipid antibody syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Purpura in antiphospholipid antibody syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:395px;\" src=\"images/DERM/65011_Antiphos_antibody_synd_purp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retiform purpura are present on the buttock.</div><div id=\"graphicVersion\">Graphic 65011 Version 1.0</div></div></div>"},"65012":{"type":"graphic_figure","displayName":"Funnel plots","title":"Funnel plots","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Funnel plots</div><div class=\"cntnt\"><img style=\"width:525px; height:265px;\" src=\"images/PC/65012_Funnel-plots.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The above graphs represent funnel plots. In each figure, the x-axis represents the magnitude of the effect and the y-axis the &quot;precision.&quot; The dotted line on the x-axis represents &quot;no effect&quot;; to the right of this line, the effect favors the control group while to the left the effect favors the intervention. Circles represent individual studies. Generally, larger studies have higher precision.<br> The funnel plot on the left shows several smaller studies symmetrically clustered around the &quot;no effect&quot; line. In contrast, the funnel plot on the right appears to be missing smaller studies that favored the control arm, suggesting that there may have been publication bias in favor of studies where the intervention succeeded.<br> Unfortunately, the graphical depiction of studies using this approach is subject to variable interpretation among raters, particularly when there are relatively few studies. Thus, funnel plots are not always a reliable method to clarify whether there is publication bias.</div><div class=\"graphic_reference\">Figure courtesy of Gordon Guyatt, MD.</div><div id=\"graphicVersion\">Graphic 65012 Version 3.0</div></div></div>"},"65014":{"type":"graphic_picture","displayName":"Fetal membranes","title":"Fetal membranes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal membranes</div><div class=\"cntnt\"><img style=\"width:432px; height:329px;\" src=\"images/OBGYN/65014_Fetalmembranes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross photograph of a normal placenta with clear membranes. The amnion has been peeled off of the chorion focally to demonstrate the thinness and clarity of the amnion.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 65014 Version 2.0</div></div></div>"},"65015":{"type":"graphic_table","displayName":"Core cross cultural issues","title":"Core cross-cultural issues","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Core cross-cultural issues</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Styles of communication</td>\n</tr>\n<tr>\n<td>Mistrust and prejudice</td>\n</tr>\n<tr>\n<td>Decision-making and family dynamics</td>\n</tr>\n<tr>\n<td>Traditions, customs, and spirituality</td>\n</tr>\n<tr>\n<td>Sexual and gender issues</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 65015 Version 1.0</div></div></div>"},"65016":{"type":"graphic_picture","displayName":"TE fistula Endosc","title":"Tracheoesophageal fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheoesophageal fistula</div><div class=\"cntnt\"><img style=\"width:320px; height:320px;\" src=\"images/PULM/65016_TE_fistula_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoscopic view of a 2 cm tracheoesophageal fistula that developed following prolonged intubation and endotracheal tube cuff overinflation. Arrow demonstrates nasogastric tube within the fistula.</div><div class=\"graphic_reference\">Courtesy of Charles Marquette, MD.</div><div id=\"graphicVersion\">Graphic 65016 Version 1.0</div></div></div>"},"65018":{"type":"graphic_diagnosticimage","displayName":"Complete midshaft forearm fracture 2","title":"Minimally displaced midshaft forearm fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Minimally displaced midshaft forearm fracture</div><div class=\"cntnt\"><img style=\"width:442px; height:489px;\" src=\"images/EM/65018_Complete_fx_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">3-year-old with midforearm complete fracture of distal radius and ulna, with minimal displacement of radius and no angluation. This fracture was casted without reduction.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 65018 Version 3.0</div></div></div>"},"65019":{"type":"graphic_figure","displayName":"Pelvic arteries","title":"Arteries of the pelvis","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Arteries of the pelvis</div><div class=\"cntnt\"><img style=\"width:477px; height:556px;\" src=\"images/EM/65019_Pelvicarteries.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 65019 Version 10.0</div></div></div>"},"65020":{"type":"graphic_diagnosticimage","displayName":"Adrenal adenoma MRI","title":"Adrenocortical adenoma","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Adrenocortical adenoma</div><div class=\"cntnt\"><img style=\"width:453px; height:167px;\" src=\"images/ENDO/65020_Adrenal_adenoma_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance images of an adrenocortical adenoma. Left: T1-weighted scan showing a left adrenal mass with low signal intensity similar to that of liver tissue. Right: The low signal intensity of this mass did not change during the T2-weighted scan.</div><div class=\"graphic_reference\">Courtesy of George P Chrousos, MD.</div><div id=\"graphicVersion\">Graphic 65020 Version 2.0</div></div></div>"},"65021":{"type":"graphic_figure","displayName":"T3 resin test TBG deficiency","title":"T3-resin test in TBG deficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">T3-resin test in TBG deficiency</div><div class=\"cntnt\"><img style=\"width:182px; height:216px;\" src=\"images/ENDO/65021_T3_resin_test_TBG_deficienc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiolabeled T3 (*T3) cannot bind to diminished or absent TBG; as a result, the amount left over to bind to the resin is higher than normal. The serum total T4 is low; the T3-resin uptake and THBR are high, and the serum free T4 index is normal.</div><div class=\"graphic_footnotes\">T3: triiodothyronine; T4: thyroxine; TBG: thyroxine-binding globulin; THBR: thyroid hormone binding ratio.</div><div id=\"graphicVersion\">Graphic 65021 Version 2.0</div></div></div>"},"65022":{"type":"graphic_diagnosticimage","displayName":"Hydrosalpinx 3D","title":"Hydrosalpinx","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hydrosalpinx</div><div class=\"cntnt\"><img style=\"width:504px; height:216px;\" src=\"images/OBGYN/65022_Hydrosalpinx_3D.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound image of the adnexa showing a<br>hydrosalpinx with three-dimensional rendering. A cystic structure<br>with a septation (arrow) is identified in the adnexa. The rendered image (on right side of illustration) demonstrates a tubular fluid collection with incomplete septations indicating a serpiginously dilated fallopian tube.</div><div class=\"graphic_reference\">Reproduced with permission from: Thomas D Shipp, MD. Copyright © Thomas D Shipp, MD.</div><div id=\"graphicVersion\">Graphic 65022 Version 2.0</div></div></div>"},"65023":{"type":"graphic_picture","displayName":"FL with leukemic cells","title":"Circulating lymphoma cells in follicular lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circulating lymphoma cells in follicular lymphoma</div><div class=\"cntnt\"><img style=\"width:300px; height:288px;\" src=\"images/HEME/65023_FL_with_leukemic_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two fields of a peripheral blood smear from a patient with follicular lymphoma are shown here. Several cells with a &quot;notched nucleus&quot; (centrocytes) are seen; nuclei are partially or completely divided by a characteristic cleft (arrows). The chromatin stains intensely and is compactly clumped. These cells have also been called &quot;buttock&quot; cells.</div><div class=\"graphic_reference\">From Warnke RA, Weiss LM, Chan JK, Cleary ML, Dorfman RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 65023 Version 3.0</div></div></div>"},"65024":{"type":"graphic_figure","displayName":"Spinal cord cross-section","title":"Cross-sectional anatomy of the spinal cord","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Cross-sectional anatomy of the spinal cord</div><div class=\"cntnt\"><img style=\"width:539px; height:294px;\" src=\"images/NEURO/65024_X_section_spinal_cord.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65024 Version 3.0</div></div></div>"},"65025":{"type":"graphic_picture","displayName":"Anal squamous intraep neoplasia","title":"Anal squamous intraepithelia neoplasia","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Anal squamous intraepithelia neoplasia</div><div class=\"cntnt\"><img style=\"width:519px; height:353px;\" src=\"images/ONC/65025_Anal_squam_intra_neopl_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Bowenoid anal intraepithelia neoplasia.<br />(B) Erythroplakic anal intraepithelial neoplasia.<br />(C) Leukoplakic anal intraepithelial neoplasia.<br />(D) Verrucous anal intraepithelial neoplasia.</div><div class=\"graphic_reference\">Reproduced with permission from: Kreuter A, Brockmeyer NH, Hochdorfer B, et al. Clinical spectrum and virologic characteristics of anal intraepithelial neoplasia in HIV. J Am Acad Dermatol 2005; 52:603. Copyright © 2005 The American Academy of Dermatology.</div><div id=\"graphicVersion\">Graphic 65025 Version 4.0</div></div></div>"},"65030":{"type":"graphic_figure","displayName":"Hip prosthesis PI","title":"Hip replacement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hip replacement</div><div class=\"cntnt\"><img style=\"width:438px; height:587px;\" src=\"images/PI/65030_HipprosthesisPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For a hip replacement, your doctor will do surgery to replace your hip joint with a new joint called a \"prosthesis.\" The prosthesis might be made out of plastic, metal, and/or ceramic.</div><div id=\"graphicVersion\">Graphic 65030 Version 6.0</div></div></div>"},"65031":{"type":"graphic_picture","displayName":"Pendulum exercise","title":"Pendulum (Codman's) exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pendulum (Codman's) exercise</div><div class=\"cntnt\"><img style=\"width:304px; height:348px;\" src=\"images/RHEUM/65031_Pendulum_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bending over with the affected arm hanging down, the patient swings the arm from the shoulder in 6 to 12 inch circles. A three to five pound weight on the wrist or in the hand provides additional traction and momentum to the swing.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 65031 Version 2.0</div></div></div>"},"65032":{"type":"graphic_figure","displayName":"Capillary electrophoresis of hemoglobins","title":"Capillary electrophoresis of hemoglobin variants","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Capillary electrophoresis of hemoglobin variants</div><div class=\"cntnt\"><img style=\"width:598px; height:580px;\" src=\"images/HEME/65032_Capillary_electro_Hgb_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Separation pattern and quantification of an artificial mixture of normal and some common variant hemoglobins by capillary electrophoresis (courtesy of Sebia&#174;). The first of the two boxed items (top) is the actual capillary electrophoretic separation pattern of the hemoglobins seen in the graph. For quantification, these are scanned at 415 nm wavelength and the relative percentage is calculated, as shown in the second (bottom) box.</div><div id=\"graphicVersion\">Graphic 65032 Version 2.0</div></div></div>"},"65035":{"type":"graphic_figure","displayName":"MHC class II antigen processing and presentation pathway","title":"The MHC class II antigen processing and presentation pathway","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">The MHC class II antigen processing and presentation pathway</div><div class=\"cntnt\"><img style=\"width:549px; height:358px;\" src=\"images/ALLRG/65035_MHC_class_II_antigen_processing_and presentation_pathway.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a figure showing antigen processing and presentation via cells utilizing MHC class II. Initially, exogenous antigen is taken up and broken down by proteases (at acidic pH) into peptides in the endocytic compartment. MHC class II alpha-beta heterodimers are assembled in the ER with the invariant chain (Ii) polypeptide. These complexes are targeted from the Golgi complex to the endocytic compartment by Ii, where they encounter peptides generated from exogenous antigen. Ii is degraded to the CLIP peptide by proteases at low pH, and CLIP exchange is facilitated by acidic conditions and catalyzed by HLA-DM. MHC II molecules that have stably bound new peptides are then exported to the cell surface for presentation to CD4+ T cells.</div><div class=\"graphic_footnotes\">MHC: major histocompatibility complex; ER: endoplasmic reticulum; Ii: invariant chain polypeptide; CLIP: class II-associated invariant chain peptide; HLA-DM: human leukocyte antigen-DM.</div><div id=\"graphicVersion\">Graphic 65035 Version 5.0</div></div></div>"},"65036":{"type":"graphic_picture","displayName":"Persistent perforation","title":"Persistent perforation after tube extrusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Persistent perforation after tube extrusion</div><div class=\"cntnt\"><img style=\"width:396px; height:388px;\" src=\"images/PEDS/65036_Persistent_perforation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Persistent perforation after tube extrusion, as depicted above, is a potential complication of tympanostomy tube placement.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 65036 Version 1.0</div></div></div>"},"65038":{"type":"graphic_figure","displayName":"Aspirin provocation in AERD","title":"Aspirin provocation test in aspirin-exacerbated respiratory disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aspirin provocation test in aspirin-exacerbated respiratory disease</div><div class=\"cntnt\"><img style=\"width:440px; height:269px;\" src=\"images/PULM/65038_Aspirin_provocation_in_AIA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Provocation test in which either placebo (dashed blue line) or aspirin (solid red line) was given to a patient with aspirin-exacerbated asthma. The administration of aspirin led to a marked and transient reduction in FEV<SUB>1</SUB>.</div><div class=\"graphic_footnotes\">FEV<sub>1</sub>: forced expiratory volume in one second.</div><div id=\"graphicVersion\">Graphic 65038 Version 5.0</div></div></div>"},"65039":{"type":"graphic_diagnosticimage","displayName":"Lung cancer extension MRI II","title":"Transdiaphragmatic extension of lung carcinoma on MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transdiaphragmatic extension of lung carcinoma on MRI</div><div class=\"cntnt\"><img style=\"width:357px; height:285px;\" src=\"images/PULM/65039_Lung_cancer_extension_MRI1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal T2-weighted section shows transdiaphragmatic extension of the lesion (arrow). There is also a posterior pleural effusion (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 65039 Version 3.0</div></div></div>"},"65040":{"type":"graphic_figure","displayName":"Neuromuscular disease on PFT","title":"Impact of neuromuscular disease on pulmonary function","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Impact of neuromuscular disease on pulmonary function</div><div class=\"cntnt\"><img style=\"width:473px; height:299px;\" src=\"images/PULM/65040_Neuromuscular_disease_on_PF.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65040 Version 1.0</div></div></div>"},"65046":{"type":"graphic_table","displayName":"Drugs Crohns children","title":"Induction and maintenance therapies commonly used in the treatment of Crohn's disease in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Induction and maintenance therapies commonly used in the treatment of Crohn's disease in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">US trade name(s)</td> <td class=\"subtitle1\">Dose in children</td> <td class=\"subtitle1\">Dose in adults</td> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Important side effects</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Prednisone or Prednisolone</td> <td>&nbsp;</td> <td>1 to 2 mg/kg/day PO (maximum, 60 mg/dose), then taper after two weeks if patient is in remission</td> <td>40 to 60 mg/day PO, then taper after two weeks if patient is in remission</td> <td>Short-term induction therapy for moderate Crohn's disease.</td> <td>Facial swelling, moodiness, sleep disturbance, hirsutism, adrenal suppression (with physiologic doses for more than two to three weeks); hyperglycemia, osteoporosis, increased risk of varicella infection; cataracts, aseptic necrosis of bone.</td> <td>Onset of action rapid (3 to 14 days). Long-term use causes growth failure; not appropriate for long-term use.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Budesonide (enteric coated)</td> <td rowspan=\"2\">Entocort</td> <td colspan=\"2\"><em>Age &#8805;6 years:</em></td> <td rowspan=\"2\">Short-term induction therapy for mild to moderate Crohn's disease affecting the <em>ileum and right colon</em>.</td> <td rowspan=\"2\">Similar to prednisone, but fewer systemic effects including adrenal suppression.</td> <td rowspan=\"2\">May be less effective than prednisone. Pediatric dosing is based on limited data from clinical trials in children six years and older. Taper by 3 mg increments as tolerated, for a total course of up to three months.</td> </tr> <tr> <td class=\"indent1\"> <p>9 mg/day PO, then taper<sup>[1]</sup></p> <p><em>Or:</em></p> 0.45 mg/kg/day PO (maximum dose 9 mg/day), then taper<sup>[2]</sup></td> <td class=\"indent1\">9 mg/day PO, then taper</td> </tr> <tr> <td class=\"indent1\">Methylprednisolone</td> <td>Solu-Medrol</td> <td>1 mg/kg q 12 hours IV (maximum 30 mg per dose)</td> <td>25 to 35 mg q 12 hours IV</td> <td>Induction of remission in severe Crohn's disease of the small bowel and colon.</td> <td>As described above for other systemic corticosteroids.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Aminosalicylates (derivatives of 5-aminosalicylate, 5-ASA)</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"7\">Mesalamine*</td> </tr> <tr> <td class=\"sublist2\">Time-released</td> <td class=\"sublist_other\">Pentasa</td> <td class=\"sublist_other\">50 to 75 mg/kg/day PO in three to four divided doses (maximum 1 gram/dose)<sup>[3]</sup></td> <td class=\"sublist_other\"> <p><em>Induction:</em></p> <p>4 to 6 g/day PO in three to four divided doses</p> <p><em>Maintenance:</em></p> 2 to 4 g/day PO in three to four divided doses</td> <td class=\"sublist_other\"> <p>Maintenance of remission in mild mucosal Crohn's disease in <em>small bowel or colon</em>.</p> May also be useful for initial therapy in patients with mild disease.</td> <td class=\"sublist_other\">Generally well-tolerated. Rare reactions include rashes, pancreatitis, and interstitial nephritis (rare but serious).</td> <td class=\"sublist_other\"> <p>Low efficacy (35 to 40 percent, versus 30 percent for placebo in randomized studies).</p> <p>Capsules may be opened and sprinkled on soft food.</p> <p>Patient adherence can be a problem because of requirement for frequent dosing.</p> Suggest monitoring BUN/creatinine, urine analysis, CBC and LFTs (eg, twice yearly).</td> </tr> <tr> <td class=\"sublist2\">pH-released</td> <td class=\"sublist_other\">Asacol</td> <td class=\"sublist_other\">50 to 80 mg/kg/day PO divided in three or four doses (maximum 1 gram/dose)</td> <td class=\"sublist_other\">3.6 to 4.8 g/day PO, in three to four divided doses</td> <td class=\"sublist_other\"> <p>Maintenance of remission in mild mucosal Crohn's disease <em>(ileum or colon)</em>.</p> May also be useful for initial therapy in patients with mild disease.</td> <td class=\"sublist_other\">As above.</td> <td class=\"sublist_other\"> <p>Low efficacy (35 to 40 percent, versus 30 percent for placebo in randomized studies).</p> <p>Patient adherence can be a problem because of requirement for frequent dosing.</p> Suggest monitoring BUN/creatinine, urine analysis, CBC and LFTs (eg, twice yearly).</td> </tr> <tr> <td class=\"indent1\">Sulfasalazine</td> <td> <p>Azulfidine</p> Sulfazine</td> <td>50 to 75 mg/kg/day PO, divided in three or four doses (maximum 1 g/dose)</td> <td> <p><em>Induction:</em></p> <p>1 g PO, three to four times daily</p> <p><em>Maintenance:</em></p> 1 g PO, two to three times daily</td> <td> <p>Maintenance of remission in mild mucosal <em>colonic</em> Crohn's disease.</p> May also be useful for initial therapy in patients with mild disease.</td> <td> <p>Sulfasalazine consists of a 5-ASA component linked to sulfapyridine; hypersensitivity to the sulfonamide component is common (drug fever, arthritis, or rash).</p> <p>Headache, photosensitivity, leukopenia, hepatitis.</p> Rare but serious reactions include pancreatitis, pericarditis, myocarditis, and pneumonitis.</td> <td> <p>To minimize side effects, start treatment at a low dose and increase to full dose as tolerated over one to two weeks.</p> <p>Low efficacy (35 to 40 percent, versus 30 percent for placebo in randomized studies).</p> <p>Also give folic acid, 1 mg daily.</p> Suggest monitoring BUN/creatinine, urine analysis, CBC and LFTs (eg, twice yearly).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Nutritional therapy</td> </tr> <tr> <td class=\"indent1\">Elemental or polymeric formula - no other food by mouth</td> <td>&nbsp;</td> <td>Dose to meet nutritional needs for four to six weeks</td> <td>&nbsp;</td> <td>Mucosal Crohn's disease, growth failure.</td> <td>Formulas may be administered orally or by nasogastric tube.</td> <td>Efficacy 50 to 60 percent; children may refuse NG, NPO; may relapse rapidly once feeds discontinued.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Immunomodulators</td> </tr> <tr> <td class=\"indent1\"> <p>Mercaptopurine</p> (also known as 6-mercaptopurine, 6MP)</td> <td>Purinethol</td> <td> <p>1 to 1.5 mg/kg/day PO<sup>&#916;</sup> (maximum dose 150 mg/day)<sup>[3]</sup></p> Much lower doses are used for patients with reduced TPMT activity (see \"comments\")</td> <td> <p>1 to 1.5 mg/kg/day PO (maximum dose 150 mg/day)<sup>[3]</sup></p> Much lower doses are used for patients with reduced TPMT activity (see \"comments\")</td> <td>Maintenance of remission in medically refractory Crohn's disease, especially for patients with growth failure or fistulizing disease.</td> <td> <p>Pancreatitis, myelosuppression, hepatitis, pneumonitis, opportunistic infections.</p> <p>Hypersensitivity (drug fever, arthritis or rash). Anorexia, nausea, vomiting.</p> Increased risk of lymphoma (usually related to concomitant Epstein-Barr virus [EBV] infection).</td> <td> <p>Assess thiopurine methyltransferase (TPMT) genotype or enzyme activity prior to starting therapy. Dosage should then be modified based on the TPMT genotype or activity.</p> Starting dosage of Mercaptopurine should be modified based on the TPMT genotype or activity:<sup>[4]</sup> <ul> <li>TPMT genotype 1/1 (normal or increased activity): 1 to 1.5 mg/kg/day </li> <li>TPMT genotype 1/3a (reduced activity): 0.5 mg/kg/day </li> <li>TPMT genotype 3a/3a (absent activity): Mercaptopurine or azathioprine should not be used </li> </ul> <br /> <p>Monitor CBC, LFTs and amylase/lipase during therapy.</p> Slow onset of therapeutic effects (three to four months). Therapeutic drug level monitoring available. Possible risks of birth defects. Increased risk of lymphoma.</td> </tr> <tr> <td class=\"indent1\">Azathioprine</td> <td>&nbsp;</td> <td> <p>1.5 to 2.5 mg/kg/day PO (maximum dose 200 mg/day)<sup>[3]</sup></p> Much lower doses are used for patients with reduced TPMT activity (see \"comments\")</td> <td> <p>1.5 to 2.5 mg/kg/day PO (maximum dose 200 mg/day)<sup>[3]</sup></p> Much lower doses are used for patients with reduced TPMT activity (see \"comments\")</td> <td>Same as Mercaptopurine; these are maintenance agents only.</td> <td>Same as Mercaptopurine.</td> <td> <p>Assess thiopurine methyltransferase (TPMT) genotype or enzyme activity prior to starting therapy.</p> <p>Starting dosage of Azathioprine should then be modified based on the TPMT genotype or activity:<sup>[4]</sup></p> <ul> <li>TPMT genotype 1/1 (normal or increased activity): 2 to 2.5 mg/kg/day </li> <li>TPMT genotype 1/3a (reduced activity): 1 mg/kg/day </li> <li>TPMT genotype 3a/3a (absent activity): Mercaptopurine or azathioprine should not be used. </li> </ul> <p>Monitor CBC, LFTs and amylase/lipase during therapy.</p> Azathioprine is metabolized to 6-MP in the liver. Slow onset of therapeutic effects (three to four months). Adverse effects are the same as 6-MP.</td> </tr> <tr> <td class=\"indent1\">Methotrexate</td> <td> <p>Reumatrex</p> Trexall</td> <td>15 to 25 mg/m<sup>2</sup>/week SQ (maximum dose 25 mg once weekly for induction, 15 mg once weekly for maintenance)</td> <td> <p><em>Induction:</em></p> <p>15 to 25 mg SQ weekly</p> <p><em>Maintenance:</em></p> 15 mg SQ weekly</td> <td> <p>Refractory Crohn's disease.</p> Primarily used as maintenance therapy.</td> <td>Bone marrow suppression, hepatotoxicity, oral ulcers, nausea, pneumonitis.</td> <td> <p>Contraindicated in pregnancy.</p> <p>Monitor CBC and LFTs during therapy.</p> <p>Folic acid 1 mg daily should be given to all patients.</p> The oral route of administration also has been used for maintenance of remission.<sup>[5]</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Anti-tumor necrosis factor (TNF) inhibitors</td> </tr> <tr> <td class=\"indent1\"> <p>Infliximab</p> (chimeric monoclonal antibody, 75 percent humanized)</td> <td>Remicade</td> <td> <p><em>Induction:</em></p> <p>5 mg/kg per dose IV, at weeks zero, two, and six. (May increase to 10 mg/kg if response is incomplete).</p> <p><em>Maintenance:</em></p> 5 mg/kg per dose IV, every eight weeks (may increase to 10 mg/kg if response is incomplete, and/or decrease the interval between infusions)</td> <td> <p><em>Induction:</em></p> <p>5 mg/kg per dose IV, at weeks zero, two, and six. (May increase to 10 mg/kg if response is incomplete).</p> <p><em>Maintenance:</em></p> 5 mg/kg per dose IV, every eight weeks (may increase to 10 mg/kg if response is incomplete, and/or decrease the interval between infusions)</td> <td>Refractory Crohn's disease.</td> <td> <p>Infusion reactions, infections, psoriasis.</p> <p>Increased risk of tuberculosis.</p> Increased risk of lymphoma, including hepatosplenic T-cell lymphoma.</td> <td> <p>Evaluate with tuberculin skin test or chest x-ray prior to starting therapy.</p> Monitor CBC and LFTs during therapy.</td> </tr> <tr> <td class=\"indent1\"> <p>Adalimumab</p> (humanized monoclonal antibody)</td> <td>Humira</td> <td> <p>Dosing used in clinical trials in children:<sup>[6]</sup></p> <p><em>Induction:</em></p> <p>&#60;40 kg: 80 mg/dose SQ on week zero, followed by 40 mg on week two</p> <p>&#8805;40 kg: 160 mg/dose SQ on week zero, followed by 80 mg on week two</p> <p><em>Maintenance:</em></p> <p>(start on week four)</p> <p>&#60;40 kg: 20 mg/dose SQ every two weeks</p> &#8805;40 kg: 40 mg SQ every two weeks</td> <td> <p><em>Induction:</em></p> <p>160 mg SQ first dose</p> <p>80 mg SQ two weeks later</p> <p><em>Maintenance:</em></p> 40 mg SQ on alternate weeks thereafter. Some patients may require weekly maintenance therapy,<sup>[7]</sup> or a higher maintenance dose.</td> <td>Refractory Crohn's disease.</td> <td>Infections, increased risk of lymphoma and tuberculosis.</td> <td> <p>Little published data in children and adolescents.</p> <p>Sometimes used as rescue therapy for children failing to respond to Infliximab.</p> <p>Evaluate with tuberculosis skin test prior to starting therapy.</p> Monitor CBC and LFTs during therapy.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Antibiotics</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin</td> <td>Cipro</td> <td> <p><em>Induction of remission:</em></p> <p>Dose not established in children<sup>&#9674;</sup></p> <p><em>Treatment of infectious complications:</em></p> 20 to 30 mg/kg/day PO, divided in three doses (up to 500 mg/dose)<sup>[3]</sup></td> <td> <p><em>Induction of remission:</em></p> 250 to 500 mg PO, twice or three times daily<sup>&#9674;</sup></td> <td> <p>Induction of remission in perianal or mucosal disease.</p> Treatment of infectious complications (eg, abdominal or perianal abscess).</td> <td> <p>Hypersensitivity reactions.</p> <p>Risk of C. difficile colitis.</p> Tendon inflammation and rupture; arthropathy, photosensitivity.</td> <td>Moderate efficacy. Avoid in pregnancy.</td> </tr> <tr> <td class=\"indent1\">Metronidazole</td> <td>Flagyl</td> <td> <p><em>Induction of remission:</em></p> <p>Dose not established in children<sup>&#9674;</sup></p> <p><em>Treatment of infectious complications:</em></p> 20 to 30 mg/kg/day PO, divided in three doses (up to 500 mg/dose)<sup>[3,8]</sup></td> <td> <p><em>Induction of remission:</em></p> 250 to 500 mg PO, twice or three times daily<sup>&#9674;</sup></td> <td>Same as ciprofloxacin, postoperative recurrence.</td> <td>Nausea, disulfiram reaction (occurs with ingestion of alcohol), alteration of taste. Peripheral neuropathy often develops with chronic use.</td> <td> <p>May delay recurrence of mucosal disease after surgical resection.</p> Avoid in pregnancy.<sup>&#167;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BUN: blood urea nitrogen; CBC: complete blood count; LFTs: liver function tests (ie, alanine aminotransferase, ALT, and aspartate aminotransferase, AST); NG: nasogastric; NPO: nil per os (nothing by mouth); 6-MP: 6-mercaptopurine; PO: per os (by mouth); IM: intramuscular; SQ: subcutaneous route of administration.<br />* Outside of the United States, mesalamine is known as mesalazine.<br />Δ Some patients (especially younger children) may benefit from 6-MP doses above this range (eg, up to 2 mg/kg/day), if appropriately monitored for toxicity.<br /><FONT class=lozenge>◊</FONT> There is some evidence in adults that ciprofloxacin and/or metronidazole have modest efficacy to induce remission in Crohn's disease; typical doses used for this purpose are 10 to 20 mg/kg/day, divided in two or three doses, with courses ranging from two to six months.<SUP>[9]</SUP> The efficacy and doses of these antibiotics for induction of remission in children with Crohn's disease have not been established. (Refer to topic review on antibiotics for treatment of inflammatory bowel disease).<br />§&nbsp;We are reluctant to prescribe&nbsp;metronidazole during pregnancy because existing safety information is based on short duration of treatment.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Escher JC, European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004; 16:47.</li>&#xD;&#xA;    <li>Levine A, Broide E, Stein M, et al. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children. J Pediatr 2002; 140:75.</li>&#xD;&#xA;    <li>Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012; 55:93. </li>&#xD;&#xA;    <li>Levesque BG, Loftus EV. Initiating azathioprine for Crohn's disease. Clin Gastroenterol Hepatol 2012; 10:460.</li>&#xD;&#xA;    <li>Stevens MC, Baldassano RN, York A, et al. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2005; 40:445.</li>&#xD;&#xA;    <li>Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012; 143:365.</li>&#xD;&#xA;    <li>Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010; 31:1296.</li>&#xD;&#xA;    <li>Levine A, Turner D. Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease. J Crohns Colitis 2011; 5:222.</li>&#xD;&#xA;    <li>Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104:465.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 65046 Version 9.0</div></div></div>"},"65048":{"type":"graphic_table","displayName":"ACC AHA skills internal CV II","title":"Technical skills necessary to perform internal DC cardioversion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Technical skills necessary to perform internal DC cardioversion</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Competency in performing diagnostic cardiac electrophysiology studies</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ability to place electrode catheters in appropriate locations for intracardiac synchronization and DC cardioversion</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Familiarity with the catheter characteristics, synchronization, and DC cardioversion equipment</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Ability to confirm the timing and energy of the shock for safe shock delivery</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Adequate electrocardiographic and rhythm monitoring equipment</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ability to handle complications, including the use of temporary pacing and defibrillation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Proficiency in the appropriate use of sedation during procedures, including airway management</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">2.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=2030&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>ACC_AHA_skills_internal_C1.htm</title></head></div><div class=\"graphic_reference\">Data from Tracy CM, Akhtar M, DiMarco JP, et al. Circulation 2000; 102:2309.</div><div id=\"graphicVersion\">Graphic 65048 Version 2.0</div></div></div>"},"65049":{"type":"graphic_movie","displayName":"Midurethral transobturator sling","title":"Midurethral transobturator sling","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Midurethral transobturator sling</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/65049_Midurethtransobslingconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:454px; height:350px;\" src=\"images/OBGYN/65049_Midurethraltransobsling.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65049 Version 2.0</div></div></div>"},"65051":{"type":"graphic_figure","displayName":"10-point perceived exertion scale","title":"10-point scale of perceived exertion","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">10-point scale of perceived exertion</div><div class=\"cntnt\"><img style=\"width:485px; height:680px;\" src=\"images/PC/65051_Perceived_exertion_scale_edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Scale reproduced and illustrated with permission from: Borg G. Psychophysical bases of percived exertion. Med Sci Sports Exerc 1982; 14:377.</div><div id=\"graphicVersion\">Graphic 65051 Version 2.0</div></div></div>"},"65052":{"type":"graphic_table","displayName":"Cyanide poisoning - Rapid overview","title":"Cyanide poisoning: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cyanide poisoning: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">General information</td> </tr> <tr> <td class=\"indent1\">Cyanide poisoning is rapidly lethal unless treated with antidote</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_single\">History</td> </tr> <tr> <td class=\"indent1\">Ascertain if patient has access to cyanide, or if patient was part of a high-risk event (eg, fire, industrial exposure)</td> </tr> <tr> <td class=\"indent1\">Initial symptoms are nonspecific: headache, anxiety, confusion, abdominal pain</td> </tr> <tr> <td class=\"subtitle2_single\">Physical examination</td> </tr> <tr> <td class=\"indent1\">Vital signs: initial hypertension/tachycardia/tachypnea progresses to respiratory and circulatory collapse</td> </tr> <tr> <td class=\"indent1\">Skin: may be flushed with \"cherry red\" color</td> </tr> <tr> <td class=\"indent1\">Neurologic: seizures and coma as poisoning progresses</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory evaluation</td> </tr> <tr> <td class=\"subtitle2_single\">Obtain the following:</td> </tr> <tr> <td class=\"indent1\">Fingerstick glucose, acetaminophen and salicylate levels, electrocardiogram, and pregnancy test (when appropriate)</td> </tr> <tr> <td class=\"sublist2_start\">Basic chemistries and serum lactate</td> </tr> <tr> <td class=\"sublist2\">Elevated anion gap acidosis, with elevated lactate, expected in cyanide poisoning</td> </tr> <tr> <td class=\"sublist2\">Venous blood appears bright red</td> </tr> <tr> <td class=\"sublist2_start\">Central venous blood gas with concomitant arterial blood gas</td> </tr> <tr> <td class=\"sublist2\">Narrowed venous-arterial PO2 gradient supports cyanide toxicity</td> </tr> <tr> <td class=\"sublist2_start\">Carboxyhemoglobin and methemoglobin levels</td> </tr> <tr> <td class=\"sublist2\">Rule out dyshemoglobinemias</td> </tr> <tr> <td class=\"sublist2\">Use nitrites (see below) cautiously or not at all in presence of dyshemoglobinemias</td> </tr> <tr> <td class=\"indent1\">Cyanide poisoning can cause: renal failure, hepatic failure, rhabdomyolysis, pulmonary edema; obtain relevant studies as indicated</td> </tr> <tr> <td class=\"subtitle1_single\">General treatment</td> </tr> <tr> <td class=\"indent1\"><strong>Secure airway, breathing, and circulation.</strong> Intubation is usually required. Administer high-flow oxygen by nonrebreather face mask regardless of pulse oximetry reading.</td> </tr> <tr> <td class=\"indent1\"><strong>Do NOT perform mouth to mouth resuscitation</strong> in cases of suspected cyanide toxicity. Patients with dermal exposure must be decontaminated using proper precautions.</td> </tr> <tr> <td class=\"indent1\">Give a single dose of activated charcoal if the airway is adequately protected (50 g in adults; 1 g/kg in children with maximum dose of 50 g)</td> </tr> <tr> <td class=\"indent1\">Treat hypotension with rapid IV boluses of isotonic fluid and vasopressors as needed. Treat seizures with a benzodiazepine (eg, diazepam 5 mg IV).</td> </tr> <tr> <td class=\"indent1\">Obtain assistance from medical toxicologist or poison control center</td> </tr> <tr> <td class=\"subtitle1_single\">Antidotal treatment</td> </tr> <tr> <td class=\"sublist2_start\"><strong>Administer cyanide antidote</strong> when cyanide poisoning is clinically suspected. Hydroxocobalamin is the preferred antidote.</td> </tr> <tr> <td class=\"sublist3_start\">If hydroxocobalamin is available, give the following:</td> </tr> <tr> <td class=\"sublist3\">Hydroxocobalamin 70 mg/kg up to 5 g IV (5 g is standard adult dose)</td> </tr> <tr> <td class=\"sublist3\">Sodium thiosulfate (25 percent): 1.65 mL/kg up to 50 mL IV; may repeat once (maximum dose 12.5 g)</td> </tr> <tr> <td class=\"sublist3_start\">If hydroxocobalamin is not available, cyanide toxicity is known or strongly suspected, and there are no contraindications to nitrites, give the following:</td> </tr> <tr> <td class=\"sublist3\">Sodium nitrite 10 mg/kg - up to 300 mg - by&nbsp;slow IV infusion; may repeat once</td> </tr> <tr> <td class=\"sublist3\">Sodium thiosulfate (25 percent) 1.65 mL/kg up to 50 mL IV; may repeat once</td> </tr> <tr> <td class=\"sublist3_start\">If hydroxocobalamin is not available and cyanide toxicity is possible but not certain, or the patient has contraindications to nitrites, give the following:</td> </tr> <tr> <td class=\"sublist3\">Sodium thiosulfate (25 percent) 1.65 mL/kg up to 50 mL IV; may repeat once</td> </tr> <tr> <td class=\"indent1\">Refer to topic for details about nitrite treatment for children and patients with anemia, and for treatment in cases of unlikely cyanide poisoning</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65052 Version 12.0</div></div></div>"},"65053":{"type":"graphic_figure","displayName":"Octreotide adenoma size","title":"Effect of octreotide on adenoma size","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Effect of octreotide on adenoma size</div><div class=\"cntnt\"><img style=\"width:486px; height:291px;\" src=\"images/ENDO/65053_Octreotide_adenoma_size.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In 20 previously untreated acromegalic patients with macroadenomas, short-acting octreotide was administered for 24 weeks and then long-acting octreotide for another 24 weeks to 10 patients.</div><div class=\"graphic_reference\">Data from: Bevan, JS, Atkin, SL, Atkinson, AB, et al. J Clin Endocrinol Metab 2002; 87:4554.</div><div id=\"graphicVersion\">Graphic 65053 Version 1.0</div></div></div>"},"65054":{"type":"graphic_diagnosticimage","displayName":"T3 rectal cancer EUS","title":"Rectal cancer seen on endoscopic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rectal cancer seen on endoscopic ultrasound</div><div class=\"cntnt\"><img style=\"width:371px; height:275px;\" src=\"images/GAST/65054_T3_rectal_cancer_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound image of a T3 rectal cancer with extension of the tumor into the perirectal space (arrow).</div><div class=\"graphic_reference\">Courtesy of Gavin C Harewood, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 65054 Version 3.0</div></div></div>"},"65055":{"type":"graphic_table","displayName":"Anticoagulant coagulant herbs","title":"Anticoagulant and coagulant herbal ingredients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anticoagulant and coagulant herbal ingredients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Effect</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Anticoagulants</td> </tr> <tr> <td class=\"indent1\">Alfalfa</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Angelica</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Aniseed</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Arnica</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Asafoetida</td> <td>Coumarin constituents, anticoagulant in vivo</td> </tr> <tr> <td class=\"indent1\">Celery</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Chamomile, German</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Chamomile, Roman</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Clove</td> <td>Eugenol powerful inhibitor of platelet activity</td> </tr> <tr> <td class=\"indent1\">Fenugreek</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Feverfew</td> <td>Inhibits platelet aggregation</td> </tr> <tr> <td class=\"indent1\">Fucus</td> <td>Anticoagulant action</td> </tr> <tr> <td class=\"indent1\">Garlic</td> <td>Interaction with warfarin reported</td> </tr> <tr> <td class=\"indent1\">Ginger</td> <td>Inhibition of platelet activity</td> </tr> <tr> <td class=\"indent1\">Ginseng, Panax</td> <td>Reduction of blood coagulation</td> </tr> <tr> <td class=\"indent1\">Horse-chestnut</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Horseradish</td> <td>Peroxidase stimulates synthesis of arachidonic acid metabolites</td> </tr> <tr> <td class=\"indent1\">Liquorice</td> <td>Inhibition of platelet activity</td> </tr> <tr> <td class=\"indent1\">Meadowsweet</td> <td>Salicylate constituents</td> </tr> <tr> <td class=\"indent1\">Poplar</td> <td>Salicylate constituents</td> </tr> <tr> <td class=\"indent1\">Prickly ash, northern</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Prickly ash, southern</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Quassia</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Red clover</td> <td>Coumarin constituents</td> </tr> <tr> <td class=\"indent1\">Willow</td> <td>Salicylate constituents</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Coagulants</td> </tr> <tr> <td class=\"indent1\">Agrimony</td> <td>Coagulant, human</td> </tr> <tr> <td class=\"indent1\">Goldenseal</td> <td>Heparin antagonist</td> </tr> <tr> <td class=\"indent1\">Mistletoe</td> <td>Lectins, agglutinating activity</td> </tr> <tr> <td class=\"indent1\">Yarrow</td> <td>Coagulant, in vivo</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.282.</div><div id=\"graphicVersion\">Graphic 65055 Version 3.0</div></div></div>"},"65057":{"type":"graphic_figure","displayName":"Flow volume curve variations","title":"Flow-volume curve variations","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flow-volume curve variations</div><div class=\"cntnt\"><img style=\"width:324px; height:298px;\" src=\"images/PULM/65057_Flow_volume_curve_variation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow-volume curves from (A) a healthy person or from patients with (B) severe obstruction (emphysema), (C) severe restriction from interstitial disease (radiation fibrosis), (D) upper airways obstruction (tracheal stenosis), and (E) poor effort.</div><div id=\"graphicVersion\">Graphic 65057 Version 1.0</div></div></div>"},"65058":{"type":"graphic_table","displayName":"Acute hemarthrosis of the knee","title":"Causes of acute hemarthrosis of the knee","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acute hemarthrosis of the knee</div><div class=\"cntnt\"><table cellspacing=\"0\">\n  <tbody>\n    <tr>\n      <td class=\"subtitle1\">Injury</td>\n      <td class=\"subtitle1\">&nbsp;</td>\n    </tr>\n    <tr>\n      <td>Anterior cruciate ligament tear</td>\n      <td>70-72 percent</td>\n    </tr>\n    <tr>\n      <td>Patellar subluxation or dislocation</td>\n      <td>10-15 percent</td>\n    </tr>\n    <tr>\n      <td>Peripheral meniscal tear</td>\n      <td>10 percent</td>\n    </tr>\n    <tr>\n      <td>Osteochondral fracture</td>\n      <td>2-5 percent</td>\n    </tr>\n    <tr>\n      <td>Posterior cruciate tear, capsular tear, other</td>\n      <td>5 percent</td>\n    </tr>\n  </tbody>\n</table></div><div class=\"graphic_reference\">Modified with permission from Baker, C. Journal of MAG 1992; 81:301.</div><div id=\"graphicVersion\">Graphic 65058 Version 1.0</div></div></div>"},"65059":{"type":"graphic_diagnosticimage","displayName":"Pericardial effusion due to hypothyroidism","title":"Pericardial effusion due to hypothyroidism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericardial effusion due to hypothyroidism</div><div class=\"cntnt\"><img style=\"width:432px; height:356px;\" src=\"images/ENDO/65059_Pericard_eff_due_hypothyr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large pericardial effusion in a severely hypothyroid woman with no underlying heart disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Neha Malhotra.</div><div id=\"graphicVersion\">Graphic 65059 Version 3.0</div></div></div>"},"65060":{"type":"graphic_picture","displayName":"Systemic AL amyloidosis macroglossia","title":"Immunoglobulin light chain (AL) amyloidosis - macroglossia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunoglobulin light chain&nbsp;(AL) amyloidosis - macroglossia</div><div class=\"cntnt\"><img style=\"width:432px; height:351px;\" src=\"images/DERM/65060_Systemic_AL_amy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An enlarged tongue is present in this patient with systemic amyloidosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65060 Version 6.0</div></div></div>"},"65062":{"type":"graphic_table","displayName":"Causes of TEN","title":"Causes of toxic epidermal necrolysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of toxic epidermal necrolysis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td>Alka-Seltzer</td> </tr> <tr> <td>Allopurinol*</td> </tr> <tr> <td>Amiodarone</td> </tr> <tr> <td>Antibiotics, especially tetracyclines and penicillin*</td> </tr> <tr> <td>Anticonvulsants*</td> </tr> <tr> <td>Barbiturates*</td> </tr> <tr> <td>Brompheniramine</td> </tr> <tr> <td>Chlorpromazine</td> </tr> <tr> <td>Dapsone</td> </tr> <tr> <td>Ethambutol</td> </tr> <tr> <td>Fansidar</td> </tr> <tr> <td>Gold</td> </tr> <tr> <td>Griseofulvin</td> </tr> <tr> <td>Ipecac</td> </tr> <tr> <td>Isoniazid</td> </tr> <tr> <td>NSAIDs</td> </tr> <tr> <td>Pentamidine</td> </tr> <tr> <td>Phenolphthalein</td> </tr> <tr> <td>Quinine</td> </tr> <tr> <td>Streptomycin</td> </tr> <tr> <td>Sulfonamides*</td> </tr> <tr> <td>Tolbutamide</td> </tr> <tr> <td>Trimethoprim</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td>Aspergillosis (pulmonary)</td> </tr> <tr> <td><em>Escherichia coli</em> (septicemia)</td> </tr> <tr> <td>Herpes simplex virus</td> </tr> <tr> <td>Measles virus</td> </tr> <tr> <td>Varicella-zoster virus</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td>Graft-versus-host disease</td> </tr> <tr> <td>Idiopathic</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplasia</td> </tr> <tr> <td>Hodgkin's disease</td> </tr> <tr> <td>Leukemia</td> </tr> <tr> <td>Non-Hodgkin's lymphoma</td> </tr> <tr> <td class=\"subtitle1_single\">Vaccinations</td> </tr> <tr> <td>BCG</td> </tr> <tr> <td>Diphtheria toxoid</td> </tr> <tr> <td>Measles</td> </tr> <tr> <td>Poliomyelitis</td> </tr> <tr> <td>Tetanus antitoxin</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal anti-inflammatory drugs; BCG: Bacillus Calmette-Guérin.<br />* Most commonly associated with toxic epidermal necrolysis (TEN).</div><div class=\"graphic_reference\">Adapted with permission from Sanders CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore, 1995. With permission from Rohrer TE, Ahmed AR. Toxic epidermal necrolysis. Int J Dermatol 1991; 30:457.</div><div id=\"graphicVersion\">Graphic 65062 Version 5.0</div></div></div>"},"65065":{"type":"graphic_picture","displayName":"Aluminum in bone","title":"Micrograph showing aluminum deposition in bone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Micrograph showing aluminum deposition in bone</div><div class=\"cntnt\"><img style=\"width:378px; height:265px;\" src=\"images/NEPH/65065_Aluminum_in_bone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone biopsy with Villanueva and aurintricarboxylic acid stains. Deposited aluminum appears as a red band at the osteoid-bone interface.</div><div class=\"graphic_reference\">Courtesy of L Darryl Quarles, MD.</div><div id=\"graphicVersion\">Graphic 65065 Version 2.0</div></div></div>"},"65066":{"type":"graphic_diagnosticimage","displayName":"Gelatinous effusion MRI","title":"Magnetic resonance imaging of gelatinous effusion of knee explaining dry tap","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of gelatinous effusion of knee explaining dry tap</div><div class=\"cntnt\"><img style=\"width:611px; height:233px;\" src=\"images/RHEUM/65066_Gelatinous_effusion_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A series of axial T1 weighted images through the midportion of the patella from a patient with rheumatoid arthritis prior to and following the injection of intravenous gadolinium. Pre-injection image (left panel) demonstrates a large joint effusion (E). An image taken five minutes after the intravenous injection of gadolinium (middle panel) shows a rim of enhancing synovial fluid at the periphery of the joint, adjacent to the synovium (small arrows). A third image obtained 30 minutes later, after passive exercise and manual massage of the knee joint to diffuse the gadolinium, shows enhancement of most of the effusion (E), with the exception of a small area on the medial side of the joint (white arrow). This area presumably represents a semisolid or gelatinous area of the effusion. Placement of an arthrocentesis needle directly into this area could yield a dry tap in spite of the patient's obvious effusion.</div><div class=\"graphic_footnotes\">M: medial; L: lateral.</div><div class=\"graphic_reference\">Reproduced with permission from Roberts WN, Hayes CW, Breitbach SA, et al. Am J Med 1996; 100:461.</div><div id=\"graphicVersion\">Graphic 65066 Version 2.0</div></div></div>"},"65067":{"type":"graphic_figure","displayName":"Distribution of colon ischemia","title":"Distribution of colon ischemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distribution of colon ischemia</div><div class=\"cntnt\"><img style=\"width:448px; height:218px;\" src=\"images/GAST/65067_Distribution_colonic_ischem.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Other areas refer to combination of different regions.</div><div class=\"graphic_reference\">Data from: Reinus JF, Brandt LJ, Boley SJ. Ischemic diseases of the bowel.&nbsp;Gastroenterol Clin North Am 1990; 19:319.</div><div id=\"graphicVersion\">Graphic 65067 Version 5.0</div></div></div>"},"65068":{"type":"graphic_figure","displayName":"Regulation of acid secretion","title":"Regulation of acid secretion","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Regulation of acid secretion</div><div class=\"cntnt\"><img style=\"width:471px; height:530px;\" src=\"images/GAST/65068_Regulation_of_acid_secretio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Release of histamine by gastrin from enterochrommafin-like cells (ECL, in green) appears to be the major physiologic mechanism by which gastrin stimulates acid secretion, although parietal cells (in blue) also have gastrin receptors. In addition, the ECL cells integrate stimulatory messages from cholinergic nerves and inhibition by locally released somatostatin.</div><div class=\"graphic_reference\">Modified from: Soll AH, Berglindh T. Receptors regulating acid secretory function. In: Physiology of the Gastrointestinal Tract, volume 1, Johnson LR, Christensen MJ, Jackson ED, et al (Eds), Raven Press, New York 1994. p.11.</div><div id=\"graphicVersion\">Graphic 65068 Version 4.0</div></div></div>"},"65069":{"type":"graphic_diagnosticimage","displayName":"Mediastinal lymphoma Gallium","title":"Diffuse large B cell lymphoma as anterior mediastinal mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse large B cell lymphoma as anterior mediastinal mass</div><div class=\"cntnt\"><img style=\"width:358px; height:544px;\" src=\"images/HEME/65069_Mediastinal_lymphoma_Galliu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (upper panel) shows a large anterior mediastinal mass (arrow). A Gallium scan performed at 72 hours (lower panel) shows bilateral uptake of isotope within this large, multi-lobulated mass. Biopsy showed a histologic pattern consistent with diffuse large B-cell lymphoma.</div><div class=\"graphic_reference\">Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.</div><div id=\"graphicVersion\">Graphic 65069 Version 3.0</div></div></div>"},"65075":{"type":"graphic_picture","displayName":"Candida esophagitis CPC Endosc","title":"<EM>Candida </EM>esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Candida </EM>esophagitis</div><div class=\"cntnt\"><img style=\"width:252px; height:259px;\" src=\"images/GAST/65075_Candidal_esophagitis_CPC_En.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic evaluation of the esophagus revealed an erythematous mucosa covered with white plaque-like lesions through the esophagus.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 65075 Version 4.0</div></div></div>"},"65076":{"type":"graphic_table","displayName":"Prevention of infection with arterial catheters","title":"Prevention of infection with arterial catheters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevention of infection with arterial catheters</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Replacement and relocation of catheter</td> </tr> <tr> <td>Do not routinely replace peripheral arterial catheters.</td> </tr> <tr> <td>Perform inspection of site daily&nbsp;for signs of infection, distal ischemia, or embolization.</td> </tr> <tr> <td>Replace disposable or reusable transducers at 96-hours intervals. Replace other components of the system, including tubing, continuous flush device, and flush solutions at the time the transducer is changed.</td> </tr> <tr> <td class=\"subtitle1_single\">Replacement of catheter-site dressing</td> </tr> <tr> <td>Replace dressing when the catheter is removed or replaced, or when the dressing becomes damp, loosened, or soiled. Replace dressings more frequently in diaphoretic patients.</td> </tr> <tr> <td>There is no need to remove a gauze or opaque dressing if the patient has no clinical signs of infection.</td> </tr> <tr> <td class=\"subtitle1_single\">Replacement of administration sets</td> </tr> <tr> <td>Replace the intravenous tubing, continuous flush device at the time the transducer is replaced (ie, 96-hour intervals).</td> </tr> <tr> <td class=\"subtitle1_single\">Hang time for parenteral fluids</td> </tr> <tr> <td>Replace the flush solution at the time the transducer is replaced (ie, 96-hour intervals).</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65076 Version 4.0</div></div></div>"},"65077":{"type":"graphic_figure","displayName":"CT scan and dx analgesic nephro","title":"CT criteria for analgesic nephropathy","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">CT criteria for analgesic nephropathy</div><div class=\"cntnt\"><img style=\"width:552px; height:365px;\" src=\"images/NEPH/65077_CT_scan_dx_anal_nephro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagnostic criteria of analgesic nephropathy.<br />(A) Macroscopic aspect of an AN kidney from a patient with ESRD.<br />(B) Diagnostic criteria used.<br />(C) CT scans without contrast material of an individual with normal kidneys and patients with AN and with stage 3 CKD and ESRD.</div><div class=\"graphic_footnotes\">AN: analgesic nephropathy; ESRD: end-stage renal disease; CT: computed tomography; CKD: chronic kidney disease.</div><div class=\"graphic_reference\">Reproduced with permission from: De Broe ME, Elseviers MM. Over-the-counter analgesic use. J Am Soc Nephrol 2009; 20:2098. Copyright © 2009 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 65077 Version 4.0</div></div></div>"},"65079":{"type":"graphic_figure","displayName":"Exercise in HF","title":"Impaired hemodynamic response to exercise in HF","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Impaired hemodynamic response to exercise in HF</div><div class=\"cntnt\"><img style=\"width:495px; height:227px;\" src=\"images/CARD/65079_ExerciseinHF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peak V<SUB>O2</SUB> achieved with exercise in normal subjects and those with chronic heart failure (HF) in relation to peak leg blood flow and cardiac output (CO). These parameters were linearly related in both groups, an expected finding since peak V<SUB>O2</SUB> is determined in part by tissue perfusion. However, when compared&nbsp;with normals, patients with HF had lower levels of oxygen consumption, leg blood flow, and cardiac output.</div><div class=\"graphic_reference\">Data from: Sullivan MJ, Knight JD, Higginbotham MB, Cobb FR. Circulation 1989; 80:769.</div><div id=\"graphicVersion\">Graphic 65079 Version 3.0</div></div></div>"},"65080":{"type":"graphic_table","displayName":"Coagulation test Preterm NB","title":"Reference values for coagulation tests in healthy premature infants (30 to 36 weeks gestation) during first 6 months of life","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reference values for coagulation tests in healthy premature infants (30 to 36 weeks gestation) during first 6 months of life</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"5%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"5%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"5%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"5%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"5%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"5%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Tests</td> <td class=\"subtitle1\" colspan=\"2\">Day 1</td> <td class=\"subtitle1\" colspan=\"2\">Day 5</td> <td class=\"subtitle1\" colspan=\"2\">Day 30</td> <td class=\"subtitle1\" colspan=\"2\">Day 90</td> <td class=\"subtitle1\" colspan=\"2\">Day 180</td> <td class=\"subtitle1\" colspan=\"2\">Adult</td> </tr> <tr> <td class=\"subtitle2\">M</td> <td class=\"subtitle2\">B</td> <td class=\"subtitle2\">M</td> <td class=\"subtitle2\">B</td> <td class=\"subtitle2\">M</td> <td class=\"subtitle2\">B</td> <td class=\"subtitle2\">M</td> <td class=\"subtitle2\">B</td> <td class=\"subtitle2\">M</td> <td class=\"subtitle2\">B</td> <td class=\"subtitle2\">M</td> <td class=\"subtitle2\">B</td> </tr> <tr> <td>PT (s)</td> <td>13</td> <td>(10.6-16.2)*</td> <td>12.5</td> <td>(10-15.3)*<sup>&#182;</sup></td> <td>11.8</td> <td>(10-13.6)*</td> <td>12.3</td> <td>(10-14.6)*</td> <td>12.5</td> <td>(10-15)*</td> <td>12.4</td> <td>(10.8-13.9)</td> </tr> <tr> <td>APTT (s)</td> <td>53.6</td> <td>(27.5-79.4)<sup>&#916;</sup></td> <td>50.5</td> <td>(26.9-74.1)<sup>&#916;</sup></td> <td>44.7</td> <td>(26.9-62.5)</td> <td>39.5</td> <td>(28.3-50.7)</td> <td>37.5</td> <td>(21.7-53.3)*</td> <td>33.5</td> <td>(26.6-40.3)</td> </tr> <tr> <td>TCT (s)</td> <td>24.8</td> <td>(19.2-30.4)*</td> <td>24.1</td> <td>(18.8-29.4)*</td> <td>24.4</td> <td>(18.8-29.9)*</td> <td>25.1</td> <td>(19.4-30.8)*</td> <td>25.2</td> <td>(18.9-31.5)*</td> <td>25</td> <td>(19.7-30.3)</td> </tr> <tr> <td>Fibrinogen (g/L)</td> <td>2.43</td> <td>(1.5-3.73)*<sup>&#182;</sup><sup>&#916;</sup></td> <td>2.80</td> <td>(1.6-4.18)*<sup>&#182;</sup><sup>&#916;</sup></td> <td>2.54</td> <td>(1.5-4.14)*<sup>&#182;</sup></td> <td>2.46</td> <td>(1.5-3.52)*<sup>&#182;</sup></td> <td>2.28</td> <td>(1.5-3.6)<sup>&#182;</sup></td> <td>2.78</td> <td>(1.56-4)</td> </tr> <tr> <td>II (u/mL)</td> <td>0.45</td> <td>(0.2-0.77)<sup>&#182;</sup></td> <td>0.57</td> <td>(0.29-0.85)&#916;</td> <td>0.57</td> <td>(0.36-0.95)<sup>&#182;</sup><sup>&#916;</sup></td> <td>0.68</td> <td>(0.3-1.06)</td> <td>0.87</td> <td>(0.51-1.23)</td> <td>1.08</td> <td>(0.7-1.46)</td> </tr> <tr> <td>V (U/mL)</td> <td>0.88</td> <td>(0.41-1.44)*<sup>&#182;</sup><sup>&#916;</sup></td> <td>1</td> <td>(0.46-1.54)</td> <td>1.02</td> <td>(0.48-1.56)</td> <td>0.99</td> <td>(0.59-1.39)</td> <td>1.02</td> <td>(0.58-1.46)</td> <td>1.06</td> <td>(0.62-1.5)</td> </tr> <tr> <td>VII (U/mL)</td> <td>0.67</td> <td>(0.21-1.13)</td> <td>0.84</td> <td>(0.3-1.38)</td> <td>0.83</td> <td>(0.21-1.45)</td> <td>0.87</td> <td>(0.31-1.43)</td> <td>0.99</td> <td>(0.47-1.51)*</td> <td>1.05</td> <td>(0.67-1.43)</td> </tr> <tr> <td>VIII (U/mL)</td> <td>1.11</td> <td>(0.5-2.13)*<sup>&#182;</sup></td> <td>1.15</td> <td>(0.53-2.05)*<sup>&#182;</sup><sup>&#916;</sup></td> <td>1.11</td> <td>(O.50-l.99)*<sup>&#182;</sup><sup>&#916;</sup></td> <td>1.06</td> <td>(0.58-1.88)*<sup>&#182;</sup><sup>&#916;</sup></td> <td>0.99</td> <td>(0.5-1.87)*<sup>&#182;</sup><sup>&#916;</sup></td> <td>0.99</td> <td>(0.5-1.49)</td> </tr> <tr> <td>vWF (U/mL)</td> <td>1.36</td> <td>(0.78-2.1)<sup>&#182;</sup></td> <td>1.33</td> <td>(0.72-2.19)<sup>&#182;</sup></td> <td>1.36</td> <td>(0.66-2.16)<sup>&#182;</sup></td> <td>1.12</td> <td>(0.75-l.84)*</td> <td>0.98</td> <td>(0.54-1.58)*<sup>&#182;</sup></td> <td>0.92</td> <td>(0.5-1.58)</td> </tr> <tr> <td>IX (U/mL)</td> <td>0.35</td> <td>(0.19-0.65)<sup>&#182;</sup><sup>&#916;</sup></td> <td>0.42</td> <td>(0.14-0.74)<sup>&#182;</sup><sup>&#916;</sup></td> <td>0.44</td> <td>(0.13-0.80)<sup>&#182;</sup></td> <td>0.59</td> <td>(0.25-0.93)</td> <td>0.81</td> <td>(0.5-1.2)<sup>&#182;</sup></td> <td>1.09</td> <td>(0.55-1.63)</td> </tr> <tr> <td>X (U/mL)</td> <td>0.41</td> <td>(0.11-0.71)</td> <td>0.51</td> <td>(0.19-0.83)</td> <td>0.56</td> <td>(0.2-0.92)</td> <td>0.67</td> <td>(0.35-0.99)</td> <td>0.77</td> <td>(0.35-1.19)</td> <td>1.06</td> <td>(0.7-1.52)</td> </tr> <tr> <td>XI (U/mL)</td> <td>0.3</td> <td>(0.08-0.52)<sup>&#182;</sup><sup>&#916;</sup></td> <td>0.41</td> <td>(0.13-0.69)<sup>&#916;</sup></td> <td>0.43</td> <td>(0.15-0.71)<sup>&#916;</sup></td> <td>0.59</td> <td>(0.25-0.93)<sup>&#916;</sup></td> <td>0.78</td> <td>(0.46-1.1)</td> <td>0.97</td> <td>(0.67-1.27)</td> </tr> <tr> <td>XII (U/mL)</td> <td>0.38</td> <td>(0.1-0.66)<sup>&#916;</sup></td> <td>0.39</td> <td>(0.09-0.69)<sup>&#916;</sup></td> <td>0.43</td> <td>(0.11-0.75)</td> <td>0.61</td> <td>(0.15-1.07)</td> <td>0.82</td> <td>(0.22-1.42)</td> <td>1.08</td> <td>(0.52-1.64)</td> </tr> <tr> <td>PK (U/mL)</td> <td>0.33</td> <td>(0.09-0.57)</td> <td>0.45</td> <td>(0.26-0.75)<sup>&#182;</sup></td> <td>0.59</td> <td>(0.31-0.87)</td> <td>0.79</td> <td>(0.37-1.21)</td> <td>0.78</td> <td>(0.4-1.16)</td> <td>1.12</td> <td>(0.62-1.62)</td> </tr> <tr> <td>HMWK (U/mL)</td> <td>0.49</td> <td>(0.09-0.89)</td> <td>0.62</td> <td>(0.24-1)<sup>&#916;</sup></td> <td>0.64</td> <td>(0.16-1.12)<sup>&#916;</sup></td> <td>0.78</td> <td>(0.32-1.24)</td> <td>0.83</td> <td>(0.41-1.25)*</td> <td>0.92</td> <td>(0.5-1.36)</td> </tr> <tr> <td>XIIIa (U/mL)</td> <td>0.7</td> <td>(0.32-1.08)</td> <td>1.01</td> <td>(0.57-1.45)*</td> <td>0.99</td> <td>(0.51-1.47)*</td> <td>1.13</td> <td>(0.71-1.55)*</td> <td>1.13</td> <td>(0.65-1.61)*</td> <td>1.05</td> <td>(0.55-1.55)</td> </tr> <tr> <td>XIIIb (U/mL)</td> <td>0.81</td> <td>(0.35-1.27)</td> <td>1.1</td> <td>(0.68-1.58)*</td> <td>1.07</td> <td>(0.57-1.57)*</td> <td>1.21</td> <td>(0.75-1.67)</td> <td>1.15</td> <td>(0.67-1.63)</td> <td>0.97</td> <td>(0.57-1.37)</td> </tr> <tr> <td>Plasminogen (CTA, U/mL)</td> <td>1.7</td> <td>(1.12-2.48)<sup>&#182;</sup><sup>&#916;</sup></td> <td>1.91</td> <td>(1.21-2.61)<sup>&#916;</sup></td> <td>1.81</td> <td>(1.09-2.53)</td> <td>2.38</td> <td>(1.58-3.18)</td> <td>2.75</td> <td>(1.91-3.59)<sup>&#916;</sup></td> <td>3.36</td> <td>(2.48-4.24)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All factors except fibrinogen and plasminogen are expressed as U/mL, where pooled plasma contains 1.0 U/mL. Plasminogen units are those recommended by the Committee on Thrombolytic Agents (CTA). All values are given as a mean (m) followed by lower and upper boundary encompassing 95 percent of the population (B). Between 40 and 96 samples were assayed for each value for newborns.</div><div class=\"graphic_footnotes\">PT: prothrombin time; APTT: activated partial thromboplastin time; TCT: thrombin clotting time; vWF: von Willebrand factor; PK: prekallikrein; HMWK: high molecular weight kininogen.<br />* Values indistinguishable from those of adults.<br />¶ Measurements are skewed owing to a disproportionate number of high values. Lower limit which excludes the lower 2.5 percent of the population is given (B).<br />Δ Values different from those of full term infants.</div><div class=\"graphic_reference\">Reprinted from: Andrew M, Paes B, Milner R, et al. Development of the Human Coagulation System in the Healthy Premature Infant. Blood 1988; 72:1651. Copyright &copy;1988 The American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 65080 Version 4.0</div></div></div>"},"65081":{"type":"graphic_table","displayName":"ACCESS criteria sarcoid A","title":"ACCESS study criteria for organ involvement in patients with biopsy-confirmed sarcoidosis-I","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACCESS study criteria for organ involvement in patients with biopsy-confirmed sarcoidosis-I</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"subtitle1\">Organ</td>\n\n\t\t\t<td class=\"subtitle1\">Definite</td>\n\n\t\t\t<td class=\"subtitle1\">Probable</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td rowspan=\"5\">Lungs</td>\n\n\t\t\t<td class=\"sublist1_start\">1. Chest roentgenogram with one or more of the following:</td>\n\t\t\t<td>1. Lymphocytic alveolitis by bronchoalveolar lavage (BAL)</td></tr>\n\t\t\t\n\t\t\t<tr>\n\n\t\t\t\t<td class=\"sublist1\">Bilateral hilar adenopathy</td>\n\t\t\t\t\t<td>2. Any pulmonary infiltrates</td></tr>\n\t\t\t\t\t\n\t\t\t\t\t<tr>\n\n\t\t\t\t<td class=\"sublist1\">Diffuse infiltrates</td>\n\t\t\t\t\t<td rowspan=\"3\">3. Isolated reduced diffusing capacity for carbon monoxide</td></tr>\n\t\t\t\t\t<tr>\n\n\t\t\t\t<td class=\"sublist1\">Upper lobe fibrosis</td></tr>\n\t\t\t\t\n\t\t\t\t<tr>\n\n\t\t\t\t<td>2. Restriction on pulmonary function tests</td></tr>\n\t\t\n\n\t\t<tr>\n\t\t\t<td rowspan=\"3\">Skin</td>\n\n\t\t\t<td>1. Lupus pernio</td>\n\t\t\t<td>1. Macular/papular</td></tr>\n\t\t\t\n\t\t\t<tr>\n\t\t\t\t<td>2. Annular lesion</td>\n\t\t\t\t\t<td rowspan=\"2\">2. New nodules</td></tr>\n\n\t\t\t<tr>\t<td>3. Erythema nodosum\t</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td rowspan=\"3\">Eyes</td>\n\n\t\t\t<td>1. Lacrimal gland swelling</td>\n\t\t\t<td rowspan=\"3\">1. Blindness</td></tr>\n\t\t\t\n\t\t\t<tr>\n\t\t\t\t<td>2. Uveitis</td></tr>\n\n\t\t\t\t<tr><td>3. Optic neuritis</td>\n\n\t\t\t\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td rowspan=\"6\">Neurologic</td>\n\n\t\t\t<td>1. Positive magnetic resonanceimaging (MRI) with uptake in meninges or brainstem</td>\n\t\t\t<td>1. Other abnormalities on magnetic resonance imaging (MRI)</td></tr>\n\t\t\t\n\t\t\t\n<tr>\n\t\t\t\t<td>2. Cerebrospinal fluid with increased lymphocytes and/or protein</td>\n\t\t\t\t\t<td>2. Unexplained neuropathy</td></tr>\n<tr>\n\t\t\t\t<td>3. Diabetes insipidus</td>\n\t\t\t\t\t<td rowspan=\"4\">3. Positive electromyogram</td></tr>\n<tr>\n\t\t\t\t<td>4. Bell's palsy</td></tr>\n<tr>\n\t\t\t\t<td>5. Cranial nerve dysfunction</td></tr>\n<tr>\n\t\t\t\t<td>6. Peripheral nerve biopsy</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td rowspan=\"2\">\n\t\t\t\t<p>Hypercalcemia</p>\n\n\t\t\t\t<p>Hypercalciuria</p>\n\n\t\t\t\t<p>Nephrolithiasis</p>\n\t\t\t</td>\n\n\t\t\t<td rowspan=\"2\">1. Increased serum calcium with no other cause</td>\n\n\t\t\t<td>1. Increased urine calcium</td></tr>\n<tr>\t\t\t\t<td>2. Nephrolithiasis analysis showing calcium</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td rowspan=\"4\">Cardiac</td>\n\n\t\t\t<td>1. Treatment responsive cardiomyopathy</td>\n\t\t\t<td class=\"sublist1_start\">1. No other cardiac problem and either:</td></tr>\n<tr>\n\t\t\t\t<td rowspan=\"2\">2. Electrocardiogram showing intraventricular conduction defect or nodal block</td>\n\t\t\t\t<td class=\"sublist1\">Ventricular arrhythmias</td></tr>\n\t\t\t\t<tr><td class=\"sublist1\">Cardiomyopathy</td></tr>\n<tr>\n\t\t\t\t<td rowspan=\"2\">3. Positive gallium scan of heart</td>\t\t\n\t<td>2. Positive thallium scan</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Judson, MA, RP Baughman, AS. Teirstein, ML Terrin, and H Yeager, Jr. 1999. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 16:75-86. Copyright &#169; 1999 Sarcoidosis, Vasculitis, and Diffuse Lung Diseases.</div><div id=\"graphicVersion\">Graphic 65081 Version 1.0</div></div></div>"},"65082":{"type":"graphic_diagnosticimage","displayName":"FDG scan II","title":"Positron emission tomography scan of peripheral lung cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Positron emission tomography&nbsp;scan of peripheral lung cancer</div><div class=\"cntnt\"><img style=\"width:368px; height:266px;\" src=\"images/PULM/65082_FDG_scan_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral bronchogenic carcinoma in left upper lobe.&nbsp;This 18-fluoro-2-deoxyglucose positron emission tomography (FDG PET) scan shows a small peripheral left upper lobe nodule in cross-sectional display.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 65082 Version 3.0</div></div></div>"},"65085":{"type":"graphic_algorithm","displayName":"Steroid dependent UC","title":"Steroid-dependent ulcerative colitis","html":"<div class=\"graphic\"><div style=\"width: 698px\" class=\"figure\"><div class=\"ttl\">Steroid-dependent ulcerative colitis</div><div class=\"cntnt\"><img style=\"width:678px; height:605px;\" src=\"images/GAST/65085_Steroid_dependent_UC.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">6-MP: 6-mercaptopurine; AZA: azathioprine; anti-TNF: anti-tumor necrosis factor agents.<br />* Infliximab, adalimumab, golimumab, or other approved anti-TNF therapy.<br /><FONT class=bullet>•</FONT> Anti-TNF agent or vedolizumab.</div><div id=\"graphicVersion\">Graphic 65085 Version 3.0</div></div></div>"},"65087":{"type":"graphic_diagnosticimage","displayName":"Chondro low radiographs","title":"Radiological presentation of a conventional lowgrade chondrosarcoma","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Radiological presentation of a conventional lowgrade chondrosarcoma</div><div class=\"cntnt\"><img style=\"width:485px; height:516px;\" src=\"images/ONC/65087_Chondro_low_radiographs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Conventional low-grade chondrosarcoma in the proximal humerus with chondroid mineralization on conventional radiograph.<br />(B) Discrete endosteal scalloping of the anterior cortex is seen on the T1-weighted magnetic resonance image.<br />(C) Axial T1-weighted magnetic resonance image with fat suppression after IV contrast injection demonstrates the typical peripheral ring-and-arc pattern of enhancement. No soft tissue extension is noted.</div><div class=\"graphic_footnotes\">IV: intravenous.</div><div class=\"graphic_reference\">Reproduced with permission from: Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist 2008; 13:320. Copyright &copy;2008 AlphaMed Press.</div><div class=\"contractual\"><br/><a href=\"http://www.theoncologist.com/\">http://www.TheOncologist.com</a></div><div id=\"graphicVersion\">Graphic 65087 Version 4.0</div></div></div>"},"65088":{"type":"graphic_diagnosticimage","displayName":"Mammo benign calcification","title":"Mammographic calcifications","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mammographic calcifications</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ONC/65088_Mammo_benign_calcification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oblique mammogram demonstrates a classic benign, partially calcified fibroadenoma with typical coarse, popcorn-like calcifications. These findings are not suspicious and do not require biopsy.</div><div class=\"graphic_reference\">Courtesy of Lisa Esserman, MD.</div><div id=\"graphicVersion\">Graphic 65088 Version 2.0</div></div></div>"},"65089":{"type":"graphic_picture","displayName":"Squamous cell ca","title":"Squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:516px; height:201px;\" src=\"images/ONC/65089_Squamous_cell_ca.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A: Well-differentiated invasive squamous cell carcinoma. Islands of cells demonstrating keratinization, prominent cell border, and nuclear pleomorphism are present. B: Squamous cell carcinoma with focal keratinization.</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 65089 Version 1.0</div></div></div>"},"65090":{"type":"graphic_figure","displayName":"Hormones in THCD","title":"Serum hormone concentrations in patients with MCT8 defects","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Serum hormone concentrations in patients with MCT8 defects</div><div class=\"cntnt\"><img style=\"width:547px; height:341px;\" src=\"images/PEDS/65090_Hormones_in_THCD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thyroid function tests from seven families studied at the University of Chicago: 11 affected males (M: red squares), 15 carrier females (F: green circles), and 15 unaffected family members (N: blue triangles). (* P &lt;0.05; ** P &lt;0.01; *** P &lt;0.001). Shaded areas represent the normal range for each test. Bars are 2 SDs.</div><div id=\"graphicVersion\">Graphic 65090 Version 1.0</div></div></div>"},"65091":{"type":"graphic_table","displayName":"Neutropenic children infections","title":"Risk and types of infections in pediatric hematology patients with neutropenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk and types of infections in pediatric hematology patients with neutropenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Predominant causes of fever</td> <td class=\"subtitle1\">Initial management</td> </tr> <tr> <td>Low risk</td> <td>Otherwise healthy child with transient, isolated neutropenia</td> <td>Viral infection</td> <td>Appropriate treatment for age or site of localized infection; careful follow-up</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Low-moderate risk</td> <td rowspan=\"2\"> <p>Chronic benign neutropenia</p> <p>(chronic autoimmune and idiopathic neutropenia)</p> </td> <td>Common &mdash; Upper respiratory tract infections, acute otitis media, skin infections, gingivitis, mouth ulcers, labial cellulitis or abscess in girls</td> <td>Oral antibiotics and close outpatient management for patients with adequate marrow reserves</td> </tr> <tr> <td>Less common &mdash; Pneumonia, periorbital cellulitis, meningitis, sepsis</td> <td>Hospitalization and parenteral antibiotics for complicated febrile illnesses (eg, hemodynamic instability, skin or soft-tissue infection, pneumonia, concern for catheter-related infection); hospitalization also may be warranted in patients with prior complicated febrile illness</td> </tr> <tr> <td rowspan=\"3\">Cyclic neutropenia</td> <td>Frequent &mdash; Oral ulcers, gingivitis, periodontitis, pharyngitis, adenopathy</td> <td>Generally do not require antibiotics for fevers or mucocutaneous inflammatory lesions that are typical during neutrophil nadirs</td> </tr> <tr> <td>Less frequent &mdash; Bacteremia, cellulitis, acute otitis media, sinusitis, pneumonia, appendicitis</td> <td>Careful assessment of the need for hospitalization as well as administration of antibiotics for atypical fevers or lesions, or infections such as acute otitis media, sinusitis, and lower respiratory tract disease; hospitalization also may be warranted in patients with prior complicated febrile illness</td> </tr> <tr> <td>Uncommon &mdash; <em>Clostridium</em>-associated necrotizing enterocolitis</td> <td>Hospitalization and broad-spectrum parenteral antibiotics for complaints of abdominal pain, significant localized infection, or signs of sepsis</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">High risk</td> <td>Severe congenital neutropenia (Kostmann syndrome)</td> <td>Omphalitis, cellulitis, perirectal abscess, sepsis</td> <td>Hospitalization and initiation of broad-spectrum antibiotics</td> </tr> <tr> <td>Aplastic anemia</td> <td>Respiratory tract infections, soft tissue infections, bacteremia, invasive fungal disease, especially due to <em>Aspergillus</em> spp.</td> <td>Hospitalization and initiation of broad-spectrum antibiotics; antifungal agents may be warranted</td> </tr> <tr> <td>Ill-appearing child with neutropenia</td> <td>&nbsp;</td> <td>Hospitalization and initiation of broad-spectrum antibiotics</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65091 Version 11.0</div></div></div>"},"65092":{"type":"graphic_figure","displayName":"Gene fusion","title":"Gene fusion","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Gene fusion</div><div class=\"cntnt\"><img style=\"width:598px; height:260px;\" src=\"images/PC/65092_Gene_fusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Translocation between chromosomal regions <EM>ABL</EM> (on chromosome 9) and <EM>BCR</EM> (on chromosome 22), resulting in creation of fusion protein. Chromosomal translocation depicted on left. On right, illustration of exon-intron gene structure of <EM>ABL</EM> and <EM>BCR</EM>, and of fusion protein.</div><div class=\"graphic_reference\">Modified from: Dr. A Obeidat. Available at http://commons.wikimedia.org/wiki/File:Bcr-abl_fusion_gene.jpg.</div><div id=\"graphicVersion\">Graphic 65092 Version 2.0</div></div></div>"},"65094":{"type":"graphic_picture","displayName":"Nonendem Burkitt NHL Light","title":"Nonendemic (sporadic) Burkitt lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nonendemic (sporadic) Burkitt lymphoma</div><div class=\"cntnt\"><img style=\"width:440px; height:288px;\" src=\"images/GAST/65094_Nonendem_Burkitts_NHL_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of nonendemic Burkitt non-Hodgkin's lymphoma shows sheets of small, undifferentiated cells with interspersed tingible-body macrophages (starry-sky pattern) (arrows, 400x).</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy, III, MD.</div><div id=\"graphicVersion\">Graphic 65094 Version 3.0</div></div></div>"},"65095":{"type":"graphic_figure","displayName":"Serial WBC after radiation","title":"Leukocyte counts in Chernobyl accident victims","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Leukocyte counts in Chernobyl accident victims</div><div class=\"cntnt\"><img style=\"width:530px; height:329px;\" src=\"images/HEME/65095_Serial_WBC_after_radiation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graph shows serial changes in the total white blood cell count (WBC, vertical axis) as a function of the time following radiation exposure (days, weeks; horizontal axis) for victims of the Chernobyl reactor accident. The data are separated into five groups, with exposures ranging from 1.0 to &gt;5 Gy. Because of the profound radiation-induced lymphocytopenia at these doses, the total WBC counts shown here are almost entirely composed of neutrophils. Note that the time of the initial WBC nadir at 7 to 9 days post-exposure (shown in orange) is similar in all five exposure groups. This is followed by a transient (&quot;abortive&quot;) rise, shown by the (*) symbol, in those groups receiving a dose of 5 Gy (500 rads) or less. A period of profound leukopenia/neutropenia follows this abortive rise, which may be delayed for up to 5 weeks in those with lower exposures (eg, 2 Gy). At the higher exposures (eg, &#8805;5 Gy), profound neutropenia may last for several weeks before recovery ensues.</div><div class=\"graphic_reference\">Reproduced with permission from: Vorobiev, AI. Acute radiation disease and biological dosimetry in 1993. Stem Cells 1997; 15:269. Copyright &#169; 1997 AlphaMed Press.</div><div class=\"contractual\"><br/><a href=\"http://www.stemcells.com/\">http://www.StemCells.com</a></div><div id=\"graphicVersion\">Graphic 65095 Version 1.0</div></div></div>"},"65099":{"type":"graphic_figure","displayName":"Methacholine test in pregnancy","title":"Improvement in bronchial responsiveness during pregnancy","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Improvement in bronchial responsiveness during pregnancy</div><div class=\"cntnt\"><img style=\"width:475px; height:212px;\" src=\"images/PULM/65099_Methacholine_test_in_pregna.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchial responsiveness, as measured by the dose of methacholine required to produce a 20 percent fall in FEV1 (PC20) before, during, and after pregnancy in 16 women with asthma. The PC20 increased 1.5 to 2-fold during pregnancy, indicating improved bronchial responsiveness.</div><div class=\"graphic_reference\">Data from Juniper, EF, Daniel, EE, Roberts, RS, et al. Am Rev Respir Dis 1989; 140:924.</div><div id=\"graphicVersion\">Graphic 65099 Version 1.0</div></div></div>"},"65101":{"type":"graphic_form","displayName":"CUDOS","title":"CUDOS","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">CUDOS</div><div class=\"cntnt\"><img style=\"width:500px; height:759px;\" src=\"images/PSYCH/65101_CUDOS.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Mark Zimmerman, MD. For more information please visit <a href=\"http://www.outcometracker.org/\">www.outcometracker.org</a>. Copyright © 2010. All rights reserved.</div><div id=\"graphicVersion\">Graphic 65101 Version 6.0</div></div></div>"},"65102":{"type":"graphic_table","displayName":"Postoperative bile leak results","title":"Endoscopic management of postoperative bile leak - results of therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endoscopic management of postoperative bile leak - results of therapy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Author</td>\n\n      <td class=\"subtitle1\">N</td>\n\n      <td class=\"subtitle1\">SP, percent</td>\n\n      <td class=\"subtitle1\">SP+ST, percent</td>\n\n      <td class=\"subtitle1\">ST only, percent</td>\n\n      <td class=\"subtitle1\">ERCP complic., percent</td>\n\n      <td class=\"subtitle1\">Perc drain, percent</td>\n\n      <td class=\"subtitle1\">Surgery, percent</td>\n\n      <td class=\"subtitle1\">Death, percent</td>\n\n      <td class=\"subtitle1\">Endo success</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Liguory '91</td>\n\n      <td>52</td>\n\n      <td>71</td>\n\n      <td>15</td>\n\n      <td>0</td>\n\n      <td>8</td>\n\n      <td>n/r</td>\n\n      <td>10</td>\n\n      <td>0</td>\n\n      <td>77</td>\n\n    </tr>\n\n    <tr>\n      <td>Davids '92</td>\n      <td>55</td>\n      <td>42</td>\n      <td>58</td>\n      <td>0</td>\n      <td>2</td>\n      <td>n/r</td>\n      <td>n/r</td>\n      <td>10*</td>\n      <td>90</td>\n    </tr>\n    <tr>\n      <td>Bourke '95</td>\n      <td>85 </td>\n      <td>33</td>\n      <td>67</td>\n      <td>0</td>\n      <td>1</td>\n      <td>29</td>\n      <td>4</td>\n      <td>0</td>\n      <td>95</td>\n    </tr>\n    <tr>\n      <td>Barkun '97</td>\n      <td>52</td>\n      <td>48</td>\n      <td>23</td>\n      <td>15</td>\n      <td>6</td>\n      <td>53</td>\n      <td>10</td>\n      <td>0</td>\n      <td>88</td>\n    </tr>\n    <tr>\n      <td>Ryan '98</td>\n      <td>50</td>\n      <td>12</td>\n      <td>26</td>\n      <td>62</td>\n      <td>4</td>\n      <td>26</td>\n      <td>6</td>\n      <td>0</td>\n      <td>100</td>\n    </tr>\n    <tr>\n      <td>Hourigan '99</td>\n      <td>53</td>\n      <td>15</td>\n      <td>15</td>\n      <td>70</td>\n      <td>6</td>\n      <td>30</td>\n      <td>4</td>\n      <td>0</td>\n      <td>96</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">SP: sphincterotomy; ST: stent or nasobiliary drain insertion.<br> *: Death due to sepsis</div><div id=\"graphicVersion\">Graphic 65102 Version 1.0</div></div></div>"},"65104":{"type":"graphic_figure","displayName":"Melanoma pathology worksheet","title":"Massachusetts General Hospital malignant melanoma worksheet","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Massachusetts General Hospital malignant melanoma worksheet</div><div class=\"cntnt\"><img style=\"width:551px; height:701px;\" src=\"images/ONC/65104_Melanoma_pathology_workshee.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Liu ,V, Mihm, MC. Pathology of malignant melanoma. Surg Clin North Am 2003; 83:31. Copyright &#169; 2003 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 65104 Version 2.0</div></div></div>"},"65105":{"type":"graphic_figure","displayName":"Subdivisions pharynx","title":"Subdivisions of the pharynx","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Subdivisions of the pharynx</div><div class=\"cntnt\"><img style=\"width:600px; height:600px;\" src=\"images/ONC/65105_Subdivisions_pharynx.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\"><strong>A)</strong> Nasopharynx.<br> <strong>B)</strong> Oropharynx.<br> <strong>C)</strong> Laryngopharynx (hypopharynx and larynx).</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. General Anatomy. Copyright &#169;2008 Anatomical Chart Company.</div><div id=\"graphicVersion\">Graphic 65105 Version 1.0</div></div></div>"},"65106":{"type":"graphic_table","displayName":"Postexposure rabies PI","title":"Rabies postexposure guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rabies postexposure guidelines</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1\">\n   Type of animal\n   </td>\n   <td   class=\"subtitle1\">\n   Observation or testing of animal\n   </td>\n   <td   class=\"subtitle1\">\n   Postexposure prophylaxis recommendations\n   </td>\n   </tr>\n   <tr>\n   <td   colspan=\"1\" rowspan=\"3\">\n   Dogs, cats, and ferrets\n   </td>\n   <td>Rabid or suspicion of rabies</td>\n   <td   colspan=\"1\">\n   Immediately begin prophylaxis\n   </td>\n   </tr>\n   <tr>\n   <td   colspan=\"1\" rowspan=\"1\">\n   Healthy and available for 10 days' observation\n   </td>\n   <td   colspan=\"1\">\n   \t<p>Do not begin prophylaxis unless:</p>\n\t<p>Bite or non-bite exposure is to the head and neck OR</p>\n\t<p>Animal develops signs of rabies</p>\n   </td>\n   </tr>\n   <tr>\n   <td>Unavailable for observation or testing</td>\n   <td   colspan=\"1\">\n   Consult public health officials; consider immediate vaccination\n   </td>\n   </tr>\n   <tr>\n   <td>Raccoons, foxes, skunks, coyotes and other carnivores; bats</td>\n   <td>Consider rabid unless available for testing and proven not to be infected</td>\n   <td   colspan=\"1\">\n   Consider immediate vaccination\n   </td>\n   </tr>\n   <tr>\n   <td>Large rodents, small rodents, livestock, lagomorphs and other mammals</td>\n   <td>Consider on an individual basis</td>\n   <td   colspan=\"1\">\n   Consult public health officials\n   </td>\n   </tr>\n   <tr>\n   <td>Non-mammals</td>\n   <td>Do not harbor rabies</td>\n   <td>Prophylaxis <strong>never</strong> required</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 65106 Version 1.0</div></div></div>"},"65107":{"type":"graphic_table","displayName":"Television guidelines","title":"Parental guidelines for television","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parental guidelines for television</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Rating</td> <td class=\"subtitle1\">Explanation</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">TV-Y</td> <td class=\"subtitle2_left\">All children</td> </tr> <tr> <td>The program is designed to be appropriate for all children. Whether animated or live-action, the themes and elements of the program are specifically designed for a very young audience, including children from ages&nbsp;two to six&nbsp;years. The program is not expected to frighten younger children.</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">TV-Y7</td> <td class=\"subtitle2_left\">Dir<span>e</span>cted to older children</td> </tr> <tr> <td>The program is designed for children older than&nbsp;seven years. It may be more appropriate for children who have the developmental skills to distinguish fantasy from reality. Themes and elements in the program may include mild fantasy or comedic violence, or may frighten children younger than seven.</td> </tr> <tr> <td class=\"subtitle2_left\">TV-Y7-FV</td> <td>As above, but fantasy violence may be more intense or more combative than other programs in TV-Y7.</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">TV-G</td> <td class=\"subtitle2_left\">General audience</td> </tr> <tr> <td>Most parents would find the program suitable to all ages. Although the rating does not signify a program designed specifically for children, most parents may let younger children watch the program unattended. It contains little or no violence, no strong language, and little or no sexual dialogue or situations.</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">TV-PG</td> <td class=\"subtitle2_left\">Parental guidance suggested</td> </tr> <tr> <td>The program contains material that parents may find unsuitable for younger children. Many parents may want to watch it with their younger children. The theme itself may call for parental guidance and/or the program contains one or more of the following: moderate violence (V), some sexual situations (S), infrequent coarse language (L), or some suggestive dialogue (D).</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">TV-14</td> <td class=\"subtitle2_left\">Parents strongly cautioned</td> </tr> <tr> <td>The program contains some material that many parents would find unsuitable for children younger than 14. Parents are strongly urged to exercise greater care in monitoring the program and are cautioned against letting children younger than 14 watch unattended. The program contains one or more of the following: intense violence (V), intense sexual situations (S), strong coarse language (L), or intensely suggestive dialogue (D).</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">TV-MA</td> <td class=\"subtitle2_left\">Mature audience only</td> </tr> <tr> <td>The program is specifically designed to be viewed by adults and therefore may be unsuitable for children younger than 17. The program contains one of more of the following: graphic violence (V), explicit sexual activity (S), or crude indecent language (L).</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from <A href=\"http://transition.fcc.gov/vchip/#guidelines\">http://transition.fcc.gov/vchip/#guidelines</A>. Accessed on June 19, 2012.</div><div id=\"graphicVersion\">Graphic 65107 Version 2.0</div></div></div>"},"65108":{"type":"graphic_table","displayName":"Causes of chronic muscle weakness in children","title":"Causes of chronic muscle weakness in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of chronic muscle weakness in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n <tr>\n    <td class=\"subtitle1\">Anatomic region</td>\n    <td class=\"subtitle1\">Condition</td>\n  </tr>\n  <tr>\n    <td rowspan=\"3\">Cerebral cortex</td>\n    <td>Brain tumor</td>\n  </tr>\n  <tr>\n    <td>Cerebral palsy</td>\n  </tr>\n  <tr>\n    <td>Juvenile amyotrophic lateral sclerosis and other neurodegenerative disorders*</td>\n  </tr>\n  <tr>\n    <td rowspan=\"4\">Spinal cord</td>\n    <td>Myelomeningocele</td>\n  </tr>\n  <tr>\n    <td>Tethered spinal cord</td>\n  </tr>\n  <tr>\n    <td>Chiari malformations</td>\n  </tr>\n  <tr>\n    <td>Amyotrophic lateral sclerosis</td>\n  </tr>\n  <tr>\n    <td rowspan=\"3\">Anterior horn cell</td>\n    <td>Spinal muscular atrophy</td>\n  </tr>\n  <tr>\n    <td>Postasthmatic amyotrophy</td>\n  </tr>\n  <tr>\n    <td>Amyotrophic lateral sclerosis</td>\n  </tr>\n  <tr>\n    <td rowspan=\"3\">Peripheral nerve</td>\n    <td>Erb palsy</td>\n  </tr>\n  <tr>\n    <td>Heavy metal poisoning</td>\n  </tr>\n  <tr>\n    <td>Congenital peripheral neuropathies</td>\n  </tr>\n  <tr>\n    <td>Neuromuscular junction</td>\n    <td>Myasthenia gravis</td>\n  </tr>\n  <tr>\n    <td rowspan=\"4\">Muscle</td>\n    <td>Congenital myopathies/muscular dystrophy</td>\n  </tr>\n  <tr>\n    <td>Myotonic dystrophy</td>\n  </tr>\n  <tr>\n    <td>Dermatomyositis</td>\n  </tr>\n  <tr>\n    <td>Steroid myopathy</td>\n  </tr>\n  <tr>\n    <td rowspan=\"3\">Other</td>\n    <td>Congenital hypothyroidism</td>\n  </tr>\n  <tr>\n    <td>Cushing syndrome</td>\n  </tr>\n  <tr>\n    <td>Conversion disorder</td>\n  </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=10767&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Chronic_weakness_child.htm</title></head></div><div class=\"graphic_footnotes\">* For example, metachromatic leukodystrophy, Alexander disease, Krabbe disease.</div><div id=\"graphicVersion\">Graphic 65108 Version 2.0</div></div></div>"},"65109":{"type":"graphic_figure","displayName":"Mechanism for medial condyle elbow fracture","title":"Mechanism for medial condyle elbow fracture","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Mechanism for medial condyle elbow fracture</div><div class=\"cntnt\"><img style=\"width:564px; height:598px;\" src=\"images/EM/65109_Mechmedcondyleelbowfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A direct force applied to the posterior aspect of the elbow causes the sharp articular margin of the olecranon to wedge the medial condyle from the distal humerus.<br />(B) Falling on the outstretched arm with the elbow extended and the wrist dorsiflexed causes the medial condyle to be avulsed by both ligamentous and muscular forces.</div><div class=\"graphic_reference\">Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001.&nbsp;Copyright © 2001 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 65109 Version 14.0</div></div></div>"},"65110":{"type":"graphic_table","displayName":"Staging of cutaneous lymphoma other than MF SS","title":"ISCL/EORTC proposal on TNM classification of cutaneous lymphoma other than mycosis fungoides or Sézary syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ISCL/EORTC proposal on TNM classification of cutaneous lymphoma other than mycosis fungoides or S&eacute;zary syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">T</td> </tr> <tr> <td class=\"sublist2_start\">T1: Solitary skin involvement</td> </tr> <tr> <td class=\"sublist2\">T1a: A solitary lesion &#60;5 cm diameter</td> </tr> <tr> <td class=\"sublist2\">T1b: A solitary lesion &#62;5 cm diameter</td> </tr> <tr> <td class=\"sublist2_start\">T2: Regional skin involvement: multiple lesions limited to one body region or two contiguous body regions*</td> </tr> <tr> <td class=\"sublist2\">T2a: All-disease-encompassed in a &#60;15 cm-diameter circular area</td> </tr> <tr> <td class=\"sublist2\">T2b: All-disease-encompassed in a &#62;15 cm- and &#60;30 cm-diameter circular area</td> </tr> <tr> <td class=\"sublist2\">T2c: All-disease-encompassed in a &#62;30 cm-diameter circular area</td> </tr> <tr> <td class=\"sublist2_start\">T3: Generalized skin involvement</td> </tr> <tr> <td class=\"sublist2\">T3a: Multiple lesions involving two noncontiguous body regions*</td> </tr> <tr> <td class=\"sublist2\">T3b: Multiple lesions involving &#8805;3 body regions</td> </tr> <tr> <td class=\"subtitle1_single\">N</td> </tr> <tr> <td class=\"indent1\">N0: No clinical or pathologic lymph node involvement</td> </tr> <tr> <td class=\"indent1\">N1: Involvement of one peripheral lymph node region that drains an area of current or prior skin involvement</td> </tr> <tr> <td class=\"indent1\">N2: Involvement of two or more peripheral lymph node regions or involvement of any lymph node region<sup>&#182;</sup> that does not drain an area of current or prior skin involvement</td> </tr> <tr> <td class=\"indent1\">N3: Involvement of central lymph nodes</td> </tr> <tr> <td class=\"subtitle1_single\">M</td> </tr> <tr> <td class=\"indent1\">M0: No evidence of extracutaneous non-lymph node disease</td> </tr> <tr> <td class=\"indent1\">M1: Extracutaneous non-lymph node disease present</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Definition of body regions:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Head and neck: inferior border- superior border of clavicles, T1 spinous process.</li>&#xD;&#xA;    <li>Chest: superior border- superior border of clavicles; inferior border- inferior margin of rib cage; lateral borders- mid-axillary lines, glenohumeral joints (inclusive of axillae).</li>&#xD;&#xA;    <li>Abdomen/genital: superior border- inferior margin of rib cage; inferior border- inguinal folds, anterior perineum; lateral borders- mid-axillary lines.</li>&#xD;&#xA;    <li>Upper back: superior border- T1 spinous process; inferior border- inferior margin of rib cage; lateral borders- mid-axillary lines.</li>&#xD;&#xA;    <li>Lower back/buttocks: superior border- inferior margin of rib cage; inferior border- inferior gluteal fold, anterior perineum (inclusive of perineum); lateral borders- mid-axillary lines.</li>&#xD;&#xA;    <li>Each upper arm: superior borders- glenohumeral joints (exclusive of axillae); inferior borders- ulnar/radial-humeral (elbow) joint.</li>&#xD;&#xA;    <li>Each lower arm/hand: superior borders- ulnar/radial-humeral (elbow) joint.</li>&#xD;&#xA;    <li>Each upper leg (thigh): superior borders- inguinal folds, inferior gluteal folds; inferior borders- mid-patellae, mid-popliteal fossae.</li>&#xD;&#xA;    <li>Each lower leg/foot: superior borders- mid-patellae, mid-popliteal fossae.</li>&#xD;&#xA;</ul>&#xD;&#xA;&para; Definition of lymph node regions is consistent with the Ann Arbor system: Peripheral sites: antecubital, cervical, supraclavicular, axillary, inguinal-femoral, and popliteal. Central sites: mediastinal, pulmonary hilar, paraortic, iliac.</div><div class=\"graphic_reference\">This research was originally published in Blood. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:479.</div><div id=\"graphicVersion\">Graphic 65110 Version 10.0</div></div></div>"},"65111":{"type":"graphic_figure","displayName":"Classification of insects in the family Reduviidae","title":"Classification of insects in the family Reduviidae","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Classification of insects in the family Reduviidae</div><div class=\"cntnt\"><img style=\"width:519px; height:204px;\" src=\"images/ALLRG/65111_Family_reduviidae.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Moffitt JE, Venarske D, Goddard J, et al. Allergic reactions to Triatoma bites. Ann Allergy Asthma Immunol 2003; 91:122. Copyright © 2003 American College of Allergy, Asthma, and Immunology.</div><div id=\"graphicVersion\">Graphic 65111 Version 3.0</div></div></div>"},"65112":{"type":"graphic_picture","displayName":"Metacarpophalangeal hyperext","title":"Severe metacarpophalangeal hyperextension deformity combined with fixed proximal interphalangeal joint flexion treated with resection arthroplasties","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe metacarpophalangeal hyperextension deformity combined with fixed proximal interphalangeal joint flexion treated with resection arthroplasties</div><div class=\"cntnt\"><img style=\"width:371px; height:275px;\" src=\"images/RHEUM/65112_Metacarpophalangeal_hyperex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperatively the patient required the use of both hands to grasp a moderate size object.</div><div class=\"graphic_reference\">Reproduced with permission from: Nalebuff EA. Surgery in patients with systemic sclerosis of the hand. Clin Orthop Rel Res 1999; 91:366. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65112 Version 9.0</div></div></div>"},"65113":{"type":"graphic_diagnosticimage","displayName":"Hepatic venogram - jaundice and elevated ALT and AST levels","title":"Hepatic venogram in a 37-year-old man with jaundice and elevated ALT and AST levels","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic venogram in a 37-year-old man with jaundice and elevated ALT and AST levels</div><div class=\"cntnt\"><img style=\"width:432px; height:283px;\" src=\"images/GAST/65113_Hepat_venogram_elev_ALT_AST.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hepatic veins are not seen; rather, there are small tortuous veins in the liver. This is diagnostic of Budd-Chiari syndrome.</div><div class=\"graphic_footnotes\">ALT: alanine transaminase; AST: aspartate transaminase.</div><div class=\"graphic_reference\">Courtesy of Marshall M. Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 65113 Version 4.0</div></div></div>"},"65114":{"type":"graphic_table","displayName":"Maternal outcomes from TOLAC versus PRCD","title":"Maternal outcomes from TOLAC versus PRCD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maternal outcomes from&nbsp;TOLAC versus PRCD</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"30%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Maternal outcome</td> <td class=\"subtitle1\" rowspan=\"2\">Number of studies/subjects</td> <td class=\"subtitle1\" colspan=\"3\">Frequency of outcome</td> </tr> <tr> <td class=\"subtitle2\">TOLAC&nbsp;(95% CI)</td> <td class=\"subtitle2\" colspan=\"2\">PRCD (95% CI)</td> </tr> <tr> <td>Maternal death</td> <td>12/402,883</td> <td>0.004% (0.001-0.015)</td> <td>0.013% (0.004-0.042)</td> <td>RR 0.33, 95% CI 0.13-0.88</td> </tr> <tr> <td>Uterine rupture</td> <td>8/63,4999</td> <td>0.47% (0.28-0.77)</td> <td>0.026% (0.009-0.082)</td> <td>RR 20.7, 95% CI 9.8-44</td> </tr> <tr> <td>Hysterectomy</td> <td>8/402,059</td> <td>0.17%(0.12-0.26)</td> <td>0.28% (0.12-0.76)</td> <td>NS</td> </tr> <tr> <td>Hemorrhage</td> <td>6/47,754</td> <td colspan=\"3\">Insufficient data to evaluate</td> </tr> <tr> <td>Transfusion</td> <td>9/401,307</td> <td>0.9% (0.4-2.0)</td> <td>1.2% 0.5-2.6)</td> <td>NS</td> </tr> <tr> <td>Infection</td> <td>22/354,060</td> <td>4.6% (0.15-13.5)</td> <td>3.2% (1.3-7.3)</td> <td>NS</td> </tr> <tr> <td>Surgical injury</td> <td>4/53,282</td> <td colspan=\"3\">Insufficient data to evaluate</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TOLAC: trial of labor after cesarean delivery; PRCD:&nbsp;planned repeat cesarean delivery; RR: relative risk; NS: not significantly different.</div><div class=\"graphic_reference\">Data from: Guise JM, Denman MA, Emeis C, et al. Vaginal birth after cesarean: New insights on maternal and neonatal outcomes. Obstet Gynecol 2010; 115:1267.</div><div id=\"graphicVersion\">Graphic 65114 Version 14.0</div></div></div>"},"65115":{"type":"graphic_figure","displayName":"SCD and risk factors in HCM","title":"Sudden cardiac death and risk factors in hypertrophic cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sudden cardiac death and risk factors in hypertrophic cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:434px; height:520px;\" src=\"images/CARD/65115_SCD_and_risk_factors_in_HCM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier estimates of the proportions of patients surviving from sudden cardiac death, appropriate ICD discharge, or resuscitated ventricular fibrillation in relation to number of risk factors in patients with obstruction.</div><div class=\"graphic_footnotes\">ICD: implantable cardioverter-defibrillator.</div><div class=\"graphic_reference\">Reproduced with permission from: Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006; 27:1933. Copyright &copy; 2006 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 65115 Version 2.0</div></div></div>"},"65116":{"type":"graphic_figure","displayName":"Renin release","title":"Regulation of renin release","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Regulation of renin release</div><div class=\"cntnt\"><img style=\"width:490px; height:417px;\" src=\"images/NEPH/65116_Renin_release.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The renin-angiotensin-aldosterone system and the maintenance of sodium and volume balance.</div><div id=\"graphicVersion\">Graphic 65116 Version 1.0</div></div></div>"},"65117":{"type":"graphic_figure","displayName":"Response to antihypertensives in blacks","title":"Antihypertensive response to different drugs in blacks","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Antihypertensive response to different drugs in blacks</div><div class=\"cntnt\"><img style=\"width:487px; height:234px;\" src=\"images/NEPH/65117_Singledruginblacks.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Response rates to single drug therapy for hypertension in blacks over the age of 60 years. The highest response was seen with diltiazem and hydrochlorothiazide (HCTZ) and the lowest with captopril. A response was defined as a diastolic pressure below 90 mmHg at the end of the titration phase and below 95 mmHg at one year. The pattern of response was similar, but the success rate for each drug was reduced by 5 to 15% if goal diastolic pressure were less than 90 mmHg at one year. There were between 42 and 53 patients in each group.</div><div class=\"graphic_reference\">Data from: Materson BJ, Reda DJ, Cushman WC. Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995; 8:189.</div><div id=\"graphicVersion\">Graphic 65117 Version 8.0</div></div></div>"},"65118":{"type":"graphic_picture","displayName":"Staphylococcus aureus in wound","title":"<em>Staphylococcus aureus</em> in wound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Staphylococcus aureus</em> in wound</div><div class=\"cntnt\"><img style=\"width:358px; height:240px;\" src=\"images/ID/65118_Gramposcocciclusters1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of purulent drainage from a wound (x1000) shows many inflammatory cells and gram-positive cocci in singles, pairs, and clusters. <EM>Staphylococcus aureus </EM>grew from this specimen.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 65118 Version 5.0</div></div></div>"},"65119":{"type":"graphic_picture","displayName":"Hot tub folliculitis","title":"Hot tub folliculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hot tub folliculitis</div><div class=\"cntnt\"><img style=\"width:394px; height:252px;\" src=\"images/ID/65119_Hot_tub_folliculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This form of folliculitis is caused by <EM>Pseudomonas aeruginosa</EM> and can occur after exposure to hot tubs or whirlpools.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 65119 Version 4.0</div></div></div>"},"65122":{"type":"graphic_table","displayName":"Cetuximab vinorelbine and cisplatin chemotherapy for NSCLC","title":"Cetuximab, vinorelbine, and cisplatin chemotherapy for advanced non-small cell lung cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cetuximab, vinorelbine, and cisplatin chemotherapy for advanced non-small cell lung cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days for a maximum of six cycles; this is followed by maintenance cetuximab. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cetuximab</td> <td>400 mg/m<sup>2</sup> IV</td> <td>The appropriate dose should be withdrawn from the vials (supplied in a concentration of 2 mg/mL) and aseptically transferred into an empty sterile IV bag without further dilution. The initial dose should be infused over 120 minutes (maximum 10 mg/min).*<sup>&#182;</sup> Cetuximab is given prior to chemotherapy agents on days when both are administered.</td> <td>Day 1, first cycle only</td> </tr> <tr> <td>Cetuximab</td> <td>250 mg/m<sup>2</sup> IV</td> <td>If day 1 dose is tolerated, subsequent doses may be administered over 60 minutes.<sup>&#182;</sup></td> <td>Weekly, beginning on day 8 of first cycle</td> </tr> <tr> <td>Vinorelbine</td> <td>25 mg/m<sup>2</sup> IV</td> <td>Dilute in normal saline (NS) to a final concentration between 0.5 and 2 mg/mL and administer over 6 to 10 minutes into the side port of a free-flowing IV infusion.</td> <td>Days 1 and 8</td> </tr> <tr class=\"divider_bottom\"> <td>Cisplatin</td> <td>80 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS and administer over two hours. Do not administer with aluminum needles or intravenous sets.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on prevention. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH on day 1 of each cycle (cisplatin);<br /> LOW when cetuximab plus vinorelbine or cetuximab alone are given. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedication with diphenhydramine with or without a glucocorticoid at least prior to the first infusion of cetuximab.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Vinorelbine is a vesicant and can cause significant tissue damage. Cisplatin is an irritant. Avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>The incidence of febrile neutropenia with this regimen is 16%.<sup>[1]</sup> The decision whether or not to use hematopoietic growth factors must be individualized. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial.<sup>[1]</sup> A lower starting dose of vinorelbine may be needed for patients with hepatic impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Basic metabolic panel (creatinine and electrolytes, including magnesium, calcium, and potassium) prior to each treatment dose. </li> <li>Monitor serum calcium, magnesium, and potassium levels weekly for eight weeks after completion of therapy.<sup>[2]</sup> </li> <li>Replete electrolytes as necessary. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assay for liver function prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess for skin rash. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Treatment on day 1 of each cycle with cisplatin and vinorelbine should be delayed for up to two weeks until ANC is &#62;1500/microL, platelet count &#62;100,000/microL, and hemoglobin &#62;9.0 g/dL.<sup>[3]</sup> If longer delays are required, treatment with these agents should be discontinued. Day 8 vinorelbine should be omitted if ANC &#60;1000/microL or platelets &#60;75,000/microL. Doses of vinorelbine and cisplatin should be reduced to 20 mg/m<sup>2</sup> and 60 mg/m<sup>2</sup>, respectively, for patients who have had neutropenic fever in a prior cycle. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dermatologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Severe dermatologic reactions, such as acneiform rash, require delayed administration of cetuximab and/or dose reduction. </li> <li>Refer to UpToDate topic on \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>The United States Prescribing Information recommends dose reduction for patients who develop hyperbilirubinemia during treatment with vinorelbine. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; ANC: absolute neutrophil count.<br />* A slower infusion rate should be considered in areas with a high incidence of infusion reactions (such as the southeast United States). Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".<br />¶ Cetuximab should be administered with an infusion or syringe pump, using a low protein-binding 0.22 micron in line fitter. Do not shake or dilute. Flush line with normal saline.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Pirker R, et al. Lancet 2009; 373:1525.</LI>&#xD;&#xA;<LI>Cetuximab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed December 7, 2009).</LI>&#xD;&#xA;<LI>Rosell R, et al. Ann Oncol 2008; 19:362.</LI></OL></div><div id=\"graphicVersion\">Graphic 65122 Version 30.0</div></div></div>"},"65123":{"type":"graphic_figure","displayName":"Central L femoral anatomy","title":"External landmarks for access to the femoral vein","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">External landmarks for access to the femoral vein</div><div class=\"cntnt\"><img style=\"width:435px; height:577px;\" src=\"images/EM/65123_Central_L_femoral_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The midinguinal point lying half-way between the anterior superior iliac spine and the symphysis pubis marks the normal location of the femoral artery. The femoral vein lies just medial to the artery. Remember that pulsations will be felt in the femoral vein in cardiac arrest patients receiving chest compressions.</div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 65123 Version 9.0</div></div></div>"},"65127":{"type":"graphic_figure","displayName":"Construction of ileal conduit","title":"Construction of an ileal conduit during pelvic exenteration","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Construction of an ileal conduit during pelvic exenteration</div><div class=\"cntnt\"><img style=\"width:480px; height:395px;\" src=\"images/OBGYN/65127_Construction_of_ileal_condu.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65127 Version 2.0</div></div></div>"},"65128":{"type":"graphic_diagnosticimage","displayName":"Yolk sac 2","title":"Yolk sac (transvaginal ultrasound)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Yolk sac (transvaginal ultrasound)</div><div class=\"cntnt\"><img style=\"width:354px; height:293px;\" src=\"images/OBGYN/65128_Yolk_sac_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal sagittal image shows a clear yolk sac (arrow) within the sac, diagnostic of an intrauterine pregnancy.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 65128 Version 4.0</div></div></div>"},"65129":{"type":"graphic_figure","displayName":"CDC weight for stature girls 2 to 5 years","title":"Weight-for-stature percentiles for girls 2 to 5 years, CDC growth charts: United States","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Weight-for-stature percentiles for girls 2 to 5 years, CDC growth charts: United States</div><div class=\"cntnt\"><img style=\"width:543px; height:673px;\" src=\"images/PEDS/65129_Weight_stature_girl_mor_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).</div><div id=\"graphicVersion\">Graphic 65129 Version 5.0</div></div></div>"},"65131":{"type":"graphic_figure","displayName":"Anterior neck anatomy","title":"Anterior neck anatomy ","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Anterior neck anatomy </div><div class=\"cntnt\"><img style=\"width:611px; height:437px;\" src=\"images/SURG/65131_Subclavian_anat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterosuperior view of a dissection of the root of the neck. The brachial plexus and the third part of the subclavian artery emerge&nbsp;between the anterior and middle scalene muscles.</div><div class=\"graphic_footnotes\">L. recurrent laryngeal: left recurrent laryngeal.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF II. Clinical Oriented Anatomy, Fourth Edition. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65131 Version 2.0</div></div></div>"},"65132":{"type":"graphic_diagnosticimage","displayName":"RV endomyocardial fibrosis","title":"Endomyocardial fibrosis of the right ventricle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endomyocardial fibrosis of the right ventricle</div><div class=\"cntnt\"><img style=\"width:434px; height:216px;\" src=\"images/CARD/65132_RV_endomyocardial_fibrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Echocardiogram showing endomyocardial fibrosis, a cause of segmental abnormality of the apical region of the right ventricle (RV). In this example, the disease, which is often bilateral, is limited to the right ventricular apex. The characteristic apical obliteration (O) is shown in panel A and is highlighted (arrows) by contrast injection (C) in panel B.</div><div class=\"graphic_footnotes\">ivs: interventricular septum; LV: left ventricle; LA: left atrium; RA: right atrium; ias: interatrial septum.</div><div id=\"graphicVersion\">Graphic 65132 Version 7.0</div></div></div>"},"65133":{"type":"graphic_diagnosticimage","displayName":"Fracture of the tibia-fibula with heterotopic ossification","title":"Fracture of the tibia-fibula with heterotopic ossification","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Fracture of the tibia-fibula with heterotopic ossification</div><div class=\"cntnt\"><img style=\"width:517px; height:424px;\" src=\"images/SURG/65133_Tib-fib_fracture_het_ossi_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fracture of the tibia-fibula with heterotopic ossification (bright white areas) as seen on plain extremity radiography (left) and computed tomography (right).</div><div class=\"graphic_reference\">Courtesy of Dr. Joe Hsu, San Antonio Military Medical Center Department of Orthopedic Surgery and Rehabilitation.</div><div id=\"graphicVersion\">Graphic 65133 Version 3.0</div></div></div>"},"65134":{"type":"graphic_diagnosticimage","displayName":"Disconnected Roux-en-O misconstruction","title":"Disconnected Roux-en-O misconstruction","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Disconnected Roux-en-O misconstruction</div><div class=\"cntnt\"><img style=\"width:583px; height:437px;\" src=\"images/SURG/65134_Disconrouxenomisconstr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">52-year-old woman with disconnected Roux-en-O misconstruction.<br> (A-C) Axial reconstruction CT scans show levels of gastric pouch (A), descending duodenum (B), and distal anastomosis (C). Enteric contrast medium administered orally opacifies markedly dilated gastric pouch (black asterisk, A), alimentary limb (short arrows, B and C), and extruded stomach and biliary limb (white asterisks). Common limb, beginning at supposed distal anastomosis (long arrow, C), distal small bowel, and colon (arrowheads, B and C) are collapsed and gasless. At surgery, biliary limb was found to have been incorrectly anastomosed to gastric pouch, forming Roux-en-O loop that ran from gastric pouch to end blindly in excluded distal stomach. Distal portion of bowel is collapsed and gasless because common limb was completely disconnected from Roux loop.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reprinted with the permission of the American Journal of Roentgenology. Mitchell MT, Gasparaitis AE, Alverdy JC. Imaging findings in roux-en-o and other misconstructions: Rare but serious complications of roux-en-y gastric bypass surgery. AJR Am J Roentgenol 2008; 190:367. Copyright &copy; 2008 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 65134 Version 8.0</div></div></div>"},"65135":{"type":"graphic_table","displayName":"Classification of autoantibodies in autoimmune hepatitis","title":"Classification of autoantibodies in autoimmune hepatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of autoantibodies in autoimmune hepatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Autoantibodies</td> </tr> <tr> <td class=\"divider_bottom centered\" rowspan=\"5\">1<br /> (classic)</td> <td>Antinuclear antibodies (ANA)</td> </tr> <tr> <td>Anti-smooth muscle antibodies (ASMA)</td> </tr> <tr> <td>Anti-actin antibodies (AAA)</td> </tr> <tr> <td>Anti-soluble liver/liver pancreas antigen (anti-SLA/LP)</td> </tr> <tr class=\"divider_bottom\"> <td>Atypical perinuclear antineutrophil cytoplasmic antibodies (pANCA)</td> </tr> <tr> <td class=\"centered\" rowspan=\"3\">2</td> <td>Anti-liver/kidney microsomal-1 (anti-LKM-1) antibodies</td> </tr> <tr> <td>Anti-liver cytosol-1 (anti-LC1) antibodies</td> </tr> <tr> <td>Anti-SLA/LP</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65135 Version 5.0</div></div></div>"},"65136":{"type":"graphic_table","displayName":"Measurement of blood pressure ","title":"Guidelines for the measurement of blood pressure to diagnose and treat hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for the measurement of blood pressure to diagnose and treat hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Patient conditions </td> </tr> <tr> <td class=\"subtitle2_single\">Posture </td> </tr> <tr> <td class=\"indent1\">Initially, check for postural changes by taking readings after five minutes supine, then immediately and two minutes after standing; this is particularly important in patients over age 65 years, diabetics, or those taking antihypertensive drugs </td> </tr> <tr> <td class=\"indent1\">Sitting pressures are recommended for routine follow-up; the patient should sit quietly with the back supported for five minutes and the arm supported at the level of the heart </td> </tr> <tr> <td class=\"subtitle2_single\">Circumstances </td> </tr> <tr> <td class=\"indent1\">No caffeine during the hour preceding the reading, and no smoking during the preceding 30 minutes </td> </tr> <tr> <td class=\"indent1\">No exogenous adrenergic stimulants, such as phenylephrine in decongestants or eye drops for pupillary dilatation </td> </tr> <tr> <td class=\"indent1\">A quiet, warm setting </td> </tr> <tr> <td class=\"indent1\">Home readings should be taken upon varying circumstances </td> </tr> <tr> <td class=\"subtitle1_single\">Equipment </td> </tr> <tr> <td class=\"subtitle2_single\">Cuff size </td> </tr> <tr> <td class=\"indent1\">The length of the bladder should be 80%, and the width of the bladder should be at least 40% of the circumference of the upper arm </td> </tr> <tr> <td class=\"subtitle2_single\">Manometer </td> </tr> <tr> <td class=\"indent1\">Aneroid gauges should be calibrated every six months against a mercury manometer </td> </tr> <tr> <td class=\"subtitle1_single\">Technique </td> </tr> <tr> <td class=\"subtitle2_single\">Number of readings </td> </tr> <tr> <td class=\"indent1\">Take at least two readings on each visit, separated by as much time as possible; if readings vary by more than 5 mmHg, take additional readings until two consecutive readings are close </td> </tr> <tr> <td class=\"indent1\">For the diagnosis of hypertension, take three readings at least one week apart </td> </tr> <tr> <td class=\"indent1\">Initially, take blood pressure in both arms; if pressures differ, use the higher arm </td> </tr> <tr> <td class=\"indent1\">If the arm pressure is elevated, take the pressure in one leg, particularly in patients under age 30 years</td> </tr> <tr> <td class=\"subtitle2_single\">Performance </td> </tr> <tr> <td class=\"indent1\">Inflate the bladder quickly to 20 mmHg above the systolic pressure as estimated from loss of radial pulse </td> </tr> <tr> <td class=\"indent1\">Deflate the bladder by 3 mmHg per second </td> </tr> <tr> <td class=\"indent1\">Record the Korotkoff phase V (disappearance) as the diastolic pressure except in children in whom use of phase IV (muffling) may be preferable </td> </tr> <tr> <td class=\"indent1\">If the Korotkoff sounds are weak, have the patient raise the arm, open and close the hand&nbsp;5 to&nbsp;10 times, and then inflate the bladder quickly </td> </tr> <tr> <td class=\"subtitle1_single\">Recordings </td> </tr> <tr> <td>Note the pressure, patient position, arm, and cuff size: eg, 140/90, seated, right arm, large adult cuff</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65136 Version 5.0</div></div></div>"},"65137":{"type":"graphic_movie","displayName":"Mitral valve prolapse four chamber echocardiogram","title":"Mitral valve prolapse","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral valve prolapse</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/65137_4chmvproconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:253px; height:437px;\" src=\"images/CARD/65137_4chmvpro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view from a 2-D echocardiogram shows prolapse of the posterior mitral valve leaflet. The left atrium and ventricle are dilated, suggesting that significant mitral regurgitation is present.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 65137 Version 2.0</div></div></div>"},"65139":{"type":"graphic_figure","displayName":"Coronary artery territories","title":"Coronary artery territories","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Coronary artery territories</div><div class=\"cntnt\"><img style=\"width:540px; height:329px;\" src=\"images/CARD/65139_Coron_art_territories_JASE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical distributions of the right coronary artery (RCA), the left anterior descending artery (LAD), and the circumflex artery (CX). The arterial distribution varies between patients. Some segments have variable coronary perfusion.</div><div class=\"graphic_reference\">Reproduced from: Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 65139 Version 6.0</div></div></div>"},"65140":{"type":"graphic_picture","displayName":"Urothelial CIS A","title":"Urothelial carcinoma in situ (CIS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urothelial carcinoma in situ (CIS)</div><div class=\"cntnt\"><img style=\"width:433px; height:296px;\" src=\"images/ONC/65140_Urothelial_CIS_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 65140 Version 1.0</div></div></div>"},"65141":{"type":"graphic_table","displayName":"Respiratory disease from RA drugs","title":"Pulmonary complications from drugs for rheumatoid arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pulmonary complications from drugs for rheumatoid arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pneumonitis</td> </tr> <tr> <td class=\"indent1\">Anakinra</td> </tr> <tr> <td class=\"indent1\">Azathioprine</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> </tr> <tr> <td class=\"indent1\">Methotrexate*</td> </tr> <tr> <td class=\"indent1\">Leflunomide</td> </tr> <tr> <td class=\"indent1\">NSAID<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Rituximab</td> </tr> <tr> <td class=\"indent1\">TNF inhibitors<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Tocilizumab</td> </tr> <tr> <td class=\"indent1\">Sulfasalazine</td> </tr> <tr> <td class=\"indent1\">Chlorambucil</td> </tr> <tr> <td class=\"indent1\">Gold*</td> </tr> <tr> <td class=\"indent1\">d-Penicillamine</td> </tr> <tr> <td class=\"subtitle1_single\">Fibrosis</td> </tr> <tr> <td class=\"indent1\">Methotrexate</td> </tr> <tr> <td class=\"indent1\">Gold</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> </tr> <tr> <td class=\"indent1\">Chlorambucil</td> </tr> <tr> <td class=\"indent1\">Azathioprine</td> </tr> <tr> <td class=\"indent1\">Sulfasalazine</td> </tr> <tr> <td class=\"subtitle1_single\">Obliterative bronchiolitis</td> </tr> <tr> <td class=\"indent1\">d-Penicillamine</td> </tr> <tr> <td class=\"indent1\">Gold</td> </tr> <tr> <td class=\"indent1\">Sulfasalazine</td> </tr> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"indent1\">TNF inhibitors<sup>&#916;</sup>*</td> </tr> <tr> <td class=\"indent1\">IL-1 inhibitors<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Methotrexate*</td> </tr> <tr> <td class=\"indent1\">Glucocorticoids*</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> </tr> <tr> <td class=\"indent1\">Abatacept</td> </tr> <tr> <td class=\"indent1\">Rituximab</td> </tr> <tr> <td class=\"subtitle1_single\">Noncardiogenic pulmonary edema </td> </tr> <tr> <td class=\"indent1\">Aspirin (high doses)</td> </tr> <tr> <td class=\"indent1\">NSAID<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Methotrexate</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> </tr> <tr> <td class=\"indent1\">Colchicine (overdose)</td> </tr> <tr> <td class=\"indent1\">Rituximab</td> </tr> <tr> <td class=\"indent1\">Tocilizumab</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary renal syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary hemorrhage</td> </tr> <tr> <td class=\"indent1\">d-Penicillamine</td> </tr> <tr> <td class=\"subtitle1_single\">Drug-induced lupus</td> </tr> <tr> <td class=\"indent1\">d-Penicillamine</td> </tr> <tr> <td class=\"indent1\">TNF inhibitors<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Sulfasalazine</td> </tr> <tr> <td class=\"subtitle1_single\">Bronchospasm</td> </tr> <tr> <td class=\"indent1\">Aspirin</td> </tr> <tr> <td class=\"indent1\">NSAID<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Methotrexate</td> </tr> <tr> <td class=\"subtitle1_single\">Air trapping</td> </tr> <tr> <td class=\"indent1\">? Methotrexate</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Most common reactions reported.<br />&para; Nonsteroidal anti-inflammatory medications.<br />&Delta; Tumor necrosis factor modifying agents (infliximab, etanercept, adalimumab).<br /><span class=\"lozenge\">&loz;</span> Interleukin-1 blocking agents (anakinra).</div><div id=\"graphicVersion\">Graphic 65141 Version 5.0</div></div></div>"},"65142":{"type":"graphic_figure","displayName":"Temporal arteritis PI","title":"Temporal arteritis","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Temporal arteritis</div><div class=\"cntnt\"><img style=\"width:489px; height:486px;\" src=\"images/PI/65142_Temporal_arteritis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Temporal arteritis is also called giant cell arteritis. It frequently affects medium and large artery branches that originate from the neck and travel into the head. People with temporal arteritis sometimes have a raised, tender blood vessel located in the temple.</div><div id=\"graphicVersion\">Graphic 65142 Version 3.0</div></div></div>"},"65144":{"type":"graphic_table","displayName":"Fertility preservation for women treated w gonadotoxic therapies","title":"Fertility preservation options for women treated with gonadotoxic therapies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fertility preservation options for women treated with gonadotoxic therapies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Investigational</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Cryopreservation of embryos for future implantation</td> <td>Typically requires ovarian stimulation, which takes 10 to 14 days from the beginning of a menstrual cycle. Oocytes are harvested under ultrasound guidance and fertilized in vitro.</td> <td>No</td> <td> <p>Requires sperm from the woman's partner. If no partner, then donor sperm can be used.</p> <p>Induction of high estrogen levels during ovarian stimulation is a concern in women with estrogen-responsive malignancies. Aromatase inhibitors can be used to minimize estrogen exposure.</p> Costly. Approximately $8000 to 12,000 per cycle, $500 to 1000/year storage fees.</td> </tr> <tr class=\"divider_bottom\"> <td>Oocyte cryopreservation (mature oocytes)</td> <td>Typically requires ovarian stimulation, which takes 10 to 14 days from the beginning of a menstrual cycle. Oocytes are harvested under ultrasound guidance and frozen without being fertilized.</td> <td>No</td> <td> <p>Induction of high estrogen levels during ovarian stimulation is a concern in women with estrogen-responsive malignancies. Aromatase inhibitors can be used to minimize estrogen exposure.</p> Costly. Approximately $8000 to 12,000 per cycle, $500 to 1000/year storage fees.</td> </tr> <tr class=\"divider_bottom\"> <td>Oocyte cryopreservation (immature oocytes)</td> <td>Does not require ovarian stimulation. Germinal oocytes are harvested under ultrasound guidance and frozen without being fertilized.</td> <td>Yes</td> <td>Only a few pregnancies have been reported.</td> </tr> <tr class=\"divider_bottom\"> <td>Ovarian cryopreservation and transplantation</td> <td>Outpatient surgical procedure to obtain strips of ovarian tissue, which are frozen and reimplanted when pregnancy is desired.</td> <td>Yes</td> <td>Ovarian transplantation is not recommended in women at increased risk of developing ovarian cancer.</td> </tr> <tr class=\"divider_bottom\"> <td>Gonadal shielding during radiation therapy</td> <td>Shielding gonads during radiation therapy reduces gonadal exposure to scatter radiation.</td> <td>No</td> <td> <p>Not possible if gonads are in the radiation field.</p> Requires expertise to properly place shields.</td> </tr> <tr class=\"divider_bottom\"> <td>Ovarian transposition (oophoropexy)</td> <td> <p>Outpatient surgical procedure to reposition the ovaries away from the radiation field.</p> Should be performed just before radiation therapy to minimize chance that ovaries will return to their former position.</td> <td>No</td> <td> <p>Approximately 50 percent chance of success.</p> Ovaries may need to be repositioned to allow assisted or natural conception.</td> </tr> <tr class=\"divider_bottom\"> <td>Trachelectomy</td> <td>Inpatient surgical procedure to remove the cervix while preserving the uterus.</td> <td>No</td> <td> <p>Only useful for women with early stage cervical cancer.</p> <p>Prior to attempting pregnancy following trachelectomy, the patient may require an abdominal cerclage.</p> Pregnancy following abdominal cerclage may be complicated due to the difficulty in differentiating preterm labor from preterm contractions, the risk of uterine rupture, and the need for cesarean delivery.</td> </tr> <tr> <td>Ovarian suppression with gonadotropin releasing hormone (GnRH) analogs or antagonists</td> <td>Administer before and concurrent with chemotherapy to protect ovarian tissue.</td> <td>Yes</td> <td> <p>True efficacy unknown. No randomized trial has shown benefit to fertility.</p> <p>Side effects include hot flashes and vaginal atrophy. Suppression of menses is a benefit in women at risk of menorrhagia from thrombocytopenia.</p> Approximately $500/month.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Lee SJ, Schover LR, Patridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24:2917.</div><div id=\"graphicVersion\">Graphic 65144 Version 6.0</div></div></div>"},"65145":{"type":"graphic_figure","displayName":"Capillaria philippinensis life cycle","title":"<em>Capillaria philippinensis</em> life cycle","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\"><em>Capillaria philippinensis</em> life cycle</div><div class=\"cntnt\"><img style=\"width:457px; height:597px;\" src=\"images/ID/65145_Capillaria_philippinensis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typically, unembryonated eggs are passed in the human stool <strong>(1)</strong> and become embryonated in the external environment <strong>(2)</strong>; after ingestion by freshwater fish, larvae hatch, penetrate the intestine, and migrate to the tissues <strong>(3)</strong>. Ingestion of raw or undercooked fish results in infection of the human host <strong>(4)</strong>. The adults of <em>Capillaria philippinensis</em> (males: 2.3 to 3.2 mm; females: 2.5 to 4.3 mm) reside in the human small intestine, where they burrow in the mucosa <strong>(5)</strong>. The females deposit unembryonated eggs. Some of these become embryonated in the intestine, and release larvae that can cause autoinfection. This leads to hyperinfection (a massive number of adult worms) <strong>(6)</strong>. <em>Capillaria philippinesis</em> is currently considered a parasite of fish eating birds, which seem to be the natural definitive host <strong>(7)</strong>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Instestinal capillariasis. Available at: <a href=\"http://www.cdc.gov/dpdx/intestinalCapillariasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/intestinalCapillariasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 65145 Version 4.0</div></div></div>"},"65146":{"type":"graphic_algorithm","displayName":"Management of acute embolic mesenteric occlusion","title":"Management of acute embolic mesenteric occlusion","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Management of acute embolic mesenteric occlusion</div><div class=\"cntnt\"><img style=\"width:559px; height:760px;\" src=\"images/SURG/65146_Mng_act_embl_msnt_occl.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.<br />* Diagnosis typically made on CT angiography of the abdomen (refer to associated UpToDate&nbsp;algorithm on intestinal ischemia).<br />¶ In the absence of contraindications to thrombolytic therapy (eg, active bleeding).<br />Δ Includes thromboendarterectomy, mesenteric bypass, retrograde mesenteric stent, or a combination of these.</div><div id=\"graphicVersion\">Graphic 65146 Version 4.0</div></div></div>"},"65147":{"type":"graphic_table","displayName":"Follow-up neonatal jaundice","title":"Recommended timing of follow-up visits for term and near term infants (>35 weeks gestation)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended timing of follow-up visits for term and near term infants (>35 weeks gestation)</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Age infant discharged</td>\r\n                    <td class=\"subtitle1\">Timing of follow-up visit*</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Less than 24 hours of age </td>\r\n                    <td>72 hours</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Between 24 and 47.9 hours of age</td>\r\n                    <td>96 hours</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Between 48 and 72 hours of age</td>\r\n                    <td>120 hours</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_footnotes\">* Earlier follow-up visits and perhaps more frequent visits are required for infants who have risk factors for hyperbilirubinemia. If appropriate follow-up cannot be ensured, especially in infants with an increased risk for severe hyperbilirubinemia, then discharge should be delayed until appropriate follow-up can be ensured or the period of greatest risk has passed (72 to 96 hours).</div><div id=\"graphicVersion\">Graphic 65147 Version 2.0</div></div></div>"},"65148":{"type":"graphic_table","displayName":"Noninfectious mimics of pediatric pneumonia","title":"Noninfectious conditions that can mimic pneumonia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Noninfectious conditions that can mimic pneumonia in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Anatomical considerations</td> </tr> <tr> <td>Prominent thymus</td> </tr> <tr> <td>Breast shadows</td> </tr> <tr> <td>Bronchogenic cyst</td> </tr> <tr> <td>Vascular ring</td> </tr> <tr> <td>Pulmonary sequestration</td> </tr> <tr> <td>Congenital lobar emphysema</td> </tr> <tr> <td>Atelectasis (due to a foreign body or mucus plug)</td> </tr> <tr> <td class=\"subtitle1_single\">Aspiration of gastric contents</td> </tr> <tr> <td>Gastroesophageal reflux</td> </tr> <tr> <td>Tracheoesophageal fistula</td> </tr> <tr> <td>Cleft palate</td> </tr> <tr> <td>Neuromuscular disorders</td> </tr> <tr> <td class=\"subtitle1_single\">Chronic pulmonary disorders</td> </tr> <tr> <td>Asthma</td> </tr> <tr> <td>Bronchiectasis</td> </tr> <tr> <td>Bronchopulmonary dysplasia</td> </tr> <tr> <td>Cystic fibrosis</td> </tr> <tr> <td>Pulmonary fibrosis</td> </tr> <tr> <td>Alpha-1 antitrypsin deficiency</td> </tr> <tr> <td>Pulmonary hemosiderosis</td> </tr> <tr> <td>Alveolar proteinosis</td> </tr> <tr> <td>Desquamative interstitial pneumonitis</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Histiocytosis X</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Drugs and chemical exposures</td> </tr> <tr> <td>Nitrofurantoin</td> </tr> <tr> <td>Bleomycin</td> </tr> <tr> <td>Cytotoxic drugs</td> </tr> <tr> <td>Opiates</td> </tr> <tr> <td>Radiation therapy</td> </tr> <tr> <td>Smoke inhalation</td> </tr> <tr> <td>Lipoid pneumonia</td> </tr> <tr> <td class=\"subtitle1_single\">Vasculitic disorders</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Granulomatosis with polyangiitis (Wegener)</td> </tr> <tr> <td>Juvenile idiopathic arthritis</td> </tr> <tr> <td class=\"subtitle1_single\">Others</td> </tr> <tr> <td>Hypersensitivity pneumonitis</td> </tr> <tr> <td>Neoplasm</td> </tr> <tr> <td>Pulmonary edema due to heart failure</td> </tr> <tr> <td>Pulmonary infarction</td> </tr> <tr> <td>Acute respiratory distress syndrome</td> </tr> <tr> <td>Graft-versus-host disease</td> </tr> <tr> <td>Poor inspiratory film</td> </tr> <tr> <td>Near drowning event</td> </tr> <tr> <td>Underpenetrated film</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Klein JO. Bacterial pneumonias. In: Textbook of Pediatric Infectious Diseases, 5<SUP>th</SUP> ed, Feigin RD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia 2004. p.299. </LI>&#xD;&#xA;<LI>McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429. </LI>&#xD;&#xA;<LI>Gaston B. Pneumonia. Pediatr Rev 2002; 23:132. </LI>&#xD;&#xA;<LI>Boyer KM. Nonbacterial pneumonia. In: Textbook of Pediatric Infectious Disease, 5<SUP>th</SUP> ed, Feigin RD, Cherry JD, Demmler GJ, Kaplan SL (Eds), WB Saunders, Philadelphia 2004. p.286. </LI></OL></div><div id=\"graphicVersion\">Graphic 65148 Version 8.0</div></div></div>"},"65149":{"type":"graphic_figure","displayName":"VO2 plateau","title":"VO<sub>2</sub> plateau","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">VO<sub>2</sub> plateau</div><div class=\"cntnt\"><img style=\"width:398px; height:356px;\" src=\"images/PEDS/65149_VO2_plateau.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oxygen consumption plateaus at approximately 45 mL/kg per minute as the workload increases from stage 5 to stage 6. Once VO<sub>2</sub> plateau has been reached, exercise continues primarily through anaerobic metabolism.</div><div class=\"graphic_footnotes\">VO<SUB>2</SUB>: volume of oxygen consumed.</div><div id=\"graphicVersion\">Graphic 65149 Version 4.0</div></div></div>"},"65151":{"type":"graphic_waveform","displayName":"M mode left ventricle","title":"Left ventricle on M-mode echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricle on M-mode echocardiogram</div><div class=\"cntnt\"><img style=\"width:412px; height:211px;\" src=\"images/CARD/65151_M_mode_left_ventricle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The M-mode echocardiogram shows the posterior wall and interventricular septum of the left ventricle (LV) in systole and diastole. The LV pressure tracing (red arrow) is superimposed. LV size is measured in end diastole (LVd) and end systole (LVs).</div><div id=\"graphicVersion\">Graphic 65151 Version 2.0</div></div></div>"},"65152":{"type":"graphic_diagnosticimage","displayName":"Med bronchogen cyst CT II","title":"Infected subcarinal bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infected subcarinal bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:360px; height:281px;\" src=\"images/PULM/65152_Med_bronchogen_cyst_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan with lung window settings shows a gas containing cyst, surrounded by ground-glass opacity and consolidation in the right lower lobe, which represents a pneumonia that caused infection of the adjacent bronchogenic cyst.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 65152 Version 4.0</div></div></div>"},"65153":{"type":"graphic_figure","displayName":"Ixodes tick transmission cycle","title":"Transmission cycle of infection by <EM>Ixodes</EM> ticks","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transmission cycle of infection by <EM>Ixodes</EM> ticks</div><div class=\"cntnt\"><img style=\"width:450px; height:460px;\" src=\"images/ID/65153_Lyme_transmission.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Ixodes scapularis </EM>ticks are capable of transmitting Lyme disease, babesiosis, and human granulocytic anaplasmosis.</div><div class=\"graphic_reference\">Available at: <A href=\"http://www.cdc.gov/lyme/transmission/blacklegged.html\" target=_blank>http://www.cdc.gov/lyme/transmission/blacklegged.html</A>.</div><div id=\"graphicVersion\">Graphic 65153 Version 12.0</div></div></div>"},"65155":{"type":"graphic_table","displayName":"Frequency ALL subtypes children","title":"Relative frequency of acute lymphoblastic leukemia subtypes in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative frequency of acute lymphoblastic leukemia subtypes in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">ALL Type</td>\n\n      <td class=\"subtitle1\">Percent</td>\n\n      <td class=\"subtitle1\">CD Designation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>B-precursor ALL</td>\n\n      <td>70</td>\n\n      <td>10, 19, 20, 22, 24</td>\n\n    </tr>\n\n    <tr>\n\n      <td>B-precursor with myeloid features</td>\n\n      <td>10</td>\n\n      <td>Also express: 11, 13, 14, 15, 33, 34, 41, 42</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mature B cell</td>\n\n      <td>2 to 5</td>\n\n      <td>10&plusmn;, 19, 20, 22, 25, sIg</td>\n\n    </tr>\n\n    <tr>\n\n      <td>T-cell</td>\n\n      <td>16</td>\n\n      <td>2,3,4,5,7,8</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">slg: surface immunoglobulin.</div><div class=\"graphic_reference\">Reproduced with permission from: Zipf, TF, Berg, SL, Roberts, WM, et al. Childhood Leukemias. In: Clinical Oncology (2nd ed), Abeloff, MD, Armitage, JO, Lichter, AS, et al (Eds), Churchill Livingstone, New York, 2000. p.2402. Copyright &#169; 2000 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 65155 Version 2.0</div></div></div>"},"65156":{"type":"graphic_figure","displayName":"Ventral suspension","title":"Infant ventral suspension","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Infant ventral suspension</div><div class=\"cntnt\"><img style=\"width:487px; height:619px;\" src=\"images/PEDS/65156_Ventral_suspension.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ventral suspension measures the strength of the infant's trunk and neck. The infant is held in a suspended prone position in the air by placing a hand under the chest. A normal term infant will keep his/her head in the horizontal plane momentarily with flexion of both the upper and lower extremities. An infant with decreased muscle tone will appear limp with extended limbs and a drooping head, as shown in the inset.</div><div id=\"graphicVersion\">Graphic 65156 Version 2.0</div></div></div>"},"65157":{"type":"graphic_table","displayName":"Criteria preventive care","title":"Criteria for deciding whether a medical condition should be included in preventive care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for deciding whether a medical condition should be included in preventive care</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\"><strong>1. How great is the burden of suffering caused by the condition in terms of:</strong></td> </tr> <tr> <td class=\"indent1\">Death</td> </tr> <tr> <td class=\"indent1\">Disease</td> </tr> <tr> <td class=\"indent1\">Disability</td> </tr> <tr> <td class=\"indent1\">Discomfort</td> </tr> <tr> <td class=\"indent1\">Dissatisfaction</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Destitution</td> </tr> <tr> <td class=\"sublist1_start\"><strong>2. How good is the screening test, if one is to be performed, in terms of:</strong></td> </tr> <tr> <td class=\"indent1\">Sensitivity</td> </tr> <tr> <td class=\"indent1\">Specificity</td> </tr> <tr> <td class=\"indent1\">Simplicity</td> </tr> <tr> <td class=\"indent1\">Cost</td> </tr> <tr> <td class=\"indent1\">Safety</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Acceptability</td> </tr> <tr> <td class=\"sublist1_start\"><strong>3. A. For primary and tertiary prevention, how good is the therapeutic intervention in terms of:</strong></td> </tr> <tr> <td class=\"indent1\">Effectiveness</td> </tr> <tr> <td class=\"indent1\">Safety</td> </tr> <tr> <td class=\"indent1\">Cost-effectiveness</td> </tr> <tr> <td class=\"sublist3_start\"><em>Or</em></td> </tr> <tr> <td class=\"sublist1_start\"><strong>3. B. For secondary prevention, if the condition is found, how good is the ensuing treatment in terms of:</strong></td> </tr> <tr> <td class=\"indent1\">Effectiveness</td> </tr> <tr> <td class=\"indent1\">Safety</td> </tr> <tr> <td class=\"indent1\">Early treatment after screening being more effective than later treatment without screening, when the patient becomes symptomatic</td> </tr> <tr> <td class=\"indent1\">Cost-effectiveness</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 65157 Version 12.0</div></div></div>"},"65159":{"type":"graphic_table","displayName":"Patch test interpretation","title":"Interpretation of patch test reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretation of patch test reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Score</td> <td class=\"subtitle1\">Interpretation</td> <td class=\"subtitle1\">Tips and advice</td> </tr> <tr> <td>-</td> <td>Negative reaction</td> <td>&nbsp;</td> </tr> <tr> <td>? or +/- </td> <td>Doubtful reaction, faint erythema</td> <td>Caution with interpretation, especially with less common allergens. Consider repeat testing or follow-up with ROAT testing.</td> </tr> <tr> <td>+ </td> <td>Weak reaction, erythema, slight infiltration</td> <td>Erythema should be palpable and occupy &#62;50 percent of patch test site.</td> </tr> <tr> <td>++ </td> <td>Strong reaction, erythema, infiltration, vesicles</td> <td>Look for microvesicles to occupy at least 50 percent of the patch test site.</td> </tr> <tr> <td>+++ </td> <td>Extreme, bullous, ulcerative</td> <td>Confluent vesicles.</td> </tr> <tr> <td>IR </td> <td>Irritant reactions</td> <td>There is a broad range. Mild irritant reactions have a glazed appearance. Moderate reactions are follicular (pustular in atopics). Extreme reactions can be ulcerative.</td> </tr> <tr> <td>NT </td> <td>Not tested</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65159 Version 1.0</div></div></div>"},"65160":{"type":"graphic_picture","displayName":"Perforation of TM","title":"Traumatic tympanic membrane perforation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traumatic tympanic membrane perforation</div><div class=\"cntnt\"><img style=\"width:378px; height:289px;\" src=\"images/EM/65160_Perforation_of_TM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior canal wall skin is on the left side; the malleus is on the right side. The perforation appears dark and is surrounded by mildly hyperemic smooth edges.</div><div class=\"graphic_reference\">Courtesy of Adele Karen Evans, MD, FAAP and Steven D Handler MD, MBE.</div><div id=\"graphicVersion\">Graphic 65160 Version 1.0</div></div></div>"},"65161":{"type":"graphic_table","displayName":"Comorbidities and medications affecting severity and treatment","title":"Comorbidities and concurrent medications that might impact the severity and treatment of anaphylaxis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comorbidities and concurrent medications that might impact the severity and treatment of anaphylaxis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Comorbidities</td> </tr> <tr> <td class=\"indent1\">Asthma</td> </tr> <tr> <td class=\"indent1\">Other pulmonary diseases (eg, COPD, interstitial lung disease)</td> </tr> <tr> <td class=\"indent1\">Cardiovascular diseases (eg, ischemic heart disease, hypertensive vascular disease, cardiomyopathy)</td> </tr> <tr> <td class=\"indent1\">Mast cell disorder (ie, systemic mastocytosis or mast cell activation syndrome)</td> </tr> <tr> <td class=\"subtitle1_single\">Concurrently administered medications</td> </tr> <tr> <td class=\"indent1\">Beta-adrenergic blockers*</td> </tr> <tr> <td class=\"indent1\">Alpha-adrenergic blockers<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Angiotensin-converting enzyme (ACE) inhibitors<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Angiotensin II receptor blockers<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Tricyclic antidepressants<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Monoamine oxidase inhibitors<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">ADHD medications<sup>&#165;</sup> (eg, stimulants, such as methylphenidate and amphetamines)</td> </tr> <tr> <td class=\"indent1\">Recreational use of cocaine<sup>&#135;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; ADHD: attention deficit hyperactivity disorder.<br />* Beta-adrenergic blockers, administered orally or topically (eg, eye drops) may be associated with severe anaphylaxis and may also make anaphylaxis more difficult to treat by causing unopposed alpha-adrenergic effects, hypertension, and reduced bronchodilator response to the beta-adrenergic effects of endogenous or exogenous epinephrine.<br />¶ Alpha-adrenergic blockers may decrease the effects of endogenous or exogenous epinephrine at alpha-adrenergic receptors, potentially making patients less responsive to the alpha-adrenergic effects of epinephrine.<br />Δ Potential interference with endogenous compensatory responses.<br /><FONT class=lozenge>◊</FONT> Potential increase in adverse effects of epinephrine because of prevention of epinephrine uptake at adrenergic receptors.<br />§ Potentiate epinephrine's effects by inhibiting its metabolism by monoamine oxidase.<br />¥ Side effects are similar to those of epinephrine.<br />‡ Potentiates epinephrine's effects, especially cardiovascular effects, by preventing its reuptake into adrenergic neurons.</div><div class=\"graphic_reference\">Modified with permission from: Simons FER. Anaphylaxis, killer allergy: Long-term management in the community. J Allergy Clin Immunol 2006; 117:367. Copyright © 2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 65161 Version 18.0</div></div></div>"},"65162":{"type":"graphic_diagnosticimage","displayName":"2D TTE and M mode images normal tricuspid valve","title":"Two-dimensional transthoracic echocardiogram (2D TTE) and M mode images showing a normal tricuspid valve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) and M mode images showing a normal tricuspid valve</div><div class=\"cntnt\"><img style=\"width:263px; height:384px;\" src=\"images/CARD/65162_M_mode_tricuspid_valve_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tricuspid valve (tv) can be imaged from the precordial long axis view (panel A). In panel B, the M-mode beam is directed through the septal leaflet (inset); an M-mode echocardiogram typically shows a single anteriorly moving leaflet. In this example, atrial fibrillation is present, resulting in a wave form that is of irregular duration, shows early diastolic opening, and occasional small movements arising from rapid fibrillatory contraction. Additionally, the right atrium (RA) is enlarged.</div><div class=\"graphic_footnotes\">RV: right ventricle.</div><div id=\"graphicVersion\">Graphic 65162 Version 6.0</div></div></div>"},"65163":{"type":"graphic_figure","displayName":"Inhalation challenge testing II","title":"Inhalation challenge testing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inhalation challenge testing</div><div class=\"cntnt\"><img style=\"width:228px; height:501px;\" src=\"images/PULM/65163_Inhalation_challenge_test1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical asthmatic reactions after specific inhalation challenge testing.</div><div class=\"graphic_reference\">From Perrin et al, J Allergy Clin Immunol 1991; 87:630.</div><div id=\"graphicVersion\">Graphic 65163 Version 1.0</div></div></div>"},"65164":{"type":"graphic_picture","displayName":"Oblit bronchiolitis BMT II","title":"Bronchiolitis obliterans following bone marrow transplantation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchiolitis obliterans following bone marrow transplantation</div><div class=\"cntnt\"><img style=\"width:373px; height:245px;\" src=\"images/PULM/65164_Oblit_bronchiolitis_BMT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrographs of a completely obliterated bronchiole in a patient who has received an allogeneic bone marrow transplant. Left: Hematoxylin and eosin stained section shows complete replacement of a bronchiole by a collagenous scar associated with a scant inflammatory infiltrate and so-called cholesterol clefts, a nonspecific finding. Right: An elastic tissue stain is helpful in outlining the elastic layer of the same bronchiole pictured on the left and shows complete replacement of the bronchiole lumen by scar tissue.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 65164 Version 2.0</div></div></div>"},"65166":{"type":"graphic_picture","displayName":"Annular elastolytic giant cell granuloma - close view","title":"Annular elastolytic giant cell granuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Annular elastolytic giant cell granuloma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/65166_Annu_elast_giant_cell_gran.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mulitiple annular erythematous patches and plaques were present on the neck and arms. A biopsy revealed findings consistent with annular elastolytic giant cell granuloma.</div><div class=\"graphic_reference\">Copyright © Benjamin Ehst, MD, PhD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 65166 Version 5.0</div></div></div>"},"65167":{"type":"graphic_picture","displayName":"Seborrheic dermatitis face 3","title":"Seborrheic dermatitis of the face and beard area","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis of the face and beard area</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/65167_SeborrheicdermfacePR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous and scaly patches on the face and beard area.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65167 Version 5.0</div></div></div>"},"65169":{"type":"graphic_picture","displayName":"Calcium oxalate crystals","title":"Calcium oxalate crystals in the urine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcium oxalate crystals in the urine</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/NEPH/65169_Calcium_oxalate_crystals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment showing both dumbbell-shaped calcium oxalate monohydrate (long arrow) and envelope-shaped calcium oxalate dihydrate (short arrows) crystals. Although not shown, the monohydrate crystals may also have a needle-shaped appearance. The formation of calcium oxalate crystals is independent of the urine pH.</div><div class=\"graphic_reference\">Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.</div><div id=\"graphicVersion\">Graphic 65169 Version 2.0</div></div></div>"},"65171":{"type":"graphic_diagnosticimage","displayName":"MRI Focal cortical dysplasia","title":"MRI showing focal cortical dysplasia in the left temporal lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI showing focal cortical dysplasia in the left temporal lobe</div><div class=\"cntnt\"><img style=\"width:324px; height:397px;\" src=\"images/NEURO/65171_MRI_temporal_FCD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short TI Inversion Recovery (STIR) coronal oblique MR image, showing focal dysplasia in the left parahippocampal gyrus (arrow 1) and occipitotemporal gyrus (arrow 2). Cortical thickening, increased signal in the subcortical white matter, and blurring of the gray-white margin are appreciable in these two regions.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div id=\"graphicVersion\">Graphic 65171 Version 4.0</div></div></div>"},"65172":{"type":"graphic_figure","displayName":"DiGeorge chrom 22","title":"DiGeorge chromosome 22","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">DiGeorge chromosome 22</div><div class=\"cntnt\"><img style=\"width:397px; height:444px;\" src=\"images/ALLRG/65172_DiGeorge_chrom_22.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Schematic of chromosome 22 demonstrating critical DiGeorge syndrome (DGS) region, site of commercially available FISH probes and genes encoded with DGS region.<br />(B) FISH analysis of metaphase spread using commercially available chromosome 22q11.2 probe (green areas, white arrows) and control chromosome 22 probe outside of critical DGS region (red areas, orange arrows). Left panel: patient with chromosome 22q11.2 deletion as demonstrated by binding of 22q11.2 probe to only one chromosome. Right panel: normal control with binding of probe to both copies of chromosome 22.</div><div class=\"graphic_footnotes\">TUPLE1: TUP-like enhancer of SPLIT1 (a transcription regulator); IDD: integral membrane protein deleted in DiGeorge syndrome; STK22 A: homolog of mouse serine/threonine protein kinase 22 D; PRODH: proline dehydrogenase (oxidase 1); GSCL: goosecoid homeobox 2; SLC25 A1: solute carrier family 25 (mitochondrial carrier, citrate transporter), member 1; DVL1L1: dishevelled segment polarity protein 1 pseudogene 1; CLTCL1: clathrin, heavy chain-like 1; HIRA: histone cell cycle regulator; NLVCF: mitochondrial ribosomal protein L40; UFD1L: ubiquitin fusion degradation 1 like (yeast); CDC45L: cell division cycle 45; CLDN5: claudin 5; PNUTL1: septin 5; CDCrel-1: cell division cycle-related; GP1bb: glycoprotein 1b (platelet), beta polypeptide; TBX1: T-box transcription factor; COMT: catechol-O-methyltransferase; TR: T cell receptors; ARVCF: armadillo repeat gene deleted in velocardiofacial syndrome; LAMC1: laminin, gamma 1 (formerly LAMB2); DGCR6: DiGeorge critical region gene 6; RANBP1: RAN binding protein 1; ZNF74: zinc finger protein 74; HCF2: serpin peptidase inhibitor, clade D (heparin cofactor), member 1; PIK4CA: phosphatidylinositol 4-kinase, catalytic, alpha; SNAP29: synaptosomal-associated protein, 29kDa; CRKL: V-CRK avian sarcoma virus CT10 oncogene homolog-like; LZTR1: leucine-zipper-like transcription regulator 1; P2RX L1: purinergic receptor P2X, ligand gated ion channel, 6; SLC7A4: solute carrier family 7, member 4; FISH: fluorescence in situ hybridization.</div><div id=\"graphicVersion\">Graphic 65172 Version 3.0</div></div></div>"},"65173":{"type":"graphic_table","displayName":"Risk factors for chronic pancreatitis in children","title":"Causes and contributing risk factors for chronic pancreatitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes and contributing risk factors for chronic pancreatitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Causes</td> <td class=\"subtitle1\">Approximate frequency*<sup>[1]</sup><br /> (percent)</td> </tr> <tr> <td><strong>Genetic</strong></td> <td><strong>&nbsp;</strong></td> <td><strong>67</strong></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">&nbsp;</td> <td><em>PRSS1</em> mutations (serine protease 1 gene; encodes cationic trypsinogen)</td> <td>43</td> </tr> <tr> <td><em>SPINK1</em> mutations (serine protease inhibitor Kazal type 1 gene; encodes a pancreatic trypsin inhibitor)</td> <td>19</td> </tr> <tr> <td><em>CFTR</em> mutations (cystic fibrosis transmembrane regulator)</td> <td>14</td> </tr> <tr class=\"divider_bottom\"> <td><em>CTRC</em> mutations (encodes chymotrypsin C)</td> <td>3</td> </tr> <tr> <td><strong>Obstructive</strong></td> <td><strong>&nbsp;</strong></td> <td><strong>33</strong></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">&nbsp;</td> <td>Pancreas divisum</td> <td>20</td> </tr> <tr> <td>Sphincter of Oddi dysfunction</td> <td>1</td> </tr> <tr> <td>Gallstones</td> <td>4</td> </tr> <tr> <td>Pancreatic duct malunion or obstruction</td> <td>4</td> </tr> <tr class=\"divider_bottom\"> <td>Other obstruction (eg, trauma or idiopathic fibrosing pancreatitis)</td> <td>7</td> </tr> <tr> <td><strong>Toxic/metabolic</strong><sup>[2]</sup></td> <td><strong>&nbsp;</strong></td> <td><strong>11</strong></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">&nbsp;</td> <td>Alcohol</td> <td>1</td> </tr> <tr> <td>Passive smoking (exposure)</td> <td>4</td> </tr> <tr> <td>Hyperlipidemia<sup>&#182;</sup> (particularly triglycerides)</td> <td>1</td> </tr> <tr> <td>Drugs (eg, metronidazole, mercaptopurine, valproate, and isoniazid)</td> <td>1</td> </tr> <tr> <td>Metabolic disease (eg, branched-chain organic aciduria)</td> <td>1</td> </tr> <tr> <td>Chronic renal failure<sup>&#916;</sup></td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Hypercalcemia</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Autoimmune</strong></td> <td>May be isolated, or associated with systemic disorders (Sjogren syndrome, inflammatory bowel disease, or primary biliary cholangitis<sup>&#9674;</sup>)</td> <td><strong>4</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Idiopathic</strong></td> <td>No risk factors cited</td> <td><strong>11</strong><sup>&#167;</sup></td> </tr> <tr> <td><strong>Multiple risk factors</strong></td> <td>(especially pancreas divisum with a genetic risk factor)</td> <td><strong>21</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Approximate frequency of each risk factor in pediatric patients, from a large international registry study.<sup>[1]</sup><br />&para; Serum triglyceride levels of 1000 mg/dL or greater pose an absolute risk for pancreatitis, whereas levels between 500 and 1000 mg/dL may contribute as a predisposing factor.<sup>[2]</sup><br />&Delta; Mild or moderate elevations in serum amylase or lipase are common in patients with chronic renal failure, and do not necessarily indicate pancreatitis. Pancreatitis should be suspected in patients with amylase or lipase concentrations &gt;3 times the upper limit of normal.<sup>[2]</sup><br /><span class=\"lozenge\">&loz;</span> Primary biliary cholangitis was previously known as \"primary biliary cirrhosis.\"<br />&sect; Some of the patients diagnosed with \"idiopathic\" chronic pancreatitis in this study may have had genetic risk factors, because only 30 percent had undergone molecular testing for genetic causes of chronic pancreatitis.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Schwarzenberg SJ, Bellin M, Husain SZ, et al. Pediatric chronic pancreatitis is associated with genetic risk factors and substantial disease burden. J Pediatr 2015; 166:890.</li>&#xD;&#xA;    <li>Husain SZ, Morinville V, Pohl J, et al. Toxic-metabolic Risk Factors in Pediatric Pancreatitis: Recommendations for Diagnosis, Management, and Future Research. J Pediatr Gastroenterol Nutr 2016; 62:609.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 65173 Version 5.0</div></div></div>"},"65177":{"type":"graphic_table","displayName":"Causes of distress on vent","title":"Causes of respiratory distress in mechanically ventilated patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of respiratory distress in mechanically ventilated patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Ventilator</td> </tr> <tr> <td class=\"sublist1_start\">Inadequate ventilator settings</td> </tr> <tr> <td class=\"sublist1\">Tidal volume</td> </tr> <tr> <td class=\"sublist1\">FiO<sub>2</sub></td> </tr> <tr> <td class=\"sublist1\">Inspiratory flow rate (or pressure)</td> </tr> <tr> <td class=\"sublist1\">Positive end expiratory pressure (PEEP)</td> </tr> <tr> <td class=\"sublist1\">Trigger sensitivity</td> </tr> <tr> <td>Ventilator circuit leak</td> </tr> <tr> <td>Ventilator malfunction</td> </tr> <tr> <td>Inadequate ventilation due to caudal or esophageal misplacement of the endotracheal tube</td> </tr> <tr> <td class=\"subtitle1_single\">Airway (increased &#916;Ppeak-Pplat)</td> </tr> <tr> <td class=\"sublist1_start\">Endotracheal tube</td> </tr> <tr> <td class=\"sublist1\">Patient biting tube</td> </tr> <tr> <td class=\"sublist1\">Balloon cuff leak, deflation, or rupture</td> </tr> <tr> <td class=\"sublist1\">Increased airway resistance imposed by heat and moisture exchanger </td> </tr> <tr> <td class=\"sublist1\">Obstruction by secretions, blood, or foreign object</td> </tr> <tr> <td>Bronchospasm</td> </tr> <tr> <td>Obstruction of lower airways by secretions, blood, or foreign object</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary parenchymal disease (&#916;Ppeak-Pplat unchanged or decreased)</td> </tr> <tr> <td>Pneumonia</td> </tr> <tr> <td>Atelectasis</td> </tr> <tr> <td>Pulmonary edema (cardiogenic or non-cardiogenic)</td> </tr> <tr> <td>Aspiration of oropharyngeal or gastroesophageal contents</td> </tr> <tr> <td>Pulmonary embolus (thromboembolism or gas embolism)</td> </tr> <tr> <td>Migration of tube into right mainstem bronchus</td> </tr> <tr> <td class=\"subtitle1_single\">Extrapulmonary causes</td> </tr> <tr> <td>Pneumothorax</td> </tr> <tr> <td>Pleural effusion</td> </tr> <tr> <td>Abdominal distension (eg, ascites)</td> </tr> <tr> <td>Delerium, anxiety, pain, acute neurological event</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Ppeak: peak inspiratory pressure; PPlat: plateau pressure.</div><div id=\"graphicVersion\">Graphic 65177 Version 2.0</div></div></div>"},"65178":{"type":"graphic_table","displayName":"Acute eosinophilic pneumonia causes","title":"Known causes of acute eosinophilic pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Known causes of acute eosinophilic pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Drugs </td> </tr> <tr> <td>Acetaminophen</td> </tr> <tr> <td>Ampicillin and other beta-lactam antibiotics</td> </tr> <tr> <td>Daptomycin</td> </tr> <tr> <td>Fludarabine</td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Gemcitabine</span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Granulocyte macrophage colony stimulating factor</span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Imipenem/cilastatin*</span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Infliximab*</span></td> </tr> <tr> <td>Minocycline</td> </tr> <tr> <td>Nitrofurantoin</td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Nonsteroidal antiinflammatory agents* </span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Oxaliplatin</span></td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td>Inhaled pentamidine*</td> </tr> <tr> <td>Ranitidine</td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Sertraline*</span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Sulfasalazine/mesalamine</span></td> </tr> <tr> <td>Trazodone (overdose)*</td> </tr> <tr> <td>L-tryptophan</td> </tr> <tr> <td>Venlafaxine</td> </tr> <tr> <td class=\"subtitle1_single\">Infections </td> </tr> <tr> <td>Human immunodeficiency virus</td> </tr> <tr> <td>Parasitic infections (<em>Toxocara</em>, filaria, <em>Strongyloides</em>, <em>Ascaris</em>, and <em>Paragonimus</em>)</td> </tr> <tr> <td>Fungal infections (<em>Aspergillus</em>, <em>Candida albicans</em>, <em>Coccidioides immitis</em>, <em>Trichosporon</em>*, <em>Trichoderma</em> viride*)</td> </tr> <tr> <td class=\"subtitle1_single\">Other associations </td> </tr> <tr> <td>Leukemia</td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Drug rash with eosinophilia and systemic symptoms (DRESS syndrome)</span></td> </tr> <tr> <td>Guillain-Barr&#233; syndrome</td> </tr> <tr> <td>Hypersensitivity to \"red spider\" allergens</td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Idiopathic hypereosinophilic syndrome (myeloproliferative and lymphocytic variants)</span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Inhalation of cigarette smoke, electronic cigarettes, cannabis, crack cocaine, heroin, Scotchgard</span></td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\">Inhalational injury following building collapse (eg, World Trade Center)</span></td> </tr> <tr> <td>Postoperative respiratory failure of unknown etiology</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Isolated case reports.</div><div id=\"graphicVersion\">Graphic 65178 Version 2.0</div></div></div>"},"65180":{"type":"graphic_table","displayName":"Classification of panniculitis","title":"Clinical classification of panniculitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical classification of panniculitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Idiopathic</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Weber-Christian disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Physical</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cold, thermal injury, trauma, weight loss, chemical exposure</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Rheumatologic disorders</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Systemic lupus erythematosus (lupus profundus)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Complement deficiency</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Rheumatoid arthritis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Other - polymyositis, dermatositis, systemic sclerosis, vasculitis, eosinophilic fascilitis, eosinophilia-myalgia syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Malignancies</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hodgkin's disease and other lymphomas</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cytophagic histiocytic panniculitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Histiocytosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Leukemia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Dermatologic diseases</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Erythema nodosum</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Erythema induratum</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Other</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Infections</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Tuberculosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Fungal infections</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Other</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Other disorders</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Sarcoidosis, pancreatitis, amyloid, alpha-1 antitrypsin deficiency, renal failure, poststeroid withdrawal, neonatal pannniculitides, lipoatrophy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Factitial</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 65180 Version 2.0</div></div></div>"},"65181":{"type":"graphic_figure","displayName":"Subdural hematoma PI","title":"Subdural hematoma","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Subdural hematoma</div><div class=\"cntnt\"><img style=\"width:485px; height:567px;\" src=\"images/PI/65181_Subdural-hematoma-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A subdural hematoma is bleeding under the tough tissue that covers the brain, called the &quot;dura.&quot;</div><div id=\"graphicVersion\">Graphic 65181 Version 2.0</div></div></div>"},"65182":{"type":"graphic_figure","displayName":"Saline injection prior to EMR","title":"Cartoon depicting the use of saline injection prior to endoscopic mucosal resection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cartoon depicting the use of saline injection prior to endoscopic mucosal resection</div><div class=\"cntnt\"><img style=\"width:385px; height:266px;\" src=\"images/GAST/65182_EMR_submucosal_inject_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Simulated dysplastic lesion (red mark depicts dysplasia).<br> (B) Isolation of the lesion with submucosal fluid injection.<br> (C, D) Snare excision of isolated dysplastic lesion.</div><div class=\"graphic_reference\">Courtesy of Christopher Gostout, MD.</div><div id=\"graphicVersion\">Graphic 65182 Version 3.0</div></div></div>"},"65184":{"type":"graphic_figure","displayName":"Carvedilol and LVEF","title":"Carvedilol improves left ventricular ejection fraction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carvedilol improves left ventricular ejection fraction</div><div class=\"cntnt\"><img style=\"width:366px; height:314px;\" src=\"images/CARD/65184_Carvedilol_and_LVEF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After six months of therapy in patients with heart failure, carvedilol produced a dose-related increase in left ventricular ejection fraction (LVEF) which is significant with all doses used when compared to placebo.</div><div class=\"graphic_footnotes\">* p &lt;0.005 versus placebo.<BR>• p &lt;0.0001 versus placebo.</div><div class=\"graphic_reference\">Data from Bristow MR, Gilbert EM, Abraham WT, et al. Circulation 1996; 94:2807.</div><div id=\"graphicVersion\">Graphic 65184 Version 2.0</div></div></div>"},"65187":{"type":"graphic_diagnosticimage","displayName":"PML after organ transplantation","title":"Brain MRI of progressive multifocal leukoencephalopathy after cardiac transplantation","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Brain MRI of progressive multifocal leukoencephalopathy after cardiac transplantation</div><div class=\"cntnt\"><img style=\"width:541px; height:463px;\" src=\"images/NEURO/65187_Transplant_and_PML.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted (A) and FLAIR (B) images show hyperintensity in a confluent bifrontal pattern. Pre-contrast T1- weighted image (C) shows hypointensity in the lesion. Post-contrast T1-weighted image (D) demonstrates enhancement along the periphery, or advancing edge, of this lesion, suggesting a region of more active disease. The diffusion-weighted image (E) shows hyperintensity along this leading edge. The corresponding ADC map (F) shows diffuse increase in signal intensity suggesting facilitated water diffusion; however, there have been reports of restricted diffusion at the periphery (refer to text).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery.</div><div class=\"graphic_reference\">Courtesy of Eric D Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 65187 Version 3.0</div></div></div>"},"65188":{"type":"graphic_picture","displayName":"Severe hidradenitis suppurativa","title":"Severe hidradenitis suppurativa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe hidradenitis suppurativa</div><div class=\"cntnt\"><img style=\"width:396px; height:314px;\" src=\"images/OBGYN/65188_Severe_HS.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD,&nbsp;and Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 65188 Version 4.0</div></div></div>"},"65190":{"type":"graphic_figure","displayName":"Survival AML cytogenetic risk","title":"Overall survival in acute myeloid leukemia","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Overall survival in acute myeloid leukemia</div><div class=\"cntnt\"><img style=\"width:469px; height:336px;\" src=\"images/HEME/65190_Survival_AML_cytogenetic_ri.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates overall survival in adult subjects with acute myeloid leukemia (AML, age range 15 to 86 years, median 52 years), according to the following cytogenetic risk categories: Favorable risk (median survival 7.6 years): t(8;21); inv(16) or t(16;16); del(9q). Intermediate risk (median survival 1.3 years): normal karyotype; -Y; del(5q); loss of 7q; t(9;11); +11; del(11q); abn(12p); +13; del(20q); +21. Adverse risk (median survival 0.5 years): complex karyotype (&#8805;3 abnormalities); inv(3) or t(3;3); t(6;9); t(6;11); -7; +8 (sole abnormality); +8 with one other abnormality other than t(8;21), t(9;11), inv(16), or t(16;16); t(11;19)(q23;p13.1).</div><div class=\"graphic_reference\">Data from Byrd, JC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8641). Blood 2002; 100:4325.</div><div id=\"graphicVersion\">Graphic 65190 Version 3.0</div></div></div>"},"65192":{"type":"graphic_table","displayName":"Example of 16-step desensitization protocol","title":"Example of 16-step desensitization protocol for cefepime (2000 mg dose, 20 mL per solution)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of 16-step desensitization protocol for cefepime (2000 mg dose, 20 mL per solution)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle2\">Solution</td> <td class=\"subtitle2\" colspan=\"2\">Total volume</td> <td class=\"subtitle2\" colspan=\"2\">Concentration</td> <td class=\"subtitle2\" colspan=\"2\">Dose</td> </tr> <tr> <td>Solution 1</td> <td colspan=\"2\">20 mL</td> <td colspan=\"2\">0.1 mg/mL</td> <td colspan=\"2\">2 mg</td> </tr> <tr> <td>Solution 2</td> <td colspan=\"2\">20 mL</td> <td colspan=\"2\">1 mg/mL</td> <td colspan=\"2\">20 mg</td> </tr> <tr> <td>Solution 3</td> <td colspan=\"2\">20 mL</td> <td colspan=\"2\">10 mg/mL</td> <td colspan=\"2\">200 mg</td> </tr> <tr> <td>Solution 4</td> <td colspan=\"2\">20 mL</td> <td colspan=\"2\">96.053 mg/mL</td> <td colspan=\"2\">2000 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\">Step</td> <td class=\"subtitle1\">Solution</td> <td class=\"subtitle1\">Rate (mL/hour)</td> <td class=\"subtitle1\">Time (minutes)</td> <td class=\"subtitle1\">Volume infused per step (mL)</td> <td class=\"subtitle1\">Dose administered with this step (mg)</td> <td class=\"subtitle1\">Cumulative dose (mg)</td> </tr> <tr> <td>1</td> <td>1</td> <td>0.5</td> <td>15</td> <td>0.12</td> <td>0.013</td> <td>0.013</td> </tr> <tr> <td>2</td> <td>1</td> <td>1</td> <td>15</td> <td>0.25</td> <td>0.025</td> <td>0.038</td> </tr> <tr> <td>3</td> <td>1</td> <td>2</td> <td>15</td> <td>0.50</td> <td>0.050</td> <td>0.088</td> </tr> <tr> <td>4</td> <td>1</td> <td>4</td> <td>15</td> <td>1.00</td> <td>0.100</td> <td>0.188</td> </tr> <tr> <td>5</td> <td>2</td> <td>1</td> <td>15</td> <td>0.25</td> <td>0.250</td> <td>0.438</td> </tr> <tr> <td>6</td> <td>2</td> <td>2</td> <td>15</td> <td>0.50</td> <td>0.500</td> <td>0.938</td> </tr> <tr> <td>7</td> <td>2</td> <td>4</td> <td>15</td> <td>1.00</td> <td>1.000</td> <td>1.938</td> </tr> <tr> <td>8</td> <td>2</td> <td>8</td> <td>15</td> <td>2.00</td> <td>2.000</td> <td>3.938</td> </tr> <tr> <td>9</td> <td>3</td> <td>2</td> <td>15</td> <td>0.50</td> <td>5.000</td> <td>8.938</td> </tr> <tr> <td>10</td> <td>3</td> <td>4</td> <td>15</td> <td>1.00</td> <td>10.000</td> <td>18.938</td> </tr> <tr> <td>11</td> <td>3</td> <td>8</td> <td>15</td> <td>2.00</td> <td>20.000</td> <td>38.938</td> </tr> <tr> <td>12</td> <td>3</td> <td>16</td> <td>15</td> <td>4.00</td> <td>40.000</td> <td>78.938</td> </tr> <tr> <td>13</td> <td>4</td> <td>4</td> <td>15</td> <td>1.00</td> <td>96.053</td> <td>174.991</td> </tr> <tr> <td>14</td> <td>4</td> <td>10</td> <td>15</td> <td>2.50</td> <td>240.133</td> <td>415.123</td> </tr> <tr> <td>15</td> <td>4</td> <td>20</td> <td>15</td> <td>5.00</td> <td>480.266</td> <td>895.389</td> </tr> <tr> <td>16</td> <td>4</td> <td>40</td> <td>17.25</td> <td>11.50</td> <td>1104.611</td> <td>2000.000</td> </tr> <tr> <td colspan=\"7\"><strong>NOTE:</strong> Each step is administered over 15 minutes. At conclusion of protocol, observe patient for 30 minutes. Administer the next full dose at the time dictated by the medication pharmacokinetics.</td> </tr> <tr> <td colspan=\"7\">Total time = 242.25 minutes (4 hours 2 minutes).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Desensitization protocol instructions:</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\">1. Confirm written consent is in medical record.</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\">2. Ensure preceding dose of beta-blockers was held, unless otherwise advised by supervising clinician.</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\">3. Obtain IV access and vital signs (temperature, HR, BP, RR, oxygen saturation, peak flow).</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\">4. Have at bedside: Epinephrine 0.3 mg (for adults) for IM injection, oxygen, normal saline, peak flow meter, and BP cuff, albulterol, injectable preparation of diphenhydramine, and methylprednisolone.</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\">5. A nurse must closely observe the patient throughout the protocol (one-to-one).</td> </tr> <tr> <td colspan=\"7\"><strong>Administration:</strong> Hang each solution successively. Each step is administered over 15 minutes per protocol. There is no reason to wait between bags. Vital signs should be taken and recorded every 15 minutes and every 30 minutes during the last step.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Monitoring and charting during desensitization:</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"7\">Clearly document any reaction, including:</td> </tr> <tr> <td class=\"sublist2\" colspan=\"7\">a. Patient's symptoms, vital signs, and physical findings.</td> </tr> <tr> <td class=\"sublist2\" colspan=\"7\">b. Exactly when the reaction occurred (ie, what step, how many minutes into that step).</td> </tr> <tr> <td class=\"sublist2\" colspan=\"7\">c. Treatment administered, how and when the reaction resolved, and when the protocol was restarted.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Treatment of allergic reactions:</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\">1. <strong>For mild reactions:</strong> In case of isolated itching, flushing, hives, mild chest tightness, nausea, abdominal pain, or back pain with normal vital signs, stop the infusion and treat with IV diphenhydramine. Observe patient until the reaction subsides, and then resume the protocol by repeating the step at which the reaction occurred.</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\">2. <strong>For severe reactions:</strong> In case of hypotension, throat swelling, wheezing/respiratory distress, or decreased oxygen saturation, stop the infusion and treat with epinephrine 0.3 mg IM x 1, diphenhydramine and methylprednisolone IV, oxygen, inhaled albuterol for bronchospasm, and IV fluids (normal saline). Place patient in a recumbent position if hypotensive. Consider glucagon 1 to 2 mg IV bolus if patient has taken beta-blockers, followed by infusion at 1 to 5 mg/hour. <strong>Immediately alert the housestaff and supervising clinician.</strong> When the patient is stable, the protocol will be resumed as instructed by the supervising clinician.</td> </tr> <tr> <td class=\"indent1\" colspan=\"7\"><strong>Contact the supervising clinician for ANY severe or prolonged reaction or any questions regarding the protocol, reactions, and appropriate management.</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; HR: heart rate; BP: blood pressure; RR: respiratory rate; IM: intramuscular.</div><div class=\"graphic_reference\">Reproduced with permission from: Legere HJ 3rd, Palis RI, Bouza TR, et al. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros 2009; 8:418. Illustration used with the permission of Elsevier Inc. All rights reserved.<br />Instructions courtesy of Mariana Castells, MD, PhD.</div><div id=\"graphicVersion\">Graphic 65192 Version 8.0</div></div></div>"},"65193":{"type":"graphic_figure","displayName":"Anterior knee anatomy","title":"Anterior anatomy of the knee","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Anterior anatomy of the knee</div><div class=\"cntnt\"><img style=\"width:514px; height:433px;\" src=\"images/PEDS/65193_Anterior_knee_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior view of the knee with the patella removed, demonstrating the relationship between the bones, menisci, and major ligaments.</div><div id=\"graphicVersion\">Graphic 65193 Version 3.0</div></div></div>"},"65194":{"type":"graphic_algorithm","displayName":"Operative management of hepatic injury","title":"Operative management of hepatic injury","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Operative management of hepatic injury</div><div class=\"cntnt\"><img style=\"width:616px; height:525px;\" src=\"images/SURG/65194_Oper_manag_hepatic_injury.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm for operative management of blunt liver trauma.<br> (A) Minor bleeding most often from grade I or grade II injuries.<br> (B) Manual compression, fluid therapy, correct coagulopathy, acidosis, hypothermia.<br> (C) Subset of patients who would benefit from angiography is unknown.<br> (D) Placement of clamp across the porta hepatis.<br> (E) Finger fracture as needed to ligate bleeding vessels and injured bile ducts, viable omentum used to fill deadspace.<br> (F) Risk of liver necrosis.<br> (G) Rates of survivial improved with combination of packing and/or shunting compared with direct repair alone.<br> (H) Timing of interval laparotomy not well defined, formal resection rarely required.</div><div class=\"graphic_footnotes\">ICU: intensive care unit; SHAL: selective hepatic artery ligation.</div><div class=\"graphic_reference\">Reproduced with permission from: Kozar RA, Felciano DV, Moore EE, et al. Western Trauma Association/Critical Decisions in Trauma: Operative management of adult blunt hepatic trauma. J Trauma 2011; 71:1. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65194 Version 8.0</div></div></div>"},"65195":{"type":"graphic_figure","displayName":"Osmoregulation of ADH","title":"Osmotic regulation of ADH release and thirst","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Osmotic regulation of ADH release and thirst</div><div class=\"cntnt\"><img style=\"width:512px; height:313px;\" src=\"images/NEPH/65195_Osmoregulation_of_ADH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between plasma&nbsp;ADH concentration and plasma osmolality in normal humans in whom the plasma osmolality was changed by varying the state of hydration. The osmotic threshold for thirst is a few mosmol/kg higher than that for ADH.</div><div class=\"graphic_footnotes\">ADH: antidiuretic hormone.</div><div class=\"graphic_reference\">Data from Robertson GL, Aycinena P, Zerbe RL. Neurogenic disorders of osmoregulation. Am J Med 1982; 72:339.</div><div id=\"graphicVersion\">Graphic 65195 Version 5.0</div></div></div>"},"65197":{"type":"graphic_figure","displayName":"Bilirubin synthesis","title":"Bilirubin synthesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilirubin synthesis</div><div class=\"cntnt\"><img style=\"width:434px; height:356px;\" src=\"images/GAST/65197_Bilirubin_synthesis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conversion of heme to biliverdin and then bilirubin. Heme ring-opening at the alpha-carbon bridge of heme is catalyzed by heme oxygenase, resulting in the formation of biliverdin. This is followed by reduction of biliverdin to bilirubin in a reaction catalyzed by biliverdin reductase.</div><div class=\"graphic_footnotes\">NADH: reduced nicotinamide adenine dinucleotide; NADPH: reduced nicotinamide adenine dinucleotide phosphate.</div><div id=\"graphicVersion\">Graphic 65197 Version 2.0</div></div></div>"},"65199":{"type":"graphic_figure","displayName":"Cerebral vascular territories","title":"Major cerebral vascular territories","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Major cerebral vascular territories</div><div class=\"cntnt\"><img style=\"width:458px; height:306px;\" src=\"images/NEURO/65199_Supply_to_cerebral_hemisphe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representation of the territories of the major cerebral vessels shown in a coronal section of the brain.</div><div class=\"graphic_reference\">Reproduced with permission from Kistler, JP, et al, Cerebrovascular Diseases. Harrison's Principles of Internal Medicine, 13th ed, McGraw-Hill, New York 1994. Copyright 1994 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 65199 Version 2.0</div></div></div>"},"65200":{"type":"graphic_waveform","displayName":"R R interval","title":"Top portion of figure displays successive R-R intervals","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Top portion of figure displays successive R-R intervals</div><div class=\"cntnt\"><img style=\"width:470px; height:408px;\" src=\"images/OBGYN/65200_R_R_interval.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The interval, in fractions of a second, between these beats is used to calculate the instantaneous beat to beat interval and then a rolling average is taken and recorded of the fetal heart rate tracing.</div><div id=\"graphicVersion\">Graphic 65200 Version 2.0</div></div></div>"},"65201":{"type":"graphic_figure","displayName":"Anatomy of rectal prolapse","title":"Anatomy of rectal prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of rectal prolapse</div><div class=\"cntnt\"><img style=\"width:447px; height:324px;\" src=\"images/PEDS/65201_Anatomy_of_rectal_prolapse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Partial prolapse.<br />(B) Complete prolapse.<br />(C) Prolapsed intussusception.</div><div id=\"graphicVersion\">Graphic 65201 Version 2.0</div></div></div>"},"65202":{"type":"graphic_waveform","displayName":"Invasive hemodynamic tracing HCM with LVOT obstruction","title":"Invasive hemodynamic tracing obtained during cardiac catheterization in a patient with hypertrophic cardiomyopathy (HCM) with left ventricular outflow tract (LVOT) obstruction","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Invasive hemodynamic tracing obtained during cardiac catheterization in a patient with hypertrophic cardiomyopathy (HCM) with left ventricular outflow tract (LVOT) obstruction</div><div class=\"cntnt\"><img style=\"width:526px; height:330px;\" src=\"images/CARD/65202_HCM_hemodynamics.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are four surface ECG leads and the intracardiac pressure tracing obtained during cardiac catheterization. The systolic pressure in the left ventricle (LV) is 200 mmHg. When the catheter is pulled back to the LV outflow tract (LVOT), the LV systolic pressure falls to 100 mmHg, indicating that the pressure gradient across the LVOT is 100 mmHg. The aortic systolic pressure is also 100 mmHg, indicating that there is no gradient across the aortic valve.</div><div class=\"graphic_reference\">Courtesy of Lameh Fananapazir, MD.</div><div id=\"graphicVersion\">Graphic 65202 Version 4.0</div></div></div>"},"65203":{"type":"graphic_picture","displayName":"Erythema migrans - close view","title":"Erythema migrans","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Erythema migrans</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/65203_Erythema_migrans_close_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large inflammatory plaque with an annular configuration is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65203 Version 3.0</div></div></div>"},"65204":{"type":"graphic_algorithm","displayName":"Emergent evaluation of pediatric headache","title":"Headache in child with no immunocompromise, no shunt, and no known trauma","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Headache in child with no immunocompromise, no shunt, and no known trauma</div><div class=\"cntnt\"><img style=\"width:550px; height:612px;\" src=\"images/EM/65204_Emerg_eval_hdch_child_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; BP: blood pressure.</div><div id=\"graphicVersion\">Graphic 65204 Version 3.0</div></div></div>"},"65205":{"type":"graphic_table","displayName":"Causes of hirsutism in women","title":"Causes of hirsutism in women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hirsutism in women</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Common</td> </tr> <tr> <td class=\"indent1\">PCOS</td> <td>Peripubertal onset of symptoms, oligomenorrhea, obesity, polycystic ovaries on ultrasound</td> </tr> <tr> <td class=\"indent1\">Idiopathic hirsutism</td> <td>Normal menstrual cycles, normal serum androgens, and no other identifiable cause for the hirsutism</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nonclassic 21-hydroxylase deficiency</td> <td>Similar presentation to PCOS, high serum 17-hydroxyprogesterone concentration, more common in certain ethnic groups</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Uncommon</td> </tr> <tr> <td class=\"indent1\">Classic 21-hydroxylase deficiency</td> <td>Diagnosed during infancy, ambiguous genitalia</td> </tr> <tr> <td class=\"indent1\">Androgen-secreting ovarian tumors (Sertoli-Leydig cell, granulosa-theca cell, hilus cell)</td> <td>Onset in third decade or later (usually postmenopausal), rapidly progressive hirsutism, virilization</td> </tr> <tr> <td class=\"indent1\">Androgen-secreting adrenal tumors</td> <td>Some women with adrenocortical cancer present with just virilization, but a mixed Cushing's and virilization syndrome is more common</td> </tr> <tr> <td class=\"indent1\">Ovarian hyperthecosis</td> <td>Onset in third decade or later (usually postmenopausal), rapidly progressive hirsutism, virilization</td> </tr> <tr> <td class=\"indent1\">Severe insulin-resistance syndromes</td> <td>Virilization, amenorrhea, infertility, and the ovary shows histologic changes of hyperthecosis</td> </tr> <tr> <td class=\"indent1\">Cushing's disease</td> <td>Corticotroph adenoma secreting ACTH results in excess cortisol and adrenal androgens</td> </tr> <tr> <td class=\"indent1\">Drugs</td> <td>Use of exogenous androgens (testosterone or DHEA) can cause hirsutism and acne</td> </tr> <tr> <td class=\"indent1\">Acromegaly</td> <td>Enlarged jaw (macrognathia) and enlarged, swollen hands and feet, which&nbsp;result in increasing shoe, glove, and ring sizes. Patients with large pituitary tumors may have headaches, visual field defects, and cranial nerve palsies.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCOS: polycystic ovary syndrome; ACTH: corticotropin; DHEA: dehydroepiandrosterone.</div><div id=\"graphicVersion\">Graphic 65205 Version 9.0</div></div></div>"},"65207":{"type":"graphic_table","displayName":"Urodynamic patterns","title":"Urodynamic patterns in normal and abnormal bladder conditions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Urodynamic patterns in normal and abnormal bladder conditions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Filling phase</td> <td class=\"subtitle1\" colspan=\"2\">Voiding phase</td> </tr> <tr> <td class=\"subtitle2\">Detrusor contractions</td> <td class=\"subtitle2\">Sphincter activity</td> <td class=\"subtitle2\">Detrusor contractions</td> <td class=\"subtitle2\">Sphincter activity</td> </tr> <tr> <td><strong>Normal</strong></td> <td>Absent</td> <td>Present</td> <td>Present</td> <td>Absent</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"5\"><strong>Abnormalities identified on urodynamic testing</strong></td> </tr> <tr> <td class=\"sublist1\">Overactive bladder</td> <td class=\"sublist_other\">Present</td> <td class=\"sublist_other\">Present</td> <td class=\"sublist_other\">Present</td> <td class=\"sublist_other\">Absent</td> </tr> <tr> <td class=\"sublist1\">Detrusor sphincter dyssynergy</td> <td class=\"sublist_other\">Absent</td> <td class=\"sublist_other\">Present</td> <td class=\"sublist_other\">Present</td> <td class=\"sublist_other\">Present</td> </tr> <tr> <td class=\"sublist1\">Non-neurogenic dysfunctional voiding</td> <td class=\"sublist_other\">Absent</td> <td class=\"sublist_other\">Present</td> <td class=\"sublist_other\">Present</td> <td class=\"sublist_other\">Present</td> </tr> <tr> <td class=\"sublist1\">Underactive bladder</td> <td class=\"sublist_other\">Absent, large capacity bladder</td> <td class=\"sublist_other\">Present</td> <td class=\"sublist_other\">Inadequate, incomplete emptying</td> <td class=\"sublist_other\">Absent</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65207 Version 3.0</div></div></div>"},"65210":{"type":"graphic_figure","displayName":"Parotid space anatomy","title":"Parotid space anatomy","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Parotid space anatomy</div><div class=\"cntnt\"><img style=\"width:518px; height:506px;\" src=\"images/ID/65210_Parotid_space_anatomy_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65210 Version 2.0</div></div></div>"},"65211":{"type":"graphic_figure","displayName":"Risk of progressive CKD","title":"Risk of progressive CKD","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Risk of progressive CKD</div><div class=\"cntnt\"><img style=\"width:448px; height:334px;\" src=\"images/NEPH/65211_RiskprogressiveCKD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier curves showing long-term risk of progressive CKD (stage 4 or higher) among patients who did (dashed line) or did not (solid line) suffer acute kidney injury.</div><div class=\"graphic_footnotes\">CKD: chronic kidney disease.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd. Lo LJ, Go AS, Chertow GM, et al. Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int 2009; 76:893. Copyright © 2009.</div><div id=\"graphicVersion\">Graphic 65211 Version 3.0</div></div></div>"},"65212":{"type":"graphic_diagnosticimage","displayName":"String sign on MR angiography","title":"String sign on MR angiography","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">String sign on MR angiography</div><div class=\"cntnt\"><img style=\"width:582px; height:312px;\" src=\"images/NEURO/65212_String_sign_MR_angiography.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left internal carotid artery dissection in a 43-year-old man. A hemorrhagic crescent on axial T1 cervical MRI (A) and the string sign on follow-up neck MR angiography (B) are consistent with dissection.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; MR: magnetic resonance.</div><div class=\"graphic_reference\">Reproduced with permission from: Pary LF, Rodnitzky RL. Traumatic internal carotid artery dissection associated with taekwondo. Neurology 2003; 60:1392. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65212 Version 6.0</div></div></div>"},"65213":{"type":"graphic_picture","displayName":"Herpes zoster rash B","title":"Herpes zoster","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes zoster</div><div class=\"cntnt\"><img style=\"width:350px; height:360px;\" src=\"images/ID/65213_Herpes_zoster_rash_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Vaibhav Parekh, MD, MBA.</div><div id=\"graphicVersion\">Graphic 65213 Version 1.0</div></div></div>"},"65214":{"type":"graphic_diagnosticimage","displayName":"Color flow Doppler PDA","title":"Color flow Doppler in a patent ductus arteriosus","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Color flow Doppler in a patent ductus arteriosus</div><div class=\"cntnt\"><img style=\"width:547px; height:187px;\" src=\"images/CARD/65214_ColorflowDopplerPDA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The systolic image of the main pulmonary artery (MPA) shows shunt flow across a patent ductus arteriosus (PDA) (panel A). The ductal retrograde flow is seen as a bright mosaic jet superimposed on the normal blue flow in the MPA. Note that color away from the transducer is coded blue and flow towards is red. There is also a very small color jet of pulmonary regurgitation (PR) that is in the center of the pulmonary valve. Color flow image in the four-chamber apical view shows early diastolic inflow to the left side of the heart due to the large left-to-right shunt (panel B).</div><div class=\"graphic_footnotes\">RV: right ventricle; RA: right atrium; LV: left ventricle; LA: left atrium; RSPV: right superior pulmonary vein.</div><div id=\"graphicVersion\">Graphic 65214 Version 3.0</div></div></div>"},"65215":{"type":"graphic_table","displayName":"Periodic paralysis","title":"Periodic paralysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Periodic paralysis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   &nbsp;\n   </td>\n   <td  class=\"subtitle1\">\n   Hypokalemic Periodic Paralysis\n   </td>\n   <td  class=\"subtitle1\">\n   Thyrotoxic Periodic Paralysis\n   </td>\n   <td  class=\"subtitle1\">\n   Hyperkalemic Periodic Paralysis\n   </td>\n   <td  class=\"subtitle1\">\n   Andersen Syndrome\n   </td>\n   </tr>\n   <tr>\n   <td><strong>Age at onset</strong></td>\n   <td>First or second decade</td>\n   <td>&#62;20 years</td>\n   <td>First decade</td>\n   <td>First or second decade</td>\n   </tr>\n   <tr>\n   <td><strong>Attack frequency</strong></td>\n   <td>Infrequent (a few times a year)</td>\n   <td>Infrequent</td>\n   <td>Frequent (up to several a day)</td>\n   <td>Monthly</td>\n   </tr>\n   <tr>\n   <td><strong>Attack duration</strong></td>\n   <td>Hours to days</td>\n   <td>Hours to days</td>\n   <td>Minutes to hours</td>\n   <td>Days</td>\n   </tr>\n   <tr>\n   <td><strong>Precipitants</strong></td>\n   <td>\t<p>Exercise</p>\n\t<p>Carbohydrate load</p>\n\t<p>Stress</p>\n</td>\n   <td>\t<p>Exercise</p>\n\t<p>Carbohydrate load</p>\n\t<p>Stress</p>\n</td>\n   <td>\t<p>Exercise</p>\n\t<p>Fasting</p>\n\t<p>Stress</p>\n\t<p>K-rich food</p>\n</td>\n   <td>Rest after exercise</td>\n   </tr>\n   <tr>\n   <td><strong>Potassium level during attack</strong></td>\n   <td>Low</td>\n   <td>Low</td>\n   <td>Normal or elevated</td>\n   <td>Low, normal, or elevated</td>\n   </tr>\n   <tr>\n   <td><strong>Associated features</strong></td>\n   <td>Later onset myopathy</td>\n   <td>\t<p>Symptoms of thyrotoxicosis</p>\n\t<p>Low TSH with high T4 or high T3</p>\n</td>\n   <td>\t<p>Myotonia on examination and/or EMG</p>\n\t<p>Later onset myopathy</p>\n</td>\n   <td>\t<p>Dysmorphic features</p>\n\t<p>Ventricular arrhythmias</p>\n\t<p>Long QT interval</p>\n</td>\n   </tr>\n   <tr>\n   <td><strong>Etiology</strong></td>\n   <td>Autosomal dominant inherited defect in calcium or sodium ion channel on muscle membrane</td>\n   <td>\t<p>Thyrotoxicosis</p>\n\t<p>Possible inherited predisposition</p>\n</td>\n   <td>Autosomal dominant inherited defect of sodium ion channel on muscle membrane</td>\n   <td>Autosomal dominant inherited defect of inward rectifying potassium channel</td>\n   </tr>\n   <tr>\n   <td><strong>Penetrance</strong></td>\n   <td>Nonpenetrance common, especially in women</td>\n   <td>&nbsp;</td>\n   <td>High</td>\n   <td>Nonpenetrance and incomplete penetrance common</td>\n   </tr>\n   <tr>\n   <td><strong>Epidemiology</strong></td>\n   <td>Clinical expression in men more frequent than women</td>\n   <td>Highest incidence in Asians and in men more than women</td>\n   <td>Sexes equally affected</td>\n   <td>Marked intrafamilial phenotypic variation</td>\n   </tr>\n   <tr>\n   <td><strong>Preventive treatment</strong></td>\n   <td>\t<p>Carbonic anhydrase inhibitors</p>\n\t<p>Potassium-sparing diuretics</p>\n</td>\n   <td>\t<p>Euthyroid state</p>\n\t<p>Propranolol</p>\n</td>\n   <td>\t<p>Carbonic anhydrase inhibitors</p>\n\t<p>Thiazide diuretics</p>\n\t<p>Inhaled beta-agonists as needed</p>\n</td>\n   <td>Carbonic anhydrase inhibitors</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">Abbreviations: K = potassium; TSH = thyroid stimulating hormone; T4 = thyroid hormone (thyroxine); T3 = thyroid hormone (triiodothyronine); EMG = electromyography</div><div id=\"graphicVersion\">Graphic 65215 Version 1.0</div></div></div>"},"65216":{"type":"graphic_diagnosticimage","displayName":"Doppler umbilical cord prolapse","title":"Transabdominal ultrasound using color flow doppler demonstrating the presence of the umbilical cord (funic presentation) just above the cervical canal","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Transabdominal ultrasound using color flow doppler demonstrating the presence of the umbilical cord (funic presentation) just above the cervical canal</div><div class=\"cntnt\"><img style=\"width:463px; height:329px;\" src=\"images/OBGYN/65216_Doppler_umbilical_cord_prol.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65216 Version 3.0</div></div></div>"},"65218":{"type":"graphic_diagnosticimage","displayName":"Filling patterns Doppler echo","title":"Left ventricular diastolic dysfunction is a predictor of outcome after a myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular diastolic dysfunction is a predictor of outcome after a myocardial infarction</div><div class=\"cntnt\"><img style=\"width:448px; height:318px;\" src=\"images/CARD/65218_Filling_patterns_Doppler_ec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulsed Doppler recordings of transmitral filling (panel A) and color M-mode Doppler echocardiography (panel B) are methods for evaluating left ventricular (LV) diastolic function. In a normal filling pattern, the mitral E-wave deceleration time (DT) is 140 to 240 ms and the M-mode flow propagation velocity (Vp) is ≥45 cm/s). In diastolic dysfunction with impaired relaxation the DT is prolonged ≥ 240 ms and Vp is normal or reduced (&lt;45 cm/s). In a pseudonormal filling pattern the DT may be normal or prolonged, but the Vp is &lt;45 cm/s. In diastolic dysfunction with a restrictive filling, the DT is &lt;140 ms and the Vp is normal or &lt;45 cm/s. Patients with a myocardial infarction who have a restrictive or pseudonormal pattern have an increased incidence of left ventricular dilation and cardiac death.</div><div class=\"graphic_reference\">Data from Moller JE, Sondergaard E, Poulsen SH, Egstrup K. J Am Coll Cardiol 2000; 36:1841. Reprinted with permission from the American College of Cardiology.</div><div id=\"graphicVersion\">Graphic 65218 Version 3.0</div></div></div>"},"65219":{"type":"graphic_picture","displayName":"Rocking bed","title":"Rocking bed","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rocking bed</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/PULM/65219_Rocking_bed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rocking bed shown in head down position. When the bed rocks to a 27 degree foot down position, the diaphragm slides toward the feet, assisting inhalation.</div><div id=\"graphicVersion\">Graphic 65219 Version 2.0</div></div></div>"},"65220":{"type":"graphic_picture","displayName":"Skin biopsy subacute SLE II","title":"Subacute cutaneous lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subacute cutaneous lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:360px; height:231px;\" src=\"images/RHEUM/65220_Skin_biopsy_subacute_SLE_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of skin biopsy demonstrating prominent suprabasilar lymphocytosis accompanied by suprabasilar dyskeratosis in a patient with subacute lupus erythematosus. These findings reflect antibody-dependent cell-mediated injury of suprabasilar keratinocytes which manifest enhanced Ro antigen expression due to UV exposure.</div><div class=\"graphic_footnotes\">UV: ultraviolet.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 65220 Version 3.0</div></div></div>"},"65223":{"type":"graphic_table","displayName":"Comparison of diagnostic tests for Hirschsprung disease","title":"Comparison of sensitivity and specificity for rectal suction biopsy, contrast enema, and anorectal manometry in the diagnosis of Hirschsprung disease in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of sensitivity and specificity for rectal suction biopsy, contrast enema, and anorectal manometry in the diagnosis of Hirschsprung disease in children*</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Test</td>\r\n                    <td class=\"subtitle1\">Sensitivity</td>\r\n                    <td class=\"subtitle1\">Specificity</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"2\">Rectal suction biopsy</td>\r\n                    <td>93 percent</td>\r\n                    <td>100 percent</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>(95% CI, 77 - 98 percent)</td>\r\n                    <td>(95% CI, 96 - 100 percent)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"2\">Contrast enema</td>\r\n                    <td>76 percent</td>\r\n                    <td>97 percent</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>(95% CI, 57 - 89 percent)</td>\r\n                    <td>(95% CI, 91 - 99 percent)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td rowspan=\"2\">Anorectal manometry</td>\r\n                    <td>83 percent</td>\r\n                    <td>93 percent</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>(95% CI, 63 - 93 percent)</td>\r\n                    <td>(95% CI, 85 - 97 percent)</td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=51107&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_footnotes\">* Diagnosis was confirmed by full-thickness rectal biopsy and exluded by clinical follow-up for at least six months.</div><div class=\"graphic_reference\">Data from: De Lorijn, F, Reitsma, JB, Voskuijl, WP, et al. Diagnosis of Hirschsprung's disease: a prospective, comparative accuracy study of common tests. J Pediatr 2005; 146:787.</div><div id=\"graphicVersion\">Graphic 65223 Version 3.0</div></div></div>"},"65224":{"type":"graphic_diagnosticimage","displayName":"Fallen fragment sign","title":"Unicameral bone cyst: Fallen fragment sign","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Unicameral bone cyst: Fallen fragment sign</div><div class=\"cntnt\"><img style=\"width:503px; height:392px;\" src=\"images/PEDS/65224_Fallen_fragment_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) AP humerus. Observe the large metaphyseal unicameral bone cyst with a cortical fracture (arrow). The fractured fragment is demonstrated in the most caudal portion of the radiolucent defect, representing a fallen fragment sign (arrowhead), which is also known as a \"fallen leaf\" sign.<br />(B) AP humerus. Observe the radiolucent unicameral bone cyst with soap-bubbled matrix located centrally within the proximal metaphysis of the humerus. There is a small cortical fracture (arrow) with a fallen fragment sign within the cystic radiolucencies (arrowhead). About 10 percent of patients with unicameral bone cyst present with a fallen fragment sign.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65224 Version 3.0</div></div></div>"},"65226":{"type":"graphic_picture","displayName":"Local anesthetic block of the sacroiliac joint","title":"Local anesthetic block of the sacroiliac joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Local anesthetic block of the sacroiliac joint</div><div class=\"cntnt\"><img style=\"width:289px; height:351px;\" src=\"images/EM/65226_Sacroiliac_joint_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Local anesthetic block of the sacroiliac joint is used to confirm the sacroiliac joint is the source of posterior hip pain. The patient is positioned lying prone, completely flat. A 1.5 inch (3.8 cm), 22-gauge needle is inserted perpendicular to the skin, 2.5 to 3.8 cm (1 to 1.5 in) lateral to the midline, to a depth of 2.5 to 3.8 cm (1 to 1.5 in). 1 mL of local anesthetic is placed at the interface of the subcutaneous fat and the outer muscle fascia. The needle is withdrawn a 0.7 cm (0.25 in) and redirected laterally at an angle of 10-15 degrees (this point of entry and angulation allows safe passage under the wing of the posterior iliac crest). The needle is advanced through the fascia gently until the firm resistance of bone is reached. 1 to 2 mL of anesthetic is injected adjacent to the posterior aspect of the sacroiliac joint.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 65226 Version 4.0</div></div></div>"},"65227":{"type":"graphic_diagnosticimage","displayName":"Acute interstitial pneum CT","title":"CT scan of acute interstitial pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of acute interstitial pneumonia</div><div class=\"cntnt\"><img style=\"width:350px; height:287px;\" src=\"images/PULM/65227_Acute_interstitial_pneum_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan of the chest showing bilateral, diffuse areas of ground glass opacities in the midlung zones.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 65227 Version 3.0</div></div></div>"},"65230":{"type":"graphic_picture","displayName":"Sputum with Staphylococcus aureus","title":"Sputum with <em>Staphylococcus aureus</em>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sputum with <em>Staphylococcus aureus</em></div><div class=\"cntnt\"><img style=\"width:338px; height:238px;\" src=\"images/ID/65230_Saureussputum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of sputum (x1000) shows many inflammatory cells and gram-positive cocci in clusters. <EM>Staphylococcus aureus </EM>grew from this specimen on blood agar and tested positive for free coagulase activity.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 65230 Version 3.0</div></div></div>"},"65231":{"type":"graphic_picture","displayName":"Pemphigoid gestationis","title":"Pemphigoid gestationis (herpes gestationis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pemphigoid gestationis (herpes gestationis)</div><div class=\"cntnt\"><img style=\"width:356px; height:284px;\" src=\"images/OBGYN/65231_Pemphigoid_gestationis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65231 Version 1.0</div></div></div>"},"65233":{"type":"graphic_waveform","displayName":"LV Doppler flow patterns","title":"Normal left ventricular Doppler flow patterns","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal left ventricular Doppler flow patterns</div><div class=\"cntnt\"><img style=\"width:405px; height:297px;\" src=\"images/CARD/65233_LV_Doppler_flow_patterns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the Doppler beam directed from apex to base, a variety of Doppler flow velocity patterns within the left ventricle (LV) can be obtained. The position of the sample volume for recording each of these patterns is shown in the diagram of an apical &quot;five-chamber&quot; view. Pattern #1 is flow within the left ventricular (or mitral valve) inflow tract (LVIT) as recorded from the tip of the mitral valve on its left ventricular side. The M-shaped inflow pattern is nearly identical to the M-mode image of mitral leaflet motion. The initial velocity peak represents the highest velocity achieved during the passive or rapid filling (RF) phase; the lower peak velocity represents the atrial (A) inflow phase. Although there is similarity in the appearance between the mitral M-mode motion and Doppler flow signals, there is very little predictive value of one for the other. Pattern #3 is flow within the left ventricular outflow tract (LVOT), representing systolic flow leaving the LV; this systolic signal demonstrates flow away from the transducer or away from the apex. Pattern #2 (LVIT/LVOT) is a hybrid mixture of #1 and #3 and gives inaccurate information about either. It is important to sample the Doppler flow signal axial to its flow.</div><div id=\"graphicVersion\">Graphic 65233 Version 3.0</div></div></div>"},"65234":{"type":"graphic_figure","displayName":"Vitrectomy","title":"Vitrectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vitrectomy</div><div class=\"cntnt\"><img style=\"width:365px; height:327px;\" src=\"images/PC/65234_Vitrectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three sclerotomies are made on the outside of the eye, one that allows fluid to infuse into the eye, and two others that are used to introduce instruments into the back part of the eye. Using a light pipe and a vitreous cutter all of the central and peripheral vitreous is removed and all of the vitreoretinal traction on any of the breaks excised.</div><div class=\"graphic_reference\">Reproduced with permission from: Wilkinson CP, Rice TA. Michel's Retinal Detachment, 2nd ed, Mosby-Year Book, Inc., Louis 1997. Copyright © Charles P Wilkinson, MD.</div><div id=\"graphicVersion\">Graphic 65234 Version 3.0</div></div></div>"},"65235":{"type":"graphic_waveform","displayName":"Invasive hemodynamic tracing provoked LVOT gradient in HCM","title":"Invasive hemodynamic tracing in a patient with HCM showing inducible LVOT obstruction following a VPB and the Valsalva maneuver","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Invasive hemodynamic tracing in a patient with HCM showing inducible LVOT obstruction following a VPB and the Valsalva maneuver</div><div class=\"cntnt\"><img style=\"width:471px; height:184px;\" src=\"images/CARD/65235_Provoked_gradient_in_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are five surface ECG leads (I, II, aVL, V1, V6) and the left ventricular (LV, arrows) and aortic (Ao, arrows) pressure tracings from a patient with hypertrophic cardiomyopathy. In the basal state, the LV and Ao pressures are equal at over 200 mmHg and there is no LV outflow gradient. However, after ventricular premature beats (VPB, arrows), there is an LV outflow tract pressure gradient of about 140 mmHg; in addition, the LV outflow tract pressure gradient is 70 mmHg during a Valsalva maneuver. LV outflow obstruction is associated with narrowing of the arterial pulse pressure.</div><div class=\"graphic_reference\">Courtesy of Lameh Fananapazir, MD.</div><div id=\"graphicVersion\">Graphic 65235 Version 3.0</div></div></div>"},"65236":{"type":"graphic_diagnosticimage","displayName":"Lateral forearm","title":"Lateral view of normal forearm in 9-year-old","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Lateral view of normal forearm in 9-year-old</div><div class=\"cntnt\"><img style=\"width:515px; height:173px;\" src=\"images/EM/65236_Lateral_forearm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A true lateral view of the forearm has superimposition of the radial head upon the ulnar coronoid process at the proximal end, superimposition of the radius and ulna at the distal end, a view of the soft tissues around both bones, and an elbow position that is 90 degrees of flexion.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD</div><div id=\"graphicVersion\">Graphic 65236 Version 4.0</div></div></div>"},"65240":{"type":"graphic_figure","displayName":"Types of odontogenic infections","title":"Odontogenic infections","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Odontogenic infections</div><div class=\"cntnt\"><img style=\"width:546px; height:212px;\" src=\"images/ID/65240_Types_of_odontogenic_infect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Dental caries, pulpal infection, and periapical abscess. <br />Panel B: Periodontal infection with destruction of supporting structures. <br />Panel C: Pericoronal infection.</div><div class=\"graphic_reference\">Reproduced with permission from Chow AW, Roser SM, Brady FA, Ann Intern Med 1978; 88:392.</div><div id=\"graphicVersion\">Graphic 65240 Version 3.0</div></div></div>"},"65241":{"type":"graphic_picture","displayName":"White-centered hemorrhages","title":"White-centered hemorrhages","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">White-centered hemorrhages</div><div class=\"cntnt\"><img style=\"width:535px; height:417px;\" src=\"images/ID/65241_White-centered_hemorrhages.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White-centered hemorrhages in the optic fundi of patients with cerebral malaria. The image on the right is from a patient with hemorrhages and whitening (prominently seen around the macula).</div><div class=\"graphic_reference\">Courtesy of Susan Lewallen and Nicholas Beare.</div><div id=\"graphicVersion\">Graphic 65241 Version 2.0</div></div></div>"},"65244":{"type":"graphic_figure","displayName":"Position of L paratracheal node","title":"Position of the left paratracheal lymph node","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Position of the left paratracheal lymph node</div><div class=\"cntnt\"><img style=\"width:310px; height:355px;\" src=\"images/PULM/65244_Position_of_L_paratracheal.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Kavuru, MS, Mehta, AC. Applied anatomy of the airways. In: Wang, KP, Mehta, AC (Eds), Flexible Bronchoscopy, Blackwell Science Inc, Cambridge, MA 1995.</div><div id=\"graphicVersion\">Graphic 65244 Version 1.0</div></div></div>"},"65245":{"type":"graphic_picture","displayName":"Fundus of septate uterus","title":"Smooth broad fundus of septate uterus viewed through a laparoscope","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Smooth broad fundus of septate uterus viewed through a laparoscope</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/OBGYN/65245_Fundusofseptateuterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 65245 Version 14.0</div></div></div>"},"65247":{"type":"graphic_picture","displayName":"Gingival infiltration AML","title":"Gingival infiltration in acute monoblastic leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gingival infiltration in acute monoblastic leukemia</div><div class=\"cntnt\"><img style=\"width:328px; height:442px;\" src=\"images/HEME/65247_Gingival_infiltration_AML.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked gingival enlargement affecting both upper and lower gingivae in our patient affected by acute monoblastic leukemia.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Gallipoli, P, Leach, M. Gingival infiltration in acute monoblastic leukaemia. Br Dental J 2007; 203:507. Copyright &#169; 2007.</div><div id=\"graphicVersion\">Graphic 65247 Version 1.0</div></div></div>"},"65248":{"type":"graphic_picture","displayName":"Deforming arthritis in SLE","title":"Deforming lupus arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Deforming lupus arthritis</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/RHEUM/65248_Deforming_arthritis_in_SLE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe hand deformities in a 75-year-old woman with lupus for more than 20 years. Such hand abnormalities are very rare.</div><div class=\"graphic_reference\">Courtesy of Peter H Schur, MD.</div><div id=\"graphicVersion\">Graphic 65248 Version 1.0</div></div></div>"},"65249":{"type":"graphic_table","displayName":"Indications for abdominal paracentesis","title":"Indications for abdominal paracentesis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for abdominal paracentesis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>New onset ascites</td> </tr> <tr> <td>Hospitalization of a patient with ascites</td> </tr> <tr> <td>Management of tense ascites or ascites that is diuretic-resistant</td> </tr> <tr> <td class=\"sublist1_start\">Clinical deterioration of an inpatient or outpatient with ascites</td> </tr> <tr> <td class=\"sublist1\">- Fever</td> </tr> <tr> <td class=\"sublist1\">- Abdominal pain</td> </tr> <tr> <td class=\"sublist1\">- Abdominal tenderness</td> </tr> <tr> <td class=\"sublist1\">- Hepatic encephalopathy</td> </tr> <tr> <td class=\"sublist1\">- Peripheral leukocytosis</td> </tr> <tr> <td class=\"sublist1\">- Deterioration in renal function</td> </tr> <tr> <td class=\"sublist1\">- Acidosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65249 Version 3.0</div></div></div>"},"65251":{"type":"graphic_figure","displayName":"Seldinger cricothyrotomy step 5","title":"Seldinger cricothyrotomy technique: Step 5","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seldinger cricothyrotomy technique: Step 5</div><div class=\"cntnt\"><img style=\"width:415px; height:565px;\" src=\"images/EM/65251_Cric_Seldinger_step_five.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thread the combined tissue dilator-airway catheter over the guidewire and advance it, following the curve of the dilator, through the subcutaneous soft tissue and into the trachea until the cuff of the catheter is flush against the skin of the neck.</div><div id=\"graphicVersion\">Graphic 65251 Version 3.0</div></div></div>"},"65252":{"type":"graphic_figure","displayName":"Alendronate versus ERT","title":"Effects of different therapies on bone mineral density in postmenopausal osteoporosis","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Effects of different therapies on bone mineral density in postmenopausal osteoporosis</div><div class=\"cntnt\"><img style=\"width:510px; height:395px;\" src=\"images/ENDO/65252_Alendronate_versus_ERT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean percentage change (±SE) from baseline in bone mineral density at the lumbar spine, total hip, total body, and one-third distal forearm during four years of therapy in healthy postmenopausal women. Red lines represent treatment with estradiol-norethisterone acetate (E-N); blue lines represent estrogen-medroxyprogesterone acetate (E-MPA); green lines represent alendronate, 5 mg/day (Al-5); orange lines represent alendronate, 2.5 mg/day (Al-2.5); and black dashed lines represent placebo. For graphical presentation, results from groups that received the same dose of alendronate during the first two years of the study were pooled. All of the therapies prevented bone loss, with E-N having the greatest effect at the spine and total body.</div><div class=\"graphic_reference\">Data from: Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999; 131:935.</div><div id=\"graphicVersion\">Graphic 65252 Version 2.0</div></div></div>"},"65253":{"type":"graphic_diagnosticimage","displayName":"Mucinous cystic neoplasm","title":"Pancreatic mucinous cystic neoplasm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic mucinous cystic neoplasm</div><div class=\"cntnt\"><img style=\"width:400px; height:306px;\" src=\"images/GAST/65253_Mucinous_cystic_neoplasm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An incidental 3 cm unilocular mucinous cystic neoplasm in the tail of the pancreas.</div><div class=\"graphic_reference\">Courtesy of Kevin McGrath, MD, and Asif Khalid, MD.</div><div id=\"graphicVersion\">Graphic 65253 Version 3.0</div></div></div>"},"65255":{"type":"graphic_waveform","displayName":"EEG Breach rhythm","title":"Breach rhythm","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Breach rhythm</div><div class=\"cntnt\"><img style=\"width:462px; height:287px;\" src=\"images/NEURO/65255_Breach_rhythm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breach rhythm noted at the C3 electrode in a 61-year-old man with history of head trauma and a left frontoemporal craniotomy.</div><div class=\"graphic_reference\">Reproduced with permission from: Mushtaq, R, Van Cott, AC, Benign EEG variants. Am J Electroneurodiagnostic Technol 2005; 45:88. Copyright ©2005 American Society of Electroneurodiagnostic Technologists.</div><div id=\"graphicVersion\">Graphic 65255 Version 3.0</div></div></div>"},"65256":{"type":"graphic_diagnosticimage","displayName":"Heterotopic pregnancy","title":"Heterotopic pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heterotopic pregnancy</div><div class=\"cntnt\"><img style=\"width:393px; height:315px;\" src=\"images/OBGYN/65256_Heterotopic_pregnancy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Heterotopic pregnancy at 6 weeks gestational age in a patient undergoing in vitro fertilization. Note the two intrauterine gestational sacs (arrowheads) and an echogenic ring-like mass (arrow) outside of the uterus with adjacent blood clot.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 65256 Version 2.0</div></div></div>"},"65257":{"type":"graphic_table","displayName":"Causes hip pain children","title":"Causes of hip pain in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hip pain in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infectious</td> </tr> <tr> <td class=\"indent1\">Septic arthritis of the hip</td> </tr> <tr> <td class=\"indent1\">Septic arthritis of the sacroiliac joint</td> </tr> <tr> <td class=\"indent1\">Lyme disease</td> </tr> <tr> <td class=\"indent1\">Osteomyelitis of femoral head or pelvis</td> </tr> <tr> <td class=\"indent1\">Psoas abscess</td> </tr> <tr> <td class=\"indent1\">Appendicitis or abdominal/pelvic abscess</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory</td> </tr> <tr> <td class=\"indent1\">Transient synovitis</td> </tr> <tr> <td class=\"sublist2_start\">Systemic arthritis</td> </tr> <tr> <td class=\"sublist2\">- Spondyloarthropathy</td> </tr> <tr> <td class=\"sublist2\">- Juvenile idiopathic arthritis (formerly juvenile rheumatoid arthritis;&nbsp;rare as isolated hip pain)</td> </tr> <tr> <td class=\"sublist2\">- Infectious/post-infectious</td> </tr> <tr> <td class=\"indent1\">Idiopathic chondrolysis of the hip</td> </tr> <tr> <td class=\"indent1\">Chronic recurrent multifocal osteomyelitis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Mechanical/orthopedic</td> </tr> <tr> <td class=\"indent1\">Slipped capital femoral epiphysis (SCFE)</td> </tr> <tr> <td class=\"sublist2_start\">Avascular necrosis</td> </tr> <tr> <td class=\"sublist2\">- Legg-Calv&#233;-Perthes disease</td> </tr> <tr> <td class=\"sublist2\">- Secondary avascular necrosis</td> </tr> <tr> <td class=\"indent1\">Femoral stress fracture</td> </tr> <tr> <td class=\"indent1\">Muscular strain</td> </tr> <tr> <td class=\"indent1\">Iliac apophysitis</td> </tr> <tr> <td class=\"indent1\">Snapping iliopsoas tendon</td> </tr> <tr> <td class=\"indent1\">Trochanteric bursitis</td> </tr> <tr> <td class=\"indent1\">Acetabular labral tear</td> </tr> <tr> <td class=\"indent1\">Femoroacetabular impingement</td> </tr> <tr> <td class=\"subtitle1_single\">Neoplastic</td> </tr> <tr> <td class=\"indent1\">Osteoid osteoma</td> </tr> <tr> <td class=\"indent1\">Leukemia</td> </tr> <tr> <td class=\"indent1\">Solid tumor, primary or metastatic</td> </tr> <tr> <td class=\"indent1\">Pigmented villonodular synovitis (PVNS)</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Sickle cell pain crisis</td> </tr> <tr> <td class=\"indent1\">Gaucher disease</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65257 Version 8.0</div></div></div>"},"65258":{"type":"graphic_table","displayName":"Diagnostic tests developmental coordination disorder","title":"Examples of instruments used in the diagnosis of developmental coordination disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of instruments used in the diagnosis of developmental coordination disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Movement Assessment Battery for Children (MABC) or MABC, second edition (MABC2)</td> </tr> <tr> <td>McCarron Assessment of Neuromuscular Development</td> </tr> <tr> <td>Bruininks-Oseretski Test of Motor Proficiency (BOTMP)</td> </tr> <tr> <td>Beery-Buktenica Developmental Test of Visual-Motor Integration</td> </tr> <tr> <td>Peabody Developmental Motor Scales</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hendersen SE, Sugden DA. Movement assessment battery for children. The Psychological Corporation, San&nbsp;Antonio, TX&nbsp;1992. </LI>&#xD;&#xA;<LI>Brown T, Lalor A. The Movement Assessment Battery for Children--Second Edition (MABC-2): a review and critique. Phys Occup Ther Pediatr 2009; 29:86.&nbsp;</LI>&#xD;&#xA;<LI>McCarron LT. McCarron Assessment of Neuromuscular Development (revised ed). Common Market Press, Dallas, TX 1982. </LI>&#xD;&#xA;<LI>Bruininks RH. Bruininks-Oseretski test of motor proficiency. American Guidance Service, Circle Pines, MN 1978. </LI>&#xD;&#xA;<LI>Beery KE, Buktenica NA. Beery-Buktenica Developmental Test of Visual-Motor Integration, 6th ed, Pearson Assessments, Minneapolis, MN 2010. </LI>&#xD;&#xA;<LI>Folio MR, Fewell RR. Peabody Developmental Motor Scales, Second Edition (PDMS-2), Western Psychological Services, Los Angeles, CA 2000. </LI></OL></div><div id=\"graphicVersion\">Graphic 65258 Version 10.0</div></div></div>"},"65259":{"type":"graphic_figure","displayName":"Musculoskeletal screen 2","title":"The pGALS musculoskeletal screen (continued)","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">The pGALS musculoskeletal screen (continued)</div><div class=\"cntnt\"><img style=\"width:589px; height:715px;\" src=\"images/PEDS/65259_Musculoskeletal_screen_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">pGALS: pediatric Gait Arms Legs Spine.</div><div class=\"graphic_reference\">Reproduced with permission from: Foster HE, Jandial S. pGALS - A Screening Examination of the Musculoskeletal System in School-Aged Children. Reports on the Rheumatic Diseases (Series 5), Hands On 15. Arthritis Research Campaign; 2008 June. Copyright &copy; 2008 Arthritis Research Campaign.</div><div id=\"graphicVersion\">Graphic 65259 Version 3.0</div></div></div>"},"65260":{"type":"graphic_table","displayName":"US findings active celiac disease","title":"Analysis and ultrasound findings of patients with celiac disease (active versus remission)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Analysis and ultrasound findings of patients with celiac disease (active versus remission)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Active celiac disease</td> <td class=\"subtitle1\">Celiac disease in remission</td> </tr> <tr> <td>Number (female/male)</td> <td>16 (12/4)</td> <td>34 (27/7)</td> </tr> <tr> <td>Age [years]</td> <td>54 &#177; 15 [27 - 77]</td> <td>42 &#177; 14 [18 - 72]</td> </tr> <tr> <td>\"Laundry phenomenon\"</td> <td>16/16 (100 percent)</td> <td>0</td> </tr> <tr> <td>Bowel wall thickening*</td> <td>4/16 (25 percent)</td> <td>0</td> </tr> <tr> <td>Lymph node detection rate &#62;2</td> <td>11/16 (69 percent)</td> <td>1/34 (3 percent)</td> </tr> <tr> <td>Spleen volume [mL]</td> <td>118 &#177; 34 [56 - 192]</td> <td>91 &#177; 26 [33 - 129]</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* All patients with circumscribed (malignant) bowel wall thickening revealed a \"laundry phenomenon\" (hyperechoic images, like laundry in the drum of a washing machine)&nbsp;and showed enlarged mesenteric lymph nodes.</div><div id=\"graphicVersion\">Graphic 65260 Version 2.0</div></div></div>"},"65261":{"type":"graphic_figure","displayName":"Uterus didelphys bicollis","title":"Uterus didelphys, bicollis, with complete upper vaginal septum with bilateral obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterus didelphys, bicollis, with complete upper vaginal septum with bilateral obstruction</div><div class=\"cntnt\"><img style=\"width:284px; height:208px;\" src=\"images/OBGYN/65261_Uterusdidelphysbicollis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 65261 Version 13.0</div></div></div>"},"65262":{"type":"graphic_table","displayName":"Self-report measures for specific phobia by phobia subtype","title":"Self-report measures for specific phobia by phobia subtype","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Self-report measures for specific phobia by phobia subtype</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Subtype</td> <td class=\"subtitle1\">Measure</td> </tr> <tr> <td rowspan=\"3\">Blood-Injection-Injury</td> <td>Mutilation Questionnaire</td> </tr> <tr> <td>Medical Fear Survey</td> </tr> <tr> <td>Blood-Injection Symptom Scale</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Situational</td> <td>Claustrophobia Questionnaire</td> </tr> <tr> <td>Dental Anxiety Inventory</td> </tr> <tr class=\"divider_top\"> <td>Natural environment</td> <td>Acrophobia Questionnaire</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Animal</td> <td>Snake Questionnaire</td> </tr> <tr> <td>Fear of Spiders Questionnaire</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65262 Version 1.0</div></div></div>"},"65263":{"type":"graphic_table","displayName":"Recommendations for ER and PR testing by IHC in breast cancer","title":"Summary of guideline recommendations for ER and PR testing by immunohistochemistry in breast cancer patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of guideline recommendations for ER and PR testing by immunohistochemistry in breast cancer patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Optimal algorithm for ER/PR testing</td> </tr> <tr> <td class=\"subtitle2_left\">Recommendation</td> <td class=\"subtitle2_left\">Comments</td> </tr> <tr> <td>Positive for ER or PR if finding of &#8805;1 percent of tumor cell nuclei are immunoreactive.</td> <td rowspan=\"2\">These definitions depend on laboratory documentation of the following: <ol> <li>Proof of initial testing validation using clinically validated antibody </li> <li>Ongoing internal quality assurance procedures </li> <li>Participation in external proficiency testing </li> <li>Biennial accreditation by valid accrediting agency </li> </ol> </td> </tr> <tr> <td>Negative for ER or PR if finding of &#60;1 percent of tumors cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PR (positive intrinsic controls are seen).</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Optimal testing conditions</td> </tr> <tr> <td class=\"subtitle2_left\">Recommendation</td> <td class=\"subtitle2_left\">Comments</td> </tr> <tr> <td rowspan=\"2\">Large, preferably multiple core biopsies of tumor are preferred for testing if they are representative of the tumor (grade and type) at resection.</td> <td>Specimen should be rejected and repeated on a separate sample if any of the following conditions exist: <ol> <li>External controls are not as expected (scores recorded daily show variation) </li> <li>Artifacts involve most of sample </li> </ol> </td> </tr> <tr> <td>Specimen may also be rejected and repeated on another sample if: <ol> <li>Slide has no staining of included normal epithelial elements and/or normal positive control on same slide </li> <li>Specimen decalcified using strong acids </li> <li>Specimen shows an ER-/PR+ phenotype (to rule out a false-negative ER assay or a false-positive PR assay) </li> <li>Sample has prolonged cold ischemia time or fixation duration &#60;6 hours or &#62;72 hours and is negative on testing in the absence of internal control elements </li> </ol> </td> </tr> <tr> <td rowspan=\"2\">Interpretation follows guideline recommendation.</td> <td> <ul> <li>Positive ER or PR requires &#8805;1 percent of tumor cells are immunoreactive; both average intensity and extent of staining are reported </li> <li>Image analysis is a desirable method of quantifying percent of tumor cells which are immunoreactive </li> <li>H Score, Allred Score or Quick Score may be provided </li> <li>Negative ER or PR requires &#60;1 percent of tumor cells with ER or PR staining </li> </ul> </td> </tr> <tr> <td>Interpreters have method to maintain consistency and competency documented regularly.</td> </tr> <tr> <td>Accession slip and report must include guideline-detailed elements.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Optimal tissue handling requirements</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Recommendation</td> </tr> <tr> <td colspan=\"2\"> <p>Time from tissue acquisition to fixation should be as short as possible. Samples for ER and PR testing are fixed in 10 percent neutral buffered fomalin (NBF) for 6 to 72 hours. Samples should be sliced at 5 mm intervals after appropriate gross inspection and margins designation and placed in sufficient volume of NBF to allow adequate tissue penetration.</p> <p>If tumor comes from remote location, it should be bisected through the tumor on removal and sent to the laboratory immersed in a sufficient volume of NBF. Cold ischemia time, fixative type, and time the sample was placed in NBF must be recorded.</p> </td> </tr> <tr> <td colspan=\"2\">Storage of slides for more than six weeks prior to analysis is not recommended.</td> </tr> <tr> <td colspan=\"2\">Time tissue is removed from patient, time tissue is placed in fixative, duration of fixation and fixative type must be recorded and noted on accession slip or in report.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Guidelines from a combined panel from the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP).</div><div class=\"graphic_footnotes\">ER: estrogen receptor; NBF: neutral buffered formalin; PR: progesterone receptor.</div><div class=\"graphic_reference\">Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28:2784.</div><div id=\"graphicVersion\">Graphic 65263 Version 3.0</div></div></div>"},"65264":{"type":"graphic_figure","displayName":"Inguinal anatomy preperitoneal view","title":"Inguinal anatomy preperitoneal view","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Inguinal anatomy preperitoneal view</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/SURG/65264_Post_inguinal_wall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the anatomic structures of the right posterior inguinal wall as seen from the preperitoneal approach. Note the relationship of a potential direct hernia and indirect hernia and a femoral hernia.</div><div id=\"graphicVersion\">Graphic 65264 Version 4.0</div></div></div>"},"65265":{"type":"graphic_table","displayName":"Neutrophilic dermatoses I","title":"The non-infectious neutrophilic dermatoses without vasculitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The non-infectious neutrophilic dermatoses without vasculitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Involving predominantly the epidermis</td> </tr> <tr> <td>Pustular psoriasis</td> </tr> <tr> <td>Drug-induced/acute generalized exanthematous pustulosis </td> </tr> <tr> <td>Keratoderma blennorrhagicum</td> </tr> <tr> <td>Sneddon-Wilkinson disease (subcorneal pustulosis)</td> </tr> <tr> <td>IgA pemphigus (subcorneal pustular dermatosis type, intraepidermal neutrophilic IgA dermatosis type)</td> </tr> <tr> <td>Amicrobial pustulosis of the folds</td> </tr> <tr> <td>Infantile acropustulosis</td> </tr> <tr> <td>Transient neonatal pustulosis</td> </tr> <tr> <td class=\"subtitle1_single\">Involving predominantly the dermis</td> </tr> <tr> <td>Sweet's syndrome</td> </tr> <tr> <td>Pyoderma gangrenosum</td> </tr> <tr> <td>Beh&#231;et's disease</td> </tr> <tr> <td>Bowel-associated dermatosis-arthritis syndrome</td> </tr> <tr> <td>Inflammatory bowel disease (may also have small vessel vasculitis)</td> </tr> <tr> <td>Neutrophilic eccrine hidradenitis</td> </tr> <tr> <td>Rheumatoid neutrophilic dermatitis</td> </tr> <tr> <td>Neutrophilic urticaria</td> </tr> <tr> <td>Still's disease</td> </tr> <tr> <td>Erythema marginatum</td> </tr> <tr> <td>Hereditary periodic fever syndrome</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Moschella SL, Davis MDP. Neutrophilic dermatoses. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Mosby Elsevier, Spain 2008.</div><div id=\"graphicVersion\">Graphic 65265 Version 3.0</div></div></div>"},"65266":{"type":"graphic_table","displayName":"Lymphocytes in primary immunodeficiency","title":"Alterations of lymphocyte populations in some defined immunodeficiencies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Alterations of lymphocyte populations in some defined immunodeficiencies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"6\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">CD3</td> <td class=\"subtitle1\">CD4</td> <td class=\"subtitle1\">CD8</td> <td class=\"subtitle1\">CD19/20</td> <td class=\"subtitle1\">CD16/56/57</td> </tr> <tr> <td>X-linked SCID</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>nl, &#8593;</td> <td>&#8595;</td> </tr> <tr> <td>JAK3 SCID</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>nl, &#8593;</td> <td>&#8595;</td> </tr> <tr> <td>IL-7R alpha SCID</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>nl, &#8593;</td> <td>nl, &#8593;*</td> </tr> <tr> <td>SCID due to recombination defects</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>nl, &#8593;*</td> </tr> <tr> <td>ADA deficiency</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> </tr> <tr> <td>PNP deficiency</td> <td>&#8595;</td> <td>&#8595; p</td> <td>&#8595; p</td> <td>nl</td> <td>nl, &#8593;*</td> </tr> <tr> <td>MHC class II deficiency</td> <td>&#8595;</td> <td>&#8595;&#8595;</td> <td>&#8595;&#8595;</td> <td>nl</td> <td>nl</td> </tr> <tr> <td>Reticular dysgenesis</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> </tr> <tr> <td>CD3 deficiency</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>nl</td> <td>nl</td> </tr> <tr> <td>ZAP-70 deficiency</td> <td>nl</td> <td>nl</td> <td>&#8595;&#8595;</td> <td>nl</td> <td>nl</td> </tr> <tr> <td>NK deficiency</td> <td>nl</td> <td>nl</td> <td>nl</td> <td>nl</td> <td>&#8595;&#8595;&#8595;</td> </tr> <tr> <td>XLA</td> <td>nl</td> <td>nl</td> <td>nl</td> <td>&#8595;&#8595;&#8595;</td> <td>nl</td> </tr> <tr> <td>WAS</td> <td>&#8595;</td> <td>&#8595; p</td> <td>&#8595; p</td> <td>nl</td> <td>nl</td> </tr> <tr> <td>AT</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8595;</td> <td>&#8595;</td> <td>nl</td> </tr> <tr> <td>DiGeorge anomaly</td> <td>nl, &#8595;</td> <td>nl, &#8595;</td> <td>nl, &#8595;</td> <td>nl</td> <td>nl</td> </tr> <tr> <td>CVID</td> <td>nl, &#8595;</td> <td>nl, &#8595;</td> <td>nl, &#8595;</td> <td>nl, &#8595;</td> <td>nl</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SCID: severe combined immunodeficiency; JAK-3: Janus kinase 3; IL-7 R alpha: interleukin-7 receptor alpha chain (CD127) defect; SCID due to recombination defects: these include recombinase-activating genes 1 and 2 (RAG1 and RAG2), Artemis, DNA protein kinase catalytic subunit; ADA deficiency: adenosine deaminase deficiency; PNP deficiency: purine nucleoside phosphorylase deficiency; MHC: major histocompatibility complex; CD3 deficiency: deficiency of a component of CD3 (gamma, epsilon); ZAP-70 deficiency: deficiency of the CD3 zeta-associated 70 kd tyrosine kinase; NK deficiency: primary natural killer cell deficiency; XLA: X-linked agammaglobulinemia; WAS: Wiskott-Aldrich syndrome; AT: ataxia-telangiectasia; CVID: common variable immunodeficiency; nl: normal; p: the decrease is progressive over time.<br />* The percentage of natural killer (NK) cells may be increased due to the absence of the subset principally affected in the disease. The absolute NK cell number is generally normal.</div><div id=\"graphicVersion\">Graphic 65266 Version 14.0</div></div></div>"},"65267":{"type":"graphic_figure","displayName":"Puncture technique","title":"Puncture technique","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Puncture technique</div><div class=\"cntnt\"><img style=\"width:288px; height:311px;\" src=\"images/EM/65267_Puncture_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The puncture technique (the Dundee technique) may be used after failed attempts at reduction using minimally invasive methods. After appropriate local analgesia and sedation as needed, the patient is prepped with antiseptic solution. Multiple punctures are then made in the edematous foreskin using a 25 gauge or smaller needle. Subsequently, the foreskin is reduced using manual compression and reduction (Refer to UpToDate topics on treatment of paraphimosis).</div><div id=\"graphicVersion\">Graphic 65267 Version 6.0</div></div></div>"},"65268":{"type":"graphic_figure","displayName":"Myopia steep cornea","title":"Myopia with steep cornea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myopia with steep cornea</div><div class=\"cntnt\"><img style=\"width:396px; height:360px;\" src=\"images/PC/65268_Myopia_steep_cornea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When the cornea is steep, light is focused in front of the retina resulting in myopia.</div><div id=\"graphicVersion\">Graphic 65268 Version 1.0</div></div></div>"},"65273":{"type":"graphic_waveform","displayName":"Post-PVC HCM hemodynamics","title":"Post-PVC HCM hemodynamics","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Post-PVC HCM hemodynamics</div><div class=\"cntnt\"><img style=\"width:455px; height:338px;\" src=\"images/CARD/65273_PostPVCHCMhemodynamic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">LV and aortic tracings showing LVOT gradient with PVC and post-PVC HCM hemodynamic changes. Post-PVC beats show rapid aortic upstroke, narrow pulse pressure, and spike and dome configuration of aortic pressure wave.</div><div class=\"graphic_footnotes\">LV: left ventricular; LVOT: LV outflow tract; PVC: premature ventricular contractions; HCM: hypertrophic cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 65273 Version 3.0</div></div></div>"},"65274":{"type":"graphic_table","displayName":"Causes S1 abnormalities","title":"Causes of first heart sound (S1) abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of first heart sound (S1) abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\">Abnormality</td>\n\n\n      <td class=\"subtitle1\">Causes</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Increased intensity</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"sublist2_start\" colspan=\"2\" rowspan=\"1\">Atrioventricular valve obstruction</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"sublist2\">Mitral</td>\n\n\n      <td class=\"sublist_other\">Mitral stenosis and left atrial myxoma&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"sublist2\">Tricuspid</td>\n\n      <td class=\"sublist_other\">Tricuspid stenosis and right atrial myxoma</td>\n\n    </tr>\n\n    <tr>\n\n\n      <td class=\"sublist2_start\" colspan=\"2\" rowspan=\"1\">Increased transvalvular flow</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"sublist2\">Mitral</td>\n\n\n      <td class=\"sublist_other\">Patent ductus arteriosus; ventricular septal defect; atrial septal defect</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"sublist2\">Tricuspid</td>\n\n      <td class=\"sublist_other\">&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n\n      <td class=\"indent1\">Forceful ventricular systole</td>\n\n\n      <td>Hyperkinetic heart syndrome; tachycardia (eg, exercise); mitral valve prolapse</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Short PR interval</td>\n\n\n      <td>Pre-excitation syndrome; Lown-Ganong-Levine</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Decreased intensity</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Immobility of mitral valve</td>\n\n\n      <td>Calcific mitral stenosis&nbsp;</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">Lack of apposition of the mitral leaflets</td>\n\n      <td>Rheumatic mitral regurgitation</td>\n\n    </tr>\n\n    <tr>\n\n\n      <td class=\"indent1\">Presystolic semiclosure of the atrioventricular valves</td>\n\n\n      <td>Long PR interval; acute aortic regurgitation; significant aortic stenosis; dilated cardiomyopathy</td>\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Conduction anomaly</td>\n\n\n      <td>Left bundle branch block</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Wide splitting of S1</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Conduction abnormalities</td>\n\n\n      <td>Complete right bundle branch block; left ventricular\npacing; pre-excitation syndrome (left ventricular connection);\nEbstein's anomaly</td>\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Mechanical</td>\n\n\n      <td>Tricuspid stenosis; atrial septal defect; Ebstein's anomaly</td>\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Reversed splitting of S1</td>\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Arrhythmia</td>\n\n\n      <td>Premature beats (right ventricular origin)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Mechanical</td>\n\n      <td>Severe mitral stenosis and left atrial myxoma</td>\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 65274 Version 1.0</div></div></div>"},"65276":{"type":"graphic_figure","displayName":"Fetal AFP levels by GA","title":"The relationship between alpha-fetoprotein (AFP) values in fetal serum and gestational age","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">The relationship between alpha-fetoprotein (AFP) values in fetal serum and gestational age</div><div class=\"cntnt\"><img style=\"width:472px; height:338px;\" src=\"images/OBGYN/65276_Fetal_AFP_levels_by_GA.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Habib ZA. Maternal serum alpha-fetoprotein: Its value in antenatal diagnosis of genetic disease and in obstetrical-gynaecological care. Acta Obstet Gynecol Scand 1977; 61:1. </div><div id=\"graphicVersion\">Graphic 65276 Version 2.0</div></div></div>"},"65279":{"type":"graphic_table","displayName":"Vitamin K foods PI","title":"Amount of vitamin K in different foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Amount of vitamin K in different foods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"3\"> <p>Vitamin K is found in healthy foods like leafy greens. Vitamin K helps blood to clot, so it can change the way warfarin works. This does NOT mean you need to stop eating foods with vitamin K.</p> <p>Your goal is to eat about the same amount of vitamin K each day. You can do this by eating the same amount of high and medium level vitamin K foods each day using the list below.</p> <p>If you are not able to eat for a few days or are making big changes in your diet, call your doctor.</p> Vitamin pills, herbs, or other supplements such as calcium soft chews can have vitamin K in them or can interact with warfarin. Always show your doctor the label of ALL vitamins, herbs, or other supplements that you take.</td> </tr> <tr> <td class=\"subtitle1\">Food name</td> <td class=\"subtitle1\">Serving size</td> <td class=\"subtitle1\">Vitamin K (micrograms)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">High vitamin K foods</td> </tr> <tr> <td class=\"indent1\">Brussels sprouts, fresh (cooked, drained)</td> <td>1/2 cup</td> <td>110</td> </tr> <tr> <td class=\"indent1\">Brussels sprouts, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>150</td> </tr> <tr> <td class=\"indent1\">Greens, beet fresh (cooked, drained)</td> <td>1/2 cup</td> <td>350</td> </tr> <tr> <td class=\"indent1\">Greens, collard frozen (cooked, drained)</td> <td>1/2 cup</td> <td>530</td> </tr> <tr> <td class=\"indent1\">Greens, collard fresh (cooked, drained)</td> <td>1/2 cup</td> <td>365</td> </tr> <tr> <td class=\"indent1\">Greens, mustard fresh (cooked, drained)</td> <td>1/2 cup</td> <td>415</td> </tr> <tr> <td class=\"indent1\">Greens, turnip fresh (cooked, drained)</td> <td>1/2 cup</td> <td>265</td> </tr> <tr> <td class=\"indent1\">Greens, turnip frozen (cooked, drained)</td> <td>1/2 cup</td> <td>425</td> </tr> <tr> <td class=\"indent1\">Kale, fresh (cooked, drained)</td> <td>1/2 cup</td> <td>530</td> </tr> <tr> <td class=\"indent1\">Kale, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>565</td> </tr> <tr> <td class=\"indent1\">Spinach, fresh (cooked, drained)</td> <td>1/2 cup</td> <td>444</td> </tr> <tr> <td class=\"indent1\">Spinach, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>514</td> </tr> <tr> <td class=\"indent1\">Spinach, fresh (raw)</td> <td>1 cup</td> <td>150</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Medium vitamin K foods</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Asparagus, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>72</td> </tr> <tr> <td>4 spears</td> <td>48</td> </tr> <tr> <td class=\"indent1\">Asparagus, fresh (cooked, drained)</td> <td>4 spears</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Beans, green or yellow, fresh (cooked, drained)</td> <td>1/2 cup</td> <td>10</td> </tr> <tr> <td class=\"indent1\">Broccoli, fresh (cooked, drained)</td> <td>1 spear</td> <td>26</td> </tr> <tr> <td class=\"indent1\">Broccoli, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>80</td> </tr> <tr> <td class=\"indent1\">Broccoli, raw</td> <td>1/2 cup</td> <td>45</td> </tr> <tr> <td class=\"indent1\">Cabbage (cooked, drained)</td> <td>1/2 cup</td> <td>80</td> </tr> <tr> <td class=\"indent1\">Cabbage, chinese bok-choi (cooked, drained)</td> <td>1/2 cup</td> <td>28</td> </tr> <tr> <td class=\"indent1\">Cabbage, green (raw)</td> <td>1/2 cup</td> <td>26</td> </tr> <tr> <td class=\"indent1\">Cabbage, red (raw)</td> <td>1/2 cup</td> <td>14</td> </tr> <tr> <td class=\"indent1\">Cabbage, savoy (raw)</td> <td>1/2 cup</td> <td>24</td> </tr> <tr> <td class=\"indent1\">Calcium soft chews (brand name Viactiv with D) see above about other vitamin pills</td> <td>1 chew</td> <td>40</td> </tr> <tr> <td class=\"indent1\">Carrots, fresh or frozen (cooked, drained)</td> <td>1/2 cup</td> <td>10</td> </tr> <tr> <td class=\"indent1\">Cauliflower, fresh or frozen (raw or cooked, drained)</td> <td>1/2 cup</td> <td>10</td> </tr> <tr> <td class=\"indent1\">Celery, raw</td> <td>1/2 cup </td> <td>17</td> </tr> <tr> <td class=\"indent1\">Coleslaw (fast food-type)</td> <td>1/2 cup</td> <td>37</td> </tr> <tr> <td class=\"indent1\">Endive</td> <td>1/2 cup</td> <td>60</td> </tr> <tr> <td class=\"indent1\">Lettuce (butterhead, Boston, bibb)</td> <td>1/2 head</td> <td>80</td> </tr> <tr> <td class=\"indent1\">Lettuce (iceberg, crisphead)</td> <td>1/2 head</td> <td>65</td> </tr> <tr> <td class=\"indent1\">Lettuce (romaine, cos)</td> <td>1 cup</td> <td>57</td> </tr> <tr> <td class=\"indent1\">Lettuce (green leaf)</td> <td>1 cup</td> <td>97</td> </tr> <tr> <td class=\"indent1\">Oil, canola</td> <td>1 tablespoon</td> <td>17</td> </tr> <tr> <td class=\"indent1\">Okra, fresh (cooked, drained)</td> <td>1/2 cup</td> <td>32</td> </tr> <tr> <td class=\"indent1\">Okra, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>44</td> </tr> <tr> <td class=\"indent1\">Peas, frozen, with pod (cooked, drained)</td> <td>1/2 cup</td> <td>24</td> </tr> <tr> <td class=\"indent1\">Peas, fresh, with pod (cooked, drained)</td> <td>1/2 cup</td> <td>20</td> </tr> <tr> <td class=\"indent1\">Peas, green, frozen (cooked, drained)</td> <td>1/2 cup</td> <td>18</td> </tr> <tr> <td class=\"indent1\">Pickle relish, sweet</td> <td>1 tablespoon</td> <td>13</td> </tr> <tr> <td class=\"indent1\">Pickles, cucumber dill or kosher dill</td> <td>1 pickle</td> <td>25</td> </tr> <tr> <td class=\"indent1\">Sauerkraut, canned</td> <td>1/2 cup</td> <td>56</td> </tr> <tr> <td class=\"indent1\">Vegetables, mixed frozen or canned (cooked, drained)</td> <td>1/2 cup</td> <td>20</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Low vitamin K foods</td> </tr> <tr> <td class=\"indent1\">Avocado</td> <td>1 ounce</td> <td rowspan=\"12\">All of these foods have less than 10 micrograms of vitamin K per serving</td> </tr> <tr> <td class=\"indent1\">Bananas</td> <td>1 banana</td> </tr> <tr> <td class=\"indent1\">Chickpeas (garbanzo beans)</td> <td>1/2 cup</td> </tr> <tr> <td class=\"indent1\">Corn</td> <td>1/2 cup</td> </tr> <tr> <td class=\"indent1\">Fruit (fresh, frozen or canned including apples, nectarines, peaches, watermelon)</td> <td>Whole piece of fresh fruit, 1 wedge of watermelon, or 1/2 cup</td> </tr> <tr> <td class=\"indent1\">Mayonaise</td> <td>1 tablespoon</td> </tr> <tr> <td class=\"indent1\">Oil, olive</td> <td>1 tablespoon</td> </tr> <tr> <td class=\"indent1\">Oil, other (including peanut, sesame, safflower, corn, sunflower, soybean)</td> <td>1 tablespoon</td> </tr> <tr> <td class=\"indent1\">Peppers, green or red</td> <td>1/2 pepper or 1/2 cup</td> </tr> <tr> <td class=\"indent1\">Potatoes</td> <td>1 potato or 1/2 cup</td> </tr> <tr> <td class=\"indent1\">Seaweed, kelp (raw)</td> <td>1 tablespoon</td> </tr> <tr> <td class=\"indent1\">Tomatoes</td> <td>1 tomato or 1/2 cup</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Very low vitamin K foods, but MIGHT change how warfarin or other medicines work</td> </tr> <tr> <td class=\"indent1\">Cranberry juice</td> <td>4 ounces juice</td> <td rowspan=\"4\">If you eat these foods, limit the amount to one or two servings per day</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Grapefruit</td> <td>4 ounces juice</td> </tr> <tr> <td>1/2 grapefruit</td> </tr> <tr> <td class=\"indent1\">Green tea, brewed</td> <td>4 ounces</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: US Department of Agriculture, Agricultural Research Service. 2013. USDA Nutrient Database for Standard Reference, Release 25. Nutrient Data Laboratory Home Page, <a href=\"http://www.ars.usda.gov/nutrientdata\" target=\"_blank\">http://www.ars.usda.gov/nutrientdata</a>. Accessed August 7, 2013.</div><div id=\"graphicVersion\">Graphic 65279 Version 2.0</div></div></div>"},"65282":{"type":"graphic_table","displayName":"Maturation of GI tract","title":"Anatomic and functional maturation of the gastrointestinal tract","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anatomic and functional maturation of the gastrointestinal tract</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\" colspan=\"6\">\r\n  \r\n   Postconceptional age\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   &nbsp;\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   20 weeks\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   25 weeks\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   30 weeks\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   35 weeks\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\">\r\n  \r\n   40 weeks\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Mouth</td>\r\n  \r\n   <td>Salivary glands</td>\r\n  \r\n   <td>Swallow reflex present</td>\r\n  \r\n   <td>Lingual lipase</td>\r\n  \r\n   <td><em>Sucking reflex present</em></td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Esophagus</td>\r\n  \r\n   <td>Muscle layers present</td>\r\n  \r\n   <td>Striated epithelium present</td>\r\n  \r\n   <td><em>Poor lower esophageal sphincter tone</em></td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Stomach</td>\r\n  \r\n   <td>Gastric glands present</td>\r\n  \r\n   <td>G cells appear</td>\r\n  \r\n   <td><em>Gastric secretions present</em></td>\r\n  \r\n   <td><em>Slow gastric emptying</em></td>\r\n  \r\n   <td>*</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pancreas</td>\r\n  \r\n   <td>Exocrine and endocrine tissue differentiate</td>\r\n  \r\n   <td>Zymogen present</td>\r\n  \r\n   <td><em>Reduced trypsin, lipase</em></td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>*</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Liver</td>\r\n  \r\n   <td>Lobules form</td>\r\n  \r\n   <td><em>Bile secreted</em></td>\r\n  \r\n   <td><em>Fatty acids absorbed</em></td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>*</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Intestine</td>\r\n  \r\n   <td>Crypts and villi form</td>\r\n  \r\n   <td><em>Glucose transport present</em></td>\r\n  \r\n   <td><em>Dipeptidese, sucrase, and maltase active</em></td>\r\n  \r\n   <td><em>Lactase active</em></td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Colon</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td>Crypts and villi recede</td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   <td><em>Meconium passed</em></td>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_lgnd\"><em>Italics</em> indicate functional maturation.</div><div class=\"graphic_footnotes\">* Full functional maturation occurs postnatally.</div><div class=\"graphic_reference\">Reproduced with permission from: Berseth, CL. Developmental Anotomy and Physiology of the Gastrointestinal Tract. In: Avery's Diseases of the Newborn, 7th ed, Taeusch HW, Ballard RA (Eds), W.B. Saunders Company, Philadelphia, 1998. Table 78-12. Copyright 1998 W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 65282 Version 1.0</div></div></div>"},"65283":{"type":"graphic_table","displayName":"Potential toxicity herbs","title":"Cautions about herbs and dietary supplements when used in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cautions about herbs and dietary supplements when used in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Product <strong>purity</strong> is questionable; there is potential for misidentification and contamination with:</td> </tr> <tr> <td class=\"sublist1\">- Pesticides</td> </tr> <tr> <td class=\"sublist1\">- Herbicides</td> </tr> <tr> <td class=\"sublist1\">- Pharmaceuticals</td> </tr> <tr> <td class=\"sublist1\">- Heavy metals</td> </tr> <tr> <td class=\"sublist1\">- Excipients such as alcohol</td> </tr> <tr> <td>Particularly for products imported from developing countries.</td> </tr> <tr> <td><strong>Reliability</strong> of products is uncertain; there is great variability in concentration of active ingredients within plants used, growing conditions, processing, and storage.</td> </tr> <tr> <td><strong>Effectiveness</strong> of active ingredients in children often not studied.</td> </tr> <tr> <td><strong>Safety and toxicity for short-term</strong> use in children is often unknown.</td> </tr> <tr> <td><strong>Safety and toxicity for chronic use</strong> in children is often unknown.</td> </tr> <tr> <td>Unknown <strong>interactions</strong> with other medications and treatments.</td> </tr> <tr> <td>Unknown <strong>metabolism</strong> in children with renal, hepatic, and other disorders.</td> </tr> <tr> <td><strong>Cost</strong> of products is not necessarily related to quality, purity, or concentration of active ingredients.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65283 Version 4.0</div></div></div>"},"65286":{"type":"graphic_diagnosticimage","displayName":"Fibrous pleural tumor II CT","title":"Fibrous tumor of the pleura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibrous tumor of the pleura</div><div class=\"cntnt\"><img style=\"width:324px; height:323px;\" src=\"images/PULM/65286_Fibrous_pleural_tumor_II_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows a large left posterior chest mass.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 65286 Version 3.0</div></div></div>"},"65287":{"type":"graphic_table","displayName":"Diseases associated with CPPD","title":"Endocrine and metabolic disorders associated with calcium pyrophosphate crystal deposition (CPPD) disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endocrine and metabolic disorders associated with calcium pyrophosphate crystal deposition (CPPD)&nbsp;disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Probability of association</td> </tr> <tr> <td>Hemochromatosis</td> <td>Definite</td> </tr> <tr> <td>Hyperparathyroidism</td> <td>Definite</td> </tr> <tr> <td>Hypophosphatasia</td> <td>Definite</td> </tr> <tr> <td>Hypomagnesemia</td> <td>Definite</td> </tr> <tr> <td>Gitelman's syndrome</td> <td>Definite</td> </tr> <tr> <td>Gout</td> <td>Possible</td> </tr> <tr> <td>X-linked hypophosphatemic rickets</td> <td>Possible</td> </tr> <tr> <td>Familial hypocalciuric hypercalcemia</td> <td>Possible</td> </tr> <tr> <td>Hemosiderosis</td> <td>Possible</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65287 Version 5.0</div></div></div>"},"65289":{"type":"graphic_figure","displayName":"Bipolar limb leads","title":"Bipolar limb lead system","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Bipolar limb lead system</div><div class=\"cntnt\"><img style=\"width:537px; height:243px;\" src=\"images/CARD/65289_Bipolar_limb_leads.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Einthoven described a system of three bipolar leads located at the right arm, left arm, and left leg to form a triangle. Lead I represents the potential difference between the right and left arm; an electrical impulse moving from right to left generates a positive ECG deflection in this lead. Lead II is the potential difference between the right arm and leg; a positive ECG deflection occurs when the impulse direction is toward the leg. Lead III is the potential difference between the left arm and leg; there is a positive ECG deflection when the impulse direction is toward the leg.</div><div id=\"graphicVersion\">Graphic 65289 Version 1.0</div></div></div>"},"65292":{"type":"graphic_figure","displayName":"Electrical axis of ECG leads","title":"Electrical axis of ECG leads","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrical axis of ECG leads</div><div class=\"cntnt\"><img style=\"width:331px; height:271px;\" src=\"images/CARD/65292_Electrical_axis_of_ECG_lead.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The frontal plane (extremity or limb) ECG leads are represented on a hexaxial diagram. Each lead has a specific spatial orientation and polarity. The positive pole of each lead axis (red, solid line) and negative pole (blue, solid line) are designated by their angular position relative to the positive pole of lead I (0&#176;). The QRS axis, which is normally between -30&#176; and +100&#176;, can be estimated as being at right angles to the positive pole of any extremity lead in which the positive and negative deflections are of roughly equal magnitude.</div><div id=\"graphicVersion\">Graphic 65292 Version 1.0</div></div></div>"},"65293":{"type":"graphic_waveform","displayName":"ECG strip WPW concertina effect ","title":"Single-lead electrocardiogram (ECG) strip showing concertina effect in Wolff-Parkinson-White syndrome","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) strip showing concertina effect in Wolff-Parkinson-White syndrome</div><div class=\"cntnt\"><img style=\"width:464px; height:111px;\" src=\"images/CARD/65293_WPW_concertina_effect_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single channel rhythm strip from a patient with the Wolff-Parkinson-White syndrome shows progressive shortening of the PR interval with the development of a widened QRS complex due to a delta wave. The P wave appears to merge with the QRS complex (arrows). The last two QRS complexes again show a normal PR interval and a narrow QRS complex.</div><div id=\"graphicVersion\">Graphic 65293 Version 3.0</div></div></div>"},"65294":{"type":"graphic_figure","displayName":"HPG axis PI","title":"The hypothalamic-pituitary-gonadal axis","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">The hypothalamic-pituitary-gonadal axis</div><div class=\"cntnt\"><img style=\"width:530px; height:633px;\" src=\"images/PI/65294_HPG_axis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hypothalamus secretes a hormone, gonadotropin-releasing hormone (GnRH), which stimulates the pituitary to secrete&nbsp;follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH stimulates the Leydig cells in the testicles to produce testosterone. FSH promotes the development of the sperm. Testosterone levels help to regulate the production of GnRH and LH.</div><div id=\"graphicVersion\">Graphic 65294 Version 5.0</div></div></div>"},"65295":{"type":"graphic_table","displayName":"Indication RET mutation analysis","title":"Criteria for DNA analysis for MEN2/FMTC","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for DNA analysis for MEN2/FMTC</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\"><em>RET </em>mutation analysis should be performed:</td> </tr> <tr> <td class=\"sublist1_start\">In patients with:</td> </tr> <tr> <td class=\"sublist1\">1. Clinically proven MEN2 syndrome: bilateral, multicentric MTC, and/or pheochromocytoma</td> </tr> <tr> <td class=\"sublist1\">2. MTC or pheochromocytoma and a family member with MTC or pheochromocytoma</td> </tr> <tr> <td class=\"sublist1\">3. Apparently sporadic MEN2 related tumors and:</td> </tr> <tr> <td class=\"sublist2\">a. Age younger than 35 years and/or</td> </tr> <tr> <td class=\"sublist2\">b. Multicentric tumors in one organ and/or</td> </tr> <tr> <td class=\"sublist2\">c. Two different organs affected</td> </tr> <tr> <td>First- and second-degree family members of MEN2 patients</td> </tr> <tr> <td>All patients with sporadic MTC ? (may have consequences for target-directed treatment)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topic on the clinical manifestations and diagnosis of multiple endocrine neoplasia type 2.</div><div class=\"graphic_footnotes\">MEN2: multiple endocrine neoplasia type 2; FMTC: familial medullary thyroid cancer; MTC: medullary thyroid cancer.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658.</LI>&#xD;&#xA;<LI>Machens A, Dralle H.&nbsp;Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 2007; 31:957.</LI>&#xD;&#xA;<LI>American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 2009; 19:565. Comment in Thyroid 2009; 19:1295.</LI></OL></div><div id=\"graphicVersion\">Graphic 65295 Version 4.0</div></div></div>"},"65298":{"type":"graphic_figure","displayName":"WBC differential Advia2120","title":"WBC differential Advia 2120","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">WBC differential Advia 2120</div><div class=\"cntnt\"><img style=\"width:308px; height:287px;\" src=\"images/HEME/65298_WBC_differential_Advia2120.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A white cell differential on the Advia 2120 automated cell counter is shown here. Staining for peroxidase (perox) is displayed on the x axis versus cell size on the y axis. Neutrophils (pink) and eosinophils (yellow) containing the most perox activity are found to the right. Cells with little or no perox cluster to the left, such as lymphocytes/basophils (blue) and large unstained cells (blasts, variant and atypical lymphocytes, light blue). Monocytes (green) contain a small amount of perox and are located between the neutrophils and large unstained cells. Noise is indicated in the lower left hand corner (white). Nucleated red blood cells are present in the area between lymphocytes and noise; platelet clumps are found in the area to the right of the nucleated red blood cells.</div><div id=\"graphicVersion\">Graphic 65298 Version 1.0</div></div></div>"},"65303":{"type":"graphic_table","displayName":"Risk factors for CVT","title":"Systemic and local conditions increasing the risk of cerebral venous thrombosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systemic and local conditions increasing the risk of cerebral venous thrombosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Transient risk factors</td> </tr> <tr> <td class=\"indent1\"><strong>Infection</strong></td> </tr> <tr> <td class=\"indent2\">Central nervous system</td> </tr> <tr> <td class=\"indent2\">Ear, sinus, mouth, face, and neck</td> </tr> <tr> <td class=\"indent2\">Systemic infectious disease</td> </tr> <tr> <td class=\"indent1\"><strong>Pregnancy and puerperium</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Other disorders</strong></td> </tr> <tr> <td class=\"indent2\">Dehydration</td> </tr> <tr> <td class=\"indent1\"><strong>Mechanical precipitants</strong></td> </tr> <tr> <td class=\"indent2\">Head injury</td> </tr> <tr> <td class=\"indent2\">Lumbar puncture</td> </tr> <tr> <td class=\"indent2\">Neurosurgical procedures</td> </tr> <tr> <td class=\"indent2\">Jugular catheter occlusion</td> </tr> <tr> <td class=\"indent1\"><strong>Drugs</strong></td> </tr> <tr> <td class=\"indent2\">Oral contraceptives</td> </tr> <tr> <td class=\"indent2\">Hormone replacement therapy</td> </tr> <tr> <td class=\"indent2\">Androgens</td> </tr> <tr> <td class=\"indent2\">Asparaginase</td> </tr> <tr> <td class=\"indent2\">Tamoxifen</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Glucocorticoids</td> </tr> <tr> <td class=\"subtitle1_single\">Permanent risk factors</td> </tr> <tr> <td class=\"indent1\"><strong>Inflammatory diseases</strong></td> </tr> <tr> <td class=\"indent2\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent2\">Beh&#231;et disease</td> </tr> <tr> <td class=\"indent2\">Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"indent2\">Thromboangiitis obliterans</td> </tr> <tr> <td class=\"indent2\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"indent2\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\"><strong>Malignancy</strong></td> </tr> <tr> <td class=\"indent2\">Central nervous system</td> </tr> <tr> <td class=\"indent2\">Solid tumour outside central nervous system</td> </tr> <tr> <td class=\"indent2\">Hematologic</td> </tr> <tr> <td class=\"indent1\"><strong>Hematologic condition</strong></td> </tr> <tr> <td class=\"indent2\">Prothrombotic states, genetic or acquired</td> </tr> <tr> <td class=\"sublist3\">Protein C deficiency</td> </tr> <tr> <td class=\"sublist3\">Protein S deficiency</td> </tr> <tr> <td class=\"sublist3\">Antithrombin deficiency</td> </tr> <tr> <td class=\"sublist3\">Factor V Leiden mutation</td> </tr> <tr> <td class=\"sublist3\">G20210A prothrombin gene mutation</td> </tr> <tr> <td class=\"sublist3\">Antiphospholipid syndrome</td> </tr> <tr> <td class=\"sublist3\">Myeloproliferative neoplasms</td> </tr> <tr> <td class=\"sublist3\">Nephrotic syndrome</td> </tr> <tr> <td class=\"sublist3\">Paroxysmal nocturnal hemoglobinuria</td> </tr> <tr> <td class=\"sublist3\">Hyperhomocysteinemia</td> </tr> <tr> <td class=\"indent2\">Polycythemia, thrombocythemia</td> </tr> <tr> <td class=\"indent2\">Severe anemia, including paroxysmal nocturnal hemoglobinuria</td> </tr> <tr> <td class=\"indent1\"><strong>Central nervous system disorders</strong></td> </tr> <tr> <td class=\"indent2\">Dural fistulae</td> </tr> <tr> <td class=\"indent1\"><strong>Other disorders</strong></td> </tr> <tr> <td class=\"indent2\">Congenital heart disease</td> </tr> <tr> <td class=\"indent2\">Thyroid disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65303 Version 7.0</div></div></div>"},"65305":{"type":"graphic_figure","displayName":"Nomogram for BMI","title":"Nomogram for determining body mass index","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Nomogram for determining body mass index</div><div class=\"cntnt\"><img style=\"width:453px; height:511px;\" src=\"images/ENDO/65305_Nomogram_for_BMI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The nomogram is used by placing a ruler or other straight edge between the body weight in kilograms or pounds (the left-hand line) and the height in centimeters or inches (the right-hand line). The body mass index is read from the middle of the scale, in metric units.</div><div id=\"graphicVersion\">Graphic 65305 Version 1.0</div></div></div>"},"65309":{"type":"graphic_picture","displayName":"Scapular squeeze PI","title":"Scapular squeeze","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scapular squeeze</div><div class=\"cntnt\"><img style=\"width:396px; height:172px;\" src=\"images/PI/65309_Scapular_squeeze_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lie on your back with your knees bent and feet flat. Your arms should be straight out, 6 to 12 inches (15 to 30 cm) away from the side of your body, with palms facing upward. Keeping your low back flat against the ground, squeeze your shoulder blades downward and towards each other, towards the spine. Make a conscious effort not to shrug your shoulders and keep the neck relaxed. You should feel the muscles between your shoulder blades contracting.</div><div id=\"graphicVersion\">Graphic 65309 Version 4.0</div></div></div>"},"65310":{"type":"graphic_picture","displayName":"AIDS-related Kaposis sarcoma - sole of foot","title":"AIDS-related Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AIDS-related Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:288px; height:468px;\" src=\"images/DERM/65310_Kaposis_sarcoma_sole_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous, hyperkeratotic plaques are present on the sole of the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65310 Version 3.0</div></div></div>"},"65311":{"type":"graphic_figure","displayName":"Hemoglobin tetramer","title":"Three-dimensional representation of the hemoglobin tetramer","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Three-dimensional representation of the hemoglobin tetramer</div><div class=\"cntnt\"><img style=\"width:469px; height:442px;\" src=\"images/HEME/65311_Hemoglobin_tetramer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this view the alpha chains are shown in white, the beta chains in blue and blue-green, and two of the heme moieties are shown in red. The site of hemoglobin S mutation is also shown in green.</div><div id=\"graphicVersion\">Graphic 65311 Version 2.0</div></div></div>"},"65312":{"type":"graphic_table","displayName":"Biologic-behavioral-environmental risk assessment","title":"Biologic-behavioral-environmental risk assessment to guide decision-making when prescribing hormonal contraceptives for young teenagers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Biologic-behavioral-environmental risk assessment to guide decision-making when prescribing hormonal contraceptives for young teenagers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Factors</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td rowspan=\"3\">Biological</td> <td rowspan=\"3\">Pubertal and metabolic factors</td> <td>Incomplete growth</td> </tr> <tr> <td>Decreased bone density/osteoporosis</td> </tr> <tr> <td>Lack of physical activity</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Behavioral/psychological (including neurocognitive)</td> <td rowspan=\"6\">Mental health, neurologic, and emotional factors</td> <td>Poor self-esteem and self-efficacy</td> </tr> <tr> <td>Declining grades</td> </tr> <tr> <td>Learning disability</td> </tr> <tr> <td>Impulsive behavior</td> </tr> <tr> <td>Depression</td> </tr> <tr> <td>Substance abuse</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Environmental</td> <td rowspan=\"4\">Parental/other caretaker supervision and monitoring</td> <td>Chaotic living situation</td> </tr> <tr> <td>Difficulty managing behavioral issues</td> </tr> <tr> <td>Depression and/or alcohol-substance use in parent</td> </tr> <tr> <td>Parental consent (active or passive) to date in late middle school or early high school</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Mariam R Chacko, MD.</div><div id=\"graphicVersion\">Graphic 65312 Version 4.0</div></div></div>"},"65313":{"type":"graphic_table","displayName":"Pediatric pneumonia examination","title":"Important aspects of the physical examination in a child with suspected pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the physical examination in a child with suspected pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Physical examination feature</td> <td class=\"subtitle1\">Possible significance</td> </tr> <tr> <td><strong>General appearance</strong> (state of awareness, cyanosis)*</td> <td>Most children with radiographically confirmed pneumonia appear ill</td> </tr> <tr> <td colspan=\"2\"><strong>Vital signs</strong></td> </tr> <tr> <td class=\"indent1\">Temperature</td> <td>Fever may be the only sign of pneumonia in highly febrile young children; however, it is variably present and nonspecific</td> </tr> <tr> <td class=\"indent1\">Respiratory rate</td> <td> <p><span style=\"color: black;\">Tachypnea<sup>&#182;</sup> less predictive of radiographically confirmed pneumonia than hypoxemia or increased work of breathing&nbsp;</span></p> <p><span style=\"color: black;\">Tachypnea correlates with hypoxemia</span></p> <p>Absence of tachypnea helps to exclude pneumonia</p> </td> </tr> <tr> <td><strong>Degree of respiratory distress</strong></td> <td>Respiratory distress is more specific than fever or cough for lower respiratory infection</td> </tr> <tr> <td class=\"indent1\">Tachypnea</td> <td><span style=\"color: black;\">Described in section on \"Vital signs\"</span></td> </tr> <tr> <td class=\"indent1\">Hypoxemia</td> <td>Predictive of pneumonia</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Increased work of breathing:</td> </tr> <tr> <td class=\"sublist2\">Retractions</td> <td class=\"sublist_other\">More common in children with pneumonia than without; absence does not exclude pneumonia</td> </tr> <tr> <td class=\"sublist2\">Nasal flaring</td> <td class=\"sublist_other\">More common in children with pneumonia than without; absence does not exclude pneumonia</td> </tr> <tr> <td class=\"sublist2\">Grunting</td> <td class=\"sublist_other\">Sign of severe disease and impending respiratory failure</td> </tr> <tr> <td class=\"sublist2\">Accessory muscle use</td> <td class=\"sublist_other\">Sign of severe disease</td> </tr> <tr> <td class=\"sublist2\">Head bobbing</td> <td class=\"sublist_other\">Sign of severe disease</td> </tr> <tr> <td colspan=\"2\"><strong>Lung examination</strong></td> </tr> <tr> <td class=\"indent1\">Cough</td> <td>Nonspecific finding of pneumonia</td> </tr> <tr> <td class=\"indent1\">Auscultation</td> <td> <p>Findings suggestive of pneumonia include: crackles (rales, crepitations), decreased breath sounds, bronchial breath sounds, egophony, bronchophony, and whispered pectoriloquy</p> <p>Wheezing more common in viral and atypical pneumonias</p> </td> </tr> <tr> <td class=\"indent1\">Tactile fremitus</td> <td>Suggestive of parenchymal consolidation</td> </tr> <tr> <td class=\"indent1\">Dullness to percussion</td> <td>Suggestive of parenchymal consolidation or pleural effusion</td> </tr> <tr> <td><strong>Mental status</strong></td> <td>Altered mental status may be a sign of hypoxia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For young infants: Ability to attend to the environment, feed, vocalize, and be consoled.<br />&para; World Health Organization definitions of tachypnea according to age are as follows: &lt;2 months: &gt;60 breaths/min; 2 to 12 months: &gt;50 breaths/min; 1 to 5 years: &gt;40 breaths/min; &ge;5 years: &gt;20 breaths/min.</div><div id=\"graphicVersion\">Graphic 65313 Version 6.0</div></div></div>"},"65314":{"type":"graphic_picture","displayName":"Pityriasis light and dark skin PI","title":"Pityriasis rosea","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Pityriasis rosea</div><div class=\"cntnt\"><img style=\"width:513px; height:228px;\" src=\"images/PI/65314_Pityriasis_lt_drk_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pityriasis rosea is a skin rash that sometimes starts with a single large patch (see arrow). Many smaller spots appear within a few days. In people with light skin, the spots are pink or salmon-colored. In people with dark skin, the spots are a red-brown color or darker than their skin.</div><div class=\"graphic_reference\">(A) Courtesy of John T Crissey, MD.<br> (B) Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65314 Version 3.0</div></div></div>"},"65315":{"type":"graphic_table","displayName":"Antibiotic rx Legionella","title":"Antibiotic selection for Legionella infection in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic selection for Legionella infection in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antimicrobial agent</td> <td class=\"subtitle1\">Dosing*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Macrolides</td> </tr> <tr> <td class=\"indent1\">Azithromycin</td> <td>1 g for the first dose, then 500 mg orally or intravenously<sup>&#182;</sup> every 24 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Clarithromycin</td> <td>500 mg orally or intravenously<sup>&#916;</sup> every 12 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Quinolones</td> </tr> <tr> <td class=\"indent1\">Levofloxacin</td> <td>750 mg orally or intravenously every 24 hours</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Ciprofloxacin</td> <td>400 mg intravenously every 8 hours</td> </tr> <tr> <td>750 mg orally every 12 hours</td> </tr> <tr> <td class=\"indent1\">Ofloxacin</td> <td>400 mg orally or intravenously every 12 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Moxifloxacin</td> <td>400 mg orally every 24 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Tetracyclines</td> </tr> <tr> <td class=\"indent1\">Doxycycline</td> <td>100 mg orally or intravenously every 12 hours</td> </tr> <tr> <td class=\"indent1\">Minocycline</td> <td>100 mg orally or intravenously every 12 hours</td> </tr> <tr> <td class=\"indent1\">Tetracycline</td> <td>500 mg orally or intravenously every 6 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tigecycline</td> <td>100 mg intravenously for the first dose, then 50 mg every 12 hours thereafter</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole </td> <td>160 mg (of the trimethoprim component) intravenously every 8 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Doses based on clinical experience and not on controlled trials.<br />¶ Intravenous form not available in some countries.</div><div id=\"graphicVersion\">Graphic 65315 Version 5.0</div></div></div>"},"65316":{"type":"graphic_diagnosticimage","displayName":"Lung infiltrates in nocardiosis","title":"Pulmonary infiltrates in nocardiosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary infiltrates in nocardiosis</div><div class=\"cntnt\"><img style=\"width:238px; height:359px;\" src=\"images/ID/65316_Lung_infiltrates_in_nocardi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph reveals pulmonary infiltrates in this patient with disseminated nocardiosis and a cerebellar abscess.</div><div class=\"graphic_reference\">Courtesy of Stanley W Chapman, MD.</div><div id=\"graphicVersion\">Graphic 65316 Version 3.0</div></div></div>"},"65317":{"type":"graphic_movie","displayName":"Ascending aorta in Kawasaki disease","title":"Coronary artery aneurysms in Kawasaki's disease","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coronary artery aneurysms in Kawasaki's disease</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/65317_asaogkawconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:320px; height:240px;\" src=\"images/CARD/65317_asaogkaw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The aortogram in a left anterior oblique projection shows large aneurysms of both the left and right coronary arteries.</div><div id=\"graphicVersion\">Graphic 65317 Version 2.0</div></div></div>"},"65319":{"type":"graphic_diagnosticimage","displayName":"Two-dimensional method for calculating abdominal circumference","title":"Two-dimensional method for calculating abdominal circumference","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Two-dimensional method for calculating abdominal circumference</div><div class=\"cntnt\"><img style=\"width:504px; height:341px;\" src=\"images/OBGYN/65319_Two_dim_calc_abdom_cir.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The abdominal circumference measurement is&nbsp;calculated by the ultrasound machine&nbsp;by placing four calipers (+)&nbsp;around the abdomen on the skin edge, not the rib cage.</div><div class=\"graphic_reference\">Courtesy of Jennifer T Ahn, MD.</div><div id=\"graphicVersion\">Graphic 65319 Version 4.0</div></div></div>"},"65320":{"type":"graphic_table","displayName":"Bishop score","title":"Bishop scoring system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bishop scoring system</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">0</td> <td class=\"subtitle1\">1</td> <td class=\"subtitle1\">2</td> <td class=\"subtitle1\">3</td> </tr> <tr> <td>Dilation, cm</td> <td>Closed</td> <td>1 to 2</td> <td>3 to 4</td> <td>&#8805;5 to 6</td> </tr> <tr> <td>Effacement, %</td> <td>0 to 30</td> <td>40 to 50</td> <td>60 to 70</td> <td>&#8805;80</td> </tr> <tr> <td>Station*</td> <td>-3</td> <td>-2</td> <td>-1, 0</td> <td>+1, +2</td> </tr> <tr> <td>Cervical consistency</td> <td>Firm</td> <td>Medium</td> <td>Soft</td> <td>&nbsp;</td> </tr> <tr> <td>Position of the cervix</td> <td>Posterior</td> <td>Midposition</td> <td>Anterior</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Based on a -3 to +3 scale.</div><div id=\"graphicVersion\">Graphic 65320 Version 9.0</div></div></div>"},"65321":{"type":"graphic_table","displayName":"History taking in ACD","title":"History taking in allergic contact dermatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">History taking in allergic contact dermatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Demographics and occupational history</td> <td>Age, gender, race, ethnicity, religion, social aspects (marital status), job title, job description, regular and occasional chemical exposures and sources, location of employment, time at current job, previous occupations</td> </tr> <tr> <td>Family medical history</td> <td>Genetic factors, predispositions</td> </tr> <tr> <td>Personal medical history</td> <td>Drug allergies, concomitant diseases, medications, surgeries</td> </tr> <tr> <td>Dermatitis-specific history</td> <td>Onset, location, temporal associations (waxings/wanings), treatments</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">21.0000000000000</mso:Specialty>\r\n<mso:Publishable_Version msdt:dt=\"string\">0</mso:Publishable_Version>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=95989&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>History_taking_in_ACD.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Cohen DE, Jacob SE. Allergic contact dermatitis. In: Fitzpatrick's dermatology in general medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw-Hill Professional 2003. Copyright © 2003 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 65321 Version 6.0</div></div></div>"},"65322":{"type":"graphic_table","displayName":"Graded prognostic assessment for brain metastases by diagnosis","title":"Graded prognostic assessment for brain metastases by diagnosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Graded prognostic assessment for brain metastases by diagnosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"10%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"7\">Non-small-cell and small-cell lung cancer</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">Prognostic factor</td> <td class=\"subtitle2\" colspan=\"5\">Scoring criteria</td> <td class=\"subtitle2\" rowspan=\"2\">Patient score</td> </tr> <tr> <td class=\"subtitle3\" colspan=\"2\">0</td> <td class=\"subtitle3\">0.5</td> <td class=\"subtitle3\" colspan=\"2\">1.0</td> </tr> <tr> <td>Age in years</td> <td class=\"centered\" colspan=\"2\">&#62;60</td> <td class=\"centered\">50-60</td> <td class=\"centered\" colspan=\"2\">&#60;50</td> <td>&nbsp;</td> </tr> <tr> <td>KPS</td> <td class=\"centered\" colspan=\"2\">&#60;70</td> <td class=\"centered\">70-80</td> <td class=\"centered\" colspan=\"2\">90-100</td> <td>&nbsp;</td> </tr> <tr> <td>Extracranial metastases</td> <td class=\"centered\" colspan=\"2\">Present</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\" colspan=\"2\">Absent</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Number of BM</td> <td class=\"centered\" colspan=\"2\">&#62;3</td> <td class=\"centered\">2-3</td> <td class=\"centered\" colspan=\"2\">1</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"6\" align=\"right\"><strong>Total:</strong></td> <td class=\"sublist1_start\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"7\">Median survival (months) by score: 0-1.0 = 3.0; 1.5-2.0 = 5.5; 2.5-3.0 = 9.4; 3.5-4.0 = 14.8</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist_other\" colspan=\"7\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"7\">Melanoma</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">Prognostic factor</td> <td class=\"subtitle2\" colspan=\"5\">Scoring criteria</td> <td class=\"subtitle2\" rowspan=\"2\">Patient score</td> </tr> <tr> <td class=\"subtitle3\" colspan=\"2\">0</td> <td class=\"subtitle3\">1.0</td> <td class=\"subtitle3\" colspan=\"2\">2.0</td> </tr> <tr> <td>KPS</td> <td class=\"centered\" colspan=\"2\">&#60;70</td> <td class=\"centered\">70-80</td> <td class=\"centered\" colspan=\"2\">90-100</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Number of BM</td> <td class=\"centered\" colspan=\"2\">&#62;3</td> <td class=\"centered\">2-3</td> <td class=\"centered\" colspan=\"2\">1</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"6\" align=\"right\"><strong>Total:</strong></td> <td class=\"sublist1_start\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"7\">Median survival (months) by score: 0-1.0 = 3.4; 1.5-2.0 = 4.7; 2.5-3.0 = 8.8; 3.5-4.0 = 13.2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist_other\" colspan=\"7\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"7\">Breast cancer</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">Prognostic factor</td> <td class=\"subtitle2\" colspan=\"5\">Scoring criteria</td> <td class=\"subtitle2\" rowspan=\"2\">Patient score</td> </tr> <tr> <td class=\"subtitle3\">0</td> <td class=\"subtitle3\">0.5</td> <td class=\"subtitle3\">1.0</td> <td class=\"subtitle3\">1.5</td> <td class=\"subtitle3\">2.0</td> </tr> <tr> <td>KPS</td> <td class=\"centered\">&#8804;50</td> <td class=\"centered\">60</td> <td class=\"centered\">70-80</td> <td class=\"centered\">90-100</td> <td class=\"centered\">n/a</td> <td>&nbsp;</td> </tr> <tr> <td>Subtype*</td> <td class=\"centered\">Basal</td> <td class=\"centered\">n/a</td> <td class=\"centered\">Luminal A</td> <td class=\"centered\">HER2</td> <td class=\"centered\">Luminal B</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Age in years</td> <td class=\"centered\">&#8805;60</td> <td class=\"centered\">&#60;60</td> <td class=\"centered\">n/a</td> <td class=\"centered\">n/a</td> <td class=\"centered\">n/a</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"6\" align=\"right\"><strong>Total:</strong></td> <td class=\"sublist1_start\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"7\">Median survival (months) by score: 0-1.0 = 3.4; 1.5-2.0 = 7.7; 2.5-3.0 = 15.1; 3.5-4.0 = 25.3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist_other\" colspan=\"7\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"7\">Renal cell carcinoma</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">Prognostic factor</td> <td class=\"subtitle2\" colspan=\"5\">Scoring criteria</td> <td class=\"subtitle2\" rowspan=\"2\">Patient score</td> </tr> <tr> <td class=\"subtitle3\" colspan=\"2\">0</td> <td class=\"subtitle3\">1.0</td> <td class=\"subtitle3\" colspan=\"2\">2.0</td> </tr> <tr> <td>KPS</td> <td class=\"centered\" colspan=\"2\">&#60;70</td> <td class=\"centered\">70-80</td> <td class=\"centered\" colspan=\"2\">90-100</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Number of BM</td> <td class=\"centered\" colspan=\"2\">&#62;3</td> <td class=\"centered\">2-3</td> <td class=\"centered\" colspan=\"2\">1</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"6\" align=\"right\"><strong>Total:</strong></td> <td class=\"sublist1_start\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"7\">Median survival (months) by score: 0-1.0 = 3.3; 1.5-2.0 = 7.3; 2.5-3.0 = 11.3; 3.5-4.0 = 14.8</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist_other\" colspan=\"7\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"7\">Gastrointestinal cancers</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">Prognostic factor</td> <td class=\"subtitle2\" colspan=\"5\">Scoring criteria</td> <td class=\"subtitle2\" rowspan=\"2\">Patient score</td> </tr> <tr> <td class=\"subtitle3\">0</td> <td class=\"subtitle3\">1</td> <td class=\"subtitle3\">2</td> <td class=\"subtitle3\">3</td> <td class=\"subtitle3\">4</td> </tr> <tr class=\"divider_bottom\"> <td>KPS</td> <td class=\"centered\">&#60;70</td> <td class=\"centered\">70</td> <td class=\"centered\">80</td> <td class=\"centered\">90</td> <td class=\"centered\">100</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"6\" align=\"right\"><strong>Total:</strong></td> <td class=\"sublist1_start\">&nbsp;</td> </tr> <tr> <td colspan=\"7\">Median survival (months) by score: 0-1.0 = 3.1; 2.0 = 4.4; 3.0 = 6.9; 4.0 = 13.5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BM: brain metastases; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; KPS: Karnofsky performance score; PR: progesterone receptor.<br />* Basal: triple negative; Luminal A: ER/PR positive, HER2 negative; Luminal B: triple positive; HER2: ER/PR negative, HER2 positive.</div><div class=\"graphic_reference\">From: Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30:419. Reprinted with permission. Copyright &copy; 2012 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 65322 Version 3.0</div></div></div>"},"65323":{"type":"graphic_table","displayName":"Modified CCI","title":"Modified Charlson comorbidity index","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Charlson comorbidity index</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1\">Comorbid condition</td>\n\t    <td class=\"subtitle1\">Point</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Myocardial infarction</td>\n\t    <td>1</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Heart failure</td>\n\t    <td>1</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Cerebrovascular disease</td>\n\t    <td>1</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Ulcer</td>\n\t    <td>1</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Hepatic disease (mild)</td>\n\t    <td>1</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Diabetes (mild or moderate)</td>\n\t    <td>1</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Pulmonary disease (moderate or severe)</td>\n\t    <td>1</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Connective tissue disease</td>\n\t    <td>1</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Diabetes (severe with end-organ damage)</td>\n\t    <td>2</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Renal disease (moderate or severe)</td>\n\t    <td>2</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Solid tumor (without metastases)</td>\n\t    <td>2</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Hepatic disease (moderate or severe)</td>\n\t    <td>3</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Solid tumor (with metastases)</td>\n\t    <td>6</td>\n\t  </tr>\n\t  <tr>\n\t    <td><strong>Total score</strong></td>\n\t    <td>&nbsp;</td>\n\t  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Etienne, A, Esterni, B, Charbonnier, A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007; 109:1376. Copyright &#169; 2007 American Cancer Society. This material is reproduced with permission of Wiley-Liss, Inc., a subsidiary of John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 65323 Version 1.0</div></div></div>"},"65324":{"type":"graphic_figure","displayName":"CPAP PI","title":"Continuous positive airway pressure (CPAP) for sleep apnea","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Continuous positive airway pressure (CPAP) for sleep apnea</div><div class=\"cntnt\"><img style=\"width:548px; height:503px;\" src=\"images/PI/65324_CPAP_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CPAP mask gently blows air into your nose while you sleep. It puts just enough pressure on your airway to keep it from closing. The mask in this picture fits over just the nose. Other CPAP devices have masks that fit over the nose and mouth.</div><div id=\"graphicVersion\">Graphic 65324 Version 5.0</div></div></div>"},"65326":{"type":"graphic_table","displayName":"Comparison of gout and CPPD disease","title":"Comparison of gout and CPPD disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of gout and CPPD disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Characteristic</td> <td class=\"subtitle1\">Gout</td> <td class=\"subtitle1\">CPPD disease</td> </tr> <tr> <td>Prevalence</td> <td>17 to 20 per 1000 individuals, largely adult men and postmenopausal women</td> <td>&#60;1 per 1000 individuals experience acute CPP&nbsp;crystal arthritis&nbsp;(pseudogout); CPPD disease is common in osteoarthritis and increases with age</td> </tr> <tr class=\"divider_top\"> <td>Crystal chemistry</td> <td>Monosodium urate</td> <td>CPP&nbsp;dehydrate</td> </tr> <tr class=\"divider_top\"> <td>Crystal appearance</td> <td>Negatively birefringent; needle-shaped or rods</td> <td>Weakly positively birefringent;&nbsp;rods or rhomboidal</td> </tr> <tr class=\"divider_top\"> <td>Articular involvement</td> <td>Monoarticular &#62; oligoarticular; polyarticular &#60;30%</td> <td>Monoarticular &#62; oligoarticular</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Most frequently affected joints</td> <td class=\"sublist1_start\">First MTP joint</td> <td rowspan=\"4\">Knee, wrist, other</td> </tr> <tr> <td class=\"sublist1\">Initially 50%</td> </tr> <tr> <td class=\"sublist1\">Eventually 90%</td> </tr> <tr> <td>Ankle, knees, other</td> </tr> <tr class=\"divider_top\"> <td>Predisposing conditions/risk factors</td> <td>Hyperuricemia*, obesity, hypertension, hyperlipidemia, alcohol ingestion, lead ingestion, hereditary enzyme defect</td> <td>Hemochromatosis,&nbsp;osteoarthritis, hypomagnesemia,&nbsp;hyperparathyroidism, hereditary (rare), and increased age</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Therapeutic options</td> <td class=\"sublist1_start\">Acute gout&nbsp;attacks</td> <td class=\"sublist1_start\">Acute CPP crystal arthritis (pseudogout)</td> </tr> <tr> <td class=\"sublist1\">NSAIDs, glucocorticoids, colchicine</td> <td class=\"sublist1\">NSAIDs, glucocorticoids, colchicine</td> </tr> <tr> <td class=\"sublist1_start\">Chronic gout management</td> <td class=\"sublist1_start\">Chronic CPPD disease management</td> </tr> <tr> <td class=\"sublist1\">Urate-lowering agents, colchicine</td> <td class=\"sublist1\"> <p>NSAIDs, colchicine</p> </td> </tr> <tr> <td>&nbsp;</td> <td class=\"sublist1\">&nbsp;</td> <td class=\"sublist1\">DMARDs: hydroxychloroquine, methotrexate&nbsp;(no randomized trials showing clinical benefit)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CPPD: calcium pyrophosphate deposition; CPP: calcium pyrophosphate; Pseudogout: a descriptive term for the form of CPPD disease now classified as acute&nbsp;CPP crystal arthritis;&nbsp;MTP: metatarsophalangeal; NSAIDs: nonsteroidal antiinflammatory drugs; DMARDs: disease-modifying antirheumatic drugs.<br />* Drugs associated with hyperuricemia include diuretics, low-dose salicylates, nicotinic acid, cyclosporine, ethanol, and ethambutol.</div><div class=\"graphic_reference\">Adapted from: Am J Med 1997; 103:68S.</div><div id=\"graphicVersion\">Graphic 65326 Version 10.0</div></div></div>"},"65327":{"type":"graphic_figure","displayName":"Port placement for laparoscopic appendectomy","title":"Port placement for laparoscopic appendectomy*","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Port placement for laparoscopic appendectomy*</div><div class=\"cntnt\"><img style=\"width:484px; height:587px;\" src=\"images/SURG/65327_Ports_lap_appy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An open technique is used to enter the peritoneal cavity and place a 5 to 12 mm Hasson trocar at the umbilicus. The laparoscope is introduced through the umbilical port and two additional 5 mm ports are placed. The first is placed lateral to the left rectus muscle and medial to the anterior superior iliac spine. The second is placed in the suprapubic region at least 2 finger breadths superior to the pubic tubercle. Both the surgeon and the assistant stand on the patient's left side.<br> The surgeon operates using the two 5 mm ports (shown in red) and the assistant operates the laparoscope (shown in blue). One 12 mm port is needed to pass a surgical stapler to transect the appendix. The appendix is removed through the periumbilical port site, in a specimen bag.</div><div class=\"graphic_footnotes\">* Port placement and technique may vary amongst laparoscopic surgeons.</div><div id=\"graphicVersion\">Graphic 65327 Version 4.0</div></div></div>"},"65328":{"type":"graphic_picture","displayName":"Urate crystals diaper","title":"Precipitation of uric acid (urate) crystals in the diaper","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Precipitation of uric acid (urate) crystals in the diaper</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PEDS/65328_Urate_crystals_diaper.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The precipitation of uric acid crystals in the diaper (secondary to increased urinary uric acid excretion in infants) may be misidentified as blood.</div><div class=\"graphic_reference\">Courtesy of Gerardo Cabrera-Meza, MD, Associate Professor Pediatrics, Baylor College of Medicine.</div><div id=\"graphicVersion\">Graphic 65328 Version 2.0</div></div></div>"},"65329":{"type":"graphic_figure","displayName":"Urea clearance NxStage vs conventional","title":"Urea clearance with increasing dialysate flow rates: NxStage approach versus conventional dialysis where dialysate saturation defines efficiency of dialysate use","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Urea clearance with increasing dialysate flow rates: NxStage approach versus conventional dialysis where dialysate saturation defines efficiency of dialysate use</div><div class=\"cntnt\"><img style=\"width:610px; height:408px;\" src=\"images/NEPH/65329_Urea_clearance_NxStage.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Q<sub>b</sub>: blood flow rate; Q<sub>d</sub>: dialysate flow rate.</div><div class=\"graphic_reference\">Data reproduced with permission from: NxStage Medical, Inc. Copyright &copy; 2012.</div><div id=\"graphicVersion\">Graphic 65329 Version 4.0</div></div></div>"},"65331":{"type":"graphic_algorithm","displayName":"Asympt hematuria proteinuria","title":"Diagnostic algorithm for asymptomatic microscopic hematuria with proteinuria in children","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for asymptomatic microscopic hematuria with proteinuria in children</div><div class=\"cntnt\"><img style=\"width:455px; height:532px;\" src=\"images/PEDS/65331_Asympt_hematuria_proteinuri.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">U/A: urinalysis.<BR>* For children between 6 and 24 months, the threshold value is 0.5 mg protein to mg creatinine.</div><div class=\"graphic_reference\">Modified from: Diven SC, Travis LB. A practical primary care approach to hematuria in children. Pediatr Nephrol 2000; 14:65.</div><div id=\"graphicVersion\">Graphic 65331 Version 3.0</div></div></div>"},"65333":{"type":"graphic_picture","displayName":"RTT develop arrest","title":"Rett syndrome, delvelopmental arrest age one year","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rett syndrome, delvelopmental arrest age one year</div><div class=\"cntnt\"><img style=\"width:252px; height:378px;\" src=\"images/PEDS/65333_RS_stage_I_develop_arrest_b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At one year of age, she has loss of eye contact and disinterest in toys.</div><div class=\"graphic_reference\">Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright © 1997 Medscape.</div><div id=\"graphicVersion\">Graphic 65333 Version 4.0</div></div></div>"},"65334":{"type":"graphic_figure","displayName":"Dose response cessation","title":"Dose response of smoking cessation rates according to the number of counseling sessions clinicians have with patients and use of medication","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Dose response of smoking cessation rates according to the number of counseling sessions clinicians have with patients and use of medication</div><div class=\"cntnt\"><img style=\"width:579px; height:477px;\" src=\"images/PC/65334_Doseresponsecessation.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 65334 Version 9.0</div></div></div>"},"65336":{"type":"graphic_waveform","displayName":"EPS tracings AVRT into atrial tachycardia","title":"Electrophysiology study (EPS) tracings of surface and intracardiac electrograms showing degeneration of orthodromic atrioventricular reciprocating tachycardia (AVRT) into atrial tachycardia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrophysiology study (EPS) tracings of surface and intracardiac electrograms showing degeneration of orthodromic atrioventricular reciprocating tachycardia (AVRT) into atrial tachycardia</div><div class=\"cntnt\"><img style=\"width:428px; height:331px;\" src=\"images/CARD/65336_AVRT_into_atrial_tachycardi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surface ECG leads I, AVF, and VI and intracardiac electrograms are simultaneously recorded. The first three QRS complexes represent an orthodromic atrioventricular reentrant tachycardia (AVRT). The QRS complexes are narrow and there is retrograde activation of the atrium (P) which, based upon timing with the vertical line after the second QRS complex, begins at the distal coronary sinus (DCS) which is the site of earliest atrial activation and is consistent with a left lateral accessory pathway. After the third complex, the vertical line indicates atrial activation at the proximal coronary sinus (PCS) which is premature and has a different morphology (A'). This atrial premature beat initiates a rapid atrial tachycardia (*) and atrial activity now precedes the QRS complex. The atrial tachycardia has a wide complex because of antegrade conduction via the accessory pathway.</div><div class=\"graphic_footnotes\">HRA: high right atrium; HBEP: proximal His Bundle electrogram; HBED: distal His Bundle electrogram; MCS: mid coronary sinus; RVA: right ventricular apex.</div><div id=\"graphicVersion\">Graphic 65336 Version 3.0</div></div></div>"},"65338":{"type":"graphic_table","displayName":"Confounding factors","title":"Possible confounding factors in the interpretation of mainly cross-sectional information about risk factors and vascular calcification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible confounding factors in the interpretation of mainly cross-sectional information about risk factors and vascular calcification</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t\t<tbody>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1\">Risk factor</td>\n\n\t\t\t\t<td class=\"subtitle1\">Association</td>\n\n\t\t\t\t<td class=\"subtitle1\">Confounded by</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>High plasma phosphate</td>\n\n\t\t\t\t<td>Phenotypic shift of contractile vascular smooth muscle cells to secretory CVC; mortality data</td>\n\n\t\t\t\t<td>Is high phosphate a marker of severe bone disease, or noncompliance with dialysis, drugs, and diet?</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>High plasma calcium</td>\n\n\t\t\t\t<td>Hypercalcemic episodes leading to direct precipitation</td>\n\n\t\t\t\t<td>Hyperparathyroidism, vitamin D; lack of relation between calcium balance and blood calcium levels</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>High parathyroid hormone</td>\n\n\t\t\t\t<td>Increases intracellular calcium levels</td>\n\n\t\t\t\t<td>Use of more phosphate binders and vitamin D</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Low parathyroid hormone</td>\n\n\t\t\t\t<td>Lack of dynamic bone metabolic activity to buffer changes in plasma calcium</td>\n\n\t\t\t\t<td>Previous use of vitamin D and phosphate binders; parathyroidectomy</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Vitamin D therapy</td>\n\n\t\t\t\t<td>Increases plasma calcium and phosphate levels; calcifies vessel wall tunica media; vitamin D receptors on vascular smooth muscle cells (especially with hyperphosphatemia, even if calcium normal); accelerates atherosclerosis</td>\n\n\t\t\t\t<td>Hyperparathyroidism</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Inflammation/redox stress</td>\n\n\t\t\t\t<td>Reduces levels of alpha-2-Heremann Schmitt glycoprotein (fetuin) a naturally occurring inhibitor of calcification; accelerated atherosclerosis</td>\n\n\t\t\t\t<td>Vascular disease may be the cause of inflammation</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Warfarin</td>\n\n\t\t\t\t<td>Inhibits matrix GLA protein; naturally occurring inhibitor of calcification</td>\n\n\t\t\t\t<td>Often used in patients with poor hemodialysis access, including diabetics, older patients, and women; sharing risk factors for vascular disease</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Dyslipidemia</td>\n\n\t\t\t\t<td>Oxidized low-density lipoprotein causing endothelial/vascular smooth muscle cell damage; high-density lipoprotein protective against calcification</td>\n\n\t\t\t\t<td>Hyperparathyroidism associated dyslipidemia; sevelamer reduces low-density lipoprotein cholesterol and raises high-density lipoprotein cholesterol</td>\n\t\t\t</tr>\n\n\t\t\t<tr>\n\t\t\t\t<td>Avoidance of aluminum; high dose of oral calcium-containing phosphate binders</td>\n\n\t\t\t\t<td>Positive calcium balance</td>\n\n\t\t\t\t<td>High plasma phosphate levels; poor compliance with drugs, dialysis, and diet; alkalosis favors calcification (calcium carbonate/acetate); sevelamer leads to mild acidosis; aluminum is a potent inhibitor of calcification/ossification</td>\n\t\t\t</tr>\n\t\t</tbody>\n\t</table></div><div class=\"graphic_footnotes\">CVC: calcifying vascular cells.</div><div class=\"graphic_reference\">Reproduced with permission from: Goldsmith D, Ritz E, Cvic A. Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 2004; 66:1315. Copyright &#169; 2004 Blackwell Publishing.</div><div id=\"graphicVersion\">Graphic 65338 Version 1.0</div></div></div>"},"65339":{"type":"graphic_figure","displayName":"Inversions and recombinations","title":"Effects of chromosomal inversions on recombination","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Effects of chromosomal inversions on recombination</div><div class=\"cntnt\"><img style=\"width:528px; height:426px;\" src=\"images/OBGYN/65339_Inversions_and_recombinatio.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65339 Version 1.0</div></div></div>"},"65340":{"type":"graphic_figure","displayName":"Isolated limb infusion","title":"Isolated limb infusion","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Isolated limb infusion</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/ONC/65340_Isolated_limb_infusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Redrawn with permission from: Brady MS, Brown K, Patel A, et al. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Melanoma Res 2009; 19:106. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65340 Version 9.0</div></div></div>"},"65341":{"type":"graphic_diagnosticimage","displayName":"Thoracic spine meningioma MRI","title":"Thoracic spine meningioma","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Thoracic spine meningioma</div><div class=\"cntnt\"><img style=\"width:531px; height:249px;\" src=\"images/ONC/65341_Thoracic_spine_meningioma_M.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced thoracic MRI scans in a 75-year-old woman with progressive paraparesis due to a mid-thoracic spinal meningioma. Left panel: The sagittal study reveals a dural-based lesion at T7-8. Right panel: The axial image shows the ventrally-located lesion (arrow) causing spinal cord compression.</div><div class=\"graphic_reference\">Courtesy of William Welch, MD.</div><div id=\"graphicVersion\">Graphic 65341 Version 2.0</div></div></div>"},"65342":{"type":"graphic_picture","displayName":"DIP examination","title":"Examination of DIP flexion and extension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examination of DIP flexion and extension</div><div class=\"cntnt\"><img style=\"width:438px; height:216px;\" src=\"images/EM/65342_DIP_examination.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To evaluate flexion (A) and extension (B) of the distal interphalangeal (DIP) joint, immobilize the&nbsp;proximal interphalangeal (PIP)&nbsp;and metacarpophalangeal (MCP)&nbsp;joints of the finger being examined, and then have the patient actively flex and extend the DIP joint.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 65342 Version 2.0</div></div></div>"},"65343":{"type":"graphic_algorithm","displayName":"Algorithm for management of rotator cuff tendinopathy","title":"Management algorithm for rotator cuff tendinopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management algorithm for rotator cuff tendinopathy</div><div class=\"cntnt\"><img style=\"width:338px; height:706px;\" src=\"images/EM/65343_RC_approach_algo.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65343 Version 2.0</div></div></div>"},"65344":{"type":"graphic_diagnosticimage","displayName":"Intestinal pseudo-obstruction in scleroderma","title":"Intestinal pseudo-obstruction in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intestinal pseudo-obstruction in scleroderma</div><div class=\"cntnt\"><img style=\"width:322px; height:387px;\" src=\"images/GAST/65344_PSS_pseudoobstruction_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium radiograph in a patient with small bowel scleroderma and pseudo-obstruction syndrome reveals a dilated post-bulbar duodenum (megaduodenum) and jejunum, with infiltrated valvulae conniventes (arrow) in the lower jejunal loop.</div><div class=\"graphic_reference\">Courtesy of Michael Camilleri, MD.</div><div id=\"graphicVersion\">Graphic 65344 Version 4.0</div></div></div>"},"65345":{"type":"graphic_picture","displayName":"Mycosis fungoides hyperpig","title":"Mycosis fungoides - patch/plaque","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mycosis fungoides - patch/plaque</div><div class=\"cntnt\"><img style=\"width:432px; height:336px;\" src=\"images/HEME/65345_Mycosis_fungoides_hyperpig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with wide-spread mycosis fungoides exhibits numerous hyperpigmented patches and thin plaques.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65345 Version 5.0</div></div></div>"},"65346":{"type":"graphic_diagnosticimage","displayName":"MRI glioblastoma","title":"Magnetic resonance image of a glioblastoma","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance image of a glioblastoma</div><div class=\"cntnt\"><img style=\"width:493px; height:327px;\" src=\"images/PEDS/65346_MRI_glioblastoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The T2 axial image of this glioblastoma multiforme shows a heterogeneous infiltrating mass that fills large portions of the right temporal and parietal lobes.<br />(B) The axial flair image of this lesion shows the extensive edema and midline shift that have resulted from the mass.</div><div id=\"graphicVersion\">Graphic 65346 Version 5.0</div></div></div>"},"65347":{"type":"graphic_table","displayName":"Verbal multidimensional scoring system for dysmenorrhea","title":"Verbal multidimensional scoring system for assessment of dysmenorrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Verbal multidimensional scoring system for assessment of dysmenorrhea</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Grade</td>\n\n      <td class=\"subtitle1\">Working ability</td>\n\n      <td class=\"subtitle1\">Systemic symptoms</td>\n\n      <td class=\"subtitle1\">Analgesics</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Grade 0: Menstruation is not painful and daily activity\nis unaffected</td>\n\n      <td>Unaffected</td>\n\n      <td>None</td>\n\n      <td>None required</td>\n\n    </tr>\n\n    \n    <tr>\n\n      <td>Grade 1: Menstruation is painful but seldom inhibits\nnormal activity; analgesics are seldom required; mild pain</td>\n\n      <td>Rarely affected</td>\n\n      <td>None</td>\n\n      <td>Rarely required</td>\n\n    </tr>\n\n    \n    <tr>\n\n      <td>Grade 2: Daily activity is affected; analgesics\nrequired and give sufficient relief so that absence from school is\nunusual; moderate pain</td>\n\n      <td>Moderately affected</td>\n\n      <td>Few</td>\n\n      <td>Required</td>\n\n    </tr>\n\n    \n    <tr>\n\n      <td>Grade 3: Activity clearly inhibited; poor effect of\nanalgesics; vegetative symptoms (headache, fatigue, vomiting, and\ndiarrhea); severe pain</td>\n\n      <td>Clearly inhibited</td>\n\n      <td>Apparent</td>\n\n      <td>Poor effect</td>\n\n    </tr>\n    \n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=55790&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Scoring_system_for_dysmenor.htm</title></head></div><div class=\"graphic_reference\">Adapted from Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol 1982; 144:655.</div><div id=\"graphicVersion\">Graphic 65347 Version 2.0</div></div></div>"},"65349":{"type":"graphic_diagnosticimage","displayName":"RML and RLL atelectasis II","title":"Reversal of right middle and lower lobe atelectasis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reversal of right middle and lower lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:374px; height:376px;\" src=\"images/PULM/65349_RML_and_RLL_atelectasis_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upright chest radiograph from the previous patient with right middle and lower lobe atelectasis taken the next day after chest physiotherapy. The right middle and lower lobes are now partially aerated and the right heart border and the right hemidiaphragm are faintly visible.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 65349 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"65350":{"type":"graphic_diagnosticimage","displayName":"Hangmans fracture child","title":"Hangman's fracture child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hangman's fracture child</div><div class=\"cntnt\"><img style=\"width:404px; height:404px;\" src=\"images/EM/65350_Hangmans_fracture_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 3 year old boy with neck pain and a history of osteogenesis imperfecta has bilateral C2 pedicular fractures (arrow) with minimal kyphosis and anterolisthesis (forward displacement of C2 on C3).</div><div class=\"graphic_reference\">Courtesy of Alison Chantal Caviness, MD.</div><div id=\"graphicVersion\">Graphic 65350 Version 3.0</div></div></div>"},"65351":{"type":"graphic_table","displayName":"Irritant and allergic contact dermatitis","title":"Characteristics of irritant and allergic contact dermatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of irritant and allergic contact dermatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Irritant contact dermatitis</td> <td class=\"subtitle1\">Allergic contact dermatitis</td> </tr> <tr> <td><strong>Etiology</strong></td> <td>Irritant substances</td> <td>Allergens </td> </tr> <tr> <td><strong>Mechanisms</strong></td> <td> <p>Non-immunological</p> </td> <td> <p>Delayed-type hypersensitivity</p> <p>Antigen-specific T cells</p> </td> </tr> <tr> <td><strong>Sites</strong></td> <td>Localized to the contact areas</td> <td> <p>At the site of the contact</p> <p>May be widespread</p> </td> </tr> <tr> <td><strong>Symptoms</strong></td> <td> <p>Burning, stinging, and pain</p> <p>Pruritus may be present</p> </td> <td>Pruritus</td> </tr> <tr> <td><strong>Onset</strong></td> <td> <p>May appear after first contact</p> <p>Usually minutes to hours (strong irritant) or 24 hours to one week (weak irritant)</p> </td> <td> <p>Sensitization phase before onset</p> <p>Usually 24-72 hours after exposure</p> </td> </tr> <tr> <td><strong>Decrescendo phenomenon</strong></td> <td>Yes </td> <td>No </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\"><strong>Clinical manifestation</strong></td> </tr> <tr> <td class=\"sublist1\">Acute stage</td> <td class=\"sublist_other\"> <p>Erythema, edema, vesicles, and bullae</p> <p>Necrosis and ulceration in severe cases</p> </td> <td class=\"sublist_other\">Erythema, edema, vesicles</td> </tr> <tr> <td class=\"sublist1\">Chronic stage</td> <td class=\"sublist_other\">Fissuring, hyperkeratosis, and scaling</td> <td class=\"sublist_other\">Fissuring, hyperkeratosis, and scaling</td> </tr> <tr> <td><strong>Histopathology</strong></td> <td> <p>Mild spongiosis, necrosis of epidermal keratinocyte</p> </td> <td>Spongiosis </td> </tr> <tr> <td><strong>Patch testing</strong></td> <td>Negative </td> <td>Positive </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65351 Version 1.0</div></div></div>"},"65352":{"type":"graphic_diagnosticimage","displayName":"TB arthritis of the hip","title":"Tuberculosis of the right hip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberculosis of the right hip</div><div class=\"cntnt\"><img style=\"width:292px; height:288px;\" src=\"images/ID/65352_TB_arthritis_of_the_hip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain film of the right hip in a 28-year-old woman with painful joints and a productive cough demonstrates complete loss of the joint space and destruction of the cartilage and adjacent joint surfaces with severe periarticular bony demineralization (arrows).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 65352 Version 2.0</div></div></div>"},"65355":{"type":"graphic_table","displayName":"Infection related reproductive hazards in the workplace","title":"Disease causing agents that are reproductive hazards for women in the workplace","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disease causing agents that are reproductive hazards for women in the workplace</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Agent</td>\n<td class=\"subtitle1\">Observed effects</td>\n<td class=\"subtitle1\">Potentially exposed workers</td>\n<td class=\"subtitle1\">Preventative measures</td>\n</tr>\n<tr>\n<td>Cytomegalo- virus (CMV)</td>\n<td>Birth defects, low birth weight, developmental disorders</td>\n<td>Health care workers, workers in contact with infants and children</td>\n<td>Good hygienic practices such as handwashing</td>\n</tr>\n<tr>\n<td>Hepatitis B virus</td>\n<td>Low birth weight</td>\n<td>Health care workers</td>\n<td>Vaccination</td>\n</tr>\n<tr>\n<td>Human immuno-deficiency virus (HIV)</td>\n<td>Low birth weight, childhood cancer</td>\n<td>Health care workers</td>\n<td>Practice universal precautions</td>\n</tr>\n<tr>\n<td>Human parvovirus B19</td>\n<td>Miscarriage</td>\n<td>Health care workers, workers in contact with infants and children</td>\n<td>Good hygienic practices such as handwashing</td>\n</tr>\n<tr>\n<td>Rubella (German measles)</td>\n<td>Birth defects, low birth weight</td>\n<td>Health care workers, workers in contact with infants and children</td>\n<td>Vaccination before pregnancy if no prior immunity</td>\n</tr>\n<tr>\n<td>Toxoplasmosis</td>\n<td>Miscarriage, birth defects, developmental disorders</td>\n<td>Animal care workers, veterinarians</td>\n<td>Good hygiene practices such as handwashing</td>\n</tr>\n<tr>\n<td>Varicella-zoster virus (chicken pox)</td>\n<td>Birth defects, low birth weight</td>\n<td>Health care workers, workers in contact with infants and children</td>\n<td>Vaccination before pregnancy if no prior immunity</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">National Institute for Occupational Safety and Health.</div><div id=\"graphicVersion\">Graphic 65355 Version 2.0</div></div></div>"},"65357":{"type":"graphic_table","displayName":"Immunostimulating herbs","title":"Immunostimulating herbal ingredients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunostimulating herbal ingredients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Drug</td>\n<td class=\"subtitle1\">Effect</td>\n</tr>\n<tr>\n<td>Boneset</td>\n<td>Stimulant in vitro</td>\n</tr>\n<tr>\n<td>Calendula</td>\n<td>Stimulant in vitro</td>\n</tr>\n<tr>\n<td>Drosera</td>\n<td>Stimulant and depressant (in vitro)</td>\n</tr>\n<tr>\n<td>Echinacea</td>\n<td>Stimulant in vitro, in vivo</td>\n</tr>\n<tr>\n<td>Ginseng, eleutherococcus</td>\n<td>Stimulant, animal, human</td>\n</tr>\n<tr>\n<td>Mistletoe</td>\n<td>Stimulant, animal, human; suppressant (high doses), human</td>\n</tr>\n<tr>\n<td>Saw palmetto</td>\n<td>Stimulant in vivo</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.284.</div><div id=\"graphicVersion\">Graphic 65357 Version 2.0</div></div></div>"},"65358":{"type":"graphic_figure","displayName":"Direct laryngoscopy curved blade","title":"Direct laryngoscopy using a curved blade","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Direct laryngoscopy using a curved blade</div><div class=\"cntnt\"><img style=\"width:517px; height:422px;\" src=\"images/EM/65358_DLcurvedblade.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct laryngoscopy using a curved blade. The blade is inserted under direct vision until the tip is positioned in the vallecula. Pulling upward on the laryngoscope handle at 45-degree angle retracts the tongue and at the same time elevates the epiglottis, revealing the vocal cords and glottis. Selection of the appropriate laryngoscope blade is especially important with this technique. A blade that is too small will impinge on the midportion of the tongue, potentially obscuring the landmarks, whereas a blade that is too large can displace the epiglottis posteriorly over the glottic opening.</div><div class=\"graphic_reference\">Reproduced with permission from: King C, Rappaport LD. Emergent endotracheal intubation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 65358 Version 10.0</div></div></div>"},"65359":{"type":"graphic_algorithm","displayName":"Initial management of children with severe hypertension","title":"Initial management of children with severe hypertension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Initial management of children with severe hypertension</div><div class=\"cntnt\"><img style=\"width:433px; height:293px;\" src=\"images/EM/65359_Rx_severe_HTN_in_children.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HF: heart failure; IV: intravenous; PO: oral.</div><div class=\"graphic_reference\">Reproduced with permission from: Flynn, JT, Tullus, K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol 2008; Online first. Copyright &#169; 2008 Springer Science and Business Media.</div><div id=\"graphicVersion\">Graphic 65359 Version 3.0</div></div></div>"},"65360":{"type":"graphic_figure","displayName":"Vit D metabolism","title":"Pathways of vitamin D synthesis","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Pathways of vitamin D synthesis</div><div class=\"cntnt\"><img style=\"width:451px; height:388px;\" src=\"images/ENDO/65360_Vit_D_metabolism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Metabolic activation of vitamin D to calcitriol and its effects on calcium and phosphate homeostasis. The result is an increase in the serum calcium and phosphate concentrations.</div><div class=\"graphic_footnotes\">UV: ultraviolet.</div><div id=\"graphicVersion\">Graphic 65360 Version 5.0</div></div></div>"},"65361":{"type":"graphic_table","displayName":"Probability bleeding varices","title":"Probability of bleeding from esophageal varices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Probability of bleeding from esophageal varices</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\" rowspan=\"2\">Red wale markings</td>\r\n                    <td class=\"subtitle1\" colspan=\"3\">Child class A</td>\r\n                    <td class=\"subtitle1\" colspan=\"3\">Child class B</td>\r\n                    <td class=\"subtitle1\" colspan=\"3\">Child class C</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2\">F1</td>\r\n                    <td class=\"subtitle2\">F2</td>\r\n                    <td class=\"subtitle2\">F3</td>\r\n                    <td class=\"subtitle2\">F1</td>\r\n                    <td class=\"subtitle2\">F2</td>\r\n                    <td class=\"subtitle2\">F3</td>\r\n                    <td class=\"subtitle2\">F1</td>\r\n                    <td class=\"subtitle2\">F2</td>\r\n                    <td class=\"subtitle2\">F3</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>-</td>\r\n                    <td>6</td>\r\n                    <td>10</td>\r\n                    <td>15</td>\r\n                    <td>10</td>\r\n                    <td>16</td>\r\n                    <td>26</td>\r\n                    <td>20</td>\r\n                    <td>30</td>\r\n                    <td>42</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>+</td>\r\n                    <td>8</td>\r\n                    <td>12</td>\r\n                    <td>19</td>\r\n                    <td>15</td>\r\n                    <td>23</td>\r\n                    <td>33</td>\r\n                    <td>28</td>\r\n                    <td>38</td>\r\n                    <td>54</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>++</td>\r\n                    <td>12</td>\r\n                    <td>16</td>\r\n                    <td>24</td>\r\n                    <td>20</td>\r\n                    <td>30</td>\r\n                    <td>42</td>\r\n                    <td>36</td>\r\n                    <td>48</td>\r\n                    <td>64</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>+++</td>\r\n                    <td>16</td>\r\n                    <td>23</td>\r\n                    <td>34</td>\r\n                    <td>28</td>\r\n                    <td>40</td>\r\n                    <td>52</td>\r\n                    <td>44</td>\r\n                    <td>60</td>\r\n                    <td>76</td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">6</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=20588&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_lgnd\">Estimations are based upon <strong>one-year percentage</strong> probability of bleeding.<br />F1, F2, F3 refer to size of the varix.</div><div class=\"graphic_reference\">Adapted from: deFranchis R, N Engl J Med 1988; 319:983.</div><div id=\"graphicVersion\">Graphic 65361 Version 3.0</div></div></div>"},"65362":{"type":"graphic_picture","displayName":"Scabies male genitalia","title":"Scabies male genitalia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies male genitalia</div><div class=\"cntnt\"><img style=\"width:288px; height:396px;\" src=\"images/DERM/65362_Scabies_male_genitalia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scabies. Pruritic papules and nodules are present on the penis and scrotum.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65362 Version 4.0</div></div></div>"},"65365":{"type":"graphic_figure","displayName":"Venous drainage of the pancreas and variations","title":"Venous drainage of the pancreas and variations","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Venous drainage of the pancreas and variations</div><div class=\"cntnt\"><img style=\"width:606px; height:572px;\" src=\"images/SURG/65365_Venous_drain_pancr_variat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Venous drainage of the pancreas. Variations in the relation of the portal, splenic, superior mesenteric, and inferior mesenteric veins are shown at the bottom.</div><div class=\"graphic_reference\">Reproduced with permission from: Vickers SM, Arnoletti JP, Brunicardi FC, Andersen DK. Pancreas Anatomy and Physiology. In: Greenfield's Surgery: Scientific Principles and Practice, 4th Edition, Mulholland MW, Lillemoe KD, Doherty GM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65365 Version 2.0</div></div></div>"},"65366":{"type":"graphic_picture","displayName":"Enterobius eggs","title":"Enterobius eggs","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Enterobius eggs</div><div class=\"cntnt\"><img style=\"width:546px; height:546px;\" src=\"images/ID/65366_Enterobius_eggs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Eggs of <em>E. vermicularis</em> in a cellulose-tape preparation.<br />(B) Eggs of <em>E. vermicularis</em> in a wet mount.<br />(C) Egg of <em>E. vermicularis</em> in an iodine-stained wet mount from a formalin concentrate.<br />(D) Eggs of <em>E. vermicularis</em> viewed under UV microscopy.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Enterobiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/enterobiasis/index.html\">http://www.cdc.gov/dpdx/enterobiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 65366 Version 5.0</div></div></div>"},"65367":{"type":"graphic_picture","displayName":"Severe perioral dermatitis 2","title":"Severe perioral dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Severe perioral dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/65367_Severe_perioral_dermat_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous inflammatory papules are present on the perioral skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65367 Version 3.0</div></div></div>"},"65368":{"type":"graphic_figure","displayName":"Window period acute HBV","title":"Window period of acute HBV infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Window period of acute HBV infection</div><div class=\"cntnt\"><img style=\"width:302px; height:180px;\" src=\"images/GAST/65368_Wndw_prd_act_HBV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the serologic findings during the window period of acute hepatitis B virus infection. The disappearance of HBsAg (hepatitis B surface antigen) is followed by the appearance of anti-HBs. In some patients, however, anti-HBs may not be detectable until after a window period of several weeks to months. At this time, neither HBsAg nor anti-HBs can be detected, the serologic diagnosis may be made by the detection of IgM antibodies against hepatitis B core antigen (IgM anti-HBc).</div><div class=\"graphic_footnotes\">* Window period.</div><div id=\"graphicVersion\">Graphic 65368 Version 5.0</div></div></div>"},"65369":{"type":"graphic_table","displayName":"Antimicrobial prophylaxis for gastrointestinal surgery","title":"Antimicrobial prophylaxis for gastrointestinal surgery in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial prophylaxis for gastrointestinal surgery in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nature of operation</td> <td class=\"subtitle1\">Common pathogens</td> <td class=\"subtitle1\">Recommended antimicrobials</td> <td class=\"subtitle1\">Usual adult dose*</td> <td class=\"subtitle1\">Redose interval<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Gastroduodenal surgery</td> </tr> <tr> <td class=\"indent1\">Procedures involving entry into lumen of gastrointestinal tract</td> <td>Enteric gram-negative bacilli, gram-positive cocci</td> <td>Cefazolin<sup>&#916;</sup></td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>Four hours</td> </tr> <tr> <td class=\"indent1\">Procedures not involving entry into lumen of gastrointestinal tract (selective vagotomy, antireflux)</td> <td>Enteric gram-negative bacilli, gram-positive cocci</td> <td>High risk<sup>&#9674;</sup> only: cefazolin<sup>&#916;</sup></td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>Four hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Biliary tract surgery (including pancreatic procedures)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Open procedure or laparoscopic procedure (high risk)<sup>&#167;</sup></td> <td rowspan=\"4\">Enteric gram-negative bacilli, enterococci, clostridia</td> <td>Cefazolin<sup>&#916;</sup><sup>&#165;</sup></td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>Four hours</td> </tr> <tr> <td><strong>OR</strong> cefotetan</td> <td>2 g IV</td> <td>Six hours</td> </tr> <tr> <td><strong>OR</strong> cefoxitin</td> <td>2 g IV</td> <td>Two hours</td> </tr> <tr> <td><strong>OR</strong> ampicillin-sulbactam</td> <td>3 g IV</td> <td>Two hours</td> </tr> <tr> <td class=\"indent1\">Laparoscopic procedure (low risk)</td> <td>N/A</td> <td>None</td> <td>None</td> <td>None</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Appendectomy<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">&nbsp;</td> <td rowspan=\"4\">Enteric gram-negative bacilli, anaerobes, enterococci</td> <td>Cefoxitin<sup>&#916;</sup></td> <td>2 g IV</td> <td>Two hours</td> </tr> <tr> <td><strong>OR</strong> cefotetan<sup>&#916;</sup></td> <td>2 g IV</td> <td>Six hours</td> </tr> <tr> <td><strong>OR</strong> cefazolin<sup>&#916;</sup></td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>Four hours</td> </tr> <tr> <td>PLUS metronidazole</td> <td>500 mg IV</td> <td>N/A</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Small intestine surgery</td> </tr> <tr> <td class=\"indent1\">Nonobstructed</td> <td>Enteric gram-negative bacilli, gram-positive cocci</td> <td>Cefazolin<sup>&#916;</sup></td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>Four hours</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Obstructed</td> <td rowspan=\"4\">Enteric gram-negative bacilli, anaerobes, enterococci</td> <td>Cefoxitin<sup>&#916;</sup></td> <td>2 g IV</td> <td>Two hours</td> </tr> <tr> <td><strong>OR</strong> cefotetan<sup>&#916;</sup></td> <td>2 g IV</td> <td>Six hours</td> </tr> <tr> <td><strong>OR</strong> cefazolin<sup>&#916;</sup></td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>Four hours</td> </tr> <tr> <td>PLUS metronidazole</td> <td>500 mg IV</td> <td>N/A</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Hernia repair</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Aerobic gram-positive organisms</td> <td>Cefazolin<sup>&#916;</sup></td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>Four hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Colorectal surgery<sup>&#134;</sup></td> </tr> <tr> <td rowspan=\"8\">&nbsp;</td> <td rowspan=\"8\">Enteric gram-negative bacilli, anaerobes, enterococci</td> <td class=\"sublist1_start\" colspan=\"3\">Parenteral:</td> </tr> <tr> <td class=\"indent1\">Cefoxitin<sup>&#916;</sup></td> <td>2 g IV</td> <td>Two hours</td> </tr> <tr> <td class=\"indent1\"><strong>OR</strong> cefotetan<sup>&#916;</sup></td> <td>2 g IV</td> <td>Six hours</td> </tr> <tr> <td class=\"indent1\"><strong>OR</strong> cefazolin<sup>&#916;</sup></td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>Four hours</td> </tr> <tr> <td class=\"indent1\">PLUS metronidazole</td> <td>500 mg IV</td> <td>N/A</td> </tr> <tr> <td class=\"indent1\"><strong>OR</strong> ampicillin-sulbactam<sup>&#916;,</sup>**</td> <td>3 g IV (based on combination)</td> <td>Two hours</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Oral (used in conjunction with mechanical bowel preparation):</td> </tr> <tr> <td class=\"indent1\">Neomycin PLUS erythromycin base or metronidazole</td> <td>&#182;&#182;</td> <td>&#182;&#182;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous.<br />* Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. If vancomycin or a fluoroquinolone is used, the infusion should be started within 60 to 120 minutes before the initial incision to have adequate tissue levels at the time of incision and to minimize the possibility of an infusion reaction close to the time of induction of anesthesia.<br />¶ For prolonged procedures (&gt;3 hours) or those with major blood loss or in patients with extensive burns, additional intraoperative doses should be given at intervals one to two times the half-life of the drug.<br />Δ For patients allergic to penicillins and cephalosporins, clindamycin (900 mg) or vancomycin (15 mg/kg IV; not to exceed 2 g) with either gentamicin (5 mg/kg IV), ciprofloxacin (400 mg IV), levofloxacin (500 mg IV), or aztreonam (2 g IV) is a reasonable alternative. Metronidazole (500 mg IV) plus an aminoglycoside or fluoroquinolone are also acceptable alternative regimens, although metronidazole plus aztreonam should not be used, since this regimen does not have aerobic gram-positive activity.<br /><FONT class=lozenge>◊</FONT> Morbid obesity, gastrointestinal (GI) obstruction, decreased gastric acidity or GI motility, gastric bleeding, malignancy or perforation, or immunosuppression.<br />§ Factors that indicate high risk may include age &gt;70 years, pregnancy, acute cholecystitis, nonfunctioning gall bladder, obstructive jaundice, common bile duct stones, immunosuppression.<br />¥ Cefotetan, cefoxitin, and ampicillin-sulbactam are reasonable alternatives.<br />‡ For a ruptured viscus, therapy is often continued for approximately five days.<br />† Use of ertapenem or other carbapenems not recommended due to concerns of resistance.<br />** Due to increasing resistance of <EM>Escherichia coli</EM> to fluoroquinolones and ampicillin-sulbactam, local sensitivity profiles should be reviewed prior to use.<br />¶¶ In addition to mechanical bowel preparation, the following oral antibiotic regimen is administered. 1 g of neomycin plus 1 g of erythromycin base at 1 PM, 2 PM, and 11 PM, or 2 g of neomycin plus 2 g of metronidazole at 7 PM and 11 PM the day before an 8 AM operation. Issues related to mechanical bowel preparation are discussed further separately. Refer to UpToDate topic on overview of colon resection.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Antimicrobial prophylaxis for surgery. Med Lett Drugs Ther 2016; 58:63.</LI>&#xD;&#xA;<LI>Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infec (Larchmt) 2013; 14:73.</LI></OL></div><div id=\"graphicVersion\">Graphic 65369 Version 31.0</div></div></div>"},"65372":{"type":"graphic_picture","displayName":"Leptomeningeal melanoma","title":"Leptomeningeal metastasis from malignant melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leptomeningeal metastasis from malignant melanoma</div><div class=\"cntnt\"><img style=\"width:450px; height:607px;\" src=\"images/ONC/65372_LM_malignant_melanoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A)Pigmented tumor cells are seen filling the subarachnoid space over the convexity of the brain. B) The tumor cells fill the subarachnoid space (1), have grown down the Virchow-Robin spaces into the brain (2) and have breached that space to invade the brain (3).</div><div class=\"graphic_reference\">Courtesy of Alexis Demopoulos, MD, and Jerome Posner, MD.</div><div id=\"graphicVersion\">Graphic 65372 Version 2.0</div></div></div>"},"65373":{"type":"graphic_figure","displayName":"Events in AF according to INR","title":"Optimal INR which minimizes both bleeding and thromboembolism in patients with atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Optimal INR which minimizes both bleeding and thromboembolism in patients with atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:512px; height:751px;\" src=\"images/CARD/65373_Events_AF_accord_INR_new.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Odds ratios (ORs) for thromboembolism (TE, 396 cases, 1581 controls) and intracranial hemorrhage (ICH, 164 cases, 656 controls) by INR level in adults with nonvalvular atrial fibrillation, with 8 INR categories using INR 2.0 to 2.5 as the referent. Vertical bars indicate 95 percent confidence intervals (CIs). The numbers of cases and controls for each INR category are given below the figure.<br> (B) ORs for TE (396 cases, 1581 controls) and ICH (164 cases, 656 controls) by INR level in adults with nonvalvular AF, with 6 INR categories using INR 2.0 to 2.5 as the referent. Vertical bars indicate 95 percent CIs. The numbers of cases and controls for each INR category are given below the figure.</div><div class=\"graphic_reference\">Reproduced with permission from: Singer DE, Chang Y, Fang MC, et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation? The ATRIA study. Circ Cardiovasc Qual Outcomes 2009; 2:297. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65373 Version 12.0</div></div></div>"},"65374":{"type":"graphic_table","displayName":"PPI recommended doses","title":"Recommendations for PPI doses in the treatment of acid-related disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for PPI doses in the treatment of acid-related disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose (adult) oral</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Active and maintenance therapy of gastroduodenal ulcers*</td> </tr> <tr> <td class=\"indent1\">Dexlansoprazole</td> <td>30 to 60 mg</td> </tr> <tr> <td class=\"indent1\">Esomeprazole</td> <td>20 to 40 mg</td> </tr> <tr> <td class=\"indent1\">Lansoprazole</td> <td>15 to 30 mg</td> </tr> <tr> <td class=\"indent1\">Omeprazole</td> <td>20 to 40 mg</td> </tr> <tr> <td class=\"indent1\">Pantoprazole</td> <td>20 to 40 mg</td> </tr> <tr> <td class=\"indent1\">Rabeprazole</td> <td>20 mg</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">All administered daily before breakfast</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Primary and secondary prevention of NSAID-induced ulcers</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">All PPIs as above</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Treatment of erosive or nonerosive gastroesophageal reflux disease</td> </tr> <tr> <td class=\"indent1\">Dexlansoprazole</td> <td>30 mg daily or 30 mg twice daily</td> </tr> <tr> <td class=\"indent1\">Esomeprazole</td> <td>20 or 40 mg daily</td> </tr> <tr> <td class=\"indent1\">Lansoprazole</td> <td>30 mg daily or 30 mg twice daily</td> </tr> <tr> <td class=\"indent1\">Omeprazole</td> <td>20 to 40 mg daily or 20 mg twice daily</td> </tr> <tr> <td class=\"indent1\">Pantoprazole</td> <td>40 mg daily or 40 mg twice daily</td> </tr> <tr> <td class=\"indent1\">Rabeprazole</td> <td>20 mg daily or 20 mg twice daily</td> </tr> <tr> <td colspan=\"2\">All administered daily before breakfast, second dose if necessary should be given before evening meal<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPI: proton pump inhibitor; NSAID: nonsteroidal antiinflammatory drug.<br />* As a general rule, active duodenal ulcers should be treated for four weeks and gastric ulcers for eight weeks.<br />¶ Meals should ideally contain protein to enhance parietal cell stimulation.</div><div class=\"graphic_reference\">Adapted from: Wolfe MM, Sachs G. Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118:S9.</div><div id=\"graphicVersion\">Graphic 65374 Version 9.0</div></div></div>"},"65376":{"type":"graphic_picture","displayName":"Ulnar gutter splint","title":"Ulnar gutter splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulnar gutter splint</div><div class=\"cntnt\"><img style=\"width:384px; height:288px;\" src=\"images/EM/65376_Ulnar_gutter_splint_for_MC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulnar gutter splint that supports the fourth and fifth fingers and leaves the index and middle fingers free.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 65376 Version 4.0</div></div></div>"},"65377":{"type":"graphic_diagnosticimage","displayName":"MRI clavicle osteolysis","title":"MRI of osteolysis of the clavicle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of osteolysis of the clavicle</div><div class=\"cntnt\"><img style=\"width:360px; height:342px;\" src=\"images/EM/65377_MRI_clavicle_osteolysis_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MRI pictured here shows increased signal in the distal clavicle (arrow) indicating the presence of bone marrow edema. This finding is consistent with osteolysis.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance image.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 65377 Version 4.0</div></div></div>"},"65378":{"type":"graphic_diagnosticimage","displayName":"TEE vegetation pulmonic valve","title":"Transesophageal echocardiogram (TEE) showing a vegetation on the pulmonic valve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram (TEE) showing a vegetation on the pulmonic valve</div><div class=\"cntnt\"><img style=\"width:267px; height:242px;\" src=\"images/CARD/65378_TEE_vegetation_pulmonic_val.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiographic image, obtained with the longitudinal plane through the junction of the right ventricular outflow tract and the pulmonary artery, shows a vegetation of the pulmonic valve (arrow). This mass was not seen on transthoracic echocardiography.</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventricle; RV: right ventricle; PA: pulmonary artery.</div><div id=\"graphicVersion\">Graphic 65378 Version 3.0</div></div></div>"},"65379":{"type":"graphic_picture","displayName":"Scleral rupture","title":"Patient with 360 degrees of bullous subconjunctival hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient with 360 degrees of bullous subconjunctival hemorrhage</div><div class=\"cntnt\"><img style=\"width:360px; height:269px;\" src=\"images/EM/65379_Scleral_rupture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient had a history of prior scleral buckle surgery. The patient was found to have a severe posterior scleral rupture that was not closable posteriorly due to extension to the optic nerve on surgical exploration.</div><div id=\"graphicVersion\">Graphic 65379 Version 2.0</div></div></div>"},"65380":{"type":"graphic_table","displayName":"Abnormal pressure SOD","title":"Abnormal pressure profile of sphincter of Oddi measured at common bile duct and pancreatic duct","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Abnormal pressure profile of sphincter of Oddi measured at common bile duct and pancreatic duct</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td>Basal pressure (mmHg)</td>\n\t    <td>&#62;40</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Phasic contractions (mmHg)</td>\n\t    <td>&#62;350</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Frequency (per minute)</td>\n\t    <td>&#62;7</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Retrograde sequence (percent)</td>\n\t    <td>&#62;50</td>\n\t  </tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 65380 Version 1.0</div></div></div>"},"65383":{"type":"graphic_picture","displayName":"Inflammatory breast cancer","title":"Inflammatory breast cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflammatory breast cancer</div><div class=\"cntnt\"><img style=\"width:396px; height:304px;\" src=\"images/PC/65383_Inflammatory_breast_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">It is important to rule out inflammatory breast cancer if a suspected breast infection does not respond to antibiotics.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 65383 Version 3.0</div></div></div>"},"65385":{"type":"graphic_figure","displayName":"COP vs IPF outcome","title":"Comparison of outcome in COP and IPF","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Comparison of outcome in COP and IPF</div><div class=\"cntnt\"><img style=\"width:507px; height:279px;\" src=\"images/PULM/65385_BOOP_vs_IPF_outcome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Review of nine major published reports in 157 subjects with COP and IPF in whom the diagnosis was confirmed by lung biopsy. The rate of recovery is much higher and that of persistent disease is much lower in the patients with COP. Patients with IPF rarely improved completely with therapy.</div><div class=\"graphic_footnotes\">COP: cryptogenic organizing pneumonia, also known as bronchiolitis obliterans organizing pneumonia (BOOP); IPF: idiopathic pulmonary fibrosis.</div><div class=\"graphic_reference\">Redrawn from: King TE Jr, Mortenson RL, Immunol Allergy Clin North Am 1992; 12:461.</div><div id=\"graphicVersion\">Graphic 65385 Version 2.0</div></div></div>"},"65386":{"type":"graphic_figure","displayName":"Effect of dynamic extrathoracic airway obstruction","title":"Effect of dynamic extrathoracic airway obstruction","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Effect of dynamic extrathoracic airway obstruction</div><div class=\"cntnt\"><img style=\"width:560px; height:368px;\" src=\"images/PULM/65386_Extrathoracic_airway_obstr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effects of forced expiration and inspiration in dynamic extrathoracic airway obstruction. Left panel, during forced expiration, intratracheal pressure (P<sub>tr</sub>) exceeds the pressure around the airway (P<sub>atm</sub>), lessening the obstruction. Right panel, during forced inspiration, when P<sub>tr</sub> falls below P<sub>atm</sub>, the obstruction worsens resulting in flow limitation.</div><div class=\"graphic_reference\">Redrawn from: Kryger M, Bode F, Antic R, et al. Am J Med 1976; 61:85.</div><div id=\"graphicVersion\">Graphic 65386 Version 4.0</div></div></div>"},"65389":{"type":"graphic_waveform","displayName":"Basic case 15","title":"Basic case 15","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Basic case 15</div><div class=\"cntnt\"><img style=\"width:540px; height:277px;\" src=\"images/CARD/65389_Basic_case_15.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65389 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"65391":{"type":"graphic_picture","displayName":"Chronic rejection Light III","title":"Light micrograph showing late-stage chronic renal transplant rejection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing late-stage chronic renal transplant rejection</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/65391_Chronic_rejection_Light_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power light micrograph in chronic rejection reveals marked tubular dropout and interstitial fibrosis (in the area between the glomeruli). These findings represent the end-stage of a process induced by ischemia from the associated vascular lesions and repeated episodes of interstitial inflammation (acute cellular rejection).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 65391 Version 3.0</div></div></div>"},"65393":{"type":"graphic_table","displayName":"Breast Cancer TNM 2010","title":"Breast carcinoma TNM staging AJCC UICC 2010","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Breast carcinoma TNM staging AJCC UICC 2010</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">Primary tumor (T)*<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td>TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td>T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td>Tis</td> <td colspan=\"3\">Carcinoma in situ</td> </tr> <tr> <td>Tis (DCIS)</td> <td colspan=\"3\">Ductal carcinoma in situ</td> </tr> <tr> <td>Tis (LCIS)</td> <td colspan=\"3\">Lobular carcinoma in situ</td> </tr> <tr> <td>Tis (Paget's)</td> <td colspan=\"3\">Paget's disease (Paget disease) of the nipple NOT associated with invasive carcinoma and/or carcinoma in situ (DCIS and/or LCIS) in the underlying breast parenchyma. Carcinomas in the breast parenchyma associated with Paget's disease are categorized based on the size and characteristics of the parenchymal disease, although the presence of Paget's disease should still be noted.</td> </tr> <tr> <td class=\"sublist1_start\">T1</td> <td class=\"sublist_other_start\" colspan=\"3\">Tumor &#8804;20 mm in greatest dimension</td> </tr> <tr> <td class=\"sublist1\">T1mi</td> <td class=\"sublist_other\" colspan=\"3\">Tumor &#8804;1 mm in greatest dimension</td> </tr> <tr> <td class=\"sublist1\">T1a</td> <td class=\"sublist_other\" colspan=\"3\">Tumor &#62;1 mm but &#8804;5 mm in greatest dimension</td> </tr> <tr> <td class=\"sublist1\">T1b</td> <td class=\"sublist_other\" colspan=\"3\">Tumor &#62;5 mm but &#8804;10 mm in greatest dimension</td> </tr> <tr> <td class=\"sublist1\">T1c</td> <td class=\"sublist_other\" colspan=\"3\">Tumor &#62;10 mm but &#8804;20 mm in greatest dimension</td> </tr> <tr> <td>T2</td> <td colspan=\"3\">Tumor &#62;20 mm but &#8804;50 mm in greatest dimension</td> </tr> <tr> <td>T3</td> <td colspan=\"3\">Tumor &#62;50 mm in greatest dimension</td> </tr> <tr> <td class=\"sublist1_start\">T4<sup>&#9674;</sup></td> <td class=\"sublist_other_start\" colspan=\"3\">Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules)</td> </tr> <tr> <td class=\"sublist1\">T4a</td> <td class=\"sublist_other\" colspan=\"3\">Extension to the chest wall, not including only pectoralis muscle adherence/invasion</td> </tr> <tr> <td class=\"sublist1\">T4b</td> <td class=\"sublist_other\" colspan=\"3\">Ulceration and/or ipsilateral satellite nodules and/or edema (including peau d'orange) of the skin, which do not meet the criteria for inflammatory carcinoma</td> </tr> <tr> <td class=\"sublist1\">T4c</td> <td class=\"sublist_other\" colspan=\"3\">Both T4a and T4b</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">T4d</td> <td class=\"sublist_other\" colspan=\"3\">Inflammatory carcinoma<sup>&#167;</sup></td> </tr> <tr> <td colspan=\"4\"><strong>Posttreatment ypT.<sup>&#165;</sup></strong> The use of neoadjuvant therapy does not change the clinical (pretreatment) stage. Clinical (pretreatment) T will be defined by clinical and radiographic findings, while y pathologic (posttreatment) T will be determined by pathologic size and extension. The ypT will be measured as the largest single focus of invasive tumor, with the modifier \"m\" indicating multiple foci. The measurement of the largest tumor focus should not include areas of fibrosis within the tumor bed.</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Clinical</td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed (eg, previously removed)</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastases</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastases to movable ipsilateral level I, II axillary lymph node(s)</td> </tr> <tr> <td class=\"sublist2_start\">N2</td> <td class=\"sublist_other_start\" colspan=\"3\">Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected<sup>&#135;</sup> ipsilateral internal mammary nodes in the <em>absence</em> of clinically evident axillary lymph node metastases</td> </tr> <tr> <td class=\"sublist2\">N2a</td> <td class=\"sublist_other\" colspan=\"3\">Metastases in ipsilateral level I, II axillary lymph nodes fixed to one another (matted) or to other structures</td> </tr> <tr> <td class=\"sublist2\">N2b</td> <td class=\"sublist_other\" colspan=\"3\">Metastases only in clinically detected<sup>&#135;</sup> ipsilateral internal mammary nodes and in the <em>absence</em> of clinically evident level I, II axillary lymph node metastases</td> </tr> <tr> <td class=\"sublist2_start\">N3</td> <td class=\"sublist_other_start\" colspan=\"3\">Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or without level I, II axillary lymph node involvement; or in clinically detected<sup>&#135;</sup> ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement</td> </tr> <tr> <td class=\"sublist2\">N3a</td> <td class=\"sublist_other\" colspan=\"3\">Metastases in ipsilateral infraclavicular lymph node(s)</td> </tr> <tr> <td class=\"sublist2\">N3b</td> <td class=\"sublist_other\" colspan=\"3\">Metastases in ipsilateral internal mammary lymph node(s) and axillary lymph node(s)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">N3c</td> <td class=\"sublist_other\" colspan=\"3\">Metastases in ipsilateral supraclavicular lymph node(s)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Pathologic (pN)<sup>&#134;</sup>**</td> </tr> <tr> <td class=\"indent1\">pNX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed (eg, previously removed, or not removed for pathologic study)</td> </tr> <tr> <td class=\"indent1\">pN0</td> <td colspan=\"3\">No regional lymph node metastasis identified histologically</td> </tr> <tr> <td class=\"indent1\">pN0(i-)</td> <td colspan=\"3\">No regional lymph node metastases histologically, negative immunohistochemistry (IHC)</td> </tr> <tr> <td class=\"indent1\">pN0(i+)</td> <td colspan=\"3\">Malignant cells in regional lymph node(s) no greater than 0.2 mm (detected by H&#38;E or IHC including isolated tumor cell clusters (ITC))</td> </tr> <tr> <td class=\"indent1\">pN0(mol-)</td> <td colspan=\"3\">No regional lymph node metastases histologically, negative molecular findings (RT-PCR)<sup>&#182;&#182;</sup></td> </tr> <tr> <td class=\"indent1\">pN0(mol+)</td> <td colspan=\"3\">Positive molecular findings (RT-PCR)<sup>&#182;&#182;</sup>, but no regional lymph node metastases detected by histology or IHC</td> </tr> <tr> <td class=\"sublist2_start\">pN1</td> <td class=\"sublist_other_start\" colspan=\"3\">Micrometastases; or metastases in 1-3 axillary lymph nodes; and/or in internal mammary nodes with metastases detected by sentinel lymph node biopsy but not clinically detected <sup>&#916;&#916;</sup></td> </tr> <tr> <td class=\"sublist2\">pN1mi</td> <td class=\"sublist_other\" colspan=\"3\">Micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater than 2.0 mm)</td> </tr> <tr> <td class=\"sublist2\">pN1a</td> <td class=\"sublist_other\" colspan=\"3\">Metastases in 1-3 axillary lymph nodes, at least one metastasis greater than 2 mm</td> </tr> <tr> <td class=\"sublist2\">pN1b</td> <td class=\"sublist_other\" colspan=\"3\">Metastases in internal mammary nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected <sup>&#916;&#916;</sup></td> </tr> <tr> <td class=\"sublist2\">pN1c</td> <td class=\"sublist_other\" colspan=\"3\">Metastases in 1-3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected</td> </tr> <tr> <td class=\"sublist2_start\">pN2</td> <td class=\"sublist_other_start\" colspan=\"3\">Metastases in 4-9 axillary lymph nodes; or in clinically detected<sup>&#9674;&#9674;</sup> internal mammary lymph nodes in the <em>absence</em> of axillary lymph node metastases</td> </tr> <tr> <td class=\"sublist2\">pN2a</td> <td class=\"sublist_other\" colspan=\"3\">Metastases in 4-9 axillary lymph nodes (at least one tumor deposit greater than 2.0 mm)</td> </tr> <tr> <td class=\"sublist2\">pN2b</td> <td class=\"sublist_other\" colspan=\"3\">Metastases in clinically detected<sup>&#9674;&#9674;</sup> internal mammary lymph nodes in the <em>absence</em> of axillary lymph node metastases</td> </tr> <tr> <td class=\"sublist2_start\">pN3</td> <td class=\"sublist_other_start\" colspan=\"3\">Metastases in ten or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or in clinically detected<sup>&#9674;&#9674;</sup> ipsilateral internal mammary lymph nodes in the <em>presence</em> of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected <sup>&#916;&#916;</sup>; or in ipsilateral supraclavicular lymph nodes</td> </tr> <tr> <td class=\"sublist2\">pN3a </td> <td class=\"sublist_other\" colspan=\"3\">Metastases in ten or more axillary lymph nodes (at least one tumor deposit greater than 2.0 mm); or metastases to the infraclavicular (level III axillary lymph) nodes</td> </tr> <tr> <td class=\"sublist2\">pN3b</td> <td class=\"sublist_other\" colspan=\"3\">Metastases in clinically detected<sup>&#9674;&#9674;</sup> ipsilateral internal mammary lymph nodes in the <em>presence</em> of one or more positive axillary lymph nodes; or in more than three axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected <sup>&#916;&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">pN3c</td> <td class=\"sublist_other\" colspan=\"3\">Metastases in ipsilateral supraclavicular lymph nodes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Posttreatment ypN</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <ul> <li>Post-treatment yp \"N\" should be evaluated as for clinical (pretreatment) \"N\" methods above. The modifier \"sn\" is used only if a sentinel node evaluation was performed after treatment. If no subscript is attached, it is assumed that the axillary nodal evaluation was by axillary node dissection (AND). </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <ul> <li>The X classification will be used (ypNX) if no yp posttreatment SN or AND was performed </li> </ul> </td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <ul> <li>N categories are the same as those for pN </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr> <td>M0</td> <td colspan=\"3\">No clinical or radiographic evidence of distant metastases</td> </tr> <tr> <td>cM0(i+)</td> <td colspan=\"3\">No clinical or radiographic evidence of distant metastases, but deposits of molecularly or microscopically detected tumor cells in circulating blood, bone marrow, or other nonregional nodal tissue that are no larger than 0.2 mm in a patient without symptoms or signs of metastases</td> </tr> <tr class=\"divider_bottom\"> <td>M1</td> <td colspan=\"3\">Distant detectable metastases as determined by classic clinical and radiographic means and/or histologically proven larger than 0.2 mm</td> </tr> <tr> <td colspan=\"4\"><strong>Posttreatment yp M classification.</strong> The M category for patients treated with neoadjuvant therapy is the category assigned in the clinical stage, prior to initiation of neoadjuvant therapy. Identification of distant metastases after the start of therapy in cases where pretherapy evaluation showed no metastases is considered progression of disease. If a patient was designated to have detectable distant metastases (M1) before chemotherapy, the patient will be designated as M1 throughout.</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Anatomic stage/prognostic groups<sup>&#167;&#167;</sup></td> </tr> <tr> <td>0</td> <td>Tis</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>IA</td> <td>T1<sup>&#165;&#165;</sup></td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan=\"2\">IB</td> <td>T0</td> <td>N1mi</td> <td>M0</td> </tr> <tr> <td>T1<sup>&#165;&#165;</sup></td> <td>N1mi</td> <td>M0</td> </tr> <tr> <td rowspan=\"3\">IIA</td> <td>T0</td> <td>N1<sup>&#135;&#135;</sup></td> <td>M0</td> </tr> <tr> <td>T1<sup>&#165;&#165;</sup></td> <td>N1<sup>&#135;&#135;</sup></td> <td>M0</td> </tr> <tr> <td>T2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan=\"2\">IIB</td> <td>T2</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan=\"5\">IIIA</td> <td>T0</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T1<sup>&#165;&#165;</sup></td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T2</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N2</td> <td>M0</td> </tr> <tr> <td rowspan=\"3\">IIIB</td> <td>T4</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T4</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T4</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>IIIC</td> <td>Any T</td> <td>N3</td> <td>M0</td> </tr> <tr> <td>IV</td> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The T classification of the primary tumor is the same regardless of whether it is based on clinical or pathologic criteria, or both. Designation should be made with the subscript \"c\" or \"p\" modifier to indicate whether the T classification was determined by clinical (physical examination or radiologic) or pathologic measurements, respectively. In general, pathologic determination should take precedence over clinical determination of T size.<br />&para; Size should be measured to the nearest millimeter. If the tumor size is slightly less than or greater than a cutoff for a given T classification, it is recommended that the size be rounded to the millimeter reading that is closest to the cutoff.<br />&Delta; Multiple simultaneous ipsilateral primary carcinomas are defined as infiltrating carcinomas in the same breast, which are grossly or macroscopically distinct and measurable. T stage is based only on the largest tumor. The presence and sizes of the smaller tumor(s) should be recorded using the \"(m)\" modifier.<br /><span class=\"lozenge\">&loz;</span> Invasion of the dermis alone does not qualify as T4; dimpling of the skin, nipple retraction, or any other skin change except those described under T4b and T4d may occur in T1, T2, or T3 without changing the classification. The chest wall includes ribs, intercostal muscles, and serratus anterior muscle, but not the pectoralis muscles.<br />&sect; Inflammatory carcinoma is a clinical-pathologic entity characterized by diffuse erythema and edema (peau d'orange) involving a third or more of the skin of the breast. These skin changes are due to lymphedema caused by tumor emboli within dermal lymphatics. Although dermal lymphatic involvement supports the diagnosis of inflammatory breast cancer, it is neither necessary nor sufficient, in the absence of classical clinical findings, for the diagnosis of inflammatory breast cancer.<br />&yen; If a cancer was designated as inflammatory before neoadjuvant chemotherapy, the patient will be designated to have inflammatory breast cancer throughout, even if the patient has complete resolution of inflammatory findings.<br />&Dagger;<em> Clinically detected</em> is defined as detecting by imaging studies (excluding lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based on fine needle aspiration biopsy with cytologic examination. Confirmation of clinically detected metastatic disease by fine needle aspiration without excision biopsy is designated with an (f) suffix, for example, cN3a(f). Excisional biopsy of a lymph node or biopsy of a sentinel node, in the absence of assignment of a pT, is classified as a clinical N, for example, cN1. Information regarding the confirmation of the nodal status will be designated in site specific factors as clinical, fine needle aspiration, core biopsy, or sentinel lymph node biopsy. Pathologic classification (pN) is used for excision or sentinel lymph node biopsy only in conjunction with a pathologic T assignment.<br />&dagger; Classification is based on axillary lymph node dissection with or without sentinel lymph node biopsy. Classification based solely on sentinel lymph node biopsy without subsequent axillary lymph node dissection is designated (sn) for \"sentinel node,\" for example, pN0(sn).<br />** Isolated tumor cell clusters (ITC) are defined as small clusters of cells not greater than 0.2 mm, or single tumor cells, or a cluster of fewer than 200 cells in a single histologic cross-section. ITCs may be detected by routine histology or by immunohistochemical (IHC) methods. Nodes containing only ITCs are excluded from the total positive node count for purposes of N classification but should be included in the total number of nodes evaluated.<br />&para;&para; RT-PCR: reverse transcriptase/polymerase chain reaction.<br />&Delta;&Delta; \"Not clinically detected\" is defined as not detected by imaging studies (excluding lymphoscintigraphy) or not detected by clinical examination.<br /><span class=\"double_lozenge\">&loz;&loz;</span> \"Clinically detected\" is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based on fine needle aspiration biopsy with cytologic examination.<br />&sect;&sect; Anatomic stage:&#xD;&#xA;<ul class=\"decimal_heading\"><li>M0 includes M0(i+).</li>&#xD;&#xA;<li>The designation pM0 is not valid; any M0 should be clinical.</li>&#xD;&#xA;<li>If a patient presents with M1 prior to neoadjuvant systemic therapy, the stage is considered Stage IV and remains Stage IV regardless of response to neoadjuvant therapy.</li>&#xD;&#xA;<li>Stage designation may be changed if postsurgical imaging studies reveal the presence of distant metastases, provided that the studies are carried out within 4 months of diagnosis in the absence of disease progression and provided that the patient has not received neoadjuvant therapy.</li>&#xD;&#xA;<li>Postneoadjuvant therapy is designated with the \"y\" prefix. For patients with a pathologic complete response (pCR) to neoadjuvant therapy, no stage group is assigned (ie, yT0N0M0).</li></ul>&#xD;&#xA;&yen;&yen; T1 includes T1mi.<br />&Dagger;&Dagger; T0 and T1 tumors with nodal micrometastases only are excluded from Stage IIA and are classified Stage IB.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 65393 Version 14.0</div></div></div>"},"65394":{"type":"graphic_diagnosticimage","displayName":"Esophageal cancer HFUS","title":"High frequency ultrasound catheter examination of a T2 esophageal adenocarcinoma ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High frequency ultrasound catheter examination of a T2 esophageal adenocarcinoma </div><div class=\"cntnt\"><img style=\"width:333px; height:308px;\" src=\"images/GAST/65394_Esophageal_cancer_HFUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Esophageal adenocarcinoma with invasion into the muscularis propria (T2) demonstrated with a high frequency ultrasound probe.</div><div class=\"graphic_footnotes\">MP: muscularis propria; TU: tumor.</div><div class=\"graphic_reference\">Courtesy of Maurits Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 65394 Version 4.0</div></div></div>"},"65396":{"type":"graphic_table","displayName":"Characteristics suture material","title":"Characteristics of sutures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of sutures</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Material</td>\n<td class=\"subtitle1\">Knot security</td>\n<td class=\"subtitle1\">Tensile strength</td>\n<td class=\"subtitle1\">Tissue reaction</td>\n<td class=\"subtitle1\">Wound security, days</td>\n</tr>\n<tr>\n<td>Plain gut</td>\n<td>+</td>\n<td>+</td>\n<td>++++</td>\n<td>5</td>\n</tr>\n<tr>\n<td>Chromic gut</td>\n<td>++</td>\n<td>++</td>\n<td>++++</td>\n<td>14</td>\n</tr>\n<tr>\n<td>Polyglycolic acid</td>\n<td>++++</td>\n<td>+++</td>\n<td>++</td>\n<td>21</td>\n</tr>\n<tr>\n<td>Polyglactin</td>\n<td>+++</td>\n<td>+++</td>\n<td>++</td>\n<td>30</td>\n</tr>\n<tr>\n<td>Polydioxanone</td>\n<td>++</td>\n<td>++++</td>\n<td>++</td>\n<td>60</td>\n</tr>\n<tr>\n<td>Polyglyconate</td>\n<td>++</td>\n<td>++++</td>\n<td>++</td>\n<td>60</td>\n</tr>\n<tr>\n<td>Poliglecaprone</td>\n<td>++</td>\n<td>+++</td>\n<td>++</td>\n<td>14</td>\n</tr>\n<tr>\n<td>Polyamide</td>\n<td>+</td>\n<td>+++</td>\n<td>+</td>\n<td>300</td>\n</tr>\n<tr>\n<td>Polyester</td>\n<td>++++</td>\n<td>++++</td>\n<td>++</td>\n<td>300+</td>\n</tr>\n<tr>\n<td>Polybutester</td>\n<td>+++</td>\n<td>++++</td>\n<td>++</td>\n<td>300+</td>\n</tr>\n<tr>\n<td>Polypropylene</td>\n<td>+++</td>\n<td>++++</td>\n<td>+</td>\n<td>300+</td>\n</tr>\n<tr>\n<td>Stainless steel</td>\n<td>++++</td>\n<td>++++</td>\n<td>++</td>\n<td>300+</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 65396 Version 2.0</div></div></div>"},"65400":{"type":"graphic_table","displayName":"Lab findings in osteomalacia","title":"Laboratory findings in the different causes of osteomalacia and osteoporosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory findings in the different causes of osteomalacia and osteoporosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Serum phosphate</td> <td class=\"subtitle1\">Serum calcium</td> <td class=\"subtitle1\">Serum alkaline phosphatase</td> <td class=\"subtitle1\">Parathyroid hormone</td> <td class=\"subtitle1\">25-hydroxyvitamin D</td> <td class=\"subtitle1\">1,25-dihydroxyvitamin D</td> </tr> <tr> <td>Vitamin D deficiency</td> <td>&#8595; or N</td> <td>&#8595; or N</td> <td>&#8593;</td> <td>&#8593;</td> <td>&#8595;&#8595;</td> <td>N or &#8593; or &#8595;</td> </tr> <tr> <td>Conditions associated with urinary phosphate wasting</td> <td>&#8595;&#8595;</td> <td>N</td> <td>N or &#8593;</td> <td>N</td> <td>N</td> <td>N</td> </tr> <tr> <td>Proximal renal tubular acidosis</td> <td>&#8595;</td> <td>N</td> <td>N</td> <td>N</td> <td>N</td> <td>N</td> </tr> <tr> <td>Hypophosphatasia</td> <td>N</td> <td>N</td> <td>&#8595;</td> <td>N</td> <td>N</td> <td>N</td> </tr> <tr> <td>Osteogenesis imperfecta and axial osteomalacia</td> <td>N</td> <td>N</td> <td>N or &#8593;</td> <td>N</td> <td>N</td> <td>N</td> </tr> <tr> <td>Osteoporosis</td> <td>N</td> <td>N</td> <td>N</td> <td>N</td> <td>N or &#8595;</td> <td>N</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">N: normal; &#8595;: reduced; &#8595;&#8595;: very reduced; &#8593;: elevated.</div><div id=\"graphicVersion\">Graphic 65400 Version 3.0</div></div></div>"},"65401":{"type":"graphic_picture","displayName":"Achalasia Gross","title":"Achalasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Achalasia</div><div class=\"cntnt\"><img style=\"width:418px; height:252px;\" src=\"images/GAST/65401_Achalasia_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross specimen of the esophagus from a patient with achalasia shows marked luminal dilatation of the proximal esophagus due to functional distal obstruction at the distal esophagus at the gastroesophageal junction (left).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 65401 Version 1.0</div></div></div>"},"65403":{"type":"graphic_figure","displayName":"Estrogen progestin on lipids","title":"Estrogen replacement therapy improves lipid profile","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Estrogen replacement therapy improves lipid profile</div><div class=\"cntnt\"><img style=\"width:436px; height:417px;\" src=\"images/ENDO/65403_Estrogen_progestin_on_lipid.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect on serum LDL and HDL cholesterol concentrations of placebo or four hormone replacement regimens in postmenopausal women:&nbsp;CEE alone, with either cyclic or continuous&nbsp;MPA, or with micronized progesterone. CEE had the favorable effects of lowering serum LDL cholesterol and raising HDL cholesterol concentrations. The effect on serum LDL cholesterol was not changed with addition of a progestin (left panel), but only micronized progesterone caused an equivalent elevation in serum HDL cholesterol (right panel).</div><div class=\"graphic_footnotes\">CEE: conjugated equine estrogens; LDL: low-density lipoprotein; HDL: high-density lipoprotein; MPA: medroxyprogesterone acetate.</div><div class=\"graphic_reference\">Data from: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial, JAMA 1995; 273:199.</div><div id=\"graphicVersion\">Graphic 65403 Version 2.0</div></div></div>"},"65405":{"type":"graphic_picture","displayName":"Intertrigo","title":"Intertrigo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intertrigo</div><div class=\"cntnt\"><img style=\"width:432px; height:473px;\" src=\"images/PC/65405_Intertrigo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intertrigo before and after skin care. The patient was on antifungal creams for one month with no improvement prior to the top photo. The lower photo shows the effect of simply keeping the skin clean and dry.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 65405 Version 2.0</div></div></div>"},"65406":{"type":"graphic_picture","displayName":"Mallet finger deformity","title":"Resisting the action of the terminal extensor tendon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Resisting the action of the terminal extensor tendon</div><div class=\"cntnt\"><img style=\"width:313px; height:324px;\" src=\"images/RHEUM/65406_Mallet_finger_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The affected finger is grasped with one hand and the finger of the second hand is placed atop the distal phalanges. The patient is asked to actively extend the DIP joint.</div><div class=\"graphic_footnotes\">DIP: distal interphalangeal.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 65406 Version 5.0</div></div></div>"},"65407":{"type":"graphic_picture","displayName":"Severe atopic dermatitis","title":"Atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PC/65407_Severeatopicdermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe atopic dermatitis in a 12-year-old girl showing in the typical location of the popliteal fossae. Note the oozing of serous fluid from the most involved areas, plus the papular component and erythema.</div><div class=\"graphic_reference\">Courtesy of Scott Walsh, MD, FRPCP.</div><div id=\"graphicVersion\">Graphic 65407 Version 2.0</div></div></div>"},"65408":{"type":"graphic_picture","displayName":"Bilevel airway pressure","title":"Bilevel positive airway pressure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilevel positive airway pressure</div><div class=\"cntnt\"><img style=\"width:450px; height:483px;\" src=\"images/PULM/65408_Bilevel_airway_pressure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Philips Respironics V60 (Murrysville, PA) is a bilevel positive airway pressure ventilator designed for acute administration of noninvasive ventilation. It has a graphic screen, an alarm system, an oxygen blender capable of delivering high inspired oxygen concentrations, and an internal battery that lasts up to 6 hours. It can deliver up to 40 cm H2O airway pressure.</div><div class=\"graphic_reference\">Reproduced with permission from: Philips Healthcare. Copyright © 2010.</div><div id=\"graphicVersion\">Graphic 65408 Version 2.0</div></div></div>"},"65409":{"type":"graphic_diagnosticimage","displayName":"CPA radiograph and CT","title":"Chronic pulmonary aspergillosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic pulmonary aspergillosis</div><div class=\"cntnt\"><img style=\"width:324px; height:482px;\" src=\"images/ID/65409_CPA_radiograph_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest radiograph showing several left upper lobe cavities, tracheal deviation indicating collapse due to contraction and fibrosis, as well as marked pleural thickening. There are marked infiltrates inferior to the largest cavity and a linear opacity extending inferiorly from there. No overt aspergilloma is visible.<br />(B) Computed&nbsp;tomography scan of the same patient, showing multi-cavity disease on the left and some emphysema on the right. There is gross mediastinal shift to the left. The cavities in the left are of variable size and at least one contains an aspergilloma. The pleural thickening is variable in thickness, and some fibrosis is visible between the cavities.</div><div class=\"graphic_reference\">Reproduced with permission from: Denning DW. Chronic aspergillosis. In: Aspergillus fumigatus and aspergillosis, Latge JP, Steinbach WJ (Eds). ASM Press, Washington, DC 2009. Copyright © 2009 ASM Press.</div><div id=\"graphicVersion\">Graphic 65409 Version 6.0</div></div></div>"},"65410":{"type":"graphic_diagnosticimage","displayName":"JE MRI","title":"Thalamic lesions in Japanese encephalitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thalamic lesions in Japanese encephalitis</div><div class=\"cntnt\"><img style=\"width:377px; height:437px;\" src=\"images/ID/65410_JE_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance image of a child with Japanese encephalitis, demonstrating characteristic bilateral thalamic hyperintensities (arrows).</div><div class=\"graphic_reference\">Courtesy of Dr. James Sejvar, US Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 65410 Version 2.0</div></div></div>"},"65411":{"type":"graphic_table","displayName":"Occult primary breast cancer and radiation treatments","title":"Results of whole breast irradiation for node-positive occult primary breast cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of whole breast irradiation for node-positive occult primary breast cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author, year</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Median follow-up</td> <td class=\"subtitle1\">Breast treatment</td> <td class=\"subtitle1\">Breast-only control, percent</td> <td class=\"subtitle1\">Survival (percent)</td> </tr> <tr> <td>Vilcoq J; 1982</td> <td class=\"centered\">11</td> <td>&#62;5 yr</td> <td>XRT</td> <td class=\"centered\">73</td> <td class=\"centered\">10/11 (5 year)</td> </tr> <tr> <td rowspan=\"3\">Ellerbroek N; 1990</td> <td class=\"centered\">16</td> <td rowspan=\"3\">133 months</td> <td>XRT</td> <td class=\"centered\">83</td> <td class=\"centered\">&ndash;*</td> </tr> <tr> <td class=\"centered\">13</td> <td>None</td> <td class=\"centered\">43</td> <td class=\"centered\">&ndash;*</td> </tr> <tr> <td class=\"centered\">13</td> <td>Mastectomy</td> <td class=\"centered\">N/A</td> <td class=\"centered\">&ndash;*</td> </tr> <tr> <td>Foroudi F; 2000</td> <td class=\"centered\">12</td> <td>73 months</td> <td>XRT</td> <td class=\"centered\">75</td> <td class=\"centered\">11/12 (5 year)</td> </tr> <tr> <td rowspan=\"2\">Vlastos G; 2001</td> <td class=\"centered\">25</td> <td rowspan=\"2\">7 years</td> <td>XRT</td> <td class=\"centered\">92</td> <td class=\"centered\">79 percent (5 year)</td> </tr> <tr> <td class=\"centered\">13</td> <td>Mastectomy</td> <td class=\"centered\">85</td> <td class=\"centered\">75 percent (5 year)</td> </tr> <tr> <td>Medina-Franco H; 2002</td> <td class=\"centered\">6</td> <td>48 months</td> <td>XRT</td> <td class=\"centered\">100</td> <td class=\"centered\">100 percent</td> </tr> <tr> <td>Varadarajan R; 2006</td> <td class=\"centered\">8</td> <td>57 months</td> <td>XRT</td> <td class=\"centered\">100</td> <td class=\"centered\">100 percent</td> </tr> <tr> <td rowspan=\"3\">He D; 2012</td> <td class=\"centered\" rowspan=\"3\">95</td> <td rowspan=\"3\">38.2 months</td> <td>Mastectomy + ALND<sup>&#182;</sup></td> <td class=\"centered\">89</td> <td class=\"centered\">85 (3 year)</td> </tr> <tr> <td>Breast XRT + ALND</td> <td class=\"centered\">92</td> <td class=\"centered\">81</td> </tr> <tr> <td>ALND</td> <td class=\"centered\">72</td> <td class=\"centered\">71</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">XRT: whole breast radiation therapy; N/A: not available.<br />* Survival described as \"no different\" when patients undergoing mastectomy were compared to those who did not undergo mastectomy. Actuarial survival for entire group was 72 percent at five years and 65 percent at 10 years.<br />¶ ALND: axillary lymph node dissection.</div><div id=\"graphicVersion\">Graphic 65411 Version 4.0</div></div></div>"},"65412":{"type":"graphic_table","displayName":"Calculation maintenance fluid","title":"Calculation of maintenance fluids based on body weight (Wt) in children and infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Calculation of maintenance fluids based on body weight (Wt) in children and infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Body Wt<br /> (kg)</td> <td class=\"subtitle1\"> <p>Daily maintenance fluid</p> <p>(mL/24 hours)</p> </td> <td class=\"subtitle1\"> <p>Hourly maintenance fluid</p> <p>(mL/hour)</p> </td> </tr> <tr> <td>1 to 10</td> <td>100 x Wt (kg)</td> <td>4 x Wt (kg)</td> </tr> <tr> <td>&#62;10 to 20</td> <td>1000 plus 50 x Wt over 10 kg</td> <td>40 plus 2 x Wt over 10 kg</td> </tr> <tr> <td>&#62;20</td> <td>1500 plus 20 x Wt over 20 kg*</td> <td>60 plus 1 x Wt over 20 kg*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Maximum maintenance fluid per 24 hours is 2400 mL or 100 mL/hour.</div><div id=\"graphicVersion\">Graphic 65412 Version 7.0</div></div></div>"},"65413":{"type":"graphic_figure","displayName":"Ectopic ureter female","title":"Location of ectopic ureteral orifices in females","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Location of ectopic ureteral orifices in females</div><div class=\"cntnt\"><img style=\"width:482px; height:383px;\" src=\"images/PEDS/65413_Ectopic_ureter_female.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Possible sites for ectopic ureters noted by arrows. The green dotted line demonstrates other potential sites for ectopic ureters in females.</div><div id=\"graphicVersion\">Graphic 65413 Version 2.0</div></div></div>"},"65415":{"type":"graphic_figure","displayName":"Resection of uterus","title":"Resection of uterus","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Resection of uterus</div><div class=\"cntnt\"><img style=\"width:486px; height:511px;\" src=\"images/OBGYN/65415_Resection_of_uterus.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65415 Version 1.0</div></div></div>"},"65416":{"type":"graphic_picture","displayName":"AML FAB M7","title":"Acute megakaryoblastic leukemia (M7)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute megakaryoblastic leukemia (M7)</div><div class=\"cntnt\"><img style=\"width:397px; height:288px;\" src=\"images/HEME/65416_AML_FAB_M7.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow smear from a patient with acute megakaryoblastic leukemia (FAB classification M7). Panel A shows large blasts and promegakaryocytes; the latter cells are larger than the blasts and have coarse nuclear chromatin and irregularly shaped nuclei (Wright-Giemsa stain). Panel B shows staining of these cells with a monoclonal antibody to platelet glycoprotein IIIa (CD61).</div><div class=\"graphic_reference\">From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 65416 Version 1.0</div></div></div>"},"65418":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound image of multivessel umbilical cord","title":"Prenatal ultrasound image of multivessel umbilical cord","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of multivessel umbilical cord</div><div class=\"cntnt\"><img style=\"width:285px; height:514px;\" src=\"images/OBGYN/65418_US_multives_umbil_cord.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multivessel cord.<br />(Panel A) Several umbilical vessels are identified in the single umbilical cord from thoracopagus conjoined twins.<br />(Panel B) An umbilical cord knot, which&nbsp;can mimic a multivessel umbilical cord.</div><div id=\"graphicVersion\">Graphic 65418 Version 3.0</div></div></div>"},"65419":{"type":"graphic_figure","displayName":"Responses to nasal allergen challenge","title":"Responses to nasal allergen challenge","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Responses to nasal allergen challenge</div><div class=\"cntnt\"><img style=\"width:455px; height:655px;\" src=\"images/ALLRG/65419_Histamine_allergen_challeng.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Responses to allergen challenge. Time course of histamine release and physiologic changes after allergen challenge during the early-phase response. The time course of histamine concentration, symptoms (sneezing), and increases in nasal airway resistance are closely correlated.</div><div class=\"graphic_reference\">Reproduced with permission from: Baroody FM, Naclerio RM. Chapter 48. In: Second Edition Clinical Immunology Principles and Practice, Volume 1, Rich RR, Fleisher TA, Shearer WT, et al (Eds), Mosby 2001. p.48.3. Copyright &copy; 2001 Elsevier.</div><div id=\"graphicVersion\">Graphic 65419 Version 4.0</div></div></div>"},"65420":{"type":"graphic_table","displayName":"Rapid overview severe COPD exacerbation","title":"Rapid overview: Emergency management of severe COPD exacerbations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview: Emergency management of severe COPD exacerbations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Clinical features</strong></td> </tr> <tr> <td class=\"indent1\">Features of COPD exacerbation: Diffuse wheezing, distant breath sounds, barrel-shaped chest, tachypnea, tachycardia, smoking &#62;20 pack years</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Features of severe respiratory insufficiency: Use of accessory muscles; brief, fragmented speech; inability to lie supine; profound diaphoresis; agitation; asynchrony between chest and abdominal motion with respiration; failure to improve with initial emergency treatment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Features of impending respiratory arrest:</strong> Inability to maintain respiratory effort, cyanosis, hemodynamic instability, and depressed mental status</td> </tr> <tr> <td class=\"indent1\">Features of cor pulmonale: Jugular venous distension, prominent left parasternal heave, peripheral edema</td> </tr> <tr> <td class=\"indent1\">COPD exacerbations are most often precipitated by infection (viral or bacterial)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Severe respiratory distress in a patient with known or presumed COPD can be due to an exacerbation of COPD or a comorbid process, such as acute coronary syndrome, decompensated heart failure, pulmonary embolism, pneumonia, pneumothorax, sepsis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Management</strong></td> </tr> <tr> <td class=\"indent1\">Assess patient's airway, breathing, and circulation; secure as necessary</td> </tr> <tr> <td class=\"indent1\">Provide supplemental oxygen to target a pulse oxygen saturation of 88 to 92% or PaO<sub>2</sub> of 60 to 70 mmHg (7.98 to 9.31 kPa); Venturi mask can be useful for titrating FiO<sub>2</sub>; high FiO<sub>2</sub> usually not needed and can contribute to hypercapnia (high FiO<sub>2</sub> requirement should prompt consideration of alternative diagnosis [eg, PE])</td> </tr> <tr> <td class=\"indent1\">Determine patient preferences regarding intubation based on direct questioning or advance directive whenever possible</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Provide combination of aggressive bronchodilator therapy and ventilatory support (NPPV or invasive ventilation)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Noninvasive positive pressure ventilation (NPPV):</strong> Appropriate for the majority of patients with severe exacerbations of COPD unless immediate intubation is needed or NPPV is otherwise contraindicated</td> </tr> <tr> <td class=\"indent1\">Contraindications to NPPV include: Severely impaired consciousness, inability to clear secretions or protect airway, high aspiration risk</td> </tr> <tr> <td class=\"indent1\">Initial settings for bilevel NPPV: 8 cm H<sub>2</sub>O inspiratory pressure (may increase up to 15 cm H<sub>2</sub>O if needed to aid ventilation); 3 cm H<sub>2</sub>O expiratory pressure</td> </tr> <tr> <td class=\"indent1\">Administer bronchodilators via nebulizer or MDI: Nebulizer usually requires interruption of NPPV; MDIs can be delivered in line using adaptor (see dosing below)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Obtain ABG after two hours of NPPV and compare with baseline: Worsening or unimproved gas exchange and pH &#60;7.25 are indications for invasive ventilation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Tracheal intubation and mechanical ventilation:</strong> Indicated for patients with acute respiratory failure, hemodynamic instability (eg, heart rate &#60;50/minute, uncontrolled arrhythmia) and those in whom NPPV is contraindicated or who fail to improve with NPPV and aggressive pharmacotherapy</td> </tr> <tr> <td class=\"indent1\">Rapid sequence induction (eg, etomidate, ketamine, or propofol)</td> </tr> <tr> <td class=\"indent1\">Intubate with #8 endotracheal tube (8 mm internal diameter) or larger, if possible</td> </tr> <tr> <td class=\"indent1\">Initial ventilator settings aim to maintain adequate oxygenation and ventilation while minimizing elevated airway pressures: SIMV, tidal volume 6 to 8 mL/kg, respiratory rate 10 to 12/minute, inspiratory flow rate 60 L/min (increase if needed to enable longer expiratory phase), PEEP 5 cm H<sub>2</sub>O. May need to tolerate elevated PaCO<sub>2</sub> to avoid barotrauma (ie, permissive hypercapnia). In patients with chronic hypercapnia, aim for PaCO<sub>2</sub> close to baseline.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Administer inhaled bronchodilator therapy: Usually via MDI with in-line adaptor (see dosing below)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Diagnostic testing</strong></td> </tr> <tr> <td class=\"indent1\">Assess oxygen saturation with continuous pulse oximetry</td> </tr> <tr> <td class=\"indent1\">Obtain ABG in all patients with severe COPD exacerbation</td> </tr> <tr> <td class=\"indent1\">ETCO<sub>2</sub> monitoring (capnography) has only moderate correlation with arterial PaCO<sub>2</sub> in COPD exacerbations</td> </tr> <tr> <td class=\"indent1\">Do not assess peak expiratory flow or spirometry in acute severe COPD exacerbations as results are not accurate</td> </tr> <tr> <td class=\"indent1\">Obtain portable chest radiograph: Look for signs of pneumonia, acute heart failure, pneumothorax</td> </tr> <tr> <td class=\"indent1\">Obtain complete blood count, electrolytes (Na+, K+, Cl&ndash;, HCO3&ndash;), BUN, and creatinine; also obtain cardiac troponin, BNP, or NT-proBNP, if diagnosis is uncertain</td> </tr> <tr> <td class=\"indent1\">Test for influenza infection during influenza season</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Obtain ECG: Look for arrhythmia, ischemia, cor pulmonale</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Pharmacotherapy</strong></td> </tr> <tr> <td class=\"indent1\">Inhaled beta agonist: Albuterol 2.5 mg diluted to 3 mL via nebulizer or 4 to 8 inhalations from MDI every hour</td> </tr> <tr> <td class=\"indent1\">Inhaled anticholinergic agent: Ipratropium 500 micrograms via nebulizer or 4 to 8 inhalations from MDI every four hours</td> </tr> <tr> <td class=\"indent1\">Intravenous glucocorticoid (eg, methylprednisolone 60 mg to 125 mg IV, repeat every 6 to 12 hours)</td> </tr> <tr> <td class=\"sublist2_start\">Antibiotic therapy*: Appropriate for majority of severe COPD exacerbations; select antibiotic based on likelihood of particular pathogens (eg, <em>Pseudomonas</em> risk factors<sup>&#182;</sup>, prior sputum cultures, local patterns of resistance)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>No <em>Pseudomonas</em> risk factor(s)<sup>&#182;</sup>: Ceftriaxone 1 to 2 grams IV, <strong>OR</strong> levofloxacin 750 mg IV or orally, <strong>OR</strong> moxifloxacin 400 mg IV or orally </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li><em>Pseudomonas</em> risk factor(s)<sup>&#182;</sup>: Levofloxacin 750 mg IV or orally, <strong>OR</strong> piperacillin-tazobactam 4.5 grams IV, <strong>OR</strong> cefepime 1 to 2 grams IV, <strong>OR</strong> ceftazidime 1 to 2 grams IV </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Antiviral therapy (influenza suspected)*: Oseltamivir 75 mg orally every 12 hours <strong>OR</strong> peramivir 600 mg IV once (for patients unable to take oral medication)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Monitoring</strong></td> </tr> <tr> <td class=\"indent1\">Perform continual monitoring of oxygen saturation, blood pressure, heart rate, respiratory rate</td> </tr> <tr> <td class=\"indent1\">Close monitoring of respiratory status</td> </tr> <tr> <td class=\"indent1\">Continuous ECG monitoring</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Monitor blood glucose</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>Disposition</strong></td> </tr> <tr> <td class=\"sublist2_start\">Criteria for ICU admission include:</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Patients with high-risk comorbidities (pneumonia, cardiac arrhythmia, heart failure, diabetes mellitus, renal failure, liver failure) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Continued need for NPPV or invasive ventilation </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Hemodynamic instability </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Need for frequent nebulizer treatments or monitoring </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; PaO<SUB>2</SUB>: arterial tension of oxygen; FIO<SUB>2</SUB>: fraction of inspired oxygen; PE: pulmonary embolism; NPPV: noninvasive mechanical ventilation; MDI: metered dose inhaler; ABG: arterial blood gas; SIMV: synchronized intermittent mechanical ventilation; PEEP: positive end-expiratory pressure; PaCO<SUB>2</SUB>: arterial tension of carbon dioxide; ETCO<SUB>2</SUB>: end-tidal carbon dioxide; BUN: blood urea nitrogen; BNP: brain natriuretic peptide; NT-ProBNP: N-terminal pro-BNP; ECG: electrocardiogram; IV: intravenous; ICU: intensive care unit.<br />* Doses shown are for patients with normal renal function. Some agents require dose adjustment for renal impairment; refer to separate UpToDate algorithms of antibiotic treatment of exacerbations of COPD.<br />¶ <EM>Pseudomonas</EM> infection risk factors: Frequent administration of antibiotics (four or more courses over the past year); recent hospitalization (two or more days duration in the past 90 days); isolation of <EM>Pseudomonas</EM> during a previous hospitalization; severe underlying COPD (FEV<SUB>1</SUB> &lt;50 percent predicted).</div><div id=\"graphicVersion\">Graphic 65420 Version 4.0</div></div></div>"},"65421":{"type":"graphic_figure","displayName":"Closure of vaginal cuff","title":"Closure of vaginal cuff during abdominal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Closure of vaginal cuff during abdominal hysterectomy</div><div class=\"cntnt\"><img style=\"width:521px; height:319px;\" src=\"images/OBGYN/65421_Closure_of_vaginal_cuff.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">0 or 2-0 gauge synthetic absorbable figure of eight stitches are used to close the vaginal cuff. The suture incorporates the uterosacral and cardinal ligaments at the angle of the vagina.<BR></div><div id=\"graphicVersion\">Graphic 65421 Version 2.0</div></div></div>"},"65425":{"type":"graphic_picture","displayName":"Disseminated acral lesions","title":"Child","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Child</div><div class=\"cntnt\"><img style=\"width:540px; height:174px;\" src=\"images/ID/65425_Disseminated_acral_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Disseminated acral lesions 5/27/03.</div><div class=\"graphic_reference\">Reproduced with permission from: Marshfield Clinic. Copyright &#169; 2005 Marshfield Clinic.</div><div id=\"graphicVersion\">Graphic 65425 Version 2.0</div></div></div>"},"65426":{"type":"graphic_table","displayName":"In vitro activity against Scedosporium and Lomentospora spp","title":"In vitro activity of antifungals against <EM>Scedosporium</EM> and <EM>Lomentospora </EM>spp","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">In vitro activity of antifungals against <EM>Scedosporium</EM> and <EM>Lomentospora </EM>spp</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\"><em>Scedosporium apiospermum</em></td> <td class=\"subtitle1\"><em>Lomentospora prolificans</em></td> </tr> <tr> <td>Amphotericin B</td> <td>-</td> <td>-</td> </tr> <tr> <td>Voriconazole</td> <td>+</td> <td>-</td> </tr> <tr> <td>Posaconazole</td> <td>+</td> <td>-</td> </tr> <tr> <td>Isavuconazole</td> <td>+</td> <td>-</td> </tr> <tr> <td>Terbinafine</td> <td>-</td> <td>-*</td> </tr> <tr> <td>Echinocandins</td> <td>-</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Terbinafine is sometimes used in combination with other antifungal agents for the treatment of <EM>L. prolificans</EM> infections for possible synergistic effect.</div><div id=\"graphicVersion\">Graphic 65426 Version 6.0</div></div></div>"},"65427":{"type":"graphic_table","displayName":"Causes bradycardia children","title":"Causes of bradycardia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of bradycardia in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Intrinsic causes</td> <td class=\"subtitle1\">Associated clinical and laboratory findings</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Structural congenital heart disease</td> </tr> <tr> <td class=\"indent1\">Atrial septal defect</td> <td> <ul> <li>Infants with a large ASD present with signs of heart failure (eg, tachypnea and dyspnea, poor feeding, failure to thrive) </li> <li>Physical exam findings may include fixed S2 split and/or midsystolic pulmonary flow or ejection murmur </li> <li>ECG may show incomplete right bundle branch pattern </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Atrioventricular canal</td> <td> <ul> <li>Typically presents in early infancy with signs of heart failure (eg, tachypnea and dyspnea, poor feeding, failure to thrive) </li> <li>Physical exam findings may include hyperactive precordium with inferior and laterally displaced precordial impulse, increased P2, and systolic ejection murmur due to increased blood flow across the pulmonary valve </li> <li>ECG shows leftward and superior QRS axis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Heritable arrhythmia syndromes</td> </tr> <tr> <td class=\"indent1\">Long QT syndrome</td> <td> <ul> <li>ECG shows prolonged QTc for age, often with biphasic or notched T wave </li> <li>Suggestive family history (family member with LQTS or sudden cardiac death) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Brugada syndrome</td> <td> <ul> <li>ECG shows shortened right ventricular conduction delay with abnormal ST segments in anterior precordial leads </li> <li>May be associated with sinus bradycardia and/or atrioventricular block in some cases </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Collagen vascular disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Systemic lupus erythematosus</td> <td> <ul> <li>Involvement of other organs, including skin, joints, kidneys, lungs, nervous system, serous membranes </li> <li>Elevated inflammatory markers (ESR and CRP) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Surgical trauma</td> </tr> <tr> <td class=\"indent1\">Sinus node dysfunction</td> <td> <ul> <li>Surgical closure of ASD </li> <li>Fontan </li> <li>Atrial switch operation </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Atrioventricular block</td> <td> <ul> <li>Septal defect closures </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\">Extrinsic causes</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Medications*</strong></td> <td> <ul> <li>History of exposure (either via prescribed medication or accidental ingestion) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Beta-adrenergic blockers</td> <td> <ul> <li>Also may cause hypotension and hypoglycemia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Calcium channel blockers</td> <td> <ul> <li>Also causes hypotension, which may be severe in large overdoses </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Clonidine</td> <td> <ul> <li>Also may cause hypotension and sedation; in large overdoses may cause hypertension </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Opioids</td> <td> <ul> <li>Constricted pupils, CNS depression, respiratory depression </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hypothermia</strong></td> <td> <ul> <li>Bradycardia may occur with core temperature &#60;35&#176;C </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Elevated intracranial pressure</strong></td> <td> <ul> <li>Associated with hypertension, abnormal respirations, and abnormal pupillary response </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hypervagotonia/neurally mediated (reflex) syncope</strong></td> <td> <ul> <li>Usually triggered by a precipitating event (eg, nasopharyngeal or esophageal stimulation, breath-holding spell, coughing, vomiting) </li> </ul> </td> </tr> <tr> <td><strong>Sleep</strong></td> <td> <ul> <li>Heart rates during sleep can be as low as 60 to 80 bpm in infants and young children; 40 to 50 bpm in school-aged children; and 30 to 40 bpm in adolescents </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; S2: second heart sound; LQTS: long QT syndrome; ASD: atrial septal defect; CNS: central nervous syndrome; bpm: beats per minute.<br />* Medications that are common causes of bradycardia in children are listed here. For a more complete list, refer to table on 'Medications that can cause bradycardia in children'.</div><div id=\"graphicVersion\">Graphic 65427 Version 3.0</div></div></div>"},"65429":{"type":"graphic_picture","displayName":"Immunofluorescence findings I","title":"Immunofluorescence findings in urticarial vasculitis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence findings in urticarial vasculitis</div><div class=\"cntnt\"><img style=\"width:468px; height:306px;\" src=\"images/ALLRG/65429_Immunofluorescence_findings.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct immunofluorescence of a biopsy specimen from a patient with urticarial vasculitis, demonstrating IgM deposits along the dermal-epidermal junction as well as involving blood vessel walls in the dermis.</div><div id=\"graphicVersion\">Graphic 65429 Version 3.0</div></div></div>"},"65431":{"type":"graphic_figure","displayName":"Apoptosis in thalassemia","title":"Apoptosis in thalassemia variants","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apoptosis in thalassemia variants</div><div class=\"cntnt\"><img style=\"width:387px; height:306px;\" src=\"images/HEME/65431_Apoptosis_in_thalassemia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These graphs show the percentage of erythroid precursors undergoing apoptosis (mean ± 1 SD) in normal controls and in patients from Thailand with clinical diagnoses of&nbsp;alpha and&nbsp;beta thalassemia, using both the annexin V and the Hoechst 33342 methodologies.</div><div class=\"graphic_footnotes\">HbH: hemoglobin H disease; H/CS: hemoglobin H/hemoglobin constant spring; CS/CS: homozygous hemoglobin constant spring; bthal/hbE: beta thalassemia/hemoglobin E disease; SD: standard deviation. </div><div class=\"graphic_reference\">Reproduced with permission from: Pootrakul, P, et al. Blood 2000; 96:2610. Copyright © 2000 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 65431 Version 2.0</div></div></div>"},"65432":{"type":"graphic_figure","displayName":"PARMA trial survival","title":"Overall survival of patients in the PARMA trial of transplantation in relapsed aggressive non-Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Overall survival of patients in the PARMA trial of transplantation in relapsed aggressive non-Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:477px; height:294px;\" src=\"images/HEME/65432_PARMA_trial_survival.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier plots of overall survival of patients with relapsed aggressive non-Hodgkin lymphoma in the PARMA trial randomized to receive either 6 cycles of DHAP chemotherapy plus radiotherapy (blue curve) or 2 cycles of DHAP followed by radiotherapy, intensive chemotherapy, and autologous bone marrow transplantation (red curve).</div><div class=\"graphic_reference\">Data from Philip, T, et al. N Engl J Med 1995; 333:1540.</div><div id=\"graphicVersion\">Graphic 65432 Version 2.0</div></div></div>"},"65433":{"type":"graphic_figure","displayName":"Normal urinary voiding","title":"Coordination of the central and peripheral nervous systems for normal urinary voiding","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Coordination of the central and peripheral nervous systems for normal urinary voiding</div><div class=\"cntnt\"><img style=\"width:539px; height:441px;\" src=\"images/PEDS/65433_Normal_urinary_voiding.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The coordination of the central and peripheral nervous systems during bladder filling and voiding required for normal urinary continence.</div><div id=\"graphicVersion\">Graphic 65433 Version 3.0</div></div></div>"},"65435":{"type":"graphic_picture","displayName":"Lidocaine injection test for shoulder","title":"Lidocaine injection test for shoulder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lidocaine injection test for shoulder</div><div class=\"cntnt\"><img style=\"width:373px; height:376px;\" src=\"images/EM/65435_Lidocaine_injection_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lidocaine injection test is used to exclude intrinsic glenohumeral joint pathology (eg, rotator cuff tear,&nbsp;frozen shoulder. To increase the space for needle insertion, the clinician may need to apply downward traction&nbsp;to the elbow. The point of entry is 1 to 1.5 inches (2.5 to&nbsp;4 cm)&nbsp;below the midpoint of the acromion. The angle of entry parallels the acromion. A 1.5 inch (4 cm), 22-gauge needle is inserted&nbsp;to a depth of 1 to 1.5 inches (2.5 to&nbsp;4 cm) and&nbsp;1 mL of lidocaine is injected into the deltoid and 1 to 2 mL into the subacromial bursa.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 65435 Version 3.0</div></div></div>"},"65436":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of frontal bossing flat nose flat face retrognathia","title":"Ultrasound images showing of frontal bossing, flat nose/face, retrognathia","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Ultrasound images showing of frontal bossing, flat nose/face, retrognathia</div><div class=\"cntnt\"><img style=\"width:500px; height:313px;\" src=\"images/OBGYN/65436_Frontal_bossing_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal ultrasound images of the fetal profile.<br />(A) Thanatophoric dysplasia at 20.3 weeks gestation demonstrates frontal bossing (arrow) and flattened nasal bridge (arrowhead).<br />(B) Campomelic dysplasia at 22 weeks demonstrates markedly flat facies and retrognathia (arrow).</div><div id=\"graphicVersion\">Graphic 65436 Version 5.0</div></div></div>"},"65438":{"type":"graphic_table","displayName":"Docetaxel cisplatin and FU plus chemoRT HNC ver1","title":"Docetaxel, cisplatin and fluorouracil induction chemotherapy followed by chemoradiotherapy for locally advanced, squamous cell carcinoma of the head and neck (TAX324)<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Docetaxel, cisplatin and fluorouracil induction chemotherapy followed by chemoradiotherapy for locally advanced, squamous cell carcinoma of the head and neck (TAX324)<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"5\"><strong>Cycle length:</strong> Every 21 days for three cycles.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\" colspan=\"2\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Docetaxel</td> <td>75 mg/m<sup>2</sup> IV</td> <td colspan=\"2\">Dilute in 250 mL normal saline (NS) to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.</td> <td>Day 1</td> </tr> <tr> <td>Cisplatin</td> <td>100 mg/m<sup>2</sup> IV</td> <td colspan=\"2\">Dilute in 250 mL NS and administer over 30 minutes to three hours. Do not administer with aluminum needles or IV sets.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Fluorouracil (FU)</td> <td>1000 mg/m<sup>2</sup>/day IV</td> <td colspan=\"2\">Dilute in 500 to 1000 mL 5% dextrose in water or NS and administer as a continuous infusion over 24 hours.</td> <td>Days 1 through 4</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"4\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for two hours before and two hours after cisplatin administration. Total hydration of 2 to 3 liters NS on day 1 and 1 to 2 liters NS on day 2 to prevent nephrotoxicity. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"4\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"4\"> <ul> <li>Premedicate with dexamethasone prior to docetaxel administration. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"4\"> <ul> <li>Prophylactic therapy with a fluoroquinolone antibiotic is indicated on days 5 to 15 of each cycle because of the high frequency of grade 3 or 4 neutropenia.<sup>[1]</sup> Primary prophylaxis with recombinant G-CSF was not permitted in the original protocol. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"4\"> <ul> <li>Docetaxel and cisplatin are irritants, but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"4\"> <ul> <li>Docetaxel should not be given if bilirubin is &#62;ULN, or if AST and/or ALT &#62;1.5 times the ULN with AP &#62;2.5 times the ULN.<sup>[2]</sup> Dose adjustments for FU may be needed for patients with hepatic impairment.<sup>[2]</sup> The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial.<sup>[1]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for known drug interactions</strong></td> <td colspan=\"4\"> <ul> <li>Caution is needed when administering docetaxel with strong CYP3A4 inhibitors. Although specific dose recommendations are not available, the United States Prescribing Information suggests close monitoring for toxicity and consideration of docetaxel dose reduction if coadministration with a strong CYP3A4 inhibitor cannot be avoided.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"5\"> <ul class=\"decimal_heading\"> <li>CBC, differential, and platelet count on day 1 on each cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"5\"> <ul class=\"decimal_heading\"> <li>Creatinine and electrolytes on day 5 or 6 of each treatment cycle; additional hydration of 1 liter of NS is recommended. </li> </ul> </td> </tr> <tr> <td colspan=\"5\"> <ul class=\"decimal_heading\"> <li>Basic metabolic panel, including creatinine and electrolytes, and liver function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"5\"> <ul class=\"decimal_heading\"> <li>Monitor for neurotoxicity, diarrhea, and palmar-plantar erythrodysesthesias prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"7\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"4\"> <ul> <li>Doses of docetaxel and FU should be reduced for grade 3 or 4 diarrhea or mucositis:<sup>[2]</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle3\" colspan=\"2\">Toxicity</td> <td class=\"subtitle3\" colspan=\"2\">Dose adjustment</td> </tr> <tr> <td colspan=\"2\">Diarrhea grade 3</td> <td colspan=\"2\">First episode: Reduce FU dose by 20%.<br /> Second episode: Reduce FU dose by an additional 20%.</td> </tr> <tr> <td colspan=\"2\">Diarrhea grade 4</td> <td colspan=\"2\">First episode: Reduce docetaxel and FU doses by 20%.<br /> Second episode: Discontinue treatment.</td> </tr> <tr> <td colspan=\"2\">Stomatitis/mucositis grade 3</td> <td colspan=\"2\">First episode: Reduce FU dose by 20%.<br /> Second episode: Stop FU only at all subsequent cycles.<br /> Third episode: Reduce docetaxel dose by 20%.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Stomatitis/mucositis grade 4</td> <td colspan=\"2\">First episode: Stop FU only at all subsequent cycles.<br /> Second episode: Reduce docetaxel dose by 20%.</td> </tr> <tr> <td class=\"divider_bottom\" colspan=\"4\"> <ul> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression or severe, prolonged neutropenia and/or thrombocytopenia after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"4\"> <ul> <li>Docetaxel should not be given if bilirubin is &#62;ULN, or if AST and/or ALT &#62;1.5 times the ULN with AP &#62;2.5 times the ULN.<sup>[2]</sup> For intracycle increases of AST/ALT &#62;2.5 to &#8804;5 times the ULN and AP &#8804;2.5 times the ULN, <strong>OR</strong> AST/ALT &#62;1.5 to &#8804;5 times the ULN <strong>AND</strong> AP &#62;2.5 to &#8804;5 times the ULN, docetaxel should be reduced by 20%. In case of AST/ALT &#62;5 times the ULN <strong>AND/OR</strong> AP &#62;5 times the ULN, docetaxel should be stopped.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"4\"> <ul> <li>Patients should not be retreated with docetaxel until the neutrophil count is &#62;1500 cells/microL.<sup>[2]</sup> In the original protocol, G-CSF was allowed during the second and/or subsequent cycles in case of febrile neutropenia, or documented infection with neutropenia, or neutropenia lasting more than seven days. If an episode of febrile neutropenia, prolonged neutropenia, or neutropenic infection occurs, the United States Prescribing Information suggests reduction of docetaxel dose from 75 to 60 mg/m<sup>2</sup>. If subsequent episodes of complicated neutropenia occur, the docetaxel dose should be reduced further from 60 mg/m<sup>2</sup> to 45 mg/m<sup>2</sup>. In case of grade 4 thrombocytopenia, the docetaxel dose should be reduced from 75 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup>. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"4\"> <ul> <li>Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL. For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &#60;60 mL/min. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"4\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Reduce cisplatin dose 20% for grade 2 peripheral neuropathy and discontinue for grade 3 neuropathy.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Palmar-plantar erythrodysesthesia</strong></td> <td colspan=\"4\"> <ul> <li>Hold FU for grade 2 or greater palmar-plantar erythrodysesthesia, and reduce subsequent dose by 20%.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity</strong></td> <td colspan=\"4\"> <ul> <li>For other grade 3 or worse toxicity except for alopecia and anemia, delay chemotherapy (maximum of two weeks) until resolution to &#60;grade 1, then restart if medically appropriate. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"5\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ULN: upper limit of normal; AP: alkaline phosphatase; G-CSF: granulocyte colony-stimulating factors.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Posner MR, et al. N Engl J Med 2007; 357:1705.</LI>&#xD;&#xA;<LI>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 65438 Version 14.0</div></div></div>"},"65440":{"type":"graphic_table","displayName":"Causes nonfatal injury in children","title":"10 leading causes of nonfatal unintentional injury in children and adolescents, United States, 2015, all races, both sexes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">10 leading causes of nonfatal unintentional injury in children and adolescents, United States, 2015, all races, both sexes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Rank</td> <td class=\"subtitle1\" colspan=\"5\">Age groups, years</td> </tr> <tr> <td class=\"subtitle2\">&#60;1</td> <td class=\"subtitle2\">1 to 4</td> <td class=\"subtitle2\">5 to 9</td> <td class=\"subtitle2\">10 to 14</td> <td class=\"subtitle2\">15 to 19</td> </tr> <tr> <td>1</td> <td> <p>Unintentional fall</p> <p>121,531</p> </td> <td> <p>Unintentional fall</p> <p>770,250</p> </td> <td> <p>Unintentional fall</p> <p>617,362</p> </td> <td> <p>Unintentional fall</p> <p>528,190</p> </td> <td> <p>Unintentional struck by/against</p> <p>493,123</p> </td> </tr> <tr class=\"divider_top\"> <td>2</td> <td> <p>Unintentional struck by/against</p> <p>27,829</p> </td> <td> <p>Unintentional struck by/against</p> <p>295,509</p> </td> <td> <p>Unintentional struck by/against</p> <p>362,955</p> </td> <td> <p>Unintentional struck by/against</p> <p>516,099</p> </td> <td> <p>Unintentional fall</p> <p>398,076</p> </td> </tr> <tr class=\"divider_top\"> <td>3</td> <td> <p>Unintentional other bite/sting</p> <p>12,987</p> </td> <td> <p>Unintentional other bite/sting</p> <p>157,851</p> </td> <td> <p>Unintentional other bite/sting</p> <p>102,571</p> </td> <td> <p>Unintentional overexertion</p> <p>273,389</p> </td> <td> <p>Unintentional overexertion</p> <p>333,062</p> </td> </tr> <tr class=\"divider_top\"> <td>4</td> <td> <p>Unintentional other specified</p> <p>10,506</p> </td> <td> <p>Unintentional foreign body</p> <p>119,900</p> </td> <td> <p>Unintentional cut/pierce</p> <p>96,322</p> </td> <td> <p>Unintentional cut/pierce</p> <p>104,152</p> </td> <td> <p>Unintentional MV-occupant</p> <p>261,636</p> </td> </tr> <tr class=\"divider_top\"> <td>5</td> <td> <p>Unintentional foreign body </p> <p>8181</p> </td> <td> <p>Unintentional cut/pierce</p> <p>73,358</p> </td> <td> <p>Unintentional overexertion</p> <p>79,715</p> </td> <td> <p>Unintentional MV-occupant</p> <p>75,145</p> </td> <td> <p>Unintentional cut/pierce</p> <p>158,692</p> </td> </tr> <tr class=\"divider_top\"> <td>6</td> <td> <p>Unintentional fire/burn</p> <p>7882</p> </td> <td> <p>Unintentional overexertion</p> <p>61,032</p> </td> <td> <p>Unintentional pedal cyclist</p> <p>61,477</p> </td> <td> <p>Unintentional unknown/unspecified</p> <p>68,522</p> </td> <td> <p>Unintentional other specified</p> <p>123,893</p> </td> </tr> <tr class=\"divider_top\"> <td>7</td> <td> <p>Unintentional inhalation/suffocation</p> <p>7674</p> </td> <td> <p>Unintentional other specified</p> <p>58,548</p> </td> <td> <p>Unintentional MV-occupant</p> <p>61,222</p> </td> <td> <p>Unintentional pedal cyclist</p> <p>67,167</p> </td> <td> <p>Unintentional poisoning</p> <p>80,971</p> </td> </tr> <tr class=\"divider_top\"> <td>8</td> <td> <p>Unintentional cut/pierce</p> <p>5601</p> </td> <td> <p>Unintentional fire/burn</p> <p>44,985</p> </td> <td> <p>Unintentional foreign body</p> <p>57,911</p> </td> <td> <p>Unintentional other bite/sting</p> <p>63,771</p> </td> <td> <p>Unintentional other bite/sting</p> <p>73,611</p> </td> </tr> <tr class=\"divider_top\"> <td>9</td> <td> <p>Unintentional overexertion</p> <p>4433</p> </td> <td> <p>Unintentional unknown unspecified</p> <p>39,407</p> </td> <td> <p>Unintentional dog bite</p> <p>34,955</p> </td> <td> <p>Unintentional other transport</p> <p>42,389</p> </td> <td> <p>Unintentional unknown unspecified</p> <p>68,321</p> </td> </tr> <tr class=\"divider_top\"> <td>10</td> <td> <p>Unintentional poisoning</p> <p>4153</p> </td> <td> <p>Unintentional dog bite</p> <p>32,425</p> </td> <td> <p>Unintentional unknown/unspecified</p> <p>33,131</p> </td> <td> <p>Unintentional dog bite</p> <p>27,675</p> </td> <td> <p>Unintentional other transport 52,348</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MV: motor vehicle.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Leading causes of nonfatal injury reports, 2000-2015. Available at: <A spellcheck=true href=\"https://webapp.cdc.gov/sasweb/ncipc/nfilead.html\" target=_blank>https://webapp.cdc.gov/sasweb/ncipc/nfilead.html</A> (Accessed on April 27, 2017).</div><div id=\"graphicVersion\">Graphic 65440 Version 7.0</div></div></div>"},"65441":{"type":"graphic_table","displayName":"Gest age and BW in multiples","title":"Gestational age and birth weight characteristics by plurality: United States, 2013","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gestational age and birth weight characteristics by plurality: United States, 2013</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"5\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gestational age</td> <td class=\"subtitle1\">Singletons</td> <td class=\"subtitle1\">Twins</td> <td class=\"subtitle1\">Triplets</td> <td class=\"subtitle1\">Quadruplets</td> <td class=\"subtitle1\">Quintuplets and higher order multiples*</td> </tr> <tr> <td>Number</td> <td class=\"centered\">3,795,157</td> <td class=\"centered\">132,324</td> <td class=\"centered\">4364</td> <td class=\"centered\">270</td> <td class=\"centered\">66</td> </tr> <tr> <td>Percent very preterm<sup>&#182;</sup></td> <td class=\"centered\">1.54</td> <td class=\"centered\">11.31</td> <td class=\"centered\">40.77</td> <td class=\"centered\">69.63</td> <td class=\"centered\">92.42</td> </tr> <tr> <td>Percent preterm<sup>&#916;</sup></td> <td class=\"centered\">9.71</td> <td class=\"centered\">56.56</td> <td class=\"centered\">93.12</td> <td class=\"centered\">96.30</td> <td class=\"centered\">100</td> </tr> <tr> <td>Percent very low birth weight<sup>&#9674;</sup></td> <td class=\"centered\">1.08</td> <td class=\"centered\">9.75</td> <td class=\"centered\">37.22</td> <td class=\"centered\">66.91</td> <td class=\"centered\">87.93</td> </tr> <tr> <td>Percent low birth weight<sup>&#167;</sup></td> <td class=\"centered\">6.27</td> <td class=\"centered\">55.39</td> <td class=\"centered\">94.54</td> <td class=\"centered\">98.51</td> <td class=\"centered\">100</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Quintuplets, sextuplets, and higher order multiple births are not differentiated in the national data set.<br />&para; Very preterm is less than 32 completed weeks of gestation.<br />&Delta; Preterm is less than 37 completed weeks of gestation.<br /><span class=\"lozenge\">&loz;</span> Very low birth weight is less than 1500 grams.<br />&sect; Low birth weight is less than 2500 grams.</div><div class=\"graphic_reference\">Reproduced from: Martin JA, Hamilton BE, Osterman MJ, et al. Births: final data for 2013. Natl Vital Stat Rep 2015; 64:1.</div><div id=\"graphicVersion\">Graphic 65441 Version 6.0</div></div></div>"},"65443":{"type":"graphic_table","displayName":"Resources for families of children with fears","title":"Resources for families of children with fears","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources for families of children with fears</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Books</td> </tr> <tr> <td class=\"subtitle2_single\">For parents:</td> </tr> <tr> <td class=\"indent1\">Monsters Under the Bed and Other Childhood Fears: Helping Your Child Overcome Anxieties, Fears and Phobias by Stephen W. Garber, Phd, Robyn Freedman Spizman, and Marianne Daniels Garber (Villard Books, 1993).</td> </tr> <tr> <td class=\"indent1\">When Your Child Is Afraid by Robert Schachter (Simon and Schuster, 1988).</td> </tr> <tr> <td class=\"indent1\">No More Monsters in the Closet: Teaching Your Children to Overcome Everyday Fears and Phobias by Jeffrey L. Brown, MD (Crown Pub 1995).</td> </tr> <tr> <td class=\"subtitle2_single\">For children:</td> </tr> <tr> <td class=\"indent1\">Night Light: A Story for Children Afraid of the Dark by Jack Dutro and Kenneth Boyle (Magination Press, 1991).</td> </tr> <tr> <td class=\"indent1\">The Blammo - Surprise! Book: A Story to Help Children Overcome Fears by Stephen R. Lankton and Nancy Wiley (Margination Press, 1989).</td> </tr> <tr> <td class=\"indent1\">Scary Night Visitors: A Story for Children with Bedtime Fears by Irene Wineman Marcus, Paul Marcus, and Susan Jeschke (Margination Press, 1991).</td> </tr> <tr> <td class=\"indent1\">Fang by Barbara Shook Hazen (Aladdin, 1991).</td> </tr> <tr> <td class=\"indent1\">Freddie's Fears by Hilary Robinson (Franklin Watts Ltd, 2001).</td> </tr> <tr> <td class=\"indent1\">Arthur Goes to Camp by Marc Brown (Econ-CladBooks, 1999).</td> </tr> <tr> <td class=\"indent1\">Franklin and the Thunderstorm by Paulette Bourgeois and Brenda Clark (Econo-Clad Books, 1998).</td> </tr> <tr> <td class=\"indent1\">Thunder Doesn't Scare Me! by Lynea Bowdish and John Wallace (Children's Press).</td> </tr> <tr> <td class=\"indent1\">Let's Go Swimming with Mr. Sillypants by M. K. Brown (Crown, 1986).</td> </tr> <tr> <td class=\"indent1\">Cannonball Chris by Jean Marzollo (Random House, 1987).</td> </tr> <tr> <td class=\"indent1\">Alexander and the Terrible, Horrible, No Good, Very Bad Day by Judith Viorst (Simon &#38; Schuster Children's Books, 1972).</td> </tr> <tr> <td class=\"indent1\">When Mama Comes Home Tonight by Eileen Spinelli (Simon &#38; Schuster, 1998).</td> </tr> <tr> <td class=\"indent1\">Owl Babies by Martin Waddel (Candlewick Press, 1996).</td> </tr> <tr> <td class=\"subtitle1_single\">Websites</td> </tr> <tr> <td class=\"indent1\">American Academy of Pediatrics - www.healthychildren.org/English/health-issues/conditions/emotional-problems/Pages/Understanding-Childhood-Fears-and-Anxieties.aspx</td> </tr> <tr> <td class=\"indent1\">Nemours -&nbsp;www.kidshealth.org/parent/emotions/feelings/anxiety.html</td> </tr> <tr> <td class=\"indent1\">Parents - www.parents.com/kids/development/behavioral/understanding-kid-fears/</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Augustyn M. Fears. In: Developmental and Behavioral Pediatrics, 2nd ed, Parker S, Zuckerman B, Augustyn M (Eds), Lippincott Williams and Wilkins, Philadelphia 2005. p.188.<br />Pediatric Advisor, McKesson Health Solutions LLC.</div><div id=\"graphicVersion\">Graphic 65443 Version 5.0</div></div></div>"},"65445":{"type":"graphic_picture","displayName":"Word catheter","title":"Word catheter (used for Bartholin gland cyst or abscess)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Word catheter (used for Bartholin gland cyst or abscess)</div><div class=\"cntnt\"><img style=\"width:358px; height:288px;\" src=\"images/OBGYN/65445_Word_catheter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Uninflated.<br />(B) Instilled with water.</div><div id=\"graphicVersion\">Graphic 65445 Version 3.0</div></div></div>"},"65446":{"type":"graphic_figure","displayName":"Ommaya","title":"The Ommaya reservoir","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The Ommaya reservoir</div><div class=\"cntnt\"><img style=\"width:400px; height:408px;\" src=\"images/HEME/65446_Ommaya.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">How the Ommaya reservoir works: To insert an Ommaya reservoir, the physician drills a burr hole and inserts the device's catheter through the patient's nondominant frontal lobe into the lateral ventricle. The reservoir, which has a self-sealing silicone injection dome, rests over the burr hole under a scalp flap. This creates a slight, soft bulge on the scalp about the size of a quarter. Usually, drugs are injected into the dome with a syringe.</div><div class=\"graphic_reference\">Reproduced with permission from: Nursing Procedures, 4th Edition, Lippincott Williams &amp; Wilkins, Ambler 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65446 Version 1.0</div></div></div>"},"65447":{"type":"graphic_picture","displayName":"Lipodermatosclerosis 2","title":"Lipodermatosclerosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lipodermatosclerosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/65447_Stasisdermatitissclerotic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin induration, redness, and hyperpigmentation involving the lower third of the leg in a patient with stasis dermatitis and lipodermatosclerosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65447 Version 8.0</div></div></div>"},"65448":{"type":"graphic_figure","displayName":"Fasciolopsiasis life cycle","title":"Fasciolopsiasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Fasciolopsiasis life cycle</div><div class=\"cntnt\"><img style=\"width:584px; height:477px;\" src=\"images/ID/65448_Fasciolopsiasis_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immature eggs are discharged into the intestine and stool <STRONG>(1)</STRONG>. Eggs become embryonated in water <STRONG>(2)</STRONG>, eggs release miracidia <STRONG>(3)</STRONG>, which invade a suitable snail intermediate host <STRONG>(4)</STRONG>. In the snail, the parasites undergo several developmental stages [sporocysts <STRONG>(4a)</STRONG>, rediae <STRONG>(4b)</STRONG>, and cercariae <STRONG>(4c)]</STRONG>. The cercariae are released from the snail <STRONG>(5)</STRONG> and encyst as metacercariae on aquatic plants <STRONG>(6)</STRONG>. The mammalian hosts become infected by ingesting metacercariae on the aquatic plants. After ingestion, the metacercariae excyst in the duodenum <STRONG>(7)</STRONG> and attach to the intestinal wall. There they develop into adult flukes (20 to 75 mm by 8 to 20 mm) in approximately three months, attached to the intestinal wall of the mammalian hosts (humans and pigs) <STRONG>(8)</STRONG>. The adults have a lifespan of about one year.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Fasciolopsiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/fasciolopsiasis/index.html\">http://www.cdc.gov/dpdx/fasciolopsiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 65448 Version 5.0</div></div></div>"},"65449":{"type":"graphic_diagnosticimage","displayName":"Drug packets seen in stomach on plain abdominal radiograph","title":"Drug packets seen in stomach on plain abdominal radiograph","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Drug packets seen in stomach on plain abdominal radiograph</div><div class=\"cntnt\"><img style=\"width:456px; height:504px;\" src=\"images/EM/65449_Drug_packets_stom_plain_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this plain radiograph, multiple drug packets are seen in the stomach of a patient who presented with vomiting secondary to gastric outlet obstruction.</div><div class=\"graphic_reference\">Courtesy of Robert Hoffman, MD.</div><div id=\"graphicVersion\">Graphic 65449 Version 2.0</div></div></div>"},"65452":{"type":"graphic_figure","displayName":"Urethral pressure profile","title":"Urethral pressure profile","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urethral pressure profile</div><div class=\"cntnt\"><img style=\"width:416px; height:379px;\" src=\"images/OBGYN/65452_Urethral_pressure_profile.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Robinson, D, Norton, PA. Diagnosis and Management of Urinary Incontinence. In: Gynecologic Surgery. William, WM, Stovall, TG (Eds), Churchill Livingstone, New York 1996. p.704.</div><div id=\"graphicVersion\">Graphic 65452 Version 1.0</div></div></div>"},"65453":{"type":"graphic_table","displayName":"Ethics living donor transplant","title":"American Society of Transplant Surgeons Ethics Committee position paper on living donor liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Society of Transplant Surgeons Ethics Committee position paper on living donor liver transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n\n\n  <tbody>\n\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"subtitle1_single\">Donor selection and evaluation</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td>\nPotential donors should be healthy individuals who are carefully\nevaluated and approved by a multidisciplinary team, including\nhepatologists and surgeons, to ensure that they can tolerate the\nprocedure</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n\n    <tr>\n\n\n\n\n      <td> Potential donors should undergo evaluation to ensure that they fully understand the procedure and associated risks</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n\n    <tr>\n\n\n\n\n      <td>\nPotential donors must be of legal age and have sufficient intellectual\nability to understand the procedure and give informed consent</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n\n    <tr>\n\n\n\n\n      <td> Potential donors who are believed or known to be coerced must be excluded</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td> Potential donors need to have the ability and willingness to comply with long-term follow-up</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"subtitle1_single\">Recipient criteria</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td> Recipients need to be medically suitable for liver transplantation by standard criteria of the transplant center</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n      <td> Recipients need to understand and accept that the donation will put the donor at significant risk</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n\n      <td>Although it may not be possible to firmly state\nthat adult-to-adult living donor liver transplantation should not be\nperformed in situations in which the recipient has a poor chance of\nsurvival, the added risk to the donor must be balanced with a realistic\nestimate of the chances of success.</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"subtitle1_single\">Center criteria</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n      <td class=\"subtitle2_single\"> Centers should undergo careful institutional planning that shows the following:</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"indent1\"> Consideration of the significant risk of the procedure to the donor</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"indent1\"> Establishment of an appropriate informed consent process</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"indent1\"> Surgical expertise in liver transplantation and hepatobiliary surgery</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"indent1\"> An\nexisting need for living donation versus cadaveric donation, shown by\ninsufficient cadaver organs for transplantation resulting in\npotentially avoidable deaths on the waiting list</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"indent1\"> Adequate resources, eg, multiple surgical teams, adequate operating room resources, and institutional support</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"indent1\"> Ongoing oversight</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"subtitle1_single\">Consent</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n      <td class=\"subtitle2_single\">Informed consent for the procedure should contain the following elements:</td>\n\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"indent1\"> The risk for death during or after the operation</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"indent1\"> The risk for liver failure resulting in the need for transplantation</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"indent1\"> The risk for life-threatening infection resulting from the operation</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"indent1\"> The risk for blood-borne infection acquired through transfusion</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"indent1\"> The risk for temporary or permanent disability</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"indent1\"> The ability to withdraw from participation at any time before surgery</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td class=\"subtitle1_single\">Registry</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n    <tr>\n\n\n\n\n      <td>The American Society of Transplant Surgeons\nshould implement a national registry for all living donor\nliver transplant procedures</td>\n\n\n\n\n\n    </tr>\n\n\n\n\n\n  \n  \n  \n  </tbody>\n</table></div><div class=\"graphic_reference\">From: the American Society of Transplant Surgeons: Ethics Committee. Liver Transplant 2000; 6:815.</div><div id=\"graphicVersion\">Graphic 65453 Version 3.0</div></div></div>"},"65454":{"type":"graphic_picture","displayName":"Inverse psoriasis PI","title":"Inverse psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inverse psoriasis</div><div class=\"cntnt\"><img style=\"width:217px; height:145px;\" src=\"images/PI/65454_Inverse_psoriasis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inverse psoriasis of the axilla (armpit) is characterized by erythema without visible scaling.</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 65454 Version 1.0</div></div></div>"},"65455":{"type":"graphic_table","displayName":"Causes spontaneous pneumothorax","title":"Causes of spontaneous pneumothorax","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of spontaneous pneumothorax</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Primary pneumothorax</td> </tr> <tr> <td class=\"subtitle2_single\">Asthenic body habitus/subpleural blebs</td> </tr> <tr> <td class=\"subtitle2_single\">Drug use</td> </tr> <tr> <td class=\"indent1\">Cigarette smoking</td> </tr> <tr> <td class=\"indent1\">Snorting cocaine</td> </tr> <tr> <td class=\"indent1\">Smoking marijuana</td> </tr> <tr> <td class=\"subtitle2_single\">Increased transpulmonary pressure</td> </tr> <tr> <td class=\"indent1\">Valsalva maneuver</td> </tr> <tr> <td class=\"indent1\">Diving, military flying</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Secondary pneumothorax</td> </tr> <tr> <td class=\"subtitle2_single\">Airway disease</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> </tr> <tr> <td class=\"indent1\">Asthma</td> </tr> <tr> <td class=\"indent1\">Chronic obstructive pulmonary disease (COPD)</td> </tr> <tr> <td class=\"subtitle2_single\">Infection</td> </tr> <tr> <td class=\"indent1\">Pneumocystis jirovecii (carinii)</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Necrotizing pneumonia</td> </tr> <tr> <td class=\"subtitle2_single\">Congenital lung disease</td> </tr> <tr> <td class=\"indent1\">Congenital pulmonary adenomatous malformation</td> </tr> <tr> <td class=\"indent1\">Congenital lobar emphysema</td> </tr> <tr> <td class=\"subtitle2_single\">Interstitial lung disease</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Langerhans'-cell granulomatosis</td> </tr> <tr> <td class=\"indent1\">Other</td> </tr> <tr> <td class=\"subtitle2_single\">Connective tissue/inflammatory disease</td> </tr> <tr> <td class=\"indent1\">Marfan syndrome</td> </tr> <tr> <td class=\"indent1\">Ehlers-Danlos syndrome</td> </tr> <tr> <td class=\"indent1\">Juvenile idiopathic&nbsp;arthritis</td> </tr> <tr> <td class=\"indent1\">Polymyositis or dermatomyositis</td> </tr> <tr> <td class=\"indent1\">Birt-Hogg-Dube syndrome&nbsp;</td> </tr> <tr> <td class=\"indent1\">Other</td> </tr> <tr> <td class=\"subtitle2_single\">Malignancy</td> </tr> <tr> <td class=\"indent1\">Primary lung cancer</td> </tr> <tr> <td class=\"indent1\">Metastatic disease</td> </tr> <tr> <td class=\"subtitle2_single\">Airway obstruction</td> </tr> <tr> <td class=\"indent1\">Foreign body aspiration</td> </tr> <tr> <td class=\"subtitle2_single\">Thoracic endometriosis</td> </tr> <tr> <td class=\"indent1\">Catamenial pneumothorax</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65455 Version 8.0</div></div></div>"},"65456":{"type":"graphic_figure","displayName":"Embryonic development","title":"Embryonic development","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Embryonic development</div><div class=\"cntnt\"><img style=\"width:597px; height:517px;\" src=\"images/PEDS/65456_Embryonicdevelopment.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The black bars represent the critical period during which development may be disrupted by a teratogen resulting in a major structural malformation. Cell differentiation occurs over a longer period (hatched bars); exposure during this period can result in minor structural malformations, growth restriction, or functional deficiency. Note, embryonic&nbsp;age is counted from fertilization, whereas menstrual age (ie, gestational age)&nbsp;is counted from the first day of the last menstrual period. Thus, an embryonic age of&nbsp;six weeks corresponds to a menstrual age (gestational age)&nbsp;of&nbsp;eight weeks. </div><div class=\"graphic_footnotes\">CNS: central nervous system.</div><div id=\"graphicVersion\">Graphic 65456 Version 4.0</div></div></div>"},"65457":{"type":"graphic_figure","displayName":"Nomenclature nevi","title":"Nomenclature for acquired melanocytic nevi","html":"<div class=\"graphic\"><div style=\"width: 593px\" class=\"figure\"><div class=\"ttl\">Nomenclature for acquired melanocytic nevi</div><div class=\"cntnt\"><img style=\"width:573px; height:411px;\" src=\"images/PEDS/65457_Nomenclature_nevi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The names applied to acquired nevi reflect the location of the nests of melanocytes (asterisks above). In junctional nevi, nests are at the dermal-epidermal junction (DEJ); in dermal nevi, nests are in the dermis, and in compound nevi, nests are at the dermal-epidermal junction and in the dermis.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 65457 Version 1.0</div></div></div>"},"65458":{"type":"graphic_table","displayName":"Sample PT prescriptions","title":"Sample physical therapy prescriptions for nonoperative musculoskeletal trauma in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample physical therapy prescriptions for nonoperative musculoskeletal trauma in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Phase of healing/rehabilitation</td> <td class=\"subtitle1\">Sample prescription</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Inflammatory</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Goals:</strong></p> <p>- Protection of injured structures</p> <p>- Relative rest</p> <p>- Decreased swelling and inflammation (ice, elevation, compression)</p> <p>- Maintenance of cardiovascular fitness</p> </td> <td> <p><strong>Diagnosis:</strong> Grade 2 ankle sprain</p> <p>Passive support/air cast. <span style=\"font-size: 10px;\"></span></p> <p>Lace up brace/air cast. Evaluate for/fit assistive device (crutch, roll-about).</p> <p>Ice, compression, elevation, local modalities as indicated for edema reduction and restoration of ROM.</p> <p>Cycling, aquatics, upper extremity ergometer.</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Reparative</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Goals:</strong></p> <p>- Protection of injured structures</p> <p>- Range of motion, <strong>joint mobility</strong>, and flexibility</p> <p>- Reestablish proprioception</p> <p>- Maintenance of cardiovascular fitness</p> <p>- Progression from voluntary muscle firing patterns to strength, endurance, and power</p> </td> <td> <p><strong>Diagnosis:</strong> Grade 2 ankle sprain</p> <p>Manual therapy, progressive resistive exercise, balance training, and lace-up ankle brace&nbsp;for ROM, flexibility, and proprioception.</p> <p>Progressive weight bearing exercise as tolerated.</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Transition from reparative to maturation</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Goals:</strong></p> <p>- Maintenance of cardiovascular fitness</p> <p>- Range of motion and flexibility</p> <p>- Normalize proprioception</p> <p>- Increased strength, endurance, power, speed and agility. Progress to sport-specific skills.</p> </td> <td> <p><strong>Diagnosis:</strong> Grade 2 ankle sprain</p> <p>Functional exercise progression, closed chain strengthening, agility drills as tolerated.</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Maturation</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Goals:</strong></p> <p>- As above for \"Transition from reparative to maturation\"</p> </td> <td> <p><strong>Diagnosis:</strong> Grade 2 ankle sprain</p> <p>Sports specific speed, agility, plyometric training.</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ROM: range of motion.</div><div id=\"graphicVersion\">Graphic 65458 Version 4.0</div></div></div>"},"65459":{"type":"graphic_figure","displayName":"Neutrophil count in measles","title":"White cell count in measles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">White cell count in measles</div><div class=\"cntnt\"><img style=\"width:329px; height:399px;\" src=\"images/HEME/65459_Neutrophil_count_in_measles.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean absolute neutrophil and lymphocyte counts during measles in 16 uncomplicated cases. Normal levels indicated by the broken line. There is a mild leukocytosis for a few days before the onset of fever. This is followed by leukopenia during the week of cough, coryza, conjunctivitis, Koplik spots and rash.</div><div id=\"graphicVersion\">Graphic 65459 Version 1.0</div></div></div>"},"65460":{"type":"graphic_figure","displayName":"Abx for infect conjunctivitis","title":"Effect of antibiotics on cure","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Effect of antibiotics on cure</div><div class=\"cntnt\"><img style=\"width:553px; height:379px;\" src=\"images/PC/65460_Abx_for_infect_conjunctivit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the rates of cure in children with acute infectious conjunctivitis treated with chloramphenicol eye drops or placebo drops. Data are reported on intention-to-treat analysis and children lost to follow-up are included in the denominator in calculating percentages. Children clinically cured after 7 days were censored from the study. With exclusion of children lost to follow-up, the cumulative cure rate at 7 days was 86 percent in the chloramphenicol group and 83 percent in the placebo group. Day zero is the day of recruitment.</div><div class=\"graphic_reference\">Reproduced with permission from: Rose, P, Harnden, A, Brueggemann, A, et al. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomized double-blind placebo-controlled trial. Lancet 2005; 366:41. Copyright &#169; Elsevier.</div><div id=\"graphicVersion\">Graphic 65460 Version 1.0</div></div></div>"},"65462":{"type":"graphic_picture","displayName":"Glabellar line botulinum toxin injection sites","title":"Botulinum toxin injection sites for glabellar lines","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Botulinum toxin injection sites for glabellar lines</div><div class=\"cntnt\"><img style=\"width:502px; height:230px;\" src=\"images/DERM/65462_Glab_line_inject_sites_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The five central injections represent the primary sites for botulinum toxin injection for glabellar lines (red). Some patients may benefit from two additional injections into the lateral orbicularis oculi muscle (white).</div><div id=\"graphicVersion\">Graphic 65462 Version 3.0</div></div></div>"},"65464":{"type":"graphic_table","displayName":"LMWH doses in obese patients","title":"Suggested doses of low molecular weight heparins in obese patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested doses of low molecular weight heparins in obese patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"4\" width=\"21%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">VTE treatment</td> <td class=\"subtitle1\">VTE prophylaxis</td> <td class=\"subtitle1\">United States&nbsp;product label information on use in obese patients</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Enoxaparin</strong>*</td> <td> <p>Use standard treatment dosing (ie, 1 mg/kg every 12 hours based on ABW).</p> <p>In patients with a BMI &#8805;40 kg/m<sup>2</sup>, a lower dose (ie, 0.74 mg/kg every 12 hours, based on ABW), was suggested in a small case series based on peak anti-factor Xa levels, but has not been clinically evaluated.<sup>[1]</sup>&nbsp;</p> Once daily dosing regimens of enoxaparin are <strong>not</strong> recommended.</td> <td> <p><strong>BMI 30 to 39 kg/m<sup>2</sup>:</strong> Use standard prophylaxis dosing (ie, 30 mg every 12 hours or 40 mg once daily).</p> <p><strong>BMI &#8805;40 kg/m<sup>2</sup>:</strong> Empirically increase standard prophylaxis dose by 30 percent (ie, to 40 mg every 12 hours).<sup>&#916;&#9674;</sup></p> <p><strong>High VTE-risk bariatric surgery with BMI &#8804;50 kg/m<sup>2</sup>:</strong> 40 mg every 12 hours.<sup>[4,5]</sup>&nbsp;</p> <strong>High VTE-risk bariatric surgery with BMI &#62;50 kg/m<sup>2</sup>:</strong> 60 mg every 12 hours.<sup>[5]</sup>&nbsp;</td> <td> <p>Safety and efficacy of prophylactic doses&nbsp;in obese patients (BMI &#62;30 kg/m<sup><span style=\"font-size: 13px;\">2) </span></sup><span style=\"font-size: 13px;\">has not been&nbsp;fully determined and there is no consensus for dose adjustment. Observe carefully for signs and symptoms of&nbsp;VTE.</span><span style=\"font-size: 13px;\"><sup>[3]</sup></span></p> <p>Marginal increase observed in mean anti-factor Xa activity using actual body weight [ABW] and 1.5 mg/kg&nbsp;once daily dosing in healthy obese persons (BMI 30 to 48 kg/m<sup>2</sup>) compared with non-obese persons.<sup>[3]</sup></p> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Dalteparin</strong></td> <td> <p>Approved by the US FDA only for extended treatment of cancer-associated VTE. Use standard treatment dosing (ie, 200 units/kg once daily based on ABW for the first month, followed by 150 units/kg once daily for subsequent months).<sup>&#182;</sup></p> Consider using 100 units/kg every 12 hours based on ABW for patients weighing &#62;100 kg.<sup>&#182;[4]</sup>&nbsp;</td> <td> <p><strong>BMI 30 to 39 kg/m<sup>2</sup>:</strong> Use standard prophylaxis dosing (ie, 2500 or 5000 units once daily).</p> <strong>BMI &#8805;40 kg/m<sup>2</sup>:</strong> Empirically increase standard prophylaxis dose by 30 percent (ie, increase to 3250 or 6500 units once daily).<sup>&#916;&#9674;</sup><sup>[2]</sup>&nbsp;</td> <td>Use ABW-based dosing for patients weighing up to 90 kg (acute coronary syndromes) or 99 kg (cancer-associated VTE). Use a maximum dose of 10,000 units per dose for patients weighing &#62;90 kg (acute coronary syndromes) or 18,000 units per day for patients weighing &#62;99 kg (cancer-associated VTE).<sup>&#182;[7]</sup>&nbsp;</td> </tr> <tr> <td><strong>Tinzaparin<br /> (not available in the United States)</strong></td> <td>Use standard treatment dosing (ie, 175 units/kg once daily based on ABW).</td> <td> <p><strong>BMI 30 to 39 kg/m<sup>2</sup>:</strong> For orthopedic surgery use standard prophylaxis dosing (ie, 50 or 75 anti-factor Xa units/kg based on ABW once daily); for general surgery use standard fixed dosing (ie, 3500 anti-factor Xa units once daily).</p> <strong>BMI &#8805;40 kg/m<sup>2</sup>:</strong> For orthopedic surgery use standard prophylaxis dosing (ie, 50 or 75 anti-factor Xa units/kg based on ABW once daily); for general surgery empirically increase fixed dose by 30 percent (ie, increase to 4500 anti-factor Xa units once daily).<sup>&#916;&#9674;</sup><sup>[2]</sup>&nbsp;</td> <td>Safety and efficacy in patients weighing &#62;120 kg has not been fully determined. Individualized clinical and laboratory monitoring is recommended (Canada product monograph).<sup>[8]</sup>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All doses shown are for patients with normal renal function and are for subcutaneous administration (except initial intravenous bolus of enoxaparin for treatment of STEMI in patients &lt;75 years old). For dose adjustment due to renal impairment, refer to individual Lexicomp monograph.<br /><strong>Anti-factor Xa testing:</strong> Clinically stable patients weighing up to 144 kg (enoxaparin) or 190 kg (dalteparin<sup>&Delta;</sup>) or 165 kg (tinzaparin) with BMI &lt;40 kg/m<sup>2</sup> may receive low molecular weight heparin for VTE treatment adjusted according to ABW without anti-factor Xa testing<sup>[6]</sup>. Generally, anti-factor Xa monitoring is not recommended, but it can be considered for patients with BMI &ge;40 kg/m<sup>2</sup> who are unstable, experience unexpected thromboembolic or bleeding complications, or require prolonged VTE treatment.</div><div class=\"graphic_footnotes\">VTE: venous thromboembolism; ABW: actual (total) body weight; STEMI: ST elevation myocardial infarction; UFH: unfractionated heparin; US FDA: US Food and Drug Administration.<br />* Conversion: 1 mg enoxaparin ≈ 100 international units enoxaparin.<br />¶&nbsp;According to the dalteparin prescribing information, a fixed dose of 18,000 units per day is recommended for patients weighing &gt;99 kg who are being treated for cancer-associated VTE. However, guidelines suggest that dalteparin dose should be based on actual body weight<SUP>[2]</SUP>. Capped dalteparin dose of 18,000 units per day is <STRONG>not</STRONG> recommended.<br />Δ Empiric dose adjustment is approximate and rounding of dose may be needed depending on product detail. Refer to Lexicomp monograph included with UpToDate.<br /><FONT class=lozenge>◊</FONT> An empiric dose increase of 30 percent for fixed prophylactic of doses of low molecular weight heparin for VTE prophylaxis for patients who are morbidly obese is based on <SPAN style=\"COLOR: black\">clinical experience </SPAN>and analysis of pharmacodynamic and clinical outcomes data<SUP>[2]</SUP>.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Deal EN, Hollands JM, Riney JN, et al. Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series. J Thromb Thrombolysis 2011; 32:188.</LI>&#xD;&#xA;<LI>Nutescu EA, Spinler SA, Wittkowsky A, et al. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009; 43:1064. </LI>&#xD;&#xA;<LI>Enoxaparin sodium US prescribing information <FONT color=red><FONT color=black>(revised </FONT><FONT color=black>October, 2013)</FONT></FONT><FONT color=black>&nbsp;available at&nbsp;US NIH DailyMed website</FONT> <A spellcheck=true href=\"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5017a927-2a24-4f27-89f9-27c805bf7d59\" target=_blank>http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5017a927-2a24-4f27-89f9-27c805bf7d59</A>.</LI>&#xD;&#xA;<LI>Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002, 12:19. </LI>&#xD;&#xA;<LI>Borkgren-Okonek MJ, Hart RW, Pantano JE, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 2008; 4:625. </LI>&#xD;&#xA;<LI>Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). Chest 2012; 141:e24S. </LI>&#xD;&#xA;<LI><FONT color=black>Dalteparin sodium injection. US FDA approved prescribing information (revised September, 2015</FONT>). Available at <A spellcheck=true href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020287s063lbl.pdf\" target=_blank>http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020287s063lbl.pdf</A>.</LI>&#xD;&#xA;<LI>Tinzaparin sodium injection. Canada product monograph (May 26, 2017). Available at <A spellcheck=true href=\"https://pdf.hres.ca/dpd_pm/00040736.PDF\" target=_blank>https://pdf.hres.ca/dpd_pm/00040736.PDF</A>.</LI></OL></div><div id=\"graphicVersion\">Graphic 65464 Version 14.0</div></div></div>"},"65466":{"type":"graphic_table","displayName":"Acute paracocci findings","title":"Clinical manifestations at hospital admission in 70 episodes of paracoccidioidomycosis in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations at hospital admission in 70 episodes of paracoccidioidomycosis in children and adolescents</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1\">\n   Clinical manifestation\n   </td>\n   <td   class=\"subtitle1\">\n   Number\n   </td>\n   <td   class=\"subtitle1\">\n   Percent\n   </td>\n   </tr>\n   <tr>\n   <td>Lymph node enlargement</td>\n   <td>61</td>\n   <td>87.1</td>\n   </tr>\n   <tr>\n   <td>Fever</td>\n   <td>53</td>\n   <td>75.7</td>\n   </tr>\n   <tr>\n   <td>Weight loss</td>\n   <td>53</td>\n   <td>75.7</td>\n   </tr>\n   <tr>\n   <td>Weakness</td>\n   <td>34</td>\n   <td>48.6</td>\n   </tr>\n   <tr>\n   <td>Pallor</td>\n   <td>29</td>\n   <td>41.4</td>\n   </tr>\n   <tr>\n   <td>Hepatomegaly</td>\n   <td>28</td>\n   <td>40.0</td>\n   </tr>\n   <tr>\n   <td>Splenomegaly</td>\n   <td>25</td>\n   <td>35.7</td>\n   </tr>\n   <tr>\n   <td>Osteoarticular pain or tumefaction</td>\n   <td>14</td>\n   <td>20.0</td>\n   </tr>\n   <tr>\n   <td>Jaundice</td>\n   <td>9</td>\n   <td>12.9</td>\n   </tr>\n   <tr>\n   <td>Cutaneous lesions</td>\n   <td>7</td>\n   <td>10.0</td>\n   </tr>\n   <tr>\n   <td>Lymph node fistulization</td>\n   <td>7</td>\n   <td>10.0</td>\n   </tr>\n   <tr>\n   <td>Abdominal pain</td>\n   <td>5</td>\n   <td>7.1</td>\n   </tr>\n </table></div><div class=\"graphic_lgnd\">This study included 63 children and adolescents under 15 years of age who developed 70 episodes of paracoccidioidomycosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Pereira RM, Bucaretchi F, Barison EM, et al. Paracoccidioidomycosis in children: Clinical presentation, follow-up and outcome. Rev Inst Med Trop S Paulo 2004; 46:127. Copyright © 2004 Instituto de Medicina Tropical de São Paulo.</div><div id=\"graphicVersion\">Graphic 65466 Version 3.0</div></div></div>"},"65468":{"type":"graphic_table","displayName":"WFNS SAH grading scale","title":"World Federation of Neurological Surgeons subarachnoid hemorrhage grading scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Federation of Neurological Surgeons subarachnoid hemorrhage grading scale</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Grade</td>\n\n      <td class=\"subtitle1\">GCS score</td>\n\n      <td class=\"subtitle1\">Motor deficit</td>\n\n    </tr>\n\n    <tr>\n\n      <td>1</td>\n\n      <td>15</td>\n\n      <td>Absent</td>\n\n    </tr>\n\n    <tr>\n      <td>2</td>\n      <td>13 to 14</td>\n      <td>Absent</td>\n    </tr>\n    <tr>\n      <td>3</td>\n      <td>13 to 14</td>\n      <td>Present</td>\n    </tr>\n    <tr>\n      <td>4</td>\n      <td>7 to 12</td>\n      <td>Present or absent</td>\n    </tr>\n    <tr>\n      <td>5</td>\n      <td>3 to 6</td>\n      <td>Present or absent</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">GCS: Glasgow Coma Scale.</div><div class=\"graphic_reference\">Based upon data from: Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. J Neurosurg 1988; 68:985.</div><div id=\"graphicVersion\">Graphic 65468 Version 1.0</div></div></div>"},"65469":{"type":"graphic_figure","displayName":"Endarterectomy mild stenosis","title":"Carotid endarterectomy is not beneficial for symptomatic patients with a mild stenosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Carotid endarterectomy is not beneficial for symptomatic patients with a mild stenosis</div><div class=\"cntnt\"><img style=\"width:504px; height:241px;\" src=\"images/CARD/65469_Endarterectomy_mild_stenosi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The European Carotid Surgical Trial included 374 patients with a prior stroke, TIA, or retinal infarct who had a mild (0 to 29 percent) carotid stenosis. The incidence of disabling or fatal stroke or surgical death (left panel) or of any stroke that lasted more than seven days or surgical death (right panel) were higher in patients who had carotid endarterectomy compared to those on medical therapy.</div><div class=\"graphic_reference\">Data from European Carotid Surgery Trialist Collaborative Group. Lancet 1991; 337:1235.</div><div id=\"graphicVersion\">Graphic 65469 Version 1.0</div></div></div>"},"65472":{"type":"graphic_diagnosticimage","displayName":"Duplication cyst EUS","title":"Duplication cyst in the esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Duplication cyst in the esophagus</div><div class=\"cntnt\"><img style=\"width:405px; height:390px;\" src=\"images/GAST/65472_Duplication_cyst_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endosonographic view of an esophageal duplication cyst. Duplication cysts are usually anechoic homogeneous lesions with regular margins arising from the submucosal (third layer) or extrinsic to the gastrointestinal wall.</div><div class=\"graphic_reference\">Courtesy of Mary Lee Krinsky, DO and Kenneth Binmoeller, MD.</div><div id=\"graphicVersion\">Graphic 65472 Version 3.0</div></div></div>"},"65474":{"type":"graphic_picture","displayName":"Lymphoblasts in ALL","title":"Lymphoblasts in acute lymphoblastic leukemia ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphoblasts in acute lymphoblastic leukemia </div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/HEME/65474_Lymphoblasts_FAB_L2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blood smear showing large lymphoblasts with prominent nucleoli and light blue cytoplasm, as seen in acute lymphoblastic leukemia&nbsp;of the World Health Organization classification. (Wright-Giemsa stain)</div><div class=\"graphic_reference\">Courtesy of Robert Baehner, MD.</div><div id=\"graphicVersion\">Graphic 65474 Version 4.0</div></div></div>"},"65477":{"type":"graphic_figure","displayName":"Hip bursae PI","title":"Bursae near the hip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bursae near the hip</div><div class=\"cntnt\"><img style=\"width:368px; height:412px;\" src=\"images/PI/65477_Hip_bursae_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These sacs, called \"bursae,\" are filled with fluid. They help cushion and protect the joints. \"Bursitis\" is the medical term for when one of these sacs gets irritated or inflamed.</div><div id=\"graphicVersion\">Graphic 65477 Version 7.0</div></div></div>"},"65479":{"type":"graphic_table","displayName":"General management of patients with complicated PUD","title":"General management of patients with complicated peptic ulcer disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General management of patients with complicated peptic ulcer disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Initial management</td> </tr> <tr> <td>1. Careful monitoring, preferably in an intensive care unit.</td> </tr> <tr> <td>2. Fluid resuscitation, plus blood transfusions, as needed.</td> </tr> <tr> <td>3. Give intravenous, full dose PPI (eg, 180 mg bolus followed by 8 mg/hour pantoprazole or esomeprazole).</td> </tr> <tr> <td> <p>4. Endoscopy for possible therapeutic intervention:</p> <ul> <ul> <li>within 24 hours in most cases</li> <li>as soon as patient is stable in severe hemorrhage</li> </ul> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Once patient is tolerating oral intake</td> </tr> <tr> <td>1. Switch to full dose oral PPI twice daily.</td> </tr> <tr> <td>2. Treat for <em>H. pylori</em> if tests are positive*.</td> </tr> <tr> <td>3. Ensure non-aspirin NSAIDs are stopped, if at all possible.</td> </tr> <tr> <td>4. Stop aspirin, including low-dose aspirin, if cardiovascular status permits.</td> </tr> <tr> <td>5. For gastric ulcers, at&nbsp;8 to 12&nbsp;weeks, perform upper endoscopy to evaluate healing and exclude neoplasia (unless there is confidence that the stomach and duodenum were adequately evaluated endoscopically or surgically during hospitalization). Giant duodenal ulcers also warrant follow-up endoscopy to ensure healing and exclude rare malignancy or other etiologies.</td> </tr> <tr> <td class=\"sublist1_start\">6. If initial tests for<em> H. pylori</em> are negative, at roughly four weeks (or later for large ulcers):</td> </tr> <tr> <td class=\"indent2\">a. Switch to full dose H2 receptor antagonists and continue for two weeks</td> </tr> <tr> <td class=\"indent2\">b. If an upper endoscopy will be performed, biopsy for <em>H. pylori</em> urease testing and histology</td> </tr> <tr> <td class=\"indent2\">c. If upper endoscopy will not be performed, obtain an<em> H. pylori</em> breath test or stool antigen test</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PPI: proton pump inhibitor; <EM>H. pylori</EM>: <EM>Helicobacter pylori</EM>; NSAID: nonsteroidal anti-inflammatory drug.<BR>* With an established ulcer, <EM>H. pylori</EM> is only ruled out when two tests obtained while the patient is off of antibiotics, PPIs, and bismuth are negative.</div><div id=\"graphicVersion\">Graphic 65479 Version 4.0</div></div></div>"},"65480":{"type":"graphic_figure","displayName":"Development external genitalia","title":"Phenotypic differentiation of the external genitalia in female and male embryos","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Phenotypic differentiation of the external genitalia in female and male embryos</div><div class=\"cntnt\"><img style=\"width:497px; height:581px;\" src=\"images/ENDO/65480_Development_external_genita.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In females, the genital tubercle becomes the clitoris, the genital swellings become the labia majora, and the genital folds become the labia minora. In males, the genital tubercle becomes the glans penis, the genital swellings fuse to become the scrotum, the genital folds elongate and fuse to form the shaft of the penis and the penile urethra, and the prostate forms in the wall of the urogenital sinus.</div><div id=\"graphicVersion\">Graphic 65480 Version 4.0</div></div></div>"},"65482":{"type":"graphic_picture","displayName":"Histoplasmosis silver stain","title":"Pulmonary histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary histoplasmosis</div><div class=\"cntnt\"><img style=\"width:371px; height:240px;\" src=\"images/ID/65482_Histoplasmosissilverstain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Silver-stained section of lung tissue (x1000) shows the budding yeast forms of <EM>Histoplasma capsulatum</EM>.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 65482 Version 3.0</div></div></div>"},"65483":{"type":"graphic_picture","displayName":"Waxy cast","title":"Waxy cast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Waxy cast</div><div class=\"cntnt\"><img style=\"width:360px; height:269px;\" src=\"images/NEPH/65483_Waxy_cast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment showing a waxy cast (arrow) and many small fine granular casts. Note the cast outline and its amorphous appearance. The high optical density, smooth surface, and blunt ends of waxy casts, which appear to represent degenerated cellular or granular casts, allows them to be distinguished from hyaline casts. The latter are composed solely of precipitated Tamm-Horsfall mucoprotein.</div><div class=\"graphic_reference\">Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.</div><div id=\"graphicVersion\">Graphic 65483 Version 1.0</div></div></div>"},"65484":{"type":"graphic_table","displayName":"Differential diagnosis LIS","title":"Differential diagnosis of locked-in syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of locked-in syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Distinguishing clinical features</td> <td class=\"subtitle1\">Anatomical lesion</td> </tr> <tr> <td><strong>Locked-in syndrome</strong></td> <td>Quadriplegia with preserved vertical eye movements and consciousness</td> <td>Pontine base</td> </tr> <tr> <td><strong>Coma</strong></td> <td>Unresponsive to stimuli, does not follow commands</td> <td>Bilateral cerebral or upper brain stem</td> </tr> <tr> <td><strong>Akinetic mutism</strong></td> <td>No spontaneity or motivation</td> <td>Bifrontal, deep gray matter, upper brain stem</td> </tr> <tr> <td><strong>Catatonia</strong></td> <td>Maintenance of body posture</td> <td>No CNS lesions</td> </tr> <tr> <td><strong>Persistent vegetative state</strong></td> <td>No higher cortical functions, does not follow commands, retained cardiovascular and respiratory functions</td> <td>Diffuse cerebral hemisphere</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.</div><div id=\"graphicVersion\">Graphic 65484 Version 3.0</div></div></div>"},"65485":{"type":"graphic_picture","displayName":"Forearm extensor stretch PI","title":"Forearm extensor stretch","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Forearm extensor stretch</div><div class=\"cntnt\"><img style=\"width:520px; height:276px;\" src=\"images/PI/65485_Forearm_extensor_stretch_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hold your injured arm straight out in front of you, palm down, with your fingers pointing toward the ground. Use your other hand to grab the hand on the injured side, pressing your thumb into the palm. Then press down on the back of the hand on the injured side so that your wrist bends further than it does on its own. Hold this position for 30 seconds.</div><div id=\"graphicVersion\">Graphic 65485 Version 5.0</div></div></div>"},"65488":{"type":"graphic_table","displayName":"Causes of acute abdominal pain in children by age","title":"Causes of acute abdominal pain in children by age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acute abdominal pain in children by age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Neonate</td> <td class=\"subtitle1\">1&nbsp;month to 2 years</td> <td class=\"subtitle1\">2 to 5 years</td> <td class=\"subtitle1\">&#62;5 years</td> </tr> <tr> <td> <p>Adhesions*</p> <p>Necrotizing enterocolitis*</p> <p>Volvulus*</p> <p>Colic<sup>&#182;</sup></p> <p>Dietary protein allergy</p> Testicular torsion</td> <td> <p>Adhesions*</p> <p>Foreign body ingestion*</p> <p>Hemolytic uremic syndrome*</p> <p>Hirschsprung disease*</p> <p>Incarcerated hernia*</p> <p>Intussusception*</p> <p>Trauma (including inflicted injury)*</p> <p>Gastroenteritis<sup>&#182;</sup></p> <p>Viral illness<sup>&#182;</sup></p> <p>Dietary protein allergy</p> <p>Hepatitis</p> <p>Inflammatory bowel disease</p> <p>Meckel's diverticulum</p> <p>Sickle cell syndrome vasoocclusive crisis</p> <p>Toxin</p> <p>Tumor</p> Urinary tract infection</td> <td> <p>Adhesions*</p> <p>Appendicitis*</p> <p>Foreign body ingestion*</p> <p>Hemolytic uremic syndrome*</p> <p>Intussusception*</p> <p>Primary bacterial peritonitis*</p> <p>Trauma (including inflicted injury)*</p> <p>Gastroenteritis<sup>&#182;</sup></p> <p>Viral illness<sup>&#182;</sup></p> <p>Pharyngitis<sup>&#182;</sup></p> <p>Constipation<sup>&#182;</sup></p> <p>Henoch Sch&#246;nlein purpura</p> <p>Hepatitis</p> <p>Inflammatory bowel disease</p> <p>Intraabdominal abscess</p> <p>Meckel's diverticulum</p> <p>Urinary tract infection</p> <p>Ovarian torsion</p> <p>Pancreatitis</p> <p>Pneumonia</p> <p>Sickle cell syndrome vasoocclusive crisis</p> <p>Toxin</p> Tumor</td> <td> <p>Adhesions*</p> <p>Appendicitis*</p> <p>Diabetic ketoacidosis*</p> <p>Hemolytic uremic syndrome*</p> <p>Myocarditis, pericarditis*</p> <p>Perforated ulcer*</p> <p>Primary bacterial peritonitis*</p> <p>Trauma*</p> <p>Constipation<sup>&#182;</sup></p> <p>Gastroenteritis<sup>&#182;</sup></p> <p>Pharyngitis<sup>&#182;</sup></p> <p>Viral illness<sup>&#182;</sup></p> <p>Abdominal migraine</p> <p>Cholecystitis or cholelithiasis</p> <p>Familial Mediterranean fever</p> <p>Gastrointestinal dysmotility</p> <p>Henoch Sch&#246;nlein purpura</p> <p>Hepatitis</p> <p>Inflammatory bowel disease</p> <p>Intraabdominal abscess</p> <p>Meckel's diverticulum</p> <p>Ovarian torsion</p> <p>Pancreatitis</p> <p>Pneumonia</p> <p>Ruptured ovarian cyst</p> <p>Sickle cell syndrome vasoocclusive crisis</p> <p>Testicular torsion</p> <p>Urinary tract infection</p> Urolithiasis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Life-threatening condition.<br />&para; Common condition.</div><div id=\"graphicVersion\">Graphic 65488 Version 9.0</div></div></div>"},"65489":{"type":"graphic_figure","displayName":"Inlet view for radiograph of pelvis","title":"Inlet view for radiograph of pelvis","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Inlet view for radiograph of pelvis</div><div class=\"cntnt\"><img style=\"width:526px; height:329px;\" src=\"images/EM/65489_Pelvic_inlet_view_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The inlet view of the pelvis is performed with the x-ray beam oriented 40 degrees caudad.</div><div class=\"graphic_reference\">Reproduced with permission from: Gibbs, MA, Bosse, MJ. Pelvic Ring Fractures. In: Trauma Management: An Emergency Medicine Approach, Ferrara, PC, Colucciello, SA, Marx, JA, Verdile, VP, Gibbs, MA (Eds), Mosby, St. Louis 2001. p. 331. Illustrations used with permission of Elsevier Inc. All rights reserved. Copyright ©2001 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 65489 Version 4.0</div></div></div>"},"65490":{"type":"graphic_picture","displayName":"Gastric large cell lymphoma II","title":"Gastric large cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric large cell lymphoma</div><div class=\"cntnt\"><img style=\"width:425px; height:216px;\" src=\"images/GAST/65490_High_grade_gastric_MALTom1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal whole mount section on a gastric large cell lymphoma with annular ulcerations and full- thickness infiltration of the gastric wall.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy III, MD.</div><div id=\"graphicVersion\">Graphic 65490 Version 2.0</div></div></div>"},"65491":{"type":"graphic_table","displayName":"Neurologic causes vulvar pain","title":"Neurologic triggers of vulvar pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neurologic triggers of vulvar pain</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Referred pain from the piriformis, pubococcygeus, obturator internus and externus muscles, or sacroiliac joint due to injury, spasm, dysfunction, or orthopedic conditions affecting these muscles and joints (eg, injury to back, hips, or knees, repetitive musculoskeletal or postural stressors)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Referred pain from a ruptured disc or scarring around sacral nerve roots after disc surgery or from spinal stenosis or significant spinal arthritis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Multiple sclerosis or neurofibromatosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pudendal nerve injury related to labor and delivery, recreational activities (horseback riding, biking), vaginal or transvaginal surgery</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Postherpetic neuralgia from herpes zoster</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pudendal nerve entrapment</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Sacral-menigeal (Tarlov's) cysts</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted from: Bachmann G, Rosen RC. Vulvodynia and menopause. Menopause Management. March/April 2006, pages 14-21.</div><div id=\"graphicVersion\">Graphic 65491 Version 3.0</div></div></div>"},"65492":{"type":"graphic_figure","displayName":"Thrombocytopenia from a drug metabolite","title":"Antibody-mediated drug-induced thrombocytopenia: The patient's antibody reacted with normal platelets in the presence of acetaminophen glucuronide, but not with acetaminophen or acetaminophen sulfate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Antibody-mediated drug-induced thrombocytopenia: The patient's antibody reacted with normal platelets in the presence of acetaminophen glucuronide, but not with acetaminophen or acetaminophen sulfate</div><div class=\"cntnt\"><img style=\"width:428px; height:458px;\" src=\"images/HEME/65492_Thrombopen_drug_metabolite.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Washed platelets (5 x 10<SUP>6</SUP>) were combined with patient serum in the presence or absence of 0.4 mM acetaminophen or the metabolite indicated in a final volume of 50 microL. After incubation for&nbsp;one hour, the platelets were washed in the presence or absence of the indicated drug or metabolite (0.2 mM). Bound human IgG was detected by the addition of FITC goat (Fab')2 anti-human IgG (H+L) (1:200; Jackson Immunoresearch, West Grove, PA). No reaction occurred with normal serum under same conditions. Abscissa indicates mean platelet fluorescence intensity in arbitrary units.</div><div class=\"graphic_reference\">Reproduced with permission from: Bougie DW, Benito AI, Sanchez-Abarca LI, et al. Acute thrombocytopenia caused by sensitivity to the glucuronide conjugate of acetaminophen. Blood 2007; 109:3608. Copyright ©2007 The American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 65492 Version 3.0</div></div></div>"},"65493":{"type":"graphic_table","displayName":"Interventions based on stage","title":"Effective physician lifestyle interventions based upon patient's stage of change","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effective physician lifestyle interventions based upon patient's stage of change</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Precontemplation stage</td>\n\n      <td>Provide background information on medical and personal reasons for change.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Contemplation stage</td>\n\n      <td>Support patient's own motivation to make change; develop greater awareness of personal benefits to patient.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Preparation stage </td>\n\n      <td>Assist in dealing with issues and barriers; collaborate on developing a specific plan.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Action stage </td>\n\n      <td>Follow through with the plan; deal with issues related to\nadherence to the initiation of change (issues may be present for weeks or months).\n</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Maintenance stage</td>\n\n      <td>Continue to emphasize long-term medical benefits and\npersonal motivation; deal with relapses as \"normal\" (reassess patient's\nStage of Change and continue to work with patient on change issues).</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 65493 Version 1.0</div></div></div>"},"65496":{"type":"graphic_figure","displayName":"Theophylline to treat asthma","title":"Addition of theophylline to inhaled glucocorticoids","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Addition of theophylline to inhaled glucocorticoids</div><div class=\"cntnt\"><img style=\"width:360px; height:341px;\" src=\"images/PULM/65496_Theophylline_to_treat_asthm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean frequency of symptoms in 21 children with asthma who were receiving a constant dose of chlorofluorocarbon (CFC) beclomethasone dipropionate and were treated in randomized sequence for four weeks each with placebo (P) and theophylline (T). The dose of theophylline was individualized to achieve a peak serum concentration of 10 to 20 &#181;g per milliliter. The dose of CFC beclomethasone averaged 550 &#181;g daily. Nocturnal symptoms of cough, wheezing, or dyspnea that disturbed sleep were recorded each morning, and symptoms that interfered with normal activity and any episodes of cough or wheezing during the day were recorded each evening.</div><div class=\"graphic_reference\">Redrawn from: Weinberger M, Hendeles L, N Engl J Med 1996; 334:1380.</div><div id=\"graphicVersion\">Graphic 65496 Version 3.0</div></div></div>"},"65497":{"type":"graphic_figure","displayName":"Penicillins and cephalosporins: Common side chains","title":"Side chains shared by aminopenicillins and aminocephalosporins","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Side chains shared by aminopenicillins and aminocephalosporins</div><div class=\"cntnt\"><img style=\"width:712px; height:814px;\" src=\"images/ALLRG/65497_Pen_ceph_Common_side_chains.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Some penicillins and cephalosporins share identical or similar side chain groups, leading to possible clinical cross-reactivity. Ampicillin has the same side chain in the R1 position as cephalexin and cefaclor, as well as cephradine, cephaloglycin, and loracarbef (not shown). Amoxicillin has the same side chain as cefadroxil, cefatrizine, and cefprozil (not shown).</div><div class=\"graphic_reference\">Courtesy of Antonino Romano, MD.</div><div id=\"graphicVersion\">Graphic 65497 Version 12.0</div></div></div>"},"65498":{"type":"graphic_figure","displayName":"Reported cases of tularemia in US in 2015","title":"Reported cases of tularemia in the United States and territories in 2015, by state","html":"<div class=\"graphic\"><div style=\"width: 652px\" class=\"figure\"><div class=\"ttl\">Reported cases of tularemia in the United States and territories in 2015, by state</div><div class=\"cntnt\"><img style=\"width:632px; height:444px;\" src=\"images/ID/65498_ReportdtularemiaUS2015.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DC: District of Columbia; NYC: New York City; AS: American Samoa; CNMI: Commonwealth of the Northern Mariana Islands; GU: Guam; PR: Puerto Rico; VI: United States Virgin Islands.</div><div class=\"graphic_reference\">Reproduced from: Adams DA, Thomas KR, Jajosky RA, et al. Summary of notifiable infectious diseases and conditions - United States, 2015. MMWR Morb Mortal Wkly Rep 2017; 64:1.</div><div id=\"graphicVersion\">Graphic 65498 Version 7.0</div></div></div>"},"65499":{"type":"graphic_figure","displayName":"Cat (Felis domesticus) allergogram","title":"Cat (<EM>Felis domesticus</EM>) allergogram","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Cat (<EM>Felis domesticus</EM>) allergogram</div><div class=\"cntnt\"><img style=\"width:595px; height:336px;\" src=\"images/ALLRG/65499_Cat_allergogram.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Allergogram showing the number of patients with IgE reactivity toward each of the precipitates identified in the figure. Precipitates are arbitrarily labeled in alphabetical order from left to right. Allergen D is Fel d 1. The total number of patients in the analysis is 22. The IgE binding score for each allergen is calculated as the sum of the weighted scores for each patient. Arbitrary weights are assigned as follows: 1 = low IgE binding; 2 = intermediate IgE binding; and 3 = high IgE binding.</div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div class=\"graphic_reference\">Courtesy of Jørgen Nedergaard Larsen, PhD and Henning Løwenstein, PhD, DSc.</div><div id=\"graphicVersion\">Graphic 65499 Version 8.0</div></div></div>"},"65500":{"type":"graphic_picture","displayName":"Palmar rash secondary syphilis","title":"Secondary syphilis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Secondary syphilis</div><div class=\"cntnt\"><img style=\"width:382px; height:252px;\" src=\"images/ID/65500_Palmar_rash_secondary_syphi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Maculopapular rash on the palms, which rarely can be pustular, in a patient with secondary syphilis. Patients can be quite contagious at this stage.</div><div class=\"graphic_reference\">Courtesy of David H Martin and Tomasz F Mroczkowski. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 65500 Version 6.0</div></div></div>"},"65501":{"type":"graphic_diagnosticimage","displayName":"Retropharyngeal abscess xray","title":"Lateral soft tissue radiographic demonstration of retropharyngeal abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral soft tissue radiographic demonstration of retropharyngeal abscess</div><div class=\"cntnt\"><img style=\"width:396px; height:258px;\" src=\"images/ID/65501_Retropharyngeal_abscess_xra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral radiographs of the neck show: (A) normal lateral cervical view; (B) expansion of the prevertebral soft tissues by a retropharyngeal abscess.</div><div class=\"graphic_reference\">Courtesy of Alfred L Weber, MD.</div><div id=\"graphicVersion\">Graphic 65501 Version 2.0</div></div></div>"},"65504":{"type":"graphic_picture","displayName":"Photo birth 5","title":"Delivery sequence from crowning through birth of the newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Delivery sequence from crowning through birth of the newborn</div><div class=\"cntnt\"><img style=\"width:432px; height:290px;\" src=\"images/OBGYN/65504_Photo_birth_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The shoulders are born. Notice how the head has turned to line up with the shoulders-the cardinal movement of external rotation.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &#169;2009.</div><div id=\"graphicVersion\">Graphic 65504 Version 1.0</div></div></div>"},"65507":{"type":"graphic_table","displayName":"Drugs associated with agranulocytosis","title":"Major medications with a definite association with agranulocytosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major medications with a definite association with agranulocytosis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Antithyroid drugs (thionamides) </td> </tr> <tr> <td>Methimazole</td> </tr> <tr> <td>Carbimazole</td> </tr> <tr> <td>Propylthiouracil</td> </tr> <tr> <td class=\"subtitle1_single\">Antiinflammatory drugs </td> </tr> <tr> <td>Sulfasalazine</td> </tr> <tr> <td>Nonsteroidal antiinflammatory drugs</td> </tr> <tr> <td>Gold salts</td> </tr> <tr> <td>Penicillamine</td> </tr> <tr> <td>Phenylbutazone</td> </tr> <tr> <td>Antipyrine</td> </tr> <tr> <td>Dipyrone</td> </tr> <tr> <td>Phenacetin</td> </tr> <tr> <td class=\"subtitle1_single\">Psychotropic drugs </td> </tr> <tr> <td>Clozapine</td> </tr> <tr> <td>Phenothiazines</td> </tr> <tr> <td>Tricyclic and tetracyclic antidepressants</td> </tr> <tr> <td> <p>Meprobamate</p> <p>Cocaine/heroin (adulterated with levamisole)</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal drugs </td> </tr> <tr> <td>Sulfasalazine</td> </tr> <tr> <td>Histamine H2- receptor antagonists</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular drugs </td> </tr> <tr> <td>Antiarrhythmic agents (tocainide, procainamide, flecainide)</td> </tr> <tr> <td>Ticlopidine</td> </tr> <tr> <td>ACE inhibitors (enalapril, captopril)</td> </tr> <tr> <td>Propranolol</td> </tr> <tr> <td>Dipyridamole</td> </tr> <tr> <td>Digoxin</td> </tr> <tr> <td class=\"subtitle1_single\">Dermatologic drugs </td> </tr> <tr> <td>Dapsone</td> </tr> <tr> <td>Isotretinoin</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Antibiotics </td> </tr> <tr> <td>Macrolides</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole</td> </tr> <tr> <td>Chloramphenicol</td> </tr> <tr> <td>Sulfonamides</td> </tr> <tr> <td>Semisynthetic penicillins</td> </tr> <tr> <td>Vancomycin</td> </tr> <tr> <td>Cephalosporins</td> </tr> <tr> <td>Dapsone</td> </tr> <tr> <td class=\"subtitle1_single\">Antimalarial drugs </td> </tr> <tr> <td>Amodiaquine</td> </tr> <tr> <td>Chloroquine</td> </tr> <tr> <td>Quinine</td> </tr> <tr> <td class=\"subtitle1_single\">Antifungal agents </td> </tr> <tr> <td>Amphotericin B</td> </tr> <tr> <td>Flucytosine</td> </tr> <tr> <td class=\"subtitle1_single\">Anticonvulsants </td> </tr> <tr> <td>Carbamazepine</td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td>Ethosuximide</td> </tr> <tr> <td>Valproate</td> </tr> <tr> <td class=\"subtitle1_single\">Diuretics </td> </tr> <tr> <td>Thiazides</td> </tr> <tr> <td>Acetazolamide</td> </tr> <tr> <td>Furosemide</td> </tr> <tr> <td>Spironolactone</td> </tr> <tr> <td class=\"subtitle1_single\">Sulfonylureas </td> </tr> <tr> <td>Chlorpropamide</td> </tr> <tr> <td>Tolbutamide</td> </tr> <tr> <td class=\"subtitle1_single\">Iron chelating agents</td> </tr> <tr> <td>&nbsp;Deferiprone</td> </tr> </tbody> </table> </td> </tr> <tr> <td class=\"container\">&nbsp;</td> <td class=\"container\">&nbsp;</td> </tr> <tr> <td class=\"container\">&nbsp;</td> <td class=\"container\">&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65507 Version 5.0</div></div></div>"},"65509":{"type":"graphic_picture","displayName":"Snuffles of congenital syphilis","title":"Congenital syphilis: Snuffles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Snuffles</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/PEDS/65509_Snuffles_cong_syphilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: the Public Health Image Library, Centers for Disease Control and Prevention. Photo by Dr. Norman Cole.</div><div id=\"graphicVersion\">Graphic 65509 Version 2.0</div></div></div>"},"65510":{"type":"graphic_picture","displayName":"Claw hand deformity","title":"Claw hand deformity from ulnar neuropathy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Claw hand deformity from ulnar neuropathy</div><div class=\"cntnt\"><img style=\"width:504px; height:335px;\" src=\"images/NEURO/65510_Claw_hand_deformity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image of a patient with a partial ulnar nerve paralysis who&nbsp;is asked to extend the digits. Hyperextension of the MCP joints of the ring and small fingers occurs with the loss of intrinsic ulnar-innervated MCP flexors. The index and middle fingers have median innervated intrinsics (lumbricals) that allow the extrinsics to extend the IP joints.</div><div class=\"graphic_footnotes\">MCP: metacarpophalangeal; IP: interphalangeal.</div><div class=\"graphic_reference\">Image reprinted with permission from: Medscape.com, 2011. Available at: <a href=\"http://emedicine.medscape.com/article/1243669-overview\" target=\"_blank\">http://emedicine.medscape.com/article/1243669-overview</a>.</div><div id=\"graphicVersion\">Graphic 65510 Version 2.0</div></div></div>"},"65511":{"type":"graphic_figure","displayName":"Model of the TSHR","title":"Model of the TSH receptor","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Model of the TSH receptor</div><div class=\"cntnt\"><img style=\"width:512px; height:412px;\" src=\"images/ENDO/65511_ModelTSHRPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The TSHR first appears on the plasma membrane as an intact holoreceptor. This model shows the seven transmembrane domains and the large extracellular domain. The extracellular domain consists of the nine leucine-rich repeats in the ectodomain, which is the major site of TSH binding, and the 50 amino acid cleaved region.</div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone; TSHR: TSH receptor.</div><div class=\"graphic_reference\">Adapted from: Latif R, Morshed SA, Zaidi M, Davies TF. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol Metab Clin North Am. 2009; 38:319.</div><div id=\"graphicVersion\">Graphic 65511 Version 5.0</div></div></div>"},"65512":{"type":"graphic_table","displayName":"IPEX clinical features","title":"Clinical features of immune dysregulation, polyendocrinopathy, and enteropathy, X-linked (IPEX)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of immune dysregulation, polyendocrinopathy, and enteropathy, X-linked (IPEX)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical features of IPEX</td> </tr> <tr> <td class=\"indent1\">Chronic diarrhea due to autoimmune enteropathy</td> </tr> <tr> <td class=\"indent1\">Type 1 diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Dermatitis, usually eczematous</td> </tr> <tr> <td class=\"indent1\">Severe food allergies</td> </tr> <tr> <td class=\"indent1\">Thyroiditis</td> </tr> <tr> <td class=\"indent1\">Immune-mediated cytopenias</td> </tr> <tr> <td class=\"indent1\">Increased infections</td> </tr> <tr> <td class=\"indent1\">Nephritis</td> </tr> <tr> <td class=\"indent1\">Failure to thrive</td> </tr> <tr> <td class=\"indent1\">Developmental delay</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65512 Version 3.0</div></div></div>"},"65513":{"type":"graphic_picture","displayName":"Scabies skin scraping","title":"Scabies skin scraping","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies skin scraping</div><div class=\"cntnt\"><img style=\"width:430px; height:359px;\" src=\"images/DERM/65513_Scabies_skin_scraping.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several oval eggs and multiple small, brown feces are present in this specimen. A mite is visible in the upper right corner of the image.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65513 Version 6.0</div></div></div>"},"65514":{"type":"graphic_figure","displayName":"Transabdominal cerclage","title":"Transabdominal cerclage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transabdominal cerclage</div><div class=\"cntnt\"><img style=\"width:439px; height:311px;\" src=\"images/OBGYN/65514_Transabdominal_cerclage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transabdominal cerclage tied at the level of the insertion of the uterosacral ligaments.</div><div id=\"graphicVersion\">Graphic 65514 Version 1.0</div></div></div>"},"65515":{"type":"graphic_waveform","displayName":"Ectopic atrial rhythm tutorial","title":"Ectopic atrial rhythm","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ectopic atrial rhythm</div><div class=\"cntnt\"><img style=\"width:418px; height:105px;\" src=\"images/CARD/65515_Ectopic_atrial_rhythm_tutor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ectopic atrial rhythm occurs when the dominant pacemaker is an ectopic focus in the atrium. The direction of atrial activation may be altered when an atrial rhythm is present since the pacemaker focus is within the atrial myocardium. In this tracing, the P wave is inverted due to retrograde atrial activation from a pacemaker focus in the low atrium, the area of the coronary sinus, or the left atrium. The QRS complexes of an atrial tachycardia resemble those seen during sinus rhythm, since myocardial activation is via the His-Purkinje system.</div><div id=\"graphicVersion\">Graphic 65515 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"65516":{"type":"graphic_table","displayName":"Bleomycin etoposide and cisplatin regimen","title":"Bleomycin, etoposide, and cisplatin (BEP) chemotherapy for germ cell tumors<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bleomycin, etoposide, and cisplatin (BEP) chemotherapy for germ cell tumors<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.<br /> <strong>Total cycles:</strong> 3 to 4.* </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Bleomycin<sup>&#182;</sup></td> <td>30 units<sup>&#916;</sup> IV per dose</td> <td>Dilute in 50 mL normal saline (NS) and administer over 10 minutes.</td> <td>Days 1, 8, and 15</td> </tr> <tr> <td>Etoposide</td> <td>100 mg/m<sup>2</sup> IV per day</td> <td>Dilute in 500 mL NS (concentration less than 0.4 mg/mL) and administer over one hour.</td> <td>Days 1 through 5</td> </tr> <tr class=\"divider_bottom\"> <td>Cisplatin</td> <td>20 mg/m<sup>2</sup> IV per day</td> <td>Dilute in 250 mL NS and administer over two hours. Do not administer with aluminum needles or intravenous sets.</td> <td>Days 1 through 5</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Induction of diuresis using at least 2000 mL of NS minimizes the risk of cisplatin nephrotoxicity. Fluid administration should be adequate to establish a urine flow of at least 100 mL/hour for two hours prior to and two hours after cisplatin administration. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity.\" </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults.\" </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Bleomycin, etoposide, and cisplatin are classified as irritants. Cisplatin can cause significant tissue damage; avoid extravasation.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants.\" </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors (G-CSF) is not indicated. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation.\" </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Bleomycin should not be administered in patients with a baseline creatinine &#62;2.0 mg/dL. A lower initial dose of cisplatin or etoposide may be needed for patients with renal or hepatic dysfunction.<sup>[2,3]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents.\"</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Basic metabolic panel (creatinine and electrolytes) prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Liver function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assessment of baseline pulmonary function tests (PFTs), including a diffusing capacity for carbon monoxide (DLCO), should be performed prior to bleomycin treatment and repeated at intervals during therapy. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Each cycle should begin on schedule regardless of the degree of myelosuppression.<sup>[1]</sup> If febrile neutropenia or thrombocytopenic bleeding occurs, a dose reduction of 25% for etoposide should be used for subsequent cycles. If neutrophil count remains &#8804;2500 cells/microL or platelets remain &#8804;100,000/microL, G-CSF should be administered. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation.\" </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Bleomycin can be associated with the development of life-threatening pulmonary toxicity. Maximum lifetime bleomycin dose should not exceed 400 mg. Discontinue bleomycin in patients with clinical or radiographic evidence of pulmonary injury, or decline in the DLCO of 25% or more, even if asymptomatic. Do not reintroduce bleomycin to patients with any bleomycin-induced lung injury. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen after cumulative doses of cisplatin beyond 400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. Peripheral neuropathies can occur with prolonged courses (four to seven months) of cisplatin. Cisplatin treatment should be discontinued with the first signs and symptoms of the development of neurotoxicity.<sup>[2,5]</sup> </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy.\" </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Renal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Treatment in the setting of renal impairment (ie, creatinine &#62;2.0 mg/dL or GFR &#60;50 mL/min) requires a balanced discussion of the goals of treatment and the risks of cisplatin nephrotoxiciy in the face of impaired renal function. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; GFR: glomerular filtration rate.<br />* The precise number of cycles depends on the stage of the germ cell tumor.<br />¶ Cumulative lifetime dose of bleomycin should be limited to 400 units because of the increased rates of pulmonary toxicity. Refer to UpToDate topic on \"Bleomycin-induced lung injury\".<br />Δ 1 unit = 1 mg.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Nichols CR, et al. J Clin Oncol 1998; 16:1287.</LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 8, 2011).</LI>&#xD;&#xA;<LI>Etoposide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 9, 2011).</LI>&#xD;&#xA;<LI>Bleomycin sulfate injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 8, 2011).</LI>&#xD;&#xA;<LI>Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2011; 29:4189.</LI></OL></div><div id=\"graphicVersion\">Graphic 65516 Version 37.0</div></div></div>"},"65517":{"type":"graphic_picture","displayName":"Sensory neuronopathy histopathology","title":"Dorsal root ganglia in paraneoplastic sensory neuronopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dorsal root ganglia in paraneoplastic sensory neuronopathy</div><div class=\"cntnt\"><img style=\"width:360px; height:247px;\" src=\"images/ONC/65517_Sensory_neuronopathy_Pageot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of dorsal root ganglia from a patient with small cell lung cancer, anti-Hu antibodies, and paraneoplastic sensory neuronopathy. There are conspicuous infiltrates of mononuclear cells (small dark arrow), with some neurons undergoing degeneration (large dark arrow). There is also proliferation of satellite cells replacing the disappearing neurons, called Nageotte nodules (white arrows).</div><div class=\"graphic_reference\">Courtesy of Josep Dalmau, MD, PhD.</div><div id=\"graphicVersion\">Graphic 65517 Version 2.0</div></div></div>"},"65518":{"type":"graphic_picture","displayName":"Injection for de Quervain tenosynovitis","title":"Injection for de Quervain tenosynovitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Injection for de Quervain tenosynovitis</div><div class=\"cntnt\"><img style=\"width:382px; height:268px;\" src=\"images/RHEUM/65518_de_Quervains_injection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The hand is placed in a neutral position and turned on the side with the radial side up. The radial styloid and the first and second dorsal compartments are identified and marked. The injection site is between the two tendons of abductor pollicis longus (APL) and the extensor pollicis brevis (EPB), in the first dorsal wrist compartment. The best way to identify the landmarks is by getting the patient to extend and abduct the thumb. Prep the insertion site with iodine disinfectant or a chlorhexidine scrub. Using an aseptic technique, ethyl chloride is applied to the skin for anesthesia. Load the syringe with one-fourth to one-half mL of methylprednisolone (80 mg/mL) with 1 to 2 mL of lidocaine 1%. The needle should be aligned parallel to tendons of the APL and EPB, while aiming proximally towards the radial styloid (enter about 3/8 inch distal to the tip of the radial styloid). A 5/8-inch, 25 gauge needle is inserted at a 45-degree angle to a depth of 3/8 to 1/2 inch, flush against the periosteum of the radial styloid. Insert needle between the two tendons (do not inject into the tendon). There should be no resistance to injection flow. Moderate pressure to injection, a poorly distensible sac, or both may indicate chronic stenosis of the tendons.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 65518 Version 4.0</div></div></div>"},"65519":{"type":"graphic_diagnosticimage","displayName":"LIP CT scan","title":"Lymphocytic interstitial pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphocytic interstitial pneumonia</div><div class=\"cntnt\"><img style=\"width:324px; height:263px;\" src=\"images/PULM/65519_LIP_CT_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prone&nbsp;high resolution computed tomography (HRCT) scan&nbsp;shows diffuse ground glass attenuation with multiple lung cysts.</div><div id=\"graphicVersion\">Graphic 65519 Version 3.0</div></div></div>"},"65520":{"type":"graphic_table","displayName":"Treatment of Whipple's disease","title":"Antimicrobial therapy in Whipple's disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial therapy in Whipple's disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Duration</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Initial therapy</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"><strong>Initial phase</strong>*</td> </tr> <tr> <td class=\"indent2\">General infection</td> <td> <p>Ceftriaxone 2 g IV once daily</p> <p><strong>OR</strong></p> Penicillin G 2 million units IV every four hours</td> <td>Two weeks</td> </tr> <tr> <td class=\"indent2\">Endocarditis</td> <td> <p>Penicillin G 2 million units IV every four hours</p> <p><strong>OR</strong></p> Ceftriaxone 2 g IV once daily</td> <td>Four weeks</td> </tr> <tr> <td class=\"indent2\">Central nervous system disease<sup>&#182;</sup></td> <td> <p>Ceftriaxone 2 g IV once daily</p> <p><strong>OR</strong></p> Penicillin G 4 million units IV every four hours</td> <td>Two to four weeks</td> </tr> <tr> <td class=\"indent2\">If ceftriaxone and penicillin allergic</td> <td>Meropenem 1 g IV every eight hours</td> <td>Two to four weeks</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"><strong>Maintenance phase</strong></td> </tr> <tr> <td class=\"indent2\">All infections</td> <td>Trimethoprim-sulfamethoxazole one DS tablet twice daily</td> <td>One year</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">If sulfa allergic</td> <td> <p>Doxycycline 100 mg PO twice daily</p> <p><strong>PLUS</strong></p> Hydroxychloroquine 200 mg PO thrice daily</td> <td>One year</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Therapy for relapse</td> </tr> <tr> <td class=\"indent1\">Initial phase*</td> <td> <p>Penicillin G 4 million units IV every four hours</p> <p><strong>OR</strong></p> Ceftriaxone 2 g IV twice daily</td> <td>Four weeks</td> </tr> <tr> <td class=\"indent1\">Maintenance phase</td> <td> <p>Doxycycline 100 mg PO twice daily <strong>PLUS</strong> hydroxychloroquine 200 mg PO thrice daily</p> <p><strong>OR</strong></p> Trimethoprim-sulfamethoxazole one DS tablet twice daily for one year</td> <td>One year</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenously; IM: intramuscularly; DS: double-strength (one double-strength tablet is equivalent to 160 mg trimethoprim and 800 mg sulfamethoxazole); PO: orally.<br />* The initial phase is followed by the maintenance phase.<br />¶ Central nervous system disease includes neurologically asymptomatic patients with a positive cerebrospinal fluid (CSF) polymerase chain reaction (PCR) test for <EM innerHtml>Tropheryma whipplei </EM>as well as patients with Whipple's disease and neurologic symptoms despite a negative CSF PCR test.&nbsp;</div><div id=\"graphicVersion\">Graphic 65520 Version 5.0</div></div></div>"},"65521":{"type":"graphic_table","displayName":"Causes of bradycardia","title":"Causes of bradycardia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of bradycardia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Intrinsic</td> </tr> <tr> <td class=\"indent1\">Idiopathic degenerative disorder</td> </tr> <tr> <td class=\"indent1\">Ischemic heart disease</td> </tr> <tr> <td class=\"indent1\">Chronic ischemia</td> </tr> <tr> <td class=\"indent1\">Acute myocardial infarction</td> </tr> <tr> <td class=\"indent1\">Hypertensive heart disease</td> </tr> <tr> <td class=\"indent1\">Cardiomyopathy</td> </tr> <tr> <td class=\"indent1\">Trauma</td> </tr> <tr> <td class=\"indent1\">Surgery for congenital heart disease</td> </tr> <tr> <td class=\"indent1\">Heart transplant</td> </tr> <tr> <td class=\"indent1\">Inflammation</td> </tr> <tr> <td class=\"indent1\">Collagen vascular disease</td> </tr> <tr> <td class=\"indent1\">Rheumatic fever</td> </tr> <tr> <td class=\"indent1\">Pericarditis</td> </tr> <tr> <td class=\"indent1\">Infection</td> </tr> <tr> <td class=\"indent1\">Viral myocarditis</td> </tr> <tr> <td class=\"indent1\">Lyme disease (Borrelia burgdorfer I)</td> </tr> <tr> <td class=\"indent1\">Neuromuscular disorder</td> </tr> <tr> <td class=\"indent1\">Friedreich ataxia</td> </tr> <tr> <td class=\"indent1\">X-linked muscular dystrophy</td> </tr> <tr> <td class=\"indent1\">Familial disorder</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Extrinsic</td> </tr> <tr> <td class=\"sublist2_start\">Drugs</td> </tr> <tr> <td class=\"sublist2\">Antiarrhythmic agents</td> </tr> <tr> <td class=\"sublist2\">Class IA - quinidine, procainamide</td> </tr> <tr> <td class=\"sublist2\">Class IC - propafenone, flecainide</td> </tr> <tr> <td class=\"sublist2\">Class II - &#946;-blockers</td> </tr> <tr> <td class=\"sublist2\">Class III - sotalol, amiodarone, dronedarone</td> </tr> <tr> <td class=\"sublist2\">Class IV - diltiazem, verapamil</td> </tr> <tr> <td class=\"indent1\">Cardiac glycosides</td> </tr> <tr> <td class=\"sublist2_start\">Antihypertensive agents</td> </tr> <tr> <td class=\"sublist2\">Clonidine, reserpine, methyldopa</td> </tr> <tr> <td class=\"sublist2_start\">Antipsychotic agents</td> </tr> <tr> <td class=\"sublist2\">Lithium, phenothiazines, amitriptyline</td> </tr> <tr> <td class=\"sublist2_start\">Autonomically mediated</td> </tr> <tr> <td class=\"sublist2\">Vasovagal syncope (cardioinhibitory)</td> </tr> <tr> <td class=\"sublist2\">Carotid sinus hypersensitivity</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Intracranial hypertension</td> </tr> <tr> <td class=\"indent1\">Hypothermia</td> </tr> <tr> <td class=\"indent1\">Hyperkalemia</td> </tr> <tr> <td class=\"indent1\">Hypoxia</td> </tr> <tr> <td class=\"indent1\">Anorexia nervosa</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Fuster V, Walsh R, Harrington R. Hurst's the Heart, 13th ed, McGraw-Hill Professional, New York 2010. Copyright &copy; 2010 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 65521 Version 11.0</div></div></div>"},"65525":{"type":"graphic_table","displayName":"Modified de Gramont schedule for gastrointestinal cancer","title":"Short-term infusional fluorouracil and leucovorin for gastrointestinal cancer (modified de Gramont schedule)*<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Short-term infusional fluorouracil and leucovorin for gastrointestinal cancer (modified de Gramont schedule)*<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 14 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Leucovorin<sup>&#182;</sup></td> <td>400 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL 5% dextrose in water (D5W)<sup>&#916;</sup> and administer over two hours.</td> <td>Day 1</td> </tr> <tr> <td>Fluorouracil (FU)</td> <td>400 mg/m<sup>2</sup> IV bolus</td> <td>Slow IV push over five minutes (administer immediately after leucovorin).</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>FU</td> <td>2400 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 to 1000 mL D5W and administer over 46 hours (begin immediately after FU IV bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL normal saline.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia &#60;5%<sup>[1,2]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose of FU may be needed in patients with impaired liver function. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease.\" </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count prior to each treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes and liver and renal function prior to each treatment. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Delay treatment by one week if the total white blood cell count is &#60;3000 cells/microL, absolute neutrophil count is &#60;1500 cells/microL, or platelets are &#60;100,000/microL. If treatment is delayed for two weeks or delayed for one week on two separate occasions, eliminate the day 1 FU bolus. With the second occurrence, reduce infusional FU by 20%. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Withhold treatment for grade 2 or worse diarrhea and restart at a lower dose after complete resolution.<sup>[3]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents.\" </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count.<br />* This is a modification of the original de Gramont regimen of short-term infusional FU plus leucovorin<SUP>[4]</SUP>, which eliminates the day 2 bolus doses of FU and leucovorin.<br />¶ Leucovorin dose is given for d,l-racemic mixture.<SUP>[5]</SUP> Use half the dose for LEVOleucovorin (l-leucovorin).<br />Δ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Cheeseman SL, et al. Br J Cancer 2002; 87:393.</LI>&#xD;&#xA;<LI>Hochster HS, et al. J Clin Oncol 2008; 26:3523.</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 30, 2011).</LI>&#xD;&#xA;<LI>de Gramont A, et al. J Clin Oncol 1997; 15:808.</LI>&#xD;&#xA;<LI>Leucovorin calcium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 30, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 65525 Version 21.0</div></div></div>"},"65526":{"type":"graphic_figure","displayName":"Outcome from medical termination","title":"Pregnancy termination with mifepristone and oral misoprostol","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Pregnancy termination with mifepristone and oral misoprostol</div><div class=\"cntnt\"><img style=\"width:527px; height:346px;\" src=\"images/OBGYN/65526_Outcomefrommedicaltermin.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65526 Version 2.0</div></div></div>"},"65527":{"type":"graphic_picture","displayName":"Periungual squamous cell carcinoma","title":"Periungual squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Periungual squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/65527_Periungual_squamous_carcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ulcerated papule is present on the periungual skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65527 Version 3.0</div></div></div>"},"65528":{"type":"graphic_picture","displayName":"DLBCL BCL-2 staining","title":"Diffuse large B-cell lymphoma BCL-2 staining","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Diffuse large B-cell lymphoma BCL-2 staining</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/HEME/65528_DLBCLBCL2staining.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse large B-cell lymphoma, centroblast variant. Membrane staining for BCL-2 in a large number of cells. BCL-2/peroxidase immunostaining.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Diffuse large B-cell lymphoma. In: Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 65528 Version 6.0</div></div></div>"},"65533":{"type":"graphic_table","displayName":"Adoption resources","title":"Resources for adopted children and adoptive parents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources for adopted children and adoptive parents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Books for children: </td> </tr> <tr> <td>Entering adoptive home from foster care: <em>Zachary's New Home</em> by GM Blomquist</td> </tr> <tr> <td>Of school age: <em>So You're Adopted</em> by F Powledge</td> </tr> <tr> <td>In adolescence: <em>Who is David?</em> by E Nerlove</td> </tr> <tr> <td class=\"subtitle1_single\">References&nbsp;for adoptive parents: </td> </tr> <tr> <td><em>Adoptive Families</em> magazine</td> </tr> <tr> <td><em>Adoption Medicine: Caring for Children and Families</em> by American Academy of Pediatrics Council on Foster Care, Adoption, and Kinship Care</td> </tr> <tr> <td><em>Raising Adopted Children: A Manual for Adoptive Parents</em> by LR Melina</td> </tr> <tr> <td><em>Talking With Young Children About Adoption</em> by M Watkins and S Fisher</td> </tr> <tr> <td><em>The Essential Adoption Handbook</em> by CT Alexander-Roberts</td> </tr> <tr> <td class=\"subtitle1_single\">Internet resources: </td> </tr> <tr> <td>American Academy of Pediatrics: www.healthychildren.org/English/family-life/family-dynamics/adoption-and-foster-care</td> </tr> <tr> <td>Books on adoption: www.adoptivefamilies.com/books/index.php</td> </tr> <tr> <td>Child Welfare&nbsp;Information Gateway Adoption: www.childwelfare.gov/topics/adoption/</td> </tr> <tr> <td>National Adoption Information Clearinghouse: www.adoption.org/adopt/national-adoption-clearinghouse.php</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65533 Version 3.0</div></div></div>"},"65535":{"type":"graphic_picture","displayName":"Reaction pelagia noctiluca","title":"Reaction pelagia noctiluca","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reaction pelagia noctiluca</div><div class=\"cntnt\"><img style=\"width:288px; height:294px;\" src=\"images/PC/65535_Reaction_pelagia_noctiluca.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flare-up reaction of a Pelagia noctiluca print 10 days after the primary contact.</div><div class=\"graphic_reference\">Reproduced with permission from Junghanss, T, Bodio, M. Medically important venomous animals: Biology, prevention, first aid, and clinical management. CID 2006; 32:1309. Copyright &#169; 2006 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 65535 Version 1.0</div></div></div>"},"65537":{"type":"graphic_picture","displayName":"Alcoholic steatohepatitis and cirrhosis II - low power","title":"Alcoholic steatohepatitis and cirrhosis in a 35-year-old woman (low power, Masson trichrome)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Alcoholic steatohepatitis and cirrhosis in a 35-year-old woman (low power, Masson trichrome)</div><div class=\"cntnt\"><img style=\"width:504px; height:252px;\" src=\"images/GAST/65537_Alc_steatohep_cirrho_low_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This section demonstrates more scarring and advanced cirrhosis than in the other sections from the same patient. There was more sampling variation in this biopsy than is typically seen in alcoholic liver disease.</div><div class=\"graphic_reference\">Courtesy of Marshall M. Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 65537 Version 1.0</div></div></div>"},"65541":{"type":"graphic_table","displayName":"Clinical features of TACs","title":"Clinical features of the trigeminal autonomic cephalalgias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of the trigeminal autonomic cephalalgias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Cluster headache</td> <td class=\"subtitle1\">Paroxysmal hemicrania</td> <td class=\"subtitle1\">SUNCT and SUNA</td> <td class=\"subtitle1\">Hemicrania continua</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Sex (female:male)</strong></td> <td>1:3 to 1:7</td> <td>1:1 to 2.7:1</td> <td>1:1.5</td> <td>2:1</td> </tr> <tr> <td colspan=\"4\"><strong>Pain</strong></td> <td class=\"subtitle2_left\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Type</td> <td>Stabbing, boring</td> <td>Sharp, stabbing, throbbing</td> <td>Burning, stabbing, sharp</td> <td>Throbbing, sharp, pressure, dull, burning, aching, or stabbing</td> </tr> <tr> <td class=\"indent1\">Severity</td> <td>Excruciating</td> <td>Excruciating</td> <td>Severe to excruciating</td> <td>Mild to severe</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Site</td> <td>Orbit, temple</td> <td>Orbit, temple</td> <td>Periorbital</td> <td>Orbital, frontal, temporal; less often occipital</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Attack frequency</strong></td> <td>1 every other day to 8 per day</td> <td>1 to 40 a day (&#62;5 per day for more than half the time)</td> <td>1 to 200 per day</td> <td>Continuous pain with exacerbations</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Duration of attack</strong></td> <td>15 to 180 minutes</td> <td>2 to 30 minutes</td> <td>1 to 600 seconds</td> <td>Months to years</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Autonomic features</strong></td> <td>Yes</td> <td>Yes</td> <td>Yes (prominent conjunctival injection and lacrimation with SUNCT)</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Restlessness and/or agitation</strong></td> <td>Yes</td> <td>Yes</td> <td>Frequent</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Migrainous features (nausea, photophobia, or phonophobia)</strong></td> <td>Yes</td> <td>Yes</td> <td>Rare</td> <td>Frequent</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Alcohol trigger</strong></td> <td>Yes</td> <td>Occasional</td> <td>No</td> <td>Occasional</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cutaneous triggers</strong></td> <td>No</td> <td>Rare</td> <td>Yes</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Indomethacin effect</strong></td> <td>None</td> <td>Absolute</td> <td>None</td> <td>Absolute</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Abortive treatment</strong></td> <td> <p>Sumatriptan injection or nasal spray</p> Oxygen</td> <td>Nil</td> <td>Lidocaine intravenous infusion</td> <td>Nil</td> </tr> <tr> <td><strong>Prophylactic treatment</strong></td> <td> <p>Verapamil</p> <p>Methysergide</p> Lithium</td> <td>Indomethacin</td> <td> <p>Lamotrigine</p> <p>Topiramate</p> Gabapentin</td> <td>Indomethacin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SUNCT: short-lasting unilateral neuralgiform pain with conjunctival injection and tearing; SUNA: short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms.</div><div id=\"graphicVersion\">Graphic 65541 Version 9.0</div></div></div>"},"65545":{"type":"graphic_waveform","displayName":"Third degree or complete AV block with narrow QRS escape","title":"Third degree (complete) atrioventricular block with narrow QRS escape rhythm","html":"<div class=\"graphic normal\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Third degree (complete) atrioventricular block with narrow QRS escape rhythm</div><div class=\"cntnt\"><img style=\"width:509px; height:101px;\" src=\"images/CARD/65545_3rd_degree_AV_block_tutoria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The P waves are completely dissociated from the QRS complexes. The QRS complexes are narrow, indicating a junctional escape rhythm. The atrial and ventricular rates are stable; the former is faster than the latter.</div><div id=\"graphicVersion\">Graphic 65545 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"65546":{"type":"graphic_diagnosticimage","displayName":"CMV pneumonitis 2","title":"Cytomegalovirus pneumonitis","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Cytomegalovirus pneumonitis</div><div class=\"cntnt\"><img style=\"width:522px; height:477px;\" src=\"images/ID/65546_CMVpneumonitis2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) High-resolution computed tomography images (1.0 mm collimation) at the levels of the azygos arch (A) and bronchus intermedius (B) show bilateral ground-glass opacities and poorly defined small nodules (arrows). A small right pleural effusion is also present.<br />(C) Photomicrograph of a biopsy specimen shows a moderate degree of interstitial fibrosis and chronic inflammation (thick arrow) as well as plugs of fibroblastic tissue in the lumens of several airspaces (thin arrows).<br />(D) Highly magnified photomicrograph shows several large cells containing intranuclear inclusions consistent with cytomegalovirus (thin arrows). (Compare size with hyperplastic type 2 pneumocytes [thick arrow].) The patient was a 28-year-old man with acute myelogenous leukemia.</div><div class=\"graphic_reference\">Reproduced with permission from: Muller NL, Fraser RS, Lee KS, Johkoh T. Pulmonary Infection. In: Diseases of the Lung - Radiologic and Pathologic Correlations, Lippincott Williams &amp; Wilkins, Philadelphia, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 65546 Version 12.0</div></div></div>"},"65547":{"type":"graphic_table","displayName":"Assessment for weight-related comorbidities","title":"Additional assessment for weight-related comorbidities to be considered for selected children with obesity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Additional assessment for weight-related comorbidities to be considered for selected children with obesity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Tests</td> <td class=\"subtitle1\">Reason</td> <td class=\"subtitle1\">Note</td> </tr> <tr class=\"divider_bottom\"> <td>Early atherosclerotic cardiovascular disease</td> <td>Fasting lipid profile</td> <td>Hyperlipidemia, hypertriglyceridemia, cardiovascular disease risk</td> <td> <ul> <li>Age&nbsp;2-8 years: test every 2 years if BMI &#8805;95%ile </li> <li>Age 9-11 years: universal screening suggested regardless of BMI </li> <li>Age 12-16 years: test every 2 years if BMI &#8805;85%ile </li> <li>Age 17-21 years: universal screening suggested for all adolescents </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Hypertension</td> <td>BP measurement</td> <td>Multiple measurements are required to diagnose or exclude hypertension</td> <td>Use appropriately sized cuffs and age-appropriate norms. Measure&nbsp;BP at all healthcare visits (and at least annually)</td> </tr> <tr> <td>24-hour ambulatory BP monitoring</td> <td>Evaluate for \"masked\" hypertension; rule out \"white coat\" hypertension</td> <td>Suggested if the diagnosis is unclear from random office measurements</td> </tr> <tr class=\"divider_bottom\"> <td>CBC, metabolic panel, renin assay, urinalysis, renal ultrasound</td> <td>Exclude other causes of hypertension</td> <td>Suggested if hypertension is confirmed</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Fatty liver disease</td> <td>Serum ALT</td> <td>&nbsp;</td> <td>Initial screening with serum ALT for all obese children&nbsp;starting between 9 and 11&nbsp;years of age. If normal,&nbsp;repeat at least every 2 to 3 years.*&nbsp;</td> </tr> <tr> <td> <p>Laboratory evaluation for liver disease:</p> <p>Perform screening labs, and viral hepatitis, endocrine disorders, autoimmune hepatitis. </p> <p>Exclude genetic disorders in selected patients.<sup>&#182;</sup> </p> </td> <td>Determine cause of elevated transaminases</td> <td>Perform this evaluation if&nbsp;ALT is persistently elevated &#62;2 x the upper limit of normal*&nbsp;(&#62;44 U/L for girls, and &#62;52 U/L for boys) for 6 months, or if other signs/symptoms of advanced liver disease are present.</td> </tr> <tr class=\"divider_bottom\"> <td>Liver biopsy</td> <td>Determine cause of elevated transaminases, assess degree of hepatitis</td> <td>Perform liver biopsy if&nbsp;ALT&nbsp;&#62;2 x ULN for&nbsp;&#62;6 months. Imaging cannot accurately determine inflammation and fibrosis.</td> </tr> <tr class=\"divider_bottom\"> <td>Type 2 diabetes mellitus or impaired glucose tolerance</td> <td>Fasting glucose, HbA1c, or oral glucose tolerance test</td> <td>Assess for insulin resistance and hyperglycemia</td> <td> <p>Perform in children &#8805;10 years old&nbsp;who are overweight or obese, and have&nbsp;one or more risk factors for type 2 diabetes.<sup>&#916; </sup></p> <ul> <li>Diabetes is diagnosed if fasting glucose &#8805;126 mg/dL or HbA1c &#8805;6.5 percent on 2 occasions </li> <li>Pre-diabetes is diagnosed if fasting glucose 100-125 mg/dL or HbA1c 5.7-6.4 percent on 2 occasions. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Sleep apnea</td> <td>Polysomnogram (sleep study)</td> <td>Evaluate sleep related breathing disorders</td> <td>Perform in patients who are obese and have symptoms suggesting obstructive sleep apnea.<sup>&#9674;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Orthopedic disease</td> <td>Hip x-rays</td> <td>Evaluate for SCFE</td> <td>Perform in patients with unexplained aching pain in hip, groin, thigh, or knee. Use frog-leg positioning for radiograph</td> </tr> <tr class=\"divider_bottom\"> <td>Knee x-rays</td> <td>Evaluate for Blount disease</td> <td>Perform in patients with&nbsp;genu varum&nbsp;(bow legs) or genu valgum (knock knees)&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Polycystic ovary syndrome</td> <td>Total testosterone (or free testosterone)</td> <td>To confirm whether hyperandrogenemia is present, and exclude other causes of hyperandrogenemia</td> <td>Perform in girls with irregular menses or hirsutism. If testosterone is elevated, additional endocrine workup is indicated.</td> </tr> <tr class=\"divider_bottom\"> <td>Precocious puberty</td> <td>LH, FSH, testosterone or estradiol, DHEAS</td> <td>Early onset of obesity</td> <td>Physical exam often is sufficient to evaluate</td> </tr> <tr> <td>Pseudotumor cerebri</td> <td>Fundoscopic exam, lumbar puncture</td> <td>Increased intracranial pressure suggested by papilledema, and confirmed by lumbar puncture</td> <td>Perform&nbsp;funduscopic exam in patients with frequent headaches. &nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BP: blood pressure; CBC: complete blood count; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ANA: antinuclear antibodies; HbA1c: hemoglobin A1c; SCFE: slipped capital femoral epiphysis; DHEAS: dehydroepiandrosterone sulfate; SHBG: sex hormone binding globulin; LH: luteinizing hormone; FSH: follicle-stimulating hormone.<br />* For interpretation of serum ALT, use the upper limit of normal of 22 U/L for girls, and 26 U/L for boys, as determined from healthy lean children in the National Health and Nutrition Examination Survey (NHANES).<SUP>3</SUP> Note that these values are substantially lower than the upper limits reported in most pediatric hospital laboratories.<br />¶ Screening labs for suspected fatty liver disease include a CBC with differential, AST, alkaline phosphatase, gamma glutamyl transpeptidase (GGTP), total and direct bilirubin, albumin, and HbA1c. <br />Δ Risk factors for type 2 diabetes include: family history of type 2 diabetes, high-risk race/ethnicity (Native American, African-American, Latino, Asian American, Pacific Islander), signs of insulin resistance (eg, acanthosis nigricans), or conditions associated with diabetes (hypertension, dyslipidemia or polycystic ovary syndrome).&nbsp;<br />◊ Symptoms suggesting obstructive sleep apnea include persistent snoring (most nights, most sleeping positions), observed gasping or apneas, nocturnal enuresis, and morning headaches. </div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Barlow SE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007 Dec; 120 Suppl 4:S164-92. </LI>&#xD;&#xA;<LI>Krebs NF, et al. Assessment of child and adolescent overweight and obesity. Pediatrics. 2007 Dec; 120 Suppl 4:S193-228. </LI>&#xD;&#xA;<LI>Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017; 64:319.</LI>&#xD;&#xA;<LI>American Diabetes Association. 12. Children and Adolescents: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41:S126.</LI></OL></div><div id=\"graphicVersion\">Graphic 65547 Version 18.0</div></div></div>"},"65548":{"type":"graphic_picture","displayName":"Pemphigoid gestationis immunofluorescence ","title":"Pemphigoid gestationis - direct immunofluorescence","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pemphigoid gestationis - direct immunofluorescence</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/65548_Pemphigoid_gestationis_IF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct immunofluorescence microscopy shows linear deposition of C3 along the dermal-epidermal junction.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65548 Version 5.0</div></div></div>"},"65549":{"type":"graphic_figure","displayName":"Fracture identification practice tool","title":"Fracture identification practice tool","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Fracture identification practice tool</div><div class=\"cntnt\"><img style=\"width:600px; height:396px;\" src=\"images/EM/65549_Fracture_ID_tool.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65549 Version 3.0</div></div></div>"},"65550":{"type":"graphic_table","displayName":"Insulin sliding scale","title":"Insulin sliding scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Insulin sliding scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Blood glucose, mg/dL</td> <td class=\"subtitle1\">Dose of regular insulin, units</td> </tr> <tr> <td>&#60;200</td> <td>No insulin</td> </tr> <tr> <td>201 to 250</td> <td>4</td> </tr> <tr> <td>251 to 300</td> <td>6</td> </tr> <tr> <td>301 to 350</td> <td>8</td> </tr> <tr> <td>351 to 400</td> <td>10</td> </tr> <tr> <td>&#62;400</td> <td>12 and call physician</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65550 Version 2.0</div></div></div>"},"65552":{"type":"graphic_picture","displayName":"Partial thickness burn PI","title":"Superficial partial-thickness burn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial partial-thickness burn</div><div class=\"cntnt\"><img style=\"width:367px; height:283px;\" src=\"images/PI/65552_Partial_thickness_burn_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial partial-thickness burns can form blisters, and they turn white when you press them. They might feel moist and leak fluid.</div><div class=\"graphic_reference\">Courtesy of Eric D Morgan and William F Miser, MD.</div><div id=\"graphicVersion\">Graphic 65552 Version 2.0</div></div></div>"},"65554":{"type":"graphic_figure","displayName":"Effect of carboxyhemoglobin","title":"Effect of carboxyhemoglobin on measured oxygen saturation by pulse oximetry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of carboxyhemoglobin on measured oxygen saturation by pulse oximetry</div><div class=\"cntnt\"><img style=\"width:382px; height:293px;\" src=\"images/PULM/65554_Effect_of_carboxyhemoglobin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">SpO<sub>2</sub> and cooximetry versus carboxyhemoglobin (COHb) at FiO<sub>2</sub> = 1.0. SpO<sub>2</sub> consistently overestimates O<sub>2</sub> saturation in the presence of COHb. At COHb = 70 percent, SpO<sub>2</sub> is still roughly 90 percent, while oxyhemoglobin has fallen to 30 percent.</div><div class=\"graphic_footnotes\">FiO<sub>2</sub>: fraction of inspired oxygen; O<sub>2</sub>: oxygen; SpO<sub>2</sub>: standard pulse oximetry.</div><div class=\"graphic_reference\">Redrawn from: Barker SJ, Tremper KK, Anesthesiology 1987; 66:677.</div><div id=\"graphicVersion\">Graphic 65554 Version 4.0</div></div></div>"},"65555":{"type":"graphic_figure","displayName":"Hypertension and AHI","title":"Hypertension (HT) and the apnea hypopnea index (AHI)","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Hypertension (HT) and the apnea hypopnea index (AHI)</div><div class=\"cntnt\"><img style=\"width:500px; height:524px;\" src=\"images/PULM/65555_Hypertension_and_AHI.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AHI: apnea hypopnea index; OR: odds ratio; HT: hypertension; BMI: body mass index.</div><div class=\"graphic_reference\">Data from: Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342:1378.</div><div id=\"graphicVersion\">Graphic 65555 Version 3.0</div></div></div>"},"65557":{"type":"graphic_picture","displayName":"Thumb splint","title":"Thumb splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thumb splint</div><div class=\"cntnt\"><img style=\"width:362px; height:247px;\" src=\"images/RHEUM/65557_Thumb_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A thumb splint may be useful to rest the region of the first carpometacarpal joint for repetitive movement disorders including trigger thumb, de Quervain's tenosynovitis, and osteoarthritis. The splint immobilizes the wrist in a small degree of extension and radial deviation, while maintaining slight extension of the first metacarpophalangeal (MCP) joint.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon RP, Moskowitz RW, Goldberg,VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 65557 Version 2.0</div></div></div>"},"65560":{"type":"graphic_picture","displayName":"Light microscopy kid LPG","title":"Light microscopic findings in lipoprotein glomerulopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light microscopic findings in lipoprotein glomerulopathy</div><div class=\"cntnt\"><img style=\"width:433px; height:327px;\" src=\"images/NEPH/65560_Light_microscopy_kid_LPG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Capillary lumina are markedly dilated and contain pale-stained thrombus-like substances (*). (Periodic acid-Schiff stain; original magnification: x200.)</div><div class=\"graphic_reference\">Reproduced with permission from: Saito, T, et al. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006; 47:199. Copyright ©2006 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 65560 Version 2.0</div></div></div>"},"65561":{"type":"graphic_form","displayName":"Birth center consent 3","title":"Birth center consent form (continued)","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Birth center consent form (continued)</div><div class=\"cntnt\"><img style=\"width:603px; height:520px;\" src=\"images/OBGYN/65561_Birth_center_consent_3.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: the American Association of Birth Centers. Copyright ©2007.</div><div id=\"graphicVersion\">Graphic 65561 Version 2.0</div></div></div>"},"65562":{"type":"graphic_figure","displayName":"Relationship between fetal pH and BPP","title":"The relationship between fetal umbilical venous pH (±2 SD) by cordocentesis and the fetal biophysical profile score","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The relationship between fetal umbilical venous pH (±2 SD) by cordocentesis and the fetal biophysical profile score</div><div class=\"cntnt\"><img style=\"width:333px; height:362px;\" src=\"images/OBGYN/65562_FetalpHversusBPP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The correlation was linear, inverse, and very significant (R<SUP>2</SUP> 0.912; p &lt;0.01).</div><div class=\"graphic_footnotes\">SD: standard deviation.</div><div class=\"graphic_reference\">Data from: Manning FA. Dynamic ultrasound-based fetal assessment: The fetal biophysical profile score. Clin Obstet Gynecol 1995; 38:26.</div><div id=\"graphicVersion\">Graphic 65562 Version 5.0</div></div></div>"},"65564":{"type":"graphic_picture","displayName":"Bruising in Cushings disease","title":"Easy bruisability in Cushing's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Easy bruisability in Cushing's disease</div><div class=\"cntnt\"><img style=\"width:360px; height:278px;\" src=\"images/ENDO/65564_Bruising_in_Cushings_diseas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Forearm of a 42-year-old man with Cushing's disease showing multiple ecchymoses due to minimal trauma.</div><div class=\"graphic_reference\">Courtesy of David N Orth, MD.</div><div id=\"graphicVersion\">Graphic 65564 Version 1.0</div></div></div>"},"65568":{"type":"graphic_table","displayName":"Side effects of quinidine","title":"Side effects induced by quinidine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Side effects induced by quinidine</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Side effect</td>\n\n      <td class=\"subtitle1\">Relative frequency</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">Cardiovascular</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Proarrhythmia</td>\n\n      <td>+++</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Torsades de pointes</td>\n\n      <td>+++</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Prolonged QT interval</td>\n\n      <td>++</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Hypotension</td>\n\n      <td>++</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Sinus arrest</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Heart failure</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">AV block</td>\n\n      <td>&plusmn;</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Gastrointestinal</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Diarrhea</td>\n\n      <td>+++</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Nausea, abdominal pain</td>\n\n      <td>++</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Hepatotoxicity</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Central nervous system</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Cinchonism</td>\n\n      <td>++</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Psychosis</td>\n\n      <td>++</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Depression</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Blurred vision</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Hematologic</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Thrombocytopenia</td>\n\n      <td>+++</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Agranulocytosis</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Hemolytic anemia</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Hypoprothrombinemia</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Other</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Fever</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Lupus-like syndrome</td>\n\n      <td>+</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Major side effects induced by quinidine and their relative frequency.</div><div id=\"graphicVersion\">Graphic 65568 Version 1.0</div></div></div>"},"65570":{"type":"graphic_picture","displayName":"Erythema multiforme face","title":"Erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema multiforme</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/65570_Erythema_multiforme_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with erythema multiforme presented with non-targetoid erythematous papules on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65570 Version 4.0</div></div></div>"},"65571":{"type":"graphic_table","displayName":"Causes of coma","title":"Causes of coma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of coma</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">I. Symmetrical, nonstructural</td> </tr> <tr> <td class=\"subtitle2_single\">Toxins</td> </tr> <tr> <td class=\"indent1\">Lead</td> </tr> <tr> <td class=\"indent1\">Thallium</td> </tr> <tr> <td class=\"indent1\">Mushrooms</td> </tr> <tr> <td class=\"indent1\">Cyanide</td> </tr> <tr> <td class=\"indent1\">Methanol</td> </tr> <tr> <td class=\"indent1\">Ethylene glycol</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Carbon monoxide</td> </tr> <tr> <td class=\"subtitle2_single\">Drugs</td> </tr> <tr> <td class=\"indent1\">Sedatives</td> </tr> <tr> <td class=\"indent1\">Barbiturates*</td> </tr> <tr> <td class=\"indent1\">Other hypnotics</td> </tr> <tr> <td class=\"indent1\">Tranquilizers</td> </tr> <tr> <td class=\"indent1\">Bromides</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> </tr> <tr> <td class=\"indent1\">Opiates</td> </tr> <tr> <td class=\"indent1\">Paraldehyde</td> </tr> <tr> <td class=\"indent1\">Salicylate</td> </tr> <tr> <td class=\"indent1\">Psychotropics</td> </tr> <tr> <td class=\"indent1\">Anticholinergics</td> </tr> <tr> <td class=\"indent1\">Amphetamines</td> </tr> <tr> <td class=\"indent1\">Lithium</td> </tr> <tr> <td class=\"indent1\">Phencyclidine</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Monoamine oxidase inhibitors</td> </tr> <tr> <td class=\"subtitle2_single\">Metabolic</td> </tr> <tr> <td class=\"indent1\">Hypoxia</td> </tr> <tr> <td class=\"indent1\">Hypercapnia</td> </tr> <tr> <td class=\"indent1\">Hypernatremia*</td> </tr> <tr> <td class=\"indent1\">Hypoglycemia*</td> </tr> <tr> <td class=\"indent1\">Hyperglycemic nonketotic coma</td> </tr> <tr> <td class=\"indent1\">Diabetic ketoacidosis</td> </tr> <tr> <td class=\"indent1\">Lactic acidosis</td> </tr> <tr> <td class=\"indent1\">Hypercalcemia</td> </tr> <tr> <td class=\"indent1\">Hypocalcemia</td> </tr> <tr> <td class=\"indent1\">Hypermagnesemia</td> </tr> <tr> <td class=\"indent1\">Hyperthermia</td> </tr> <tr> <td class=\"indent1\">Hypothermia</td> </tr> <tr> <td class=\"indent1\">Reye syndrome</td> </tr> <tr> <td class=\"indent1\">Aminoacidemia</td> </tr> <tr> <td class=\"indent1\">Wernicke encephalopathy</td> </tr> <tr> <td class=\"indent1\">Porphyria</td> </tr> <tr> <td class=\"indent1\">Hepatic encephalopathy*</td> </tr> <tr> <td class=\"indent1\">Uremia</td> </tr> <tr> <td class=\"indent1\">Dialysis encephalopathy</td> </tr> <tr> <td class=\"indent1\">Addisonian crisis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypothyroidism</td> </tr> <tr> <td class=\"subtitle2_single\">Infections</td> </tr> <tr> <td class=\"indent1\">Bacterial meningitis</td> </tr> <tr> <td class=\"indent1\">Viral encephalitis</td> </tr> <tr> <td class=\"indent1\">Postinfectious encephalomyelitis</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Sepsis</td> </tr> <tr> <td class=\"indent1\">Typhoid fever</td> </tr> <tr> <td class=\"indent1\">Malaria</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Waterhouse-Friderichsen syndrome</td> </tr> <tr> <td class=\"subtitle2_single\">Psychiatric</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Catatonia</td> </tr> <tr> <td class=\"subtitle2_single\">Other</td> </tr> <tr> <td class=\"indent1\">Postictal seizure*</td> </tr> <tr> <td class=\"indent1\">Diffuse ischemia (myocardial infarction, heart failure, arrhythmia)</td> </tr> <tr> <td class=\"indent1\">Hypotension</td> </tr> <tr> <td class=\"indent1\">Fat embolism*</td> </tr> <tr> <td class=\"indent1\">Hypertensive encephalopathy</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Nonconvulsive status epilepticus</td> </tr> <tr> <td class=\"indent1\">Heat stroke</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">II. Symmetrical, structural</td> </tr> <tr> <td class=\"subtitle2_single\">Supratentorial</td> </tr> <tr> <td class=\"indent1\">Bilateral internal carotid occlusion</td> </tr> <tr> <td class=\"indent1\">Bilateral anterior cerebral artery occlusion</td> </tr> <tr> <td class=\"indent1\">Sagittal sinus thrombosis</td> </tr> <tr> <td class=\"indent1\">Subarachnoid hemorrhage</td> </tr> <tr> <td class=\"indent1\">Thalamic hemorrhage*</td> </tr> <tr> <td class=\"indent1\">Trauma-contusion, concussion*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hydrocephalus</td> </tr> <tr> <td class=\"subtitle2_single\">Infratentorial</td> </tr> <tr> <td class=\"indent1\">Basilar occlusion*</td> </tr> <tr> <td class=\"indent1\">Midline brainstem tumor</td> </tr> <tr> <td class=\"indent1\">Pontine hemorrhage*</td> </tr> <tr> <td class=\"indent1\">Central pontine myelinolysis</td> </tr> <tr> <td class=\"subtitle1_single\">III. Asymmetrical, structural</td> </tr> <tr> <td class=\"subtitle2_single\">Supratentorial</td> </tr> <tr> <td class=\"indent1\">Thrombotic thrombocytopenic purpura<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Disseminated intravascular coagulation</td> </tr> <tr> <td class=\"indent1\">Nonbacterial thrombotic endocarditis (marantic endocarditis)</td> </tr> <tr> <td class=\"indent1\">Subacute bacterial endocarditis</td> </tr> <tr> <td class=\"indent1\">Fat emboli</td> </tr> <tr> <td class=\"indent1\">Unilateral hemispheric mass (tumor, abscess, bleed) with herniation</td> </tr> <tr> <td class=\"indent1\">Subdural hemorrhage bilateral</td> </tr> <tr> <td class=\"indent1\">Intracerebral bleed</td> </tr> <tr> <td class=\"indent1\">Pituitary apoplexy<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Massive or bilateral supratentorial infarction</td> </tr> <tr> <td class=\"indent1\">Multifocal leukoencephalopathy</td> </tr> <tr> <td class=\"indent1\">Creutzfeldt-Jakob disease</td> </tr> <tr> <td class=\"indent1\">Adrenal leukodystrophy</td> </tr> <tr> <td class=\"indent1\">Cerebral vasculitis</td> </tr> <tr> <td class=\"indent1\">Cerebral abscess</td> </tr> <tr> <td class=\"indent1\">Subdural empyema</td> </tr> <tr> <td class=\"indent1\">Thrombophlebitis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">Leukoencephalopathy associated with chemotherapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Acute disseminated encephalomyelitis</td> </tr> <tr> <td class=\"subtitle2_single\">Infratentorial</td> </tr> <tr> <td class=\"indent1\">Brainstem infarction</td> </tr> <tr> <td class=\"indent1\">Brainstem hemorrhage</td> </tr> <tr> <td class=\"indent1\">Brainstem thrombencephalitis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Relatively common asymmetrical presentation.<br />¶ Relatively symmetrical presentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Berger JR. Clinical Approach to Stupor and Coma. In: Neurology in Clinical Practice: Principles of Diagnosis and Management, 4th ed, Bradley WG, Daroff RB, Fenichel GM, Jankovic J (Eds), Butterworth Heinemann, Philadelphia, PA 2004. p.46. Copyright © 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 65571 Version 5.0</div></div></div>"},"65573":{"type":"graphic_diagnosticimage","displayName":"Dedifferent parosteal osteosarc","title":"Dedifferentiated parosteal osteosarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dedifferentiated parosteal osteosarcoma</div><div class=\"cntnt\"><img style=\"width:335px; height:306px;\" src=\"images/ONC/65573_Dedifferent_parosteal_osteo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT image from a CT-guided needle biopsy procedure. The non-ossified anteromedial portions of the tumor into which the needle is guided are more likely to contain high grade tumor than the posterolaterally located densely ossifed portions.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Daniel Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 65573 Version 3.0</div></div></div>"},"65574":{"type":"graphic_figure","displayName":"Vertebral column","title":"Vertebral column","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vertebral column</div><div class=\"cntnt\"><img style=\"width:353px; height:620px;\" src=\"images/PC/65574_Vertebral_column.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65574 Version 1.0</div></div></div>"},"65575":{"type":"graphic_picture","displayName":"Endobronchial bx asthma High","title":"Histology of asthma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histology of asthma</div><div class=\"cntnt\"><img style=\"width:287px; height:192px;\" src=\"images/PULM/65575_Endobronchial_bx_asthma_Hig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endobronchial biopsy taken from a six-year-old girl with severe, steroid-dependent asthma. The airway epithelium is heaped up in places, alternating with areas of squamous metaplasia. There is marked thickness of the basement membrane, and the underlying smooth muscle is hyperplastic with some fibrosis. There is little submucosal inflammation evident in this biopsy.</div><div class=\"graphic_reference\">Courtesy of Susan Brugman, MD and Leland Fan, MD.</div><div id=\"graphicVersion\">Graphic 65575 Version 1.0</div></div></div>"},"65577":{"type":"graphic_table","displayName":"Use of SCOOP system IV","title":"Patient management tips for the SCOOP transtracheal oxygen system - IV","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient management tips for the SCOOP transtracheal oxygen system - IV</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Phase</td> <td class=\"subtitle1\">Goal</td> <td class=\"subtitle1\">Management strategy</td> </tr> <tr> <td class=\"centered\" rowspan=\"6\">IV</td> <td>Teach skills used in removal and reinsertion of the catheter</td> <td>Teach the procedure and have the patient give a return demonstration two times. If removal and reinsertion of the catheter is not smooth, delay removal for cleaning for two weeks to give the tract more time to heal.</td> </tr> <tr> <td>Prevent loss of the tract</td> <td>Instruct the patient to remove the catheter between 8:00 AM and 4:00 PM so that assistance can be easily obtained if problems develop.</td> </tr> <tr> <td>Prevent trauma to the tract</td> <td>Instruct the patient to limit removal for cleaning to two times daily. Some patients remove their catheter daily. Others follow Phase III by cleaning the catheter in place on most days and remove the catheter once per week.</td> </tr> <tr> <td>Prevent infection</td> <td>Teach the patient to clean the catheter with antibacterial soap after removal from the tract and store it in a clean, dry place until used for the next insertion. Reinforce need to clean the site daily; evaluate for warmth, redness, swelling, or drainage; and report these symptoms.</td> </tr> <tr> <td>Recognize signs and symptoms of keloid development</td> <td>Instruct the patient to call if there is difficulty inserting the catheter. If a keloid has formed or the tract is no longer straight, cleaning in place may be required. When the catheter is replaced, a guide wire should be used.</td> </tr> <tr> <td>Recognize signs and symptoms of chondritis</td> <td>Instruct the patient to report any tract tenderness or persistent drainage. The catheter should be cleaned in place.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Hoffman LA, Wesmiller SW. Transtracheal oxygen. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Mount Kisco, NY, 1991.</div><div id=\"graphicVersion\">Graphic 65577 Version 4.0</div></div></div>"},"65578":{"type":"graphic_picture","displayName":"Ganglion on wrist","title":"Ganglion on the dorsum of the wrist","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ganglion on the dorsum of the wrist</div><div class=\"cntnt\"><img style=\"width:313px; height:207px;\" src=\"images/RHEUM/65578_Ganglion_on_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The wrist is a common location for the cystic swelling that is characteristic of ganglia (arrow). Aspiration reveals a clear gelatinous fluid.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 65578 Version 3.0</div></div></div>"},"65580":{"type":"graphic_figure","displayName":"Cortical trabecular BMD IHH","title":"Bone mineral density in men with IHH","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Bone mineral density in men with IHH</div><div class=\"cntnt\"><img style=\"width:596px; height:333px;\" src=\"images/ENDO/65580_Cortical_trabecular_BMD_IHH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Initial and final cortical (Panel A) and trabecular (Panel B) bone densities after 12 to 31 months of androgen replacement in men with idiopathic hypogonadotropic hypogonadism who initially had fused epiphyses (shown in red: Group I) or open epiphyses (shown in blue: Group II). The solid horizontal black lines represent the mean values.</div><div class=\"graphic_reference\">Reproduced with modifications from Finkelstein et al, J Clin Endocrinol Metab 1989; 69:776.</div><div id=\"graphicVersion\">Graphic 65580 Version 1.0</div></div></div>"},"65581":{"type":"graphic_movie","displayName":"Angiogram_Total anomalous pulmonary venous connection","title":"Angiogram showing mixed pulmonary venous return of the left lung in a patient with total anomalous pulmonary venous connection","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angiogram showing mixed pulmonary venous return of the left lung in a patient with total anomalous pulmonary venous connection</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/65581_tapvrangconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:376px; height:452px;\" src=\"images/CARD/65581_tapvrang.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left upper pulmonary vein connects to the left innominate vein via a vertical vein. The left lower pulmonary vein, along with the right pulmonary veins (not shown), drain through a dilated coronary sinus.</div><div class=\"graphic_reference\">Courtesy of Dr. Brian Soriano.</div><div id=\"graphicVersion\">Graphic 65581 Version 3.0</div></div></div>"},"65585":{"type":"graphic_table","displayName":"Evaluation of transverse myelitis","title":"Potential medical work-up for suspected acute transverse myelitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential medical work-up for suspected acute transverse myelitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indicative signs and symptoms</td> <td class=\"subtitle1\">Suggested evaluation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Infectious etiology</td> </tr> <tr> <td class=\"indent1\">Fever</td> <td>CSF Gram stain and bacterial culture</td> </tr> <tr> <td class=\"indent1\">Meningismus</td> <td>CSF PCR: HSV-1, HSV-2, HHV-6, VZV, CMV, EBV, enteroviruses</td> </tr> <tr> <td class=\"indent1\">Rash</td> <td>CSF viral culture</td> </tr> <tr> <td class=\"indent1\">Concurrent systemic infection</td> <td>CSF acid-fast bacilli smear and tuberculous culture</td> </tr> <tr> <td class=\"indent1\">Immunocompromised state</td> <td>CSF HSV, VZV, and HTLV-1 antibodies</td> </tr> <tr> <td class=\"indent1\">Recurrent genital infection</td> <td>CSF anti-<em>Borrelia burgdorferi</em> antibodies</td> </tr> <tr> <td class=\"indent1\">Symptoms of zoster radiculopathy</td> <td>CSF VDRL</td> </tr> <tr> <td class=\"indent1\">Adenopathy</td> <td>CSF India ink and fungal culture</td> </tr> <tr> <td class=\"indent1\">Residence in area endemic for parasitic infections</td> <td>Chest radiograph</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Lymphadenopathy</td> <td>Serology for antibodies to HIV, HSV, VZV, HTLV-1, <em>B. burgdorferi</em></td> </tr> <tr> <td>Serology for hepatitis A, B, C, and <em>Mycoplasma</em></td> </tr> <tr> <td>Consider serology for parasites</td> </tr> <tr> <td>Blood cultures</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Systemic inflammatory disease (vasculitis, collagen vascular diseases, mixed connective tissue disease)</td> </tr> <tr> <td class=\"indent1\">Rash</td> <td>Serum ACE</td> </tr> <tr> <td class=\"indent1\">Oral or genital ulcers</td> <td>Auto-antibodies: ANA, ds-DNA, Ro/SSA, La/SSB, Sm, RNP</td> </tr> <tr> <td class=\"indent1\">Adenopathy</td> <td>Complement levels</td> </tr> <tr> <td class=\"indent1\">Livedo reticularis</td> <td>Urinalysis with microscopic analysis for hematuria</td> </tr> <tr> <td class=\"indent1\">Serositis</td> <td>Lip/salivary gland biopsy</td> </tr> <tr> <td class=\"indent1\">Photosensitivity</td> <td>Chest CT with intravenous contrast</td> </tr> <tr> <td class=\"indent1\">Inflammatory arthritis</td> <td>Schirmer test</td> </tr> <tr> <td class=\"indent1\">Erythema nodosum</td> <td>Chest radiograph</td> </tr> <tr> <td class=\"indent1\">Xerostomia</td> <td>Gallium scan</td> </tr> <tr> <td class=\"indent1\">Keratitis</td> <td rowspan=\"6\">Antiphospholipid antibodies (anticardiolipin antibodies, Russel viper venom time, partial thromboplastin time)</td> </tr> <tr> <td class=\"indent1\">Conjunctivitis</td> </tr> <tr> <td class=\"indent1\">Contractures or thickening of skin</td> </tr> <tr> <td class=\"indent1\">Anemia/leukopenia/thrombocytopenia</td> </tr> <tr> <td class=\"indent1\">Raynaud phenomenon</td> </tr> <tr> <td class=\"indent1\">History of arterial and venous thrombosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">Previous demyelination event</td> <td>Brain MRI</td> </tr> <tr> <td class=\"indent1\">Incomplete deficit clinically with MRI abnormality &#8804;2 spinal segments and &#60;50 percent of cord diameter</td> <td>Evoked potentials</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>CSF oligoclonal bands and IgG index</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neuromyelitis optica (Devic's disease)</td> </tr> <tr> <td class=\"indent1\">Optic neuritis</td> <td>Evoked potentials</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Clinical deficit with MRI abnormality &#8805;3 spinal segments</td> <td>Brain MRI (usually negative)</td> </tr> <tr> <td>NMO-IgG testing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Idiopathic transverse myelitis</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">No clinical or paraclinical features suggestive of another diagnostic category</td> <td>Evoked potentials</td> </tr> <tr> <td>Electromyography/nerve conduction velocity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; ANA: anti-nuclear antibodies; CMV: cytomegalovirus; CSF: cerebrospinal fluid; EBV: Epstein-Barr virus; HHV: human herpes virus; HIV: humam immunodeficiency virus; HSV: herpes simplex virus; HTLV-1: human T-cell lymphotropic virus 1; IgG: immunoglobulin G; NMO-IgG: neuromyelitis optica IgG autoantibody; VDRL: Veneral Disease Research Laboratory; VZV: varicella zoster virus.</div><div class=\"graphic_reference\">Modified with permission from: Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59:499. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65585 Version 13.0</div></div></div>"},"65589":{"type":"graphic_figure","displayName":"Transducer position apical 4 ch","title":"Transducer positon for apical four-chamber view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transducer positon for apical four-chamber view</div><div class=\"cntnt\"><img style=\"width:356px; height:364px;\" src=\"images/CARD/65589_Transducer_position_apica1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transducer position and beam plane used to image the heart in the apical four-chamber view is shown. The transducer is on the apex impulse location and is directed toward the right shoulder.</div><div id=\"graphicVersion\">Graphic 65589 Version 2.0</div></div></div>"},"65590":{"type":"graphic_picture","displayName":"Lateral anatomy of tibia and fibula","title":"Lateral anatomy of tibia and fibula","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Lateral anatomy of tibia and fibula</div><div class=\"cntnt\"><img style=\"width:521px; height:591px;\" src=\"images/EM/65590_Anatomy_tibia_fibula_latera.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65590 Version 6.0</div></div></div>"},"65591":{"type":"graphic_table","displayName":"ECG manifestations of acute myocardial ischemia ","title":"ECG manifestations of acute myocardial ischaemia (in absence of LVH and LBBB)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ECG manifestations of acute myocardial ischaemia (in absence of LVH and LBBB)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">ST elevation</td></tr>\n\n<tr><td>New ST elevation at the J-point in two contiguous leads with the cut-off points: &#8805;0.2 mV in men or &#8805;0.15 mV in women in leads V<sub>2</sub>-V<sub>3</sub> and/or &#8805;0.1 mV in other leads</td></tr>\n\n<tr>\n<td class=\"subtitle1_single\">ST depression and T-wave changes</td></tr>\n\n<tr><td> New horizontal or down-sloping ST depression &#8805;0.05 mV in two contiguous leads; and/or T inversion &#8805;0.1 mVin two contiguous leads with prominent R-wave or R/S ratio &#62;1</td></tr>\n\t\n\t\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Eur Heart J 2007; 28:2525. Copyright &#169;2007 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 65591 Version 3.0</div></div></div>"},"65592":{"type":"graphic_table","displayName":"Killip classification of acute MI","title":"Killip classification of acute myocardial infarction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Killip classification of acute myocardial infarction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\">Class I</td> <td>No evidence of heart failure</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Class II</td> <td>Findings consistent with mild to moderate heart failure (S3 gallop, lung rales less than one-half way up the posterior lung fields, or jugular venous distension)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Class III</td> <td>Overt pulmonary edema</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Class IV</td> <td>Cardiogenic shock</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65592 Version 5.0</div></div></div>"},"65594":{"type":"graphic_diagnosticimage","displayName":"Panacinar emphysema chest radiograph","title":"Panacinar emphysema in alpha-1 antitrypsin deficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Panacinar emphysema in alpha-1 antitrypsin deficiency</div><div class=\"cntnt\"><img style=\"width:352px; height:345px;\" src=\"images/PULM/65594_Panacinar_emphysema_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows marked hyperexpansion with paucity of vascular strucures at the bases and redistribution of vascular flow to the lesser involved upper lobes. These findings are typical of severe panacinar emphysema.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 65594 Version 3.0</div></div></div>"},"65595":{"type":"graphic_diagnosticimage","displayName":"RUL RLL atelectasis","title":"Frontal chest radiograph displays combined partial atelectasis of the right upper lobe and complete atelectasis of the right lower lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frontal chest radiograph displays combined partial atelectasis of the right upper lobe and complete atelectasis of the right lower lobe</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/PULM/65595_RUL_RLL_atelectasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increased opacification of the right paratracheal region, obscuration of the right descending pulmonary artery, and mediastinal shift to the right are evident. The residual hyperlucent right lung is formed by hyperexpansion of the right middle lobe and parts of the aerated right upper lobe.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 65595 Version 2.0</div></div></div>"},"65598":{"type":"graphic_movie","displayName":"Apical 4-chamber echocardiogram MR 2","title":"Apical four-chamber echocardiogram showing mitral regurgitation view 2","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical four-chamber echocardiogram showing mitral regurgitation view 2</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/65598_4chcdmr2conv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:229px; height:436px;\" src=\"images/CARD/65598_4chcdmr2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four chamber view from a 2-D echocardiogram with color flow Doppler shows significant mitral regurgitation with the &quot;jet&quot; directed anteromedially toward the interatrial septum.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 65598 Version 4.0</div></div></div>"},"65600":{"type":"graphic_figure","displayName":"Cervical cerclage procedure with dilated cervix","title":"Cervical cerclage procedure with dilated cervix","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Cervical cerclage procedure with dilated cervix</div><div class=\"cntnt\"><img style=\"width:520px; height:509px;\" src=\"images/OBGYN/65600_Cerclage_with_membra_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Membranes herniating through effaced and widely dilated cervix (A). Replacement of membranes into the uterus by gentle traction on stay sutures (B). Placement of 2 rows of encircling sutures (C). Final appearance of the cervix (D).</div><div class=\"graphic_reference\">Reproduced with permission from Olatunbosun, OA, Dyck, F. Cervical cerclage operation for a dilated cerfix. Obstet Gynecol 1981; 57:166. Reprinted with permission from the American College of Obstetricians and Gynecologists.</div><div id=\"graphicVersion\">Graphic 65600 Version 3.0</div></div></div>"},"65601":{"type":"graphic_picture","displayName":"Oligodendroglioma Light","title":"Oligodendroglioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oligodendroglioma</div><div class=\"cntnt\"><img style=\"width:390px; height:252px;\" src=\"images/ONC/65601_Oligodendroglioma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of an oligodendroglioma. The tumor appears as a sheet of rounded cells with a well-defined cytoplasmic membrane and an empty-looking cytoplasm (fried egg appearance).</div><div class=\"graphic_reference\">Courtesy of Thomas Smith, MD, University of Massachusetts.</div><div id=\"graphicVersion\">Graphic 65601 Version 1.0</div></div></div>"},"65603":{"type":"graphic_table","displayName":"Coronary artery stents approved in the United States","title":"Coronary artery stents approved in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Coronary artery stents approved in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name</td> <td class=\"subtitle1\">Manufacturer</td> <td class=\"subtitle1\">Stent material</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Polymer (thickness) and drug elution kinetics</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Bare metal stents</td> </tr> <tr> <td class=\"indent1\">Vision</td> <td>Abbott Vascular</td> <td>Cobalt chromium</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent1\">VeriFLEX</td> <td>Boston Scientific</td> <td>Stainless steel</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"indent1\">REBEL</td> <td>Boston Scientific</td> <td>Platinum chromium</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Integrity</td> <td>Medtronic</td> <td>Cobalt chromium</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Durable polymer drug-eluting stents currently in use</td> </tr> <tr> <td class=\"indent1\">EluNIR stent</td> <td>Cordis/Medinol</td> <td>Cobalt chromium</td> <td>Ridaforolimus</td> <td>PBMA/CarboSil* 7 micrometers; &#62;50% within 14 days and 90% by 90 days</td> </tr> <tr> <td class=\"indent1\">Xience (V, Prime, Xpedition)</td> <td>Abbott Vascular</td> <td>Cobalt chromium</td> <td>Everolimus</td> <td>PBMA/PVDF-HFP 7.6 micrometers; 80% within four weeks</td> </tr> <tr> <td class=\"indent1\">Promus (Element, Premier)</td> <td>Boston Scientific</td> <td>Platinum chromium</td> <td>Everolimus</td> <td>PMAM/PVDF-HFP 7.6 micrometers; 80% within four weeks</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Resolute</td> <td>Medtronic</td> <td>Cobalt chromium</td> <td>Zotarolimus</td> <td>Biolynx* 5.6 micrometers; 85% within eight weeks</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\"><strong>Bioabsorbable polymer drug-eluting stents currently in use</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">SYNERGY</td> <td>Boston Scientific</td> <td>Platinum chromium</td> <td>Everolimus</td> <td>Poly-lactide-co-glycide<sup>&#182;</sup> 4 micrometers; &#62;95% within two weeks</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Previously approved drug-eluting stents</td> </tr> <tr> <td class=\"indent1\">Cypher</td> <td>Cordis/J&#38;J</td> <td>Stainless steel</td> <td>Sirolimus</td> <td>PEVA/PBMA 12.6 micrometers; &#62;80% within four weeks</td> </tr> <tr> <td class=\"indent1\">Taxus</td> <td>Boston Scientific</td> <td>Stainless steel</td> <td>Paclitaxel</td> <td>SIBS 16 micrometers; approximately 10% over two weeks</td> </tr> <tr> <td class=\"indent1\">Taxus Ion</td> <td>Boston Scientific</td> <td>Platinum chromium</td> <td>Paclitaxel</td> <td>SIBS 16 micrometers; approximately 10% over two weeks</td> </tr> <tr> <td class=\"indent1\">Endeavor</td> <td>Medtronic</td> <td>Cobalt chromium</td> <td>Zotarolimus</td> <td>Phosphoryl Choline 5.3 micrometers; 95% within two weeks</td> </tr> <tr> <td class=\"indent1\">Promus</td> <td>Boston Scientific</td> <td>Cobalt chromium</td> <td>Everolimus</td> <td>PBMA/PVDF-HFP 7.6 micrometers; 80% within four weeks</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PBMA: poly(n-butyl methacrylate); PVDF-HFP: poly(vinylidene fluoride-hexafluoropropylene); PEVA: polyethylene-co-vinyl acetate; SIBBS: poly(styrene-b-isobutylene-b-styrene).<br />* Proprietary polymer.<br />&para; Biodegradable polymer (&gt;90% of polymer absorbed by 120 days).</div><div class=\"graphic_reference\">Courtesy of J Dawn Abbott, MD.</div><div id=\"graphicVersion\">Graphic 65603 Version 14.0</div></div></div>"},"65604":{"type":"graphic_table","displayName":"Recurrence rates after MMS","title":"Local recurrence rates following Mohs micrographic surgery compared with standard excision","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Local recurrence rates following Mohs micrographic surgery compared&nbsp;with standard excision</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Skin cancer</td> <td class=\"subtitle1\">Mohs micrographic surgery (MMS)</td> <td class=\"subtitle1\">Wide excision</td> <td class=\"subtitle1\">Follow-up period</td> </tr> <tr class=\"divider_bottom\"> <td>Basal cell carcinoma<sup>[1-3]</sup></td> <td> <p>1.4 to&nbsp;4.4%</p> <p>2.4 to 6.7%*</p> </td> <td> <p>4.1 to 12.2%</p> <p>13.5%*</p> </td> <td>5 to 10&nbsp;years</td> </tr> <tr class=\"divider_bottom\"> <td>Squamous cell carcinoma<sup>[4,5]</sup></td> <td> <p>1.2 to 2.6%<sup>&#182;</sup></p> <p>5.9%<sup>&#182;&#916;</sup></p> </td> <td>5.7 to 8.1% (literature review rate)<sup>[6]</sup></td> <td>3.9 years (mean)</td> </tr> <tr class=\"divider_bottom\"> <td>Dermatofibrosarcoma protuberans<sup>[7,8]</sup></td> <td>0 to 6.6%<sup>&#9674;</sup></td> <td>13.2%</td> <td>4.8 to 5.4 years</td> </tr> <tr class=\"divider_bottom\"> <td>Atypical fibroxanthoma<sup>[9,10]</sup></td> <td>0</td> <td>8.7 to 12<sup>&#167;</sup>%</td> <td>4.5 to 8.7 years (median)</td> </tr> <tr class=\"divider_bottom\"> <td>Extramammary Paget disease<sup>[11,12]</sup></td> <td>8<sup>&#165;</sup> to 18.2%</td> <td>22<sup>&#165;</sup> to 36.4%</td> <td>62.7 months (mean)</td> </tr> <tr class=\"divider_bottom\"> <td>Sebaceous carcinoma<sup>[13,14]</sup></td> <td>11.1 to 12<sup>&#135;</sup>%</td> <td>30%</td> <td>37 months (mean)</td> </tr> <tr> <td>Microcystic adnexal carcinoma<sup>[15,16]</sup></td> <td>0<sup>&#134;</sup> to 5%</td> <td>50%</td> <td>5 years; only 13 cases</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Recurrent facial tumors.<br />¶ 5 years.<br />Δ Recurrent tumor.<br /><FONT class=lozenge>◊</FONT> Based on a literature review.<br />§ 73.6 m.<br />¥ 24 m for MMS and 65 m for excision.<br />‡ 3.1 years (literature review rate).<br />† Mean.<br /></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Smeets NW, Krekels GA, Ostertag JU, et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: Randomised controlled trial. Lancet 2004; 364:1766. </LI>&#xD;&#xA;<LI>Leibovitch I, Huilgol SC, Selva D, et al. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol 2005; 53:452. </LI>&#xD;&#xA;<LI>Van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs micrographic surgery for basal cell carcinoma of the face: A&nbsp;randomized clinical trial with 10 year follow-up. Eur J&nbsp;Cancer 2014; 50:3011.</LI>&#xD;&#xA;<LI>Leibovitch I, Huilgol SC, Selva D, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005; 53:253. </LI>&#xD;&#xA;<LI>Pugliano-Mauro M, Goldman G. Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma. Dermatol Surg 2010; 36:1544. </LI>&#xD;&#xA;<LI>Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26:976. </LI>&#xD;&#xA;<LI>Snow SN, Gordon EM, Larson PO, et al. Dermatofibrosarcoma protuberans: A report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer 2004; 101:28. </LI>&#xD;&#xA;<LI>Paradisi A, Abeni D, Rusciani A, et al. Dermatofibrosarcoma protuberans: Wide local excision vs. Mohs micrographic surgery. Cancer Treat Rev 2008; 34:728. </LI>&#xD;&#xA;<LI>Ang GC, Roenigk RK, Otley CC, et al. More than 2 decades of treating atypical fibroxanthoma at mayo clinic: What have we learned from 91 patients? Dermatol Surg 2009; 35:765. </LI>&#xD;&#xA;<LI>Davis JL, Randle HW, Zalla MJ, et al. A comparison of Mohs micrographic surgery and wide excision for the treatment of atypical fibroxanthoma. Dermatol Surg 1997; 23:105. </LI>&#xD;&#xA;<LI>Lee KY, Roh MR, Chung WG, Chung KY. Comparison of Mohs micrographic surgery and wide excision for extramammary Paget's Disease: Korean experience. Dermatol Surg 2009; 35:34. </LI>&#xD;&#xA;<LI>O'Connor WJ, Lim KK, Zalla MJ, et al. Comparison of mohs micrographic surgery and wide excision for extramammary Paget's disease. Dermatol Surg 2003; 29:723. </LI>&#xD;&#xA;<LI>Snow SN, Larson PO, Lucarelli MJ, et al. Sebaceous carcinoma of the eyelids treated by mohs micrographic surgery: Report of nine cases with review of the literature. Dermatol Surg 2002; 28:623. </LI>&#xD;&#xA;<LI>Spencer JM, Nossa R, Tse DT, Sequeira M. Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. J Am Acad Dermatol 2001; 44:1004. </LI>&#xD;&#xA;<LI>Leibovitch I, Huilgol SC, Selva D, et al. Microcystic adnexal carcinoma: Treatment with Mohs micrographic surgery. J Am Acad Dermatol 2005; 52:295. </LI>&#xD;&#xA;<LI>Snow S, Madjar DD, Hardy S, et al. Microcystic adnexal carcinoma: Report of 13 cases and review of the literature. Dermatol Surg 2001; 27:401. </LI></OL></div><div id=\"graphicVersion\">Graphic 65604 Version 3.0</div></div></div>"},"65605":{"type":"graphic_diagnosticimage","displayName":"Midshaft greenstick fracture","title":"Midshaft greenstick fracture","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Midshaft greenstick fracture</div><div class=\"cntnt\"><img style=\"width:458px; height:453px;\" src=\"images/EM/65605_Midshaft_greenstick_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 7-year-old child sustained a midforearm greenstick fracture with 35 degrees of angulation but no displacement.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD</div><div id=\"graphicVersion\">Graphic 65605 Version 2.0</div></div></div>"},"65606":{"type":"graphic_figure","displayName":"Bisphosphonate vs pyrophosphate","title":"Structure of bisphosphonates and pyrophosphate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structure of bisphosphonates and pyrophosphate</div><div class=\"cntnt\"><img style=\"width:347px; height:126px;\" src=\"images/ENDO/65606_Bisphosphonate_vs_pyrophosp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bisphosphonates share a P-C-P structure compared with the P-O-P structure of pyrophosphate. The different bisphosphonates vary at the two R groups.</div><div id=\"graphicVersion\">Graphic 65606 Version 2.0</div></div></div>"},"65607":{"type":"graphic_picture","displayName":"Bivalving of torsed ovary 2","title":"A second bivalve of this ovary leads to further release of capsular pressure allowing increased arterial perfusion and thus a less dusky appearance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">A second bivalve of this ovary leads to further release of capsular pressure allowing increased arterial perfusion and thus a less dusky appearance</div><div class=\"cntnt\"><img style=\"width:432px; height:293px;\" src=\"images/OBGYN/65607_Bivalvingoftorsedovary2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ovarian bivalve procedure demonstrates that the ovarian tissue, despite an initially non-viable appearance, can retain perfused and viable tissues. Bivalving may serve as a valuable intra-operative triage tool to assess viability and avoid unnecessary extirpation of viable ovaries.</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 65607 Version 12.0</div></div></div>"},"65608":{"type":"graphic_table","displayName":"Causes of anemia in HIV","title":"Causes of anemia in HIV-infected patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of anemia in HIV-infected patients</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td>Anemia of chronic disease</td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Infections\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Sepsis/bacteremia\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Bone marrow infiltration\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Disseminated fungal infections\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist3\">\n   Histoplasmosis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist3\">\n   Penicillium marneffei\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist3\">\n   Pneumocystis jiroveci\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Disseminated mycobacterial infections\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist3\">\n   Mycobacterium tuberculosis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist3\">\n   Mycobacterium avium intracellulare complex\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist3\">\n   Other non-tuberculous mycobacteria\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Visceral leishmaniasis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Viral infections\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Parvovirus B19\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Cytomegalovirus\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Epstein Barr virus (EBV)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Human immunodeficiency virus (HIV)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Malignancy/bone marrow involvement\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Non-Hodgkin lymphoma\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Hodgkin lymphoma\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Castleman's disease\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Kaposi's sarcoma (rare)\n   </td>\n   </tr>\n   <tr>\n   <td>Autoimmune hemolytic anemia</td>\n   </tr>\n   <tr>\n   <td>Hypersplenism</td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Megaloblastic anemia\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Vitamin B12 or folate deficiency\n   </td>\n   </tr>\n   <tr>\n   <td>Iron deficiency</td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Bleeding\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Gastrointestinal blood loss\n   </td>\n   </tr>\n   <tr>\n   <td>Medications</td>\n   </tr>\n   <tr>\n   <td>Thrombotic thrombocytopenic purpura</td>\n   </tr>\n   <tr>\n   <td>Disseminated intravascular coagulation</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 65608 Version 1.0</div></div></div>"},"65609":{"type":"graphic_picture","displayName":"Preauricular cyst","title":"Preauricular pit","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Preauricular pit</div><div class=\"cntnt\"><img style=\"width:378px; height:389px;\" src=\"images/PEDS/65609_Preauricular_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This histologic specimen demonstrates a preauricular pit with cyst (s). Note the proximity of the cyst to the cartilage at the root of the helix (c).</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 65609 Version 1.0</div></div></div>"},"65610":{"type":"graphic_figure","displayName":"Velpeau bandage","title":"Velpeau bandage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Velpeau bandage</div><div class=\"cntnt\"><img style=\"width:432px; height:536px;\" src=\"images/PEDS/65610_Velpeau_bandage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To apply a Velpeau bandage, start as in A and repeat B and C until several layers are applied. The weight of the arm is supported by looping the stockinette over the shoulder and around the elbow.</div><div class=\"graphic_reference\">Reproduced with permission from: Shaw, DC, Heckman, JD. Principles and techniques of splinting musculocutaneous injuries. Emerg Med Clin North Am 1984; 2:391. Copyright &#169;1984 Elsevier.</div><div id=\"graphicVersion\">Graphic 65610 Version 1.0</div></div></div>"},"65611":{"type":"graphic_table","displayName":"Drugs interact theophylline I","title":"Clinically significant drug interactions with theophylline","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinically significant drug interactions with theophylline</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Drug</td>\n\n      <td class=\"subtitle1\">Type of interaction</td>\n\n      <td class=\"subtitle1\">Effect on theophylline serum\nconcentrations or pharmacologic effect</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Adenosine</td>\n\n      <td>Theophylline blocks adenosine receptors</td>\n\n      <td>Higher doses of adenosine may be required to achieve\ndesired anti-arrhythmic effect</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Alcohol</td>\n\n      <td>A single large dose of alcohol (3 ml/kg of whiskey)\ndecreases theophylline clearance for up to 24 hours</td>\n\n      <td>33 percent increase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Allopurinol</td>\n\n      <td>Decreases theophylline clearance at allopurinol doses &#8805;600 mg/day </td>\n\n      <td>25 percent increase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aminoglutethimide</td>\n\n      <td>Increases theophylline clearance by induction of\nmicrosomal enzyme activity</td>\n\n      <td>25 percent decrease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Carbamazepine</td>\n\n      <td>Similar to aminoglutethimide</td>\n\n      <td>30 percent decrease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cimetidine</td>\n\n      <td>Decreases theophylline clearance by inhibiting\ncytochrome P450 1A2</td>\n\n      <td>70 percent increase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ciprofloxacin</td>\n\n      <td>Similar to cimetidine</td>\n\n      <td>40 percent increase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Clarithromycin</td>\n\n      <td>Similar to erythromycin</td>\n\n      <td>25 percent increase </td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Diazepam</td>\n\n      <td colspan=\"1\" rowspan=\"2\">Benzodiazepines increase CNS concentrations of\nadenosine, a potent CNS depressant, while theophylline blocks adenosine\nreceptors</td>\n\n      <td>Larger diazepam doses may be required to produce\ndesired level of sedation</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      \n\n      <td>Discontinuation of theophylline without reduction of\ndiazepam dose may result in respiratory depression</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Disulfiram</td>\n\n      <td>Decreases theophylline clearance by inhibiting\nhydroxylation and demethylation</td>\n\n      <td>50 percent increase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Enoxacin</td>\n\n      <td>Similar to cimetidine</td>\n\n      <td>300 percent increase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ephedrine</td>\n\n      <td>Synergistic CNS effects</td>\n\n      <td>Increased frequency of nausea, nervousness, and insomnia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Erythromycin</td>\n\n      <td>Erythromycin metabolite decreases theophylline\nclearance by inhibiting cytochrome P450 3A3</td>\n\n      <td>35 percent increase. Erythromycin steady-state serum\nconcentrations decrease by a similar amount </td>\n\n    </tr>\n\n    <tr>\n\n      <td>Estrogen</td>\n\n      <td>Estrogen-containing oral contraceptives decrease\ntheophylline clearance in a dose-dependent fashion. The effect of\nprogesterone on theophylline clearance is unknown</td>\n\n      <td>30 percent increase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Flurazepam</td>\n\n      <td>Similar to diazepam</td>\n\n      <td>Similar to diazepam</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fluvoxamine</td>\n\n      <td>Similar to cimetidine</td>\n\n      <td>Similar to cimetidine</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Halothane</td>\n\n      <td>Halothane sensitizes the myocardium to catecholamines;\ntheophylline increases release of endogenous catecholamines</td>\n\n      <td>Increased risk of\nventricular arrhythmias</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Redrawn from Hendeles, L, Jenkins, J, Temple, R, Pharmacotherapy 1995; 15:409.</div><div id=\"graphicVersion\">Graphic 65611 Version 1.0</div></div></div>"},"65613":{"type":"graphic_figure","displayName":"Trends in cigarette smoking","title":"Trends in cigarette smoking among persons ≥18 years old, by gender - United States, 1955-2006","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Trends in cigarette smoking among persons &#8805;18 years old, by gender - United States, 1955-2006</div><div class=\"cntnt\"><img style=\"width:535px; height:304px;\" src=\"images/PULM/65613_Trends_in_cigarette_smoking.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Before 1992, current smokers were defined as persons who reported having smoked &#8805;100 cigarettes during their lifetime and who reported smoking every day or some days.</div><div class=\"graphic_reference\">Data from: Cigarette smoking among adults-United States, 2006. MMWR Morb Mortal Wkly Rep, November 2007.</div><div id=\"graphicVersion\">Graphic 65613 Version 1.0</div></div></div>"},"65614":{"type":"graphic_picture","displayName":"Subcutaneous granuloma annulare - finger","title":"Subcutaneous granuloma annulare","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subcutaneous granuloma annulare</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/65614_Subcut_gran_annul_finger.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple nontender subcutaneous nodules are distorting the shape of the fifth finger in this 10-year-old boy with subcutaneous granuloma annulare.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 65614 Version 5.0</div></div></div>"},"65615":{"type":"graphic_figure","displayName":"Bilirubin and UGT","title":"UDP-glucuronosyltransferases (UGT)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">UDP-glucuronosyltransferases (UGT)</div><div class=\"cntnt\"><img style=\"width:349px; height:217px;\" src=\"images/GAST/65615_Bilirubin_and_UGT.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65615 Version 1.0</div></div></div>"},"65618":{"type":"graphic_movie","displayName":"Long axis echo HCM","title":"Parasternal long axis echocardiogram in a patient with hypertrophic cardiomyopathy (HCM)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal long axis echocardiogram in a patient with hypertrophic cardiomyopathy (HCM)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/65618_palaxhcmconv.mp4\" style=\"width:383px;height:276px\"></div><img style=\"width:430px; height:226px;\" src=\"images/CARD/65618_palaxhcm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parasternal view from a two-dimensional echocardiogram of a patient with a hypertrophic cardiomyopathy shows a very thick interventricular septum (IVS) and thickened mitral valve (MV) leaflets. During systole, there is systolic anterior movement of MV leaflet, which is in contact with the septum and obstructs left ventricular (LV) outflow.</div><div class=\"graphic_footnotes\">Ao: aortic root; LV: left ventricle; LA: left atrium.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 65618 Version 4.0</div></div></div>"},"65619":{"type":"graphic_waveform","displayName":"Right bundle branch block 1","title":"Complete right bundle branch block","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Complete right bundle branch block</div><div class=\"cntnt\"><img style=\"width:488px; height:142px;\" src=\"images/CARD/65619_Complete_RBBB_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The initial myocardial activation is normal; thus, there is a normal septal q wave in leads 1 and V6, followed by a tall R wave. Similarly, there is a normal initial septal R wave followed by a deep S wave in leads aVR and V1. However, the subsequent abnormal right ventricular activation occurs from left to right and goes through the ventricular myocardium instead of the His-Purkinje system; thus, there will be a tall and broad secondary R wave (R') in leads aVR and V1 (a RSR' complex), and a deep and broad S wave in leads I and V6. The width of the QRS complex is &gt;0.12 sec.</div><div id=\"graphicVersion\">Graphic 65619 Version 4.0</div></div></div>"},"65622":{"type":"graphic_figure","displayName":"CVS PI","title":"Chorionic villus sampling (CVS)","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Chorionic villus sampling (CVS)</div><div class=\"cntnt\"><img style=\"width:528px; height:337px;\" src=\"images/PI/65622_CVS_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chorionic villus sampling (CVS) can be done in one of two ways. In transcervical CVS (shown on left), the doctor inserts a tube in through the vagina to take the sample of placenta, which is also called the \"chorionic villus.\" In transabdominal CVS (shown on right), the doctor inserts a needle straight into the belly. In both cases, the doctor uses ultrasound images to guide where the tube or needle goes.</div><div id=\"graphicVersion\">Graphic 65622 Version 3.0</div></div></div>"},"65624":{"type":"graphic_figure","displayName":"Survival retransplantation","title":"One-year survival after retransplantation is related to the transplant interval","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">One-year survival after retransplantation is related to the transplant interval</div><div class=\"cntnt\"><img style=\"width:506px; height:296px;\" src=\"images/CARD/65624_Survivalretransplantation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A review of 514 patients who underwent retransplantation found that the one-year survival after retransplantation is significantly lower when the interval between the initial transplantation and retransplantation is &lt;2 years (60&nbsp;versus 75 percent for an interval &gt;2 years).</div><div class=\"graphic_reference\">Data from Srivastava R, Keck BM, Bennett LE, Hosenpud JD. Transplantation 2000; 70:606.</div><div id=\"graphicVersion\">Graphic 65624 Version 2.0</div></div></div>"},"65625":{"type":"graphic_table","displayName":"Heat stroke versus heat exhaustion","title":"Clinical features of heat stroke and heat exhaustion*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of heat stroke and heat exhaustion*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Heat stroke</td> <td class=\"subtitle1\">Heat exhaustion</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Core body temperature</strong></td> <td>&#62;40&#176;C (104&#176;F)<sup>&#916;</sup></td> <td>&#8804;40&#176;C (104&#176;F)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Mental status</strong></td> <td>Abnormal mental status (eg, obtunded, coma, delirium, hallucinations, seizures, ataxia, slurred speech)</td> <td>Normal mental status, dizziness, or mild confusion that rapidly normalizes within 30 minutes of treatment. May see syncope with rapid recovery of alertness.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Airway and breathing</strong></td> <td>May be compromised due to altered mental status, tachypneic</td> <td>Clear airway, may be tachypneic</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Circulation</strong></td> <td>Tachycardia with hypotension, moderate to severe dehydration</td> <td>Tachycardia with normal blood pressure, mild to moderate dehydration</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Skin findings</strong></td> <td>Dry skin (classic heat stroke) or sweating (exertional heat stroke)</td> <td>Sweating</td> </tr> <tr> <td><strong>Other clinical features</strong></td> <td> <ul> <li>Vomiting </li> <li>Diarrhea </li> <li>Clinical and laboratory findings of DIC, rhabdomyolysis, acute renal failure, cardiogenic shock, and liver failure </li> </ul> </td> <td> <ul> <li>Nausea, vomiting </li> <li>Headache </li> <li>Fatigue, weakness </li> <li>In some patients, hyponatremia or hypernatremia </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For a discussion of treatment refer to UpToDate topics on heat illness in children.<br />&Delta; Some patients with heat stroke may have a core body temperature &lt;40&deg;C (104&deg;F) if cooling measures were initiated in the prehospital setting.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Jardine DS. Heat illness and heat stroke. Pediatr Rev 2007; 28:249.</li>&#xD;&#xA;    <li>Glazer JL. Management of heatstroke and heat exhaustion. Am Fam Physician 2005; 71:2133.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 65625 Version 6.0</div></div></div>"},"65626":{"type":"graphic_table","displayName":"Paclitaxel and carboplatin chemotherapy for EOC","title":"Paclitaxel and carboplatin chemotherapy for advanced epithelial ovarian cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Paclitaxel and carboplatin chemotherapy for advanced epithelial ovarian cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.<br /> <strong>Total cycles:</strong> 6 (in first-line setting). </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Paclitaxel</td> <td>175 mg/m<sup>2</sup> IV</td> <td>Dilute in 1000 mL normal saline (NS) or 5% dextrose in water (D5W) and administer over three hours.*</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Carboplatin</td> <td>AUC<sup>&#182;</sup> = 6<sup>&#916;</sup> mg/mL per min IV</td> <td>Dilute in 250 mL NS or D5W and administer over 30 minutes (administer after the completion of the paclitaxel infusion).</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE (30 to 90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula.<sup>&#182;</sup> A lower starting dose of paclitaxel may be needed in patients with liver impairment.</li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Dosing of anticancer agents in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Paclitaxel may cause severe hypersensitivity reactions. Premedication regimen should include dexamethasone (either 20 mg orally 12 and 6 hours before, or 20 mg IV 30 minutes before drug administration) plus both an H1 (diphenhydramine 25 to 50 mg IV) and an H2 receptor antagonist (ranitidine 50 mg or famotidine 20 mg IV) 30 to 60 minutes prior to paclitaxel administration.<sup>[2]</sup> Severe infusion reactions (eg, skin rash, flushing, dyspnea, urticaria, back pain, hypotension, chest pain, tachycardia) occur primarily during the first and second infusions, typically within the first hour after the start of the infusion. Further information on infusion reactions, including management, is available. Carboplatin is also associated with infusion reactions. However, they usually occur after six cycles, and no specific premedication regimen is recommended. Further information on infusion reactions, including skin testing and desensitization, is available.</li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Paclitaxel can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Serum electrolytes and liver and renal function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Treatment with paclitaxel and carboplatin should be delayed until the absolute neutrophil count is &#62;1500/microL and platelet count is &#62;100,000/microL.<sup>[2,3]</sup> If a patient developed severe neutropenia (&#60;500/microL) for a week or longer, or febrile neutropenia during the prior course, then the paclitaxel and carboplatin doses should be reduced by 20 to 25% for subsequent courses or initiation of hematopoietic growth factor support. Both the carboplatin and paclitaxel doses should be decreased by 25% in patients whose platelet count nadir is &#60;25,000/microL for longer than five days. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For patients who develop severe neuropathy (grade 3 or 4) for a week or longer, then the dose of paclitaxel should be reduced by 20% for subsequent courses.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Alterations in renal function during therapy may require a recalculation of the carboplatin dose. Paclitaxel dose may need to be adjusted for hepatic impairment on day 1 of each cycle. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; GFR: glomerular filtration rate.<br />* Paclitaxel can be administered in NS, D5W, or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.<br />¶ AUC (area under the concentration × time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) × (GFR + 25). If an estimated GFR based upon measured serum creatinine is used in the Calvert equation, and renal function is normal, clinicians should consider capping the GFR at 125 mL/min, at least for the first dose. This recommendation does not apply if the GFR is directly measured. Refer to UpToDate topic on \"Dosing of anticancer agents in adults\", section on carboplatin.<br />Δ Many clinicians use a slightly higher carboplatin dose (AUC 7.5 mg/mL × min) for patients with a good performance status.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Bolis G, et al. J Clin Oncol 2004; 22:686.</LI>&#xD;&#xA;<LI>Paclitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 8, 2011).</LI>&#xD;&#xA;<LI>Carboplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 8, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 65626 Version 27.0</div></div></div>"},"65630":{"type":"graphic_figure","displayName":"Urinary anatomy child PI","title":"Anatomy of the urinary tract in children","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Anatomy of the urinary tract in children</div><div class=\"cntnt\"><img style=\"width:542px; height:402px;\" src=\"images/PI/65630_UrinaryanatomypediPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These drawings show the parts of the urinary tract in a girl and a boy. Urine is made by the kidneys. It passes from the kidneys into the bladder through two tubes called the ureters. Then it leaves the bladder through another tube, called the urethra.</div><div id=\"graphicVersion\">Graphic 65630 Version 5.0</div></div></div>"},"65631":{"type":"graphic_figure","displayName":"M mode mitral stenosis II","title":"Mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral stenosis</div><div class=\"cntnt\"><img style=\"width:261px; height:189px;\" src=\"images/CARD/65631_M_mode_mitral_stenosis_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">M-mode echocardiogram of severe mitral stenosis shows concordant motion of anterior and posterior mitral valve (MV) leaflets which are thickened. The E-F slope is flat, resulting from very elevated left atrial pressure throughout diastole, suggesting a marked gradient across the mitral valve.</div><div class=\"graphic_reference\">Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.</div><div id=\"graphicVersion\">Graphic 65631 Version 3.0</div></div></div>"},"65634":{"type":"graphic_figure","displayName":"Cavernous sinus anatomy","title":"Anatomy of the cavernous sinus and surrounding nerves and vessels","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Anatomy of the cavernous sinus and surrounding nerves and vessels</div><div class=\"cntnt\"><img style=\"width:568px; height:432px;\" src=\"images/ID/65634_Cavernous_sinus_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CN: Cranial nerve</div><div id=\"graphicVersion\">Graphic 65634 Version 2.0</div></div></div>"},"65636":{"type":"graphic_figure","displayName":"Continuous wave Doppler MV area","title":"Calculation of mitral valve area from continuous wave Doppler","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calculation of mitral valve area from continuous wave Doppler</div><div class=\"cntnt\"><img style=\"width:395px; height:261px;\" src=\"images/CARD/65636_ContinuouswaveDopplerMV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mitral valve area can be obtained from the continuous wave Doppler by calculating the time required for the opening pressure to reach one half of its value (P 1/2); this is called P 1/2 time and is calculated as shown. By regression analysis, a critically stenotic valve measuring 1 cm<SUP>2</SUP> has a pressure half time of 220 ms; the valve area can be calculated as shown above.</div><div id=\"graphicVersion\">Graphic 65636 Version 5.0</div></div></div>"},"65637":{"type":"graphic_table","displayName":"Cystic fibrosis basic and expanded screening panels","title":"Basic and expanded screening panels for cystic fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic and expanded screening panels for cystic fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Standard or basic mutation panel</td> </tr> <tr> <td class=\"indent1\">&#916;F508, &#916;I507, G542X, G551D, W1282X, N1303K, R553X, 621+1G&#62;T, R117H, 1717-1G&#62;A, A455E, R560T, R1162X, G85E, R334W, R347P, 711+1G&#62;T, 1898+1G&#62;A, 2184delA, 3849+10kbC&#62;T, 2789+5G&#62;A, 3659delC, 3120+1G&#62;A</td> </tr> <tr> <td class=\"subtitle1_single\">Expanded 32 mutation panel</td> </tr> <tr> <td class=\"indent1\">G85E, &#916;I507, R553X, 711+1G&#62;T, 3659delC, R117H, &#916;F508, R560T, 1078delT, 3849+10kbC&#62;T, I148T, V520F, R1162X, 1717-1G&#62;A, 3876delA, R334W, G542X, W1282X, 1898+1G&#62;A, 3905insT, R347P, S549N, N1303K, 2184delA, R347H, S549R, 394delTT, 2789+5G&#62;A, A455E, G551D, 621+1G&#62;T, 3120+1G&#62;A</td> </tr> <tr> <td class=\"subtitle1_single\">Reflex tests</td> </tr> <tr> <td class=\"indent1\">I506V*, I507V*, F508C*, 5T/7T/9T<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CF: cystic fibrosis.<br />* Benign variants. This test distinguishes between the ΔF508 CF mutation and these benign variants. I506V, I507V, and F508C testing is performed only as reflex tests for unexpected homozygosity for ΔF508 and/or ΔI507.<br />¶ 5T/7T/9T analysis is performed only when R117H is detected, for the following reasons: The R117H mutation can result in classic CF only if there is a 5T variant on the same chromosome and another CF mutation on the opposite chromosome. R117H on one chromosome and 5T or 7T on the opposite chromosome, or homozygosity for 5T (5T on each chromosome) can result in congenital bilateral absence of the vas deferens (CBAVD).</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>American College of Medical Genetics. Technical standards and guidelines for CFTR mutation testing. 2006.</LI>&#xD;&#xA;<LI>Committee on Genetics, American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Number 325, December 2005. Update on carrier screening for cystic fibrosis. Obstet Gynecol 2005; 106;1465.</LI></OL></div><div id=\"graphicVersion\">Graphic 65637 Version 5.0</div></div></div>"},"65639":{"type":"graphic_diagnosticimage","displayName":"Intussusception Air contrast II","title":"Intussusception","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intussusception</div><div class=\"cntnt\"><img style=\"width:369px; height:396px;\" src=\"images/GAST/65639_Intussusception_Air_contr1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Air contrast enema in the same patient showing that the intussusception in mid-transverse colon has been reduced to the ascending colon.</div><div class=\"graphic_reference\">Courtesy of Nancy Fitzgerald, MD and Taylor Chung, MD.</div><div id=\"graphicVersion\">Graphic 65639 Version 3.0</div></div></div>"},"65640":{"type":"graphic_table","displayName":"ACC AHA gas exchange exercise","title":"ACC/AHA guideline summary: Exercise testing with ventilatory gas analysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA guideline summary: Exercise testing with ventilatory gas analysis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Class I - There is evidence and/or general agreement that exercise testing with ventilatory gas analysis should be performed in the following settings:\n   </td>\n   </tr>\n   <tr>\n   <td>&#8226;  To evaluate exercise capacity and the response to therapy in patients with heart failure who are being considered for heart transplantation.</td>\n   </tr>\n   <tr>\n   <td>&#8226;  To assist in the differentiation between cardiac and pulmonary causes of exercise-induced dyspnea or impaired exercise capacity when the cause is uncertain.</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Class IIa - The weight of evidence or opinion is in favor of the usefulness of exercise testing with ventilatory gas analysis in the following setting:\n   </td>\n   </tr>\n   <tr>\n   <td>&#8226;  To evaluate exercise capacity when indicated for medical reasons when estimated exercise capacity from exercise test time or work rate is unreliable.</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Class IIb - The weight of evidence or opinion is less well established for the usefulness of exercise testing with ventilatory gas analysis in the following settings:\n   </td>\n   </tr>\n   <tr>\n   <td>&#8226;  To evaluate the response to specific therapeutic interventions when improvement in exercise tolerance is important goal or end point.</td>\n   </tr>\n   <tr>\n   <td>&#8226;  To determine the intensity for exercise training as part of comprehensive cardiac rehabilitation.</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Class III - There is evidence and/or general agreement that exercise testing with ventilatory gas analysis is not useful in the following setting:\n   </td>\n   </tr>\n   <tr>\n   <td>&#8226;  Routine use to assess exercise capacity.</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Data from Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.</div><div id=\"graphicVersion\">Graphic 65640 Version 2.0</div></div></div>"},"65642":{"type":"graphic_figure","displayName":"Alpha and beta globin gene clusters","title":"Alpha and beta globin gene clusters","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Alpha and beta globin gene clusters</div><div class=\"cntnt\"><img style=\"width:496px; height:254px;\" src=\"images/HEME/65642_Globin_gene_clusters.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the human&nbsp;beta globin gene cluster on chromosome 11&nbsp;(upper panel) and alpha&nbsp;globin gene cluster&nbsp;on chromosome 16&nbsp;(lower panel). These illustrate the position of the globin genes, the locus control region (LCR) for the beta globin gene cluster, and hypersensitive sites for the beta globin gene cluster (HS 1 to 5) and the alpha gene cluster (HS-40). After birth, the&nbsp;active genes&nbsp;in the beta globin gene cluster are those for G-gamma, A-gamma, delta, and beta globin; the genes active after birth in the alpha globin gene cluster are alpha-2 and alpha-1. Shown between the two panels is hemoglobin A (HbA), a tetramer of two beta globin chains and two alpha globin chains.</div><div class=\"graphic_reference\">Figure originally&nbsp;drawn by Dr. Ross Hardison and reproduced with permission from the <A spellcheck=true href=\"http://globin.cse.psu.edu/\" target=_blank>Globin Gene Server</A>, which can be found at: <A spellcheck=true href=\"http://globin.cse.psu.edu/html/images.html\" target=_blank>http://globin.cse.psu.edu/html/images.html</A>.</div><div id=\"graphicVersion\">Graphic 65642 Version 6.0</div></div></div>"},"65643":{"type":"graphic_table","displayName":"Comparison of UIP and DIP","title":"Comparison of UIP and DIP","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of UIP and DIP</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">UIP</td>\n\n      <td class=\"subtitle1\">DIP</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mean age</td>\n\n      <td>50.9 yrs</td>\n\n      <td>42.3 yrs</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cigarette smokers</td>\n\n      <td>71 percent</td>\n\n      <td>90 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Abnormal CXR</td>\n\n      <td class=\"sublist_other_start\">92.4 percent</td>\n\n      <td class=\"sublist_other_start\">77.5 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Low volumes</td>\n\n      <td class=\"sublist_other\">45.0 percent</td>\n\n      <td class=\"sublist_other\">23.0 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Honeycombing</td>\n\n      <td class=\"sublist_other\">49.1 percent</td>\n\n      <td class=\"sublist_other\">12.5 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Mean severity</td>\n\n      <td class=\"sublist_other\">2/3</td>\n\n      <td class=\"sublist_other\">1/2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mortality</td>\n\n      <td>66.0 percent</td>\n\n      <td>27.5 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mean survival</td>\n\n      <td>5.6 &plusmn; 3.7 yrs</td>\n\n      <td>12.2 &plusmn; 5.5 yrs</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data summarized from Carrington, C, Gaensler, E, Coutu, R, et al, N Engl J Med 1978; 298:801.</div><div id=\"graphicVersion\">Graphic 65643 Version 1.0</div></div></div>"},"65644":{"type":"graphic_diagnosticimage","displayName":"Proximal PA interrupt II","title":"Proximal interruption of the right pulmonary artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proximal interruption of the right pulmonary artery</div><div class=\"cntnt\"><img style=\"width:360px; height:343px;\" src=\"images/PULM/65644_Proximal_PA_interrupt_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pulmonary arteriogram demonstrates the filling of the left pulmonary artery, yet also shows the absence of the right pulmonary artery.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 65644 Version 2.0</div></div></div>"},"65645":{"type":"graphic_table","displayName":"Conditions associated with malignant hyperthermia","title":"Conditions associated with malignant hyperthermia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with malignant hyperthermia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"20%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Condition</td> <td class=\"subtitle1\" rowspan=\"2\">Clinical features</td> <td class=\"subtitle1\" rowspan=\"2\">Problems with anesthetics</td> <td class=\"subtitle1\" rowspan=\"2\">Inheritance</td> <td class=\"subtitle1\" colspan=\"2\">Recommendations</td> </tr> <tr> <td class=\"subtitle2\">Volatile anesthetics</td> <td class=\"subtitle2\">Succinylcholine</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Myopathies</td> </tr> <tr> <td class=\"indent2\">Central core myopathy<sup>[1-5]</sup></td> <td>Hypotonia in infancy, delayed motor development, proximal lower-limb muscle weakness, associated musculoskeletal abnormalities</td> <td>RYR1 receptor abnormality; high incidence of MHS</td> <td>Autosomal dominant with variable penetrance</td> <td>Contraindicated</td> <td>Contraindicated</td> </tr> <tr> <td class=\"indent2\">Multicore myopathy<sup>[6]</sup></td> <td>Similar to central core myopathy</td> <td>RYR1 receptor abnormalities; high incidence of MHS</td> <td>Autosomal recessive</td> <td>Contraindicated</td> <td>Contraindicated</td> </tr> <tr> <td class=\"indent2\">King-Denborough syndrome<sup>[7,8]</sup></td> <td>Hypotonia at birth, mild proximal muscle weakness, delayed motor development, dysmorphic facial features (ptosis, low-set ears, malar hypoplasia, micrognathia, and a high-arched palate), pectus excavatum, winged scapulae, lumbar lordosis and thoracic scoliosis</td> <td>RYR1 receptor abnormality; high incidence of MHS</td> <td>Autosomal recessive</td> <td>Contraindicated</td> <td>Contraindicated</td> </tr> <tr> <td class=\"indent2\">Native American myopathy<sup>[9]</sup></td> <td>Affects Lumbee Indians of North Carolina; congenital weakness, arthrogryposis, cleft palate, ptosis, short stature, kyphoscoliosis</td> <td>High incidence of MHS</td> <td>Autosomal recessive</td> <td>Contraindicated</td> <td>Contraindicated</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Conditions associated with rhabdomyolysis</td> </tr> <tr> <td class=\"indent2\">Exertional rhabdomyolysis<sup>[10-15]</sup></td> <td>Extreme exercise and/or hot/humid conditions leading to muscle injury (increased CK, hyperkalemia, myoglobinemia, myoglobinuria)</td> <td>Some individuals have RYR1 receptor abnormalities; increased incidence of MHS</td> <td>Unknown; heterogenous condition</td> <td>No</td> <td>No</td> </tr> <tr> <td class=\"indent2\">Dystrophinopathies<sup>[16-27]</sup></td> <td>Progressive weakness from about age two years, dilated cardiomyopathy, conduction abnormalities. While this clinical syndrome can closely resemble acute MH and is related to abnormal calcium release in the muscle, the etiology is thought to be different. Some experts recommend administration of non-triggering anesthetics to these patients; however, many patients with dystrophinopathies have received halogenated volatile agents safely.</td> <td>Severe hyperkalemia from upregulated acetylcholine receptors following succinylcholine; possible rhabdomyolysis following volatile anesthetics</td> <td> <p>Duchenne: X-linked recessive</p> Becker: X-linked recessive</td> <td>Only if essential, in limited amounts</td> <td>Contraindicated</td> </tr> <tr> <td class=\"indent2\">Myoadenylate deaminase deficiency<sup>[28]</sup></td> <td>Muscles cramps, elevated CK levels (baseline and increased after exercise), and occasionally rhabdomyolysis</td> <td>May develop rhabdomyolysis</td> <td>Autosomal recessive</td> <td>Try to avoid</td> <td>Try to avoid</td> </tr> <tr> <td class=\"indent2\">McArdle disease (muscle phosphorylase deficiency, glycogen storage disease V)<sup>[29,30]</sup></td> <td>Muscle cramping, exercise intolerance, rhabdomyolysis</td> <td>May exacerbate underlying symptoms</td> <td>Autosomal recessive</td> <td>Try to avoid</td> <td>Try to avoid</td> </tr> <tr> <td class=\"indent2\">Carnitine palmitoyl transferase type 2 deficiency<sup>[31,32]</sup></td> <td>Muscle weakness or cramps and exercise intolerance sometimes associated with rhabdomyolysis</td> <td>Perioperative rhabdomyolysis</td> <td>Autosomal recessive</td> <td>Try to avoid</td> <td>Try to avoid</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Other conditions</td> </tr> <tr> <td class=\"indent2\">Osteogenesis imperfecta<sup>[33-37]</sup></td> <td>Multiple fractures with minimal or no trauma</td> <td>Some reports of fever with anesthesia</td> <td>Inherited connective tissue disorder</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td class=\"indent2\">Arthrogryposis multiplex congenita<sup>[38-40]</sup></td> <td>Congenital joint contractures; occurs in a variety of inherited neurogenic or myogenic syndromes</td> <td>Some reports of fever with anesthesia</td> <td>Heterogenous disorders</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td class=\"indent2\">Myotonia<sup>[41,42]</sup></td> <td>Incomplete muscle relaxation, weakness</td> <td>Exposure to succinylcholine or anticholinesterase (reversal agent) may induce prolonged muscle rigidity</td> <td>Heterogenous disorders</td> <td>Yes</td> <td>Avoid succinylcholine or anticholinesterase reversal agents</td> </tr> <tr> <td class=\"indent2\">Neuroleptic malignant syndrome<sup>[43-47]</sup></td> <td>Muscular rigidity, hyperthermia, mental status change, autonomic instability, rhabdomyolysis, and acidosis</td> <td>May be triggered by neuroleptics used as antiemetics (dopamine antagonists), usually &#62;24 hours after administration</td> <td>Unclear</td> <td>Yes</td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RYR1: ryanodine; MHS: susceptible to malignant hyperthermia.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Quane QA, Healy JM, Manning BM, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 1993; 5:51.</li>&#xD;&#xA;    <li>Brandt A, Schleithoff L, Jurkat-Rott K, et al. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Hum Mol Genet 1999; 8:2055.</li>&#xD;&#xA;    <li>Sewry CA, Muller C, Davis M, et al. The spectrum of pathology in central core disease. Neuromuscul Disord 2002; 12:930.</li>&#xD;&#xA;    <li>Klingler W, Rueffert H, Lehmann-Horn F, et al. Core myopathies and risk of malignant hyperthermia. Anesth Analg 2009; 109:1167.</li>&#xD;&#xA;    <li>Zhang Y, Chen HS, Khanna VK, et al. A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 1993; 5:46.</li>&#xD;&#xA;    <li>Guis S, Figarella-Branger D, Monnier N, et al. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol 2004; 61:106.</li>&#xD;&#xA;    <li>Denborough M. Malignant hyperthermia. Lancet 1998; 352:1131.</li>&#xD;&#xA;    <li>D'Arcy CE, Bjorksten A, Yiu EM, et al. King-denborough syndrome caused by a novel mutation in the ryanodine receptor gene. Neurology 2008; 71:776.</li>&#xD;&#xA;    <li>Stamm DS, Aylsworth AS, Stajich JM, et al. Native American myopathy: congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia. Am J Med Genet A 2008; 146A:1832.</li>&#xD;&#xA;    <li>Tobin JR, Jason DR, Challa VR, et al. Malignant hyperthermia and apparent heat stroke. JAMA 2001; 286:168.</li>&#xD;&#xA;    <li>Denborough M, Hopkinson KC, O'Brien RO, Foster PS. Overheating alone can trigger malignant hyperthermia in piglets. Anaesth Intensive Care 1996; 24:348.</li>&#xD;&#xA;    <li>Chelu MG, Goonasekera SA, Durham WJ, et al. Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse. FASEB J 2006; 20:329.</li>&#xD;&#xA;    <li>Capacchione JF, Muldoon SM. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth Analg 2009; 109:1065.</li>&#xD;&#xA;    <li>Kochling A, Wappler F, Winkler G, Schulte am Esch JS. Rhabdomyolysis following severe physical exercise in a patient with predisposition to malignant hyperthermia. Anaesth Intensive Care 1998; 26:315.</li>&#xD;&#xA;    <li>Wappler F, Fiege M, Steinfath M, et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 2001; 94:95.</li>&#xD;&#xA;    <li>Bush A, Dubowitz V. Fatal rhabdomyolysis complicating general anaesthesia in a child with Becker muscular dystrophy. Neuromuscul Disord 1991; 1:201.</li>&#xD;&#xA;    <li>Tang TT, Oechler HW, Siker D, et al. Anesthesia-induced rhabdomyolysis in infants with unsuspected Duchenne dystrophy. Acta Paediatr 1992; 81:716.</li>&#xD;&#xA;    <li>Obata R, Yasumi Y, Suzuki A, et al. Rhabdomyolysis in association with Duchenne's muscular dystrophy. Can J Anaesth 1999; 46:564.</li>&#xD;&#xA;    <li>Kerr TP, Duward A, Hodgson SV, et al. Hyperkalaemic cardiac arrest in a manifesting carrier of Duchenne muscular dystrophy following general anaesthesia. Eur J Pediatr 2001; 160:579.</li>&#xD;&#xA;    <li>Girshin M, Mukherjee J, Clowney R, et al. The postoperative cardiovascular arrest of a 5-year-old male: an initial presentation of Duchenne's muscular dystrophy. Paediatr Anaesth 2006; 16:170.</li>&#xD;&#xA;    <li>Kleopa KA, Rosenberg H, Heiman-Patterson T. Malignant hyperthermia-like episode in Becker muscular dystrophy. Anesthesiology 2000; 93:1535.</li>&#xD;&#xA;    <li>Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51:919.</li>&#xD;&#xA;    <li>Larach MG, Rosenberg H, Gronert GA, Allen GC. Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies. Clin Pediatr (Phila) 1997; 36:9.</li>&#xD;&#xA;    <li>Goresky GV, Cox RG. Inhalation anesthetics and Duchenne's muscular dystrophy. Can J Anaesth 1999; 46:525.</li>&#xD;&#xA;    <li>Boba A. Fatal postanesthetic complications in two muscular dystrophic patients. J Pediatr Surg 1970; 5:71.</li>&#xD;&#xA;    <li>Kelfer HM, Singer WD, Reynolds RN. Malignant hyperthermia in a child with Duchenne muscular dystrophy. Pediatrics 1983; 71:118.</li>&#xD;&#xA;    <li>Gurnaney H, Brown A, Litman RS. Malignant hyperthermia and muscular dystrophies. Anesth Analg 2009; 109:1043.</li>&#xD;&#xA;    <li>Fricker RM, Raffelsberger T, Rauch-Shorny S, et al. Positive malignant hyperthermia susceptibility in vitro test in a patient with mitochondrial myopathy and myoadenylate deaminase deficiency. Anesthesiology 2002; 97:1635.</li>&#xD;&#xA;    <li>Lobato EB, Janelle GM, Urdaneta F, Malias MA. Noncardiogenic pulmonary edema and rhabdomyolsis after protamine administration in a patient with unrecognized McArdle's disease. Anesthesiology 1999; 91:303.</li>&#xD;&#xA;    <li>Bollig G, Mohr S, Raeder J. McArdle's disease and anaesthesia: case reports. Review of potential problems and association with malignant hyperthermia. Acta Anaesthesiol Scand 2005; 49:1077.</li>&#xD;&#xA;    <li>Katsuya H, Misumi M, Ohtani Y, Miike T. Postanesthetic acute renal failure due to carnitine palmityl transferase deficiency. Anesthesiology 1988; 68:945.</li>&#xD;&#xA;    <li>Hogan KJ, Vladutiu GD. Malignant hyperthermia-like syndrome and carnitine palmitoyltransferase II deficiency with heterozygous R503C mutation. Anesth Analg 2009; 109:1070.</li>&#xD;&#xA;    <li>Ryan CA, Al-Ghamdi AS, Gayle M, Finer NN. Osteogenesis imperfecta and hyperthermia. Anesth Analg 1989; 68:811.</li>&#xD;&#xA;    <li>Bojanic K, Kivela JE, Guerrieri C, et al. Perioperative course and intraoperative temperatures in patients with osteogenesis imperfecta. Eur J Anaesthesiol 2011; 28:370.</li>&#xD;&#xA;    <li>Rampton AJ, Kelly DA, Shanahan EC, Ingram GS. Occurrence of malignant hyperpyrexia in a patient with osteogenesis imperfecta. Br J Anaesth 1984; 56:1443.</li>&#xD;&#xA;    <li>Porsborg P, Astrup G, Bendixen D, et al. Osteogenesis imperfecta and malignant hyperthermia. Is there a relationship?. Anaesthesia 1996; 51:863.</li>&#xD;&#xA;    <li>Martin S, Tobias JD. Perioperative care of the child with arthrogryposis. Paediatr Anaesth 2006; 16:31.</li>&#xD;&#xA;    <li>Baines DB, Douglas ID, Overton JH. Anaesthesia for patients with arthrogryposis multiplex congenita: what is the risk of malignant hyperthermia?. Anaesth Intensive Care 1986; 14:370.</li>&#xD;&#xA;    <li>Hopkins PM, Ellis FR, Halsall PJ. Hypermetabolism in arthrogryposis multiplex congenita. Anaesthesia 1991; 46:374.</li>&#xD;&#xA;    <li>Martin S, Tobias JD. Perioperative care of the child with arthrogryposis. Paediatr Anaesth 2006; 16:31.</li>&#xD;&#xA;    <li>Parness J, Bandschapp O, Girard T. The myotonias and susceptibility to malignant hyperthermia. Anesth Analg 2009; 109:1054.</li>&#xD;&#xA;    <li>Buzello W, Krieg N, Schlickewei A. Hazards of neostigmine in patients with neuromuscular disorders. Report of two cases. Br J Anaesth 1982; 54:529.</li>&#xD;&#xA;    <li>Smego RA Jr, Durack DT. The neuroleptic malignant syndrome. Arch Intern Med 1982; 142:1183.</li>&#xD;&#xA;    <li>Caroff SN, Rosenberg H, Fletcher JE, et al. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology 1987; 67:20.</li>&#xD;&#xA;    <li>Ward A, Chaffman MO, Sorkin EM. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986; 32:130.</li>&#xD;&#xA;    <li>Bello N, Adnet P, Saulnier F, et al. [Lack of sensitivity to per-anesthetic malignant hyperthermia in 32 patients who developed neuroleptic malignant syndrome]. Ann Fr Anesth Reanim 1994; 13:663.</li>&#xD;&#xA;    <li>Musselman ME, Saely S. Diagnosis and treatment of drug-induced hyperthermia. Am J Health Syst Pharm 2013; 70:34.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 65645 Version 7.0</div></div></div>"},"65646":{"type":"graphic_picture","displayName":"Stretch for calf muscles and Achilles tendon","title":"Flexibility exercise: Calf muscles and Achilles tendon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flexibility exercise: Calf muscles and Achilles tendon</div><div class=\"cntnt\"><img style=\"width:374px; height:306px;\" src=\"images/PC/65646_Calf_stretch_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Because many people have tight calf muscles, it's important to stretch them. <ol> <li>Stand facing a wall slightly farther than arm's length from the wall, feet shoulder-width apart. </li> <li>Put your palms flat against the wall at shoulder height and shoulder-width apart. </li> <li>Step forward with right leg and bend right knee. Keeping both feet flat on the floor, bend left knee slightly until you feel a stretch in your left calf muscle. It shouldn't feel uncomfortable. If you don't feel a stretch, bend your right knee until you do. </li> <li>Hold position for 10 to 30 seconds, and then return to starting position. </li> <li>Repeat with left leg. </li> <li>Continue alternating legs for at least three to five times on each leg. </li> </ol></div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 65646 Version 3.0</div></div></div>"},"65647":{"type":"graphic_table","displayName":"Risk for high altitude illness","title":"Risk for high altitude illness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk for high altitude illness</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk of HAI</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td rowspan=\"3\">Low</td> <td>No prior history of altitude illness and planning ascent to &#60;2800 m</td> </tr> <tr> <td>Taking two days or more to arrive at 2500 to 3000 m from low altitude</td> </tr> <tr> <td>Ascending no more than 500 m/day (sleeping altitude) once over 2500 m <strong>and</strong> taking one extra day to acclimatize for every additional 1000 m of ascent</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Moderate</td> <td>Prior history of AMS and ascending to 2500 to 2800 m in less than two days</td> </tr> <tr> <td>No history of AMS and ascending to 2800 m or higher in less than two days</td> </tr> <tr> <td>Ascending &#62;500 m/day (increase in sleeping elevation) at altitudes above 3000 m <strong>with</strong> one extra day for acclimatization for every additional 1000 m of ascent</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">High</td> <td>History of severe altitude illness (HACE, HAPE)</td> </tr> <tr> <td>History of AMS and ascending to 2800 m or higher in less than two days</td> </tr> <tr> <td>Ascending over 3500 m in less than two days</td> </tr> <tr> <td>Ascending &#62;500 m/day (increase in sleeping elevation) above 3000 m without extra days for acclimatization; rapid guided ascents (eg, Mt. Kilimanjaro in &#60;7 days)</td> </tr> <tr> <td>Persons with medical conditions predisposing to altitude illness</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">3</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=11624&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Notes:<br> Altitudes listed refer to the altitude at which the person sleeps.<br> Ascent is assumed to begin at low altitude (&lt;1200m).<br> Risk categories are for unacclimatized persons.</div><div class=\"graphic_footnotes\">AMS: acute mountain sickness; HACE: high altitude cerebral edema; HAPE: high altitude pulmonary edema; m: meters.</div><div class=\"graphic_reference\">Adapted&nbsp;from: Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 Update. Wilderness Environ Med 25, S4–S14 (2014). <br /></div><div id=\"graphicVersion\">Graphic 65647 Version 6.0</div></div></div>"},"65648":{"type":"graphic_diagnosticimage","displayName":"Crohns B mode US","title":"Crohn's disease on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crohn's disease on ultrasound</div><div class=\"cntnt\"><img style=\"width:360px; height:281px;\" src=\"images/GAST/65648_Crohns_B_mode_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">B-mode ultrasound image of a patient with ileocecal Crohn's disease showing bowel wall thickening of the cecum with transmural inflammatory reaction. Bowel wall thickening (6 mm) of the hypoechoic mucosa (M), echorich submucosa (SM) and echopoor muscularis propria (Musc) is indicated. The lumen is not seen due to mucosal swelling.</div><div class=\"graphic_reference\">Courtesy of Christoph F Dietrich, MD.</div><div id=\"graphicVersion\">Graphic 65648 Version 3.0</div></div></div>"},"65649":{"type":"graphic_table","displayName":"NCI CTCAE v5 diarrhea","title":"NCI CTCAE v5.0 diarrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 diarrhea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Diarrhea</td> <td>Increase of &#60;4 stools per day over baseline; mild increase in ostomy output compared with baseline</td> <td>Increase of four to six stools per day over baseline; moderate increase in ostomy output compared with baseline; limiting instrumental ADL*</td> <td>Increase of seven or more stools per day over baseline; hospitalization indicated; severe increase in ostomy output compared with baseline; limiting self-care ADL*</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Diarrhea is characterized by an increase in frequency and/or loose or watery bowel movements.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ADL: activities of daily living.<br />* Instrumental ADLs include preparing meals, shopping, using the telephone, managing money. Self-care ADLs include bathing, dressing/undressing, using the toilet, taking medications, and not bedridden.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 65649 Version 10.0</div></div></div>"},"65650":{"type":"graphic_picture","displayName":"Cherry red spot","title":"Macular cherry red spot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Macular cherry red spot</div><div class=\"cntnt\"><img style=\"width:331px; height:309px;\" src=\"images/PEDS/65650_Cherry_red_spot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sphingolipids accumulate in the retinal ganglion cells in the perifoveal area of patients with sphingolipidoses causing the perifoveal area to appear pale. The fovea, which has no ganglion cells, retains its &quot;cherry red&quot; color.</div><div class=\"graphic_reference\">Courtesy of Robert P Cruse, DO.</div><div id=\"graphicVersion\">Graphic 65650 Version 1.0</div></div></div>"},"65651":{"type":"graphic_diagnosticimage","displayName":"Osgood-Schlatter radiographic findings","title":"Osgood-Schlatter radiographic findings","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Osgood-Schlatter radiographic findings</div><div class=\"cntnt\"><img style=\"width:479px; height:325px;\" src=\"images/PEDS/65651_Osgood-Schlatter_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the soft tissue swelling anterior to the tibial tuberosity (before ossification).</div><div class=\"graphic_reference\">Courtesy of Andrew Kienstra, MD.</div><div id=\"graphicVersion\">Graphic 65651 Version 2.0</div></div></div>"},"65653":{"type":"graphic_table","displayName":"Pharmacology benzodiazepines","title":"Pharmacology of benzodiazepines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacology of benzodiazepines</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Adult oral total daily dose (mg)*</td> <td class=\"subtitle1\">Comparative potency (mg)<sup>&#182;</sup></td> <td class=\"subtitle1\">Onset after oral dose (hours)</td> <td class=\"subtitle1\">Metabolism</td> <td class=\"subtitle1\">Elimination half-life (hours)<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Used primarily to treat anxiety symptoms/anxiety disorders</td> </tr> <tr> <td class=\"indent1\">Alprazolam</td> <td>0.5 to 6</td> <td>0.5</td> <td>1</td> <td rowspan=\"2\">CYP3A4 to minimally active metabolites.</td> <td rowspan=\"2\"> <p>11 to 15</p> <p>16 (older adults)</p> <p>20 (hepatic impairment)</p> 22 (obesity)</td> </tr> <tr> <td class=\"indent1\">Alprazolam extended release</td> <td>0.5 to 6 once daily</td> <td>0.5</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Bromazepam<sup>&#9674;</sup></td> <td>6 to 30</td> <td>7.5</td> <td>1</td> <td>CYP1A2. No active metabolite.</td> <td>8 to 20</td> </tr> <tr> <td class=\"indent1\">Chlordiazepoxide</td> <td>5 to 100</td> <td>10</td> <td>1</td> <td>CYP3A4 to active metabolites.</td> <td>30 to 100</td> </tr> <tr> <td class=\"indent1\">Clonazepam</td> <td>0.5 to 4</td> <td>0.25 to 0.5</td> <td>0.5 to 1</td> <td>CYP3A4. No active metabolite.</td> <td>18 to 50</td> </tr> <tr> <td class=\"indent1\">Clorazepate</td> <td>15 to 60</td> <td>7.5</td> <td>0.5 to 1</td> <td>CYP3A4 to active metabolite.</td> <td>36 to 200</td> </tr> <tr> <td class=\"indent1\">Diazepam</td> <td>4 to 40</td> <td>5</td> <td>0.25 to 0.5</td> <td>CYP2C19 and 3A4 to active metabolites.</td> <td> <p>50 to 100</p> Prolonged in older adults and renal or hepatic impairment</td> </tr> <tr> <td class=\"indent1\">Lorazepam</td> <td> <p>0.5 to 6</p> 0.5 to 4 (hypnotic)</td> <td>1</td> <td>0.5 to 1</td> <td>Non-CYP glucuronidation in liver. No active metabolite.</td> <td>10 to 14</td> </tr> <tr> <td class=\"indent1\">Oxazepam</td> <td> <p>30 to 120</p> 15 to 30 (hypnotic)</td> <td>15 to 30</td> <td>1 to 2</td> <td>Non-CYP glucuronidation in liver. No active metabolite.</td> <td>5 to 15</td> </tr> <tr> <td class=\"indent1\">Prazepam<sup>&#9674;</sup></td> <td>15 to 60</td> <td>15</td> <td>2 to 3</td> <td>CYP3A4 to active metabolites.</td> <td> <p>30 to 200</p> Prolonged in older adults</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Used primarily to treat insomnia<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Estazolam</td> <td>1 to 2</td> <td>0.3</td> <td>0.5 to 1</td> <td>CYP3A4 to minimally active metabolite.</td> <td>10 to 24</td> </tr> <tr> <td class=\"indent1\">Flurazepam</td> <td>15 to 30</td> <td>5</td> <td>0.5 to 1</td> <td>CYP3A4 to active metabolites.</td> <td> <p>40 to 114</p> 120 to 160 (older adults)</td> </tr> <tr> <td class=\"indent1\">Nitrazepam<sup>&#9674;</sup></td> <td>5 to 10</td> <td>5</td> <td>0.5 to 1</td> <td>Non-CYP acetylation in liver. No active metabolites.</td> <td> <p>24 to 30</p> 40 (older adults)</td> </tr> <tr> <td class=\"indent1\">Temazepam</td> <td>7.5 to 30</td> <td>5</td> <td>0.5 to 1</td> <td>Primarily non-CYP glucuronidation in liver to minimally active metabolite.</td> <td>8 to 15</td> </tr> <tr> <td class=\"indent1\">Triazolam</td> <td>0.125 to 0.25</td> <td>0.1</td> <td>0.25 to 0.5</td> <td>CYP3A4. No active metabolite.</td> <td>2 to 5</td> </tr> <tr> <td class=\"indent1\">Quazepam</td> <td>7.5 to 15</td> <td>5</td> <td>1</td> <td>CYP3A4 and non-CYP metabolism in liver to active metabolites.</td> <td> <p>28 to 84</p> 190 (older adults)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Data on drug metabolism and activity of metabolite(s) are for assessment of potential for CYP drug interactions and risk of accumulation. Risk of accumulation is greater, and dose reduction necessary, for older or debilitated adults and for patients with renal or hepatic insufficiency.</div><div class=\"graphic_footnotes\">* Range of usual <strong>total</strong> daily dose for treatment of adults with anxiety or panic disorder typically given in divided doses two to four times daily.<br />&para; Important: Data shown are approximate equal potencies relative to lorazepam 1 mg orally and are NOT recommendations for initiation of therapy or for conversion between agents.<br />&Delta; Half-life of parent drug and pharmacologically active metabolite, if any.<br /><span class=\"lozenge\">&loz;</span> Not available in US.<br />&sect; Range of usual hypnotic dose for adults, given at bedtime.</div><div id=\"graphicVersion\">Graphic 65653 Version 10.0</div></div></div>"},"65657":{"type":"graphic_picture","displayName":"Histoplasma oral ulcers","title":"Mucosal ulcers due to histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mucosal ulcers due to histoplasmosis</div><div class=\"cntnt\"><img style=\"width:392px; height:260px;\" src=\"images/ID/65657_Histoplasma_oral_ulcers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulcerative lesions on the oral mucosa in a patient with disseminated histoplasmosis.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt Jr, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Lippincott Williams &amp; Wilkins, Baltimore 1995. p.268.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 65657 Version 7.0</div></div></div>"},"65658":{"type":"graphic_diagnosticimage","displayName":"Pneumococcal pneumonia CXR","title":"Pneumococcal pneumonia chest radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumococcal pneumonia chest radiograph</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/ID/65658_Pneumococcal_pneumonia_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">64-year-old male with insulin-dependent diabetes mellitus. He was admitted with bacteremic pneumococcal pneumonia. Note the left lower lobe opacity.</div><div class=\"graphic_reference\">Courtesy of Thomas J Marrie, MD.</div><div id=\"graphicVersion\">Graphic 65658 Version 3.0</div></div></div>"},"65660":{"type":"graphic_diagnosticimage","displayName":"Stenosis basilic vein","title":"Multiple areas of stenosis affecting the basilic vein","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple areas of stenosis affecting the basilic vein</div><div class=\"cntnt\"><img style=\"width:432px; height:223px;\" src=\"images/NEPH/65660_Stenosis_basilic_vein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As can be seen, the graft extends above the elbow. There is also stenosis at the venous anastomosis. On the left is the post-treatment appearance.</div><div class=\"graphic_reference\">Courtesy of Gerald Beathard, MD.</div><div id=\"graphicVersion\">Graphic 65660 Version 3.0</div></div></div>"},"65661":{"type":"graphic_table","displayName":"Lab findings protein-losing gastroenteropathy","title":"Clinical manifestations and laboratory abnormalities in patients with protein-losing gastroenteropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations and laboratory abnormalities in patients with protein-losing gastroenteropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical manifestations</td> </tr> <tr> <td class=\"indent1\">Edema</td> </tr> <tr> <td class=\"indent1\">Ascites</td> </tr> <tr> <td class=\"indent1\">Pleural effusion</td> </tr> <tr> <td class=\"indent1\">Pericardial effusion</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory abnormalities</td> </tr> <tr> <td class=\"indent1\">Hypoalbuminemia without proteinuria, disorders associated with decreased protein synthesis, or malnutrition</td> </tr> <tr> <td class=\"sublist2_start\">Reduced plasma concentrations of:</td> </tr> <tr> <td class=\"sublist2\">Gamma globulins</td> </tr> <tr> <td class=\"sublist2\">Cholesterol</td> </tr> <tr> <td class=\"sublist2\">Alpha-1 antitrypsin</td> </tr> <tr> <td class=\"sublist2\">Fibrinogen</td> </tr> <tr> <td class=\"sublist2\">Ceruloplasmin</td> </tr> <tr> <td class=\"indent1\">Lymphopenia</td> </tr> <tr> <td class=\"indent1\">Malabsorption of fat and fat-soluble vitamins</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65661 Version 3.0</div></div></div>"},"65662":{"type":"graphic_table","displayName":"Risk death MI unstable angina","title":"Short-term risk of death or nonfatal MI in patients with UA/NSTEMI","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Short-term risk of death or nonfatal MI in patients with UA/NSTEMI</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">High risk (at least one of the following features must be present):</td> </tr> <tr> <td class=\"subtitle2_single\">History:</td> </tr> <tr> <td class=\"indent1\">Accelerating tempo of ischemic symptoms in preceding 48 h</td> </tr> <tr> <td class=\"subtitle2_single\">Character of pain:</td> </tr> <tr> <td class=\"indent1\">Prolonged ongoing (&#62;20 min) rest pain</td> </tr> <tr> <td class=\"subtitle2_single\">Clinical findings:</td> </tr> <tr> <td class=\"indent1\">Pulmonary edema, most likely due to ischemia</td> </tr> <tr> <td class=\"indent1\">New or worsening MR murmur</td> </tr> <tr> <td class=\"indent1\">S<sub>3</sub> or new/worsening rales</td> </tr> <tr> <td class=\"indent1\">Hypotension, bradycardia, tachycardia</td> </tr> <tr> <td class=\"indent1\">Age &#62;75 years</td> </tr> <tr> <td class=\"subtitle2_single\">ECG:</td> </tr> <tr> <td class=\"indent1\">Angina at rest with transient ST-segment changes &#62;0.5 mm</td> </tr> <tr> <td class=\"indent1\">Bundle-branch block, new or presumed new</td> </tr> <tr> <td class=\"indent1\">Sustained ventricular tachycardia</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiac markers:</td> </tr> <tr> <td class=\"indent1\">Elevated cardiac TnT, TnI, or CK-MB (eg, TnT or TnI &#62;0.1 ng per ml)</td> </tr> <tr> <td class=\"subtitle1_single\">Intermediate risk (no high-risk feature but must have one of the following):</td> </tr> <tr> <td class=\"subtitle2_single\">History:</td> </tr> <tr> <td class=\"indent1\">Prior MI, peripheral or cerebrovascular disease, or CABG; prior aspirin use</td> </tr> <tr> <td class=\"subtitle2_single\">Character of pain:</td> </tr> <tr> <td class=\"indent1\">Prolonged (&#62;20 min) rest angina, now resolved, with moderate or high likelihood of CAD</td> </tr> <tr> <td class=\"indent1\">Rest angina (&#62;20 min) or relieved with rest or sublingual NTG</td> </tr> <tr> <td class=\"indent1\">Nocturnal angina</td> </tr> <tr> <td class=\"indent1\">New-onset or progressive CCS class III or IV angina in the past&nbsp;two weeks without prolonged (&#62;20 min) rest pain but with intermediate or high likelihood of CAD</td> </tr> <tr> <td class=\"subtitle2_single\">Clinical findings:</td> </tr> <tr> <td class=\"indent1\">Age &#62;70 years</td> </tr> <tr> <td class=\"subtitle2_single\">ECG:</td> </tr> <tr> <td class=\"indent1\">T-wave changes</td> </tr> <tr> <td class=\"indent1\">Pathological Q waves or resting ST-depression less than 1 mm in multiple lead groups (anterior, inferior, lateral)</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiac markers:</td> </tr> <tr> <td class=\"indent1\">Slightly elevated cardiac TnT, TnI, or CK-MB (eg, TnT greater than 0.01 but less than 0.1 ng per ml)</td> </tr> <tr> <td class=\"subtitle1_single\">Low risk (no high- or intermediate-risk features, but may have any of the following features):</td> </tr> <tr> <td class=\"subtitle2_single\">Character of pain:</td> </tr> <tr> <td class=\"indent1\">Increased angina frequency, severity, or duration</td> </tr> <tr> <td class=\"indent1\">Angina provoked at a lower threshold</td> </tr> <tr> <td class=\"indent1\">New onset angina with onset&nbsp;two weeks to&nbsp;two months prior to presentation</td> </tr> <tr> <td class=\"subtitle2_single\">ECG:</td> </tr> <tr> <td class=\"indent1\">Normal or unchanged ECG</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiac markers:</td> </tr> <tr> <td class=\"indent1\">Normal</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1.</div><div id=\"graphicVersion\">Graphic 65662 Version 2.0</div></div></div>"},"65663":{"type":"graphic_picture","displayName":"ECD skin biopsy","title":"Skin biopsy in Erdheim-Chester disease","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Skin biopsy in Erdheim-Chester disease</div><div class=\"cntnt\"><img style=\"width:585px; height:245px;\" src=\"images/HEME/65663_ECD_skin_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Left temporal lesion showed dermal infiltration of foamy histiocytes with giant cells (H&amp;E, x100).<br> (B) Scalp lesion also showed infiltrating histiocytes and multiple Touton-type giant cells with dermal fibrosis (H&amp;E, x100).</div><div class=\"graphic_reference\">Reproduced with permission from: Kim MS, Kim CH, Choi SJ, et al. Erdheim-Chester disease. Ann Dermatol 2010; 22:439. Copyright &#169; 2010 Korean Dermatological Association.</div><div id=\"graphicVersion\">Graphic 65663 Version 1.0</div></div></div>"},"65664":{"type":"graphic_figure","displayName":"Left hemicolectomy for a benign process","title":"Left hemicolectomy for a benign process","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left hemicolectomy for a benign process</div><div class=\"cntnt\"><img style=\"width:434px; height:544px;\" src=\"images/SURG/65664_Left-hemi--benign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a resection of the left colon for a benign process, such as colitis. The mesentery is not resected at its root, and care must be taken to anastomose the bowel in areas of adequate blood supply.</div><div id=\"graphicVersion\">Graphic 65664 Version 2.0</div></div></div>"},"65666":{"type":"graphic_figure","displayName":"Morton neuroma","title":"Morton neuroma","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Morton neuroma</div><div class=\"cntnt\"><img style=\"width:492px; height:480px;\" src=\"images/EM/65666_Morton_neuroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Symptoms of a Morton neuroma include hyperesthesia of the toes, numbness and tingling, and aching and burning in the distal forefoot. Pain radiates forward from the metatarsal heads to the third and fourth toes. It is aggravated by walking on hard surfaces and wearing tight or high-heeled shoes. Physical examination reveals tenderness in the plantar aspect of the distal foot over the third and fourth metatarsals; compressing the forefoot reproduces the symptoms.</div><div id=\"graphicVersion\">Graphic 65666 Version 3.0</div></div></div>"},"65667":{"type":"graphic_table","displayName":"Complications of cirrhosis","title":"Common complications of cirrhosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common complications of cirrhosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Variceal hemorrhage</td> </tr> <tr> <td>Ascites</td> </tr> <tr> <td>Spontaneous bacterial peritonitis</td> </tr> <tr> <td>Hepatic encephalopathy</td> </tr> <tr> <td>Hepatocellular carcinoma</td> </tr> <tr> <td>Hepatorenal syndrome</td> </tr> <tr> <td>Hepatopulmonary syndrome</td> </tr> <tr> <td>Hepatic hydrothorax</td> </tr> <tr> <td>Portopulmonary hypertension</td> </tr> <tr> <td>Cirrhotic cardiomyopathy</td> </tr> <tr> <td>Portal vein thrombosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65667 Version 3.0</div></div></div>"},"65671":{"type":"graphic_picture","displayName":"Posterior scleritis","title":"Posterior scleritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior scleritis</div><div class=\"cntnt\"><img style=\"width:326px; height:216px;\" src=\"images/RHEUM/65671_Posterior_scleritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior scleral wall inflammation with involvement of the optic disc. The disc margin is blurred in association with vascular engorgement and flame-shaped nerve fiber layer hemorrhages.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 65671 Version 2.0</div></div></div>"},"65672":{"type":"graphic_figure","displayName":"Unequal z-plasty","title":"Unequal Z-plasty","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Unequal Z-plasty</div><div class=\"cntnt\"><img style=\"width:502px; height:418px;\" src=\"images/SURG/65672_Unequal_z-plasty.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65672 Version 1.0</div></div></div>"},"65673":{"type":"graphic_diagnosticimage","displayName":"Percutaneous transluminal angioplasty of iliac stenosis","title":"Percutaneous transluminal angioplasty of iliac stenosis","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Percutaneous transluminal angioplasty of iliac stenosis</div><div class=\"cntnt\"><img style=\"width:501px; height:247px;\" src=\"images/CARD/65673_PTA_iliac_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angiography in a patient with rest pain shows an eccentric, 90 percent stenosis of the left common iliac artery (left image, arrow). The stenosis of the diseased segment is eliminated by angioplasty and stenting (right image).</div><div class=\"graphic_reference\">Courtesy Julie Zaetta, MD.</div><div id=\"graphicVersion\">Graphic 65673 Version 3.0</div></div></div>"},"65674":{"type":"graphic_table","displayName":"Differential dx lab values","title":"Frequency and severity of laboratory findings among imitators of preeclampsia-eclampsia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency and severity of laboratory findings among imitators of preeclampsia-eclampsia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Laboratory findings</td> <td class=\"subtitle1\">HELLP syndrome</td> <td class=\"subtitle1\">AFLP</td> <td class=\"subtitle1\">TTP</td> <td class=\"subtitle1\">HUS</td> <td class=\"subtitle1\">Exacerbation of SLE</td> </tr> <tr> <td>Thrombocytopenia (less than 100,000/mm<sup>3</sup>)</td> <td>More than 20,000</td> <td>More than 50,000</td> <td>20,000 or less</td> <td>More than 20,000</td> <td>More than 20,000</td> </tr> <tr> <td>Hemolysis (%)</td> <td>50 to 100</td> <td>15 to 20</td> <td>100</td> <td>100</td> <td>14 to 23 with APA</td> </tr> <tr> <td>Anemia (%)</td> <td>Less than 50</td> <td>Absent</td> <td>100</td> <td>100</td> <td>14 to 23 with APA</td> </tr> <tr> <td>DIC (%)</td> <td>Less than 20</td> <td>50 to 100</td> <td>Rare</td> <td>Rare</td> <td>Rare</td> </tr> <tr> <td>Hypoglycemia (%)</td> <td>Absent</td> <td>50 to 100</td> <td>Absent</td> <td>Absent</td> <td>Absent</td> </tr> <tr> <td>VW factor multimers (%)</td> <td>Absent</td> <td>Absent</td> <td>80 to 90</td> <td>80</td> <td>Less than 10</td> </tr> <tr> <td>ADAMTS13 less than 5% (%)</td> <td>Absent</td> <td>Absent</td> <td>33 to 100</td> <td>Rare</td> <td>Rare</td> </tr> <tr> <td>Impaired renal function (%)</td> <td>50</td> <td>90 to 100</td> <td>30</td> <td>100</td> <td>40 to 80</td> </tr> <tr> <td>LDH (international units/L)</td> <td>600 or more</td> <td>Variable</td> <td>More than 1000</td> <td>More than 1000</td> <td>With APA</td> </tr> <tr> <td>Elevated ammonia (%)</td> <td>Rare</td> <td>50</td> <td>Absent</td> <td>Absent</td> <td>Absent</td> </tr> <tr> <td>Elevated bilirubin (%)</td> <td>50 to 60</td> <td>100</td> <td>100</td> <td>NA</td> <td>Less than 10</td> </tr> <tr> <td>Elevated transaminases (%)</td> <td>100</td> <td>100</td> <td>Usually mild*</td> <td>Usually mild*</td> <td>With APA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HELLP: hemolysis, elevated liver enzymes, low platelets; AFLP: acute fatty liver of pregnancy; TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic syndrome; SLE: systemic lupus erythematosus; APA: antiphospholipid antibodies with or without catastrophic antiphospholipid syndrome; DIC: disseminated intravascular coagulopathy; VW: von Willebrand; ADAMTS13: von Willebrand factor-cleaving metalloprotease; LDH: lactic dehydrogenase; NR: values not reported.<br />* Levels less than 100 international units/L.</div><div class=\"graphic_reference\">Reproduced with permission from: Sibai BM. Imitators of severe preeclampsia. Obstet Gynecol 2007; 109:956. Copyright © 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65674 Version 11.0</div></div></div>"},"65675":{"type":"graphic_figure","displayName":"Prostate PI","title":"Prostate gland","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Prostate gland</div><div class=\"cntnt\"><img style=\"width:605px; height:600px;\" src=\"images/PI/65675_Prostate_anatomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows male&nbsp;internal organs and&nbsp;a close-up of the prostate gland.</div><div id=\"graphicVersion\">Graphic 65675 Version 5.0</div></div></div>"},"65676":{"type":"graphic_diagnosticimage","displayName":"Anomalous pancreaticobiliary union long Y","title":"Anomalous pancreaticobiliary union, long Y type","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anomalous pancreaticobiliary union, long Y type</div><div class=\"cntnt\"><img style=\"width:360px; height:498px;\" src=\"images/PEDS/65676_Choledochal_cyst_type_IV-A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography (ERCP) showing an anomalous pancreaticobiliary union, type long \"Y\". There is no cystic dilatation of the common bile duct.</div><div class=\"graphic_reference\">Reproduced with permission from: Guelrud M, Carr-Locke DL, Fox VL. ERCP in Pediatric Practice: Diagnosis and Treatment. Isis Medical Media, London 1997. Copyright © 1997 Taylor and Francis.</div><div id=\"graphicVersion\">Graphic 65676 Version 12.0</div></div></div>"},"65677":{"type":"graphic_table","displayName":"Differential diagnosis of anaphylaxis","title":"Differential diagnosis of anaphylaxis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of anaphylaxis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Common disorders</td> </tr> <tr> <td class=\"indent1\">Acute generalized urticaria and/or angioedema*</td> </tr> <tr> <td class=\"indent1\">Acute asthma*</td> </tr> <tr> <td class=\"indent1\">Vasovagal syncope (faint)</td> </tr> <tr> <td class=\"indent1\">Panic attack/acute anxiety attack</td> </tr> <tr> <td class=\"indent1\"> <p>Aspiration of a foreign body</p> </td> </tr> <tr> <td class=\"indent1\">Cardiovascular events (myocardial infarction*, pulmonary embolus)</td> </tr> <tr> <td class=\"indent1\">Neurologic events (eg,&nbsp;seizure, cerebrovascular event [stroke])</td> </tr> <tr> <td class=\"subtitle1_single\">Shock </td> </tr> <tr> <td class=\"indent1\">Hypovolemic<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Cardiogenic</td> </tr> <tr> <td class=\"indent1\">Distributive<sup><span style=\"font-size: 13px;\">&#182; </span></sup><span style=\"font-size: 13px;\">(eg, sepsis, spinal cord injury)</span></td> </tr> <tr> <td class=\"indent1\">Obstructive&nbsp;(eg, pulmonary embolism, tension pneumothorax, cardiac tamponade)</td> </tr> <tr> <td class=\"subtitle1_single\">Excess production of endogenous histamine</td> </tr> <tr> <td class=\"indent1\">Mast cell activation syndromes, including mastocytosis</td> </tr> <tr> <td class=\"indent1\">Basophilic leukemia</td> </tr> <tr> <td class=\"indent1\">Hydatid cyst&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Flush syndromes</td> </tr> <tr> <td class=\"indent1\">Perimenopause</td> </tr> <tr> <td class=\"indent1\">Carcinoid syndrome</td> </tr> <tr> <td class=\"indent1\">Autonomic epilepsy</td> </tr> <tr> <td class=\"indent1\">Medullary carcinoma of the thyroid</td> </tr> <tr> <td class=\"subtitle1_single\">Other nonorganic disease</td> </tr> <tr> <td class=\"indent1\">Vocal cord dysfunction</td> </tr> <tr> <td class=\"indent1\">Hyperventilation</td> </tr> <tr> <td class=\"indent1\">Psychosomatic episode</td> </tr> <tr> <td class=\"subtitle1_single\">Postprandial syndromes</td> </tr> <tr> <td class=\"indent1\">Scombroidosis</td> </tr> <tr> <td class=\"indent1\">Anisakiasis</td> </tr> <tr> <td class=\"indent1\">Pollen-food allergy syndrome</td> </tr> <tr> <td class=\"indent1\">Food poisoning</td> </tr> <tr> <td class=\"indent1\">Caustic ingestion (children)</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Nonallergic angioedema (hereditary angioedema, angiotensin-converting enzyme [ACE] inhibitor-associated angioedema)</td> </tr> <tr> <td class=\"indent1\">Systemic capillary leak syndrome</td> </tr> <tr> <td class=\"indent1\">Red man syndrome (vancomycin)</td> </tr> <tr> <td class=\"indent1\">Pheochromocytoma (paradoxical response)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The differential diagnosis in children and adults is shown. In infants, the differential diagnosis of anaphylaxis is unique.</div><div class=\"graphic_footnotes\">* Acute asthma symptoms, acute generalized urticaria, or myocardial infarction symptoms can also occur during an anaphylactic episode.<br />¶&nbsp;In anaphylaxis, shock is distributive and hypovolemic. Distributive shock may be due to anaphylaxis or to spinal cord injury.</div><div class=\"graphic_reference\">Original figure modified for this publication. Simons FER. Anaphylaxis. J Allergy Clin Immunol 2010; 125:S161. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 65677 Version 18.0</div></div></div>"},"65679":{"type":"graphic_diagnosticimage","displayName":"Long axis view dilated CM","title":"Long axis echocardiogram in dilated cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Long axis echocardiogram in dilated cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:227px; height:233px;\" src=\"images/CARD/65679_Long_axis_view_dilated_CM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The long axis echocardiogram from a patient with a dilated cardiomyopathy demonstrates spherical or globular dilation. The long and short axis dimensions now appear to have a nearly 1:1 ratio (normal 2:1),&nbsp;although are&nbsp;unable to confirm the long-axis dimension&nbsp;from this image alone since the&nbsp;apex is not visualized.</div><div class=\"graphic_footnotes\">AV: aortic valve; LV: left ventricle; MV: mitral valve; LA: left atrium; dAo: descending aorta.</div><div id=\"graphicVersion\">Graphic 65679 Version 3.0</div></div></div>"},"65680":{"type":"graphic_picture","displayName":"Eyebrow paucity","title":"Patient eye, leprosy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient eye, leprosy</div><div class=\"cntnt\"><img style=\"width:360px; height:305px;\" src=\"images/ID/65680_Eyebrow_paucity.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Plantar ulcers and eyebrow-hair paucity. Photo Quiz. Clin Infect Dis 2006; 42:684. Copyright &#169; 2006 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 65680 Version 1.0</div></div></div>"},"65682":{"type":"graphic_algorithm","displayName":"Source androgen excess","title":"Determining source of androgen excess","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Determining source of androgen excess</div><div class=\"cntnt\"><img style=\"width:598px; height:366px;\" src=\"images/PEDS/65682_Source_androgen_excess.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dexamethasone androgen-suppression test (DAST) often permits a positive diagnosis of the characteristic ovarian and adrenal dysfunction of polycystic ovary syndrome (PCOS) and will elucidate rare disorders that mimic PCOS. The responses to dexamethasone of serum androgens (testosterone and DHEAS) and serum cortisol are the primary outcome measures.</div><div class=\"graphic_footnotes\">PCOS: polycystic ovary syndrome; ACTH: adrenocorticotropic hormone; SD: standard deviations; CAH: congenital adrenal hyperplasia; FAH: functional adrenal hyperandrogenism; DHEAS: dehydroepiandrosterone sulfate.<br />* After obtaining an early morning blood sample for baseline steroid intermediates (eg, 17-hydroxypregnenolone, 17-hydroxyprogesterone, 11-deoxycortisol, dehydroepiandrosterone, androstenedione) and a 24-hour urine for corticoids (ie, free cortisol and 17&alpha;-hydroxycorticoids, as well as creatinine to control for completeness of collection), a dexamethasone androgen-suppression test (DAST) is performed.<br />&para; A long DAST is a definitive test. This consists of a four-day course of dexamethasone 0.5 mg four times daily prior to an early morning post-test blood sample on day five after a final dexamethasone dose. A short DAST (sampling blood four hours after a single noon-time 0.5 mg dexamethasone dose) maximally suppresses total and free testosterone and 17-hydroxyprogesterone, but DHEAS and cortisol are not maximally suppressed in comparison with the four-day DAST.<br />&Delta; Normal androgen suppression in response to the four-day DAST is indicated in our laboratory (95 percent cut-off levels) by total testosterone &lt;28 ng/dL (1.0 nmol/L), free testosterone &lt;8 pg/mL (28 pmol/L), DHEAS &lt;40 mcg/dL (1.0 micromol/L) (&gt;75 percent fall), and 17-hydroxyprogesterone &lt;26 ng/dL (0.8 nmol/L).<br /><span class=\"lozenge\">&loz;</span> Normal corticoid suppression is indicated by serum cortisol &lt;1.5 &micro;g/dL (40 nmol/L) and urinary cortisol &lt;10 mcg (27 nmol) per 24 hours by the second day of dexamethasone administration.<br />&sect; If androgen excess is suppressed by dexamethasone, further evaluation with a cosyntropin (ACTH) stimulation test is indicated. To perform the ACTH test, cosyntropin 250 micrograms is given, and blood is drawn for steroid measurements 30 to 60 minutes later.<br />&yen; Subnormal suppression of testosterone (as well as androstenedione and 17-hydroxyprogesterone) and a normal suppression of cortisol and DHEAS is characteristic of PCOS, but the rare virilizing tumor or adrenal rests should be considered on the basis of clinical factors.<br />&Dagger; If androgen and cortisol are both not normally suppressed, Cushing syndrome and cortisol resistance should be considered. Poor suppression can also result from non-compliance with the dexamethasone regimen.<br />&dagger; Steroid levels are assessed 30 to 60 minutes after ACTH administration. A post-ACTH 17-OHP value &gt;1000 ng/dL (30 nmol/L) is highly suggestive, and &gt;1500 ng/dL is definitive for nonclassical CAH due to 21-hydroxylase deficiency. A post-ACTH value of 17-hydroxypregnenolone &gt;4500 ng/dL (150 nmol/L) suggests nonclassical 3&szlig;-hydroxysteroid dehydrogenase deficiency, and a post-ACTH value of 11-deoxycortisol &gt;4000 ng/dL (116 nmol/L) suggests nonclassical 11&szlig;-hydroxylase deficiency. A serum cortisol level &ge;18 mcg/dL (500 nmol/L) validates the administration of ACTH.<br />** Primary functional adrenal hyperandrogenism (FAH) (suggested by a modest rise in 17-hydroxypregnenolone or 17-hydroxyprogesterone that does not meet the criteria for the diagnosis of CAH) is sometimes the only demonstrable source of androgen excess in PCOS. (Apparent) cortisone reductase deficiency is a rare mime of FAH and idiopathic hyperandrogenemia; baseline urinary corticoids consist primarily of cortisone metabolites rather than cortisol metabolites, so 17&alpha;-hydroxycorticoid excretion is elevated, but cortisol excretion is normal.<br />&para;&para; When the source of hyperandrogenemia remains unexplained after intensive investigation (approximately 10 percent of cases), it usually appears to be due to obesity. Otherwise, the diagnosis is idiopathic hyperandrogenism (distinct from idiopathic hirsutism), if (apparent) cortisone reductase deficiency has been excluded.</div><div class=\"graphic_reference\">Modified with permission from: Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 2005; 34:677.</div><div id=\"graphicVersion\">Graphic 65682 Version 13.0</div></div></div>"},"65684":{"type":"graphic_table","displayName":"Epinepherine actions","title":"Beneficial effects and adverse effects of epinephrine in the treatment of anaphylaxis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Beneficial effects and adverse effects of epinephrine in the treatment of anaphylaxis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Beneficial effects</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"12\">&nbsp;</td> <td class=\"sublist1_start\">At alpha-1 receptor:</td> </tr> <tr> <td class=\"sublist1\">Increased vasoconstriction (at low doses)</td> </tr> <tr> <td class=\"sublist1\">Increased peripheral vascular resistance</td> </tr> <tr> <td class=\"sublist1\">Increased blood pressure</td> </tr> <tr> <td class=\"sublist1\">Decreased mucosal edema (eg, in larynx)</td> </tr> <tr> <td class=\"sublist1_start\">At beta-1 receptor:</td> </tr> <tr> <td class=\"sublist1\">Increased heart rate (chronotropy)</td> </tr> <tr> <td class=\"sublist1\">Increased force of cardiac contraction (inotropy)</td> </tr> <tr> <td class=\"sublist1_start\">At beta-2 receptor:</td> </tr> <tr> <td class=\"sublist1\">Decreased mediator release from mast cells and basophils</td> </tr> <tr> <td class=\"sublist1\">Increased bronchodilation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Increased vasodilation</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Adverse effects*<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Common and transient</td> <td>Anxiety, palpitations, pallor, tremor, fear, restlessness, dizziness, headache</td> </tr> <tr> <td class=\"indent1\">Uncommon (typically occur after overdose)</td> <td>Ventricular arrhythmias, angina, myocardial infarction, pulmonary edema, sudden sharp increase in blood pressure, intracranial hemorrhage</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Risk of adverse effects may be increased in the following conditions: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Use of tricyclic antidepressants, monoamine oxidase inhibitors, or cocaine.</LI>&#xD;&#xA;<LI>Some pre-existing cardiovascular, central nervous system, or thyroid diseases. Examples include intracranial surgery, acute aneurysm, or untreated hyperthyroidism.</LI></UL>¶ Serious adverse effects such as those listed in the table potentially occur when epinephrine is given in overdose by any route, most commonly after an intravenous bolus injection, an overly rapid intravenous infusion, or an erroneous intravenous injection of a 1 mg/mL (1:1000) epinephrine solution instead of an appropriately diluted 0.1 mg/mL (1:10,000) or a 0.01 mg/mL epinephrine solution.<br />Δ Anaphylaxis can present as an acute coronary syndrome, arrhythmias, myocardial infarction, or angina, before or in the absence of epinephrine injection. This potentially occurs in patients with known coronary artery disease, patients in whom subclinical coronary artery disease is unmasked, and patients (including children) with transient coronary artery vasospasm in whom no cardiovascular abnormalities can be detected by electrocardiogram or echocardiography after recovery from anaphylaxis.</div><div id=\"graphicVersion\">Graphic 65684 Version 13.0</div></div></div>"},"65686":{"type":"graphic_table","displayName":"Lugano staging GI lymphoma","title":"Lugano staging system for gastrointestinal lymphomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lugano staging system for gastrointestinal lymphomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Stage I</strong> - The tumor is confined to the gastrointestinal tract. It can be a single primary lesion or multiple, noncontiguous lesions.</td> </tr> <tr> <td><strong>Stage II</strong> - The tumor extends into the abdomen. This is further subdivided based upon the location of nodal involvement:</td> </tr> <tr> <td class=\"indent1\">&#8226; Stage II<sub>1</sub>: Involvement of local nodes (paragastric nodes for gastric lymphoma or para-intestinal nodes for intestinal lymphoma)</td> </tr> <tr> <td class=\"indent1\">&#8226; Stage II<sub>2</sub>: Involvement of distant nodes (para-aortic, para-caval, pelvic, or inguinal nodes for most tumors; mesenteric nodes in the case of intestinal lymphoma)</td> </tr> <tr> <td class=\"indent1\">&#8226; Stage IIE: The tumor penetrates the serosa to involve adjacent organs or tissues</td> </tr> <tr> <td><strong>Stage III</strong> - There is no stage III disease in this system.</td> </tr> <tr> <td><strong>Stage IV</strong> - There is disseminated extranodal involvement or concomitant supra-diaphragmatic nodal involvement.</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">7</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">9/23/2009--Requested permission (JD). 9/25/2009--Permissions contact received, agreed to terms (JD). 10/6/2009--Figure to Terrence (JD). 11/3/2009--Invoice received, to Catherine (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=25786&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Modified with permission from: Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classification of gastrointestinal tract lymphoma. Ann Oncol 1994; 5:397. Copyright © 1994 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 65686 Version 16.0</div></div></div>"},"65688":{"type":"graphic_figure","displayName":"Vascular exclusion technique to control liver bleeding","title":"Vascular exclusion technique to control liver bleeding","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Vascular exclusion technique to control liver bleeding</div><div class=\"cntnt\"><img style=\"width:474px; height:644px;\" src=\"images/SURG/65688_Vascular-exclusion-technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vascular exclusion occludes all the inflow and outflow vessels of the liver. As a result, venous return to the heart is severely reduced, which can lead to cardiac arrest.</div><div id=\"graphicVersion\">Graphic 65688 Version 3.0</div></div></div>"},"65689":{"type":"graphic_figure","displayName":"Balantidium coli life cycle","title":"<EM>Balantidium coli</EM> life cycle","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\"><EM>Balantidium coli</EM> life cycle</div><div class=\"cntnt\"><img style=\"width:457px; height:578px;\" src=\"images/ID/65689_Balantidium_coli_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cysts are the parasite stage responsible for transmission of balantidiasis <strong>(1)</strong>. The host most often acquires the cyst through ingestion of contaminated food or water <strong>(2)</strong>. Following ingestion, excystation occurs in the small intestine, and the trophozoites colonize the large intestine <strong>(3)</strong>. The trophozoites reside in the lumen of the large intestine of humans and animals, where they replicate by binary fission, during which conjugation may occur <strong>(4)</strong>. Trophozoites undergo encystation to produce infective cysts <strong>(5)</strong>. Some trophozoites invade the wall of the colon and multiply. Some return to the lumen and disintegrate. Mature cysts are passed with feces <strong>(1)</strong>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Balantidiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/balantidiasis/index.html\">http://www.cdc.gov/dpdx/balantidiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 65689 Version 3.0</div></div></div>"},"65690":{"type":"graphic_figure","displayName":"Testost formation metabolism","title":"Testosterone formation and metabolism","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Testosterone formation and metabolism</div><div class=\"cntnt\"><img style=\"width:552px; height:898px;\" src=\"images/ENDO/65690_Testost_formation_metabolis.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65690 Version 2.0</div></div></div>"},"65692":{"type":"graphic_waveform","displayName":"Advanced case 12 with answer","title":"Normal neonatal ECG","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Normal neonatal ECG</div><div class=\"cntnt\"><img style=\"width:540px; height:325px;\" src=\"images/CARD/65692_Advancedcase12withanswe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram from a healthy neonate resembles right ventricular hypertrophy in adults (tall right precordial R waves with right axis deviation). Right ventricular preponderance in neonates is a physiologic finding related to fetal circulatory dynamics; resting sinus tachycardia is expected. The very narrow QRS (only about 0.05 sec) is a major clue in differentiating this pattern from a pathologic one in adults. </div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 65692 Version 3.0</div></div></div>"},"65695":{"type":"graphic_picture","displayName":"Hunter syndrome papular rash","title":"Papular rash in a patient with mucopolysaccharidosis type II (MPS II, Hunter syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Papular rash in a patient with mucopolysaccharidosis type II (MPS II, Hunter syndrome)</div><div class=\"cntnt\"><img style=\"width:409px; height:250px;\" src=\"images/PEDS/65695_Hunter_syndrome_papular_ras.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papular rash across the shoulders of a six-year-old boy with MPS II, Hunter syndrome.</div><div class=\"graphic_reference\">Courtesy of Ed Wraith, MD.</div><div id=\"graphicVersion\">Graphic 65695 Version 2.0</div></div></div>"},"65696":{"type":"graphic_figure","displayName":"Volar forearm splint","title":"Volar forearm splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Volar forearm splint</div><div class=\"cntnt\"><img style=\"width:308px; height:396px;\" src=\"images/EM/65696_Volar_forearm_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The volar short arm splint is used for fractures or injuries of the wrist, fractures of the second to fifth metacarpals, carpal tunnel syndrome, and soft tissue injuries of the hand. It is applied from the midpalmar crease almost to the elbow ventrally.</div><div id=\"graphicVersion\">Graphic 65696 Version 4.0</div></div></div>"},"65697":{"type":"graphic_picture","displayName":"Cutaneous horn eyelid","title":"Cutaneous horn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous horn</div><div class=\"cntnt\"><img style=\"width:342px; height:298px;\" src=\"images/PC/65697_Cutaneous_horn_eyelid.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.</div><div id=\"graphicVersion\">Graphic 65697 Version 1.0</div></div></div>"},"65699":{"type":"graphic_picture","displayName":"Perianal fistulas and ulcers","title":"Perianal Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perianal Crohn disease</div><div class=\"cntnt\"><img style=\"width:260px; height:324px;\" src=\"images/GAST/65699_Perianal_fistulas_and_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perianal fistulas and ulcers in a patient with Crohn disease. There are bilateral posterior perianal fistulas (arrows) and two right posterior ulcers (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Alain Bitton, MD, FRCPC.</div><div id=\"graphicVersion\">Graphic 65699 Version 2.0</div></div></div>"},"65700":{"type":"graphic_figure","displayName":"Activity of ECG leads","title":"Electrical activity of ECG leads","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Electrical activity of ECG leads</div><div class=\"cntnt\"><img style=\"width:478px; height:258px;\" src=\"images/CARD/65700_Activity_of_ECG_leads.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The six frontal plane (left panel) and six horizontal plane or precordial leads (right panel) permit a three-dimensional evaluation of myocardial electrical activity. An electrical vector directed toward a lead generates a positive deflection on the ECG, while a vector directed away from a lead generates a negative deflection.</div><div id=\"graphicVersion\">Graphic 65700 Version 1.0</div></div></div>"},"65701":{"type":"graphic_table","displayName":"Laboratory findings in anemias","title":"Laboratory findings in iron deficiency anemia, thalassemia, and anemia of chronic disease/inflammation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory findings in iron deficiency anemia, thalassemia, and anemia of chronic disease/inflammation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Iron deficiency anemia</td> <td class=\"subtitle1\">Alpha or beta thalassemia</td> <td class=\"subtitle1\">Anemia of chronic disease/inflammation</td> </tr> <tr> <td colspan=\"4\">Complete blood count</td> </tr> <tr> <td class=\"indent1\">Hemoglobin</td> <td>Decreased</td> <td>Decreased</td> <td>Decreased</td> </tr> <tr> <td class=\"indent1\">Mean corpuscular volume (MCV)</td> <td>Decreased</td> <td>Decreased</td> <td>Normal to decreased</td> </tr> <tr> <td class=\"indent1\">Red cell distribution width (RDW)</td> <td>Increased</td> <td>Increased or normal</td> <td>Normal to increased</td> </tr> <tr> <td class=\"indent1\">Red blood cell count</td> <td>Decreased</td> <td>Increased or normal</td> <td>Decreased</td> </tr> <tr> <td colspan=\"4\">Iron studies</td> </tr> <tr> <td class=\"indent1\">Serum iron</td> <td>Decreased</td> <td>Normal or increased</td> <td>Decreased</td> </tr> <tr> <td class=\"indent1\">Total iron-binding capacity (TIBC); transferrin</td> <td>Increased</td> <td>Normal</td> <td>Decreased</td> </tr> <tr> <td class=\"indent1\">Transferrin saturation</td> <td>Decreased</td> <td>Normal</td> <td>Decreased</td> </tr> <tr> <td class=\"indent1\">Serum ferritin</td> <td>Decreased</td> <td>Normal or increased</td> <td>Increased</td> </tr> <tr> <td>Erythrocyte protoporphyrin*</td> <td>Increased</td> <td>Normal or increased</td> <td>Increased</td> </tr> <tr> <td>Soluble transferrin receptor*</td> <td>Increased</td> <td>Increased</td> <td>Normal</td> </tr> <tr> <td>Reticulocyte hemoglobin equivalent (Ret-he or CHr)&nbsp;</td> <td>Decreased</td> <td>Decreased</td> <td>Normal</td> </tr> <tr> <td>C-reactive protein</td> <td>Normal</td> <td>Normal</td> <td>Increased</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on anemia for further details of the evaluation and interpretation. Refer to UpToDate topic on iron deficiency anemia for early changes associated with iron deficiency (before anemia develops).</div><div class=\"graphic_footnotes\">* Not used in the routine evaluation of anemia.</div><div id=\"graphicVersion\">Graphic 65701 Version 6.0</div></div></div>"},"65702":{"type":"graphic_table","displayName":"Revised Edmonton symptom assessment scale","title":"Revised Edmonton symptom assessment scale: Numeric scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised Edmonton symptom assessment scale: Numeric scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"28%\"></colgroup><colgroup span=\"11\" width=\"4%\"></colgroup><colgroup width=\"28%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"13\"><br /> Patient name:</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"13\"><br /> Date:</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"13\"><br /> Time:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_blue_text sublis1\" colspan=\"13\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"13\"><strong>Please circle the number that best describes how you feel NOW:</strong></td> </tr> <tr class=\"highlight_gray_text\"> <td>No pain</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> <td class=\"centered\">7</td> <td class=\"centered\">8</td> <td class=\"centered\">9</td> <td class=\"centered\">10</td> <td>Worst possible pain</td> </tr> <tr> <td>No tiredness<br /> (Tiredness = lack of energy)</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> <td class=\"centered\">7</td> <td class=\"centered\">8</td> <td class=\"centered\">9</td> <td class=\"centered\">10</td> <td>Worst possible tiredness</td> </tr> <tr class=\"highlight_gray_text\"> <td>No drowsiness<br /> (Drowsiness = feeling sleepy)</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> <td class=\"centered\">7</td> <td class=\"centered\">8</td> <td class=\"centered\">9</td> <td class=\"centered\">10</td> <td>Worst possible drowsiness</td> </tr> <tr> <td>No nausea</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> <td class=\"centered\">7</td> <td class=\"centered\">8</td> <td class=\"centered\">9</td> <td class=\"centered\">10</td> <td>Worst possible nausea</td> </tr> <tr class=\"highlight_gray_text\"> <td>No lack of appetite</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> <td class=\"centered\">7</td> <td class=\"centered\">8</td> <td class=\"centered\">9</td> <td class=\"centered\">10</td> <td>Worst possible lack of appetite</td> </tr> <tr> <td>No shortness of breath</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> <td class=\"centered\">7</td> <td class=\"centered\">8</td> <td class=\"centered\">9</td> <td class=\"centered\">10</td> <td>Worst possible shortness of breath</td> </tr> <tr class=\"highlight_gray_text\"> <td>No depression<br /> (Depression = feeling sad)</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> <td class=\"centered\">7</td> <td class=\"centered\">8</td> <td class=\"centered\">9</td> <td class=\"centered\">10</td> <td>Worst possible depression</td> </tr> <tr> <td>No anxiety<br /> (Anxiety = feeling nervous)</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> <td class=\"centered\">7</td> <td class=\"centered\">8</td> <td class=\"centered\">9</td> <td class=\"centered\">10</td> <td>Worst possible anxiety</td> </tr> <tr class=\"highlight_gray_text\"> <td>Best well-being<br /> (Well-being = how you feel overall)</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> <td class=\"centered\">7</td> <td class=\"centered\">8</td> <td class=\"centered\">9</td> <td class=\"centered\">10</td> <td>Worst possible well-being</td> </tr> <tr> <td>No __________<br /> Other problem (for example, constipation)</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> <td class=\"centered\">6</td> <td class=\"centered\">7</td> <td class=\"centered\">8</td> <td class=\"centered\">9</td> <td class=\"centered\">10</td> <td>Worst possible __________</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Watanabe SM, Nekolaichuk C, Beaumont C, et al. A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients. J Pain Symptom Manage 2011; 41:456. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 65702 Version 2.0</div></div></div>"},"65703":{"type":"graphic_diagnosticimage","displayName":"Normal cc views","title":"Normal CC (craniocaudal) views of both breasts","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Normal CC (craniocaudal) views of both breasts</div><div class=\"cntnt\"><img style=\"width:465px; height:399px;\" src=\"images/PC/65703_Normal_cc_views.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">By convention, the mammograms of both breasts are viewed as mirror images. The upper half represents the lateral or outer aspect of the breast and the lower half represents the medial or inner aspect of the breast. The nipples are in profile and normal fat is visible between the edge of the film and the glandular tissue.</div><div id=\"graphicVersion\">Graphic 65703 Version 3.0</div></div></div>"},"65704":{"type":"graphic_picture","displayName":"Nodular basal cell carcinoma","title":"Nodular basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/65704_Nod_basal_cell_carcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This pearly papule with telangiectasias is representative of a nodular basal cell carcinoma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65704 Version 4.0</div></div></div>"},"65706":{"type":"graphic_figure","displayName":"Technique of below-knee amputation with medial-based flap","title":"Technique of below-knee amputation with medial-based flap","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Technique of below-knee amputation with medial-based flap</div><div class=\"cntnt\"><img style=\"width:461px; height:667px;\" src=\"images/SURG/65706_BKA-medial-flap.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65706 Version 2.0</div></div></div>"},"65707":{"type":"graphic_picture","displayName":"Kawasakis disease - targetoid","title":"Kawasaki’s disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Kawasaki’s disease</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/65707_Kawasakis_disease_targetoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaques, some with a targetoid appearance, are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65707 Version 3.0</div></div></div>"},"65710":{"type":"graphic_picture","displayName":"NFL touchdown sign","title":"Overhead arm raise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Overhead arm raise</div><div class=\"cntnt\"><img style=\"width:391px; height:414px;\" src=\"images/EM/65710_NFL_touchdown_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This maneuver screens overall shoulder range of motion and the strength of abduction. The patient is asked to raise both arms directly overhead. The smoothness of movement, degree of discomfort, and the ability to complete the maneuver are compared side to side. Similarly, the ability to smoothly control lowering the arm is compared side to side (the latter maneuver is analagous to the &quot;drop-arm&quot; sign).</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 65710 Version 4.0</div></div></div>"},"65711":{"type":"graphic_figure","displayName":"Magnitude of proteinuria on renal survival in IgA nephropathy","title":"Effect of magnitude of proteinuria on renal survival in IgA nephropathy","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Effect of magnitude of proteinuria on renal survival in IgA nephropathy</div><div class=\"cntnt\"><img style=\"width:584px; height:468px;\" src=\"images/NEPH/65711_Magnitude_proteinuria.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal survival by category of TA-proteinuria. p&lt;0.001.</div><div class=\"graphic_reference\">Reproduced with permission from: Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007; 18:3177. Copyright &#169; 2007 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 65711 Version 1.0</div></div></div>"},"65713":{"type":"graphic_figure","displayName":"Aortic coarctation PI","title":"Aortic coarctation","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Aortic coarctation</div><div class=\"cntnt\"><img style=\"width:541px; height:512px;\" src=\"images/PI/65713_Aortic-coarctation-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The aorta is the main artery that delivers blood from the heart to the body. Aortic coarctation is a heart defect that causes the aorta to narrow (see arrow).</div><div id=\"graphicVersion\">Graphic 65713 Version 1.0</div></div></div>"},"65714":{"type":"graphic_picture","displayName":"Percutaneous gallbladder endosc","title":"Percutaneous gallbladder endoscopy showing gallstone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Percutaneous gallbladder endoscopy showing gallstone</div><div class=\"cntnt\"><img style=\"width:234px; height:242px;\" src=\"images/GAST/65714_Percutaneous_gallbladder_en.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percutaneous gallbladder endoscopy shows a small gallstone that was not detected on ultrasonography.</div><div class=\"graphic_reference\">Courtesy of Salam Zakko, MD, FACP.</div><div id=\"graphicVersion\">Graphic 65714 Version 2.0</div></div></div>"},"65715":{"type":"graphic_figure","displayName":"Modified Martius fat pad graft4","title":"Modified Martius fat pad graft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Modified Martius fat pad graft</div><div class=\"cntnt\"><img style=\"width:363px; height:363px;\" src=\"images/OBGYN/65715_Modified_Martius_fat_pad_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The graft is secured at its edges with interrupted sutures.</div><div id=\"graphicVersion\">Graphic 65715 Version 1.0</div></div></div>"},"65717":{"type":"graphic_table","displayName":"Risk assess crit breast ovar CA","title":"Risk assessment criteria for inherited breast-ovarian cancer syndome, combining several guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk assessment criteria for inherited breast-ovarian cancer syndome, combining several guidelines</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Non-Jewish families</td> </tr> <tr> <td class=\"subtitle2_single\">Any of the following:</td> </tr> <tr> <td class=\"indent1\">One case of breast cancer &#8804;40&nbsp;years old&nbsp;in a first- or second-degree relative</td> </tr> <tr> <td class=\"indent1\">One&nbsp;first- or second-degree relative with breast and ovarian cancer, at any age</td> </tr> <tr> <td class=\"indent1\">Two or more cases of breast cancer in first- or second-degree relatives if one is diagnosed at &#8804;50 years old, or is bilateral cancer</td> </tr> <tr> <td class=\"indent1\">One first- or second-degree relative with breast cancer at &#8804;50 years old, or bilateral breast cancer, and one first- or second-degree relative with ovarian cancer</td> </tr> <tr> <td class=\"indent1\">Three cases of breast and ovarian cancer (at least one case of ovarian cancer) in first- or second-degree relatives</td> </tr> <tr> <td class=\"indent1\">Two cases of ovarian cancer in first- or second-degree relatives</td> </tr> <tr> <td class=\"indent1\">One case of male breast cancer in a first- or second-degree relative if another first- or second-degree relative has (male or female) breast or ovarian cancer</td> </tr> <tr> <td class=\"subtitle1_single\">Jewish families</td> </tr> <tr> <td class=\"subtitle2_single\">Any of the following:</td> </tr> <tr> <td class=\"indent1\">One or more cases of breast cancer &#8804;50 years old in a first- or second-degree relative</td> </tr> <tr> <td class=\"indent1\">One or more cases of ovarian cancer at any age in a first- or second-degree relative</td> </tr> <tr> <td class=\"indent1\">One or more first- or second-degree relatives with breast cancer at any age, if another first- or second-degree relative has breast and/or ovarian cancer at any age</td> </tr> <tr> <td class=\"indent1\">One or more cases of male breast cancer in a first- or second-degree relative</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Hampel H, et al. J Med Genet 2004; 41:81.</div><div id=\"graphicVersion\">Graphic 65717 Version 5.0</div></div></div>"},"65718":{"type":"graphic_table","displayName":"Intrauterine nutrient accretion","title":"Estimated daily intrauterine nutrient accretion rates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated daily intrauterine nutrient accretion rates</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Nutrient*</td> <td class=\"subtitle1\">Unit/kg</td> </tr> <tr> <td>Calcium (mg)</td> <td class=\"centered\">105</td> </tr> <tr> <td>Copper (mcg)</td> <td class=\"centered\">50</td> </tr> <tr> <td>Magnesium (mg)</td> <td class=\"centered\">2.7</td> </tr> <tr> <td>Nitrogen (mg)</td> <td class=\"centered\">325</td> </tr> <tr> <td>Phosphorus (mg)</td> <td class=\"centered\">70</td> </tr> <tr> <td>Potassium (meq)</td> <td class=\"centered\">0.7</td> </tr> <tr> <td>Sodium (meq)</td> <td class=\"centered\">1.2</td> </tr> <tr> <td>Zinc (mcg)</td> <td class=\"centered\">240</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Values are averaged from last trimester and adjusted for body weight.</div><div class=\"graphic_reference\">Adapted from: Widdowson EM. Importance of nutrition in development, with special reference to feeding low-birth-weight infants. In: Meeting Nutritional Goals for Low-Birth-Weight Infants, Sauls HS, Bachhuber WL, Lewis LA. (Eds), Ross Laboratories, Columbus, 1982, p.4; and Ziegler EE, O'Donnell AM, Nelson SE, Fomon SJ, Growth 1976; 40:329.</div><div id=\"graphicVersion\">Graphic 65718 Version 4.0</div></div></div>"},"65719":{"type":"graphic_figure","displayName":"Pathogenesis osteomyelitis children","title":"Pathogenesis of acute osteomyelitis in children","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of acute osteomyelitis in children</div><div class=\"cntnt\"><img style=\"width:486px; height:557px;\" src=\"images/PEDS/65719_Pathogen_osteo_children.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) During an episode of bacteremia, bacteria are deposited in the metaphysis from the metaphyseal vessels (nutrient artery and vein).<br />(B) A focus of infection develops in the metaphysis, which leads to cellulitis in the bone marrow.<br />(C) Exudate under pressure is forced laterally through the Haversian systems and Volkmann canals and into the cortex of the bone, where it can lift or rupture through the periosteum.</div><div id=\"graphicVersion\">Graphic 65719 Version 4.0</div></div></div>"},"65721":{"type":"graphic_picture","displayName":"Infantile hemangioma - arrested growth","title":"Infantile hemangioma with minimal or arrested growth","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Infantile hemangioma with minimal or arrested growth</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/65721_Infant_heman_arrest_gr_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous patch with fine and coarse telangiectasias is present. Note the perilesional blanching and small proliferative component.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 65721 Version 6.0</div></div></div>"},"65723":{"type":"graphic_figure","displayName":"Femoral anteversion and in-toeing","title":"Excessive femoral anteversion and in-toeing","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Excessive femoral anteversion and in-toeing</div><div class=\"cntnt\"><img style=\"width:513px; height:372px;\" src=\"images/PEDS/65723_Femoral-anteversion-and-in-toeing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In normal gait, the greater trochanter is positioned to allow the hip abductor muscles (the gluteus medius and minimus) to function most efficiently. In a child with normal femoral anteversion, where the greater trochanter is relatively laterally placed, this results in a normal, straight-ahead foot progression angle. In a child with increased femoral anteversion (left panel), the greater trochanter has to rotate to the more lateral position, resulting in an in-toed gait. When reminded by parents, a child with excessive femoral anteversion can walk with her feet straight ahead, but less efficiently because of the posterior position of the greater trochanter (right panel). As the child tires, she will tend to select a more efficient gait and rotate the greater trochanter more laterally, resulting in an increasingly in-toed gait.</div><div class=\"graphic_reference\">Courtesy of William Phillips, MD.</div><div id=\"graphicVersion\">Graphic 65723 Version 2.0</div></div></div>"},"65724":{"type":"graphic_picture","displayName":"Ocular cicatricial pemphigoid stage 1","title":"Stage 1 ocular cicatricial pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Stage 1 ocular cicatricial pemphigoid</div><div class=\"cntnt\"><img style=\"width:540px; height:348px;\" src=\"images/DERM/65724_Ocular_cicatricial_stage_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the conjuncitivits. Subepithelial fibrosis, with a white &quot;feltwork&quot; of new collagen deposited under the conjunctival epithelium also is evident.</div><div id=\"graphicVersion\">Graphic 65724 Version 2.0</div></div></div>"},"65725":{"type":"graphic_picture","displayName":"Fasciola hepatica adult","title":"<em>Fasciola hepatica</em> adult","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\"><em>Fasciola hepatica</em> adult</div><div class=\"cntnt\"><img style=\"width:584px; height:239px;\" src=\"images/ID/65725_Fasciola_hepatica_adult.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Adults of <em>F. hepatica</em>, observed with endoscopic retrograde cholangiopancreatography (ERCP) imaging in the common bile duct of a human patient.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Fascioliasis. Available at: <a href=\"http://www.cdc.gov/dpdx/fascioliasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/fascioliasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 65725 Version 4.0</div></div></div>"},"65727":{"type":"graphic_picture","displayName":"Foamy degeneration in PBC","title":"Foamy degeneration in primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Foamy degeneration in primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:386px; height:260px;\" src=\"images/GAST/65727_Foamy_degeneration_in_PBC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Foamy degeneration of hepatocytes adjacent to portal triads in a patient with primary biliary cholangitis. There are hyaline droplets in many of these swollen hepatocytes, which are similar to those seen in alcoholic hepatitis. The lesion is thought to be due to the toxic effect of retained bile acids (Masson trichrome, x496).</div><div class=\"graphic_reference\">Courtesy of Marshall M Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 65727 Version 2.0</div></div></div>"},"65728":{"type":"graphic_table","displayName":"Signs of systolic flow murmurs without significant obstruction","title":"Bedside diagnosis of causes of systolic ejection murmurs without significant obstruction (flow and innocent murmurs) in adult patients ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bedside diagnosis of causes&nbsp;of systolic ejection murmurs without significant obstruction (flow and innocent murmurs)&nbsp;in adult patients </div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Identification of flow murmur </td> </tr> <tr> <td>A systolic ejection murmur (SEM) begins after S1, terminates before A2 and/or P2-A2, is clearly heard over the cardiac apex, and is usually crescendo-decrescendo configuration.</td> </tr> <tr> <td class=\"sublist1_start\">Useful maneuvers to differentiate from regurgitant murmur:</td> </tr> <tr> <td class=\"sublist1\">Hand grip usually decreases the intensity of the ejection murmur</td> </tr> <tr> <td class=\"sublist1\">Amyl nitrite usually increases the intensity of the ejection murmur</td> </tr> <tr> <td class=\"subtitle1_single\">Types of flow murmurs without significant obstruction (all have&nbsp;normal carotid pulse)</td> </tr> <tr> <td class=\"sublist1_start\">Increased flow across the aortic valve</td> </tr> <tr> <td class=\"sublist1\">Aortic regurgitation: aortic diastolic murmur and other features of aortic regurgitation</td> </tr> <tr> <td class=\"sublist1\">Hypermetabolic state: hyperdynamic cardiac impulse</td> </tr> <tr> <td>Aortic sclerosis</td> </tr> <tr> <td class=\"sublist1_start\">&nbsp;&nbsp;&nbsp;&nbsp;Elderly patients</td> </tr> <tr> <td class=\"sublist1\">Short and soft SEM</td> </tr> <tr> <td class=\"sublist1\">Normal S1 and S2</td> </tr> <tr> <td class=\"sublist1\">Normal cardiac impulse</td> </tr> <tr> <td class=\"sublist1\">\"Grunting\" quality of the murmur may be present.</td> </tr> <tr> <td class=\"sublist1_start\">Uncomplicated bicuspid aortic valve</td> </tr> <tr> <td class=\"sublist1\">Short and soft SEM</td> </tr> <tr> <td class=\"sublist1\">Normal S1 and S2</td> </tr> <tr> <td class=\"sublist1\">Aortic ejection sound in the absence of aortic aneurysm, hypertension</td> </tr> <tr> <td class=\"sublist1\">Short, early aortic diastolic murmur may be present.</td> </tr> <tr> <td class=\"sublist1\">Normal cardiac impulse</td> </tr> <tr> <td>Atrial septal defect</td> </tr> <tr> <td class=\"sublist1_start\">&nbsp;&nbsp;&nbsp; Short and soft SEM</td> </tr> <tr> <td class=\"sublist1\">Wide and fixed splitting of S2</td> </tr> <tr> <td class=\"sublist1\">Wide splitting of S1; tricuspid opening snap; mid-diastolic rumble over the lower left sternal border may be present.</td> </tr> <tr> <td class=\"sublist1\">Hyperdynamic left parasternal impulse</td> </tr> <tr> <td class=\"sublist1_start\">Suspected idiopathic dilatation of the pulmonary artery</td> </tr> <tr> <td class=\"sublist1\">Short and soft SEM</td> </tr> <tr> <td class=\"sublist1\">S1 normal; S2 may be widely split; normal inspiratory increase in A2-P2 interval</td> </tr> <tr> <td class=\"sublist1\">Pulmonary ejection sound</td> </tr> <tr> <td class=\"sublist1\">Short, early pulmonary diastolic murmur may be present.</td> </tr> <tr> <td class=\"sublist1\">Normal cardiac impulse</td> </tr> <tr> <td class=\"sublist1_start\">Innocent murmur</td> </tr> <tr> <td class=\"sublist1\">Short and soft SEM</td> </tr> <tr> <td class=\"sublist1\">Normal S1 and S2</td> </tr> <tr> <td class=\"sublist1\">Normal cardiac impulse</td> </tr> <tr> <td class=\"sublist1\">No evidence for any hemodynamic abnormality</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65728 Version 2.0</div></div></div>"},"65729":{"type":"graphic_picture","displayName":"Tubular epithelial cell cast in acute tubular necrosis","title":"Photomicrograph showing tubular epithelial cell casts","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Photomicrograph showing tubular epithelial cell casts</div><div class=\"cntnt\"><img style=\"width:513px; height:171px;\" src=\"images/NEPH/65729_Tubul_epitheli_necros.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Epithelial cell cast containing cells that are larger than white cells.<br />(B) Epithelial cell cast with free epithelial cells (arrow) in the urine sediment. Renal tubular epithelial cells are larger than white cells and have a single, large central nucleus.</div><div class=\"graphic_reference\">Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.</div><div id=\"graphicVersion\">Graphic 65729 Version 6.0</div></div></div>"},"65730":{"type":"graphic_picture","displayName":"Fenestrated cube pessary","title":"Fenestrated cube vaginal pessary","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fenestrated cube vaginal pessary</div><div class=\"cntnt\"><img style=\"width:432px; height:317px;\" src=\"images/OBGYN/65730_Fenestrated_cube_pessary.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Using a cube pessary with fenestrations may decrease ulcerations and discharge.</div><div class=\"graphic_reference\">Courtesy of Leah Moynihan, RNC, MSN.</div><div id=\"graphicVersion\">Graphic 65730 Version 2.0</div></div></div>"},"65731":{"type":"graphic_diagnosticimage","displayName":"Radiographic features of meningioma","title":"Radiographic features of meningioma","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Radiographic features of meningioma</div><div class=\"cntnt\"><img style=\"width:468px; height:146px;\" src=\"images/ONC/65731_MRI_meningioma_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A: Tail sign: tapering dural thickening (arrow) due to direct tumor involvement or reactive change in the dura, is a highly characteristic sign of meningioma; note also the small reactive arachnoid cyst, reflecting the extra-axial site of this lesion (arrowhead). B: Reactive cerebral white matter changes. C: Bony reactive changes: reactive bone sclerosis, reflected in the increased vault thickness (arrows) is seen most commonly in patients with multiple meningiomas associated with neurofibromatosis type 2; invasive tumors such as these can cause problematic extracranial facial masses.</div><div class=\"graphic_reference\">Reproduced with permission from: Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. The Lancet 2004; 363:1536. Copyright ©2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 65731 Version 4.0</div></div></div>"},"65732":{"type":"graphic_diagnosticimage","displayName":"Bilateral pneumothoraces","title":"Bilateral pneumothoraces with accumulation of air visible in lateral as well as anteromedial aspect of lung, in radiograph taken in infant lying supine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral pneumothoraces with accumulation of air visible in lateral as well as anteromedial aspect of lung, in radiograph taken in infant lying supine</div><div class=\"cntnt\"><img style=\"width:354px; height:289px;\" src=\"images/PEDS/65732_Bilateral_pneumothoraces.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Gerardo Cabrera-Meza, MD.</div><div id=\"graphicVersion\">Graphic 65732 Version 2.0</div></div></div>"},"65733":{"type":"graphic_figure","displayName":"Repair of through and through lip laceration","title":"Repair of through and through lip laceration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of through and through lip laceration</div><div class=\"cntnt\"><img style=\"width:296px; height:716px;\" src=\"images/EM/65733_Repairthroughliplacer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note: Closure of muscle layer (orbicularis oris) not shown in diagram.<br> (A) Opposition of vermilion border.<br> (B) Closure of the inner dermal-fat junction.<br> (C) Closure of the outer dermal-fat junction.<br> (D) Closure of the epidermal layer, with joining of the dermal-fat junction at the free wound edge.</div><div class=\"graphic_reference\">Reproduced with permission from: Attia MW, Loiselle J. Management of soft-tissue injuries of the mouth. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 65733 Version 6.0</div></div></div>"},"65734":{"type":"graphic_algorithm","displayName":"Approach to abdominal pain in patients over 50","title":"Approach to abdominal pain in patients over 50","html":"<div class=\"graphic\"><div style=\"width: 633px\" class=\"figure\"><div class=\"ttl\">Approach to abdominal pain in patients over 50</div><div class=\"cntnt\"><img style=\"width:613px; height:793px;\" src=\"images/EM/65734_Abd_pain_over_50.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AAA: abdominal aortic aneurysm; ACS: acute coronary syndrome; CT: computed tomography; CXR: chest x-ray; ECG: electrocardiogram; IVC: inferior vena cava; LFT: liver function test; RLQ: right lower quadrant; RUQ: right upper quadrant; US: ultrasound.</div><div id=\"graphicVersion\">Graphic 65734 Version 4.0</div></div></div>"},"65735":{"type":"graphic_picture","displayName":"Hepatic hemangioma Light","title":"Cavernous hepatic hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cavernous hepatic hemangioma</div><div class=\"cntnt\"><img style=\"width:370px; height:276px;\" src=\"images/GAST/65735_Hepatic_hemangioma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple vascular channels of various sizes lined by a single layer of flattened endothelium and supported by thin fibrous septae (hematoxylin and eosin).</div><div class=\"graphic_reference\">Courtesy of Imad Nasser, MD.</div><div id=\"graphicVersion\">Graphic 65735 Version 2.0</div></div></div>"},"65736":{"type":"graphic_table","displayName":"Intravenous medications for sedation and analgesia in endoscopy","title":"Intravenous medications used for sedation and analgesia in endoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intravenous medications used for sedation and analgesia in endoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Initial dose<br /> (adult)*</td> <td class=\"subtitle1\">Onset<br /> (minutes)</td> <td class=\"subtitle1\">Duration<br /> (minutes)</td> <td class=\"subtitle1\">Repeat dose<sup>&#182;</sup><br /> (minutes)</td> <td class=\"subtitle1\">Effects</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Benzodiazepines</td> </tr> <tr> <td class=\"indent1\">Midazolam</td> <td>0.02 to 0.03 mg/kg (1 to 2 mg) over 2 to 3 minutes</td> <td>1 to 2</td> <td>15 to 80</td> <td>2 to 5</td> <td>Sedative, amnestic, anxiolytic. Nonanalgesic. Delayed recovery in older adults, with obesity or impaired hepatic function. Reduce dose in combination with opiate analgesic.</td> </tr> <tr> <td class=\"indent1\">Lorazepam</td> <td>0.044 mg/kg (2 to 4 mg) over 1 to 2 minutes</td> <td>15 to 20</td> <td>360 to 480</td> <td>15 to 20</td> <td>Sedative, amnestic, anxiolytic. Prolonged onset, slow recovery, variable response.</td> </tr> <tr> <td class=\"indent1\">Diazepam<sup>&#916;</sup></td> <td>0.03 to 0.1 mg/kg (5 to 10 mg) over 2 to 3 minutes</td> <td>2 to 3</td> <td>360</td> <td>2 to 5</td> <td>Sedative, amnestic, anxiolytic. Phlebitis, IV incompatibility, prolonged onset, slow recovery.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Opiate analgesics</td> </tr> <tr> <td class=\"indent1\">Fentanyl</td> <td>0.5 to 1 micrograms/kg over 3 or more minutes</td> <td>2 to 3</td> <td>30 to 60</td> <td>2</td> <td>Sedative, analgesic. Nonamnestic. Minimal hypotension and histamine release. Reduce dose in combination with benzodiazepine.</td> </tr> <tr> <td class=\"indent1\">Morphine</td> <td>2.5 to 5 mg over 3 to 5 minutes</td> <td>5 to 10</td> <td>120 to 240</td> <td>5 to 10</td> <td>Sedative, analgesic. Histamine release, hypotension. Prolonged duration and recovery.</td> </tr> <tr> <td class=\"indent1\">Meperidine</td> <td>25 to 50 mg over 3 to 5 minutes</td> <td>5</td> <td>60 to 180</td> <td>5 to 10</td> <td>Sedative, analgesic. Histamine release, hypotension, nausea. Prolonged duration and recovery. Interaction with MAO inhibitors.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Sedative-hypnotic anesthetic</td> </tr> <tr> <td class=\"indent1\">Propofol continuous infusion<sup>&#9674;</sup></td> <td>Initiate infusion at 25 micrograms/kg per minute; titrate gradually to response (consult detailed reference)<sup>&#9674;</sup></td> <td>&#60;1</td> <td>Approximately 3 to 10 upon discontinuation</td> <td>Continuous infusion</td> <td>Sedative, amnestic. Nonanalgesic. Rapid onset and neurologic recovery upon discontinuation. Respiratory depression, O<sub>2</sub> desaturation, apnea, hypotension with overly rapid administration. Injection site pain. Older adults: Reduce dose by 20%. Contains egg lecithin, soybean oil (potential allergens).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Antagonist agents for reversal of overdose</td> </tr> <tr> <td class=\"indent1\">Naloxone</td> <td>0.1 to 0.2 mg</td> <td>2 to 3</td> <td>45 to 120</td> <td>2 to 3</td> <td>Overcomes respiratory depression, sedation and hypotension of opiates. Reverses analgesia. Acute narcotic withdrawal if tolerant.</td> </tr> <tr> <td class=\"indent1\">Flumazenil</td> <td>0.2 mg over 30 seconds</td> <td>1 to 3 (peak 6 to 10)</td> <td>Approximately 60</td> <td>1</td> <td>Overcomes sedation and partially reverses respiratory depression of benzodiazepines. Agitation, acute withdrawal and risk of withdrawal seizures if benzodiazepine tolerant.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><SPAN style=\"COLOR: black\">IV: intravenous; MAO: monoamine oxidase.</SPAN><br />* Initial dose for healthy adults &lt;60 years of age. Older, debilitated persons and/or those with compromised cardiorespiratory function or hepatic or renal insufficiency are at increased risk of adverse events with these agents, and dosing should be adjusted accordingly. See text for details.<br />¶ Sedatives and analgesics: Repeat one-half initial dose at interval noted if needed to achieve desired depth and duration of sedation. Additional titration may be needed.<br />Δ Dose for conventional (nonemulsion) diazepam injection. Diazepam emulsion is not available in United States.<br /><FONT class=lozenge>◊</FONT> Bolus injection of propofol alone or in combination with small doses of an opiate and/or benzodiazepine is commonly practiced as an alternative to administration by IV infusion. When given as a bolus, it should be administered by an anesthesiologist or certified registered nurse anesthetist.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Cohen LB, DeLegge MH, Aisenberg J, et al. AGA institute review of endoscopic sedation. Gastroenterology 2007; 133:675.</li>&#xD;&#xA;    <li>Gahart BL, Nazareno AR. Intravenous medications 27th ed, Mosby Elsevier, St. Louis, MO 2011.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 65736 Version 6.0</div></div></div>"},"65739":{"type":"graphic_picture","displayName":"Punch biopsy","title":"Punch biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Punch biopsy</div><div class=\"cntnt\"><img style=\"width:425px; height:250px;\" src=\"images/DERM/65739_Punch_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin is stabilized with the thumb and forefinger and stretched slightly perpendicular to the skin tension lines. A punch is held perpendicular to the skin and is rotated into the skin with a firm, constant pressure.</div><div class=\"graphic_reference\">Reprinted with permission from Alguire, PC, Mathes, BM, J. Gen Intern Med 1998; 13:46.</div><div id=\"graphicVersion\">Graphic 65739 Version 3.0</div></div></div>"},"65740":{"type":"graphic_picture","displayName":"Suction device","title":"Suction device to remove tight fitting contact lenses","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Suction device to remove tight fitting contact lenses</div><div class=\"cntnt\"><img style=\"width:412px; height:175px;\" src=\"images/PC/65740_Suction_device.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65740 Version 1.0</div></div></div>"},"65742":{"type":"graphic_table","displayName":"Some adverse effects of antihistamines and decongestants","title":"Some adverse effects of antihistamines and decongestants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some adverse effects of antihistamines and decongestants</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Antihistamines</td> </tr> <tr> <td class=\"subtitle2_single\">Anticholinergic effects</td> </tr> <tr> <td class=\"indent1\">Dry mouth and eyes</td> </tr> <tr> <td class=\"indent1\">Impotence</td> </tr> <tr> <td class=\"indent1\">Urinary hesitancy</td> </tr> <tr> <td class=\"indent1\">Glaucoma</td> </tr> <tr> <td class=\"subtitle2_single\">Central nervous system effects</td> </tr> <tr> <td class=\"indent1\">Sedation</td> </tr> <tr> <td class=\"indent1\">Rarely stimulation (usually children)</td> </tr> <tr> <td class=\"indent1\">Confusion (older patients)</td> </tr> <tr> <td class=\"indent1\">Cognitive impairment</td> </tr> <tr> <td class=\"subtitle2_single\">Miscellaneous effects</td> </tr> <tr> <td class=\"indent1\">Weight gain</td> </tr> <tr> <td class=\"indent1\">Hypersensitivity</td> </tr> <tr> <td class=\"indent1\">Prolonged QT interval</td> </tr> <tr> <td class=\"indent1\">Ventricular arrhythmias</td> </tr> <tr> <td class=\"subtitle1_single\">Decongestants</td> </tr> <tr> <td class=\"indent1\">Nervousness</td> </tr> <tr> <td class=\"indent1\">Irritability</td> </tr> <tr> <td class=\"indent1\">Insomnia</td> </tr> <tr> <td class=\"indent1\">Headache</td> </tr> <tr> <td class=\"indent1\">Urinary hesitancy</td> </tr> <tr> <td class=\"indent1\">Tachycardia/palpitations</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> </tr> <tr> <td class=\"indent1\">Nausea</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65742 Version 4.0</div></div></div>"},"65743":{"type":"graphic_table","displayName":"Proposed diagnostic criteria for short QT syndrome","title":"Proposed diagnostic criteria for short QT syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed diagnostic criteria for short QT syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">Points</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">QTc, msec</td> </tr> <tr> <td class=\"indent1\">&#60;370</td> <td>1</td> </tr> <tr> <td class=\"indent1\">&#60;350</td> <td>2</td> </tr> <tr> <td class=\"indent1\">&#60;330</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Jpoint-Tpeak interval &#60;120 msec</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Clinical history*</td> </tr> <tr> <td class=\"indent1\">History of sudden cardiac arrest</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Documented polymorphic VT or VF</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Unexplained syncope</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Atrial fibrillation</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Family history*</td> </tr> <tr> <td class=\"indent1\">First- or second-degree relative with high probability of SQTS</td> <td>2</td> </tr> <tr> <td class=\"indent1\">First- or second-degree relative with autopsy-negative sudden cardiac death</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Sudden infant death syndrome</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Genotype*</td> </tr> <tr> <td class=\"indent1\">Genotype positive</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Mutation of undetermined significance in a culprit gene</td> <td>1</td> </tr> <tr class=\"divider_top\"> <td align=\"right\"><strong>Total</strong></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">High-probability SQTS: &#8805;4 points.<br> Intermediate-probability SQTS: 3 points.<br> Low-probability SQTS: &#8804;2 points.</div><div class=\"graphic_footnotes\"><br> VF: ventricular fibrillation; VT: ventricular tachycardia; SQTS: short QT syndrome; QT: Bazett corrected QT interval; msec: milliseconds.<br> <br> * A minimum of 1 point must be obtained in the electrocardiographic section in order to obtain additional points.</div><div class=\"graphic_reference\"><br> Original table modified for this publication. Gollob MH, Redpath CJ, Roberts JD: The short QT syndrome: proposed diagnostic criteria. J Am Coll Cardiol 2011; 57:802. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 65743 Version 3.0</div></div></div>"},"65745":{"type":"graphic_table","displayName":"Treatment of Chagas disease","title":"Treatment of Chagas disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of Chagas disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Treatment of Chagas disease by phase of disease, form of disease, and demographic group</td> </tr> <tr> <td class=\"subtitle2_single\">Should always be offered</td> </tr> <tr> <td class=\"indent1\">Acute <em>Trypanosoma</em><em> cruzi</em> infection&nbsp;(acquired via any form of transmission)</td> </tr> <tr> <td class=\"indent1\">Congenital <em>T. cruzi</em> infection</td> </tr> <tr> <td class=\"indent1\">Children &#8804;18 years old with chronic <em>T. cruzi</em> infection</td> </tr> <tr> <td class=\"indent1\">Reactivated <em>T. cruzi</em> infection in patient with HIV/AIDS or other immunosuppression</td> </tr> <tr> <td class=\"subtitle2_single\">Should generally be offered</td> </tr> <tr> <td class=\"indent1\">Adults* 19 to 50 years old without advanced cardiomyopathy (normal ECG or minor abnormalities on ECG, no evidence of congestive heart failure)</td> </tr> <tr> <td class=\"subtitle2_single\">Optional</td> </tr> <tr> <td class=\"indent1\">Adults &#62;50 years old without advanced cardiomyopathy (normal ECG or minor abnormalities on ECG, no evidence of congestive heart failure)</td> </tr> <tr> <td class=\"indent1\">Chagas gastrointestinal disease patients without advanced cardiomyopathy<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Should generally not be offered</td> </tr> <tr> <td class=\"indent1\">Advanced chagasic cardiomyopathy with congestive heart failure</td> </tr> <tr> <td class=\"indent1\">Megaesophagus with significant impairment of swallowing</td> </tr> <tr> <td class=\"subtitle2_single\">Should never be offered</td> </tr> <tr> <td class=\"indent1\">During pregnancy</td> </tr> <tr> <td class=\"indent1\">Severe renal or hepatic insufficiency</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram.<br />* Strong recommendation for non-pregnant women of reproductive age, based on data suggesting significant decrease in risk of vertical transmission in post-treatment pregnancies.&nbsp;<br />¶ There are no data to suggest that treatment affects progression of gastrointestinal disease. Decisions should be based on the potential to decrease risk of development or progression of heart disease.</div><div class=\"graphic_reference\">Modified&nbsp;with permission from: Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States:&nbsp;A systematic review. JAMA 2007; 298:2171. Copyright © 2007 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 65745 Version 22.0</div></div></div>"},"65747":{"type":"graphic_table","displayName":"ACOG fragile X screening","title":"American College of Obstetricians and Gynecologists Committee on Genetics recommendations for testing for fragile X syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American College of Obstetricians and Gynecologists Committee on Genetics recommendations for testing for fragile X syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Fragile X premutation carrier screening is recommended for women with a family history of fragile X-related disorders or intellectual disability suggestive of fragile X syndrome and who are considering pregnancy or are currently pregnant.</td> </tr> <tr> <td>2. If a woman has unexplained ovarian insufficiency or failure or an elevated follicle-stimulating hormone level before age 40 years, fragile X carrier screening is recommended to determine whether she has an <em><span style=\"font-size: 13px; font-family: MinionPro-It;\">FMR1 </span></em><span>​</span><span>​</span><span style=\"font-size: 13px; font-family: MinionPro-Regular;\">premutation.​​</span><span>​</span><span>​</span><span>​</span><span>​</span><span>​</span><span>​</span><span>​</span></td> </tr> <tr> <td>3.&nbsp;All identified individuals with intermediate results and carriers of a fragile X premutation or full mutation should be provided follow-up genetic counseling to discuss the risk to their offspring of inheriting an expanded full-mutation fragile X allele and to discuss fragile X-associated disorders (premature ovarian insufficiency and fragile X tremor/ataxia syndrome).</td> </tr> <tr> <td>4.&nbsp;Prenatal diagnostic testing for fragile X syndrome should be offered to known carriers of the fragile X premutation or full mutation.</td> </tr> <tr> <td>5.&nbsp;DNA-based molecular analysis (eg, Southern blot analysis and polymerase chain reaction) is the preferred method of diagnosis of fragile X syndrome <span style=\"font-size: 13px; font-family: MinionPro-Regular;\"><span style=\"font-size: 13px; font-family: MinionPro-Regular;\">and of determining </span>​<em><span style=\"font-size: 13px; font-family: MinionPro-It;\">FMR1 ​</span></em><span style=\"font-size: 13px; font-family: MinionPro-Regular;\">triplet repeat number (eg, </span></span>premutations). In rare cases, the size of the triplet repeat and the methylation status do not correlate, which makes it difficult to predict the clinical phenotype. In cases of this discordance, the patient should be referred to a genetics professional.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><EM>FMR1</EM>: fragile X mental retardation 1.</div><div class=\"graphic_reference\">American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 691: Carrier screening for genetic conditions. Obstet Gynecol 2017; 129:e41.</div><div id=\"graphicVersion\">Graphic 65747 Version 10.0</div></div></div>"},"65748":{"type":"graphic_picture","displayName":"Well diff sinonasal CA Light","title":"Well-differentiated sinonasal adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Well-differentiated sinonasal adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:548px; height:256px;\" src=\"images/ONC/65748_Well_diff_sinonasal_CA_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph, demonstrating a large mass composed of well-formed glandular structures (left panel). The cribriform arrangement of these glandular structures (right panel) is a key feature in recognizing this tumor.</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 65748 Version 1.0</div></div></div>"},"65749":{"type":"graphic_waveform","displayName":"Invasive hemodynamic tracing HCM with variable LVOT obstruction","title":"Invasive hemodynamic tracing in a patient with HCM showing variable left ventricular outflow tract obstruction","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Invasive hemodynamic tracing in a patient with HCM showing variable left ventricular outflow tract obstruction</div><div class=\"cntnt\"><img style=\"width:530px; height:268px;\" src=\"images/CARD/65749_HCM_and_variable_obstructio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are four surface ECG leads (I, II, III, and V6) and simultaneous pressure tracings from the left ventricle (LV, arrow) and aorta (Ao, arrow). Although no change in heart rate occurs during this tracing, a spontaneous increase in the LV outflow tract obstruction and LV pressure is observed with the gradient increasing from 10 to 80 mmHg. The increase in gradient is associated with a narrowing of the aortic pulse pressure and the development of a spike-and-dome arterial configuration (SD, arrow).</div><div class=\"graphic_reference\">Courtesy of Lameh Fananapazir, MD.</div><div id=\"graphicVersion\">Graphic 65749 Version 3.0</div></div></div>"},"65750":{"type":"graphic_table","displayName":"Features distinguishing dissociative PTSD from other disorders","title":"Features that typically distinguish the dissociative subtype of PTSD from borderline personality disorder, bipolar disorder and schizophrenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features that typically distinguish the dissociative subtype of PTSD from borderline personality disorder, bipolar disorder and schizophrenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Dissociative subtype PTSD</td> <td class=\"subtitle1\">Schizophrenia and psychotic disorders</td> <td class=\"subtitle1\">Bipolar disorder</td> <td class=\"subtitle1\">Borderline personality disorder</td> </tr> <tr> <td><strong>Trauma</strong></td> <td>Typically report early onset, severe, chronic childhood trauma.</td> <td>Less likely to have severe, chronic childhood trauma.</td> <td>Less likely to have severe, chronic childhood trauma.</td> <td>Although may report a history of childhood trauma, it may be less severe or chronic than with dissociative disorders.</td> </tr> <tr> <td><strong>Dissociative symptoms</strong></td> <td> <p>Typically endorse high levels (eg, DES average score high 20s or more) with intact reality testing.</p> <p>Often prefer to feel numb than to have strong feelings. May self-harm to induce a state of dissociation from traumatic experiences.</p> </td> <td>Endorse mildly high symptoms (eg, DES average score 17.6) with poor reality testing.</td> <td>Lower dissociation scores expected.</td> <td> <p>Moderate symptoms (eg, DES average in the low 20s) but significantly lower than DID with intact reality testing; may not be different from dPTSD on derealization and depersonalization, but usually lower on amnesia.</p> <p>Often find it distressing to feel numb and may self-harm to end an episode of dissociation.</p> </td> </tr> <tr> <td><strong>Hallucinatory experiences</strong></td> <td>In severe cases, may endorse hearing voice(s) but aware of the \"as if\" quality (\"I know they're not real but I hear a child crying as she gets yelled at\"); may experience brief periods of \"seeing\" past traumatic events in flashback; reality testing otherwise intact; auditory and visual hallucinations relate to high dissociativity/hypnotizability.</td> <td>May endorse voices without awareness of the hallucinatory quality; may have visual hallucinations without recognition they are not real; hallucinations are due to psychotic process.</td> <td>Experiences hallucinations only during episodes of psychotic mania- or depression; in psychotic depression, any voices are typically solely persecutory.</td> <td>If experiences hallucinatory experiences, they are brief, distressing and occur during stress; if endorses voices, they express patient's polarized thoughts.</td> </tr> <tr> <td><strong>Affect</strong></td> <td>Typically experience a range of affective states including numbed and detached; severe cases may have inexplicable, rapid mood changes that may be triggered by internal or external precipitants (eg, sad to angry to helpless and afraid). Many mood shifts can occur per day; rarely complain of \"emptiness\".</td> <td>Flat and/or inappropriate affect.</td> <td>Shifts in mood state occur more slowly (take at least 12 hours to shift mood state and usually much longer than that).</td> <td>Affect is typically less modulated than in dPTSD and shifts according to external precipitants; often the most frequent affects are emptiness and intense anger.</td> </tr> <tr> <td><strong>Ability to perceive accurately and think logically</strong></td> <td>Perceptions are generally accurate; thinking is usually logical and organized except for brief periods following traumatic intrusions or periods of intense flooding of traumatic symptoms.</td> <td>Perception may be less accurate than in dPTSD; thinking tends to be less logical and organized.</td> <td>Disturbed only during mood episodes.</td> <td>Perception tends to be distorted and thinking is less logical, particularly when stressed.</td> </tr> <tr> <td><strong>Working alliance</strong></td> <td>Generally capable of developing a working alliance with therapist; interested in others despite fear of being hurt; usually capable of self-reflection; may have long-standing relationships and/or be avoidant and prefer to be alone because it feels \"safer\".</td> <td>Less capable of developing a working alliance; generally less interested in others; less capacity for self-reflection.</td> <td>Capable of developing a working alliance.</td> <td>Often less capable of developing a working alliance; pattern of overvaluing/devaluing therapist, provocations and fear of abandonment; may expect others to be less cooperative than dPTSD; often have about the same level of interest in others as in DID; less capacity for self-reflection than in DID; history of tumultuous, chaotic relationships and difficulty tolerating being alone.</td> </tr> <tr> <td><strong>Comorbidity</strong></td> <td> <p>Usually meet criteria for multiple comorbid disorders including mood disorders, PTSD and other anxiety disorders, substance disorders, mixed personality disorders, somatoform disorders as well as multiple medical illnesses such as headaches, fibromyalgia, gastrointestinal, and gynecological problems.</p> <p>Usually meet BPD criteria when severely decompensated/having overwhelming PTSD/dissociative disorder symptoms; most do not meet BPD criteria once stabilized.</p> </td> <td>Typically meet criteria for fewer comorbid conditions although substance disorders are common.</td> <td>Typically meet criteria for fewer comorbid conditions, but comorbid substance abuse is common.</td> <td>Often have a variety of comorbid disorders, but less prevalence of PTSD, somatoform disorders.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DES: Dissociative Experiences Scale; DID: dissociative identitiy disorder; dPTSD: dissociative subtype of PTSD; PTSD: posttraumatic stress disorder; BPD: borderline personality disorder.</div><div class=\"graphic_reference\">References:<br> <ol> <li>Brand B, Loewenstein RJ. Dissociative disorders: an overview of assessment, phenomenology and treatment. Psychiatric Times 2010. </li> <li>Brand BL, Armstrong JG, Loewenstein RJ, McNary SW. Personality differences on the Rorschach of dissociative identity disorder, borderline personality disorder and psychotic inpatients. Psychol Trauma 2009; 1:188. </li> <li>Briere J, Weathers FW, Runtz M. Is dissociation a multidimensional construct? Data from the Multiscale Dissociation Inventory. J Traumatic Stress 2005; 18:221. </li> <li>Boon S, Draijer N. The differentiation of patients with MPD or DDNOS from patients with a Cluster B personality disorder. Dissociation 1993; 6:126. </li> </ol></div><div id=\"graphicVersion\">Graphic 65750 Version 2.0</div></div></div>"},"65751":{"type":"graphic_figure","displayName":"V-Y advancement flap","title":"V-Y advancement flap","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">V-Y advancement flap</div><div class=\"cntnt\"><img style=\"width:305px; height:405px;\" src=\"images/SURG/65751_VY-flap-edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The V-Y advancement flap is performed by making a V-shaped incision in the skin, after which the skin on each side of the V is advanced and the incision is closed as a Y.</div><div id=\"graphicVersion\">Graphic 65751 Version 3.0</div></div></div>"},"65753":{"type":"graphic_picture","displayName":"Cutaneous lichen amyloid general view","title":"Cutaneous lichen amyloidosis in a patient with MEN2: General view","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Cutaneous lichen amyloidosis in a patient with MEN2: General view</div><div class=\"cntnt\"><img style=\"width:468px; height:323px;\" src=\"images/ENDO/65753_Cutaneous_lichen_amyloid1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin lesion is usually described as pruritic, scaly, papular, pigmented, and located in the interscapular region or on the extensor surfaces of the extremities. Amyloid deposition has been documented histologically.</div><div class=\"graphic_reference\">Courtesy of Cornelis J Lips, MD, PhD.</div><div id=\"graphicVersion\">Graphic 65753 Version 3.0</div></div></div>"},"65754":{"type":"graphic_diagnosticimage","displayName":"Fitz-Hugh-Curtis syndrome","title":"Fitz-Hugh Curtis syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fitz-Hugh Curtis syndrome</div><div class=\"cntnt\"><img style=\"width:447px; height:168px;\" src=\"images/GAST/65754_Fitz-Hugh-Curtis_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT-scan image (left) of a young female with Fitz-Hugh Curtis Syndrome. Note the contracted gallbladder in the very center giving the appearance of a gallstone and the large amount of pericholecystic fluid around it. The ultrasound image (right) confirms the contracted gallbladder with the double wall sign.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP.</div><div id=\"graphicVersion\">Graphic 65754 Version 4.0</div></div></div>"},"65755":{"type":"graphic_picture","displayName":"Anteriorly displaced anus","title":"Nineteen-year-old woman with life-long history of severe constipation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nineteen-year-old woman with life-long history of severe constipation</div><div class=\"cntnt\"><img style=\"width:396px; height:328px;\" src=\"images/PEDS/65755_Rectal_shelf.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) In this 19 year-old woman with a life-long history of constipation, the&nbsp;anus is clearly anteriorly located,&nbsp;with a short perineal body. Normally, the anus should be located in the&nbsp;shiny pigmented skin, which is&nbsp;posterior to anal opening in this patient. B) Barium enema in the same patient. There is&nbsp;marked dilatation of rectum,&nbsp;extending to the anus. This is the typical appearance of so-called \"habit constipation\" or \"psychogenic\" constipation. However, some of these cases are probably caused by unrecognized slight anorectal malformation, as in this case.&nbsp;After anoplasty, this patient&nbsp;developed normal&nbsp;defecation patterns.</div><div class=\"graphic_reference\">Reproduced with permission from: Hendren WH. Pediatric rectal and perineal problems. Pediatr Clin North Am 1998; 45:1353. Copyright ©1998 Elsevier.</div><div id=\"graphicVersion\">Graphic 65755 Version 3.0</div></div></div>"},"65756":{"type":"graphic_table","displayName":"Return to play guidelines A","title":"Recommendations for participation in contact sports in certain cervical spine conditions, part A","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for participation in contact sports in certain cervical spine conditions, part A</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"3\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Condition</td> <td class=\"subtitle1\" colspan=\"3\">Contraindication to play</td> </tr> <tr> <td class=\"subtitle2\">Absolute</td> <td class=\"subtitle2\">Relative*</td> <td class=\"subtitle2\">None*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Congenital anomalies</td> </tr> <tr> <td class=\"indent1\">Odontoid agenesis, hypoplasia or os odontoidium</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Type 1 Klippel-Feil<sup>&#182;</sup> mass fusion</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Type 2 Klippel-Feil<sup>&#916;</sup> congenital one-level fusion</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Atlanto-occipital fusion</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Spina bifida occulta</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Atlantoaxial conditions</td> </tr> <tr> <td class=\"indent1\">Atlantoaxial instability</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Atlantoaxial rotary fixation</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Stenosis of the spinal canal</td> </tr> <tr> <td class=\"indent1\">Spear tackler's spine</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Developmental stenosis of the spinal canal (canal/vertebral body ratio &#60;0.8)</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"4\">Developmental stenosis of the spinal canal with:</td> </tr> <tr> <td class=\"sublist2\">Ligamentous instability</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Cervical cord neurapraxia with signs or symptoms lasting more than 36 hours</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Multiple episodes of cervical cord neurapraxia</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"4\">Developmental stenosis of the spinal canal with:</td> </tr> <tr> <td class=\"sublist2\">Episode of cervical cord neurapraxia</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Intervertebral disk disease</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">MRI evidence of cord compression</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Burners</td> </tr> <tr> <td class=\"indent1\">Recurrent acute and chronic burners</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Resolved burner</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Provided individual is asymptomatic and neurologically normal and has full range of pain-free cervical motion. <br />&para; Type 1 Klippel-Feil anomaly: a mass fusion of the cervical and upper thoracic vertebrae.<br />&Delta; Type 2 Klippel-Feil anomaly: one- or two-level cervical fusion with full range of cervical motion, with no evidence of spinal instability or the presence of cervical disk disease or other degenerative changes.</div><div class=\"graphic_reference\">Adapted from Torg, JS, Ramsey-Emrhein, JA. Cervical spine and brachial plexus injuries: Return-to-play recommendations. Phys Sportsmed 1997; 25.</div><div id=\"graphicVersion\">Graphic 65756 Version 2.0</div></div></div>"},"65757":{"type":"graphic_picture","displayName":"Post-fistula excision with transverse incision","title":"Post-fistula excision with transverse incision","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Post-fistula excision with transverse incision</div><div class=\"cntnt\"><img style=\"width:432px; height:358px;\" src=\"images/PC/65757_Mammary_duct_fistula_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fistulectomy can be performed with an incision across the nipple, directly over the fistula.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 65757 Version 5.0</div></div></div>"},"65758":{"type":"graphic_figure","displayName":"Outcome repeat valvuloplasty","title":"Outcome after repeat PMBV is related to comorbid diseases","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Outcome after repeat PMBV is related to comorbid diseases</div><div class=\"cntnt\"><img style=\"width:377px; height:439px;\" src=\"images/CARD/65758_Outcome_repeat_valvuloplast.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a group of 36 patients who underwent repeat percutaneous mitral balloon valvulotomy for mitral valve restenosis developing 37 months after the first procedure, the presence of a comorbid disease significantly reduced overall survival (panel A) and event-free survival (panel B).</div><div class=\"graphic_reference\">Data from Pathan AZ, Mahdi NA, Leon MN, et al. J Am Coll Cardiol 1999; 34:49.</div><div id=\"graphicVersion\">Graphic 65758 Version 2.0</div></div></div>"},"65760":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of popliteal artery aneursym","title":"Ultrasound of popliteal artery aneursym","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Ultrasound of popliteal artery aneursym</div><div class=\"cntnt\"><img style=\"width:452px; height:344px;\" src=\"images/SURG/65760_Popliteal_aneurysm_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrsound demonstrating a 6.37 x 6.01 centimeter popliteal artery aneurysm.</div><div class=\"graphic_footnotes\">%: percent.</div><div id=\"graphicVersion\">Graphic 65760 Version 4.0</div></div></div>"},"65763":{"type":"graphic_picture","displayName":"Typical molluscum bumps","title":"Typical molluscum bumps","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical molluscum bumps</div><div class=\"cntnt\"><img style=\"width:262px; height:288px;\" src=\"images/ID/65763_Typical_molluscum_bumps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the pearly appearance and the dimple in the center of the bumps.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Overview of Molluscum Contagiosum. http://www.cdc.gov/ncidod/dvrd/molluscum/overview.htm. Accessed May 30, 2008.</div><div id=\"graphicVersion\">Graphic 65763 Version 3.0</div></div></div>"},"65765":{"type":"graphic_figure","displayName":"Mesorectal excision rect CA","title":"Mesorectal excision","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Mesorectal excision</div><div class=\"cntnt\"><img style=\"width:517px; height:409px;\" src=\"images/ONC/65765_Mesorectal_excision_rect_CA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This illustration of a median (sagittal) section of a male pelvis depicts the boundaries for mesorectal excision of a rectal adenocarcinoma.</div><div id=\"graphicVersion\">Graphic 65765 Version 4.0</div></div></div>"},"65766":{"type":"graphic_figure","displayName":"Cushing's appearance PI","title":"Appearance of Cushing's syndrome","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Appearance of Cushing's syndrome</div><div class=\"cntnt\"><img style=\"width:506px; height:633px;\" src=\"images/PI/65766_Cushings_appearance_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawings shows some of the common outer symptoms of people with Cushing's syndrome. Different people can have different symptoms.</div><div id=\"graphicVersion\">Graphic 65766 Version 6.0</div></div></div>"},"65767":{"type":"graphic_figure","displayName":"Gelpi retractor","title":"Gelpi retractor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gelpi retractor</div><div class=\"cntnt\"><img style=\"width:209px; height:375px;\" src=\"images/OBGYN/65767_Gelpi_retractor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tips are designed to limit tissue penetration.</div><div id=\"graphicVersion\">Graphic 65767 Version 1.0</div></div></div>"},"65769":{"type":"graphic_figure","displayName":"Taking infundibulopelvic ligamt","title":"Creation of a window in the posterior peritoneum during gynecologic surgery","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Creation of a window in the posterior peritoneum during gynecologic surgery</div><div class=\"cntnt\"><img style=\"width:474px; height:332px;\" src=\"images/OBGYN/65769_Taking_infundibulopelvic_li.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A window is made in the posterior peritoneum allowing the infundibulopelvic ligament to be isolated and clamped.</div><div id=\"graphicVersion\">Graphic 65769 Version 2.0</div></div></div>"},"65772":{"type":"graphic_table","displayName":"Treatment of hyponatremia in SAH","title":"Protocol for management of hyponatremia in patients with subarachnoid hemorrage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Protocol for management of hyponatremia in patients with subarachnoid hemorrage</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">For Na level &#60;133 mEq/L or a decrease of 6 mEq/L in 24 to 48 hours:</td> </tr> <tr> <td class=\"indent1\">1. NaCl tabs 3 g PO/NGT every 6 h</td> </tr> <tr> <td class=\"indent1\">2. Initiate 3 percent NaCl infusion at 20 mL/h IV</td> </tr> <tr> <td class=\"sublist2_start\">3. Check serum Na every 6 hours</td> </tr> <tr> <td class=\"sublist3_start\">a. If Na &#60;130 mEq/L:</td> </tr> <tr> <td class=\"sublist3\">Increase rate by 20 mL/h (max rate = 80 mL/h)</td> </tr> <tr> <td class=\"sublist3\">If on hold at present, initiate 3 percent NaCl infusion at 20 mL/h IV</td> </tr> <tr> <td class=\"sublist3_start\">b. If Na = 130 to 135 mEq/L:</td> </tr> <tr> <td class=\"sublist3\">Increase rate by 10 mL/h (max rate = 80 mL/h)</td> </tr> <tr> <td class=\"sublist3\">If on hold at present, initiate 3 percent NaCl infusion at 10 mL/h IV</td> </tr> <tr> <td class=\"sublist3_start\">c. If Na = 136 to 140 mEq/L:</td> </tr> <tr> <td class=\"sublist3\">No change</td> </tr> <tr> <td class=\"sublist3_start\">d. If Na &#8805;140 mEq/L:</td> </tr> <tr> <td class=\"sublist3\">Hold infusion</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Woo CH, Roa VA, Sheridan W, Flint A. Performance characteristics of a sliding-scale hypertonic saline infusion protocol for the treatment of acute neurologic hyponatremia. Neurocrit Care 2009; 11:228, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2009.</div><div id=\"graphicVersion\">Graphic 65772 Version 13.0</div></div></div>"},"65774":{"type":"graphic_table","displayName":"Pallor differential diagnosis in children","title":"Differential diagnosis for pallor in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis for pallor in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Decreased erythrocyte or hemoglobin production</td> </tr> <tr> <td class=\"indent1\">Iron deficiency</td> </tr> <tr> <td class=\"indent1\">Folic acid</td> </tr> <tr> <td class=\"indent1\">Vitamin B12 deficiency</td> </tr> <tr> <td class=\"indent1\">Diamond-Blackfan anemia</td> </tr> <tr> <td class=\"indent1\">Fanconi's anemia</td> </tr> <tr> <td class=\"indent1\">Aplastic anemia</td> </tr> <tr> <td class=\"indent1\">Transient erythroblastopenia of childhood (TEC)</td> </tr> <tr> <td class=\"indent1\">Malignancy*</td> </tr> <tr> <td class=\"indent1\">Thalassemias</td> </tr> <tr> <td class=\"indent1\">Sideroblastic anemia</td> </tr> <tr> <td class=\"indent1\">Lead poisoning</td> </tr> <tr> <td class=\"indent1\">Anemia of chronic disease</td> </tr> <tr> <td class=\"subtitle1_single\">Increased erythrocyte destruction</td> </tr> <tr> <td class=\"indent1\">Hereditary spherocytosis</td> </tr> <tr> <td class=\"indent1\">Elliptocytosis</td> </tr> <tr> <td class=\"indent1\">Stomatocytosis</td> </tr> <tr> <td class=\"indent1\">Pyknocytosis</td> </tr> <tr> <td class=\"indent1\">G6PD deficiency</td> </tr> <tr> <td class=\"indent1\">Pyruvate kinase deficiency</td> </tr> <tr> <td class=\"indent1\">Sickle cell syndromes*</td> </tr> <tr> <td class=\"indent1\">Unstable hemoglobins</td> </tr> <tr> <td class=\"indent1\">Autoimmune hemolytic anemia*<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Isoimmune hemolytic anemia*</td> </tr> <tr> <td class=\"indent1\">Disseminated intravascular coagulation*</td> </tr> <tr> <td class=\"indent1\">Hemolytic uremic syndrome*</td> </tr> <tr> <td class=\"indent1\">Thrombotic thrombocytopenic Purpura*</td> </tr> <tr> <td class=\"indent1\">Cavernous hemangioma (Kasabach Merritt syndrome)</td> </tr> <tr> <td class=\"subtitle1_single\">Blood loss</td> </tr> <tr> <td class=\"indent1\">Severe trauma*</td> </tr> <tr> <td class=\"indent1\">Meckel's diverticulum</td> </tr> <tr> <td class=\"indent1\">Peptic ulcer</td> </tr> <tr> <td class=\"indent1\">Idiopathic pulmonary hemosiderosis</td> </tr> <tr> <td class=\"subtitle1_single\">Nonhematologic</td> </tr> <tr> <td class=\"indent1\">Respiratory failure*</td> </tr> <tr> <td class=\"indent1\">Shock*</td> </tr> <tr> <td class=\"indent1\">Hypoglycemia*</td> </tr> <tr> <td class=\"indent1\">Pheochromocytoma*</td> </tr> <tr> <td class=\"indent1\">Skin edema</td> </tr> <tr> <td class=\"indent1\">Fair skinned complexion</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Life threatening.<br />¶ Potential causes of autoimmune hemolytic anemia include idiopathic, viral infection (eg, mononucleosis, influenza, coxsackie, measles, varicella, cytomegalovirus), bacterial infection (eg, <EM>Escherichia coli</EM>, Pneumococcus, Streptococcus, typhoid fever, mycoplasma), drugs, inflammatory and collagen vascular disease (eg, systemic lupus erythematosus), and malignancy.</div><div id=\"graphicVersion\">Graphic 65774 Version 3.0</div></div></div>"},"65775":{"type":"graphic_picture","displayName":"Follicular lesions","title":"Follicular lesions: Appearance on fine-needle aspirate of a thyroid nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Follicular lesions: Appearance on fine-needle aspirate of a thyroid nodule</div><div class=\"cntnt\"><img style=\"width:290px; height:436px;\" src=\"images/ENDO/65775_follicular_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple fine-needle aspiration specimens from thyroid nodules revealing microfollicles in syncytia with nuclear atypia and little or no colloid.</div><div class=\"graphic_reference\">Courtesy of Stephanie L Lee, MD, PhD.</div><div id=\"graphicVersion\">Graphic 65775 Version 3.0</div></div></div>"},"65776":{"type":"graphic_figure","displayName":"Neuropathy screening instrument","title":"Michigan Neuropathy Screening Instrument form","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Michigan Neuropathy Screening Instrument form</div><div class=\"cntnt\"><img style=\"width:436px; height:449px;\" src=\"images/NEURO/65776_Neuropathy_screening_score.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Redrawn from: Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17:1281.</div><div id=\"graphicVersion\">Graphic 65776 Version 4.0</div></div></div>"},"65777":{"type":"graphic_picture","displayName":"Dacryostenosis","title":"Acute dacryocystitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute dacryocystitis</div><div class=\"cntnt\"><img style=\"width:396px; height:287px;\" src=\"images/PEDS/65777_Acute_dacryocystitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Infantile dacryocystitis is a painful, tender swelling of the inferior medial canthal area, with surrounding cellulitis. At birth, the child's parents had noticed a nontender, bluish mass in this area, which probably represents an underlying dacryocystocele that had become infected.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65777 Version 4.0</div></div></div>"},"65778":{"type":"graphic_picture","displayName":"Infected lymphangioma of the tongue","title":"Infected lymphangioma of the tongue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infected lymphangioma of the tongue</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/65778_Lymphangioma_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, MD, Ludwig W, MD, Baskin MN, MD. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65778 Version 2.0</div></div></div>"},"65779":{"type":"graphic_waveform","displayName":"Intermediate case 20 answer","title":"Acute anterior ST elevation MI (STEMI) with right bundle branch block","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Acute anterior ST elevation MI (STEMI) with right bundle branch block</div><div class=\"cntnt\"><img style=\"width:478px; height:226px;\" src=\"images/CARD/65779_Intermediate_case_20_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing an acute anterior myocardial infarction (Q waves and ST elevations in leads V2 to V4, and ST elevations alone in leads I and aVL) and right bundle branch block (terminal R wave in lead V1 and terminal S wave in leads I and V6).</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 65779 Version 3.0</div></div></div>"},"65780":{"type":"graphic_picture","displayName":"Tooth discoloration","title":"Tooth discoloration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tooth discoloration</div><div class=\"cntnt\"><img style=\"width:432px; height:546px;\" src=\"images/EM/65780_Tooth_discoloration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ischemic necrosis of the pulp may be indicated by discoloration of the crown. (A) Primary right central incisor. (B) Permanent left central incisor.</div><div class=\"graphic_reference\">Courtesy of: Dennis J. McTigue, MD.</div><div id=\"graphicVersion\">Graphic 65780 Version 2.0</div></div></div>"},"65781":{"type":"graphic_picture","displayName":"Torsion of the appendix testis","title":"Torsion of the appendix testis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Torsion of the appendix testis</div><div class=\"cntnt\"><img style=\"width:360px; height:335px;\" src=\"images/PC/65781_Appendix_testis_torsion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The appendix testis is a 0.3 cm pedunculated structure on the anterosuperior aspect of the testis. Torsion can produce testicular pain that ranges from mild to severe. Infarction and necrosis of the appendix testis can be seen as a \"blue dot\" sign (arrow) in 21% of cases.</div><div class=\"graphic_reference\">Reproduced with permission from Charise Johns, MD.</div><div id=\"graphicVersion\">Graphic 65781 Version 3.0</div></div></div>"},"65782":{"type":"graphic_table","displayName":"Fabrics for covering pillows and mattresses","title":"Fabrics for covering pillows and mattresses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fabrics for covering pillows and mattresses</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Fabric permeability to allergens</td> </tr> <tr> <td class=\"subtitle2\">Airflow through fabric</td> <td class=\"subtitle2\">Mite</td> <td class=\"subtitle2\">Cat</td> </tr> <tr> <td><strong>Plastic or vinyl covers</strong></td> <td>Unmeasurable</td> <td>&#60;1.0 ng</td> <td>&#60;1.0 ng</td> </tr> <tr> <td><strong>Semipermeable fabrics</strong>*</td> <td>&#60;0.1 L/min</td> <td>&#60;1.0 ng</td> <td>&#60;1.0 ng</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\"><strong>Unwoven synthetics</strong></td> </tr> <tr> <td class=\"sublist1\">Type 1 (Filtrete)</td> <td class=\"sublist_other\">1.3 L/min</td> <td class=\"sublist_other\">&#60;2.0 ng</td> <td class=\"sublist_other\">2.3 ng</td> </tr> <tr> <td class=\"sublist1\">Type 2 (Propore)</td> <td class=\"sublist_other\">18 L/min</td> <td class=\"sublist_other\">&#60;2.0 ng</td> <td class=\"sublist_other\">1.5 ng</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\"><strong>Finely woven fabrics</strong><sup>[1]</sup></td> </tr> <tr> <td class=\"sublist1\">2 micrometers</td> <td class=\"sublist_other\">8 L/min</td> <td class=\"sublist_other\">&#60;1 ng</td> <td class=\"sublist_other\">2 ng</td> </tr> <tr> <td class=\"sublist1\">6.6 micrometers</td> <td class=\"sublist_other\">16 L/min</td> <td class=\"sublist_other\">&#60;2 ng</td> <td class=\"sublist_other\">5.7 ng</td> </tr> <tr> <td class=\"sublist1\">10 micrometers</td> <td class=\"sublist_other\">19 L/min</td> <td class=\"sublist_other\">&#60;2 ng</td> <td class=\"sublist_other\">78 ng</td> </tr> <tr> <td><strong>Traditional cotton or synthetic covers</strong></td> <td>22 L/min</td> <td>133 ng</td> <td>580 ng</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Eg, Gortex and other porous materials.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>From: Vaughan JW, et al. J Allergy Clin Immunol 1999; 103:227.</LI></OL></div><div id=\"graphicVersion\">Graphic 65782 Version 5.0</div></div></div>"},"65783":{"type":"graphic_table","displayName":"Need for liver TPL in PBC","title":"Mayo scoring system for predicting the need for liver transplantation in primary biliary cholangitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mayo scoring system for predicting the need for liver transplantation in primary biliary cholangitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td>R = [0.871 x log<sub>e</sub> serum bilirubin (mg/dL)] - [2.53 x log<sub>e</sub> serum albumin (gm/dL)]</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>+ [0.039 x age (years)] + [2.38 x log<sub>e</sub> prothrombin time (seconds)]</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>+ [0.859 x edema score]</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle1_single\">Edema score</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>0 = no edema</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>0.5 = diuretic-controlled edema</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>1.0 = diuretic-resisitant edema</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle1_single\">Survival function [S(t)]</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>1 year = 0.970</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>2 years = 0.941</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>3 years = 0.883</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>4 years = 0.774</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>5 years = 0.721</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>6 years = 0.651</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td class=\"subtitle1_single\">Calculated patient survival = S(t)<sup>exp(R - 5.07)</sup></td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Survival probability at one year = 0.970<sup>exp(R - 5.07)</sup></td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Survival probability at three years = 0.883<sup>exp(R - 5.07)</sup></td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">6.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=27882&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Need_for_liver_TPL_in_PBC.htm</title></head></div><div class=\"graphic_reference\">Adapted from Dickson, ER, Grambsch, PM, Fleming, TR, et al, Hepatology 1989; 10:1, and Grambsch, PM, Dickson, ER, Kaplan, M, et al, Hepatology 1989; 10:846.</div><div id=\"graphicVersion\">Graphic 65783 Version 2.0</div></div></div>"},"65786":{"type":"graphic_table","displayName":"Glomerular versus extraglomerular hematuria in child","title":"Distinguishing extraglomerular from glomerular hematuria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing extraglomerular from glomerular hematuria</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Extraglomerular</td> <td class=\"subtitle1\">Glomerular</td> </tr> <tr> <td><strong>Color (if macroscopic)</strong></td> <td>Red or pink</td> <td>Red, smoky brown, or \"Coca-Cola\"</td> </tr> <tr> <td><strong>Clots</strong></td> <td>May be present</td> <td>Absent</td> </tr> <tr> <td><strong>Proteinuria</strong></td> <td>Usually absent</td> <td>May be present</td> </tr> <tr> <td><strong>RBC morphology</strong></td> <td>Normal</td> <td>Dysmorphic</td> </tr> <tr> <td><strong>RBC casts</strong></td> <td>Absent</td> <td>May be present</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RBC: red blood cell.</div><div id=\"graphicVersion\">Graphic 65786 Version 5.0</div></div></div>"},"65788":{"type":"graphic_figure","displayName":"MUAP morphology","title":"Motor unit action potential (MUAP) morphology and needle electromyography (EMG) position","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Motor unit action potential (MUAP) morphology and needle electromyography (EMG) position</div><div class=\"cntnt\"><img style=\"width:524px; height:350px;\" src=\"images/NEURO/65788_MUAP_morphology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The position of the EMG needle influences the morphology of the recorded MUAP. To properly assess MUAP parameters, the major spike must be as steep as possible, indicating the proximity of the needle to the motor unit. Note that needle electrode position E3 has the shortest major spike rise time and is the preferable position in which to assess the MUAP. Also note that although MUAP amplitude changes markedly with needle position (compare position E1 with E3), duration is relatively unaffected. (From D Dimitru, JA DeLisa. AAEM minimonograph #10: volume conduction. Muscle Nerve 1991;14:605. Reprinted by permission of Wiley.)</div><div class=\"graphic_reference\">Reproduced with permission from: Preston, DC, Shapiro, BE. Electromyography and neuromuscular disorders, Butterworth-Heinemann, Boston 1998. Copyright &#169; 1998 Elsevier.</div><div id=\"graphicVersion\">Graphic 65788 Version 1.0</div></div></div>"},"65789":{"type":"graphic_picture","displayName":"Endometriosis implants","title":"The top, middle, and bottom series are representative of red, white, and black implants, respectively","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">The top, middle, and bottom series are representative of red, white, and black implants, respectively</div><div class=\"cntnt\"><img style=\"width:543px; height:430px;\" src=\"images/OBGYN/65789_Endometriosis_implants.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67:817. Copyright &#169;1997 American Society for Reproductive Medicine.</div><div id=\"graphicVersion\">Graphic 65789 Version 1.0</div></div></div>"},"65790":{"type":"graphic_diagnosticimage","displayName":"Cephalic view of clavicle fracture","title":"Cephalic view of clavicle fracture","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Cephalic view of clavicle fracture</div><div class=\"cntnt\"><img style=\"width:566px; height:274px;\" src=\"images/EM/65790_Clavicle_fx_cephalic_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This midshaft clavicle fracture cannot be appreciated with standard views (radiograph on left).&nbsp;However,&nbsp;by using&nbsp;the 45-degree cephalic tilt view (radiograph on right), bone&nbsp;angulation and a fracture line become apparent.</div><div class=\"graphic_reference\">Reproduced with permission from: Eiff, MP, Hatch, RL, Calmbach, W (Eds). Fracture Management for Primary Care, 2nd Edition, W.B. Saunders Company, Philadelphia 2002. Illustration used with permission of Elsevier Inc. All right reserved. Copyright ©2002 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 65790 Version 2.0</div></div></div>"},"65792":{"type":"graphic_picture","displayName":"Widow spiderlings","title":"Western black widow spiderlings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Western black widow spiderlings</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/ALLRG/65792_Widow_spiderlings.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Richard S Vetter, MS.</div><div id=\"graphicVersion\">Graphic 65792 Version 1.0</div></div></div>"},"65796":{"type":"graphic_movie","displayName":"Angiogram with CAV","title":"Left coronary artery angiogram with cardiac allograft vasculopathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left coronary artery angiogram with cardiac allograft vasculopathy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/65796_angiocavconv.mp4\" style=\"width:400px;height:416px\"></div><img style=\"width:360px; height:357px;\" src=\"images/CARD/65796_AngiogramwithCAV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An almost normal angiogram of the left coronary artery of a patient eight years after transplantation. Green lines indicate the position of the IVUS image.</div><div class=\"graphic_footnotes\">IVUS: intravascular ultrasound.</div><div class=\"graphic_reference\">Courtesy of Finn Gustafsson.</div><div id=\"graphicVersion\">Graphic 65796 Version 4.0</div></div></div>"},"65797":{"type":"graphic_diagnosticimage","displayName":"Placenta adherens and trapped placenta","title":"Placenta adherens and trapped placenta","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Placenta adherens and trapped placenta</div><div class=\"cntnt\"><img style=\"width:538px; height:639px;\" src=\"images/OBGYN/65797_US_placental_detachment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound pictures (sagital midline view) of placenta adherens and a trapped placenta.</div><div id=\"graphicVersion\">Graphic 65797 Version 2.0</div></div></div>"},"65798":{"type":"graphic_figure","displayName":"Classification of distal phalanx finger fractures","title":"Classification of distal phalanx finger fractures","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Classification of distal phalanx finger fractures</div><div class=\"cntnt\"><img style=\"width:526px; height:347px;\" src=\"images/SURG/65798_Class_distal_phalanx_fxs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distal phalanx fractures can be classified into the following categories according to the location of the fracture:<br> <ul> <li>Tuft fractures - simple or comminuted </li> <li>Shaft - transverse or longitudinal </li> <li>Intra-articular fractures - palmar (volar) or dorsal </li> </ul></div><div id=\"graphicVersion\">Graphic 65798 Version 2.0</div></div></div>"},"65799":{"type":"graphic_table","displayName":"Advance directives PI","title":"Resources that can help you make advance directives","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources that can help you make advance directives</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Address</td> <td class=\"subtitle1\">Phone number</td> <td class=\"subtitle1\">Website</td> </tr> <tr class=\"divider_bottom\"> <td><strong>AARP</strong></td> <td>601 E Street NW<br /> Washington, DC 20049</td> <td>Toll-free: (888) OUR-AARP [<span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">(888) 687-2277</span>]</td> <td><a href=\"http://assets.aarp.org/external_sites/caregiving/multimedia/EG_AdvanceDirectives.html\" target=\"_blank\">http://assets.aarp.org/external_sites/<br /> caregiving/multimedia/EG_AdvanceDirectives.html</a></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Aging with Dignity<br /> (Five Wishes form)</strong></td> <td>PO Box 1661<br /> Tallahassee, FL 32302</td> <td>Toll-free: (888) 5WISHES [<span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">(888) 594-7437]</span></td> <td><a href=\"http://www.agingwithdignity.org/\" target=\"_blank\">www.agingwithdignity.org</a></td> </tr> <tr class=\"divider_bottom\"> <td><strong>CaringInfo</strong></td> <td>&nbsp;</td> <td>Toll-free: <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">(800) 658-8898</span></td> <td><a href=\"http://www.caringinfo.org/\" target=\"_blank\">www.caringinfo.org</a></td> </tr> <tr> <td><strong>POLST</strong></td> <td>National POLST Paradigm<br /> c/o Emmer Consulting, Inc.<br /> 601 13th Street, NW Ste 900 South<br /> Washington DC 20005</td> <td><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">(202) 780-8352</span></td> <td><a href=\"http://www.polst.org/\" target=\"_blank\">www.polst.org</a></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65799 Version 5.0</div></div></div>"},"65800":{"type":"graphic_waveform","displayName":"Ventricular flutter tutorial","title":"Ventricular flutter","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ventricular flutter</div><div class=\"cntnt\"><img style=\"width:400px; height:121px;\" src=\"images/CARD/65800_Ventricular_flutter_tutoria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A rapid ventricular tachycardia, with rates usually over 240 beats per minute, is characteristic of ventricular flutter, with predominantly monomorphic QRS complexes, and an absence of atrial activity (P waves).</div><div id=\"graphicVersion\">Graphic 65800 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"65802":{"type":"graphic_table","displayName":"Functions of medical interview","title":"Three functions of the medical interview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Three functions of the medical interview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Function 1</td> </tr> <tr> <td>Data gathering: Determine and monitor the nature of the problem</td> </tr> <tr> <td class=\"subtitle2_single\">Objectives</td> </tr> <tr> <td class=\"indent1\">Enable the clinician to establish a diagnosis or recommend further diagnostic procedures, suggest courses of treatment and predict the nature of the illness</td> </tr> <tr> <td class=\"subtitle1_single\">Function 2</td> </tr> <tr> <td>Relationship building: Develop, maintain, and conclude the therapeutic relationship</td> </tr> <tr> <td class=\"subtitle2_single\">Objectives</td> </tr> <tr> <td class=\"indent1\">Ensure patient's willingness to provide diagnostic information</td> </tr> <tr> <td class=\"indent1\">Ensure relief of patient's physical and psychological distress</td> </tr> <tr> <td class=\"indent1\">Ensure patient's willingness to accept the treatment plan or a process of negotiation</td> </tr> <tr> <td class=\"indent1\">Ensure patient and clinician satisfaction</td> </tr> <tr> <td class=\"subtitle1_single\">Function 3</td> </tr> <tr> <td>Patient education: Carry out patient education and implementation of treatment plans</td> </tr> <tr> <td class=\"subtitle2_single\">Objectives</td> </tr> <tr> <td class=\"indent1\">Ensure patient's understanding of the nature of the illness</td> </tr> <tr> <td class=\"indent1\">Ensure patient's understanding of suggested diagnostic procedures</td> </tr> <tr> <td class=\"indent1\">Enhance patient's understanding of the treatment possibilities</td> </tr> <tr> <td class=\"indent1\">Achieve consensus between clinician and patient</td> </tr> <tr> <td class=\"indent1\">Achieve informed consent</td> </tr> <tr> <td class=\"indent1\">Improve coping mechanisms</td> </tr> <tr> <td class=\"indent1\">Promote lifestyle change</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Lipkin M, Putnam S, Lazare A. The Medical Interview, Springer-Verlag, New York 1995.</div><div id=\"graphicVersion\">Graphic 65802 Version 3.0</div></div></div>"},"65804":{"type":"graphic_picture","displayName":"Late DAD micrograph","title":"Late diffuse alveolar damage","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Late diffuse alveolar damage</div><div class=\"cntnt\"><img style=\"width:282px; height:185px;\" src=\"images/PULM/65804_Late_DAD_micrograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows changes typical of the proliferative or late stage of diffuse alveolar damage. Although hyaline membranes are still identifiable, the histologic picture is now dominated by thickening and reorganization of interstitial structures due mainly to marked proliferation of mesenchymal spindle cells, including both fibroblasts and myofibroblasts.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 65804 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:330px;\" src=\"images/PULM/80140_Normal_lung_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows alveoli containing capillaries within a narrow interstitium. The alveoli are lined with thin, elongated type I pneumocytes (arrow) and smaller numbers of cuboidal type II pneumocytes (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 80140 Version 2.0</div></div></div>"},"65811":{"type":"graphic_figure","displayName":"Skull sagittal section","title":"Skull sagittal section","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Skull sagittal section</div><div class=\"cntnt\"><img style=\"width:514px; height:354px;\" src=\"images/ONC/65811_Skull_sagittal_section.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Co. Copyright &#169; 2009 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 65811 Version 1.0</div></div></div>"},"65812":{"type":"graphic_table","displayName":"Etiology of macrocephaly","title":"Selected causes of macrocephaly","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected causes of macrocephaly</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Increased brain (megalencephaly)</td> </tr> <tr> <td class=\"subtitle2_single\">Anatomic</td> </tr> <tr> <td class=\"indent1\">Familial megalencephaly</td> </tr> <tr> <td class=\"indent1\">Neurocutaneous disorders (eg, neurofibromatosis, tuberous sclerosis, linear sebaceous nevus syndrome, <a href=\"https://omim.org/entry/185300\" spellcheck=\"true\" target=\"_blank\">Sturge-Weber syndrome</a>, <a href=\"http://omim.org/entry/149000\" spellcheck=\"true\" target=\"_blank\">Klippel-Trenaunay-Weber syndrome</a>, <a href=\"http://omim.org/entry/109400\" spellcheck=\"true\" target=\"_blank\">basal cell nevus syndrome&nbsp;</a>syndrome])</td> </tr> <tr> <td class=\"indent1\">Autism spectrum disorder</td> </tr> <tr> <td class=\"indent1\">Achondroplasia</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/117550\" spellcheck=\"true\" target=\"_blank\">Cerebral gigantism</a> (Sotos syndrome)</td> </tr> <tr> <td class=\"indent1\"><a href=\"http://omim.org/entry/300624\" spellcheck=\"true\" target=\"_blank\">Fragile X syndrome</a></td> </tr> <tr> <td class=\"indent1\"><em>PTEN </em>hamartoma syndromes (eg, <a href=\"http://omim.org/entry/158350\" spellcheck=\"true\" target=\"_blank\">Cowden syndrome</a>, <a href=\"http://omim.org/entry/153480\" spellcheck=\"true\" target=\"_blank\">Bannayan-Riley-Ruvalcaba</a>)</td> </tr> <tr> <td class=\"subtitle2_single\">Metabolic</td> </tr> <tr> <td class=\"indent1\">Leukodystrophies (eg, <a href=\"http://omim.org/entry/203450\" spellcheck=\"true\" target=\"_blank\">Alexander disease</a>, <a href=\"http://omim.org/entry/271900\" spellcheck=\"true\" target=\"_blank\">Canavan disease</a>, megalencephalic leukoencephalopathy)</td> </tr> <tr> <td class=\"indent1\">Lysosomal storage disorders (eg, <a href=\"http://omim.org/entry/272800\" spellcheck=\"true\" target=\"_blank\">Tay-Sachs</a>, mucopolysaccharidosis, gangliosidosis)</td> </tr> <tr> <td class=\"indent1\">Organic acid disorders (eg, glutaric aciduria)</td> </tr> <tr> <td class=\"subtitle1_single\">Increased cerebrospinal fluid</td> </tr> <tr> <td>Hydrocephalus*</td> </tr> <tr> <td>Benign enlargement of the subarachnoid space</td> </tr> <tr> <td>Hydranencephaly</td> </tr> <tr> <td>Choroid plexus papilloma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Increased blood</td> </tr> <tr> <td>Hemorrhage (intraventricular, subdural, epidural, subarachnoid)</td> </tr> <tr> <td>Arteriovenous malformation</td> </tr> <tr> <td class=\"subtitle1_single\">Increased bone</td> </tr> <tr> <td>Bone marrow expansion (eg, thalassemia major)</td> </tr> <tr> <td>Primary bone disorders (eg, skeletal and cranial dysplasias such as achondroplasia, osteogenesis imperfecta, cleidocranial dysostosis, metaphyseal dysplasia, osteopetrosis, hyperphosphatasia)</td> </tr> <tr> <td class=\"subtitle1_single\">Increased intracranial pressure</td> </tr> <tr> <td>Idiopathic (pseudotumor cerebri)</td> </tr> <tr> <td>Infection or inflammation (eg, meningitis)</td> </tr> <tr> <td>Toxins (eg, lead)</td> </tr> <tr> <td>Metabolic abnormalities (eg, vitamin A deficiency or excess, galactosemia)</td> </tr> <tr> <td class=\"subtitle1_single\">Mass lesions</td> </tr> <tr> <td>Intracranial cyst</td> </tr> <tr> <td>Intracranial tumor</td> </tr> <tr> <td>Intracranial abscess</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*&nbsp;Refer to UpToDate topic on hydrocephalus for information about the causes of hydrocephalus.</div><div id=\"graphicVersion\">Graphic 65812 Version 6.0</div></div></div>"},"65814":{"type":"graphic_table","displayName":"Specimens for anthrax testing","title":"Acceptable biological specimens needed for laboratory testing for anthrax","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acceptable biological specimens needed for laboratory testing for anthrax</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Types of tests</td> <td class=\"subtitle1\">Acceptable materials</td> <td class=\"subtitle1\">Minimum amount or size</td> <td class=\"subtitle1\">Transport &#8804;2 hours</td> <td class=\"subtitle1\">Transport &#8805;2 hours</td> <td class=\"subtitle1\">Do not send</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"9\">Culture and PCR</td> <td>Isolate</td> <td>Plate, slant</td> <td>RT</td> <td>RT</td> <td>Broth</td> </tr> <tr> <td>Swabs (lesion)</td> <td>&nbsp;</td> <td>RT</td> <td>RT</td> <td>On transport medium</td> </tr> <tr> <td>Blood, whole</td> <td>1.0 mL in EDTA or sodium citrate tubes (do not use heparin)</td> <td>RT</td> <td>2 to 8&#176;C</td> <td>Blood culture bottle or heparin tube</td> </tr> <tr> <td>Fluids/aspirate (pleural, bronchial, CSF)</td> <td>0.5 mL</td> <td>RT</td> <td>2 to 8&#176;C</td> <td>&nbsp;</td> </tr> <tr> <td>Tissue, fresh</td> <td>5 mm<sup>3</sup> in container</td> <td>2 to 8&#176;C</td> <td>Frozen at -70&#176;C</td> <td>Preserved tissue</td> </tr> <tr> <td>Blood clot</td> <td>1.0 mL clot</td> <td>RT</td> <td>2 to 8&#176;C</td> <td>&nbsp;</td> </tr> <tr> <td>Serum, separated and removed from clot</td> <td>1.0 mL</td> <td>RT</td> <td>2 to 8&#176;C</td> <td>Frozen serum</td> </tr> <tr> <td>Citrated plasma, separated and removed from clot</td> <td>1.0 mL</td> <td>RT</td> <td>2 to 8&#176;C</td> <td>Frozen plasma</td> </tr> <tr> <td>Stool</td> <td>&#8805;5 g</td> <td>2 to 8&#176;C</td> <td>2 to 8&#176;C</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">Serology</td> <td>Serum, separated and removed from clot</td> <td>1.0 mL</td> <td>2 to 8&#176;C</td> <td>Frozen at &#60;-20&#176;C</td> <td>Whole blood or blood culture bottle or plasma</td> </tr> <tr> <td>Citrated plasma, separated and removed from clot</td> <td>1.0 mL</td> <td>2 to 8&#176;C</td> <td>Frozen at &#60;-20&#176;C</td> <td>Plasma from EDTA or heparin tube</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">Histopathology</td> <td>Tissues, preserved in 10 percent buffered formalin</td> <td>1.0 cm<sup>3</sup></td> <td>RT</td> <td>RT</td> <td>Fresh or frozen tissue</td> </tr> <tr> <td>Biopsies of lesions (eg, skin), preserved in 10 percent buffered formalin</td> <td>0.3 mm diameter</td> <td>RT</td> <td>RT</td> <td>Fresh or frozen tissue</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction; RT: room temperature; EDTA: ethylenediaminetetraacetic acid; CSF: cerebrospinal fluid.</div><div id=\"graphicVersion\">Graphic 65814 Version 2.0</div></div></div>"},"65815":{"type":"graphic_figure","displayName":"Peritoneal equilibration test","title":"Peritoneal equilibration test","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Peritoneal equilibration test</div><div class=\"cntnt\"><img style=\"width:491px; height:276px;\" src=\"images/NEPH/65815_Peritoneal_equilibration_te.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Time-dependent changes during peritoneal dialysis in dialysate (D) concentration of glucose (left panel) or creatinine (right panel) as a proportion of original dialysate glucose concentration (DO) or plasma creatinine concentration (P), respectively. The absorption of glucose from the dialysate gradually lowers the D/DO ratio, while the diffusion of creatinine into the dialysate raises the D/P ratio. Slow transporters may be inadequately dialyzed due to diminished solute removal. Rapid transporters can achieve a D/P creatinine ratio above 0.8 and a D/DO glucose below 0.3 at four hours; they may be predisposed to malnutrition from increased protein losses in the dialysate and to decreased fluid removal due to absorption of glucose.</div><div class=\"graphic_footnotes\">D: dialysate; DO: original dialysate glucose concentration; P: plasma creatinine concentration.</div><div class=\"graphic_reference\">Data from Twardowski ZJ. Clinical&nbsp;value of standardized equilibration tests in CAPD patients.&nbsp;Blood Purif 1989; 7:95.</div><div id=\"graphicVersion\">Graphic 65815 Version 4.0</div></div></div>"},"65816":{"type":"graphic_figure","displayName":"Risk wk for fetal abnormalities","title":"Periods of sensitivity during development","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Periods of sensitivity during development</div><div class=\"cntnt\"><img style=\"width:529px; height:267px;\" src=\"images/OBGYN/65816_Risk_wk_for_fetal_abnormali.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Unborn Patient: Prenatal Diagnosis and Treatment. Harrison, Golbus, Filly (eds). Philadelphia, Saunders, 1990. p. 44. Copyright &#169; 1990 Elsevier.</div><div id=\"graphicVersion\">Graphic 65816 Version 1.0</div></div></div>"},"65818":{"type":"graphic_diagnosticimage","displayName":"Chondro high radiographs","title":"Radiological presentation of a high-grade pelvic chondrosarcoma","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Radiological presentation of a high-grade pelvic chondrosarcoma</div><div class=\"cntnt\"><img style=\"width:457px; height:516px;\" src=\"images/ONC/65818_Chondro_high_radiographs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial T1-weighted magnetic resonance image of high-grade chondrosarcoma arising from the pelvis with cortex destruction and a large soft tissue component.<br />(B) Axial T1-weighted magnetic resonance image with fat suppression after IV contrast injection shows areas of solid peripheral enhancement.<br />(C) Computed tomography image demonstrates the bone destruction of the right os ilium and os sacrum with a large soft tissue mass with only peripheral mineralization.</div><div class=\"graphic_footnotes\">IV: intravenous.</div><div class=\"graphic_reference\">Reproduced with permission from: Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist 2008; 13:320. Copyright &copy;2008 AlphaMed Press.</div><div class=\"contractual\"><br/><a href=\"http://www.theoncologist.com/\">http://www.TheOncologist.com</a></div><div id=\"graphicVersion\">Graphic 65818 Version 3.0</div></div></div>"},"65819":{"type":"graphic_table","displayName":"Compare elemental Ca","title":"Elemental calcium content of different calcium salts","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Elemental calcium content of different calcium salts</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n    <td class=\"subtitle1\" rowspan=\"2\">Calcium salt</td>\n    <td class=\"subtitle1\" colspan=\"2\">Elemental calcium content</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2\">mg Ca++ per gram</td>\n    <td class=\"subtitle2\">mEq Ca++ per gram</td>\n  </tr>\n  <tr>\n    <td>Calcium acetate</td>\n    <td>250</td>\n    <td>12.7</td>\n  </tr>\n  <tr>\n    <td>Calcium carbonate</td>\n    <td>400</td>\n    <td>20</td>\n  </tr>\n  <tr>\n    <td>Calcium chloride</td>\n    <td>270</td>\n    <td>13.5</td>\n  </tr>\n  <tr>\n    <td>Calcium citrate</td>\n    <td>211</td>\n    <td>10.6</td>\n  </tr>\n  <tr>\n    <td>Calcium glubionate</td>\n    <td>64</td>\n    <td>3.2</td>\n  </tr>\n  <tr>\n    <td>Calcium gluconate</td>\n    <td>90</td>\n    <td>4.5</td>\n  </tr>\n  <tr>\n    <td>Calcium lactate</td>\n    <td>130</td>\n    <td>6.5</td>\n  </tr>\n  <tr>\n    <td>Calcium phosphate, tribasic</td>\n    <td>390</td>\n    <td>19.3</td>\n  </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=51101&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Compare_elemental_Ca.htm</title></head></div><div class=\"graphic_reference\">Data from: Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 65819 Version 5.0</div></div></div>"},"65820":{"type":"graphic_picture","displayName":"Resisted thumb adduction","title":"Resisted thumb adduction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Resisted thumb adduction</div><div class=\"cntnt\"><img style=\"width:432px; height:273px;\" src=\"images/EM/65820_Resisted_thumb_add_final.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65820 Version 1.0</div></div></div>"},"65821":{"type":"graphic_figure","displayName":"Digoxin structure","title":"Structure of digoxin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structure of digoxin</div><div class=\"cntnt\"><img style=\"width:432px; height:296px;\" src=\"images/EM/65821_Digoxin_structure.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65821 Version 1.0</div></div></div>"},"65822":{"type":"graphic_table","displayName":"Prevalence IgE deficiency","title":"Prevalence of IgE deficiency (<2.5 int. units/mL) ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of IgE deficiency (<2.5 int. units/mL) </div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Study group </td> <td class=\"subtitle1\" rowspan=\"2\">Number of subjects (adults) </td> <td class=\"subtitle1\" colspan=\"3\">Prevalence, percent </td> </tr> <tr> <td class=\"subtitle2\">Percentage with selective IgE deficiency*</td> <td class=\"subtitle2\"> <p>Percentage with IgE + other immunoglobulin deficiencies</p> <p>Deficient immunoglobulins, in decreasing order</p> </td> <td class=\"subtitle2\">Total </td> </tr> <tr> <td>Blood donors</td> <td>500</td> <td>0.8</td> <td> <p>1.8</p> <p>IgG4</p> </td> <td>2.6</td> </tr> <tr> <td>Allergy and Immunology clinic patients</td> <td>974</td> <td>3.1</td> <td> <p>5.0</p> <p>IgG4, IgG1, IgG2 &#38; IgG3</p> </td> <td>8.1</td> </tr> <tr> <td>Rheumatology clinic patients</td> <td>155</td> <td>1.3</td> <td> <p>8.4</p> <p>IgA2, IgA1, IgG2, IgG4</p> </td> <td>9.7</td> </tr> <tr> <td>Total</td> <td>1629</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Ig: immunoglobulin.<br />*&nbsp;Normal serum levels of IgG, IgA, IgM, IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4</div><div class=\"graphic_reference\">Courtesy of John K&nbsp;Smith, MD and Guha Krishaswamy, MD.</div><div id=\"graphicVersion\">Graphic 65822 Version 5.0</div></div></div>"},"65824":{"type":"graphic_table","displayName":"Histopathology cervical cancer","title":"Histopathology of cervical cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histopathology of cervical cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">A. Squamous cell carcinoma</td> </tr> <tr> <td class=\"sublist2\">Large cell, keratinizing squamous cell carcinoma</td> </tr> <tr> <td class=\"sublist2\">Large cell, non-keratinizing squamous cell carcinoma</td> </tr> <tr> <td class=\"sublist2\">Verrucous carcinoma</td> </tr> <tr> <td class=\"sublist2\">Papillary squamous and transitional cell carcinoma</td> </tr> <tr> <td class=\"sublist2\">Lymphoepithelioma-like carcinoma</td> </tr> <tr> <td class=\"sublist1_start\">B. Adenocarcinoma</td> </tr> <tr> <td class=\"sublist2\">Mucinous, endocervical variant</td> </tr> <tr> <td class=\"sublist2\">Mucinous, intestinal type, signet ring variant</td> </tr> <tr> <td class=\"sublist2\">Mucinous, adenoma malignum (minimal deviation variant)</td> </tr> <tr> <td class=\"sublist2\">Mucinous, villoglandular adenocarcinoma (well differentiated)</td> </tr> <tr> <td class=\"sublist2\">Endometriod type</td> </tr> <tr> <td class=\"sublist2\">Clear cell type</td> </tr> <tr> <td class=\"sublist2\">Papillary serous type</td> </tr> <tr> <td class=\"sublist2\">Mesonephric type</td> </tr> <tr> <td>C. Adenosquamous carcinoma</td> </tr> <tr> <td>D. Adenoid cystic carcinoma</td> </tr> <tr> <td>E. Neuroendocrine (carcinoid, small cell, large cell)</td> </tr> <tr> <td>F. Undifferentiated carcinoma</td> </tr> <tr> <td>G. Mixed epithelial and mesenchymal tumors</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from data in: Ngan HYS, et al. Int J Gynecol Obstet 2000; 70:207.</div><div id=\"graphicVersion\">Graphic 65824 Version 5.0</div></div></div>"},"65825":{"type":"graphic_figure","displayName":"Tonsils","title":"Tonsils in mid-sagittal section through pharynx","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tonsils in mid-sagittal section through pharynx</div><div class=\"cntnt\"><img style=\"width:420px; height:435px;\" src=\"images/PC/65825_Tonsils.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65825 Version 1.0</div></div></div>"},"65827":{"type":"graphic_diagnosticimage","displayName":"Paratracheal and subcarinal lymph node CT I","title":"Paratracheal and subcarinal lymph node involvement in lung cancer","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Paratracheal and subcarinal lymph node involvement in lung cancer</div><div class=\"cntnt\"><img style=\"width:553px; height:247px;\" src=\"images/PULM/65827_Paratracheal_lymph_node_C1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan from a patient with left upper lobe poorly differentiated adenocarcinoma invading the mediastinum. <br />(A) Axial view shows left lower paratracheal lymph node (arrow; N2 lymph nodes) and right lower&nbsp;paratracheal lymph node involvement (arrowhead; N3 lymph nodes).&nbsp;<br />(B) Additional view in the same patient shows tumor encasing the left pulmonary artery (PA; dashed arrow) and the descending aorta (Ao). Enlarged subcarinal lymph nodes are present, lateral to the aorta (ie, N2 lymph nodes).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 65827 Version 5.0</div></div></div>"},"65828":{"type":"graphic_figure","displayName":"Pathophysiology PDA","title":"Patent ductus arteriosus","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Patent ductus arteriosus</div><div class=\"cntnt\"><img style=\"width:499px; height:446px;\" src=\"images/CARD/65828_Pathophysiology_PDA.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65828 Version 2.0</div></div></div>"},"65829":{"type":"graphic_picture","displayName":"Skin in eosinophilic fasciitis","title":"Eosinophilic fasciitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic fasciitis</div><div class=\"cntnt\"><img style=\"width:437px; height:207px;\" src=\"images/RHEUM/65829_Skin_in_eosinophilic_fascii.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">&quot;Peau d'orange&quot; changes in a patient with eosinophilic fasciitis. These changes are similar to those observed in patients with morphea.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 65829 Version 1.0</div></div></div>"},"65830":{"type":"graphic_picture","displayName":"High grade spleen laceration","title":"High grade spleen laceration","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">High grade spleen laceration</div><div class=\"cntnt\"><img style=\"width:500px; height:416px;\" src=\"images/SURG/65830_High_grade_spleen_lac.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Lewis J Kaplan, MD</div><div id=\"graphicVersion\">Graphic 65830 Version 3.0</div></div></div>"},"65832":{"type":"graphic_figure","displayName":"Cervical epidural injection","title":"Cervical epidural injection","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Cervical epidural injection</div><div class=\"cntnt\"><img style=\"width:544px; height:381px;\" src=\"images/NEURO/65832_Cervical_epidural_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration of an axial view of the cervical intervertebral foramen and adjacent structures at the level of C6 with a needle inserted parallel to the axis of the foramen along its posterior wall.</div><div class=\"graphic_reference\">Adapted from Rathmell, JP, Aprill C, Bogduk, N. Cervical transforaminal injection of steroids. Anesthesiology 2004; 100:1595.</div><div id=\"graphicVersion\">Graphic 65832 Version 3.0</div></div></div>"},"65834":{"type":"graphic_table","displayName":"Distrib RP nodal metastases","title":"Distribution of retropharyngeal (RP) lymph nodes metastasis based on stage<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distribution of retropharyngeal (RP) lymph nodes metastasis based on stage<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n <tr>\n    <td class=\"subtitle1\">T stage</td>\n    <td class=\"subtitle1\">Positive RP</td>\n    <td class=\"subtitle1\">Clinical stage</td>\n    <td class=\"subtitle1\">Positive RP</td>\n  </tr>\n  <tr>\n    <td>T1</td>\n    <td>2 of 55 (3.6 percent)</td>\n    <td>I</td>\n    <td>1 of 33 (3 percent)</td>\n  </tr>\n  <tr>\n    <td>T2</td>\n    <td>14 of 156 (9 percent)</td>\n    <td>II</td>\n    <td>7 of 68 (7 percent)</td>\n  </tr>\n  <tr>\n    <td>T3</td>\n    <td>16 of 76 (21 percent)</td>\n    <td>III</td>\n    <td>5 of 51 (9.8 percent)</td>\n  </tr>\n  <tr>\n    <td>T4</td>\n    <td>22 of 79 (27.8 percent)</td>\n    <td>IV</td>\n    <td>51 of 214 (19.2 percent)</td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">1. Yoshimoto S, Kawabata K. Retropharyngeal node dissection during total pharyngolaryngectomy for hypopharyngeal cancer. Auris Nasus Larynx 2005; 32:163.</div><div id=\"graphicVersion\">Graphic 65834 Version 1.0</div></div></div>"},"65835":{"type":"graphic_figure","displayName":"Asymmetric inguinal folds","title":"Asymmetric inguinal folds","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Asymmetric inguinal folds</div><div class=\"cntnt\"><img style=\"width:486px; height:671px;\" src=\"images/PEDS/65835_Asymmetric_inguinal_folds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal inguinal folds do not extend beyond the anal aperture (*). <BR>(B) The inguinal fold on the right extends beyond the anal aperture, suggesting possible developmental dysplasia of the right hip. <BR>(C) The inguinal folds on both sides extend beyond the anal aperture, suggesting bilateral developmental dysplasia of the hip.</div><div id=\"graphicVersion\">Graphic 65835 Version 2.0</div></div></div>"},"65837":{"type":"graphic_picture","displayName":"PMLE pathology","title":"Polymorphous light eruption, histopathology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polymorphous light eruption, histopathology</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/65837_PMLE_pathology_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked papillary edema and a superficial and deep lymphocytic infiltrate are visible in this specimen from a patient with polymorphous light eruption.</div><div class=\"graphic_reference\">Copyright © Greg Hosler, MD, PhD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 65837 Version 6.0</div></div></div>"},"65838":{"type":"graphic_picture","displayName":"Finger toad splint","title":"Finger toad splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Finger toad splint</div><div class=\"cntnt\"><img style=\"width:432px; height:293px;\" src=\"images/EM/65838_Finger_toad_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 65838 Version 1.0</div></div></div>"},"65839":{"type":"graphic_table","displayName":"Renal symptoms in hyperparathyroidism","title":"Renal manifestations of primary hyperparathyroidism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Renal manifestations of primary hyperparathyroidism</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Decreased glomerular filtration rate</td>\n</tr>\n<tr>\n<td>Hypercalciuria</td>\n</tr>\n<tr>\n<td>Nephrolithiasis</td>\n</tr>\n<tr>\n<td>Nephrocalcinosis</td>\n</tr>\n<tr>\n<td>Impaired urinary concentrating ability sometimes leading to polyuria</td>\n</tr>\n<tr>\n<td>Reduced fractional phosphate reabsorption leading to hypophosphatemia</td>\n</tr>\n<tr>\n<td>Increased urinary excretion of magnesium</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">4.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=15891&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Renal_sx_in_hyperparathyroi.htm</title></head></div><div id=\"graphicVersion\">Graphic 65839 Version 2.0</div></div></div>"},"65840":{"type":"graphic_table","displayName":"Causes malignancy ascites","title":"Causes of malignancy-related ascites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of malignancy-related ascites</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Cause\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Frequency among patients with malignancy-related ascites\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Peritoneal carcinomatosis</td>\r\n  \r\n   <td>53 percent</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Massive liver metastases causing portal hypertension</td>\r\n  \r\n   <td>13 percent</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Peritoneal carcinomatosis plus massive liver metastases</td>\r\n  \r\n   <td>13 percent</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hepatocellular carcinoma plus cirrhosis</td>\r\n  \r\n   <td>13 percent</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chylous ascites due to malignancy, usually lymphoma</td>\r\n  \r\n   <td>7 percent</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Budd-Chiari syndrome due to malignancy occluding the hepatic veins</td>\r\n  \r\n   <td>Rare</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Data from: Runyon, BA, Hoefs, JC, Morgan, TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1998; 8:1104.</div><div id=\"graphicVersion\">Graphic 65840 Version 1.0</div></div></div>"},"65842":{"type":"graphic_table","displayName":"Ramsay sedation scale","title":"The Ramsay sedation scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Ramsay sedation scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical score </td> <td class=\"subtitle1\">Patient characteristics </td> </tr> <tr> <td>1</td> <td>Awake; agitated or restless or both</td> </tr> <tr> <td>2</td> <td>Awake; cooperative, oriented, and tranquil</td> </tr> <tr> <td>3</td> <td>Awake but responds to commands only</td> </tr> <tr> <td>4</td> <td>Asleep; brisk response to light glabellar tap or loud auditory stimulus</td> </tr> <tr> <td>5</td> <td>Asleep; sluggish response to light glabellar tap or loud auditory stimulus</td> </tr> <tr> <td>6</td> <td>Asleep; no response to glabellar tap or loud auditory stimulus</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Redrawn from Ramsay, MA, Savage, TM, Simpson, BR, Goodwin, R, Br Med J 1974; 2:656.</div><div id=\"graphicVersion\">Graphic 65842 Version 4.0</div></div></div>"},"65844":{"type":"graphic_figure","displayName":"Alternative port placement for cholecystectomy","title":"Alternative port placement for cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Alternative port placement for cholecystectomy</div><div class=\"cntnt\"><img style=\"width:484px; height:587px;\" src=\"images/SURG/65844_Alternative_port_lap_chole.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An alternative port placement for cholecystectomy places a 5 mm port halfway between the xiphoid and umbilical ports. The surgeon retracts the infundibulum of the gallbladder through the midline port and uses the dissector through the subxiphoid port (shown in red). The assistant retracts the fundus of the gallbladder through the right lateral port and operates the laparoscope via the periumbilical port. The gallbladder is removed through the umbilical port.</div><div class=\"graphic_footnotes\">* Port placement and technique may vary amongst laparoscopic surgeons.</div><div id=\"graphicVersion\">Graphic 65844 Version 5.0</div></div></div>"},"65845":{"type":"graphic_figure","displayName":"How doctors check breast tissue in men PI","title":"How doctors check breast tissue in men","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">How doctors check breast tissue in men</div><div class=\"cntnt\"><img style=\"width:543px; height:539px;\" src=\"images/PI/65845_Exam_for_gynecomastia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To check a man's breast, the doctor or nurse will bring his or her fingers together around the nipple (as shown). If the tissue is breast tissue and not fat, the doctor or nurse should feel a rubbery or firm circle of tissue centered under the nipple. (When men develop breast tissue, it is called \"gynecomastia.\") If the tissue is fat, the doctor or nurse will not feel any firm bit of tissue. The whole breast will feel soft.<br />The doctor or nurse will also check if the firm tissue is at the center of the breast or off to the side. If there is firm tissue that is not centered, it could be cancer.</div><div id=\"graphicVersion\">Graphic 65845 Version 4.0</div></div></div>"},"65846":{"type":"graphic_picture","displayName":"Pediculosis capitis nits","title":"Pediculosis capitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pediculosis capitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/65846_Pediculosis_capitis_nits.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple nits on the hair shafts.</div><div class=\"graphic_reference\">Reproduced with permission from: Chung EK, Boom JA, Datto GA, Matz PS (Eds). Visual Diagnosis in Pediatrics. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Courtesy of Hans B Kersten, MD. Copyright © 2006.</div><div id=\"graphicVersion\">Graphic 65846 Version 3.0</div></div></div>"},"65848":{"type":"graphic_movie","displayName":"TEE mitral valve aneurysm from endocarditis","title":"Transesophageal echocardiogram (TEE) showing a mitral valve aneurysm associated with endocarditis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transesophageal echocardiogram (TEE) showing a mitral valve aneurysm associated with endocarditis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/65848_teemvaneconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:277px; height:396px;\" src=\"images/CARD/65848_teemvane.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows vegetations of the aortic valve leaflets due to endocarditis and an abscess of the mitral valve annulus.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 65848 Version 4.0</div></div></div>"},"65853":{"type":"graphic_figure","displayName":"Intracranial compensation for mass","title":"Intracranial compensation for mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intracranial compensation for mass</div><div class=\"cntnt\"><img style=\"width:304px; height:426px;\" src=\"images/PULM/65853_Intracranial_compensation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normally, the intracranial components are in equilibrium as shown in chamber 1. Initially, the volume of a space-occupying lesion is compensated for by displacement of blood and CSF&nbsp; and ICP remains normal (chamber 2). When the limits of this &nbsp;compensation is reached; any additional increase in the volume of the mass lesion is accompanied by a corresponding increase in ICP (chamber 3, decompensated phase). </div><div class=\"graphic_reference\">Data from Pathophysiology and management of the intracranial vault. In: Textbook of Pediatric Intensive Care, 3rd ed, Rogers, MC (Ed), Williams and Wilkins 1996. p. 646; figure 18.1.</div><div id=\"graphicVersion\">Graphic 65853 Version 5.0</div></div></div>"},"65855":{"type":"graphic_figure","displayName":"Metacarpophalangeal joint collateral ligaments","title":"Metacarpophalangeal joint collateral ligaments","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Metacarpophalangeal joint collateral ligaments</div><div class=\"cntnt\"><img style=\"width:456px; height:205px;\" src=\"images/EM/65855_MCP_collateral_ligaments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The collateral ligaments of the MCP joint are relaxed in extension but become taut in full flexion.</div><div class=\"graphic_footnotes\">MCP: metacarpophalangeal.</div><div class=\"graphic_reference\">Reproduced with permission from: Eiff MP, Hatch RL, Calmbach WL. Fracture Management for Primary Care, 2nd ed., W.B. Saunders 2002. Copyright © 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 65855 Version 6.0</div></div></div>"},"65856":{"type":"graphic_picture","displayName":"Acrochordon - strangulated","title":"Strangulated acrochordon (skin tag or soft fibroma)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strangulated acrochordon (skin tag or soft fibroma)</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/65856_Acrochordon_strangulated.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Twisting of the base of this acrochordon led to loss of blood supply and tissue death.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65856 Version 4.0</div></div></div>"},"65859":{"type":"graphic_table","displayName":"NICHD definitions of FHR characteristics and patterns","title":"NICHD definitions of FHR characteristics and patterns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NICHD definitions of FHR characteristics and patterns</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Variability</td> </tr> <tr> <td class=\"indent1\">Fluctuations in baseline that are irregular in amplitude and frequency</td> </tr> <tr> <td class=\"indent1\">Absent = amplitude undetectable</td> </tr> <tr> <td class=\"indent1\">Minimal = amplitude 0 to 5 bpm</td> </tr> <tr> <td class=\"indent1\">Moderate = amplitude 6 to 25 bpm</td> </tr> <tr> <td class=\"indent1\">Marked = amplitude over 25 bpm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Measured in a 10-minute window. The amplitude is measured peak to trough. There is no distinction between short-term and long-term variability.</td> </tr> <tr> <td class=\"subtitle1_single\">Baseline rate</td> </tr> <tr> <td class=\"indent1\">Bradycardia = below 110 bpm</td> </tr> <tr> <td class=\"indent1\">Normal = 110 to 160 bpm</td> </tr> <tr> <td class=\"indent1\">Tachycardia = over 160 bpm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">The baseline rate is the mean bpm (rounded to 0 or 5) over a 10-minute interval, excluding periodic changes, periods of marked variability, and segments that differ by more than 25 bpm. The baseline must be identifiable for two minutes during the interval (but not necessarily a contiguous two minutes); otherwise, it is considered indeterminate.</td> </tr> <tr> <td class=\"subtitle1_single\">Acceleration</td> </tr> <tr> <td class=\"indent1\">An abrupt* increase in the FHR. Before 32 weeks of gestation, accelerations should last &#8805;10 sec and peak &#8805;10 bpm above baseline. As of 32 weeks gestation, accelerations should last &#8805;15 sec and peak &#8805;15 bpm above baseline.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">A prolonged acceleration is &#8805;2 minutes but less than 10 minutes. An acceleration of 10 minutes or more is considered a change in baseline.</td> </tr> <tr> <td class=\"subtitle1_single\">Late deceleration</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">A gradual* decrease and return to baseline of the FHR associated with a uterine contraction. The deceleration is delayed in timing, with the nadir of the deceleration occurring after the peak of the contraction. The onset, nadir, and recovery usually occur after the onset, peak, and termination of a contraction.</td> </tr> <tr> <td class=\"subtitle1_single\">Early deceleration</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">A gradual decrease and return to baseline of the FHR associated with a uterine contraction. The nadir of the FHR and the peak of the contraction occur at the same time. The deceleration's onset, nadir, and termination are usually coincident with the onset, peak, and termination of the contraction.</td> </tr> <tr> <td class=\"subtitle1_single\">Variable deceleration</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">An abrupt decrease in FHR below the baseline. The decrease is &#8805;15 bpm, lasting &#8805;15 secs and &#60;2 minutes from onset to return to baseline. The onset, depth, and duration of variable decelerations commonly vary with successive uterine contractions.</td> </tr> <tr> <td class=\"subtitle1_single\">Prolonged deceleration</td> </tr> <tr> <td class=\"indent1\">A decrease in FHR below the baseline of 15 bpm or more, lasting at least 2 minutes but &#60;10 minutes from onset to return to baseline. A prolonged deceleration of 10 minutes or more is considered a change in baseline.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NICHD: National Institute of Child Health and Human Development; bpm: beats per minute; sec: seconds; FHR: fetal heart rate.<br />*\"Gradual\" and \"abrupt\" changes are defined as taking ≥30 seconds or ≤30 seconds, respectively, from the onset of the deceleration/acceleration to its nadir/peak.</div><div class=\"graphic_reference\">Adapted from: National Institue of Child Health and Human Development Research Planning Workshop. Am J Obstet Gynecol 1997; 177:1385 and Macones GA, Hankins GD, Spong CY, et al. The 2008 National Institute of Child Health and Human Development Workshop Report on Electronic Fetal Monitoring: Update on Definitions, Interpretation, and Research Guidelines. Obstet Gynecol 2008; 112:661.</div><div id=\"graphicVersion\">Graphic 65859 Version 6.0</div></div></div>"},"65860":{"type":"graphic_diagnosticimage","displayName":"GBM MRI","title":"Glioblastoma","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Glioblastoma</div><div class=\"cntnt\"><img style=\"width:501px; height:288px;\" src=\"images/ONC/65860_GBMMRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left: Axial T1-weighted MRI showing edematous left temporal lobe with loss of sulci and gray-white demarcation. Right: After gadolinium infusion, a circular 2.5 cm x 2.5 cm area of irregular contrast enhancement is seen&nbsp;in the left temporal lobe (arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Harry Greenberg, MD.</div><div id=\"graphicVersion\">Graphic 65860 Version 5.0</div></div></div>"},"65861":{"type":"graphic_algorithm","displayName":"Leucine degradation pathway and branched-chain organic acidemias","title":"Pathway of leucine degradation and branched-chain organic acidemias","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathway of leucine degradation and branched-chain organic acidemias</div><div class=\"cntnt\"><img style=\"width:361px; height:370px;\" src=\"images/PEDS/65861_Lcn_dgr_pth_brn_chn_org_acd.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IVA: isovaleric acidemia; 3-MCG: 3-methylcrotonylglycinuria; 3-MGA: 3-methylglutaconic aciduria.</div><div id=\"graphicVersion\">Graphic 65861 Version 3.0</div></div></div>"},"65862":{"type":"graphic_figure","displayName":"Palpation for submucous cleft palate","title":"Palpation for diagnosis of submucous cleft palate","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Palpation for diagnosis of submucous cleft palate</div><div class=\"cntnt\"><img style=\"width:491px; height:465px;\" src=\"images/PEDS/65862_Submucous_cleft_palate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with cleft palate, either overt or submucous, adenoidectomy is usually contraindicated, since it would tend to worsen hypernasality. Submucous cleft palate, which is shown in the illustration, may be easily overlooked. Bifid uvula, widening and attenuation of the median raphe of the soft palate, and a palpable V-shaped midline notch, rather than a smooth curve, are diagnostic and should be sought.</div><div id=\"graphicVersion\">Graphic 65862 Version 3.0</div></div></div>"},"65863":{"type":"graphic_figure","displayName":"Amplitude alternans equation","title":"Equation for calculating amplitude of alternans (A) at each time sample (j) using the correlation method (ACMj)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Equation for calculating amplitude of alternans (A) at each time sample (j) using the correlation method (ACMj)</div><div class=\"cntnt\"><img style=\"width:368px; height:140px;\" src=\"images/CARD/65863_Amplitude_alternans_equatio.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65863 Version 1.0</div></div></div>"},"65864":{"type":"graphic_picture","displayName":"Exclamation point hairs","title":"Exclamation point hairs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exclamation point hairs</div><div class=\"cntnt\"><img style=\"width:432px; height:370px;\" src=\"images/PC/65864_Exclamation_point_hairs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arrow points to an exclamation point hair in a patient with alopecia areata. Exclamation point hairs are short broken hairs that can be extracted with minimal traction and where the proximal end of the hair is narrower than the distal end.</div><div class=\"graphic_reference\">Courtesy of Peter Lio, MD.</div><div id=\"graphicVersion\">Graphic 65864 Version 1.0</div></div></div>"},"65866":{"type":"graphic_diagnosticimage","displayName":"Graves disease Doppler","title":"Graves' disease Doppler","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graves' disease Doppler</div><div class=\"cntnt\"><img style=\"width:432px; height:282px;\" src=\"images/ENDO/65866_Graves_disease_doppler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal view of right lobe from a patient with Graves' disease that shows intense hyperemia on color Doppler interrogation.</div><div id=\"graphicVersion\">Graphic 65866 Version 3.0</div></div></div>"},"65867":{"type":"graphic_figure","displayName":"Pathophysiology of cardiogenic shock","title":"Pathophysiology of cardiogenic shock","html":"<div class=\"graphic\"><div style=\"width: 652px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of cardiogenic shock</div><div class=\"cntnt\"><img style=\"width:632px; height:490px;\" src=\"images/CARD/65867_Pathophys_cardiogenic_shock.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Current concept of CS pathophysiology. The classic shock spiral (bold spiral), induced by left ventricular (LV) dysfunction leading to death by further promotion of ischemia and progressive LV dysfunction if not interrupted by treatment, is shown. The shock spiral is further negatively influenced by (i) systolic dysfunction with decreased cardiac output and stroke volume leading to peripheral impaired perfusion and hypotension; (ii) diastolic dysfunction leading to hypoxemia owing to pulmonary congestion; and (iii) promotion of the systemic inflammation response syndrome (SIRS) by endothelial and inducible nitric oxide synthase (eNOS and iNOS), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α) leading to paradoxical reduced systemic vascular resistance (SVR). Adapted according to Reynolds &amp; Hochman (2008). The pathophysiological concept is expanded by bleeding complications and subsequent transfusions, which both also negatively contribute to inflammation and subsequently the shock spiral. Treatment options such as (i) reperfusion by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG); (ii) mechanical support by intra-aortic balloon pumping (IABP) or left ventricular assist devices (LVADs); and (iii) inotropes or vasopressors to reverse the shock spiral are shown in green. Potential drawbacks of therapeutic interventions including bleeding complications and influence on SIRS are shown in red.</div><div class=\"graphic_reference\">Reproduced from: Thiele H, Allam B, Chatellier G, et al. Shock in acute myocardial infarction: the Cape Horn for trials? Eur Heart J 2010; 31(15):1828-35. By permission of the European Society of Cardiology. Copyright © 2010 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 65867 Version 13.0</div></div></div>"},"65868":{"type":"graphic_figure","displayName":"Calcaneus anatomy","title":"The anatomy of the calcaneus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The anatomy of the calcaneus</div><div class=\"cntnt\"><img style=\"width:411px; height:634px;\" src=\"images/EM/65868_Calcaneusanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomical details of various angles of the calcaneus including (A) lateral view, (B) medial view, and (C) coronal view through the level of the sustentaculum tali, which correlate with the CT scan view important in reconstruction of the posterior facet.</div><div class=\"graphic_reference\">Reproduced with permission from: Jarvis JG, Moroz PJ. Fractures and Dislocations of the Foot. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 65868 Version 10.0</div></div></div>"},"65869":{"type":"graphic_diagnosticimage","displayName":"Talar neck fracture","title":"Nondisplaced talar neck fracture (Hawkins type I)","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Nondisplaced talar neck fracture (Hawkins type I)</div><div class=\"cntnt\"><img style=\"width:478px; height:362px;\" src=\"images/EM/65869_Talarneckfracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This 6-year-old boy fell from a height sustaining a Hawkins type I fracture of the talar neck of the left ankle. <br />(B) Comparison view of uninjured right ankle. <br />(C) Lateral view at four months shows degenerative changes.</div><div class=\"graphic_reference\">Reproduced with permission from: Jarvis JG, Moroz PJ. Fractures and Dislocations of the Foot. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 65869 Version 12.0</div></div></div>"},"65871":{"type":"graphic_algorithm","displayName":"MRI algorithm white matter disorders","title":"MRI algorithm for the diagnosis of white matter disorders","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">MRI algorithm for the diagnosis of white matter disorders</div><div class=\"cntnt\"><img style=\"width:608px; height:790px;\" src=\"images/NEURO/65871_MRI_algorithm_WM_disorders.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Schiffmann R, van der Knaap MS. Invited Article: An MRI-based approach to the diagnosis of white matter disorders. Neurology 2009; 72:750. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65871 Version 12.0</div></div></div>"},"65872":{"type":"graphic_figure","displayName":"MSAFP by gestational age","title":"The approximate relationship between alpha-fetoprotein (AFP) values in maternal serum and gestational age","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">The approximate relationship between alpha-fetoprotein (AFP) values in maternal serum and gestational age</div><div class=\"cntnt\"><img style=\"width:500px; height:304px;\" src=\"images/OBGYN/65872_MSAFP_by_gestational_age.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Habib ZA. Maternal serum alpha-fetoprotein: Its value in antenatal diagnosis of genetic disease and in obstetrical-gynaecological care. Acta Obstet Gynecol Scand 1977; 61:1.</div><div id=\"graphicVersion\">Graphic 65872 Version 3.0</div></div></div>"},"65874":{"type":"graphic_table","displayName":"Clinical findings associated with sexual abuse","title":"Clinical findings associated with sexual abuse","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings associated with sexual abuse</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n\t<tbody>\r\n\t\t<tr>\r\n\t\t\t<td class=\"container\">\r\n\t\t\t\t<table cellspacing=\"0\">\r\n\t\t\t\t\t<tbody>\r\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Genital-rectal complaints</td></tr>\r\n\t\t\t\t\t\t<tr><td>Genital, anal, or urethral trauma*, bleeding, or itching</td></tr>\r\n\t\t\t\t\t\t<tr><td>Chronic genital or anal pain</td></tr>\r\n\t\t\t\t\t\t<tr><td>Genital infection or discharge</td></tr>\r\n\t\t\t\t\t\t<tr><td>Vaginal or rectal foreign body</td></tr>\r\n\t\t\t\t\t\t<tr><td>Vulvitis or vulvovaginitis</td></tr>\r\n\t\t\t\t\t\t<tr><td>Anal inflammation</td></tr>\r\n\t\t\t\t\t\t<tr><td>Sexually transmitted infection*</td></tr>\r\n\t\t\t\t\t\t<tr><td>Pregnancy*</td></tr>\r\n\t\t\t\t\t\t<tr><td>Dysuria</td></tr>\r\n\t\t\t\t\t\t<tr><td>Recurrent urinary tract infection</td></tr>\r\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Medical complaints</td></tr>\r\n\t\t\t\t\t\t<tr><td>Anorexia</td></tr>\r\n\t\t\t\t\t\t<tr><td>Abdominal pain</td></tr>\r\n\t\t\t\t\t\t<tr><td>Headaches</td></tr>\r\n\t\t\t\t\t\t<tr><td>Enuresis, encopresis</td></tr>\r\n\t\t\t\t\t\t<tr><td>Chronic constipation</td></tr>\r\n\t\t\t\t\t\t<tr><td>Painful defecation</td></tr>\r\n\t\t\t\t\t\t<tr><td>Bruises to the soft or hard palate</td></tr>\r\n\t\t\t\t\t</tbody>\r\n\t\t\t\t</table>&nbsp;</td>\r\n\t\t\t<td class=\"container\">\r\n\t\t\t\t<table cellspacing=\"0\">\r\n\t\t\t\t\t<tbody>\r\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Behavioral changes</td></tr>\r\n\t\t\t\t\t\t<tr><td>Clinging</td></tr>\r\n\t\t\t\t\t\t<tr><td>Temper tantrums, aggression, self injury</td></tr>\r\n\t\t\t\t\t\t<tr><td>Sleep disturbance, nightmares</td></tr>\r\n\t\t\t\t\t\t<tr><td>Appetite disturbance</td></tr>\r\n\t\t\t\t\t\t<tr><td>Neurotic or conduct disorders</td></tr>\r\n\t\t\t\t\t\t<tr><td>Excessive fears, phobias</td></tr>\r\n\t\t\t\t\t\t<tr><td>Depression, withdrawal, low self-esteem</td></tr>\r\n\t\t\t\t\t\t<tr><td>Social problems with peers</td></tr>\r\n\t\t\t\t\t\t<tr><td>School problems</td></tr>\r\n\t\t\t\t\t\t<tr><td>Substance abuse</td></tr>\r\n\t\t\t\t\t\t<tr><td>Suicidal ideation</td></tr>\r\n\t\t\t\t\t\t<tr><td>Explicit description of sexual contact*</td></tr>\r\n\t\t\t\t\t\t<tr><td>Promiscuity, prostitution, sexual perpetration on others*</td></tr>\r\n\t\t\t\t\t\t<tr><td>Inappropriate knowledge of adult sexual behavior*</td></tr>\r\n\t\t\t\t\t\t<tr><td>Excessive sexual curiosity, sexual acting out*</td></tr>\r\n\t\t\t\t\t\t<tr><td>Compulsive masturbation*</td></tr>\r\n\t\t\t\t\t</tbody>\r\n\t\t\t\t</table>&nbsp;</td>\r\n\t\t</tr>\r\n  </tbody>\r\n</table></div><div class=\"graphic_footnotes\">*Specific, significant indicators of possible sexual abuse</div><div class=\"graphic_reference\">Adapted from Hymel, KP, Jenny, C. Child sexual abuse. Pediatr Rev 1996; 17:236 and Ludwig, S. Child abuse. In: Textbook of Pediatric Emergency Medicine, 4th ed, Fleisher, GR, Ludwig, S (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2000. p.1669.</div><div id=\"graphicVersion\">Graphic 65874 Version 2.0</div></div></div>"},"65875":{"type":"graphic_table","displayName":"FDA drug labeling with genetic data","title":"Selected genomic biomarkers in the context of US Food and Drug Administration (FDA)-approved drug labels","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected genomic biomarkers in the context of US Food and Drug Administration (FDA)-approved drug labels</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Biomarker</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Synopsis of drug label information</td> <td class=\"subtitle1\">Label recommends testing prior to instituting therapy</td> </tr> <tr class=\"divider_bottom\"> <td>ALK (anaplastic lymphoma kinase) gene rearrangements</td> <td> <p>Crizotinib</p> <p>Ceritinib</p> <p>Alectinib</p> </td> <td>Crizotinib, ceritinib and alectinib&nbsp;selectively inhibit ALK tyrosine kinase. ALK gene rearrangements, which include the echinoderm microtubule-associated protein-like 4-AKL (EML4-ALK) fusion oncogene, may result in expression of oncogenic fusion proteins and increased tumor growth. Detection of ALK-positive NSCLC is necessary for selection of patients for treatment with these agents.</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>BRAF<sup>V600</sup>, BRAF<sup>V600E</sup> mutations</td> <td> <p>Vemurafenib</p> <p>Dabrafenib</p> </td> <td>Vemurafenib and dabrafenib inhibit BRAF kinase, which inhibits tumor growth in melanomas that have specific types of mutated BRAF at the V600 site. Confirmation of a V600 BRAF mutation is required for selection of patients for treatment of melanoma with these agents.</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>c-KIT expression, c-KIT<sup>D816V</sup> mutation</td> <td>Imatinib</td> <td>Imatinib inhibits proliferation and induces apoptosis in gastrointestinal stromal tumors (GIST) that express an activating c-KIT mutation and in aggressive systemic mastocytosis (ATS) cells that lack the c-KIT<sup>D816V</sup> mutation.</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>CCR5 (Chemokine C-C motif receptor 5)</td> <td>Maraviroc</td> <td>Maraviroc is indicated for treatment-experienced adult patients infected with only CCR5-tropic strains of HIV-1 that are resistant to multiple antiretroviral agents.</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>Cystic fibrosis transmembrane conductance regulator (CFTR) gene, G551D mutation</td> <td>Ivacaftor</td> <td>Ivacaftor is indicated for treatment of patients with cystic fibrosis who harbor a G551D mutation in at least one of their CFTR genes.</td> <td>Yes</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Cytochrome P450 (CYP) 2C19 variants</td> <td>Clopidogrel</td> <td>Patients with genetically reduced CYP2C19 function have lower systemic exposure to the active metabolite of clopidogrel, diminished antiplatelet response, and higher cardiovascular event rates following myocardial infarction than do patients with normal CYP2C19 function.</td> <td>No</td> </tr> <tr> <td>Voriconazole</td> <td>CYP2C19 is significantly involved in the metabolism of voriconazole; poor metabolizers have on average four-fold higher voriconazole exposure than their homozygous counterparts.</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td>Citalopram</td> <td>Maximum recommended daily dose of 20 mg (rather than 40 mg) for CYP2C19 poor metabolizers.</td> <td>No</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">CYP2C9 variants</td> <td> <p>Warfarin*</p> For additional information on warfarin see the footnote</td> <td>Increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 allele.</td> <td>No*</td> </tr> <tr class=\"divider_bottom\"> <td>Celecoxib</td> <td>CYP2C9 poor metabolizers may have abnormally high plasma levels due to reduced metabolic clearance.</td> <td>No</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">CYP2D6 variants</td> <td>Aripiprazole</td> <td>CYP2D6 poor metabolizers should receive a reduced dose initially followed by titration according to clinical response.</td> <td>No</td> </tr> <tr> <td>Atomoxetine</td> <td>Patients with reduced activity in this pathway (poor metabolizers) have higher plasma concentrations of atomoxetine compared to people with normal activity (extensive metabolizers).</td> <td>No</td> </tr> <tr> <td>Fluoxetine</td> <td>CYP2D polymorphisms of the poor metabolizer phenotype do not affect the metabolism of fluoxetine because of compensatory mechanisms. However, fluoxetine inhibits the activity of the 2D6 isoenzyme and it may affect the metabolism of other drugs that are metabolized with this enzyme, potentially making normal metabolizers resemble poor metabolizers. Drugs that are predominantly metabolized by CYP2D6 that have a relatively narrow therapeutic index (example tricyclic antidepressants) should be initiated at the low end of the dose range if concomitant fluoxetine is being used.</td> <td>No</td> </tr> <tr> <td>Codeine</td> <td>Some individuals may be ultra-rapid metabolizers due to a specific CYP2D6* genotype; these individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels.</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td>Tetrabenazine</td> <td>Patients without expression of CYP2D6 drug metabolizing enzyme likely to have increased exposure.</td> <td>Yes, if daily doses &#62;50 mg</td> </tr> <tr class=\"divider_bottom\"> <td>Deletion of chromosome 5q(del(5q))</td> <td>Lenalidomide</td> <td>Indicated for the treatment of myelodysplastic syndrome in patients with deletion 5q cytogenetic abnormality with transfusion dependent anemia.</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>Dihydropyrimidine dehydrogenase (DPD) deficiency</td> <td>Fluorouracil, capecitabine</td> <td>Unexpected, severe toxicity (eg, stomatitis, diarrhea, neutropenia, and neurotoxicity) associated with these drugs has been attributed to a deficiency of DPD activity.</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td>Glucose-6-phosphate dehydrogenase (G6PD) deficiency</td> <td>Rasburicase, dapsone, primaquine, chloroquine</td> <td>These drugs administered to patients with glucose-phosphate dehydrogenase (G6PD) deficiency can cause severe hemolysis.</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>HER2 overexpression</td> <td> <p>Trastuzumab, pertuzumab,</p> <p>&nbsp;lapatinib</p> </td> <td>Over-expression of HER2/neu necessary for selection of patients who are appropriate for use of these agents.</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>HLA-B*1502 allele presence</td> <td>Carbamazepine, oxcarbazepine</td> <td>Serious dermatologic reactions can result in individuals with the HLA-B*1502 allele.</td> <td>Yes (in patients of Asian descent)</td> </tr> <tr class=\"divider_bottom\"> <td>HLA-B*5701 allele presence</td> <td>Abacavir</td> <td>Hypersensitivity reactions, lactic acidosis, and severe hepatomegaly can occur in patients who carry the HLA-B*5701 allele at high risk for such reactions to abacavir; screening for this allele is recommended prior to initiating treatment with abacavir.</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>HLA-B*5801 allele presence</td> <td>Allopurinol</td> <td>There is a strong association between inheritance of the HLA-B*5801 allele and severe cutaneous adverse events in patients treated with allopurinol, particularly in certain Asian populations. Allopurinol should be avoided in high-risk populations, including Han Chinese and Thai patients, and in patients with kidney disease who are of Korean descent, if they are HLA-B*5801-positive, or in patients with a family history of severe cutaneous adverse reactions to allopurinol. Screening is advised for high-risk patients, but widespread application of testing in other populations is less clear.&nbsp;</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td>KRAS mutation</td> <td>Panitumumab, cetuximab</td> <td>Use of these drugs is not recommended for the treatment of patients with colorectal cancer who have mutated KRAS in their tumors.</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>Arylamine N-acetyltransferase (NAT) variants</td> <td>Rifampin, isoniazid, pyrazinamide, isosorbide dinitrate, hydralazine</td> <td>Slow acetylation may lead to higher blood levels of these drugs and thus, an increase in toxic reactions.</td> <td>No</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Philadelphia chromosome positivity</td> <td>Busulfan</td> <td>This drug is clearly less effective in patients with chronic myelogenous leukemia (CML) who lack the Philadelphia (Ph1) chromosome.</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td>Dasatinib</td> <td>Indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>PML/RAR alpha gene expression (retinoic acid receptor) expression</td> <td>Tretinoin, arsenic trioxide</td> <td>Indicated for treatment of acute promyelocytic leukemia (APL) characterized by a t(15,17) translocation and/or the presence of PML/RAR alpha gene. The response rate of other APML subtypes has not been demonstrated and therefore, patients who lack this genetic marker should be considered for alternative treatment.</td> <td> <p>Yes, if no</p> <p>t(15,17)</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Protein C deficiency (hereditary or acquired)</td> <td> <p>Warfarin</p> For additional information on warfarin see above and below</td> <td>Hereditary or acquired deficiencies of protein C or its cofactor protein S have been associated with tissue necrosis following drug administration.</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td>Thiopurine methyltransferase (TPMT) variants</td> <td>Azathioprine, 6-mercaptopurine, thioguanine</td> <td>Individuals with TPMT deficiency or lower activity due to mutation are at increased risk for myelotoxicity.</td> <td> <p>No</p> Azathioprine label recommends consideration of TPMT testing</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Uridine diphospho- glucuronosyltransferase 1A1 (UGT 1A1) variants</td> <td>Irinotecan</td> <td>Patients exposed to this drug who have the UGT1A1*28 allele may be more susceptible to toxicity.</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td>Nilotinib</td> <td>Can increase bilirubin levels; the (TA)7/(TA)7 genotype (UGT1A1*28 allele) is associated with a statistically significant increase in the risk of hyperbilirubinemia.</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td>Urea cycle disorder (UCD) deficiency</td> <td>Valproic acid</td> <td>Use is contraindicated in individuals with urea cycle disorder. Evaluation for UCD prior to therapy should be considered for patients in certain high risk groups including those with family history of UCD.</td> <td>Yes for patients with history of unexplained encephalopathy or coma, unexplained mental retardation, cyclical vomiting and lethargy, history of elevated ammonia or glutamine, family history of UCD, or unexplained infant deaths.</td> </tr> <tr> <td>Vitamin K epoxide reductase (VKORC1) variants</td> <td> <p>Warfarin</p> For additional information on warfarin see above</td> <td>Certain single nucleotide polymorphisms in the VKORC1 gene (especially the &ndash;1639G&#62;A allele) have been associated with lower dose requirements for warfarin.</td> <td>No*</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><FONT color=black>This table is intended to illustrate basic concepts&nbsp;in the role of&nbsp;pharmacogenomic testing. For patient management, refer to UpToDate content on specific conditions and the latest product information.&nbsp;Additional information on pharmacogenomics&nbsp;is available in UpToDate</FONT><FONT color=black>.</FONT></div><div class=\"graphic_footnotes\"><SPAN style=\"COLOR: black\"><FONT color=black>* The US prescribing information for warfarin&nbsp;provides information about dosing based on VKORC1 and CYP2C9 genotype&nbsp;if this information is&nbsp;available but does not recommend testing for these variants prior to initiating therapy</FONT>.</SPAN></div><div id=\"graphicVersion\">Graphic 65875 Version 18.0</div></div></div>"},"65876":{"type":"graphic_figure","displayName":"Anatomy of the male ureter - lateral view","title":"Anatomy of the male ureter - lateral view","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Anatomy of the male ureter - lateral view</div><div class=\"cntnt\"><img style=\"width:535px; height:444px;\" src=\"images/SURG/65876_Ureter-male-lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the pathway of the ureter in the male pelvis.</div><div id=\"graphicVersion\">Graphic 65876 Version 2.0</div></div></div>"},"65877":{"type":"graphic_picture","displayName":"Metastatic tuberculous abscesses","title":"Metastatic tuberculous abscesses (tuberculous gummas)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metastatic tuberculous abscesses (tuberculous gummas)</div><div class=\"cntnt\"><img style=\"width:256px; height:322px;\" src=\"images/DERM/65877_Metast_tuberc_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple ulcers are present on the back of this patient with metastatic tuberculous abscesses, also known as tuberculous gummas.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. M Ramam, New Delhi.</div><div id=\"graphicVersion\">Graphic 65877 Version 1.0</div></div></div>"},"65878":{"type":"graphic_diagnosticimage","displayName":"Tibial tubercle avulsion","title":"Complete avulsion of the tibial tubercle","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Complete avulsion of the tibial tubercle</div><div class=\"cntnt\"><img style=\"width:516px; height:324px;\" src=\"images/EM/65878_Tibial_tubercle_avulsion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 13-year-old fell after attempting a jump. The radiograph shows complete avulsion of the tibial tuberosity with a Salter-Harris IV proximal tibial fracture (black arrow), knee joint effusion (white arrow), and proximal patellar displacement.</div><div class=\"graphic_reference\">Courtesy of Eglal Shalaby-Rana, MD.</div><div id=\"graphicVersion\">Graphic 65878 Version 3.0</div></div></div>"},"65881":{"type":"graphic_picture","displayName":"Balanoposthitis","title":"Balanoposthitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Balanoposthitis</div><div class=\"cntnt\"><img style=\"width:216px; height:271px;\" src=\"images/ID/65881_Balanoposthitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Vaibhav Parekh, MD, MBA.</div><div id=\"graphicVersion\">Graphic 65881 Version 1.0</div></div></div>"},"65883":{"type":"graphic_table","displayName":"Mental status exam terms","title":"Mental status examination terminology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mental status examination terminology</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tr>\n\t\t<td><strong>abulia:</strong> loss of initiative, willpower, or drive</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>acalculia:</strong> inability to calculate</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>agnosia:</strong> inability to recognize one or more classes of environmental stimuli, even though the necessary intellectual and perceptual functions are intact</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>agraphia:</strong> inability to write</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>alexia:</strong> inability to read for comprehension</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>amnesia:</strong> inability to retain new information</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>anomia:</strong> inability to name objects or think of words; in practice, often used as a synonym for dysnomia</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>anosognosia:</strong> inability to recognize one's own impairment</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>anterior aphasia:</strong> acquired language disorder in which verbal output is nonfluent</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>aphasia:</strong> literally, a complete loss of language function, but in practice, used as a synonym for dysphasia</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>aphemia:</strong> complete loss of the ability to speak, but retained comprehension and writing ability</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>apraxia:</strong> inability to perform a previously learned set of coordinated movements even though the necessary component skills (including intellect, language function, strength, coordination, and sensation) remain intact</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>Broca's aphasia:</strong> acquired language disorder characterized by nonfluent verbal output with omission of relational words (prepositions, conjunctions, articles, and minor modifiers) and abnormal prosody, impaired repetition, and relatively intact comprehension</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>conduction aphasia:</strong> acquired language disorder characterized by prominent impairment of repetition, relatively intact comprehension, and verbal output that is fluent but contains literal paraphasias</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>delirium:</strong> an acute confusional state characterized by clouded, reduced, or shifting attention, often associated with sensory misperception or disturbed thinking</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>dementia:</strong> acquired impairment of memory and at least one other cognitive function, without clouding of the sensorium or underlying psychiatric disease</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>dysnomia:</strong> difficulty naming objects or finding the desired words</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>dysphasia:</strong> acquired disorder of language not due to generalized intellectual impairment or psychiatric disturbance</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>expressive aphasia:</strong> acquired language disorder in which verbal output is nonfluent</td></tr>\n\t\t<tr><td> <strong>fluent:</strong> an adjective used to describe verbal output that is normal to excessive, easily produced, with normal phrase length (five or more words) and normal prosody</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>fluent aphasia:</strong> acquired language disorder in which verbal output is fluent</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>Gerstmann's syndrome:</strong> the constellation of (1) agraphia, (2) acalculia, (3) right-left confusion, and (4) finger agnosia; classically associated with lesions in the angular gyrus of the dominant hemisphere (but the subject of endless debate)</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>jargon:</strong> verbal output that contains so many literal paraphasias that the words are unrecognizable</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>nonfluent:</strong> an adjective used to describe verbal output that is sparse, with only one to four words per phrase</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>nonfluent aphasia:</strong> acquired language disorder in which verbal output is nonfluent</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>paraphasia:</strong> a substitution error in which the word produced is similar in sound or meaning to the intended word. A literal or phonemic paraphasia is a sound substitution error resulting in production of a word that is phonemically related to the intended word (eg, \"greed\" or \"greeb\" instead of \"green\"). A semantic or verbal paraphasia is a word substitution error in which the word produced is semantically related to the intended word (eg, \"blue\" instead of \"green\")</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>posterior aphasia:</strong> acquired language disorder in which comprehension is impaired</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>prosody:</strong> the rhythm and tempo of speech</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>prosopagnosia:</strong> inability to recognize faces</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>receptive aphasia:</strong> acquired language disorder in which comprehension is impaired</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>transcortical aphasia:</strong> acquired language disorder in which the ability to repeat is intact</td>\n\t</tr>\n\n\t<tr>\n\t\t<td><strong>Wernicke's aphasia:</strong> acquired language disorder characterized by markedly impaired comprehension and repetition, with verbal output that is fluent but contaminated by numerous paraphasias or, in severe cases, jargon</td>\n\t</tr>\n</table></div><div id=\"graphicVersion\">Graphic 65883 Version 2.0</div></div></div>"},"65884":{"type":"graphic_picture","displayName":"Moderate hidradenitis suppurativa","title":"Moderate hidradenitis suppurativa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Moderate hidradenitis suppurativa</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/OBGYN/65884_Moderate_HS.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&#160;and Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 65884 Version 3.0</div></div></div>"},"65885":{"type":"graphic_table","displayName":"TNM staging penile cancer","title":"TNM staging system for carcinoma of the penis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TNM staging system for carcinoma of the penis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr> <td>TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td>T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td>Tis</td> <td colspan=\"3\">Carcinoma in situ</td> </tr> <tr> <td>Ta</td> <td colspan=\"3\">Noninvasive verrucous carcinoma*</td> </tr> <tr> <td>T1a</td> <td colspan=\"3\">Tumor invades subepithelial connective tissue without lymph vascular invasion and is not poorly differentiated (ie, NOT grade 3-4)</td> </tr> <tr> <td>T1b</td> <td colspan=\"3\">Tumor invades subepithelial connective tissue with lymph vascular invasion or is poorly differentiated (grade 3-4)</td> </tr> <tr> <td>T2</td> <td colspan=\"3\">Tumor invades corpus spongiosum or cavernosum</td> </tr> <tr> <td>T3</td> <td colspan=\"3\">Tumor invades urethra</td> </tr> <tr> <td>T4</td> <td colspan=\"3\">Tumor invades other adjacent structures</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Clinical stage definition<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">cNX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">cN0</td> <td colspan=\"3\">No palpable or visibly enlarged inguinal lymph nodes</td> </tr> <tr> <td class=\"indent1\">cN1</td> <td colspan=\"3\">Palpable mobile unilateral inguinal lymph node</td> </tr> <tr> <td class=\"indent1\">cN2</td> <td colspan=\"3\">Palpable mobile multiple or bilateral inguinal lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">cN3</td> <td colspan=\"3\">Palpable fixed inguinal nodal mass or pelvic lymphadenopathy unilateral or bilateral</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Pathologic stage definition<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">pNX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">pN0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">pN1</td> <td colspan=\"3\">Metastasis in a single inguinal lymph node</td> </tr> <tr> <td class=\"indent1\">pN2</td> <td colspan=\"3\">Metastasis in multiple or bilateral inguinal lymph nodes</td> </tr> <tr> <td class=\"indent1\">pN3</td> <td colspan=\"3\">Extranodal extension of lymph node metastasis or pelvic lymph node(s) unilateral or bilateral</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr> <td>M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr> <td>MI</td> <td colspan=\"3\">Distant metastasis<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Additional descriptor</td> </tr> <tr> <td colspan=\"4\">The m suffix indicates the presence of multiple primary tumors and is recorded in parentheses - eg, pTa (m) N0M0.</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"4\">Anatomic stage/prognostic groups</td> </tr> <tr> <td rowspan=\"2\">Stage 0</td> <td>Tis</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Ta</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage I</td> <td>T1a</td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan=\"3\">Stage II</td> <td>T1b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T2</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IIIa</td> <td>T1-3</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>Stage IIIb</td> <td>T1-3</td> <td>N2</td> <td>M0</td> </tr> <tr> <td rowspan=\"3\">Stage IV</td> <td>T4</td> <td>Any N</td> <td>M0</td> </tr> <tr> <td>Any T</td> <td>N3</td> <td>M0</td> </tr> <tr> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Broad pushing penetration (invasion) is permitted; destructive invasion is against this diagnosis.<br />¶ Clinical stage definition based on palpation, imaging.<br />Δ Pathologic stage definition based on biopsy or surgical excision.<br /><FONT class=lozenge>◊</FONT> Lymph node metastasis outside of the true pelvis in addition to visceral or bone sites.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 65885 Version 14.0</div></div></div>"},"65887":{"type":"graphic_picture","displayName":"Ring sideroblasts","title":"Ring sideroblasts in refractory anemia with ring sideroblasts (RARS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ring sideroblasts in refractory anemia with ring sideroblasts (RARS)</div><div class=\"cntnt\"><img style=\"width:392px; height:259px;\" src=\"images/HEME/65887_Ringed_sideroblasts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prussian blue stain of the bone marrow in a patient with refractory anemia and ring sideroblasts (RARS). Blue-stained ferritin iron deposits in the mitochondria of erythroid precursors form an apparent ring around the nucleus (see arrows).</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 65887 Version 5.0</div></div></div>"},"65888":{"type":"graphic_diagnosticimage","displayName":"Oblique med meniscus tear","title":"Oblique tear of the medial meniscus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oblique tear of the medial meniscus</div><div class=\"cntnt\"><img style=\"width:316px; height:389px;\" src=\"images/RHEUM/65888_Oblique_med_meniscus_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sagittal short tau inversion recovery (STIR) magnetic resonance image of the knee demonstrates bright signal (arrow) extending to the inferior surface of the medial meniscus that is consistent with an oblique tear.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 65888 Version 2.0</div></div></div>"},"65889":{"type":"graphic_picture","displayName":"Subacromial palpation","title":"Subacromial palpation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subacromial palpation</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/EM/65889_Subacromial_palpation.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Stephen M Simons, MD.</div><div id=\"graphicVersion\">Graphic 65889 Version 1.0</div></div></div>"},"65890":{"type":"graphic_picture","displayName":"Antiphospholipid antibody syndrome purpura","title":"Purpura in antiphospholipid antibody syndrome","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Purpura in antiphospholipid antibody syndrome</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/DERM/65890_Antiphos_antibody_synd_purp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Noninflammatory, retiform purpura are present on the buttocks and thighs.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65890 Version 3.0</div></div></div>"},"65891":{"type":"graphic_table","displayName":"Anti-emetic agents for postoperative nausea and vomiting","title":"Anti-emetic agents for postoperative nausea and vomiting*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anti-emetic agents for postoperative nausea and vomiting*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" colspan=\"4\">Relative risk (95% CI)</td> </tr> <tr> <td class=\"subtitle2\">Nausea</td> <td class=\"subtitle2\">Vomiting</td> <td class=\"subtitle2\">Nausea and vomiting</td> <td class=\"subtitle2\">Rescue antiemetic</td> </tr> <tr> <td>Droperidol</td> <td>0.65 (0.60-0.71)</td> <td>0.65 (0.61-0.70)</td> <td>0.62 (0.58-0.67)</td> <td>0.53 (0.47-0.60)</td> </tr> <tr> <td>Dexamethasone</td> <td>0.57 (0.48-0.69)</td> <td>0.51 (0.46-0.57)</td> <td>0.49 (0.44-0.54)</td> <td>0.50 (0.42-0.59)</td> </tr> <tr> <td>Cyclizine</td> <td>0.65 (0.47-0.90)</td> <td>0.57 (0.43-0.75)</td> <td>0.68 (0.58-0.80)</td> <td>0.27 (0.14-0.62)</td> </tr> <tr> <td>Metoclopramide</td> <td>0.82 (0.76-0.88)</td> <td>0.75 (0.70-0.81)</td> <td>0.76 (0.70-0.82)</td> <td>0.78 (0.69-0.88)</td> </tr> <tr> <td>Ondansetron</td> <td>0.68 (0.63-0.74)</td> <td>0.55 (0.50-0.59)</td> <td>0.56 (0.50-0.63)</td> <td>0.55 (0.49-0.61)</td> </tr> <tr> <td>Dolasetron</td> <td>0.82 (0.76-0.90)</td> <td>0.63 (0.51-0.76)</td> <td>0.72 (0.62-0.83)</td> <td>0.67 (0.57-0.79)</td> </tr> <tr> <td>Tropisetron</td> <td>0.77 (0.71-0.84)</td> <td>0.59 (0.50-0.69)</td> <td>0.70 (0.61-0.81)</td> <td>0.62 (0.53-0.72)</td> </tr> <tr> <td>Granisetron</td> <td>0.53 (0.45-0.63)</td> <td>0.40 (0.35-0.46)</td> <td>0.39 (0.31-0.48)</td> <td>0.29 (0.22-0.39)</td> </tr> <tr> <td>Romasetron</td> <td>0.62 (0.40-0.96)</td> <td>0.42 (0.28-0.63)</td> <td>0.51 (0.39-0.68)</td> <td>0.38 (0.15-0.99)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Placebo versus drug.</div><div class=\"graphic_reference\">Data from: Carlisle J, Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev 2006; 3:CD004125.</div><div id=\"graphicVersion\">Graphic 65891 Version 1.0</div></div></div>"},"65892":{"type":"graphic_picture","displayName":"Pilar cyst 4","title":"Pilar cyst","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pilar cyst</div><div class=\"cntnt\"><img style=\"width:504px; height:335px;\" src=\"images/DERM/65892_Pilar_cyst_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 65892 Version 3.0</div></div></div>"},"65893":{"type":"graphic_picture","displayName":"Sertoli Leydig cell tumor","title":"Sertoli-Leydig cell tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sertoli-Leydig cell tumor</div><div class=\"cntnt\"><img style=\"width:398px; height:256px;\" src=\"images/OBGYN/65893_Sertoli_Leydig_cell_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross specimen of a Sertoli-Leydig cell tumor.</div><div class=\"graphic_reference\">Reproduced with the permission from Berek, JS, Hacker, NF. Practical Gynecologic Oncology, 3rd ed. Lippincott Williams &amp; Wilkins, Philadelphia, 2000, p. 225.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 65893 Version 2.0</div></div></div>"},"65894":{"type":"graphic_figure","displayName":"Cyclosporine and Ca blockers","title":"Graph showing the effect of calcium channel blockers on cyclosporine-induced vasoconstriction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graph showing the effect of calcium channel blockers on cyclosporine-induced vasoconstriction</div><div class=\"cntnt\"><img style=\"width:419px; height:228px;\" src=\"images/NEPH/65894_Cyclosporine_and_Ca_blocker.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The administration of cyclosporine to 10 renal transplant recipients on chronic maintenance therapy is associated with daily transient reductions of approximately 50 percent in RPF and GFR. These changes are prevented by chronic treatment with a calcium channel blocker (blue squares and circles), which also lowered the systemic blood pressure from mean values of 142/93 to 125/79.</div><div class=\"graphic_footnotes\">RPF: renal plasma flow; GFR: glomerular filtration rate.</div><div class=\"graphic_reference\">Data from Ruggenenti P, Perico N, Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion.&nbsp;Kidney Int 1993; 43:706.</div><div id=\"graphicVersion\">Graphic 65894 Version 3.0</div></div></div>"},"65898":{"type":"graphic_figure","displayName":"Colds symptom profile","title":"Symptom profile of the common cold in children","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Symptom profile of the common cold in children</div><div class=\"cntnt\"><img style=\"width:585px; height:376px;\" src=\"images/PEDS/65898_Colds_symptom_profile.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Symptom profile in 81 colds in healthy school children. Symptoms include congestion, runny nose, cough, sneezing, and feverish.</div><div class=\"graphic_reference\">Adapted with permission from: Pappas DE, Hendley JO, Hayden FG, Winther B. Symptom profile of common colds in school-aged children. Pediatr Infect Dis J 2008; 27:8. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65898 Version 11.0</div></div></div>"},"65905":{"type":"graphic_diagnosticimage","displayName":"Mycoplasma pneumonia CT","title":"<em>Mycoplasma</em> pneumonia with patchy ground-glass opacities","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\"><em>Mycoplasma</em> pneumonia with patchy ground-glass opacities</div><div class=\"cntnt\"><img style=\"width:584px; height:206px;\" src=\"images/ID/65905_MycoplasmapneumoniaCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) High-resolution computed tomography (HRCT) section at the level of the middle lobe bronchus demonstrates ground-glass opacification of the right lung and superior segment of the left lower lobe in a patient who had proven <EM>Mycoplasma pneumonia</EM>. (B) Follow-up HRCT at the same level as in (A) shows only minimal residual ground-glass opacification.</div><div class=\"graphic_reference\">Reproduced with permission from: Infections. In: High-Resolution CT of the Lung, 4th Ed, Webb WR, Müller NL, Naidich DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 65905 Version 9.0</div></div></div>"},"65906":{"type":"graphic_diagnosticimage","displayName":"Pancreatitis extending to the root of the mesentery","title":"Pancreatitis extending to the root of the mesentery","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Pancreatitis extending to the root of the mesentery</div><div class=\"cntnt\"><img style=\"width:501px; height:395px;\" src=\"images/SURG/65906_Pancreatitis_extend_root.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that there is inflammatory change with edema extending to the mesenteric root.</div><div class=\"graphic_reference\">Courtesy of J Pierre Sasson, MD.</div><div id=\"graphicVersion\">Graphic 65906 Version 3.0</div></div></div>"},"65909":{"type":"graphic_picture","displayName":"Buruli ulcer lower leg","title":"Buruli ulcer located on the lower leg","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Buruli ulcer located on the lower leg</div><div class=\"cntnt\"><img style=\"width:289px; height:504px;\" src=\"images/ID/65909_Buruli_ulcer_lower_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, undermined lesion at the left lower leg in a 30-year-old female farmer.</div><div class=\"graphic_reference\">Courtesy of Tjip S van der Werf, MD.</div><div id=\"graphicVersion\">Graphic 65909 Version 1.0</div></div></div>"},"65910":{"type":"graphic_movie","displayName":"Laser photocoagulation of a carcinoid tumor","title":"Laser photocoagulation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laser photocoagulation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/65910_brlasphoconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:246px; height:232px;\" src=\"images/CARD/65910_brlaspho.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Video shows photocoagulation of a smooth walled carcinoid tumor with a Nd:YAG laser. Tissue blanching is observed when the laser is used.</div><div class=\"graphic_reference\">Courtesy of Henri G Colt, MD, and Praveen Mathur, MD.</div><div id=\"graphicVersion\">Graphic 65910 Version 2.0</div></div></div>"},"65913":{"type":"graphic_table","displayName":"Plexopathies cancer pts","title":"Plexopathies in cancer patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Plexopathies in cancer patients</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Syndrome\n   </td>\n   <td  class=\"subtitle1\">\n   Description\n   </td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Cervical plexopathy\n   </td>\n   <td>Aching and burning pain in periauricular or postauricular area, or anterior neck</td>\n   </tr>\n   <tr>\n   <td>Pain may be referred to the lateral aspect of the face, head, or shoulder</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Brachial plexopathy\n   </td>\n   <td>Moderate to severe pain with component that is dysesthetic and described as burning or freezing</td>\n   </tr>\n   <tr>\n   <td>Allodynia may accompany pain</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"8\" class=\"sublist1_start\">\n   Lumbosacral plexopathies\n   </td>\n   <td>Presents as pain, followed by numbness, paresthesias, or weakness</td>\n   </tr>\n   <tr>\n   <td>Other symptoms include focal tenderness, leg edema, and positive direct or reverse straight leg raising signs</td>\n   </tr>\n   <tr>\n   <td>Distribution of pain is related to the location of the neoplasm:</td>\n   </tr>\n   <tr>\n   <td>- Upper lumbosacral plexopathy (L1-4): Pain experienced in the anterolateral thigh, knee, and proximal leg/lower abdomen; generally caused by low abdominal tumors; upper lumbosacral plexopathy associated with malignant involvement of the psoas major muscle is termed \"malignant psoas syndrome\"</td>\n   </tr>\n   <tr>\n   <td>- Lower lumbosacral plexopathy (L4-S1): Pain may be focal in buttocks and perineum and referred to posterolateral thigh and leg; weakness or sensory changes in L5 and S1 dermatomes; leg edema, bladder dysfunction, or bowel dysfunction; generally caused by sigmoid or rectal tumors</td>\n   </tr>\n   <tr>\n   <td>- Sacral plexopathy (S1-3): May lead to dysesthesias in buttocks, perineum, or posterior legs; pain often severe while sitting, less severe while standing, and least severe while walking; numbness over the dorsolateral foot and weak ankle dorsiflexion; mostly associated with low midline tumors (eg, rectal cancer)</td>\n   </tr>\n   <tr>\n   <td>- Panplexopathy: Pain anywhere from lower abdomen, back, buttocks, or perineum; referred pain experienced anywhere in the distribution of the plexus</td>\n   </tr>\n   <tr>\n   <td>- Coccygeal plexopathy (S4-coccygeal nerve): May present as anal pain, numbness, and sphincter dysfunction; most common with rectal and prostate tumors</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 65913 Version 1.0</div></div></div>"},"65914":{"type":"graphic_picture","displayName":"Lachman test","title":"Lachman test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lachman test</div><div class=\"cntnt\"><img style=\"width:432px; height:407px;\" src=\"images/EM/65914_Lachman_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Lachman test is performed by placing the knee in 30 degrees of flexion and then stabilizing the distal femur with one hand while pulling the proximal tibia anteriorly with the other hand, thereby attempting to produce anterior translation of the tibia. An intact ACL limits anterior translation and provides a distinct endpoint. Lack of a distinct endpoint suggests ACL injury.</div><div class=\"graphic_reference\">Courtesy of Ryan P Friedberg, MD.</div><div id=\"graphicVersion\">Graphic 65914 Version 2.0</div></div></div>"},"65915":{"type":"graphic_algorithm","displayName":"Suggested protocol if fire ants are found on a patient","title":"Suggested protocol if fire ants are found on a patient","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Suggested protocol if fire ants are found on a patient</div><div class=\"cntnt\"><img style=\"width:523px; height:385px;\" src=\"images/ALLRG/65915_Protocol_ants_patient_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If ants are detected on a patient, they should be removed and the patient carefully assessed. The patient should be transferred from bed and all orifices inspected. Medical personnel should use gloves to prevent stings.</div><div class=\"graphic_footnotes\">* Ants are best removed by compression with a damp towel and wiping dead ants off with a damp cloth.</div><div class=\"graphic_reference\">Reproduced with permission from: Goddard J, Jarrat J, deShazo RD. Recommendations for prevention and management of fire ant infestation of health care facilities. South Med J 2002; 95:627. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65915 Version 14.0</div></div></div>"},"65916":{"type":"graphic_table","displayName":"Major causes of chronic secretory diarrhea","title":"Major causes of chronic secretory diarrhea*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of chronic secretory diarrhea*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Factitious diarrhea (laxative abuse)</td> </tr> <tr> <td>Rectal villous adenoma</td> </tr> <tr> <td class=\"sublist1_start\">Neuroendocrine tumors</td> </tr> <tr> <td class=\"sublist1\">VIPoma</td> </tr> <tr> <td class=\"sublist1\">Carcinoid syndrome</td> </tr> <tr> <td class=\"sublist1\">Gastrinoma (Zollinger-Ellison syndrome)</td> </tr> <tr> <td>Lymphocytic or collagenous colitis</td> </tr> <tr> <td>Congenital diarrhea</td> </tr> <tr> <td>Bile salt enteropathy</td> </tr> <tr> <td>Enterotoxic <em>Escherichia coli</em></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Secretory diarrhea is defined as diarrhea associated with a stool osmolal gap less than 50 mosmol/kg.</div><div class=\"graphic_reference\">Modified from: Donowitz M, Kokke FT, Saidi R. Evaluation of patients with chronic diarrhea. N Engl J Med 1995; 332:725.</div><div id=\"graphicVersion\">Graphic 65916 Version 6.0</div></div></div>"},"65917":{"type":"graphic_table","displayName":"Gastroenteropancreatic endocrine cells","title":"Gastroenteropancreatic endocrine cells","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gastroenteropancreatic endocrine cells</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Substance</td> <td class=\"subtitle1\">Cell type</td> <td class=\"subtitle1\">Location</td> </tr> <tr> <td>Secretin</td> <td>S cells</td> <td>Small intestine</td> </tr> <tr> <td>Ghrelin</td> <td>P/D1</td> <td>Stomach</td> </tr> <tr> <td rowspan=\"2\">Gastrin</td> <td rowspan=\"2\">G cells</td> <td>Gastric antrum</td> </tr> <tr> <td>Duodenum</td> </tr> <tr> <td>Cholecystokinin</td> <td>I cells</td> <td>Small intestine</td> </tr> <tr> <td>Glucagon</td> <td>Alpha&nbsp;cells</td> <td>Pancreas</td> </tr> <tr> <td>Insulin</td> <td>Beta&nbsp;cells</td> <td>Pancreas</td> </tr> <tr> <td>Pancreatic polypeptide</td> <td>PP cells</td> <td>Pancreas</td> </tr> <tr> <td rowspan=\"3\">Somatostatin</td> <td rowspan=\"3\">Delta&nbsp;cells</td> <td>Pancreas</td> </tr> <tr> <td>Stomach</td> </tr> <tr> <td>Small and large intestine</td> </tr> <tr> <td>Glucose-dependent insulinotropic peptide</td> <td>K cells</td> <td>Small intestine</td> </tr> <tr> <td>Motilin</td> <td>Mo cells</td> <td>Small intestine</td> </tr> <tr> <td>Histamine</td> <td>ECL cells</td> <td>Stomach</td> </tr> <tr> <td>Peptide YY</td> <td>L cells</td> <td>Small and large intestine</td> </tr> <tr> <td>Glucagon-like peptide</td> <td>L cells</td> <td>Small and large intestine</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PP: pancreatic polypeptide; ECL: enterochromaffin-like.</div><div id=\"graphicVersion\">Graphic 65917 Version 6.0</div></div></div>"},"65918":{"type":"graphic_figure","displayName":"Exocervical incision cone bx","title":"Start of cervical (uterine cervix) cone biopsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Start of cervical (uterine cervix) cone biopsy</div><div class=\"cntnt\"><img style=\"width:390px; height:317px;\" src=\"images/OBGYN/65918_Exocervical_incision_cone_b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An exocervical circumferential incision is initiated.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 65918 Version 2.0</div></div></div>"},"65921":{"type":"graphic_figure","displayName":"M mode pulmonic valve","title":"M-mode echocardiogram of pulmonic valve","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram of pulmonic valve</div><div class=\"cntnt\"><img style=\"width:396px; height:254px;\" src=\"images/CARD/65921_M_mode_pulmonic_valve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior and posterior leaflets of the pulmonic valve are recorded from the left parasternal region. The leaflet movement forms a &quot;box&quot; and is similar to the movement of the aortic valve.</div><div id=\"graphicVersion\">Graphic 65921 Version 1.0</div></div></div>"},"65922":{"type":"graphic_figure","displayName":"Pleural fluid after lung transplant","title":"Changes in pleural fluid composition after lung transplantation","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Changes in pleural fluid composition after lung transplantation</div><div class=\"cntnt\"><img style=\"width:465px; height:228px;\" src=\"images/PULM/65922_Pleural_fluid_after_lung_TP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequential changes in pleural fluid&nbsp;red cell&nbsp;and white cell counts (per mm<SUP>3</SUP>) and LDH concentration (IU/L) in six patients after lung transplantation. In addition to the progressive decline in LDH and cell counts, there were also reductions in the neutrophil&nbsp;proportions (89 down to 29 percent of total WBC) and total protein content (3.4 down to 2.1 g/dL) during this time period.</div><div class=\"graphic_footnotes\">RBC: red blood cell count; WBC: white blood cell count; LDH: lactate dehydrogenase.</div><div id=\"graphicVersion\">Graphic 65922 Version 2.0</div></div></div>"},"65923":{"type":"graphic_table","displayName":"Emetogenicity oral chemotherapy agents","title":"Emetogenic potential of oral antineoplastic agents*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Emetogenic potential of oral antineoplastic agents*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Degree of emetogenicity (incidence)</td> <td class=\"subtitle1\">Agent</td> </tr> <tr class=\"divider_bottom\"> <td>High (&#62;90%)</td> <td> <p>Altretamine (hexamethylmelamine)&nbsp;</p> <p>Procarbazine</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Moderate (30 to 90%)<sup>&#182;</sup></td> <td> <p>Bosutinib</p> <p>Ceritinib</p> <p>Crizotinib</p> <p>Cyclophosphamide</p> <p>Imatinib</p> <p>Temozolomide</p> <p>Vinorelbine</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Low (10 to 30%)<sup>&#916;</sup></td> <td> <p>Afatinib</p> <p>Axitinib</p> <p>Capecitabine</p> <p>Dabrafenib</p> <p>Dasatinib</p> <p>Etoposide</p> <p>Everolimus</p> <p>Fludarabine</p> <p>Ibrutinib</p> <p>Idelalisib</p> <p>Lapatinib</p> <p>Lenalidomide</p> <p>Nilotinib</p> <p>Olararib</p> <p>Pazopanib</p> <p>Ponatinib</p> <p>Regorafenib</p> <p>Sunitinib</p> <p>Tegafur uracil</p> <p>Thalidomide</p> <p>Vandetanib</p> Vorinostat</td> </tr> <tr> <td>Minimal (&#60;10%)</td> <td> <p>Chlorambucil</p> <p>Erlotinib</p> <p>Gefitinib</p> <p>Hydroxyurea</p> <p>Melphalan (L-phenylalanine mustard)</p> <p>Methotrexate</p> <p>Pomalidomide</p> <p>Ruxolitinib</p> <p>Sorafenib</p> <p>Thioguanine</p> <p>Vemurafenib</p> <p>Vismodegib</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Considerable uncertainty prevails for the emetogenic risk of oral agents.<br />¶ Other agents that&nbsp;are considered to be moderate risk include abemaciclib, busulfan (≥4 mg/day), cabozantinib, lomustine, niraparib, olaparib, ribociclib, and rucaparib.<br />Δ Other agents that are considered to be low risk include acalabrutinib, alectinib, bexarotene, brigatinib, cobimetinib, estramustine, ixazomib, lenvatinib, osimertinib, palbociclib, panobinostat, sonedegib, topotecan, trametinib, trifluridine-tipiracil, and venetoclax.</div><div class=\"graphic_reference\">Reproduced with permission from: Aapro M, Gralla RJ, Herrstedt J, et al. MASCC/ESMO Antiemetic Guideline 2016. Copyright © 2016 Multinational Association of Supportive Care in Cancer. All rights reserved.</div><div id=\"graphicVersion\">Graphic 65923 Version 39.0</div></div></div>"},"65925":{"type":"graphic_picture","displayName":"Kayser Fleischer ring","title":"Kayser-Fleischer ring","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kayser-Fleischer ring</div><div class=\"cntnt\"><img style=\"width:332px; height:216px;\" src=\"images/GAST/65925_Kayser_Fleischer_ring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kayser-Fleischer ring (arrow) in a patient with advanced neuropsychiatric Wilson disease. The dense brown copper deposits encircle the iris. It is rare to see Kayser-Fleischer rings without the aid of a slit lamp examination because Wilson disease is usually recognized at an earlier stage when the rings are not as prominent.</div><div class=\"graphic_reference\">Courtesy of Marshall M Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 65925 Version 2.0</div></div></div>"},"65926":{"type":"graphic_picture","displayName":"Borderline tuberculoid leprosy","title":"Borderline tuberculoid leprosy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Borderline tuberculoid leprosy</div><div class=\"cntnt\"><img style=\"width:288px; height:364px;\" src=\"images/ID/65926_Borderline_tuberculoid_lepr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lesions remain macular and hypopigmented but are more numerous than in tuberculoid disease.</div><div class=\"graphic_reference\">Reproduced with permission from McDougall AC, Yuasa Y. A New Atlas of leprosy, Sasakawa Memorial Health Foundation, Tokyo, 2000, and Guinto RS, Abalos RM, Cellopna RV, Fajardo TT. An Atlas of Leprosy, Sasakawa Memorial Health Foundation, Tokyo, 1983.</div><div id=\"graphicVersion\">Graphic 65926 Version 2.0</div></div></div>"},"65928":{"type":"graphic_diagnosticimage","displayName":"Yolk sac","title":"Yolk sac (YS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Yolk sac (YS)</div><div class=\"cntnt\"><img style=\"width:410px; height:412px;\" src=\"images/OBGYN/65928_Yolk_sac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image of an early gestational sac containing a yolk sac and early embryo. The yolk sac is the circular hyperechoic structure adjacent to the embryo.</div><div class=\"graphic_footnotes\">YS: yolk sac.</div><div class=\"graphic_reference\">Courtesy of Thomas Shipp, MD.</div><div id=\"graphicVersion\">Graphic 65928 Version 3.0</div></div></div>"},"65929":{"type":"graphic_picture","displayName":"Galactocele","title":"Galactocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Galactocele</div><div class=\"cntnt\"><img style=\"width:341px; height:300px;\" src=\"images/PEDS/65929_Galactocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two needle marks resulting from bi-weekly aspiration are visible to the right of the areola.</div><div id=\"graphicVersion\">Graphic 65929 Version 1.0</div></div></div>"},"65930":{"type":"graphic_table","displayName":"MMRV febrile seizure risk","title":"Summary results from VSD- and Merck-sponsored studies for febrile seizure after the first dose of MMRV compared with the first dose of MMR and varicella vaccine administered at the same visit – United States, 2009","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary results from VSD- and Merck-sponsored studies for febrile seizure after the first dose of MMRV compared with the first dose of&nbsp;MMR and varicella vaccine administered at the same visit&nbsp;– United States, 2009</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Characteristic</td> <td class=\"subtitle1\">VSD</td> <td class=\"subtitle1\">Merck-sponsored</td> </tr> <tr> <td rowspan=\"3\"><strong>Age/No. subjects, by vaccine</strong></td> <td>All aged 12 to 23 months</td> <td>99 percent aged 12 to 23 months</td> </tr> <tr> <td>MMRV: n = 83,107</td> <td>MMRV: n = 31,298</td> </tr> <tr> <td>MMR and varicella: n = 376,354</td> <td>MMR and varicella: n = 31,298</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Postvaccination interval</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Week 1 to 2</td> <td>7 to 10 days*</td> <td>5 to 12 days*</td> </tr> <tr> <td>RR: 2.0 (CI = 1.4-2.9)</td> <td>RR: 2.2 (CI = 1.0-4.7)</td> </tr> <tr> <td>AR: 4.3 per 10,000 (CI = 2.6-5.6)</td> <td>AR: 3.8 per 10,000 (CI = 0.3-7.4)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Week 1 to 6</td> <td>0 to 42 days*</td> <td>0 to 30 days</td> </tr> <tr> <td>RR: 1.5 (CI = 1.1-1.9)</td> <td>RR: 1.1 (CI = 0.7-1.7)</td> </tr> <tr> <td>AR: 6.2 per 10,000 (CI = 2.0-9.5)</td> <td>AR: 1.3 per 10,000 (CI = -4.5-7.0)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VSD: Vaccine Safety Datalink; MMRV: measles, mumps, rubella, and varicella vaccine; MMR: measles, mumps, rubella vaccine; RR: relative risk; AR: attributable risk; CI: 95% confidence interval.<br />* Statistically significant at &lt;0.05.</div><div class=\"graphic_reference\">Data from:<br> <ol> <li>From Centers for Disease Control and Prevention. Use of Combination Measles, Mumps, Rubella, and Varicella Vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR 2010; 59:4. </li> <li>Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010. In press. </li> <li>Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 2009; 27:4656-61. </li> </ol></div><div id=\"graphicVersion\">Graphic 65930 Version 6.0</div></div></div>"},"65932":{"type":"graphic_picture","displayName":"Palpable purpura legs","title":"Palpable purpura","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Palpable purpura</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/65932_Palpable_purpura_lgs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palpable purpura are present on the legs of this patient with cutaneous small vessel vasculitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 65932 Version 1.0</div></div></div>"},"65933":{"type":"graphic_picture","displayName":"Jersey finger examination","title":"Jersey finger examination","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Jersey finger examination</div><div class=\"cntnt\"><img style=\"width:360px; height:415px;\" src=\"images/EM/65933_Jersey_finger_exam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of flexion&nbsp;at the distal interphalangeal (DIP) joint of the ring finger is seen&nbsp;when the patient actively makes a fist, suggesting a flexor tendon injury of the DIP joint&nbsp;(ie, jersey finger).&nbsp;</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 65933 Version 3.0</div></div></div>"},"65934":{"type":"graphic_table","displayName":"Types of endometriosis lesions","title":"Association between lesion type and pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Association between lesion type and pain</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Lesion type</td>\n<td class=\"subtitle1\">Pain, percent</td>\n</tr>\n<tr>\n<td> Red</td>\n<td> 84</td>\n</tr>\n<tr>\n<td> Clear </td>\n<td> 76</td>\n</tr>\n<tr>\n<td> White</td>\n<td> 44</td>\n</tr>\n<tr>\n<td> Black</td>\n<td> 22</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Demco, L. J Am Assoc Gynecol Laparosc 1998; 5:241.</div><div id=\"graphicVersion\">Graphic 65934 Version 1.0</div></div></div>"},"65935":{"type":"graphic_picture","displayName":"Assessment of optic disc B","title":"Assessment of the optic disc in healthy and glaucomatous eyes","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Assessment of the optic disc in healthy and glaucomatous eyes</div><div class=\"cntnt\"><img style=\"width:527px; height:386px;\" src=\"images/PC/65935_Assessment_of_optic_disc_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top row shows findings in normal eyes and the bottow row findings in glaucomatous eyes.<br />(C) Scanning laser polarimetry: retinal nerve fibre layer thickness is reduced inferotemporally and superonasally.<br />(D) Confocal scanning laser ophthalmoscopy: neuroretinal rim area is within normal limits (ticks) in healthy eye but reduced in inferior and superonasal regions (crosses) in glaucomatous eye.<br />(E) Standard automated perimetry: normal blind spot and superior scotomas (arrows) in glaucoma.</div><div class=\"graphic_reference\">Reprinted with permission from: Weinreb, RN, Khaw, PT. Primary open- angle glaucoma. Lancet 2004; 363:1711. Copyright © 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 65935 Version 2.0</div></div></div>"},"65937":{"type":"graphic_picture","displayName":"Pneumobelt","title":"Pneumobelt","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumobelt</div><div class=\"cntnt\"><img style=\"width:240px; height:338px;\" src=\"images/PULM/65937_Pneumobelt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pneumobelt is shown connected to the Thompson Bantam positive pressure ventilation. The ventilator intermittently inflates a rubber bladder contained within the corset.</div><div id=\"graphicVersion\">Graphic 65937 Version 2.0</div></div></div>"},"65939":{"type":"graphic_figure","displayName":"Jumping man z-plasty","title":"Jumping man Z-plasty","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Jumping man Z-plasty</div><div class=\"cntnt\"><img style=\"width:519px; height:596px;\" src=\"images/SURG/65939_Jumping_man_z-plasty.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65939 Version 1.0</div></div></div>"},"65942":{"type":"graphic_algorithm","displayName":"Mechanisms alcohol HCV","title":"Potential mechanisms by which alcohol affects hepatitis C virus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Potential mechanisms by which alcohol affects hepatitis C virus</div><div class=\"cntnt\"><img style=\"width:379px; height:228px;\" src=\"images/GAST/65942_Mechanisms_alcohol_HCV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HCV: hepatitis C virus; ROS: reactive oxygen species.</div><div id=\"graphicVersion\">Graphic 65942 Version 3.0</div></div></div>"},"65943":{"type":"graphic_table","displayName":"Melioidosis clinical features","title":"Clinical presentations and outcomes of 540 melioidosis cases over 20 years in the Northern Territory of Australia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical presentations and outcomes of 540 melioidosis cases over 20 years in the Northern Territory of Australia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"6\" width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Total</td> <td class=\"subtitle1\" colspan=\"2\">Bacteremic</td> <td class=\"subtitle1\" colspan=\"2\">Non-bacteremic</td> </tr> <tr> <td class=\"subtitle2\">Number</td> <td class=\"subtitle2\">Deaths (mortality percent)</td> <td class=\"subtitle2\">Number</td> <td class=\"subtitle2\">Deaths (mortality percent)</td> <td class=\"subtitle2\">Number</td> <td class=\"subtitle2\">Deaths (mortality percent)</td> </tr> <tr> <td class=\"subtitle2_left\">Septic shock</td> <td class=\"subtitle2_left\">116 (21%)</td> <td class=\"subtitle2_left\">58 (50)</td> <td class=\"subtitle2_left\">103</td> <td class=\"subtitle2_left\">48 (47)</td> <td class=\"subtitle2_left\">13</td> <td class=\"subtitle2_left\">10 (77)</td> </tr> <tr> <td class=\"indent1\">Pneumonia</td> <td>88</td> <td>43 (49)</td> <td>78</td> <td>35 (45)</td> <td>10*</td> <td>8 (80)</td> </tr> <tr> <td class=\"indent1\">No evident focus</td> <td>13</td> <td>8 (62)</td> <td>12</td> <td>7 (58)</td> <td>1<sup>&#182;</sup></td> <td>1 (100)</td> </tr> <tr> <td class=\"indent1\">Genitourinary</td> <td>10</td> <td>5 (50)</td> <td>9</td> <td>4 (44)</td> <td>1<sup>&#916;</sup></td> <td>1 (100)</td> </tr> <tr> <td class=\"indent1\">Osteomyelitis/septic arthritis</td> <td>4</td> <td>2 (50)</td> <td>4</td> <td>2 (50)</td> <td>0</td> <td>0 (0)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Soft tissue abscess</td> <td>1</td> <td>0 (0)</td> <td>0</td> <td>0</td> <td>1</td> <td>0 (0)</td> </tr> <tr> <td class=\"subtitle2_left\">Non-septic shock</td> <td class=\"subtitle2_left\">424 (79%)</td> <td class=\"subtitle2_left\">19 (4)</td> <td class=\"subtitle2_left\">195</td> <td class=\"subtitle2_left\">13 (7)</td> <td class=\"subtitle2_left\">229</td> <td class=\"subtitle2_left\">6 (3)</td> </tr> <tr> <td class=\"indent1\">Pneumonia</td> <td>190</td> <td>12 (6)</td> <td>89</td> <td>9 (10)</td> <td>101</td> <td>3 (3)</td> </tr> <tr> <td class=\"indent1\">Skin infection</td> <td>68</td> <td>0 (0)</td> <td>1</td> <td>0 (0)</td> <td>67</td> <td>0 (0)</td> </tr> <tr> <td class=\"indent1\">Genitourinary</td> <td>66</td> <td>2 (3)</td> <td>41</td> <td>2 (5)</td> <td>25</td> <td>0 (0)</td> </tr> <tr> <td class=\"indent1\">No evident focus</td> <td>52</td> <td>2 (4)</td> <td>47</td> <td>2 (4)</td> <td>5</td> <td>0 (0)</td> </tr> <tr> <td class=\"indent1\">Soft tissue abscess(es)</td> <td>18</td> <td>0 (0)</td> <td>4</td> <td>0 (0)</td> <td>14</td> <td>0 (0)</td> </tr> <tr> <td class=\"indent1\">Osteomyelitis/septic arthritis</td> <td>16</td> <td>0 (0)</td> <td>10</td> <td>0 (0)</td> <td>6</td> <td>0 (0)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Neurological</td> <td>14</td> <td>3 (21)</td> <td>3</td> <td>0 (0)</td> <td>11</td> <td>3 (27)</td> </tr> <tr> <td><strong>Total</strong></td> <td><strong>540</strong></td> <td><strong>77 (14)</strong></td> <td><strong>298 (55%)</strong></td> <td><strong>61 (20)</strong></td> <td><strong>242 (45%)</strong></td> <td><strong>16 (7) </strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Seven blood cultures not done, three blood cultures negative.<br />&para; Culture positive for B. pseudomallei only from rectal swab, although fatal septic shock.<br />&Delta; Blood culture not done.</div><div class=\"graphic_reference\">Reproduced from: Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 2010; 4:e900. Copyright &copy; 2010 Public Library of Science.</div><div id=\"graphicVersion\">Graphic 65943 Version 6.0</div></div></div>"},"65944":{"type":"graphic_table","displayName":"Dosing regimens for treatment of latent TB","title":"Dosing regimens for treatment of latent tuberculosis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing regimens for treatment of latent tuberculosis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Nonpregnant adults</td> <td class=\"subtitle1\">Children &#60;12</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Isoniazid<sup>&#182;</sup>&nbsp;</strong></td> <td>Standard regimen: <ul class=\"decimal_heading\"> <li>300 mg PO daily for nine months </li> </ul> Alternate regimens: <ul class=\"decimal_heading\"> <li>300 mg PO daily for six months </li> <li>900 mg PO twice weekly<sup>&#916;</sup> for nine months </li> <li>900 mg PO twice weekly<sup>&#916;</sup> for six months </li> </ul> </td> <td>Standard regimen: <ul class=\"decimal_heading\"> <li>10 to 15 mg/kg PO daily for nine months; not to exceed 300 mg/day </li> </ul> Alternate regimen: <ul class=\"decimal_heading\"> <li>20 to 30 mg/kg PO twice weekly for nine months<sup>&#9674;</sup>; not to exceed 900 mg/day </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Isoniazid and rifapentine<sup>&#167;</sup></strong></td> <td>Isoniazid (orally once weekly for 12 doses; direct observation is preferred): <ul class=\"decimal_heading\"> <li>15 mg/kg, rounded up to the nearest 50 or 100 mg; 900 mg maximum </li> </ul> Rifapentine (orally once weekly for three months; direct observation is preferred): <ul class=\"decimal_heading\"> <li>10 to 14 kg: 300 mg </li> <li>14.1 to 25 kg: 450 mg </li> <li>25.1 to 32 kg: 600 mg </li> <li>32.1 to 49.9 kg: 750 mg </li> <li>&#62;50 kg: 900 mg maximum </li> </ul> </td> <td> <p>See note<sup>&#165;</sup></p> Isoniazid (orally once weekly for 12 doses;direct observation is preferred): <ul class=\"decimal_heading\"> <li>15 mg/kg, rounded up to the nearest 50 or 100 mg; 900 mg maximum </li> </ul> Rifapentine (orally once weekly for three months; direct observation is preferred): <ul class=\"decimal_heading\"> <li>10 to 14 kg: 300 mg </li> <li>14.1 to 25 kg: 450 mg </li> <li>25.1 to 32 kg: 600 mg </li> <li>32.1 to 49.9 kg: 750 mg </li> <li>&#62;50 kg: 900 mg maximum </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Rifampin</strong></td> <td>600 mg PO daily for four months</td> <td>10 to 20 mg/kg PO daily for four months; not to exceed 600 mg/day</td> </tr> <tr> <td><strong>Isoniazid and rifampin<sup>&#135;</sup></strong></td> <td> <p>Isoniazid 300 mg PO daily for three months</p> Rifampin 600 mg PO daily for three months</td> <td> <p>Isoniazid 10 to 15 mg/kg PO daily for three months; not to exceed 300 mg/day</p> Rifampin 10 to 20 mg/kg PO daily for three months; not to exceed 600 mg/day</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PO: by mouth.<br />* For discussion of clinical approach to selecting a regimen for treatment of latent tuberculosis, refer to the UpToDate topic on treatment of latent TB infection in HIV-negative adults.<br />¶&nbsp;Pyridoxine supplementation (25 to 50 mg PO daily for adults; 1 to 2 mg/kg PO daily for children &lt;12) should be considered for patients on prolonged isoniazid; this is especially important for patients with conditions that can predispose to neuropathy (including diabetes, uremia, alcoholism, malnutrition, and HIV infection), as well as in the setting of pregnancy and seizure disorders. In addition, pyridoxine should be administered to infants of breastfeeding mothers receiving isoniazid. Among children on isoniazid, pyridoxine is warranted for exclusively breastfed infants, children on meat- and milk-deficient diets, children with nutritional deficiencies, and symptomatic HIV-infected children.<br />Δ&nbsp;Twice-weekly regimens must be administered with directly observed therapy.<br />◊&nbsp;Six-month regimens of isoniazid are not appropriate for children.<br />§&nbsp;Further study of isoniazid and rifapentine for treatment of latent tuberculosis is needed. Patient categories for which this regimen has been studied and patient categories for which this regimen is NOT appropriate (until further data are available) are discussed in the text. (Refer to the UpToDate topic on treatment of latent TB infection in HIV-negative adults.)<br />¥&nbsp;In general, directly observed treatment with isoniazid-rifapentine is a reasonable regimen for children aged 2 to 17 years when the circumstances make completion of nine months of daily isonaizid difficult and/or the likelihood of&nbsp;tuberculosis is high. (Refer to the UpToDate topic on treatment of latent tuberculosis in children for further discussion.)<br />‡&nbsp;The regimen of isoniazid and rifampin is not recommended by the United States Centers for Disease Control and Prevention; refer to text for discussion.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Blumberg HM, Leonard MK Jr, Jasmer RM. Update on treatment of tuberculosis and latent tuberculosis infection. JAMA 2005; 293:2776.</li>&#xD;&#xA;    <li>Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection. MMWR 2011; 60(48):1650.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 65944 Version 24.0</div></div></div>"},"65945":{"type":"graphic_movie","displayName":"Mitral valve prolapse M-mode echocardiogram","title":"Mitral valve prolapse","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral valve prolapse</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/65945_mmodemvpconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:268px; height:161px;\" src=\"images/CARD/65945_mmodemvp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">M-mode echocardiogram shows significant prolapse of the posterior leaflet during systole. There are multiple echos of the mitral valve suggesting redundancy of the leaflets.</div><div id=\"graphicVersion\">Graphic 65945 Version 3.0</div></div></div>"},"65947":{"type":"graphic_table","displayName":"Formula selection II","title":"Formula selection for children and adults (continued)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Formula selection for children and adults (continued)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Indications</td> <td class=\"subtitle1\">Formula description</td> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Examples (listed alphabetically, not comprehensive)</td> </tr> <tr> <td rowspan=\"3\">Hyper-metabolism</td> <td> <p>1-1.5 kcal/mL</p> <p>Polymeric</p> <p>May have higher osmolalities</p> <p>May be low-fat</p> <p>May contain MCT</p> <p>May contain increased protein</p> <p>May contain some amino acids thought to be conditionally essential (eg, glutamine, arginine)</p> <p>May contain fish oil</p> <p>Lactose free</p> <p>May contain fiber</p> </td> <td>&#62;10 years (adults)</td> <td>Impact; Impact with fiber; Impact 1.5; TraumaCal</td> </tr> <tr> <td rowspan=\"2\"> <p>1.0-1.5 kcal/mL</p> <p>Hydrolyzed protein source</p> </td> <td>1-10 years</td> <td>Pepdite Jr; Peptamen Jr; Peptamen Jr 1.5; Pediasure Peptide 1.0; Pediasure Peptide 1.5</td> </tr> <tr> <td>&#62;10 years (adults)</td> <td>Crucial; Perative; Vital 1.0 cal; Vital 1.5 cal; Pivot 1.5; Optimental; Peptamen; Peptamen 1.5</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Impaired digestion or impaired gut perfusion</td> <td> <p>0.8-1.0 kcal/mL</p> <p>Free amino acids (\"elemental\")</p> <p>May have higher osmolalities</p> <p>May contain MCT oil</p> <p>May be low fat</p> <p>May contain increased protein</p> <p>Lactose-free</p> <p>Most are fiber-free</p> </td> <td>1-10 years</td> <td>Elecare Jr; Neocate Jr; Vivonex Pediatric; EO28 Splash</td> </tr> <tr> <td>1 kcal/mL</td> <td>&#62;10 years (adults)</td> <td>Tolerex; Vivonex Plus; Vivonex TEN; Vivonex RTF</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MCT: medium-chain triglycerides.</div><div id=\"graphicVersion\">Graphic 65947 Version 5.0</div></div></div>"},"65948":{"type":"graphic_table","displayName":"Complement fragment functions","title":"Activated complement fragments: Deposition and function on cellular targets","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Activated complement fragments: Deposition and function on cellular targets</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Activation fragment</td> <td class=\"subtitle1\">Number on a single cell</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td>C4b</td> <td>2.5 million</td> <td>Cleavage by C1s generates C4b; C4b covalently binds to target</td> </tr> <tr> <td>C4bC2a</td> <td>0.5 million</td> <td>C3 convertase; one in five C4bs forms a convertase</td> </tr> <tr> <td>C3b</td> <td>20 million</td> <td>Approximately 10 times&nbsp;more C3b than C4b attaches to target (opsonization)</td> </tr> <tr> <td>C5b-C9</td> <td>1 million</td> <td>Membrane perturbation including lysis by the membrane attack complex</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These data were obtained from quantitative analysis of immunoglobulin G (IgG) antibody-mediated classical pathway activation on mammalian cells (melanoma cell line). Normal human serum was used as the source of complement, along with saturating amounts of human antibody to the cell line. Similar data have been obtained on bacterial membranes, although relative numbers were less (approximately a log) corresponding to reduced surface area and antigenic density. The complement system is the \"guardian of the intravascular space.\" It is designed to attack bacteria attempting to enter the intravascular space.</div><div id=\"graphicVersion\">Graphic 65948 Version 7.0</div></div></div>"},"65949":{"type":"graphic_waveform","displayName":"ECG sinus arrhythmia","title":"Electrocardiogram (ECG) rhythm strip demonstrating respiratory sinus arrhythmia","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) rhythm strip demonstrating respiratory sinus arrhythmia</div><div class=\"cntnt\"><img style=\"width:480px; height:87px;\" src=\"images/CARD/65949_Sinus_arrhythmia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lead II showing normal sinus rhythm with sinus arrhythmia in a healthy 26 year-old woman. Note the marked variation in the P-P intervals induced by respiration.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 65949 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"65950":{"type":"graphic_figure","displayName":"Increased motor unit size in ALS","title":"Increased motor unit size revealed by incremental motor unit number estimation (MUNE) in patients with amyotrophic lateral sclerosis","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Increased motor unit size revealed by incremental motor unit number estimation (MUNE) in patients with amyotrophic lateral sclerosis</div><div class=\"cntnt\"><img style=\"width:496px; height:314px;\" src=\"images/NEURO/65950_Increased_MU_size.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Average single motor unit size in a group of ten ALS control subjects receiving placebo in a therapeutic trial, as measured by multiple point stimulation (during MUNE assessment) in the thenar muscle group.&#160;Patients were tracked at&#160;one&#160;to&#160;two month intervals over 10 months.&#160;Note the steady and dramatic increase in average motor unit amplitude over time (more than 100 percent&#160;increase in less than one year), consistent with aggressive collateral reinnervation.&#160;This increase in motor unit size in ALS becomes especially pronounced as the MUNE falls below 50 to 100 units.</div><div class=\"graphic_reference\">Courtesy of Clifton Gooch, MD.</div><div id=\"graphicVersion\">Graphic 65950 Version 1.0</div></div></div>"},"65951":{"type":"graphic_figure","displayName":"Other spore characteristics","title":"Other spore characteristics","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Other spore characteristics</div><div class=\"cntnt\"><img style=\"width:542px; height:410px;\" src=\"images/ALLRG/65951_Other_spore_characters.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Burge HA, Burge W, Muilenberg ML, et al. Airborne pollen and fungus spore identification: Hands On Workshop, Postgraduate Course, University of Michigan Medical School, Ann Arbor, MI, May 1990.</div><div id=\"graphicVersion\">Graphic 65951 Version 3.0</div></div></div>"},"65952":{"type":"graphic_table","displayName":"Trauma secondary survey","title":"Secondary survey physical examination in the pediatric trauma patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Secondary survey physical examination in the pediatric trauma patient</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Head\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Inspect and palpate face and scalp\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Eye examination\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Visual acuity (if alert)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Pupillary size\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Hemorrhage (conjunctiva, fundi)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Penetrating injury\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Contact lenses (remove if indicated)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Ocular entrapment\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Periorbital ecchymosis (Raccoon eyes)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Ear examination\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Hemotympanum, bleeding, perforation\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Retro-auricular ecchymosis (Battle's sign)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Midface examination\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Inspect for nasal swelling, deformity, bleeding, or clear rhinorrhea\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Inspect for oral trauma, malocclusion, intraoral lacerations\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Palpate maxilla for evidence of LeFort fracture (palatal instability with anterior to posterior pressure on the upper teeth)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Cervical spine and neck\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   If maxillofacial/head trauma sustained, presume unstable cervical spine injury and immobilize neck until c-spine adequately evaluated\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Inspect and palpate neck\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Tracheal deviation\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Distended neck veins\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   C-spine tenderness\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Subcutaneous emphysema\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Crepitus over larynx (concerning for laryngeal fracture)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Carotid artery bruits\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Active range of motion (in awake, cooperative patient without distracting injuries)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Penetrating neck injury\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Inspect to determine if injury may be through the platysma\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Chest\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Inspect and palpate chest, including the clavicle, ribs, and sternum\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Open pneumothorax/large flail segment\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Crepitus\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Tenderness/bony deformity\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Auscultate\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Breath sounds\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Heart sounds\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Abdomen\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Inspect and palpate abdomen\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Seat belt sign/bruises (Cullen's sign)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Distention\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Focal tenderness\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Peritoneal signs\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Masses\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Auscultate for bowel sounds\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Perineum/rectum/vagina\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Inspection\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Contusions/lacerations/hematomas\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Males-urethral bleeding\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Females-vaginal bleeding\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Rectal examination\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   May be performed at the end of spinal examination when the body is already turned onto the side\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Assess for blood in bowel lumen\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Sphincter tone\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Males (teenage/adult)--palpate for high-riding prostate\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Muskuloskeletal\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Inspect and palpate extremities\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Identify fractures/dislocations\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Assess pulses for presence and strength\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Inspect and palpate pelvis\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Pain on palpation of pelvic ring\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Mobility of pelvis with anterior-to-posterior pressure with heels of hands on both anterior iliac spines\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Logroll patient to inspect and palpate back\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Examine for step-offs or focal tenderness\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Inspect under the axillae\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Neurologic\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Comprehensive neurological examination\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Re-evaluation of patient's level of consiousness\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Re-evaluation of patient's pupillary size\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Motor evaluation\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist2\">\r\n  \r\n   Sensory evaluation\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">1. American College of Surgeons Committee on Trauma. Advanced Trauma Life Support for Doctors, 8th ed. Chicago, IL: American College of Surgeons; 2008.<br> 2. Jaffe D, Wesson D. Emergency management of blunt trauma in children.&#160;N Engl J Med&#160;1991; 324:1477-1483.<br> 3. Waltzman, ML, Mooney, DP. Major Trauma. In: Fleisher, GR, Ludwig, S, Henretig, FM, eds. Textbook of Pediatric Emergency Medicine. 5th ed. Philadelphia, PA Lippincott Williams &amp; Wilkins; 2006.</div><div id=\"graphicVersion\">Graphic 65952 Version 2.0</div></div></div>"},"65953":{"type":"graphic_diagnosticimage","displayName":"Chronic ulcerative colitis BE","title":"Chronic ulcerative colitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic ulcerative colitis</div><div class=\"cntnt\"><img style=\"width:329px; height:285px;\" src=\"images/GAST/65953_Chronic_ulcerative_colitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double contrast barium enema in a patient with chronic ulcerative colitis shows a featureless colon with complete loss of folds in the sigmoid colon.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 65953 Version 2.0</div></div></div>"},"65954":{"type":"graphic_table","displayName":"Circumcision info sheet A","title":"Circumcision","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Circumcision</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">What is circumcision?</td> </tr> <tr> <td>When a baby boy is born, the end of his penis is covered with a layer of skin called the foreskin. This extra skin has two main functions: to protect the end of the penis, or glans, and to provide sexual pleasure. Circumcision is a procedure that surgically removes this foreskin. Importantly, this is not required by law, nor is it medically necessary&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">&ndash;</span> it is a choice made by you, the parent.</td> </tr> <tr> <td>The procedure typically takes anywhere from 10 to 20 minutes, and is performed by a doctor, usually in the nursery before the child goes home after delivery.</td> </tr> <tr> <td class=\"subtitle1_single\">Is it painful?</td> </tr> <tr> <td>Recent studies have confirmed that babies do experience pain during this procedure, but steps can be taken to minimize this. Often an injection of anesthesia into the base of the penis is given to block the feelings of pain. Also, a sugar solution can be administered to the baby by mouth. Most importantly, you should discuss pain control with the doctor who is performing the circumcision.</td> </tr> <tr> <td class=\"subtitle1_single\">What are the benefits of circumcision?</td> </tr> <tr> <td>Circumcision is often performed for religious or cultural reasons. In English-speaking, Western countries, most males are circumcised. Conversely, circumcisions for non-religious reasons are rarely done in Europe, Asia, or South America. In the past, up to 90% of all males born in the United States were circumcised, but today that number has dropped to 60%. The reasons that some parents choose to have their son circumcised: They want their son to look like other males in their family or are afraid they will be picked on for looking different. Also, circumcision has been suggested as a good way to keep the penis clean. This has not been shown to be true.</td> </tr> <tr> <td>Some research has shown some medical benefits to having your son circumcised. As an example, some studies have shown a small decrease in risk of urinary infections early in life. And, while extremely rare, the risk of penile cancer is lower in circumcised males. It also may decrease the risk of sexually transmitted diseases. Occasionally a child will need a circumcision later in life because of cancer, injury, or infection. Circumcisions may reduce some of these risks, but fewer than 10% of uncircumcised males will need the procedure later in life.</td> </tr> <tr> <td class=\"subtitle1_single\">What are the risks of circumcision?</td> </tr> <tr> <td>All surgical procedures, including circumcision, carry risks. These include excessive bleeding, infection, problems with anesthesia, and a poor cosmetic result. Rarely there can be injury to the glans, shaft ,or urethra of the penis. All of these complications, however, are very rare and affect only a small number of babies.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 65954 Version 4.0</div></div></div>"},"65956":{"type":"graphic_figure","displayName":"Asthma PI","title":"Asthma","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Asthma</div><div class=\"cntnt\"><img style=\"width:526px; height:600px;\" src=\"images/PI/65956_AsthmachildrenPIedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During an asthma attack or flare-up, the muscles around the airways tighten (constrict), and the lining of the airways gets inflamed. Then, mucus builds up. All of this makes it hard to breathe.</div><div id=\"graphicVersion\">Graphic 65956 Version 9.0</div></div></div>"},"65957":{"type":"graphic_picture","displayName":"Fluorescein AMD","title":"Fluorescein angiography and color fundus photography of the right eye in a patient with a classic choroidal neovascular membrane","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fluorescein angiography and color fundus photography of the right eye in a patient with a classic choroidal neovascular membrane</div><div class=\"cntnt\"><img style=\"width:504px; height:428px;\" src=\"images/PC/65957_Fluorescein_AMD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The first image of the fluorescein angiogram was taken 25 seconds after intravenous administration of 5 cc of 10 percent fluorescein dye. There is a well-defined focal area of hyperfluorescence seen in the macula.<br />(B) The second image was taken at&nbsp;one minute and&nbsp;two seconds after dye administration. It demonstrates fluorescein dye in both the retinal arteries and veins. The focal area of hyperfluorescence has increased in intensity.<br />(C) The third image was taken 14 minutes and 27 seconds after dye administration. Little fluorescence is seen in the retinal arteries and veins. The focal area of hyperfluorescence has developed fuzzy borders due to leakage of fluorescein dye into the subretinal space, consistent with abnormal new vessels.<br />(D) The fourth image demonstrates color fundus photography. A whitish lesion in the macula located inferonasal to the fovea corresponds to the hyperfluorescent area in the dye study.</div><div id=\"graphicVersion\">Graphic 65957 Version 3.0</div></div></div>"},"65959":{"type":"graphic_diagnosticimage","displayName":"Lumbar hernia sup triangle","title":"Lumbar hernia through the superior triangle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lumbar hernia through the superior triangle</div><div class=\"cntnt\"><img style=\"width:350px; height:332px;\" src=\"images/SURG/65959_Lumbar_hernia_sup_triangle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the multiple bony anomalies.</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg, RL. Clinical Imaging: An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65959 Version 2.0</div></div></div>"},"65962":{"type":"graphic_movie","displayName":"TTE IAS aneurysm","title":"Transthoracic echocardiogram showing an interatrial septal aneurysm","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transthoracic echocardiogram showing an interatrial septal aneurysm</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/65962_intsepatconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:260px; height:438px;\" src=\"images/CARD/65962_intsepat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The four-chamber view from a&nbsp;transthoracic echocardiogram shows a large aneurysm of the interatrial septum and an enlarged left atrium.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 65962 Version 3.0</div></div></div>"},"65963":{"type":"graphic_waveform","displayName":"ECG diffuse subendocardial ischemia","title":"ECG diffuse subendocardial ischemia","html":"<div class=\"graphic normal\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">ECG diffuse subendocardial ischemia</div><div class=\"cntnt\"><img style=\"width:548px; height:288px;\" src=\"images/CARD/65963_Diffuse_subendocardial_isch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse subendocardial ischemia manifested by prominent ST depressions in leads I, II, aVL, aVF, and V2 to V6, with ST elevation in aVR. A prolonged PR interval (0.28 sec) is also present. The findings also raise the possiblitity of severe multivessel or left main coronary artery disease.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 65963 Version 3.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"65964":{"type":"graphic_picture","displayName":"Complete mole path histo","title":"Complete hydatidform mole","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Complete hydatidform mole</div><div class=\"cntnt\"><img style=\"width:500px; height:478px;\" src=\"images/OBGYN/65964_Complete_mole_path_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complete hydatidiform mole. A) Complete mole in which the entire uterine cavity is filled with swollen villi. B) The villi are each 1 to 3 mm in diameter and appear grapelike. C) Individual molar villi, many of which have cavitated central cisterns, exhibit considerable trophoblastic hyperplasia and atypia. The blood vessels of the villi have atrophied and disappeared.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E MD and Farber JL MD. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65964 Version 1.0</div></div></div>"},"65965":{"type":"graphic_figure","displayName":"Normal vaginal delivery","title":"Normal vaginal delivery","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Normal vaginal delivery</div><div class=\"cntnt\"><img style=\"width:535px; height:405px;\" src=\"images/OBGYN/65965_Normal_vaginal_delivery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Five-step procedure for delivering an infant.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART image. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 65965 Version 3.0</div></div></div>"},"65966":{"type":"graphic_picture","displayName":"Balantis xerotica obliterans","title":"Balantis xerotica obliterans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Balantis xerotica obliterans</div><div class=\"cntnt\"><img style=\"width:281px; height:514px;\" src=\"images/PEDS/65966_Balantis_xerotica_obliteran.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These photographs depict three foreskins with the classic appearance of balanitis xerotica obliterans. The phimotic ring is closed, but the indurated, white scar is readily discernible from normal, healthy skin.</div><div class=\"graphic_reference\">Reproduced with permission from: Metcalfe PD, Elyas R. Foreskin management: Survey of Canadian pediatric urologists. Can Fam Physician 2010; 56:e290. Copyright © 2010 Canadian Family Physician.</div><div id=\"graphicVersion\">Graphic 65966 Version 2.0</div></div></div>"},"65967":{"type":"graphic_figure","displayName":"The role of collagen in the fibrous cap","title":"Collagen synthesis and breakdown in the maintenance of the integrity of the fibrous cap","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Collagen synthesis and breakdown in the maintenance of the integrity of the fibrous cap</div><div class=\"cntnt\"><img style=\"width:604px; height:338px;\" src=\"images/CARD/65967_Collagen_fibrous_cap.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration emphasizes the importance of collagen synthesis and breakdown in the maintenance of the integrity of the fibrous cap. Vascular smooth muscle cells synthesize essential extracellular matrix proteins such as collagen and elastin from amino acids. This process may be inhibited by interferon-γ (IFN-γ) secreted by activated T cells, thereby disrupting collagen synthesis, which may interfere with the maintenance and repair of collagen framework supporting the fibrous cap. Importantly, the expression of CD40 ligand on T cells may promote tissue proteolysis through the release and activation of matrix-degrading enzymes produced by vascular smooth muscle cells and inflammatory macrophages. Activated macrophages within the fibrous cap can secrete tissue proteases that facilitate the breakdown of collagen and elastin to peptides and amino acids. The loss of structural molecules provided by the extracellular matrix can thin and weaken the fibrous cap, rendering it particularly susceptible to rupture, which can manifest as acute coronary syndromes. Additional factors involved in the activation of macrophages include tumor necrosis factor-α (TNF-α), macrophage colony-stimulating factor (M-CSF), and macrophage chemoattractant protein-1 (MCP-1), among others.</div><div class=\"graphic_reference\">Reproduced with permission from: Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91:2844, with modifications by Dr. Peter Libby. Copyright © 1995 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65967 Version 8.0</div></div></div>"},"65968":{"type":"graphic_table","displayName":"Diagnostic considerations when evaluating fish/shellfish allergy","title":"Diagnostic considerations when evaluating fish and shellfish allergy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic considerations when evaluating fish and shellfish allergy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Concern</td> <td class=\"subtitle1\">Implication/approach</td> </tr> <tr> <td>Clinical cross-reactivity</td> <td>The rate of serologic (positive test) cross-reactivity exceeds the rate of true clinical reactivity, but both are high in seafood allergy. Therefore, caution is needed (evaluations with tests for IgE and possibly oral food challenges).</td> </tr> <tr> <td>Overlap of symptoms with nonallergic seafood reactions</td> <td>Spoilage of seafood most typically results in gastrointestinal reactions that are not consistent and do not mimic allergy (differentiated by history). However, spoilage of dark meat fish (scombroid poisoning) could result in symptoms that mimic allergy (pruritus, flushing).</td> </tr> <tr> <td>Reactions may vary</td> <td>Inconsistencies in reactions to fish could be attributable to manner of cooking or to which parts of the fish are eaten. Reduced digestion of fish protein is also a variable that could be altered if a patient takes antacid medication. These points should be examined in the history and considered during allergy testing.</td> </tr> <tr> <td>Reactions may be attributed to seafood, but caused by other allergens</td> <td>If a reaction occurs during a meal, ingredients must be reviewed to determine other causes (spices, etc). Other fish-related foods (caviar) or contaminants (parasites, such as <em>Anisakis</em>) could be causal.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 65968 Version 5.0</div></div></div>"},"65969":{"type":"graphic_picture","displayName":"Celiac disease Endosc","title":"Celiac disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Celiac disease</div><div class=\"cntnt\"><img style=\"width:317px; height:322px;\" src=\"images/GAST/65969_Celiac_disease_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scalloped duodenal folds seen on endoscopy in a patient with celiac disease.</div><div class=\"graphic_reference\">Courtesy of Eric D Libby, MD.</div><div id=\"graphicVersion\">Graphic 65969 Version 1.0</div></div></div>"},"65970":{"type":"graphic_picture","displayName":"Gastric carcinoid CPC Light","title":"Gastric carcinoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric carcinoid</div><div class=\"cntnt\"><img style=\"width:359px; height:501px;\" src=\"images/GAST/65970_Gastric_carcinoid_CPC_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view (upper panel) of a biopsy specimen from a gastric nodule showing replacement of the glandular compartment by an infiltrate of uniformed tumor cells. At high power (upper panel) the tumor cells have uniformed small nuclei without mitotic activity, and basophilic cytoplasm. The features are characteristic of a gastric endocrine tumor (carcinoid tumor). Immunohistochemical stains may be helpful to categorize these tumors, which are positive on staining with antibodies to chromogranin and synaptophysin.</div><div class=\"graphic_reference\">Courtesy of Donald Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 65970 Version 2.0</div></div></div>"},"65971":{"type":"graphic_diagnosticimage","displayName":"2D TTE Anteriorly angulated 4-chamber view","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from an anteriorly angulated four-chamber view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from an anteriorly angulated four-chamber view</div><div class=\"cntnt\"><img style=\"width:266px; height:270px;\" src=\"images/CARD/65971_Angulated_four_chamber.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This view is particularly useful for imaging the wall motion of other portions of the septum and for obtaining Doppler flow signals from the left ventricle outflow tract.</div><div id=\"graphicVersion\">Graphic 65971 Version 3.0</div></div></div>"},"65972":{"type":"graphic_table","displayName":"Asthma control 12 and up","title":"Assessing asthma control in youths greater than or equal to 12 years of age and adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessing asthma control in youths greater than or equal to 12 years of age and adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">Components of control</td> <td class=\"subtitle1\" colspan=\"3\">Classification of asthma control (youths &#8805;12 years of age and adults)</td> </tr> <tr> <td class=\"subtitle2\">Well controlled</td> <td class=\"subtitle2\">Not well controlled</td> <td class=\"subtitle2\">Very poorly controlled</td> </tr> <tr> <td rowspan=\"9\">Impairment</td> <td>Symptoms</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week</td> <td>Throughout the day</td> </tr> <tr> <td>Nighttime awakenings</td> <td>&#8804;2x/month</td> <td>1 to 3x/week</td> <td>&#8805;4x/week</td> </tr> <tr> <td>Interference with normal activity</td> <td>None</td> <td>Some limitation</td> <td>Extremely limited</td> </tr> <tr> <td>Short-acting beta<sub>2</sub>-agonist use for symptom control (not prevention of EIB)</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week</td> <td>Several times per day</td> </tr> <tr> <td>FEV<sub>1</sub> or peak flow</td> <td>&#62;80 percent predicted/personal best</td> <td>60 to 80 percent predicted/personal best</td> <td>&#60;60 percent predicted/personal best</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Validated questionnaires</td> </tr> <tr> <td class=\"sublist1\">ATAQ</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">1 to 2</td> <td class=\"sublist_other\">3 to 4</td> </tr> <tr> <td class=\"sublist1\">ACQ</td> <td class=\"sublist_other\">&#8804;0.75*</td> <td class=\"sublist_other\">&#8805;1.5</td> <td class=\"sublist_other\">N/A</td> </tr> <tr> <td class=\"sublist1\">ACT</td> <td class=\"sublist_other\">&#8805;20</td> <td class=\"sublist_other\">16 to 19</td> <td class=\"sublist_other\">&#8804;15</td> </tr> <tr> <td rowspan=\"4\">Risk</td> <td rowspan=\"2\"><strong>Exacerbations</strong></td> <td><strong>0 to 1/year</strong></td> <td colspan=\"2\"><strong>&#8805;2/year (see footnote)</strong></td> </tr> <tr> <td colspan=\"3\"><strong>Consider severity and interval since last exacerbation</strong></td> </tr> <tr> <td>Progressive loss of lung function</td> <td colspan=\"3\">Evaluation requires long-term follow-up care</td> </tr> <tr> <td>Treatment-related adverse effects</td> <td colspan=\"3\">Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's recall of previous&nbsp;two to four&nbsp;weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had ≥2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with not-well-controlled asthma.</div><div class=\"graphic_footnotes\">EIB: exercise-induced bronchospasm; FEV<SUB>1</SUB>: forced expiratory volume in 1 second; ATAQ: Asthma Therapy Assessment Questionnaire (Vollmer et al. 1999); ACQ: Asthma Control Questionnaire (Juniper et al. 1999b); ACT: Asthma Control Test (Nathan et al. 2004); N/A: not applicable.<br />* ACQ values of 0.76 to 1.4 are indeterminate regarding well-controlled asthma.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 65972 Version 3.0</div></div></div>"},"65973":{"type":"graphic_diagnosticimage","displayName":"Cystic hygroma CT II","title":"Cystic hygroma in newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic hygroma in newborn</div><div class=\"cntnt\"><img style=\"width:360px; height:226px;\" src=\"images/PULM/65973_Cystic_hygroma_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan shows several large cystic structures in the left chest wall and anterior mediastinum.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 65973 Version 3.0</div></div></div>"},"65975":{"type":"graphic_figure","displayName":"Resection pancreatic head","title":"Resection pancreatic head","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Resection pancreatic head</div><div class=\"cntnt\"><img style=\"width:536px; height:568px;\" src=\"images/SURG/65975_Pancreatic_tumor_resection.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 65975 Version 2.0</div></div></div>"},"65976":{"type":"graphic_picture","displayName":"Linear granuloma annulare","title":"Linear granuloma annulare","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear granuloma annulare</div><div class=\"cntnt\"><img style=\"width:432px; height:352px;\" src=\"images/DERM/65976_Linear_granuloma_annulare_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 56 year-old presented with this solitary, semi-annular plaque of granuloma annulare that slowly expanded anteriorly over 3 years. The reason this lesion did not expand in a more typical ring is unknown.</div><div id=\"graphicVersion\">Graphic 65976 Version 1.0</div></div></div>"},"65977":{"type":"graphic_figure","displayName":"Lung transplant survival by diagnosis","title":"Survival by diagnosis for lung transplants performed in adults from January 1990 to June 2013","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Survival by diagnosis for lung transplants performed in adults from January 1990 to June 2013</div><div class=\"cntnt\"><img style=\"width:506px; height:446px;\" src=\"images/PEDS/65977_Lung_transplant_surv_diag.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; A1AD: alpha 1 antitrypsin deficiency.<br />* The median survival (half-life) is the estimated timepoint at which 50 percent of recipients have died. Survival was calculated using the Kaplan Meier method, based on data from transplants performed between January 1990 and June 2013, as compiled in the International Society of Heart and Lung Transplantation registry.</div><div class=\"graphic_reference\">Data from: The International Society for Heart and Lung Transplantation. Available at: <a href=\"http://www.ishlt.org/\" target=\"_blank\">www.ishlt.org</a> (accessed 5/6/16).</div><div id=\"graphicVersion\">Graphic 65977 Version 6.0</div></div></div>"},"65978":{"type":"graphic_algorithm","displayName":"Algorithm abnormal mammogram","title":"Management algorithm for patients with abnormal mammograms","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Management algorithm for patients with abnormal mammograms</div><div class=\"cntnt\"><img style=\"width:498px; height:535px;\" src=\"images/ONC/65978_Algoabnormalmammogram.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm helps to guide management of the patient who presents with an abnormal mammogram, whether it is performed at your institution or outside. BI-RADS 4 is a broad category that includes patients with a probability of malignancy that ranges from 2 to 95%. The management of more suspicious lesions (&gt;50% probability) should include surgical evaluation before percutaneous biopsy. The designation often implies lower suspicion of malignancy. Also, some patients and some lesions are not appropriate candidates for percutaneous biopsy.</div><div class=\"graphic_footnotes\">BI-RADS: Breast Imaging Reporting and Data System; MRI: magnetic resonance imaging.<br />* A situation in which it may be useful to incorporate staging MRI.</div><div class=\"graphic_reference\">Adapted from: Esserman, L, et al. Current Oncology Reports 2000; 2:572.</div><div id=\"graphicVersion\">Graphic 65978 Version 3.0</div></div></div>"},"65979":{"type":"graphic_figure","displayName":"Bio pathways thera targets in RCC","title":"Biological pathways and the resulting therapeutic targets in renal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Biological pathways and the resulting therapeutic targets in renal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:580px; height:423px;\" src=\"images/ONC/65979_Bio_pathways_thera_targ_RCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In conditions of normoxia and normal VHL gene function, von Hippel-Landau protein is the substrate recognition component of an E3 ubiquitin ligase complex that targets hypoxia-inducible factor (HIF) for proteolysis. In cellular hypoxia or with an inactivated VHL gene, the VHL proteinHIF interaction is disrupted, leading to stabilisation and accumulation of HIF transcription factors. HIF accumulation can also result from activation of the mammalian target of rapamycin (mTOR) through cellular stimuli and the phosphoinositide 3-kinase (PI3K)/Akt (protein kinase) pathway. mTOR phosphorylates and activates p70S6 kinase (p70S6K) leading to enhanced translation of certain proteins, including HIF. Activated mTOR also phosphorylates 4E binding protein-1 (4E-BP1), promoting dissociation of this complex and allowing eukaryotic initiation factor-4 subunit E (eIF-4E) to stimulate an increase in the translation of mRNAs that encode cell-cycle regulators such as c-myc and cyclin D1. Activated HIF translocates into the nucleus and leads to transcription of a large range of hypoxia-inducible genes, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). These ligands bind to their cognate receptors present on the surface of endothelial cells, leading to cell migration, proliferation, and permeability. Temsirolimus binds to FK506-binding protein (FKBP), and the resultant proteindrug complex inhibits the kinase activity of the mTOR complex 1 (mTORC1). Bevacizumab is a VEGF ligand-binding antibody. Sunitinib and sorafenib are small molecule inhibitors of the VEGF receptor (VEGFR) and PDGF receptor (PDGRF) tyrosine kinases.</div><div class=\"graphic_footnotes\">PTEN: phosphatase and tensin homologue; Pro: proline; Ub: ubiquitin.</div><div class=\"graphic_reference\">Reproduced from: Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373:1119. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 65979 Version 2.0</div></div></div>"},"65981":{"type":"graphic_picture","displayName":"Bar dips","title":"Safe and unsafe range of motion for bar dips","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Safe and unsafe range of motion for bar dips</div><div class=\"cntnt\"><img style=\"width:584px; height:271px;\" src=\"images/PEDS/65981_Bar_dips_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture A depicts the appropriate and safe range of motion for a bar dip with the upper arm parallel to the ground. Picture B depicts a bar dip with an increased range of motion, increasing the risk of soft tissue injury.</div><div class=\"graphic_reference\">Courtesy of Pat R Vehrs, PhD, FACSM.</div><div id=\"graphicVersion\">Graphic 65981 Version 2.0</div></div></div>"},"65985":{"type":"graphic_picture","displayName":"Lymphocutaneous sporotrichosis leg","title":"Lymphocutaneous sporotrichosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphocutaneous sporotrichosis</div><div class=\"cntnt\"><img style=\"width:369px; height:248px;\" src=\"images/ID/65985_Lymphocutaneous_sporotric1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymphocutaneous sporotrichosis on the right lower extremity of a young man who overturned his dirt bike and inoculated soil in multiple places in his leg. Following a plastic surgery procedure before the diagnosis of sporotrichosis, new lesions developed at the edge of the skin graft and extended up into the thigh.</div><div class=\"graphic_reference\">Courtesy of Carol A. Kauffman, MD.</div><div id=\"graphicVersion\">Graphic 65985 Version 2.0</div></div></div>"},"65987":{"type":"graphic_diagnosticimage","displayName":"Renal arteriogram in polyarteritis nodosa","title":"Renal arteriogram in polyarteritis nodosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal arteriogram in polyarteritis nodosa</div><div class=\"cntnt\"><img style=\"width:374px; height:339px;\" src=\"images/NEPH/65987_Renal_arteriogram_in_PAN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal arteriogram in large-vessel polyarteritis nodosa showing characteristic microaneurysms (small arrows) and abrupt cutoffs of small arteries (large arrows).</div><div class=\"graphic_reference\">From: Rose BD. Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York, 1987.</div><div id=\"graphicVersion\">Graphic 65987 Version 6.0</div></div></div>"},"65988":{"type":"graphic_picture","displayName":"Halo nevus","title":"Halo nevus (Sutton's nevus)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Halo nevus (Sutton's nevus)</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/65988_Halo_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stage I halo nevus with a characteristic depigmented rim.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 65988 Version 1.0</div></div></div>"},"65989":{"type":"graphic_picture","displayName":"Carpometacarpal compression","title":"Compression of the carpometacarpal (CMC) joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Compression of the carpometacarpal (CMC) joint</div><div class=\"cntnt\"><img style=\"width:328px; height:310px;\" src=\"images/EM/65989_Carpometacarpal_compression.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The wrist is placed in a neutral position with the radial side up. The examiner grasps the base of the thumb just beyond the anatomical snuff box. The synovial lining and the base of the metacarpal are squeezed together using the thumb and finger. The compression can be enhanced by circumducting the thumb while continually holding pressure.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 65989 Version 2.0</div></div></div>"},"65990":{"type":"graphic_picture","displayName":"Clonorchiasis egg","title":"Clonorchiasis egg","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Clonorchiasis egg</div><div class=\"cntnt\"><img style=\"width:550px; height:308px;\" src=\"images/ID/65990_Clonorchiasis_egg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) <em>Clonorchis sinensis</em> eggs. The small knob at the abopercular end is visible in A. Also note the operculum resting on &quot;shoulders&quot; in B; image taken at 400x magnification.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Clonorchiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/clonorchiasis/index.html\">http://www.cdc.gov/dpdx/clonorchiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 65990 Version 3.0</div></div></div>"},"65991":{"type":"graphic_picture","displayName":"Fixed drug eruption penis","title":"Fixed drug eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fixed drug eruption</div><div class=\"cntnt\"><img style=\"width:324px; height:324px;\" src=\"images/DERM/65991_Fixeddrugeruptionpenis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fixed drug eruption. An oval erosion on the glans penis occurred in this patient who was taking minocycline. According to the patient, an identical lesion appeared when he was given minocycline previously.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 65991 Version 3.0</div></div></div>"},"65992":{"type":"graphic_algorithm","displayName":"FAP gene testing algorithm","title":"FAP gene testing algorithm","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">FAP gene testing algorithm</div><div class=\"cntnt\"><img style=\"width:553px; height:622px;\" src=\"images/GAST/65992_FAP_gene_testing_algo_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AFAP: attenuate adenomatous polyposis; FAP: familial adenomatous polyposis.</div><div class=\"graphic_reference\">Original figure modified for this publication. American Gastroenterological Association Guidelines: Reproduced with permission from the American Gastroenterological Association. Giardiello FM, Brensinger JD, Petersen GM. Gastroenterology 2001; 121:195. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 65992 Version 5.0</div></div></div>"},"65994":{"type":"graphic_figure","displayName":"Fall in thalassemia birth rate","title":"Change in birth rate of thalassemic children after the introduction of preventive programs","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Change in birth rate of thalassemic children after the introduction of preventive programs</div><div class=\"cntnt\"><img style=\"width:469px; height:322px;\" src=\"images/HEME/65994_Fall_in_thalassemia_birthra.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Cao A, Galanello R, Rosatelli MC, et al. Clinical experience of management of thalassemia: the Sardinian experience. Semin Hematol 1996; 33:66.</div><div id=\"graphicVersion\">Graphic 65994 Version 2.0</div></div></div>"},"65998":{"type":"graphic_table","displayName":"Glucocorticoid adverse effects","title":"Major adverse effects associated with glucocorticoid therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major adverse effects associated with glucocorticoid therapy</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Dermatologic and appearance</td> </tr> <tr> <td class=\"indent1\">Skin thinning,&nbsp;purpura, and/or ecchymoses</td> </tr> <tr> <td class=\"indent1\">Weight gain</td> </tr> <tr> <td class=\"indent1\">Cushingoid appearance</td> </tr> <tr> <td class=\"indent1\">Acne</td> </tr> <tr> <td class=\"indent1\">Hirsutism</td> </tr> <tr> <td class=\"indent1\">Facial erythema</td> </tr> <tr> <td class=\"indent1\">Striae</td> </tr> <tr> <td class=\"subtitle1_single\">Ophthalmologic</td> </tr> <tr> <td class=\"indent1\">Posterior subcapsular cataract</td> </tr> <tr> <td class=\"indent1\">Elevated intraocular pressure/glaucoma</td> </tr> <tr> <td class=\"indent1\">Exophthalmos</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular</td> </tr> <tr> <td class=\"indent1\">Fluid retention</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> </tr> <tr> <td class=\"indent1\">Premature arteriosclerosis</td> </tr> <tr> <td class=\"indent1\">Arrhythmias</td> </tr> <tr> <td class=\"indent1\">Perturbations of serum lipoproteins</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal</td> </tr> <tr> <td class=\"indent1\">Gastritis</td> </tr> <tr> <td class=\"indent1\">Peptic ulcer disease</td> </tr> <tr> <td class=\"indent1\">Steatohepatitis</td> </tr> <tr> <td class=\"indent1\">Visceral perforation</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Bone and muscle</td> </tr> <tr> <td class=\"indent1\">Osteoporosis</td> </tr> <tr> <td class=\"indent1\">Avascular necrosis</td> </tr> <tr> <td class=\"indent1\">Myopathy</td> </tr> <tr> <td class=\"subtitle1_single\">Neuropsychiatric</td> </tr> <tr> <td class=\"indent1\">Euphoria</td> </tr> <tr> <td class=\"indent1\">Dysphoria/depression</td> </tr> <tr> <td class=\"indent1\">Insomnia</td> </tr> <tr> <td class=\"indent1\">Akathisia</td> </tr> <tr> <td class=\"indent1\">Mania/psychosis</td> </tr> <tr> <td class=\"indent1\">Pseudotumor cerebri</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic and endocrine</td> </tr> <tr> <td class=\"indent1\">Hyperglycemia</td> </tr> <tr> <td class=\"indent1\">Hypothalamic-pituitary-adrenal insufficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Immune system</td> </tr> <tr> <td class=\"indent1\">Increased risk of infections*</td> </tr> <tr> <td class=\"subtitle1_single\">Hematologic</td> </tr> <tr> <td class=\"indent1\">Leukocytosis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Refer to UpToDate content on the effects of glucocorticoids on the immune system.</div><div id=\"graphicVersion\">Graphic 65998 Version 9.0</div></div></div>"},"65999":{"type":"graphic_figure","displayName":"Posterior approach popliteal nerve block","title":"Posterior approach nerve stimulator guided popliteal nerve block","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Posterior approach&nbsp;nerve stimulator guided&nbsp;popliteal nerve block</div><div class=\"cntnt\"><img style=\"width:529px; height:560px;\" src=\"images/SURG/65999_Poplitealblockpost.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is placed in a prone position. The tendons of the biceps femoris (lateral) and the semitendinosus/semimembranosis (medial) muscles are identified. An insulated block&nbsp;needle is&nbsp;inserted at the midpoint between these tendons approximately 7 cm above the popliteal crease. The dashed line shows the level of the cross-sectional view.<br />For further details, refer to UpToDate content on lower extremity nerve blocks.</div><div id=\"graphicVersion\">Graphic 65999 Version 5.0</div></div></div>"}};